Drug Name,Mechanism,Gene Target,ENTREZ_GENE_ID,Approval Phase
(R)-(-)-apomorphine,dopamine receptor agonist,ADRA2A,3066,Launched
(R)-(-)-apomorphine,dopamine receptor agonist,ADRA2B,5139,Launched
(R)-(-)-apomorphine,dopamine receptor agonist,ADRA2C,5140,Launched
(R)-(-)-apomorphine,dopamine receptor agonist,CALY,5141,Launched
(R)-(-)-apomorphine,dopamine receptor agonist,DRD1,5142,Launched
(R)-(-)-apomorphine,dopamine receptor agonist,DRD2,5143,Launched
(R)-(-)-apomorphine,dopamine receptor agonist,DRD3,5144,Launched
(R)-(-)-apomorphine,dopamine receptor agonist,DRD4,8654,Launched
(R)-(-)-apomorphine,dopamine receptor agonist,DRD5,1719,Launched
(R)-(-)-apomorphine,dopamine receptor agonist,HTR1A,113235,Launched
(R)-(-)-apomorphine,dopamine receptor agonist,HTR1B,983,Launched
(R)-(-)-apomorphine,dopamine receptor agonist,HTR1D,1017,Launched
(R)-(-)-apomorphine,dopamine receptor agonist,HTR2A,1020,Launched
(R)-(-)-apomorphine,dopamine receptor agonist,HTR2B,240,Launched
(R)-(-)-apomorphine,dopamine receptor agonist,HTR2C,1147,Launched
(R)-(-)-apomorphine,dopamine receptor agonist,HTR5A,30814,Launched
(R)-(-)-rolipram,phosphodiesterase inhibitor,PDE4A,5742,Phase 1
(R)-(-)-rolipram,phosphodiesterase inhibitor,PDE4B,5743,Phase 1
(R)-(-)-rolipram,phosphodiesterase inhibitor,PDE4C,140,Phase 1
(R)-(-)-rolipram,phosphodiesterase inhibitor,PDE4D,3614,Phase 1
(R)-(-)-rolipram,phosphodiesterase inhibitor,PDE5A,4843,Phase 1
(R)-baclofen,benzodiazepine receptor agonist,GABBR1,153,Phase 3
(R)-baclofen,benzodiazepine receptor agonist,GABBR2,8912,Phase 3
(S)-(+)-rolipram,phosphodiesterase inhibitor,PDE4B,9254,Phase 1
(S)-(+)-rolipram,phosphodiesterase inhibitor,PDE4D,3743,Phase 1
"[sar9,met(o2)11]-substance-p",tachykinin antagonist,TACR1,3757,Preclinical
A-1070722,glycogen synthase kinase inhibitor,GSK3A,1813,Preclinical
A-1070722,glycogen synthase kinase inhibitor,GSK3B,6530,Preclinical
A-1120,retinoid receptor ligand,RBP4,6531,Preclinical
A-317491,purinergic receptor antagonist,P2RX3,6532,Preclinical
A-366,histone lysine methyltransferase inhibitor,EHMT1,148,Preclinical
A-366,histone lysine methyltransferase inhibitor,EHMT2,150,Preclinical
A-412997,dopamine receptor agonist,DRD4,148,Preclinical
A-438079,purinergic receptor antagonist,P2RX7,147,Preclinical
A-582941,nicotinic receptor agonist,CHRNA7,146,Preclinical
A-61603,adrenergic receptor agonist,ADRA1A,150,Preclinical
A-61603,adrenergic receptor agonist,ADRA1B,153,Preclinical
A-61603,adrenergic receptor agonist,ADRA1D,154,Preclinical
A-674563,AKT inhibitor,AKT1,155,Preclinical
A-674563,AKT inhibitor,PKIA,1128,Preclinical
A-674563,AKT inhibitor,PRKACA,1129,Preclinical
A-784168,transient receptor potential channel antagonist,TRPV1,1131,Preclinical
A-803467,sodium channel blocker,SCN10A,1132,Preclinical
A-804598,purinergic receptor antagonist,P2RX7,1133,Preclinical
A-839977,purinergic receptor antagonist,P2RX7,3269,Preclinical
A-867744,acetylcholine receptor allosteric modulator,CHRNA3,3274,Preclinical
A-867744,acetylcholine receptor allosteric modulator,CHRNA4,59340,Preclinical
A-867744,acetylcholine receptor allosteric modulator,CHRNA7,3350,Preclinical
A-887826,sodium channel blocker,SCN10A,3351,Preclinical
A-922500,diacylglycerol O acyltransferase inhibitor,DGAT1,3352,Preclinical
A-939572,stearoyl-CoA desaturase inhibitor,SCD,3356,Preclinical
A-967079,transient receptor potential channel antagonist,TRPA1,3358,Preclinical
A-987306,histamine receptor antagonist,ADORA1,3362,Preclinical
A-987306,histamine receptor antagonist,AVPR1A,3363,Preclinical
A-987306,histamine receptor antagonist,CCR1,3736,Preclinical
A-987306,histamine receptor antagonist,CHRM1,3751,Preclinical
A-987306,histamine receptor antagonist,CHRM2,3752,Preclinical
A-987306,histamine receptor antagonist,CHRM3,3785,Preclinical
A-987306,histamine receptor antagonist,CHRM4,3786,Preclinical
A-987306,histamine receptor antagonist,DRD3,4914,Preclinical
A-987306,histamine receptor antagonist,HTR1A,4915,Preclinical
A-987306,histamine receptor antagonist,HTR1B,4985,Preclinical
A-987306,histamine receptor antagonist,HTR2A,4986,Preclinical
A-987306,histamine receptor antagonist,HTR2B,4988,Preclinical
A-987306,histamine receptor antagonist,HTR3A,10280,Preclinical
A-987306,histamine receptor antagonist,TACR2,6530,Preclinical
AA-29504,GABA receptor positive allosteric modulator,GABRA1,6532,Preclinical
AA-29504,GABA receptor positive allosteric modulator,GABRA4,2246,Preclinical
AA-29504,GABA receptor positive allosteric modulator,GABRB3,3562,Preclinical
abamectin,benzodiazepine receptor agonist,GABBR1,5141,Launched
abamectin,benzodiazepine receptor agonist,GABBR2,5142,Launched
abametapir,metalloproteinase inhibitor,MMP9,5143,Phase 3
abarelix,gonadotropin releasing factor hormone receptor antagonist,GNRHR,5144,Phase 3
ABC-294640,sphingosine kinase inhibitor,SPHK2,6283,Phase 2
abemaciclib,CDK inhibitor,CDK4,6284,Launched
abemaciclib,CDK inhibitor,CDK6,775,Launched
abiraterone,androgen biosynthesis inhibitor,CYP11B1,776,Launched
abiraterone,androgen biosynthesis inhibitor,CYP17A1,778,Launched
abiraterone-acetate,androgen biosynthesis inhibitor,CYP17A1,779,Launched
ABT-239,histamine receptor antagonist,HRH1,781,Phase 1
ABT-239,histamine receptor antagonist,HRH2,3290,Phase 1
ABT-239,histamine receptor antagonist,HRH3,3291,Phase 1
ABT-491,platelet activating factor receptor antagonist,PTAFR,10599,Phase 1
ABT-639,calcium channel blocker,CACNA1G,28234,Phase 2
ABT-639,calcium channel blocker,CACNA1H,27198,Phase 2
ABT-639,calcium channel blocker,CACNA1I,5292,Phase 2
ABT-702,adenosine kinase inhibitor,ADK,2917,Preclinical
ABT-724,dopamine receptor agonist,DRD4,3176,Phase 2
ABT-737,BCL inhibitor,BCL2,7153,Phase 1/Phase 2
ABT-737,BCL inhibitor,BCL2L1,7155,Phase 1/Phase 2
ABT-737,BCL inhibitor,BCL2L2,148,Phase 1/Phase 2
ABT-751,tubulin polymerization inhibitor,TUBB,147,Phase 2
AC-186,estrogen receptor agonist,ESR2,146,Preclinical
AC-261066,retinoid receptor agonist,RARB,150,Preclinical
AC-264613,PAR agonist,F2RL1,151,Preclinical
AC-55541,PARP inhibitor,PARP2,152,Preclinical
AC-55649,retinoid receptor agonist,RARA,1128,Preclinical
AC-55649,retinoid receptor agonist,RARB,1129,Preclinical
AC-710,PDGFR tyrosine kinase receptor inhibitor,CSF1R,1131,Preclinical
AC-710,PDGFR tyrosine kinase receptor inhibitor,FLT3,1132,Preclinical
AC-710,PDGFR tyrosine kinase receptor inhibitor,KIT,1129,Preclinical
AC-710,PDGFR tyrosine kinase receptor inhibitor,PDGFRA,1128,Preclinical
AC-710,PDGFR tyrosine kinase receptor inhibitor,PDGFRB,1129,Preclinical
AC-7954-(+/-),urotensin receptor agonist,UTS2R,1131,Preclinical
acalabrutinib,Bruton's tyrosine kinase (BTK) inhibitor,BTK,1132,Launched
acalisib,PI3K inhibitor,PIK3CB,1128,Phase 1
acalisib,PI3K inhibitor,PIK3CD,1129,Phase 1
acamprosate,glutamate receptor antagonist,GABRA1,1131,Launched
acamprosate,glutamate receptor antagonist,GABRA2,1132,Launched
acamprosate,glutamate receptor antagonist,GABRA3,2147,Launched
acamprosate,glutamate receptor antagonist,GABRA4,2339,Launched
acamprosate,glutamate receptor antagonist,GABRA5,4790,Launched
acamprosate,glutamate receptor antagonist,GABRA6,148,Launched
acamprosate,glutamate receptor antagonist,GABRB1,147,Launched
acamprosate,glutamate receptor antagonist,GABRB2,150,Launched
acamprosate,glutamate receptor antagonist,GABRB3,151,Launched
acamprosate,glutamate receptor antagonist,GABRD,152,Launched
acamprosate,glutamate receptor antagonist,GABRE,1128,Launched
acamprosate,glutamate receptor antagonist,GABRG1,1129,Launched
acamprosate,glutamate receptor antagonist,GABRG2,1131,Launched
acamprosate,glutamate receptor antagonist,GABRG3,1132,Launched
acamprosate,glutamate receptor antagonist,GABRP,1133,Launched
acamprosate,glutamate receptor antagonist,GABRQ,1812,Launched
acamprosate,glutamate receptor antagonist,GRIN1,1813,Launched
acamprosate,glutamate receptor antagonist,GRIN2A,1814,Launched
acamprosate,glutamate receptor antagonist,GRIN2B,1815,Launched
acamprosate,glutamate receptor antagonist,GRIN2C,1816,Launched
acamprosate,glutamate receptor antagonist,GRIN2D,3269,Launched
acamprosate,glutamate receptor antagonist,GRIN3A,3350,Launched
acamprosate,glutamate receptor antagonist,GRIN3B,3351,Launched
acamprosate,glutamate receptor antagonist,GRM5,3352,Launched
acarbose,glucosidase inhibitor,AMY2A,3354,Launched
acarbose,glucosidase inhibitor,MGAM,3356,Launched
ACDPP,glutamate receptor antagonist,GRM5,3358,Preclinical
acebutolol,adrenergic receptor antagonist,ADRB1,3359,Launched
acecainide,polarization inhibitor,SCN5A,3362,Phase 3
aceclidine,acetylcholine receptor agonist,CHRM1,3363,Launched
aceclidine,acetylcholine receptor agonist,CHRM2,5141,Launched
aceclidine,acetylcholine receptor agonist,CHRM3,155,Launched
aceclidine,acetylcholine receptor agonist,CHRM4,208,Launched
aceclidine,acetylcholine receptor agonist,CHRM5,3832,Launched
aceclofenac,prostanoid receptor antagonist,PTGS2,2064,Launched
acefylline,adenosine receptor agonist,ADORA1,4069,Launched
acemetacin,cyclooxygenase inhibitor,PTGS1,207,Launched
acemetacin,cyclooxygenase inhibitor,PTGS2,595,Launched
aceneuramic-acid,,CES1,3551,Phase 3
aceneuramic-acid,,SELE,3725,Phase 3
aceneuramic-acid,,SELP,5594,Phase 3
acenocoumarol,vitamin K antagonist,VKORC1,5595,Launched
acepromazine,dopamine receptor antagonist,ADRA1A,7296,Launched
acepromazine,dopamine receptor antagonist,ADRA1B,476,Launched
acepromazine,dopamine receptor antagonist,DRD1,1555,Launched
acepromazine,dopamine receptor antagonist,DRD2,5743,Launched
acepromazine,dopamine receptor antagonist,HTR1A,6285,Launched
acepromazine,dopamine receptor antagonist,HTR2A,23476,Launched
acetazolamide,carbonic anhydrase inhibitor,AQP1,139760,Launched
acetazolamide,carbonic anhydrase inhibitor,CA1,6093,Launched
acetazolamide,carbonic anhydrase inhibitor,CA12,3635,Launched
acetazolamide,carbonic anhydrase inhibitor,CA14,2864,Launched
acetazolamide,carbonic anhydrase inhibitor,CA2,51135,Launched
acetazolamide,carbonic anhydrase inhibitor,CA3,5294,Launched
acetazolamide,carbonic anhydrase inhibitor,CA4,5290,Launched
acetazolamide,carbonic anhydrase inhibitor,CA7,5294,Launched
acetohexamide,ATP channel blocker,ABCC8,5604,Launched
acetohexamide,ATP channel blocker,KCNJ1,5605,Launched
acetohexamide,ATP channel blocker,KCNJ10,3738,Launched
acetohexamide,ATP channel blocker,KCNJ11,3741,Launched
acetohydroxamic-acid,urease inhibitor,MMP12,3783,Launched
acetophenazine,dopamine receptor antagonist,DRD1,5743,Launched
acetophenazine,dopamine receptor antagonist,DRD2,367,Launched
acetyl-farnesyl-cysteine,methyltransferase inhibitor,PPARG,2280,Launched
acetyl-11-keto-beta-boswellic-acid,lipoxygenase inhibitor,HSD11B1,9963,Phase 2
acetyl-11-keto-beta-boswellic-acid,lipoxygenase inhibitor,HSD11B2,9962,Phase 2
acetylcholine,acetylcholine receptor agonist,ACHE,1813,Launched
acetylcholine,acetylcholine receptor agonist,CHRM1,3269,Launched
acetylcholine,acetylcholine receptor agonist,CHRM2,3350,Launched
acetylcholine,acetylcholine receptor agonist,CHRM3,3351,Launched
acetylcholine,acetylcholine receptor agonist,CHRM4,3352,Launched
acetylcholine,acetylcholine receptor agonist,CHRM5,3354,Launched
acetylcholine,acetylcholine receptor agonist,CHRNA2,3356,Launched
acetylcysteine,mucolytic agent,ACY1,5837,Launched
acetylcysteine,mucolytic agent,CHUK,4986,Launched
acetylcysteine,mucolytic agent,GRIN1,6536,Launched
acetylcysteine,mucolytic agent,GRIN2A,80834,Launched
acetylcysteine,mucolytic agent,GRIN2B,7442,Launched
acetylcysteine,mucolytic agent,GRIN2D,1645,Launched
acetylcysteine,mucolytic agent,GRIN3A,9311,Launched
acetylcysteine,mucolytic agent,GSS,1909,Launched
acetylcysteine,mucolytic agent,IKBKB,3309,Launched
acetylcysteine,mucolytic agent,RELA,3551,Launched
acetylcysteine,mucolytic agent,SLC7A11,4790,Launched
acexamic-acid,5 alpha reductase inhibitor,GAST,4791,Launched
acifran,cholesterol inhibitor,HCAR2,4792,Phase 3
acifran,cholesterol inhibitor,HCAR3,5562,Phase 3
acipimox,cholesterol inhibitor,HCAR2,5563,Launched
acitretin,retinoid receptor agonist,RARA,5564,Launched
acitretin,retinoid receptor agonist,RARB,5565,Launched
acitretin,retinoid receptor agonist,RARG,5571,Launched
acitretin,retinoid receptor agonist,RBP1,51422,Launched
acitretin,retinoid receptor agonist,RXRA,53632,Launched
acitretin,retinoid receptor agonist,RXRB,3815,Launched
acitretin,retinoid receptor agonist,RXRG,5156,Launched
acitretin,retinoid receptor agonist,STAT3,5159,Launched
acivicin,gamma glutamyltransferase inhibitor,CTPS1,2837,Phase 2
aclarubicin,topoisomerase inhibitor,TOP1,695,Launched
aclarubicin,topoisomerase inhibitor,TOP2A,5291,Launched
aclidinium,acetylcholine receptor antagonist,CHRM1,5293,Launched
aclidinium,acetylcholine receptor antagonist,CHRM2,2554,Launched
aclidinium,acetylcholine receptor antagonist,CHRM3,2555,Launched
aclidinium,acetylcholine receptor antagonist,CHRM4,2556,Launched
aclidinium,acetylcholine receptor antagonist,CHRM5,2557,Launched
acriflavine,hypoxia inducible factor inhibitor,HIF1A,2558,Launched
acriflavinium,hypoxia inducible factor inhibitor,HIF1A,2559,Launched
acrivastine,histamine receptor antagonist,HRH1,2560,Launched
ACT-132577,endothelin receptor antagonist,EDNRA,2561,Launched
ACT-132577,endothelin receptor antagonist,EDNRB,2562,Launched
ACT-462206,orexin receptor antagonist,HCRTR1,2563,Phase 1
ACT-462206,orexin receptor antagonist,HCRTR2,2564,Phase 1
ACTB-1003,FGFR inhibitor|VEGFR inhibitor,KDR,2565,Phase 1
ACTB-1003,FGFR inhibitor|VEGFR inhibitor,TEK,2566,Phase 1
ACY-1215,HDAC inhibitor,HDAC1,2567,Phase 1/Phase 2
ACY-1215,HDAC inhibitor,HDAC2,2568,Phase 1/Phase 2
ACY-1215,HDAC inhibitor,HDAC3,55879,Phase 1/Phase 2
ACY-1215,HDAC inhibitor,HDAC6,2902,Phase 1/Phase 2
ACY-1215,HDAC inhibitor,HDAC8,2903,Phase 1/Phase 2
acyclovir,DNA polymerase inhibitor,PNP,2904,Launched
AD-5467,aldose reductase inhibitor,AKR1B1,2905,Phase 2
adapalene,retinoid receptor agonist,RARA,2906,Launched
adapalene,retinoid receptor agonist,RARB,116443,Launched
adapalene,retinoid receptor agonist,RARG,116444,Launched
adapalene,retinoid receptor agonist,RXRA,2915,Launched
adapalene,retinoid receptor agonist,RXRB,279,Launched
adapalene,retinoid receptor agonist,RXRG,8972,Launched
adaprev,TGF beta receptor inhibitor,AKR1B1,2915,Phase 3
adaprev,TGF beta receptor inhibitor,GPI,153,Phase 3
adaprev,TGF beta receptor inhibitor,HK1,6331,Phase 3
adaprev,TGF beta receptor inhibitor,M6PR,1128,Phase 3
adaprev,TGF beta receptor inhibitor,PYGM,1129,Phase 3
adaptavir,CC chemokine receptor antagonist,CCR5,1131,Phase 2
adarotene,retinoid receptor agonist,RARB,1132,Phase 1
adarotene,retinoid receptor agonist,RARG,1133,Phase 1
adatanserin,serotonin receptor agonist|serotonin receptor antagonist,HTR1A,5743,Phase 2
adatanserin,serotonin receptor agonist|serotonin receptor antagonist,HTR2A,134,Phase 2
adenine,protein synthesis stimulant,ACACB,5742,Preclinical
adenine,protein synthesis stimulant,ACP1,5743,Preclinical
adenine,protein synthesis stimulant,APRT,1066,Preclinical
adenine,protein synthesis stimulant,MTAP,6401,Preclinical
adenine,protein synthesis stimulant,PECR,6403,Preclinical
adenine,protein synthesis stimulant,SRPK2,79001,Preclinical
adenosine,adenosine receptor agonist,ADORA1,148,Launched
adenosine,adenosine receptor agonist,ADORA2A,147,Launched
adenosine,adenosine receptor agonist,ADORA2B,1812,Launched
adenosine,adenosine receptor agonist,ADORA3,1813,Launched
adenosine,adenosine receptor agonist,PI4K2A,3350,Launched
adenosine,adenosine receptor agonist,PI4K2B,3356,Launched
adenosine,adenosine receptor agonist,TRPM4,358,Launched
adenosine-phosphate,adenosine receptor agonist,ACSL1,759,Launched
adenosine-phosphate,adenosine receptor agonist,ACSS1,771,Launched
adenosine-phosphate,adenosine receptor agonist,ACSS2,23632,Launched
adenosine-phosphate,adenosine receptor agonist,ADCY1,760,Launched
adenosine-phosphate,adenosine receptor agonist,ADK,761,Launched
adenosine-phosphate,adenosine receptor agonist,CREB1,762,Launched
adenosine-phosphate,adenosine receptor agonist,FBP1,766,Launched
adenosine-phosphate,adenosine receptor agonist,HINT1,6833,Launched
adenosine-phosphate,adenosine receptor agonist,PDE4B,3758,Launched
adenosine-phosphate,adenosine receptor agonist,PDE4D,3766,Launched
adenosine-phosphate,adenosine receptor agonist,PIM1,3767,Launched
adenosine-phosphate,adenosine receptor agonist,PRKAA1,4321,Launched
adenosine-phosphate,adenosine receptor agonist,PRKAB1,1812,Launched
adenosine-phosphate,adenosine receptor agonist,PRKAB2,1813,Launched
adenosine-phosphate,adenosine receptor agonist,PYGL,5468,Launched
adenosine-phosphate,adenosine receptor agonist,TRPM4,3290,Launched
adenosine-triphosphate,adenosine receptor agonist,ABCA1,3291,Phase 2
adenosine-triphosphate,adenosine receptor agonist,ABCB1,43,Phase 2
adenosine-triphosphate,adenosine receptor agonist,ABCB11,1128,Phase 2
adenosine-triphosphate,adenosine receptor agonist,ABCC2,1129,Phase 2
adenosine-triphosphate,adenosine receptor agonist,ABCC8,1131,Phase 2
adenosine-triphosphate,adenosine receptor agonist,ABCC9,1132,Phase 2
adenosine-triphosphate,adenosine receptor agonist,ABCG1,1133,Phase 2
adenosine-triphosphate,adenosine receptor agonist,ABL1,1135,Phase 2
adenosine-triphosphate,adenosine receptor agonist,ABL2,95,Phase 2
adenosine-triphosphate,adenosine receptor agonist,ACSL1,1147,Phase 2
adenosine-triphosphate,adenosine receptor agonist,ACSS1,2902,Phase 2
adenosine-triphosphate,adenosine receptor agonist,ACSS2,2903,Phase 2
adenosine-triphosphate,adenosine receptor agonist,ACVR1,2904,Phase 2
adenosine-triphosphate,adenosine receptor agonist,ACVR1B,2906,Phase 2
adenosine-triphosphate,adenosine receptor agonist,ACVRL1,116443,Phase 2
adenosine-triphosphate,adenosine receptor agonist,ADCY1,2937,Phase 2
adenosine-triphosphate,adenosine receptor agonist,ADRBK1,3551,Phase 2
adenosine-triphosphate,adenosine receptor agonist,ADRBK2,5970,Phase 2
adenosine-triphosphate,adenosine receptor agonist,AFG3L2,23657,Phase 2
adenosine-triphosphate,adenosine receptor agonist,AKT1,2520,Phase 2
adenosine-triphosphate,adenosine receptor agonist,ALK,338442,Phase 2
adenosine-triphosphate,adenosine receptor agonist,AMHR2,8843,Phase 2
adenosine-triphosphate,adenosine receptor agonist,APAF1,338442,Phase 2
adenosine-triphosphate,adenosine receptor agonist,ARAF,5914,Phase 2
adenosine-triphosphate,adenosine receptor agonist,ASNA1,5915,Phase 2
adenosine-triphosphate,adenosine receptor agonist,ASNS,5916,Phase 2
adenosine-triphosphate,adenosine receptor agonist,ASS1,5947,Phase 2
adenosine-triphosphate,adenosine receptor agonist,CDK15,6256,Phase 2
adenosine-triphosphate,adenosine receptor agonist,GPR17,150,Phase 2
adenosine-triphosphate,adenosine receptor agonist,ITPR1,151,Phase 2
adenosine-triphosphate,adenosine receptor agonist,NAE1,152,Phase 2
adenosine-triphosphate,adenosine receptor agonist,NT5C2,50632,Phase 2
adenosine-triphosphate,adenosine receptor agonist,P2RY1,1812,Phase 2
adenosine-triphosphate,adenosine receptor agonist,P2RY11,1813,Phase 2
adenosine-triphosphate,adenosine receptor agonist,P2RY13,1814,Phase 2
adenosine-triphosphate,adenosine receptor agonist,P2RY2,1815,Phase 2
adenosine-triphosphate,adenosine receptor agonist,P2RY4,1816,Phase 2
adenosine-triphosphate,adenosine receptor agonist,PRKAA1,3350,Phase 2
adenosine-triphosphate,adenosine receptor agonist,RYR1,3351,Phase 2
adenosine-triphosphate,adenosine receptor agonist,RYR2,3352,Phase 2
adenosine-triphosphate,adenosine receptor agonist,RYR3,3356,Phase 2
adenosine-triphosphate,adenosine receptor agonist,SLC25A4,3357,Phase 2
adenosine-triphosphate,adenosine receptor agonist,TNK2,3358,Phase 2
adenosine-triphosphate,adenosine receptor agonist,TRPM4,3361,Phase 2
adenosine-triphosphate,adenosine receptor agonist,TRPM7,5141,Phase 2
adiphenine,acetylcholine receptor antagonist,CHRNA1,5142,Launched
adipic-acid,solute carrier family member inhibitor,SLC22A6,5143,Preclinical
adiporon,adiponectin receptor agonist,ADIPOR1,5144,Preclinical
adiporon,adiponectin receptor agonist,ADIPOR2,8654,Preclinical
ADL5859,opioid receptor agonist,OPRD1,2550,Phase 2
adoprazine,dopamine receptor antagonist|serotonin receptor agonist,DRD2,9568,Phase 2
adoprazine,dopamine receptor antagonist|serotonin receptor agonist,HTR1A,5142,Phase 2
adrenalone,adrenergic receptor agonist,ADRA1A,5144,Launched
adrenosterone,11-beta hydroxysteroid dehydrogenase inhibitor,HSD11B1,6869,Preclinical
adrenosterone,11-beta hydroxysteroid dehydrogenase inhibitor,HSD11B2,2931,Preclinical
ADX-10059,glutamate receptor negative allosteric modulator,GRM5,2932,Phase 2
ADX-47273,glutamate receptor modulator,GRM5,5950,Preclinical
AEE788,EGFR inhibitor|VEGFR inhibitor,EGFR,5024,Phase 1/Phase 2
AEE788,EGFR inhibitor|VEGFR inhibitor,ERBB2,79813,Phase 1/Phase 2
AEE788,EGFR inhibitor|VEGFR inhibitor,ERBB4,10919,Phase 1/Phase 2
AEE788,EGFR inhibitor|VEGFR inhibitor,FGFR2,1815,Phase 1/Phase 2
AEE788,EGFR inhibitor|VEGFR inhibitor,FGFR3,5027,Phase 1/Phase 2
AEE788,EGFR inhibitor|VEGFR inhibitor,KDR,1139,Phase 1/Phase 2
afalanine,dopamine receptor agonist,DRD2,148,Phase 3
afatinib,EGFR inhibitor,EGFR,147,Launched
afatinib,EGFR inhibitor,ERBB2,146,Launched
afatinib,EGFR inhibitor,ERBB4,207,Launched
afimoxifene,estrogen receptor antagonist,ESR1,5569,Phase 2
afimoxifene,estrogen receptor antagonist,ESR2,5566,Phase 2
afimoxifene,estrogen receptor antagonist,ESRRG,7442,Phase 2
afimoxifene,estrogen receptor antagonist,PLD1,6336,Phase 2
afimoxifene,estrogen receptor antagonist,PRKCD,5027,Phase 2
afimoxifene,estrogen receptor antagonist,PRKCE,5027,Phase 2
afimoxifene,estrogen receptor antagonist,PRKCQ,1136,Phase 2
afimoxifene,estrogen receptor antagonist,PRKCZ,1137,Phase 2
AF38469,sortilin inhibitor,SORT1,1139,Preclinical
AG-1024,insulin growth factor receptor inhibitor,IGF1R,6336,Preclinical
AG-14361,PARP inhibitor,PARP1,8694,Preclinical
AG-490,EGFR inhibitor|JAK inhibitor,EGFR,6319,Preclinical
AG-490,EGFR inhibitor|JAK inhibitor,JAK2,8989,Preclinical
AG-490,EGFR inhibitor|JAK inhibitor,JAK3,134,Preclinical
AG-555,tyrosine kinase inhibitor,CDK2,552,Preclinical
AGI-5198,isocitrate dehydrogenase inhibitor,IDH1,1230,Preclinical
AGI-6780,isocitrate dehydrogenase inhibitor,IDH2,1128,Preclinical
AGM-1470,cell cycle inhibitor,METAP2,1129,Phase 2
agmatine,nitric oxide synthase inhibitor,ADRA2C,1131,Phase 3
agmatine,nitric oxide synthase inhibitor,ASIC3,1132,Phase 3
agmatine,nitric oxide synthase inhibitor,CACNA1B,1814,Phase 3
agmatine,nitric oxide synthase inhibitor,CHRNA1,3350,Phase 3
agmatine,nitric oxide synthase inhibitor,GRIN1,3351,Phase 3
agmatine,nitric oxide synthase inhibitor,KCNJ1,3356,Phase 3
agmatine,nitric oxide synthase inhibitor,NISCH,3357,Phase 3
AGN-192403,imidazoline receptor ligand,NISCH,3359,Preclinical
AGN-194310,retinoid receptor antagonist,RXRA,6865,Phase 3
AGN-194310,retinoid receptor antagonist,RXRB,2554,Phase 3
AGN-194310,retinoid receptor antagonist,RXRG,2557,Phase 3
AGN-195183,retinoid receptor agonist,RARA,2562,Phase 1/Phase 2
agomelatine,melatonin receptor agonist|serotonin receptor antagonist,HTR2A,2550,Launched
agomelatine,melatonin receptor agonist|serotonin receptor antagonist,HTR2B,9568,Launched
agomelatine,melatonin receptor agonist|serotonin receptor antagonist,HTR2C,4318,Launched
agomelatine,melatonin receptor agonist|serotonin receptor antagonist,MTNR1A,2798,Launched
agomelatine,melatonin receptor agonist|serotonin receptor antagonist,MTNR1B,56848,Launched
AH-7614,free fatty acid receptor antagonist,FFAR4,1019,Preclinical
AH11110,adrenergic receptor ligand,ADRA1B,1021,Preclinical
AH6809,prostanoid receptor antagonist,PTGDR,1584,Preclinical
AH6809,prostanoid receptor antagonist,PTGER1,1586,Preclinical
AH6809,prostanoid receptor antagonist,PTGER2,1586,Preclinical
AH6809,prostanoid receptor antagonist,PTGER3,3269,Preclinical
AI-10-49,core binding factor inhibitor,CBFB,3274,Preclinical
AIM-100,tyrosine kinase inhibitor,TNK2,11255,Preclinical
AJ76-(+),dopamine receptor antagonist,DRD2,5724,Preclinical
AJ76-(+),dopamine receptor antagonist,DRD3,8913,Preclinical
AJ76-(+),dopamine receptor antagonist,DRD4,8912,Preclinical
AK-7,SIRT inhibitor,SIRT2,8911,Preclinical
AKBA,lipoxygenase inhibitor,ALOX5,132,Phase 3
AL-8697,p38 MAPK inhibitor,MAPK14,1815,Preclinical
alacepril,angiotensin converting enzyme inhibitor,ACE,596,Launched
alantolactone,apoptosis stimulant|STAT inhibitor,STAT3,598,Preclinical
alaproclate,serotonin receptor antagonist,SLC6A4,599,Phase 2
alarelin,gonadotropin releasing factor hormone receptor antagonist,GNRH1,203068,Launched
albendazole,tubulin polymerization inhibitor,TUBA1A,2100,Launched
albendazole,tubulin polymerization inhibitor,TUBB,5915,Launched
albendazole,tubulin polymerization inhibitor,TUBB4B,2150,Launched
albuterol,adrenergic receptor agonist,ADRB2,10038,Launched
alcaftadine,histamine receptor antagonist,HRH1,5914,Launched
alclofenac,cyclooxygenase inhibitor,PTGS1,5915,Launched
alclometasone-dipropionate,glucocorticoid receptor agonist,CYP3A4,1436,Launched
alclometasone-dipropionate,glucocorticoid receptor agonist,NR3C1,2322,Launched
alclometasone-dipropionate,glucocorticoid receptor agonist,SERPINA6,1133,Launched
alcuronium,muscle relaxant,CHRM1,1812,Launched
alcuronium,muscle relaxant,CHRM2,1813,Launched
alcuronium,muscle relaxant,CHRM3,1814,Launched
alcuronium,muscle relaxant,CHRM4,1815,Launched
alcuronium,muscle relaxant,CHRNA7,1816,Launched
alda-1,aldehyde dehydrogenase activator,ALDH2,2554,Preclinical
aldoxorubicin,topoisomerase inhibitor,TOP2A,2555,Phase 3
alectinib,ALK tyrosine kinase receptor inhibitor,ALK,2556,Launched
alectinib,ALK tyrosine kinase receptor inhibitor,MET,2557,Launched
alendronate,bone resorption inhibitor,ATP6V1A,2558,Launched
alendronate,bone resorption inhibitor,FDPS,2559,Launched
alendronate,bone resorption inhibitor,PTPN4,2560,Launched
alendronate,bone resorption inhibitor,PTPRE,2561,Launched
alendronate,bone resorption inhibitor,PTPRS,2562,Launched
alexidine,phosphatidylglycerophosphatase inhibitor,PTPMT1,2563,Preclinical
alfacalcidol,vitamin D receptor agonist,CYP27B1,2564,Launched
alfacalcidol,vitamin D receptor agonist,VDR,2565,Launched
alfuzosin,adrenergic receptor antagonist,ADRA1A,2566,Launched
alfuzosin,adrenergic receptor antagonist,ADRA1B,2567,Launched
alfuzosin,adrenergic receptor antagonist,ADRA1D,2568,Launched
alfuzosin,adrenergic receptor antagonist,SCN10A,55879,Launched
alfuzosin,adrenergic receptor antagonist,SCN11A,3269,Launched
alfuzosin,adrenergic receptor antagonist,SCN1A,59340,Launched
alfuzosin,adrenergic receptor antagonist,SCN2A,3350,Launched
alfuzosin,adrenergic receptor antagonist,SCN3A,3351,Launched
alfuzosin,adrenergic receptor antagonist,SCN4A,3356,Launched
alfuzosin,adrenergic receptor antagonist,SCN5A,3357,Launched
alfuzosin,adrenergic receptor antagonist,SCN7A,3358,Launched
alfuzosin,adrenergic receptor antagonist,SCN8A,3359,Launched
alfuzosin,adrenergic receptor antagonist,SCN9A,3362,Launched
alimemazine,histamine receptor agonist|histamine receptor antagonist,HRH1,3363,Launched
alisertib,Aurora kinase inhibitor,AURKA,6530,Phase 3
aliskiren-hemifumarate,renin inhibitor,REN,6531,Launched
allicin,cytokine production inhibitor,TRPA1,6532,Phase 2
allicin,cytokine production inhibitor,TRPV1,1557,Phase 2
allopurinol,xanthine oxidase inhibitor,XDH,6564,Launched
allylestrenol,steroidal progestin,ESR1,6565,Launched
allylestrenol,steroidal progestin,PGR,9356,Launched
allylestrenol,steroidal progestin,SLC6A9,2902,Launched
allylisothiocyanate,TRPV agonist,TRPA1,2891,Preclinical
almitrine,neurotransmitter agonist,ATP1A1,2902,Launched
almorexant,orexin receptor antagonist,HCRTR1,2890,Phase 3
almorexant,orexin receptor antagonist,HCRTR2,2891,Phase 3
almotriptan,serotonin receptor agonist,HTR1B,2892,Launched
almotriptan,serotonin receptor agonist,HTR1D,2893,Launched
aloe-emodin,anticancer agent,CASP8,2166,Preclinical
alogliptin,dipeptidyl peptidase inhibitor,DPP4,3356,Launched
alosetron,serotonin receptor antagonist,HTR3A,5742,Withdrawn
aloxistatin,protease inhibitor,CTSG,5743,Phase 3
alpelisib,PI3K inhibitor,PIK3CA,5139,Launched
alpelisib,PI3K inhibitor,PIK3CB,5140,Launched
alpelisib,PI3K inhibitor,PIK3CD,5142,Launched
alpelisib,PI3K inhibitor,PIK3CG,7124,Launched
alpha-asarone,cytochrome P450 inhibitor|HMGCR inhibitor,HMGCR,7153,Preclinical
alpha-linolenic-acid,omega 3 fatty acid stimulant,ELOVL4,7155,Phase 3
alpha-linolenic-acid,omega 3 fatty acid stimulant,FADS1,3757,Phase 3
alpha-linolenic-acid,omega 3 fatty acid stimulant,FADS2,7153,Phase 3
alpha-linolenic-acid,omega 3 fatty acid stimulant,FFAR1,3274,Phase 3
alpha-linolenic-acid,omega 3 fatty acid stimulant,FFAR4,5742,Phase 3
alpha-linolenic-acid,omega 3 fatty acid stimulant,PTGS2,5743,Phase 3
alpha-linolenic-acid,omega 3 fatty acid stimulant,SLC8A1,3815,Phase 3
alpha-linolenic-acid,omega 3 fatty acid stimulant,TRPV1,4233,Phase 3
alpha-methylhistamine-dihydrobromide-(R)-(-),histamine receptor agonist,HRH3,836,Preclinical
alpha-methylhistamine-dihydrobromide-(S)-(+),histamine receptor agonist,HRH3,241,Preclinical
alpha-methylserotonin,serotonin receptor agonist,HTR1D,1268,Preclinical
alpha-methylserotonin,serotonin receptor agonist,HTR1E,1269,Preclinical
alpha-methylserotonin,serotonin receptor agonist,HTR1F,4915,Preclinical
alpha-methylserotonin,serotonin receptor agonist,HTR2A,1071,Preclinical
alpha-methylserotonin,serotonin receptor agonist,HTR2B,1803,Preclinical
alpha-methylserotonin,serotonin receptor agonist,HTR2C,5139,Preclinical
alpha-methylserotonin,serotonin receptor agonist,HTR4,2693,Preclinical
alpidem,benzodiazepine receptor agonist,GABRA1,8913,Withdrawn
alprenolol,adrenergic receptor antagonist,ADRB1,8912,Launched
alprenolol,adrenergic receptor antagonist,ADRB2,8911,Launched
alprostadil,prostanoid receptor agonist,CATSPER1,1268,Launched
alprostadil,prostanoid receptor agonist,CATSPER2,1269,Launched
alprostadil,prostanoid receptor agonist,CATSPER3,2741,Launched
alprostadil,prostanoid receptor agonist,CATSPER4,2841,Launched
alprostadil,prostanoid receptor agonist,PTGDR,9290,Launched
alprostadil,prostanoid receptor agonist,PTGER1,3737,Launched
alprostadil,prostanoid receptor agonist,PTGER2,3777,Launched
alprostadil,prostanoid receptor agonist,PTGER4,51305,Launched
alprostadil,prostanoid receptor agonist,PTGIR,79054,Launched
alrestatin,aldose reductase inhibitor,AKR1B1,7442,Preclinical
altanserin,serotonin receptor antagonist,HTR2A,1588,Phase 2
altinicline,nicotinic receptor agonist,CHRNA4,367,Phase 2
altinicline,nicotinic receptor agonist,CHRNB2,3553,Phase 2
altiratinib,MET inhibitor|VEGFR inhibitor,KDR,3569,Phase 1
altiratinib,MET inhibitor|VEGFR inhibitor,MET,4790,Phase 1
altiratinib,MET inhibitor|VEGFR inhibitor,TEK,4791,Phase 1
altrenogest,progestogen hormone,PGR,7124,Launched
alverine,muscle relaxant,HTR1A,6523,Launched
alvespimycin,HSP inhibitor,HSP90AA1,1813,Phase 2
alvimopan,opioid receptor antagonist,OPRD1,2890,Launched
alvimopan,opioid receptor antagonist,OPRK1,2891,Launched
alvimopan,opioid receptor antagonist,OPRM1,2892,Launched
alvocidib,CDK inhibitor,CDK1,2893,Phase 2
alvocidib,CDK inhibitor,CDK2,3356,Phase 2
alvocidib,CDK inhibitor,CDK4,2677,Phase 2
alvocidib,CDK inhibitor,CDK5,2840,Phase 2
alvocidib,CDK inhibitor,CDK6,3708,Phase 2
alvocidib,CDK inhibitor,CDK7,8883,Phase 2
alvocidib,CDK inhibitor,CDK8,22978,Phase 2
alvocidib,CDK inhibitor,CDK9,5028,Phase 2
alvocidib,CDK inhibitor,EGFR,5032,Phase 2
alvocidib,CDK inhibitor,PYGM,53829,Phase 2
ALX-5407,glycine transporter inhibitor,SLC6A9,5029,Phase 1
AM-1241,cannabinoid receptor agonist,CNR1,5030,Preclinical
AM-1241,cannabinoid receptor agonist,CNR2,5562,Preclinical
AM-24,lipoxygenase inhibitor,ALOX5,6261,Phase 2
AM-251,cannabinoid receptor antagonist,CNR1,6262,Preclinical
AM-251,cannabinoid receptor antagonist,GPR18,6263,Preclinical
AM-251,cannabinoid receptor antagonist,GPR55,291,Preclinical
AM-281,cannabinoid receptor antagonist,CNR1,10188,Preclinical
AM-281,cannabinoid receptor antagonist,CNR2,54795,Preclinical
AM-281,cannabinoid receptor antagonist,GPR55,54822,Preclinical
AM-404,cyclooxygenase inhibitor|FAAH inhibitor|TRPV antagonist,CNR1,1134,Preclinical
AM-404,cyclooxygenase inhibitor|FAAH inhibitor|TRPV antagonist,CNR2,9356,Preclinical
AM-404,cyclooxygenase inhibitor|FAAH inhibitor|TRPV antagonist,FAAH,51094,Preclinical
AM-404,cyclooxygenase inhibitor|FAAH inhibitor|TRPV antagonist,TRPV1,79602,Preclinical
AM-580,retinoid receptor agonist,RARA,4985,Preclinical
AM-630,cannabinoid receptor antagonist,CNR1,1813,Preclinical
AM-630,cannabinoid receptor antagonist,CNR2,3350,Preclinical
AM-92016,potassium channel blocker,GRIN1,148,Preclinical
amantadine,glutamate receptor antagonist,DRD2,3290,Launched
amantadine,glutamate receptor antagonist,GRIN2A,3291,Launched
amantadine,glutamate receptor antagonist,GRIN2B,2915,Launched
amantadine,glutamate receptor antagonist,GRIN2C,2915,Launched
amantadine,glutamate receptor antagonist,GRIN2D,1956,Launched
amantadine,glutamate receptor antagonist,GRIN3A,2064,Launched
ambenonium,cholinesterase inhibitor,ACHE,2066,Launched
ambrisentan,endothelin receptor antagonist,EDNRA,2263,Launched
ambrisentan,endothelin receptor antagonist,EDNRB,2261,Launched
ambroxol,sodium channel blocker,CYP3A4,3791,Launched
amcinonide,glucocorticoid receptor agonist,NR3C1,1813,Launched
AMD-3465,CC chemokine receptor antagonist,CXCR4,1956,Preclinical
AMD11070,CC chemokine receptor antagonist,CCR5,2064,Phase 3
AMD11070,CC chemokine receptor antagonist,CXCR4,2066,Phase 3
amezinium,adrenergic receptor agonist,ADRB2,2099,Launched
amfenac,cyclooxygenase inhibitor,PTGS1,2100,Launched
amfenac,cyclooxygenase inhibitor,PTGS2,2104,Launched
amflutizole,xanthine oxidase inhibitor,XDH,5337,Phase 2
AMG-PERK-44,PERK inhibitor,EIF2AK4,5580,Preclinical
AMG-208,tyrosine kinase inhibitor,MET,5581,Phase 1
AMG-232,MDM inhibitor,MDM2,5588,Phase 2
AMG-319,PI3K inhibitor,PIK3CD,5590,Phase 2
AMG-337,MET inhibitor,MET,6272,Phase 2
AMG-487-(+/-),CC chemokine receptor antagonist,CXCR3,3480,Phase 2
AMG-517,TRPV antagonist,TRPV1,142,Phase 1
AMG-548,MAP kinase inhibitor,MAPK11,1956,Phase 1
AMG-548,MAP kinase inhibitor,MAPK12,3717,Phase 1
AMG-548,MAP kinase inhibitor,MAPK13,3718,Phase 1
AMG-548,MAP kinase inhibitor,MAPK14,1017,Phase 1
AMG-837,free fatty acid receptor agonist,FFAR1,3417,Phase 1
AMG-925,CDK inhibitor|FLT3 inhibitor,CDK4,3418,Phase 1
AMG-925,CDK inhibitor|FLT3 inhibitor,CDK6,10988,Phase 1
AMG-925,CDK inhibitor|FLT3 inhibitor,FLT3,152,Phase 1
AMG-9810,TRPV antagonist,TRPV1,9311,Preclinical
AMG319,PI3K inhibitor,PIK3CD,774,Phase 2
AMG458,MET inhibitor,MET,1134,Preclinical
AMG900,Aurora kinase inhibitor,AURKA,2902,Phase 1
AMG900,Aurora kinase inhibitor,AURKB,3758,Phase 1
AMG900,Aurora kinase inhibitor,AURKC,11188,Phase 1
AMI-1,protein arginine N-methyltransferase inhibitor,PRMT1,11188,Preclinical
amibegron,adrenergic receptor agonist,ADRB3,6256,Phase 3
amiflamine,monoamine oxidase inhibitor,MAOA,6257,Phase 1
amiflamine,monoamine oxidase inhibitor,SLC6A2,6258,Phase 1
amifostine,reducing agent,ALPPL2,5914,Launched
amifostine,reducing agent,ENPP1,3356,Launched
amiloride,sodium channel blocker,AOC1,3357,Launched
amiloride,sodium channel blocker,ASIC1,3358,Launched
amiloride,sodium channel blocker,ASIC2,4543,Launched
amiloride,sodium channel blocker,ASIC3,4544,Launched
amiloride,sodium channel blocker,PKD2,338557,Launched
amiloride,sodium channel blocker,PKD2L1,147,Launched
amiloride,sodium channel blocker,PLAU,5729,Launched
amiloride,sodium channel blocker,SCNN1A,5731,Launched
amiloride,sodium channel blocker,SCNN1B,5732,Launched
amiloride,sodium channel blocker,SCNN1D,5733,Launched
amiloride,sodium channel blocker,SCNN1G,865,Launched
amiloride,sodium channel blocker,SLC9A1,10188,Launched
amiloride,sodium channel blocker,TRPC7,1813,Launched
amiloride,sodium channel blocker,TRPV2,1814,Launched
amineptine,dopamine receptor agonist,SLC6A2,1815,Withdrawn
amineptine,dopamine receptor agonist,SLC6A4,22933,Withdrawn
aminocaproic-acid,plasminogen activator inhibitor,LPA,240,Launched
aminocaproic-acid,plasminogen activator inhibitor,PLAT,1432,Launched
aminocaproic-acid,plasminogen activator inhibitor,PLG,1636,Launched
aminoglutethimide,glucocorticoid receptor antagonist,CYP11A1,6774,Launched
aminoglutethimide,glucocorticoid receptor antagonist,CYP19A1,6532,Launched
aminoguanidine,nitric oxide synthase inhibitor,AKR1B1,2796,Phase 3
aminoguanidine,nitric oxide synthase inhibitor,NOS2,7846,Phase 3
aminoguanidine,nitric oxide synthase inhibitor,TIMP3,203068,Phase 3
aminomethyltransferase,nitric oxide synthase inhibitor,NOS2,10383,Preclinical
aminopentamide,acetylcholine receptor antagonist,CHRM1,154,Launched
aminophylline,adenosine receptor antagonist,ADORA1,3269,Launched
aminophylline,adenosine receptor antagonist,ADORA2A,5742,Launched
aminophylline,adenosine receptor antagonist,ADORA2B,1576,Launched
aminophylline,adenosine receptor antagonist,ADORA3,2908,Launched
aminophylline,adenosine receptor antagonist,HDAC2,3791,Launched
aminophylline,adenosine receptor antagonist,PDE3A,10733,Launched
aminophylline,adenosine receptor antagonist,PDE3B,836,Launched
aminophylline,adenosine receptor antagonist,PDE4A,5027,Launched
aminophylline,adenosine receptor antagonist,PDE4B,50846,Launched
aminophylline,adenosine receptor antagonist,PDE4C,673,Launched
aminophylline,adenosine receptor antagonist,PDE4D,5894,Launched
aminophylline,adenosine receptor antagonist,PDE5A,1786,Launched
aminopterin,dihydrofolate reductase inhibitor,DHFR,1788,Phase 3
aminopterin,dihydrofolate reductase inhibitor,SLC46A1,3269,Phase 3
aminopurvalanol-a,CDK inhibitor|tyrosine kinase inhibitor,CDK1,4860,Preclinical
aminopurvalanol-a,CDK inhibitor|tyrosine kinase inhibitor,CDK2,1813,Preclinical
aminopurvalanol-a,CDK inhibitor|tyrosine kinase inhibitor,CDK5,1814,Preclinical
aminosalicylate,cyclooxygenase inhibitor,ALOX5,5743,Launched
aminosalicylate,cyclooxygenase inhibitor,CHUK,3359,Launched
aminosalicylate,cyclooxygenase inhibitor,PLA2G2E,9177,Launched
aminosalicylate,cyclooxygenase inhibitor,PTGS1,3269,Launched
aminosalicylate,cyclooxygenase inhibitor,PTGS2,3251,Launched
aminothiadiazole,inosine monophosphate dehydrogenase inhibitor,ADORA3,3614,Phase 2
aminothiadiazole,inosine monophosphate dehydrogenase inhibitor,IMPDH1,5471,Phase 2
aminothiazole,cyclin D inhibitor,NOS2,2931,Preclinical
amiodarone,potassium channel blocker,ADRB1,2932,Launched
amiodarone,potassium channel blocker,CACNA1H,5292,Launched
amiodarone,potassium channel blocker,CACNA2D2,11040,Launched
amiodarone,potassium channel blocker,KCNA7,415116,Launched
amiodarone,potassium channel blocker,KCNH2,64805,Launched
amisulpride,dopamine receptor antagonist,DRD2,1137,Launched
amitifadine,serotonin transporter (SERT) inhibitor,SLC6A2,1141,Phase 3
amitifadine,serotonin transporter (SERT) inhibitor,SLC6A3,3716,Phase 3
amitifadine,serotonin transporter (SERT) inhibitor,SLC6A4,3717,Phase 3
amitraz,adrenergic receptor agonist,ADRA1A,3718,Launched
amitraz,adrenergic receptor agonist,ADRA2A,11251,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),ADRA1A,2475,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),ADRA1B,2932,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),ADRA1D,3551,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),ADRA2A,238,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),ADRB1,3480,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),ADRB2,367,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),ADRB3,1956,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),CHRM1,23621,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),CHRM2,6566,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),CHRM3,8694,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),CHRM4,189,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),CHRM5,64902,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),HRH1,211,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),HRH2,212,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),HRH4,570,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),HTR1A,2617,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),HTR1B,2628,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),HTR1D,23464,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),HTR2A,2653,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),HTR2C,2731,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),HTR6,2741,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),HTR7,2742,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),KCNA1,8001,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),KCND2,2743,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),KCND3,10249,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),KCNQ2,92292,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),KCNQ3,219970,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),NTRK1,27232,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),NTRK2,2841,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),OPRD1,222545,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),OPRK1,2902,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),OPRM1,2903,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),SIGMAR1,2904,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),SLC6A2,2905,Launched
amitriptyline,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),SLC6A4,2906,Launched
amlexanox,histamine receptor modulator,FGF1,116444,Launched
amlexanox,histamine receptor modulator,IL3,2937,Launched
amlexanox,histamine receptor modulator,PDE4A,51268,Launched
amlexanox,histamine receptor modulator,PDE4B,6470,Launched
amlexanox,histamine receptor modulator,PDE4C,6472,Launched
amlexanox,histamine receptor modulator,PDE4D,140679,Launched
amlexanox,histamine receptor modulator,S100A12,206358,Launched
amlexanox,histamine receptor modulator,S100A13,9152,Launched
amlodipine,calcium channel blocker,CACNA1C,6536,Launched
amlodipine,calcium channel blocker,CACNA1D,2260,Launched
amlodipine,calcium channel blocker,CACNA1F,2263,Launched
amlodipine,calcium channel blocker,CACNA1S,2261,Launched
amlodipine,calcium channel blocker,CACNA2D1,2264,Launched
ammonium-glycyrrhizinate,thrombin inhibitor,HSD11B1,3480,Launched
ammonium-glycyrrhizinate,thrombin inhibitor,HSD11B2,3791,Launched
ammonium-glycyrrhizinate,thrombin inhibitor,SLCO1B1,3579,Launched
ammonium-glycyrrhizinate,thrombin inhibitor,SLCO1B3,207,Launched
ammonium-lactate,,HCAR1,208,Launched
ammonium-perfluorocaprylate,Pim kinase inhibitor,PIM1,10000,Phase 1
AMN-082,glutamate receptor modulator,GRM7,3757,Preclinical
amodiaquine,histamine receptor agonist,HNMT,329,Launched
amonafide,topoisomerase inhibitor,TOP2A,330,Phase 3
amonafide,topoisomerase inhibitor,TOP2B,331,Phase 3
amoxapine,norepinephrine reputake inhibitor,ADRA1A,5290,Launched
amoxapine,norepinephrine reputake inhibitor,ADRA1B,5291,Launched
amoxapine,norepinephrine reputake inhibitor,ADRA1D,5293,Launched
amoxapine,norepinephrine reputake inhibitor,ADRA2A,5294,Launched
amoxapine,norepinephrine reputake inhibitor,ADRA2B,545,Launched
amoxapine,norepinephrine reputake inhibitor,ADRA2C,2902,Launched
amoxapine,norepinephrine reputake inhibitor,CHRM1,5163,Launched
amoxapine,norepinephrine reputake inhibitor,CHRM2,8694,Launched
amoxapine,norepinephrine reputake inhibitor,CHRM3,1111,Launched
amoxapine,norepinephrine reputake inhibitor,CHRM4,11200,Launched
amoxapine,norepinephrine reputake inhibitor,CHRM5,6850,Launched
amoxapine,norepinephrine reputake inhibitor,DRD1,3091,Launched
amoxapine,norepinephrine reputake inhibitor,DRD2,2099,Launched
amoxapine,norepinephrine reputake inhibitor,DRD3,2100,Launched
amoxapine,norepinephrine reputake inhibitor,DRD4,7762,Launched
amoxapine,norepinephrine reputake inhibitor,DRD5,5328,Launched
amoxapine,norepinephrine reputake inhibitor,GABRA1,7442,Launched
amoxapine,norepinephrine reputake inhibitor,GABRA2,1675,Launched
amoxapine,norepinephrine reputake inhibitor,GABRA3,10280,Launched
amoxapine,norepinephrine reputake inhibitor,GABRA4,10280,Launched
amoxapine,norepinephrine reputake inhibitor,GABRA5,148,Launched
amoxapine,norepinephrine reputake inhibitor,GABRA6,2908,Launched
amoxapine,norepinephrine reputake inhibitor,GABRB1,866,Launched
amoxapine,norepinephrine reputake inhibitor,GABRB2,-,Launched
amoxapine,norepinephrine reputake inhibitor,GABRB3,2908,Launched
amoxapine,norepinephrine reputake inhibitor,GABRD,5663,Launched
amoxapine,norepinephrine reputake inhibitor,GABRE,3065,Launched
amoxapine,norepinephrine reputake inhibitor,GABRG1,83933,Launched
amoxapine,norepinephrine reputake inhibitor,GABRG2,79885,Launched
amoxapine,norepinephrine reputake inhibitor,GABRG3,3066,Launched
amoxapine,norepinephrine reputake inhibitor,GABRP,8841,Launched
amoxapine,norepinephrine reputake inhibitor,GABRQ,9759,Launched
amoxapine,norepinephrine reputake inhibitor,HRH1,10014,Launched
amoxapine,norepinephrine reputake inhibitor,HRH4,10013,Launched
amoxapine,norepinephrine reputake inhibitor,HTR1A,51564,Launched
amoxapine,norepinephrine reputake inhibitor,HTR1B,55869,Launched
amoxapine,norepinephrine reputake inhibitor,HTR2A,9734,Launched
amoxapine,norepinephrine reputake inhibitor,HTR2B,2554,Launched
amoxapine,norepinephrine reputake inhibitor,HTR2C,3359,Launched
amoxapine,norepinephrine reputake inhibitor,HTR3A,9177,Launched
amoxapine,norepinephrine reputake inhibitor,HTR6,47,Launched
amoxapine,norepinephrine reputake inhibitor,HTR7,1636,Launched
amoxapine,norepinephrine reputake inhibitor,SLC6A2,5742,Launched
amoxapine,norepinephrine reputake inhibitor,SLC6A3,5743,Launched
amoxapine,norepinephrine reputake inhibitor,SLC6A4,6557,Launched
amoxicillin,penicillin binding protein inhibitor,CYP2C19,6559,Launched
amoxicillin,penicillin binding protein inhibitor,SLC15A1,3156,Launched
amoxicillin,penicillin binding protein inhibitor,SLC15A2,1543,Launched
amoxicillin,penicillin binding protein inhibitor,SLC22A6,1544,Launched
AMPA-(RS),glutamate receptor agonist,GRIN1,1555,Preclinical
AMPA-(S),glutamate receptor agonist,GRIA2,1576,Preclinical
AMPA-(S),glutamate receptor agonist,GRIN1,2099,Preclinical
ampalex,glutamate receptor agonist,GRIA1,4312,Phase 2
ampalex,glutamate receptor agonist,GRIA2,6822,Phase 2
ampalex,glutamate receptor agonist,GRIA3,54658,Phase 2
ampalex,glutamate receptor agonist,GRIA4,177,Phase 2
amperozide,dopamine receptor antagonist,FAAH,775,Launched
amperozide,dopamine receptor antagonist,HTR2A,8913,Launched
ampiroxicam,cyclooxygenase inhibitor,PTGS1,1813,Launched
ampiroxicam,cyclooxygenase inhibitor,PTGS2,6331,Launched
amrinone,phosphodiesterase inhibitor,PDE3A,1644,Launched
amrinone,phosphodiesterase inhibitor,PDE3B,3249,Launched
amrinone,phosphodiesterase inhibitor,PDE4B,41,Launched
amrinone,phosphodiesterase inhibitor,TNF,9033,Launched
amrubicin,topoisomerase inhibitor,TOP2A,6337,Launched
amrubicin,topoisomerase inhibitor,TOP2B,6338,Launched
amsacrine,topoisomerase inhibitor,KCNH2,6339,Launched
amsacrine,topoisomerase inhibitor,TOP2A,6340,Launched
amthamine,histamine receptor agonist,HRH2,6546,Preclinical
amtolmetin-guacil,cyclooxygenase inhibitor,PTGS1,4363,Launched
amtolmetin-guacil,cyclooxygenase inhibitor,PTGS2,6336,Launched
amuvatinib,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAD51 inhibitor|RET tyrosine kinase inhibitor,KIT,6336,Phase 2
amuvatinib,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAD51 inhibitor|RET tyrosine kinase inhibitor,MET,1610,Phase 2
amygdalin,caspase activator,CASP3,10247,Phase 2
AM679,cannabinoid receptor agonist|lipoxygenase inhibitor,ALOX5AP,25824,Preclinical
AM679,cannabinoid receptor agonist|lipoxygenase inhibitor,CNR1,9367,Preclinical
AM679,cannabinoid receptor agonist|lipoxygenase inhibitor,CNR2,1066,Preclinical
ANA-12,tropomyosin receptor kinase inhibitor,NTRK2,6331,Preclinical
anacetrapib,cholesteryl ester transfer protein inhibitor,CETP,1134,Phase 3
anagliptin,dipeptidyl peptidase inhibitor,DPP4,886,Launched
anagrelide,phosphodiesterase inhibitor,PDE3A,887,Launched
anamorelin,growth hormone secretagogue receptor agonist,GHSR,760,Phase 3
anandamide,cannabinoid receptor agonist,CACNA1G,1128,Phase 2
anandamide,cannabinoid receptor agonist,CACNA1H,3269,Phase 2
anandamide,cannabinoid receptor agonist,CACNA1I,6531,Phase 2
anandamide,cannabinoid receptor agonist,CNR1,3991,Phase 2
anandamide,cannabinoid receptor agonist,CNR2,3269,Phase 2
anandamide,cannabinoid receptor agonist,GLRA1,9132,Phase 2
anandamide,cannabinoid receptor agonist,GPR18,3949,Phase 2
anandamide,cannabinoid receptor agonist,GPR55,3553,Phase 2
anandamide,cannabinoid receptor agonist,KCNA2,7124,Phase 2
anandamide,cannabinoid receptor agonist,KCNK3,351,Phase 2
anandamide,cannabinoid receptor agonist,KCNK9,2554,Phase 2
anandamide,cannabinoid receptor agonist,TRPM8,2566,Phase 2
anandamide,cannabinoid receptor agonist,TRPV1,4313,Phase 2
anastrozole,aromatase inhibitor,CYP19A1,4318,Launched
andarine,androgen receptor modulator,AR,4985,Phase 1
andrographolide,tumor necrosis factor production inhibitor,IL1B,4986,Phase 2
andrographolide,tumor necrosis factor production inhibitor,IL6,4988,Phase 2
andrographolide,tumor necrosis factor production inhibitor,NFKB1,2475,Phase 2
andrographolide,tumor necrosis factor production inhibitor,NFKB2,338442,Phase 2
andrographolide,tumor necrosis factor production inhibitor,TNF,7150,Phase 2
anguidine,protein synthesis inhibitor,SLC5A1,3269,Phase 2
aniracetam,glutamate receptor agonist,DRD2,11255,Launched
aniracetam,glutamate receptor agonist,GRIA1,2908,Launched
aniracetam,glutamate receptor agonist,GRIA2,2908,Launched
aniracetam,glutamate receptor agonist,GRIA3,2908,Launched
aniracetam,glutamate receptor agonist,GRIA4,2908,Launched
aniracetam,glutamate receptor agonist,HTR2A,153,Launched
anisindione,vitamin K antagonist,GGCX,154,Launched
anisodamine,lipid peroxidase inhibitor,ADRA1A,4023,Phase 3
anisomycin,DNA synthesis inhibitor,NHP2L1,153,Preclinical
anisomycin,DNA synthesis inhibitor,RPL10L,154,Preclinical
anisomycin,DNA synthesis inhibitor,RPL11,155,Preclinical
anisomycin,DNA synthesis inhibitor,RPL13A,150,Preclinical
anisomycin,DNA synthesis inhibitor,RPL15,151,Preclinical
anisomycin,DNA synthesis inhibitor,RPL19,152,Preclinical
anisomycin,DNA synthesis inhibitor,RPL23,5150,Preclinical
anisomycin,DNA synthesis inhibitor,RPL23A,27115,Preclinical
anisomycin,DNA synthesis inhibitor,RPL26L1,4986,Preclinical
anisomycin,DNA synthesis inhibitor,RPL3,3354,Preclinical
anisomycin,DNA synthesis inhibitor,RPL37,3355,Preclinical
anisomycin,DNA synthesis inhibitor,RPL8,6261,Preclinical
anisomycin,DNA synthesis inhibitor,RSL24D1,5742,Preclinical
anlotinib,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KDR,5743,Launched
anlotinib,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,PDGFRB,148,Launched
anpirtoline,serotonin receptor agonist,HTR1B,147,Phase 1
ANR-94,adenosine receptor antagonist,ADORA2A,146,Preclinical
antagonist-g,neuropeptide receptor antagonist,MAPK8,150,Phase 1
antalarmin,corticotropin releasing factor receptor antagonist,CRHR1,151,Preclinical
antazoline,antihistamine,HRH1,152,Launched
anthraquinone,CDC inhibitor,CDC25B,1812,Preclinical
antimycin-A,ATP synthase inhibitor,CYCS,1813,Preclinical
AP-18,transient receptor potential channel antagonist,TRPA1,1814,Preclinical
apabetalone,apolipoprotein expression enhancer,BRD3,1815,Phase 3
apafant,platelet activating factor receptor antagonist,PTAFR,1816,Phase 3
apatinib,RET tyrosine kinase inhibitor,CSK,3350,Phase 3
apatinib,RET tyrosine kinase inhibitor,KDR,3351,Phase 3
apatinib,RET tyrosine kinase inhibitor,KIT,3352,Phase 3
apatinib,RET tyrosine kinase inhibitor,RET,3356,Phase 3
APC-100,androgen receptor antagonist|anti-inflammatory agent,AR,3357,Phase 1/Phase 2
APcK-110,KIT inhibitor,KIT,3358,Preclinical
APcK-110,KIT inhibitor,STAT3,3362,Preclinical
APD597,glucose dependent insulinotropic receptor agonist,GPR119,3363,Phase 1
APD668,glucose dependent insulinotropic receptor agonist,GPR119,1813,Phase 1
API-001,sigma receptor antagonist,SIGMAR1,1813,Phase 2
API-1,AKT inhibitor,AKT1,3269,Preclinical
API-1,AKT inhibitor,AKT2,154,Preclinical
API-1,AKT inhibitor,AKT3,1128,Preclinical
apigenin,casein kinase inhibitor|cell proliferation inhibitor,AKR1B1,1129,Preclinical
apigenin,casein kinase inhibitor|cell proliferation inhibitor,AR,1131,Preclinical
apigenin,casein kinase inhibitor|cell proliferation inhibitor,CDK6,1132,Preclinical
apigenin,casein kinase inhibitor|cell proliferation inhibitor,CFTR,1133,Preclinical
apigenin,casein kinase inhibitor|cell proliferation inhibitor,CYP19A1,1022,Preclinical
apigenin,casein kinase inhibitor|cell proliferation inhibitor,CYP1B1,-,Preclinical
apigenin,casein kinase inhibitor|cell proliferation inhibitor,HSD17B1,81930,Preclinical
apixaban,coagulation factor inhibitor,F10,6530,Launched
apocynin,NADPH oxidase inhibitor,NOX4,6531,Phase 1
apoptosis-activator-II,carboxylesterase inhibitor,BCHE,6532,Preclinical
apoptosis-activator-II,carboxylesterase inhibitor,CES1,2550,Preclinical
APR-246,p53 activator,TP53,3673,Phase 3
apraclonidine,adrenergic receptor agonist,ADRA1A,3688,Launched
apraclonidine,adrenergic receptor agonist,ADRA2A,4128,Launched
apraclonidine,adrenergic receptor agonist,ADRA2B,4129,Launched
apraclonidine,adrenergic receptor agonist,ADRA2C,5566,Launched
apratastat,matrix metalloprotease inhibitor|tumor necrosis factor production inhibitor,ADAM17,3269,Phase 2
apratastat,matrix metalloprotease inhibitor|tumor necrosis factor production inhibitor,MMP1,2908,Phase 2
apratastat,matrix metalloprotease inhibitor|tumor necrosis factor production inhibitor,MMP13,2902,Phase 2
apratastat,matrix metalloprotease inhibitor|tumor necrosis factor production inhibitor,MMP9,83933,Phase 2
apremilast,phosphodiesterase inhibitor,PDE4A,10013,Launched
apremilast,phosphodiesterase inhibitor,PDE4B,148,Launched
apremilast,phosphodiesterase inhibitor,PDE4C,1080,Launched
apremilast,phosphodiesterase inhibitor,PDE4D,2859,Launched
aprepitant,tachykinin antagonist,TACR1,6557,Launched
aprindine,voltage-gated sodium channel blocker,CALM1,6558,Launched
aprindine,voltage-gated sodium channel blocker,SCN5A,6560,Launched
aptiganel,glutamate receptor antagonist,GRIN1,57468,Phase 3
APTO-253,krÃ¼ppel-like factor expression enhancer,KLF4,148,Phase 1
APY-29,serine/threonine kinase inhibitor,ERN1,5290,Preclinical
APY0201,phosphoinositide dependent kinase inhibitor,IL12A,5294,Preclinical
APY0201,phosphoinositide dependent kinase inhibitor,IL12B,154,Preclinical
APY0201,phosphoinositide dependent kinase inhibitor,PIKFYVE,153,Preclinical
AP1903,,MTOR,3741,Phase 1/Phase 2
AP26113,ALK tyrosine kinase receptor inhibitor,ALK,6336,Phase 2
AP26113,ALK tyrosine kinase receptor inhibitor,EGFR,153,Phase 2
AQ-RA741,acetylcholine receptor antagonist,CHRM2,154,Preclinical
AR-A014418,glycogen synthase kinase inhibitor,GSK3B,155,Preclinical
AR-C155858,monocarboxylate transporter inhibitor,SLC16A1,6530,Preclinical
AR-C155858,monocarboxylate transporter inhibitor,SLC16A7,6531,Preclinical
AR-12,phosphoinositide dependent kinase inhibitor,PDPK1,1813,Phase 1
AR-42,HDAC inhibitor,HDAC1,3350,Phase 1
arachidonic-acid,cytochrome P450 inhibitor,CLCN2,7174,Phase 1
arachidonic-acid,cytochrome P450 inhibitor,KCNJ4,1812,Phase 1
arachidonic-acid,cytochrome P450 inhibitor,KCNK10,1813,Phase 1
arachidonic-acid,cytochrome P450 inhibitor,KCNK18,1814,Phase 1
arachidonic-acid,cytochrome P450 inhibitor,KCNK2,1815,Phase 1
arachidonic-acid,cytochrome P450 inhibitor,PRKCZ,1816,Phase 1
arachidonic-acid,cytochrome P450 inhibitor,PTGS1,3350,Phase 1
arachidonic-acid,cytochrome P450 inhibitor,TRPC6,3356,Phase 1
arachidonic-acid,cytochrome P450 inhibitor,TRPM2,1137,Phase 1
arbidol,cytochrome P450 inhibitor,CYP3A4,1139,Launched
arbutin,melanin inhibitor,TYR,2554,Phase 2/Phase 3
ARC-239,adrenergic receptor antagonist,ADRA2A,2555,Preclinical
ARC-239,adrenergic receptor antagonist,ADRA2B,2556,Preclinical
ARC-239,adrenergic receptor antagonist,ADRA2C,2557,Preclinical
arctigenin,MEK inhibitor,CHUK,2558,Preclinical
arctigenin,MEK inhibitor,MAP2K1,2559,Preclinical
arcyriaflavin-a,CDK inhibitor,CCND1,2560,Preclinical
arcyriaflavin-a,CDK inhibitor,CDK4,2561,Preclinical
ardeparin,thrombin inhibitor,SERPIND1,2562,Withdrawn
arecaidine-but-2-ynyl-ester,acetylcholine receptor agonist,CHRM2,5742,Preclinical
arecaidine-propargyl-ester,acetylcholine receptor agonist,CHRM1,5743,Preclinical
arecaidine-propargyl-ester,acetylcholine receptor agonist,CHRM2,6197,Preclinical
arecaidine-propargyl-ester,acetylcholine receptor agonist,CHRM3,7157,Preclinical
arecaidine-propargyl-ester,acetylcholine receptor agonist,CHRM4,238,Preclinical
arecoline,acetylcholine receptor agonist,CHRM1,1956,Phase 1
arecoline,acetylcholine receptor agonist,CHRM2,2064,Phase 1
arecoline,acetylcholine receptor agonist,CHRM3,3269,Phase 1
arecoline,acetylcholine receptor agonist,CHRM4,3756,Phase 1
argatroban,thrombin inhibitor,F2,3757,Launched
arglabin,farnesyltransferase inhibitor,FNTA,4843,Launched
arglabin,farnesyltransferase inhibitor,NFKB1,4846,Launched
aripiprazole,serotonin receptor agonist|serotonin receptor antagonist,ADRA1A,3356,Launched
aripiprazole,serotonin receptor agonist|serotonin receptor antagonist,ADRA1B,983,Launched
aripiprazole,serotonin receptor agonist|serotonin receptor antagonist,ADRA2A,1017,Launched
aripiprazole,serotonin receptor agonist|serotonin receptor antagonist,ADRA2B,1019,Launched
aripiprazole,serotonin receptor agonist|serotonin receptor antagonist,ADRA2C,1020,Launched
aripiprazole,serotonin receptor agonist|serotonin receptor antagonist,CHRM1,1021,Launched
aripiprazole,serotonin receptor agonist|serotonin receptor antagonist,CHRM2,1025,Launched
aripiprazole,serotonin receptor agonist|serotonin receptor antagonist,CHRM3,6790,Launched
aripiprazole,serotonin receptor agonist|serotonin receptor antagonist,CHRM4,9212,Launched
aripiprazole,serotonin receptor agonist|serotonin receptor antagonist,CHRM5,3717,Launched
aripiprazole,serotonin receptor agonist|serotonin receptor antagonist,DRD1,3718,Launched
aripiprazole,serotonin receptor agonist|serotonin receptor antagonist,DRD2,27330,Launched
aripiprazole,serotonin receptor agonist|serotonin receptor antagonist,DRD3,9263,Launched
aripiprazole,serotonin receptor agonist|serotonin receptor antagonist,DRD4,1756,Launched
aripiprazole,serotonin receptor agonist|serotonin receptor antagonist,DRD5,5732,Launched
aripiprazole,serotonin receptor agonist|serotonin receptor antagonist,HRH1,153,Launched
aripiprazole,serotonin receptor agonist|serotonin receptor antagonist,HTR1A,154,Launched
aripiprazole,serotonin receptor agonist|serotonin receptor antagonist,HTR1B,4057,Launched
aripiprazole,serotonin receptor agonist|serotonin receptor antagonist,HTR1D,30814,Launched
aripiprazole,serotonin receptor agonist|serotonin receptor antagonist,HTR1E,3717,Launched
aripiprazole,serotonin receptor agonist|serotonin receptor antagonist,HTR2A,6774,Launched
aripiprazole,serotonin receptor agonist|serotonin receptor antagonist,HTR2C,5141,Launched
aripiprazole,serotonin receptor agonist|serotonin receptor antagonist,HTR3A,5142,Launched
aripiprazole,serotonin receptor agonist|serotonin receptor antagonist,HTR6,5143,Launched
aripiprazole,serotonin receptor agonist|serotonin receptor antagonist,HTR7,5144,Launched
arofylline,phosphodiesterase inhibitor,PDE4A,3678,Phase 3
arotinolol,adrenergic receptor antagonist,ADRB3,3685,Launched
ARQ-092,AKT inhibitor,AKT2,3688,Phase 1
ARQ-621,kinesin-like spindle protein inhibitor,KIF11,3690,Phase 1
ARRY-334543,EGFR inhibitor,ERBB2,2902,Phase 2/Phase 3
arsanilic-acid,,LYZ,2903,Phase 1
arsenic-trioxide,apoptosis stimulant,AKT1,2904,Launched
arsenic-trioxide,apoptosis stimulant,CCND1,2905,Launched
arsenic-trioxide,apoptosis stimulant,IKBKB,2906,Launched
arsenic-trioxide,apoptosis stimulant,JUN,116443,Launched
arsenic-trioxide,apoptosis stimulant,MAPK1,116444,Launched
arsenic-trioxide,apoptosis stimulant,MAPK3,6530,Launched
arsenic-trioxide,apoptosis stimulant,TXNRD1,6531,Launched
artemether,antimalarial agent,ATP1A1,6532,Launched
artemisinin,DNA synthesis inhibitor,CYP2B6,196,Launched
arundic-acid,astrocyte modulating agent,PTGS2,1803,Phase 2/Phase 3
arundic-acid,astrocyte modulating agent,S100B,3156,Phase 2/Phase 3
ARV-825,bromodomain inhibitor,BRD4,552,Preclinical
AS-1269574,glucose dependent insulinotropic receptor agonist,GPR119,553,Preclinical
AS-1892802,rho associated kinase inhibitor,ROCK1,554,Preclinical
AS-1949490,SHIP2 phosphatase inhibitor,INPP5D,5021,Preclinical
AS-2034178,free fatty acid receptor agonist,FFAR1,2897,Preclinical
AS-2444697,interleukin inhibitor,IRAK4,1909,Preclinical
AS-252424,PI3K inhibitor,PIK3CG,1128,Preclinical
AS-604850,PI3K inhibitor,PIK3CA,1129,Preclinical
AS-604850,PI3K inhibitor,PIK3CG,1131,Preclinical
AS-703026,MEK inhibitor,MAP2K1,1128,Phase 2
AS-703026,MEK inhibitor,MAP2K2,1129,Phase 2
AS-77,potassium channel blocker,KCNA3,1131,Phase 1
AS-77,potassium channel blocker,KCNA5,1132,Phase 1
AS-77,potassium channel blocker,KCNN4,1133,Phase 1
asaraldehyde,cyclooxygenase inhibitor,PTGS2,207,Preclinical
ASC-J9,androgen receptor enhancer,AR,208,Phase 2
ascomycin,calcineurin inhibitor,FKBP1A,10000,Preclinical
ascorbic-acid,antioxidant,SLC23A1,6093,Launched
ascorbic-acid,antioxidant,SLC23A2,9475,Launched
asenapine,dopamine receptor antagonist|serotonin receptor antagonist,DRD2,23678,Launched
asenapine,dopamine receptor antagonist|serotonin receptor antagonist,HRH1,3320,Launched
asenapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1A,208,Launched
asenapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1B,2932,Launched
asenapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1D,5569,Launched
asenapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1E,5566,Launched
asenapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR2A,3551,Launched
asiatic-acid,apoptosis stimulant,PYGM,25824,Preclinical
asimadoline,opioid receptor agonist,OPRK1,8989,Phase 3
ASP-2535,glycine transporter inhibitor,SLC6A9,6790,Phase 1
aspartame,,TAS1R2,5584,Launched
aspartame,,TRPV1,5168,Launched
aspirin,cyclooxygenase inhibitor,AKR1C1,1956,Launched
aspirin,cyclooxygenase inhibitor,ASIC3,2064,Launched
aspirin,cyclooxygenase inhibitor,EDNRA,6869,Launched
aspirin,cyclooxygenase inhibitor,HSPA5,5663,Launched
aspirin,cyclooxygenase inhibitor,IKBKB,8654,Launched
aspirin,cyclooxygenase inhibitor,NFKB1,1066,Launched
aspirin,cyclooxygenase inhibitor,NFKB2,4352,Launched
aspirin,cyclooxygenase inhibitor,NFKBIA,259249,Launched
aspirin,cyclooxygenase inhibitor,PRKAA1,695,Launched
aspirin,cyclooxygenase inhibitor,PRKAA2,7525,Launched
aspirin,cyclooxygenase inhibitor,PRKAB1,3614,Launched
aspirin,cyclooxygenase inhibitor,PRKAB2,3615,Launched
aspirin,cyclooxygenase inhibitor,PRKAG1,1435,Launched
aspirin,cyclooxygenase inhibitor,PRKAG2,2321,Launched
aspirin,cyclooxygenase inhibitor,PRKAG3,2324,Launched
aspirin,cyclooxygenase inhibitor,PTGS1,148,Launched
aspirin,cyclooxygenase inhibitor,PTGS2,4809,Launched
aspirin,cyclooxygenase inhibitor,RPS6KA3,140801,Launched
aspirin,cyclooxygenase inhibitor,TP53,6135,Launched
ASP3026,ALK tyrosine kinase receptor inhibitor,ALK,23521,Phase 1
AST-1306,EGFR inhibitor,EGFR,6138,Phase 1
AST-1306,EGFR inhibitor,ERBB2,6143,Phase 1
astemizole,histamine receptor antagonist,HRH1,9349,Withdrawn
astemizole,histamine receptor antagonist,KCNH1,6147,Withdrawn
astemizole,histamine receptor antagonist,KCNH2,51121,Withdrawn
asymmetrical-dimethylarginine,nitric oxide synthase inhibitor,NOS2,6122,Phase 1
asymmetrical-dimethylarginine,nitric oxide synthase inhibitor,NOS3,6167,Phase 1
AT-1015,serotonin receptor antagonist,HTR2A,6132,Preclinical
AT-7519,CDK inhibitor,CDK1,51187,Phase 2
AT-7519,CDK inhibitor,CDK2,3791,Phase 2
AT-7519,CDK inhibitor,CDK4,5159,Phase 2
AT-7519,CDK inhibitor,CDK5,3351,Phase 2
AT-7519,CDK inhibitor,CDK6,135,Phase 2
AT-7519,CDK inhibitor,CDK9,5599,Phase 2
AT-9283,Aurora kinase inhibitor|JAK inhibitor,AURKA,1394,Phase 2
AT-9283,Aurora kinase inhibitor|JAK inhibitor,AURKB,3269,Phase 2
AT-9283,Aurora kinase inhibitor|JAK inhibitor,JAK2,994,Phase 2
AT-9283,Aurora kinase inhibitor|JAK inhibitor,JAK3,54205,Phase 2
AT-9283,Aurora kinase inhibitor|JAK inhibitor,RPS6KA6,8989,Phase 2
AT-9283,Aurora kinase inhibitor|JAK inhibitor,STK17A,8019,Phase 2
ataluren,CFTR channel agonist|dystrophin stimulant,DMD,5724,Launched
ATB-346,cyclooxygenase inhibitor,PTGER2,1445,Phase 2
atenolol-(+/-),adrenergic receptor antagonist,ADRB1,3791,Launched
atenolol-(+/-),adrenergic receptor antagonist,ADRB2,3815,Launched
atenolol-(+/-),adrenergic receptor antagonist,LTF,5979,Launched
atenolol-(+/-),adrenergic receptor antagonist,PLA2G2E,367,Launched
atiprimod,JAK inhibitor|STAT inhibitor,JAK2,3815,Phase 2
atiprimod,JAK inhibitor|STAT inhibitor,STAT3,6774,Phase 2
atizoram,phosphodiesterase inhibitor,PDE4A,139760,Phase 2
atizoram,phosphodiesterase inhibitor,PDE4B,139760,Phase 2
atizoram,phosphodiesterase inhibitor,PDE4C,10280,Phase 2
atizoram,phosphodiesterase inhibitor,PDE4D,207,Phase 2
ATN-161,integrin antagonist,ITGA5,208,Phase 2
ATN-161,integrin antagonist,ITGAV,10000,Phase 2
ATN-161,integrin antagonist,ITGB1,231,Phase 2
ATN-161,integrin antagonist,ITGB3,367,Phase 2
atomoxetine,norepinephrine transporter inhibitor,GRIN1,1021,Launched
atomoxetine,norepinephrine transporter inhibitor,GRIN2A,1080,Launched
atomoxetine,norepinephrine transporter inhibitor,GRIN2B,1588,Launched
atomoxetine,norepinephrine transporter inhibitor,GRIN2C,1545,Launched
atomoxetine,norepinephrine transporter inhibitor,GRIN2D,3292,Launched
atomoxetine,norepinephrine transporter inhibitor,GRIN3A,2159,Launched
atomoxetine,norepinephrine transporter inhibitor,GRIN3B,50507,Launched
atomoxetine,norepinephrine transporter inhibitor,SLC6A2,590,Launched
atomoxetine,norepinephrine transporter inhibitor,SLC6A3,1066,Launched
atomoxetine,norepinephrine transporter inhibitor,SLC6A4,7157,Launched
atorvastatin,HMGCR inhibitor,AHR,148,Launched
atorvastatin,HMGCR inhibitor,DPP4,150,Launched
atorvastatin,HMGCR inhibitor,HMGCR,151,Launched
atosiban,oxytocin receptor antagonist,AVPR1A,152,Launched
atosiban,oxytocin receptor antagonist,AVPR1B,6868,Launched
atosiban,oxytocin receptor antagonist,AVPR2,4312,Launched
atosiban,oxytocin receptor antagonist,OXTR,4322,Launched
ATPA,glutamate receptor agonist,GRIK1,4318,Preclinical
atrasentan,endothelin receptor antagonist,EDNRA,5141,Phase 3
atropine,acetylcholine receptor antagonist,CHRM1,5142,Launched
atropine,acetylcholine receptor antagonist,CHRM2,5143,Launched
atropine,acetylcholine receptor antagonist,CHRM3,5144,Launched
atropine-oxide,acetylcholine receptor antagonist,CHRM1,6869,Preclinical
atropine-oxide,acetylcholine receptor antagonist,CHRM2,801,Preclinical
atropine-oxide,acetylcholine receptor antagonist,CHRM3,6331,Preclinical
atropine-oxide,acetylcholine receptor antagonist,CHRM4,2902,Preclinical
atropine-oxide,acetylcholine receptor antagonist,CHRM5,9314,Preclinical
AT13148,protein kinase inhibitor,AKT1,2081,Phase 1
AT13148,protein kinase inhibitor,AKT2,3592,Phase 1
AT13148,protein kinase inhibitor,AKT3,3593,Phase 1
AT13148,protein kinase inhibitor,ROCK1,200576,Phase 1
AT13148,protein kinase inhibitor,ROCK2,2475,Phase 1
AT13148,protein kinase inhibitor,SGK3,238,Phase 1
AT13387,HSP inhibitor,HSP90AA1,1956,Phase 2
AT7867,AKT inhibitor,AKT2,1129,Preclinical
AT7867,AKT inhibitor,GSK3B,2932,Preclinical
AT7867,AKT inhibitor,PKIA,6566,Preclinical
AT7867,AKT inhibitor,PRKACA,9194,Preclinical
auranofin,NFkB pathway inhibitor,IKBKB,5170,Launched
auranofin,NFkB pathway inhibitor,PRDX5,3065,Launched
auranofin,NFkB pathway inhibitor,TRPA1,1181,Launched
aurora-a-inhibitor-i,Aurora kinase inhibitor,AURKA,3761,Preclinical
aurothioglucose,PKC inhibitor,PRKCI,54207,Launched
autotaxin-modulator-1,autotaxin inhibitor,ENPP2,338567,Preclinical
AV-412,protein tyrosine kinase inhibitor,EGFR,3776,Phase 1
AV-412,protein tyrosine kinase inhibitor,ERBB2,5590,Phase 1
AV-608,tachykinin antagonist,TACR1,5742,Phase 2
avagacestat,gamma secretase inhibitor,PSEN1,7225,Phase 2
avanafil,phosphodiesterase inhibitor,PDE5A,7226,Launched
avasimibe,ACAT inhibitor,CES1,1576,Phase 3
avatrombopag,thrombopoietin receptor agonist,MPL,7299,Launched
AVE-0991,angiotensin receptor agonist,MRGPRX1,150,Preclinical
AVL-292,Bruton's tyrosine kinase (BTK) inhibitor,BTK,151,Phase 2
AVL-292,Bruton's tyrosine kinase (BTK) inhibitor,YES1,152,Phase 2
AVN-944,inosine monophosphate dehydrogenase inhibitor,IMPDH1,1147,Phase 2
AVN-944,inosine monophosphate dehydrogenase inhibitor,IMPDH2,5604,Phase 2
axitinib,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,CSF1,595,Launched
axitinib,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FLT1,1019,Launched
axitinib,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FLT4,3053,Launched
axitinib,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KDR,1020,Launched
axitinib,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,PLK4,1021,Launched
AZ-10417808,caspase inhibitor,CASP3,1022,Preclinical
AZ-10606120,purinergic receptor antagonist,P2RX7,1024,Preclinical
AZ-12080282,hedgehog pathway inhibitor,DHH,1025,Preclinical
AZ-628,RAF inhibitor,BRAF,1956,Preclinical
AZ-628,RAF inhibitor,RAF1,5837,Preclinical
azacitidine,DNA methyltransferase inhibitor,DNMT1,6536,Launched
azacitidine,DNA methyltransferase inhibitor,DNMT3A,1268,Launched
azacyclonol,histamine receptor antagonist,HRH1,1269,Preclinical
azaguanine-8,purine antagonist,PNP,240,Preclinical
azaperone,dopamine receptor antagonist,DRD2,1268,Launched
azaperone,dopamine receptor antagonist,DRD3,2841,Launched
azapropazone,cyclooxygenase inhibitor,PTGS2,9290,Withdrawn
azasetron,serotonin receptor antagonist,HTR3A,1268,Launched
azasetron,serotonin receptor antagonist,HTR3B,1269,Launched
azatadine,histamine receptor antagonist,HRH1,9290,Launched
azathioprine,dehydrogenase inhibitor,HPRT1,1268,Launched
azathioprine,dehydrogenase inhibitor,IMPDH1,1269,Launched
azathioprine,dehydrogenase inhibitor,PPAT,2166,Launched
AZD1080,glycogen synthase kinase inhibitor,GSK3A,7442,Phase 1
AZD1080,glycogen synthase kinase inhibitor,GSK3B,5914,Phase 1
AZD1208,Pim kinase inhibitor,PIM1,1268,Phase 1
AZD1208,Pim kinase inhibitor,PIM2,1269,Phase 1
AZD1208,Pim kinase inhibitor,PIM3,2902,Phase 1
AZD1283,purinergic receptor antagonist,P2RY12,1813,Preclinical
AZD1446,acetylcholine receptor agonist,CHRNA4,2903,Phase 2
AZD1446,acetylcholine receptor agonist,CHRNB2,2904,Phase 2
AZD1480,JAK inhibitor,JAK1,2905,Phase 1
AZD1480,JAK inhibitor,JAK2,2906,Phase 1
AZD1480,JAK inhibitor,JAK3,116443,Phase 1
AZD1981,CRTH receptor antagonist,PTGDR2,43,Phase 2
AZD2014,mTOR inhibitor,MTOR,1909,Phase 2
AZD2858,glycogen synthase kinase inhibitor,GSK3B,1910,Preclinical
AZD3264,IKK inhibitor,IKBKB,1576,Preclinical
AZD3463,ALK tyrosine kinase receptor inhibitor|insulin growth factor receptor inhibitor,ALK,2908,Preclinical
AZD3463,ALK tyrosine kinase receptor inhibitor|insulin growth factor receptor inhibitor,IGF1R,7852,Preclinical
AZD3514,androgen receptor modulator,AR,1234,Phase 1
AZD3759,EGFR inhibitor,EGFR,7852,Phase 2/Phase 3
AZD3839,beta-secretase inhibitor,BACE1,154,Phase 1
AZD3965,monocarboxylate transporter inhibitor,SLC16A1,5742,Phase 1
AZD3988,diacylglycerol kinase inhibitor,DGAT1,5743,Preclinical
AZD4282,glutamate receptor antagonist,AGXT,7498,Phase 1
AZD4282,glutamate receptor antagonist,AGXT2,440275,Phase 1
AZD4282,glutamate receptor antagonist,ALAS1,4233,Phase 1
AZD4282,glutamate receptor antagonist,ALAS2,4193,Phase 1
AZD4282,glutamate receptor antagonist,BAAT,5293,Phase 1
AZD4282,glutamate receptor antagonist,GARS,4233,Phase 1
AZD4282,glutamate receptor antagonist,GATM,2833,Phase 1
AZD4282,glutamate receptor antagonist,GCAT,7442,Phase 1
AZD4282,glutamate receptor antagonist,GCSH,5600,Phase 1
AZD4282,glutamate receptor antagonist,GLDC,6300,Phase 1
AZD4282,glutamate receptor antagonist,GLRA1,5603,Phase 1
AZD4282,glutamate receptor antagonist,GLRA2,1432,Phase 1
AZD4282,glutamate receptor antagonist,GLRA3,2864,Phase 1
AZD4282,glutamate receptor antagonist,GLRB,1019,Phase 1
AZD4282,glutamate receptor antagonist,GLYAT,1021,Phase 1
AZD4282,glutamate receptor antagonist,GLYATL1,2322,Phase 1
AZD4282,glutamate receptor antagonist,GLYATL2,7442,Phase 1
AZD4282,glutamate receptor antagonist,GNMT,5293,Phase 1
AZD4282,glutamate receptor antagonist,GPR18,4233,Phase 1
AZD4282,glutamate receptor antagonist,GPRC6A,6790,Phase 1
AZD4282,glutamate receptor antagonist,GRIN1,9212,Phase 1
AZD4282,glutamate receptor antagonist,GRIN2A,6795,Phase 1
AZD4282,glutamate receptor antagonist,GRIN2B,3276,Phase 1
AZD4282,glutamate receptor antagonist,GRIN2C,155,Phase 1
AZD4282,glutamate receptor antagonist,GRIN2D,4128,Phase 1
AZD4282,glutamate receptor antagonist,GRIN3B,6530,Phase 1
AZD4282,glutamate receptor antagonist,GSS,-,Phase 1
AZD4282,glutamate receptor antagonist,PIPOX,5167,Phase 1
AZD4282,glutamate receptor antagonist,SHMT1,26,Phase 1
AZD4282,glutamate receptor antagonist,SHMT2,41,Phase 1
AZD4282,glutamate receptor antagonist,SLC32A1,40,Phase 1
AZD4282,glutamate receptor antagonist,SLC36A1,9311,Phase 1
AZD4282,glutamate receptor antagonist,SLC6A5,5311,Phase 1
AZD4282,glutamate receptor antagonist,SLC6A9,9033,Phase 1
AZD4547,FGFR inhibitor,FGFR1,5328,Phase 2/Phase 3
AZD4547,FGFR inhibitor,FGFR2,6337,Phase 2/Phase 3
AZD4547,FGFR inhibitor,FGFR3,6338,Phase 2/Phase 3
AZD4547,FGFR inhibitor,FGFR4,6339,Phase 2/Phase 3
AZD4547,FGFR inhibitor,IGF1R,6340,Phase 2/Phase 3
AZD4547,FGFR inhibitor,KDR,6548,Phase 2/Phase 3
AZD5069,CC chemokine receptor antagonist,CXCR2,57113,Phase 2
AZD5363,AKT inhibitor,AKT1,51393,Phase 3
AZD5363,AKT inhibitor,AKT2,6530,Phase 3
AZD5363,AKT inhibitor,AKT3,6532,Phase 3
AZD5438,CDK inhibitor,KCNH2,4018,Phase 1
AZD5582,XIAP inhibitor,BIRC2,5327,Preclinical
AZD5582,XIAP inhibitor,BIRC3,5340,Preclinical
AZD5582,XIAP inhibitor,XIAP,1583,Preclinical
AZD6482,PI3K inhibitor,PIK3CA,1588,Phase 1
AZD6482,PI3K inhibitor,PIK3CB,231,Phase 1
AZD6482,PI3K inhibitor,PIK3CD,4843,Phase 1
AZD6482,PI3K inhibitor,PIK3CG,7078,Phase 1
AZD6738,ATR kinase inhibitor,ATR,4843,Phase 2
AZD6765,glutamate receptor antagonist,GRIN1,1128,Phase 2
AZD7545,pyruvate dehydrogenase kinase inhibitor,PDK1,134,Phase 1
AZD7687,diacylglycerol O acyltransferase inhibitor,DGAT1,135,Phase 1
AZD7762,CHK inhibitor,CHEK1,136,Phase 1
AZD7762,CHK inhibitor,CHEK2,140,Phase 1
AZD8055,mTOR inhibitor,MTOR,5599,Phase 1
AZD8186,PI3K inhibitor,PIK3CB,5578,Phase 1
AZD8186,PI3K inhibitor,PIK3CD,6093,Phase 1
AZD8330,MEK inhibitor,MAP3K1,6198,Phase 1
AZD8835,PI3K inhibitor,PIK3CA,23411,Phase 1
AZD8835,PI3K inhibitor,PIK3CD,4842,Phase 1
AZD8931,EGFR inhibitor,EGFR,153,Phase 2
AZD8931,EGFR inhibitor,ERBB2,367,Phase 2
AZD8931,EGFR inhibitor,ERBB3,2099,Phase 2
AZD9272,glutamate receptor antagonist,GRM5,2100,Preclinical
AZD9496,estrogen receptor agonist,ESR1,2104,Phase 1
AZD9668,elastase inhibitor,ELANE,5468,Phase 2
azelaic-acid,tyrosinase inhibitor,AKR1D1,2099,Launched
azelaic-acid,tyrosinase inhibitor,SRD5A2,2100,Launched
azelaic-acid,tyrosinase inhibitor,TYR,4170,Launched
azelastine,histamine receptor antagonist,HRH1,9152,Launched
azeliragon,RAGE receptor antagonist,AGER,6536,Phase 3
azelnidipine,calcium channel blocker,CACNA1C,2147,Launched
azilsartan,angiotensin receptor antagonist,AGTR1,79813,Launched
azilsartan,angiotensin receptor antagonist,AGTR2,10919,Launched
azilsartan-medoxomil,angiotensin receptor antagonist,AGTR1,5607,Launched
azilsartan-medoxomil,angiotensin receptor antagonist,AGTR2,5607,Launched
azimilide,potassium channel blocker,KCNA5,5598,Phase 3
azithromycin,bacterial 50S ribosomal subunit inhibitor,MLNR,79784,Launched
AZM-475271,SRC inhibitor,SRC,4620,Preclinical
azosemide,electrolyte reabsorption inhibitor,SLC12A1,1813,Launched
azosemide,electrolyte reabsorption inhibitor,SLC12A2,3356,Launched
AZ191,DYRK inhibitor,DYRK1B,2264,Preclinical
AZ20,ATR kinase inhibitor,ATR,1269,Preclinical
AZ20,ATR kinase inhibitor,MTOR,729230,Preclinical
AZ505,histone lysine methyltransferase inhibitor,SMYD2,1909,Preclinical
AZ5104,EGFR inhibitor,EGFR,3778,Preclinical
AZ960,JAK inhibitor,JAK2,983,Preclinical
A12B4C3,polynucleotide kinase/phosphatase inhibitor,PNKP,1017,Preclinical
A205804,ICAM1 expression inhibitor,ICAM1,2167,Preclinical
A205804,ICAM1 expression inhibitor,SELE,1147,Preclinical
A61603,adrenergic receptor agonist,ADRA1A,3551,Preclinical
A66,PI3K inhibitor,PIK3CA,1017,Preclinical
A740003,purinergic receptor antagonist,P2RX7,1022,Preclinical
A77636,dopamine receptor agonist,CALY,1025,Preclinical
A922500,diacylglycerol O acyltransferase inhibitor,DGAT1,4157,Preclinical
bacitracin,bacterial cell wall synthesis inhibitor,IDE,207,Launched
baclofen,benzodiazepine receptor agonist,GABBR1,898,Launched
baclofen,benzodiazepine receptor agonist,GABBR2,1017,Launched
baclofen,benzodiazepine receptor agonist,KCTD12,1576,Launched
baclofen,benzodiazepine receptor agonist,KCTD16,2064,Launched
baclofen,benzodiazepine receptor agonist,KCTD8,3480,Launched
BADGE,PPAR receptor antagonist,PPARG,3791,Preclinical
bafetinib,Bcr-Abl kinase inhibitor|LYN tyrosine kinase inhibitor,ABL1,3932,Phase 2
bafetinib,Bcr-Abl kinase inhibitor|LYN tyrosine kinase inhibitor,BCR,5594,Phase 2
bafetinib,Bcr-Abl kinase inhibitor|LYN tyrosine kinase inhibitor,LYN,4233,Phase 2
BAG-956,phosphoinositide dependent kinase inhibitor,PIK3CG,5156,Preclinical
baicalein,lipoxygenase inhibitor,ALOX5,5159,Preclinical
baicalein,lipoxygenase inhibitor,GLO1,3614,Preclinical
baicalein,lipoxygenase inhibitor,PREP,3615,Preclinical
baicalein,lipoxygenase inhibitor,SELL,3683,Preclinical
baicalein,lipoxygenase inhibitor,SELP,3689,Preclinical
baicalein,lipoxygenase inhibitor,TNF,1956,Preclinical
baicalein,lipoxygenase inhibitor,XDH,2064,Preclinical
baicalin,beta glucuronidase inhibitor,PREP,2066,Launched
bakuchiol,DNA polymerase inhibitor,HIF1A,6256,Phase 2
balaglitazone,insulin sensitizer|PPAR receptor partial agonist,PPARG,3383,Phase 3
balicatib,cathepsin inhibitor,CTSK,1956,Phase 2
balsalazide,cyclooxygenase inhibitor,ALOX5,2064,Launched
balsalazide,cyclooxygenase inhibitor,PPARG,2322,Launched
balsalazide,cyclooxygenase inhibitor,PTGS1,3791,Launched
balsalazide,cyclooxygenase inhibitor,PTGS2,207,Launched
bambuterol,adrenergic receptor agonist,ADRB2,3480,Launched
bambuterol,adrenergic receptor agonist,BCHE,558,Launched
BAM7,BAX activator,BAX,10461,Preclinical
BAN-ORL-24,nociceptin/orphanin FQ receptor antagonist,OPRL1,4233,Preclinical
banoxantrone,topoisomerase inhibitor,TOP2A,4486,Phase 1/Phase 2
barasertib,Aurora kinase inhibitor,AURKA,7301,Phase 2/Phase 3
barasertib,Aurora kinase inhibitor,AURKB,3791,Phase 2/Phase 3
barasertib-HQPA,Aurora kinase inhibitor,AURKB,4233,Phase 2/Phase 3
bardoxolone,nuclear factor erythroid derived|like (NRF2) activator,NOS2,6608,Phase 1
bardoxolone,nuclear factor erythroid derived|like (NRF2) activator,PPARG,8317,Phase 1
bardoxolone-methyl,nuclear factor erythroid derived|like (NRF2) activator,PPARG,5292,Phase 3
bardoxolone-methyl,nuclear factor erythroid derived|like (NRF2) activator,STAT3,1902,Phase 3
baricitinib,JAK inhibitor,JAK1,3350,Launched
baricitinib,JAK inhibitor,JAK2,5739,Launched
basimglurant,glutamate receptor antagonist,GRM5,148,Phase 2
batimastat,matrix metalloprotease inhibitor,ADAM28,147,Phase 3
batimastat,matrix metalloprotease inhibitor,ADAMTS5,146,Phase 3
batimastat,matrix metalloprotease inhibitor,MMP12,3350,Phase 3
batimastat,matrix metalloprotease inhibitor,MMP16,4985,Phase 3
batimastat,matrix metalloprotease inhibitor,MMP2,4986,Phase 3
batimastat,matrix metalloprotease inhibitor,MMP8,4988,Phase 3
bavisant,histamine receptor antagonist,HRH3,1215,Phase 2
BAX-channel-blocker,cytochrome C release inhibitor,BAX,5476,Preclinical
BAY-K-8644-(s)-(-),L-type calcium channel activator,CACNA1C,8722,Preclinical
BAY-11-7082,NFkB pathway inhibitor,RELA,1513,Preclinical
BAY-11-7085,NFkB pathway inhibitor,NFKBIA,1514,Preclinical
BAY-41-2272,guanylyl cyclase activator,GUCY1A3,1520,Preclinical
BAY-41-2272,guanylyl cyclase activator,GUCY1B3,5682,Preclinical
BAY-60-6583,adenosine receptor agonist,ADORA1,5683,Preclinical
BAY-60-6583,adenosine receptor agonist,ADORA2A,5684,Preclinical
BAY-60-6583,adenosine receptor agonist,ADORA2B,5685,Preclinical
BAY-60-6583,adenosine receptor agonist,ADORA3,5686,Preclinical
BAY-60-7550,phosphodiesterase inhibitor,PDE2A,5687,Preclinical
BAY-61-3606,SYK inhibitor,SYK,2475,Preclinical
BAY-87-2243,hypoxia inducible factor inhibitor,HIF1A,5291,Phase 1
bazedoxifene,selective estrogen receptor modulator (SERM),ESR1,5293,Launched
bazedoxifene,selective estrogen receptor modulator (SERM),ESR2,4214,Launched
BAZ2-ICR,bromodomain inhibitor,ZNF215,5290,Preclinical
BC-11,urokinase inhibitor,PLAU,5293,Preclinical
BCTC,TRPV antagonist,TRPV1,1956,Preclinical
BCX-1470,complement inhibitor|serine protease inhibitor,CFD,2064,Phase 1
BD-1047,adrenergic receptor antagonist,SIGMAR1,2065,Preclinical
BD-1063,sigma receptor antagonist,SIGMAR1,2915,Preclinical
BE-2254,adrenergic receptor antagonist,ADRA1A,2099,Phase 2
beclomethasone,glucocorticoid receptor agonist,NR3C1,1991,Launched
beclomethasone,glucocorticoid receptor agonist,SERPINA6,6718,Launched
beclomethasone-dipropionate,glucocorticoid receptor agonist,GPR97,6716,Launched
beclomethasone-dipropionate,glucocorticoid receptor agonist,NR3C1,7299,Launched
begacestat,gamma secretase inhibitor,PSEN1,3269,Phase 1
belinostat,HDAC inhibitor,HDAC1,177,Launched
belinostat,HDAC inhibitor,HDAC10,775,Launched
belinostat,HDAC inhibitor,HDAC11,185,Launched
belinostat,HDAC inhibitor,HDAC2,186,Launched
belinostat,HDAC inhibitor,HDAC3,185,Launched
belinostat,HDAC inhibitor,HDAC4,186,Launched
belinostat,HDAC inhibitor,HDAC5,3741,Launched
belinostat,HDAC inhibitor,HDAC6,2862,Launched
belinostat,HDAC inhibitor,HDAC7,6714,Launched
belinostat,HDAC inhibitor,HDAC8,6557,Launched
belinostat,HDAC inhibitor,HDAC9,6558,Launched
bemegride,chemoreceptor agonist,GABRA1,9149,Launched
bemesetron,serotonin receptor antagonist,HTR3A,545,Phase 3
bemesetron,serotonin receptor antagonist,HTR3B,2475,Phase 3
bempedoic-acid,AMPK inhibitor,ACLY,56950,Launched
benazepril,angiotensin converting enzyme inhibitor,ACE,1956,Launched
bendazac,cyclooxygenase inhibitor,PTGS1,3717,Launched
bendazac,cyclooxygenase inhibitor,PTGS2,11284,Launched
bendroflumethiazide,sodium/potassium/chloride transporter inhibitor,SLC12A1,3383,Launched
bendroflumethiazide,sodium/potassium/chloride transporter inhibitor,SLC12A3,6401,Launched
benfluorex,gluconeogenesis inhibitor,HMGCR,148,Withdrawn
benfluralin,,CYP1A1,5290,Phase 3
benfluralin,,CYP1A2,5027,Phase 3
benfluralin,,CYP2B6,50632,Phase 3
benfluralin,,CYP3A4,8694,Phase 3
benfluralin,,ESR1,3416,Phase 3
benfluralin,,MMP1,2550,Phase 3
benfluralin,,SULT2A1,9568,Phase 3
benfluralin,,UGT1A1,115207,Phase 3
benfotiamine,antioxidant,AGER,57528,Launched
benidipine,calcium channel blocker,CACNA1C,386617,Launched
benidipine,calcium channel blocker,CACNA1G,5468,Launched
benperidol,dopamine receptor antagonist,DRD2,25,Launched
benproperine,antitussive,SCN5A,613,Launched
benserazide,DOPA decarboxylase inhibitor,DDC,4067,Launched
bentiromide,,HPN,5294,Launched
benzamil,sodium channel blocker,ASIC1,240,Phase 2
benzamil,sodium channel blocker,PKD2L1,2739,Phase 2
benzamil,sodium channel blocker,SCNN1A,5550,Phase 2
benzamil,sodium channel blocker,SCNN1B,6402,Phase 2
benzamil,sodium channel blocker,SCNN1D,6403,Phase 2
benzamil,sodium channel blocker,SCNN1G,7124,Phase 2
benzamil,sodium channel blocker,SLC8A1,7498,Phase 2
benzbromarone,chloride channel blocker,ABCC1,5550,Launched
benzethonium,sodium channel blocker,SCN10A,3091,Launched
benzocaine,sodium channel blocker,SCN10A,5468,Launched
benzoic-acid,food preservative,DAO,1513,Launched
benzoic-acid,food preservative,HRSP12,240,Launched
benzoic-acid,food preservative,PRDX5,5468,Launched
benzoic-acid,food preservative,RAB9A,5742,Launched
benzoin,,CES1,5743,Preclinical
benzonatate,local anesthetic,SCN5A,154,Launched
benzoquinonium-dibromide,cholinergic receptor antagonist,CHRNA1,590,Preclinical
benzotript,CCK receptor antagonist,CCKAR,581,Phase 1
benzotript,CCK receptor antagonist,CCKBR,4987,Phase 1
benzthiazide,carbonic anhydrase inhibitor,CA2,7153,Launched
benztropine-mesylate,acetylcholine receptor antagonist,CHRM1,6790,Launched
benztropine-mesylate,acetylcholine receptor antagonist,HRH1,9212,Launched
benztropine-mesylate,acetylcholine receptor antagonist,SLC6A3,9212,Launched
benzyl-benzoate,lipase inhibitor,LIPE,4843,Launched
bepotastine,histamine receptor antagonist,HRH1,5468,Launched
bepridil,calcium channel blocker,KCNQ4,5468,Launched
berberine,LDL receptor activator,LDLR,6774,Launched
bergenin,interleukin inhibitor,IL1B,3716,Preclinical
bergenin,interleukin inhibitor,TNF,3717,Preclinical
beta-amyloid-synthesis-inhibitor,beta amyloid synthesis inhibitor,APP,2915,Preclinical
beta-CCB,benzodiazepine receptor ligand,GABRA1,10863,Launched
beta-CCB,benzodiazepine receptor ligand,GABRG2,11096,Launched
beta-elemene,apoptosis stimulant,MMP2,4321,Launched
beta-elemene,apoptosis stimulant,MMP9,4325,Launched
beta-funaltrexamine,opioid receptor antagonist,OPRD1,4313,Preclinical
beta-funaltrexamine,opioid receptor antagonist,OPRK1,4317,Preclinical
beta-funaltrexamine,opioid receptor antagonist,OPRM1,11255,Preclinical
beta-hydroxy-beta-methylbutyrate,protein synthesis stimulant,MTOR,581,Launched
beta-hydroxybutyrate,,HCAR2,775,Phase 1
beta-lapachone,topoisomerase inhibitor,TOP1,5970,Phase 2
betahistine,histamine receptor agonist|histamine receptor antagonist,HRH1,4792,Launched
betahistine,histamine receptor agonist|histamine receptor antagonist,HRH3,-,Launched
betamethasone,glucocorticoid receptor agonist,NR3C1,-,Launched
betamethasone-acetate,glucocorticoid receptor agonist,NR3C1,134,Launched
betamethasone-dipropionate,anti-inflammatory agent,NR3C1,135,Launched
betamethasone-valerate,glucocorticoid receptor agonist,NR3C1,136,Launched
betaxolol,adrenergic receptor antagonist,ADRB1,140,Launched
betaxolol,adrenergic receptor antagonist,ADRB2,5138,Launched
betazole,histamine receptor agonist,HRH2,5688,Launched
bethanechol,acetylcholine receptor agonist,CHRM1,143471,Launched
bethanechol,acetylcholine receptor agonist,CHRM2,5689,Launched
bethanechol,acetylcholine receptor agonist,CHRM3,5699,Launched
bethanechol,acetylcholine receptor agonist,CHRM4,122706,Launched
BETP,GLP receptor positive allosteric modulator,GLP1R,5690,Preclinical
betrixaban,coagulation factor inhibitor,KCNH2,5691,Launched
betulinic-acid,apoptosis stimulant|NFkB pathway inhibitor,GPBAR1,5692,Phase 1/Phase 2
bexarotene,retinoid receptor agonist,RXRA,5693,Launched
bexarotene,retinoid receptor agonist,RXRB,5694,Launched
bexarotene,retinoid receptor agonist,RXRG,5695,Launched
bezafibrate,PPAR receptor agonist,PPARA,5696,Launched
bezafibrate,PPAR receptor agonist,PPARD,5698,Launched
bezafibrate,PPAR receptor agonist,PPARG,5707,Launched
BGT226,PI3K inhibitor,MTOR,5708,Phase 1/Phase 2
BGT226,PI3K inhibitor,PIK3CA,5970,Phase 1/Phase 2
BGT226,PI3K inhibitor,PIK3CB,1909,Phase 1/Phase 2
BGT226,PI3K inhibitor,PIK3CG,1910,Phase 1/Phase 2
BHQ,ATPase inhibitor,ATP2A1,25,Preclinical
BI-D1870,ribosomal protein inhibitor,RPS6KA1,613,Preclinical
BI-D1870,ribosomal protein inhibitor,RPS6KA2,57118,Preclinical
BI-D1870,ribosomal protein inhibitor,RPS6KA3,818,Preclinical
BI-D1870,ribosomal protein inhibitor,RPS6KA6,1017,Preclinical
BI-2536,PLK inhibitor,BRD4,2444,Phase 2
BI-2536,PLK inhibitor,PLK1,2534,Phase 2
BI-2536,PLK inhibitor,PLK2,3055,Phase 2
BI-2536,PLK inhibitor,PLK3,4067,Phase 2
BI-78D3,JNK inhibitor,MAPK8,5604,Preclinical
BI-847325,Aurora kinase inhibitor|MEK inhibitor,AURKA,5605,Phase 1
BI-847325,Aurora kinase inhibitor|MEK inhibitor,AURKB,10746,Phase 1
BI-847325,Aurora kinase inhibitor|MEK inhibitor,AURKC,11183,Phase 1
BI-847325,Aurora kinase inhibitor|MEK inhibitor,MAP2K1,6714,Phase 1
BI-847325,Aurora kinase inhibitor|MEK inhibitor,MAP2K2,6793,Phase 1
BIBN4096,calcitonin antagonist,CALCA,8428,Phase 2
BIBN4096,calcitonin antagonist,CALCRL,6789,Phase 2
BIBN4096,calcitonin antagonist,RAMP1,10188,Phase 2
BIBR-1532,telomerase inhibitor,TERT,7294,Preclinical
BIBU-1361,EGFR inhibitor,EGFR,3350,Preclinical
BIBX-1382,EGFR inhibitor,EGFR,148,Phase 1
BIBX-1382,EGFR inhibitor,ERBB2,146,Phase 1
bicalutamide,androgen receptor antagonist,AR,150,Launched
bicuculline-(+),GABA receptor antagonist,GABRA1,1812,Preclinical
bicuculline-(+),GABA receptor antagonist,GABRA2,1813,Preclinical
bicuculline-(+),GABA receptor antagonist,GABRA3,1814,Preclinical
bicuculline-(+),GABA receptor antagonist,GABRA4,1815,Preclinical
bicuculline-(+),GABA receptor antagonist,GABRA5,3350,Preclinical
bicuculline-(+),GABA receptor antagonist,GABRA6,3357,Preclinical
bicuculline-(+),GABA receptor antagonist,KCNN1,1909,Preclinical
bicyclol,NFkB pathway inhibitor,HSPA1A,1910,Launched
bicyclol,NFkB pathway inhibitor,HSPB1,5898,Launched
bifemelane,acetylcholine release enhancer,MAOA,5899,Launched
bifemelane,acetylcholine release enhancer,MAOB,10919,Launched
BIIB021,HSP inhibitor,HSP90AA1,6195,Phase 2
bilastine,histamine receptor antagonist,HRH1,6196,Launched
bilobalide,GABA receptor modulator,GLRA1,6197,Preclinical
bilobalide,GABA receptor modulator,GLRA2,3832,Preclinical
bilobalide,GABA receptor modulator,GLRB,375,Preclinical
bilobalide,GABA receptor modulator,HTR3A,9266,Preclinical
bilobalide,GABA receptor modulator,HTR3B,4157,Preclinical
bimatoprost,prostanoid receptor agonist,AKR1C3,4158,Launched
bimatoprost,prostanoid receptor agonist,PTGER1,4159,Launched
bimatoprost,prostanoid receptor agonist,PTGER3,4160,Launched
bimatoprost,prostanoid receptor agonist,PTGFR,4161,Launched
BIMU-8,serotonin receptor agonist,HTR4,1723,Preclinical
BINA,glutamate receptor positive allosteric modulator,GRM2,2554,Preclinical
bindarit,NFkB pathway inhibitor,CCL2,2555,Phase 2
bindarit,NFkB pathway inhibitor,CCL7,2556,Phase 2
bindarit,NFkB pathway inhibitor,CCL8,2557,Phase 2
binimetinib,MEK inhibitor,MAP2K1,2558,Launched
binimetinib,MEK inhibitor,MAP2K2,2559,Launched
BIO-1211,integrin antagonist,ITGA4,476,Phase 2
BIO-1211,integrin antagonist,ITGB1,1813,Phase 2
BIO-5192,integrin inhibitor,ITGA4,595,Preclinical
BIO-5192,integrin inhibitor,ITGB1,238,Preclinical
biotin,vitamin B,ACACA,1956,Launched
biotin,vitamin B,ACACB,150,Launched
biotin,vitamin B,HLCS,151,Launched
biotin,vitamin B,MCCC1,152,Launched
biotin,vitamin B,MCCC2,759,Launched
biotin,vitamin B,PC,771,Launched
biotin,vitamin B,PCCA,23632,Launched
biotin,vitamin B,PCCB,760,Launched
biotin,vitamin B,SLC5A6,762,Launched
bipenamol,dipeptidyl peptidase inhibitor,CTSC,763,Phase 2
biperiden,acetylcholine receptor antagonist,CHRM1,766,Launched
biperiden,acetylcholine receptor antagonist,CHRM2,1576,Launched
biperiden,acetylcholine receptor antagonist,CHRM3,2260,Launched
biperiden,acetylcholine receptor antagonist,CHRM4,2321,Launched
biperiden,acetylcholine receptor antagonist,CHRM5,3757,Launched
birinapant,XIAP inhibitor,BIRC2,3791,Phase 2
birinapant,XIAP inhibitor,XIAP,2261,Phase 2
BIRT-377,lymphocyte function-associated antigen negative modulator,ICAM1,3350,Preclinical
bis(maltolato)oxovanadium(IV),tyrosine phosphatase inhibitor,PTPN1,3351,Phase 2
bisindolylmaleimide-IX,PKC inhibitor,AKT1,3352,Preclinical
bisindolylmaleimide-IX,PKC inhibitor,GSK3B,3354,Preclinical
bisindolylmaleimide-IX,PKC inhibitor,LCK,3355,Preclinical
bisindolylmaleimide-IX,PKC inhibitor,MAPK1,3356,Preclinical
bisindolylmaleimide-IX,PKC inhibitor,MAPK11,3357,Preclinical
bisindolylmaleimide-IX,PKC inhibitor,MAPK12,3358,Preclinical
bisindolylmaleimide-IX,PKC inhibitor,MAPK14,3362,Preclinical
bisindolylmaleimide-IX,PKC inhibitor,MAPK8,866,Preclinical
bisindolylmaleimide-IX,PKC inhibitor,PRKCA,1128,Preclinical
bisindolylmaleimide-IX,PKC inhibitor,ROCK1,1129,Preclinical
bisindolylmaleimide-IX,PKC inhibitor,RPS6KB1,1131,Preclinical
bisindolylmaleimide-IX,PKC inhibitor,SIRT1,1132,Preclinical
bismuth-subgallate,nitric oxide synthase inhibitor,NOS1,1139,Launched
bisoprolol,adrenergic receptor antagonist,ADRB1,217,Launched
bisphenol-A,synthetic estrogen,AR,7153,Phase 1
bisphenol-A,synthetic estrogen,ESR1,238,Phase 1
bisphenol-A,synthetic estrogen,ESR2,4233,Phase 1
bisphenol-A,synthetic estrogen,ESRRG,523,Phase 1
bisphenol-A,synthetic estrogen,PPARG,2224,Phase 1
bithionol,autotaxin inhibitor,ESR1,5775,Withdrawn
bithionol,autotaxin inhibitor,ESR2,5791,Withdrawn
bithionol,autotaxin inhibitor,MCL1,5802,Withdrawn
bitopertin,glycine transporter inhibitor,SLC6A5,114971,Phase 3
bitopertin,glycine transporter inhibitor,SLC6A9,1594,Phase 3
bivalirudin,thrombin inhibitor,F2,7421,Launched
BIX-01294,histone lysine methyltransferase inhibitor,EHMT1,148,Preclinical
BIX-01294,histone lysine methyltransferase inhibitor,EHMT2,147,Preclinical
BIX-02188,MEK inhibitor,MAP2K5,146,Preclinical
BIX-02189,MEK inhibitor,MAP2K5,6336,Preclinical
BIX-02189,MEK inhibitor,MAPK7,11280,Preclinical
blebbistatin-(+/-),ATPase inhibitor,MYH14,6323,Preclinical
blebbistatin-(+/-),ATPase inhibitor,MYH2,6326,Preclinical
blonanserin,dopamine receptor antagonist|serotonin receptor antagonist,DRD2,6328,Launched
blonanserin,dopamine receptor antagonist|serotonin receptor antagonist,HTR2A,6329,Launched
BLU9931,FGFR inhibitor,FGFR4,6331,Preclinical
BML-190,cannabinoid receptor inverse agonist,CNR2,6332,Preclinical
BMS-CCR2-22,CC chemokine receptor antagonist,CCR2,6334,Preclinical
BMS-182874,endothelin receptor antagonist,EDNRA,6335,Phase 2
BMS-191011,potassium channel activator,KCNMA1,3269,Preclinical
BMS-265246,CDK inhibitor,CDK1,6790,Preclinical
BMS-265246,CDK inhibitor,CDK2,5972,Preclinical
BMS-309403,fatty acid binding protein inhibitor,FABP4,8989,Preclinical
BMS-345541,IKK inhibitor,CHUK,7442,Preclinical
BMS-345541,IKK inhibitor,IKBKB,7498,Preclinical
BMS-387032,CDK inhibitor|cell cycle inhibitor|MCL1 inhibitor,CDK2,2099,Phase 1
BMS-387032,CDK inhibitor|cell cycle inhibitor|MCL1 inhibitor,CDK7,5241,Phase 1
BMS-387032,CDK inhibitor|cell cycle inhibitor|MCL1 inhibitor,CDK9,6536,Phase 1
BMS-470539,melanocortin receptor agonist,MC1R,8989,Preclinical
BMS-536924,IGF-1 inhibitor,AKT1,476,Preclinical
BMS-536924,IGF-1 inhibitor,CCNE1,3061,Preclinical
BMS-536924,IGF-1 inhibitor,CDK2,3062,Preclinical
BMS-536924,IGF-1 inhibitor,CYP3A4,3351,Preclinical
BMS-536924,IGF-1 inhibitor,ERBB2,3352,Preclinical
BMS-536924,IGF-1 inhibitor,IGF1R,841,Preclinical
BMS-536924,IGF-1 inhibitor,KDR,1803,Preclinical
BMS-536924,IGF-1 inhibitor,LCK,3359,Preclinical
BMS-536924,IGF-1 inhibitor,MAPK1,1511,Preclinical
BMS-536924,IGF-1 inhibitor,MET,5290,Preclinical
BMS-536924,IGF-1 inhibitor,PDGFRA,5291,Preclinical
BMS-536924,IGF-1 inhibitor,PDGFRB,5293,Preclinical
BMS-566419,inosine monophosphate dehydrogenase inhibitor,IMPDH1,5294,Preclinical
BMS-566419,inosine monophosphate dehydrogenase inhibitor,IMPDH2,3156,Preclinical
BMS-587101,integrin antagonist,ITGAL,6785,Phase 2
BMS-587101,integrin antagonist,ITGB2,3992,Phase 2
BMS-599626,EGFR inhibitor|protein tyrosine kinase inhibitor,EGFR,9415,Phase 1
BMS-599626,EGFR inhibitor|protein tyrosine kinase inhibitor,ERBB2,2864,Phase 1
BMS-599626,EGFR inhibitor|protein tyrosine kinase inhibitor,ERBB4,338557,Phase 1
BMS-649,retinoid receptor agonist,RXRA,5743,Preclinical
BMS-688521,ICAM1 antagonist|leukocyte function-associated antigen receptor antagonist,ICAM1,6546,Preclinical
BMS-690514,EGFR inhibitor|VEGFR inhibitor,EGFR,7442,Phase 2
BMS-690514,EGFR inhibitor|VEGFR inhibitor,ERBB2,11255,Phase 2
BMS-690514,EGFR inhibitor|VEGFR inhibitor,FLT3,11255,Phase 2
BMS-690514,EGFR inhibitor|VEGFR inhibitor,KDR,3352,Phase 2
BMS-754807,IGF-1 inhibitor,AKT1,3354,Phase 2
BMS-754807,IGF-1 inhibitor,IGF1R,3355,Phase 2
BMS-777607,AXL kinase inhibitor|c-Met inhibitor|FLT3 inhibitor|hepatocyte growth factor receptor inhibitor|macrophage migration inhibiting factor inhibitor|tyrosine kinase inhibitor,AXL,3356,Phase 1/Phase 2
BMS-777607,AXL kinase inhibitor|c-Met inhibitor|FLT3 inhibitor|hepatocyte growth factor receptor inhibitor|macrophage migration inhibiting factor inhibitor|tyrosine kinase inhibitor,MERTK,3357,Phase 1/Phase 2
BMS-777607,AXL kinase inhibitor|c-Met inhibitor|FLT3 inhibitor|hepatocyte growth factor receptor inhibitor|macrophage migration inhibiting factor inhibitor|tyrosine kinase inhibitor,MET,3358,Phase 1/Phase 2
BMS-777607,AXL kinase inhibitor|c-Met inhibitor|FLT3 inhibitor|hepatocyte growth factor receptor inhibitor|macrophage migration inhibiting factor inhibitor|tyrosine kinase inhibitor,MST1R,3360,Phase 1/Phase 2
BMS-777607,AXL kinase inhibitor|c-Met inhibitor|FLT3 inhibitor|hepatocyte growth factor receptor inhibitor|macrophage migration inhibiting factor inhibitor|tyrosine kinase inhibitor,TYRO3,2554,Phase 1/Phase 2
BMS-817378,c-Met inhibitor|VEGFR inhibitor,KDR,153,Phase 1
BMS-817378,c-Met inhibitor|VEGFR inhibitor,MET,154,Phase 1
BMS-833923,smoothened receptor antagonist,SMO,117144,Phase 2
BMS-863233,CDC inhibitor,CDC7,117155,Phase 1/Phase 2
BMS-863233,CDC inhibitor,PIM1,347732,Phase 1/Phase 2
BMS-986020,lysophosphatidic acid receptor antagonist,LPAR1,378807,Phase 2
BMY-14802,sigma receptor antagonist,HTR1A,5729,Phase 2
BMY-45778,IP1 prostacyclin receptor agonist,PTGIR,5731,Preclinical
BMY-7378,adrenergic receptor antagonist|serotonin receptor antagonist,ADRA1A,5732,Preclinical
BMY-7378,adrenergic receptor antagonist|serotonin receptor antagonist,ADRA1B,5734,Preclinical
BMY-7378,adrenergic receptor antagonist|serotonin receptor antagonist,ADRA1D,5739,Preclinical
BMY-7378,adrenergic receptor antagonist|serotonin receptor antagonist,HTR1A,231,Preclinical
BNTX,opioid receptor antagonist,OPRD1,3356,Preclinical
BNTX,opioid receptor antagonist,OPRK1,1137,Preclinical
BNTX,opioid receptor antagonist,OPRM1,1141,Preclinical
boceprevir,HCV inhibitor,CMA1,3791,Launched
boceprevir,HCV inhibitor,CTSA,4233,Launched
boceprevir,HCV inhibitor,CTSF,7010,Launched
boceprevir,HCV inhibitor,CTSK,5241,Launched
boceprevir,HCV inhibitor,CTSL,3350,Launched
boceprevir,HCV inhibitor,CTSS,3320,Launched
bortezomib,NFkB pathway inhibitor|proteasome inhibitor,PSMA1,4985,Launched
bortezomib,NFkB pathway inhibitor|proteasome inhibitor,PSMA2,4986,Launched
bortezomib,NFkB pathway inhibitor|proteasome inhibitor,PSMA3,4988,Launched
bortezomib,NFkB pathway inhibitor|proteasome inhibitor,PSMA4,983,Launched
bortezomib,NFkB pathway inhibitor|proteasome inhibitor,PSMA5,1017,Launched
bortezomib,NFkB pathway inhibitor|proteasome inhibitor,PSMA6,1019,Launched
bortezomib,NFkB pathway inhibitor|proteasome inhibitor,PSMA7,3274,Launched
bortezomib,NFkB pathway inhibitor|proteasome inhibitor,PSMA8,1128,Launched
bortezomib,NFkB pathway inhibitor|proteasome inhibitor,PSMB1,1129,Launched
bortezomib,NFkB pathway inhibitor|proteasome inhibitor,PSMB10,1131,Launched
bortezomib,NFkB pathway inhibitor|proteasome inhibitor,PSMB11,1132,Launched
bortezomib,NFkB pathway inhibitor|proteasome inhibitor,PSMB2,2740,Launched
bortezomib,NFkB pathway inhibitor|proteasome inhibitor,PSMB3,3757,Launched
bortezomib,NFkB pathway inhibitor|proteasome inhibitor,PSMB4,151306,Launched
bortezomib,NFkB pathway inhibitor|proteasome inhibitor,PSMB5,6256,Launched
bortezomib,NFkB pathway inhibitor|proteasome inhibitor,PSMB6,6257,Launched
bortezomib,NFkB pathway inhibitor|proteasome inhibitor,PSMB7,6258,Launched
bortezomib,NFkB pathway inhibitor|proteasome inhibitor,PSMB8,5465,Launched
bortezomib,NFkB pathway inhibitor|proteasome inhibitor,PSMB9,5467,Launched
bortezomib,NFkB pathway inhibitor|proteasome inhibitor,PSMD1,5468,Launched
bortezomib,NFkB pathway inhibitor|proteasome inhibitor,PSMD2,2475,Launched
bortezomib,NFkB pathway inhibitor|proteasome inhibitor,RELA,5290,Launched
bosentan,endothelin receptor antagonist,EDNRA,5291,Launched
bosentan,endothelin receptor antagonist,EDNRB,5294,Launched
bosutinib,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,ABL1,487,Launched
bosutinib,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,BCR,6195,Launched
bosutinib,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,CAMK1D,6196,Launched
bosutinib,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,CAMK2G,6197,Launched
bosutinib,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,CDK2,27330,Launched
bosutinib,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,FRK,23476,Launched
bosutinib,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,FYN,5347,Launched
bosutinib,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,HCK,10769,Launched
bosutinib,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,LYN,1263,Launched
bosutinib,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,MAP2K1,5599,Launched
bosutinib,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,MAP2K2,6790,Launched
bosutinib,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,MAP3K2,9212,Launched
bosutinib,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,MAP4K5,6795,Launched
bosutinib,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,SRC,5604,Launched
bosutinib,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,STK10,5605,Launched
bosutinib,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,STK24,796,Launched
bosutinib,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,STK4,10203,Launched
bosutinib,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,TNK2,10267,Launched
bosutinib,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,TXK,7015,Launched
BP-554,serotonin receptor agonist,HTR1A,1956,Preclinical
BP-897,dopamine receptor agonist,ADRA1A,1956,Phase 2
BP-897,dopamine receptor agonist,ADRA1D,2064,Phase 2
BP-897,dopamine receptor agonist,ADRA2A,367,Phase 2
BP-897,dopamine receptor agonist,DRD1,2554,Phase 2
BP-897,dopamine receptor agonist,DRD2,2555,Phase 2
BP-897,dopamine receptor agonist,DRD3,2556,Phase 2
BP-897,dopamine receptor agonist,DRD4,2557,Phase 2
BP-897,dopamine receptor agonist,HTR1A,2558,Phase 2
BP-897,dopamine receptor agonist,HTR2B,2559,Phase 2
BQ-123,endothelin receptor antagonist,EDNRA,3780,Phase 2
BQ-788,endothelin receptor antagonist,EDNRB,3303,Phase 1
BQU57,Ras GTPase inhibitor,RALA,3315,Preclinical
BQU57,Ras GTPase inhibitor,RALB,4128,Preclinical
BRD4770,histone lysine methyltransferase inhibitor,EHMT2,4129,Preclinical
BRD7389,ribosomal protein inhibitor,RPS6KA1,3320,Preclinical
BRD7389,ribosomal protein inhibitor,RPS6KA2,3269,Preclinical
BRD7389,ribosomal protein inhibitor,RPS6KA3,2741,Preclinical
BRD9876,kinesin inhibitor,KIF11,2742,Preclinical
brefeldin-A,protein synthesis inhibitor,ARF1,2743,Preclinical
brefeldin-A,protein synthesis inhibitor,CYTH2,3359,Preclinical
bremelanotide,melanocortin receptor agonist,MC1R,9177,Launched
bremelanotide,melanocortin receptor agonist,MC2R,8644,Launched
bremelanotide,melanocortin receptor agonist,MC3R,5731,Launched
bremelanotide,melanocortin receptor agonist,MC4R,5733,Launched
bremelanotide,melanocortin receptor agonist,MC5R,5737,Launched
brequinar,dihydroorotate dehydrogenase inhibitor,DHODH,3360,Phase 2
bretazenil,GABA benzodiazepine site receptor partial agonist,GABRA1,2912,Phase 2
bretazenil,GABA benzodiazepine site receptor partial agonist,GABRA2,6347,Phase 2
bretazenil,GABA benzodiazepine site receptor partial agonist,GABRA3,6354,Phase 2
bretazenil,GABA benzodiazepine site receptor partial agonist,GABRA4,6355,Phase 2
bretazenil,GABA benzodiazepine site receptor partial agonist,GABRA5,5604,Phase 2
bretazenil,GABA benzodiazepine site receptor partial agonist,GABRA6,5605,Phase 2
bretylium,norepinephrine inhibitor,ATP1A1,3676,Launched
brexpiprazole,dopamine receptor partial agonist,DRD2,3688,Launched
briciclib,cyclin D inhibitor,CCND1,3676,Phase 1
brigatinib,ALK tyrosine kinase receptor inhibitor|EGFR inhibitor,ALK,3688,Launched
brigatinib,ALK tyrosine kinase receptor inhibitor|EGFR inhibitor,EGFR,31,Launched
brimonidine,adrenergic receptor agonist,ADRA2A,32,Launched
brimonidine,adrenergic receptor agonist,ADRA2B,3141,Launched
brimonidine,adrenergic receptor agonist,ADRA2C,56922,Launched
brinzolamide,carbonic anhydrase inhibitor,CA1,64087,Launched
brinzolamide,carbonic anhydrase inhibitor,CA12,5091,Launched
brinzolamide,carbonic anhydrase inhibitor,CA14,5095,Launched
brinzolamide,carbonic anhydrase inhibitor,CA2,5096,Launched
brinzolamide,carbonic anhydrase inhibitor,CA4,8884,Launched
brinzolamide,carbonic anhydrase inhibitor,CA5A,1075,Launched
brinzolamide,carbonic anhydrase inhibitor,CA7,1128,Launched
brivanib,FGFR inhibitor|VEGFR inhibitor,CYP3A4,1129,Phase 3
brivanib,FGFR inhibitor|VEGFR inhibitor,FGFR1,1131,Phase 3
brivanib,FGFR inhibitor|VEGFR inhibitor,FLT1,1132,Phase 3
brivanib,FGFR inhibitor|VEGFR inhibitor,KCNH2,1133,Phase 3
brivanib,FGFR inhibitor|VEGFR inhibitor,KDR,329,Phase 3
brivanib-alaninate,FGFR inhibitor|VEGFR inhibitor,FGFR3,331,Phase 3
BRL-15572,serotonin receptor antagonist,HTR1A,3383,Preclinical
BRL-15572,serotonin receptor antagonist,HTR1B,5770,Preclinical
BRL-15572,serotonin receptor antagonist,HTR1D,207,Preclinical
BRL-15572,serotonin receptor antagonist,HTR1E,2932,Preclinical
BRL-15572,serotonin receptor antagonist,HTR1F,3932,Preclinical
BRL-15572,serotonin receptor antagonist,HTR2A,5594,Preclinical
BRL-15572,serotonin receptor antagonist,HTR2B,5600,Preclinical
BRL-15572,serotonin receptor antagonist,HTR2C,6300,Preclinical
BRL-15572,serotonin receptor antagonist,HTR6,1432,Preclinical
BRL-26314,cholesterol inhibitor,LPL,6257,Phase 1
BRL-37344,adrenergic receptor agonist,ADRB1,6258,Phase 2
BRL-37344,adrenergic receptor agonist,ADRB2,6774,Phase 2
BRL-37344,adrenergic receptor agonist,ADRB3,1503,Phase 2
BRL-44408,adrenergic receptor antagonist,ADRA2A,7150,Preclinical
BRL-44408,adrenergic receptor antagonist,ADRA2B,7153,Preclinical
BRL-44408,adrenergic receptor antagonist,ADRA2C,1128,Preclinical
BRL-50481,phosphodiesterase inhibitor,PDE7A,1129,Preclinical
BRL-50481,phosphodiesterase inhibitor,PDE7B,1131,Preclinical
BRL-52537,opioid receptor agonist,OPRK1,1132,Preclinical
BRL-54443,serotonin receptor agonist,HTR1E,1133,Preclinical
BRL-54443,serotonin receptor agonist,HTR1F,3091,Preclinical
brolitene,muscle relaxant,RYR1,3091,Launched
bromfenac,cyclooxygenase inhibitor,PTGS1,3269,Withdrawn
bromfenac,cyclooxygenase inhibitor,PTGS2,1909,Withdrawn
bromocriptine,dopamine receptor agonist,ADRA1A,1910,Launched
bromocriptine,dopamine receptor agonist,ADRA1B,3061,Launched
bromocriptine,dopamine receptor agonist,ADRA1D,3062,Launched
bromocriptine,dopamine receptor agonist,ADRA2A,3791,Launched
bromocriptine,dopamine receptor agonist,ADRA2B,7010,Launched
bromocriptine,dopamine receptor agonist,ADRA2C,3065,Launched
bromocriptine,dopamine receptor agonist,DRD1,3066,Launched
bromocriptine,dopamine receptor agonist,DRD2,8841,Launched
bromocriptine,dopamine receptor agonist,DRD3,10013,Launched
bromocriptine,dopamine receptor agonist,DRD4,55869,Launched
bromocriptine,dopamine receptor agonist,DRD5,4860,Launched
bromocriptine,dopamine receptor agonist,HTR1A,231,Launched
bromocriptine,dopamine receptor agonist,HTR1B,5914,Launched
bromocriptine,dopamine receptor agonist,HTR1D,5915,Launched
bromocriptine,dopamine receptor agonist,HTR2A,5916,Launched
bromocriptine,dopamine receptor agonist,HTR2B,6256,Launched
bromocriptine,dopamine receptor agonist,HTR2C,6257,Launched
bromocriptine,dopamine receptor agonist,HTR6,6258,Launched
bromocriptine,dopamine receptor agonist,HTR7,231,Launched
bromopride,dopamine receptor antagonist,DRD2,2821,Launched
bromperidol,dopamine receptor antagonist,DRD2,3098,Launched
brompheniramine,histamine receptor antagonist,HRH1,4074,Launched
broxaterol,adrenergic receptor agonist,ADRB2,5837,Phase 3
brucine,glycine receptor antagonist,CHRM1,1234,Preclinical
brucine,glycine receptor antagonist,CHRM2,5915,Preclinical
brucine,glycine receptor antagonist,CHRM3,5916,Preclinical
brucine,glycine receptor antagonist,CHRM4,3350,Preclinical
brucine,glycine receptor antagonist,CHRM5,3356,Preclinical
BS-181,CDK inhibitor,CDK7,32,Preclinical
BTB06584,ATPase inhibitor,ATP5F1,52,Preclinical
BTB1,mitotic kinesin inhibitor,KIF18A,353,Preclinical
BTS-54505,dopamine reuptake inhibitor,SLC6A2,4507,Withdrawn
BTS-54505,dopamine reuptake inhibitor,SLC6A3,55825,Withdrawn
BTS-54505,dopamine reuptake inhibitor,SLC6A4,6733,Withdrawn
BTS-72664,GABA receptor antagonist,GABBR1,134,Phase 1
BTT-3033,integrin inhibitor,ITGA2,135,Preclinical
BTT-3033,integrin inhibitor,ITGB1,136,Preclinical
BU-224,imidazoline receptor ligand,MAOA,140,Preclinical
BU-224,imidazoline receptor ligand,MAOB,55361,Preclinical
bucladesine,adenosine receptor agonist|cAMP stimulant,PRKACA,55300,Launched
buclizine,histamine receptor antagonist,HRH1,54795,Launched
budesonide,glucocorticoid receptor agonist,NR3C1,2180,Launched
budipine,glutamate receptor antagonist,GRIN1,84532,Launched
bufexamac,cyclooxygenase inhibitor,HDAC10,55902,Withdrawn
bufexamac,cyclooxygenase inhibitor,HDAC6,107,Withdrawn
buflomedil,adrenergic receptor antagonist|calcium channel blocker,ADRA1A,132,Launched
bumetanide,solute carrier family member inhibitor,CFTR,1385,Launched
bumetanide,solute carrier family member inhibitor,GPR35,2203,Launched
bumetanide,solute carrier family member inhibitor,SLC12A1,3094,Launched
bumetanide,solute carrier family member inhibitor,SLC12A2,5142,Launched
bumetanide,solute carrier family member inhibitor,SLC12A4,5144,Launched
bumetanide,solute carrier family member inhibitor,SLC12A5,5292,Launched
bunazosin,adrenergic receptor antagonist,ADRA1A,5562,Launched
buparlisib,PI3K inhibitor,PIK3CA,5564,Phase 3
buparlisib,PI3K inhibitor,PIK3CG,5565,Phase 3
buphenine,adrenergic receptor agonist,ADRB2,5836,Launched
bupicomide,adrenergic receptor antagonist,ADRB1,54795,Phase 1
bupivacaine,sodium channel blocker,KCNA5,19,Launched
bupivacaine,sodium channel blocker,SCN10A,5243,Launched
bupranolol,adrenergic receptor antagonist,ADRB1,8647,Launched
bupranolol,adrenergic receptor antagonist,ADRB2,1244,Launched
bupranolol,adrenergic receptor antagonist,ADRB3,6833,Launched
bupropion,dopamine reuptake inhibitor,SLC6A2,10060,Launched
bupropion,dopamine reuptake inhibitor,SLC6A3,9619,Launched
buspirone,serotonin receptor agonist,DRD2,25,Launched
buspirone,serotonin receptor agonist,HTR1A,27,Launched
butabindide,tripeptidyl peptidase inhibitor,TPP2,2180,Preclinical
butaclamol,dopamine receptor antagonist,DRD1,84532,Phase 2
butaclamol,dopamine receptor antagonist,DRD2,55902,Phase 2
butaclamol,dopamine receptor antagonist,DRD3,90,Phase 2
butaclamol,dopamine receptor antagonist,DRD4,91,Phase 2
butaclamol,dopamine receptor antagonist,DRD5,94,Phase 2
butaclamol,dopamine receptor antagonist,HTR1A,107,Phase 2
butaclamol,dopamine receptor antagonist,HTR2A,156,Phase 2
butalbital,GABA receptor antagonist,CHRNA4,157,Launched
butalbital,GABA receptor antagonist,CHRNA7,10939,Launched
butalbital,GABA receptor antagonist,GABRA1,207,Launched
butalbital,GABA receptor antagonist,GABRA2,238,Launched
butalbital,GABA receptor antagonist,GABRA3,269,Launched
butalbital,GABA receptor antagonist,GABRA4,317,Launched
butalbital,GABA receptor antagonist,GABRA5,369,Launched
butalbital,GABA receptor antagonist,GABRA6,-,Launched
butalbital,GABA receptor antagonist,GABRB1,440,Launched
butalbital,GABA receptor antagonist,GABRB2,445,Launched
butalbital,GABA receptor antagonist,GABRB3,65061,Launched
butalbital,GABA receptor antagonist,GABRD,6240,Launched
butalbital,GABA receptor antagonist,GABRE,6241,Launched
butalbital,GABA receptor antagonist,GABRG1,50484,Launched
butalbital,GABA receptor antagonist,GABRG2,3269,Launched
butalbital,GABA receptor antagonist,GABRG3,4023,Launched
butalbital,GABA receptor antagonist,GABRP,5465,Launched
butalbital,GABA receptor antagonist,GABRQ,5465,Launched
butalbital,GABA receptor antagonist,GRIA2,3741,Launched
butalbital,GABA receptor antagonist,GRIK2,3756,Launched
butein,EGFR inhibitor|SRC inhibitor,ACE,2554,Preclinical
butenafine,fungal squalene epoxidase inhibitor,SQLE,2099,Launched
buthionine-sulfoximine,glutathione transferase inhibitor,GCLM,2950,Phase 1
butylated-hydroxytoluene,carbonic anhydrase inhibitor,CA2,3356,Phase 1
butylphthalide,potassium channel antagonist,KCNK2,3357,Launched
BVT-2733,11-beta hydroxysteroid dehydrogenase inhibitor,HSD17B1,3358,Preclinical
BVT-948,tyrosine phosphatase inhibitor,PTPN1,6530,Preclinical
BVT-948,tyrosine phosphatase inhibitor,PTPN11,6531,Preclinical
BVT-948,tyrosine phosphatase inhibitor,PTPN2,6532,Preclinical
BW-A4C,lipoxygenase inhibitor,ALOX5,148,Phase 1
BW-B70C,lipoxygenase inhibitor,ALOX5,147,Preclinical
BW-180C,opioid receptor agonist,OPRD1,146,Phase 2
BW-180C,opioid receptor agonist,OPRM1,150,Phase 2
BW-373U86,opioid receptor agonist,OPRD1,151,Preclinical
BW-616U,monoamine oxidase inhibitor,MAOA,152,Preclinical
BW-723C86,serotonin receptor agonist,HTR2A,5742,Preclinical
BW-723C86,serotonin receptor agonist,HTR2B,5743,Preclinical
BW-723C86,serotonin receptor agonist,HTR2C,64805,Preclinical
BX-795,IKK inhibitor,CDK2,5729,Preclinical
BX-795,IKK inhibitor,CHEK1,5731,Preclinical
BX-795,IKK inhibitor,GSK3B,5733,Preclinical
BX-795,IKK inhibitor,KDR,5737,Preclinical
BX-795,IKK inhibitor,PDK1,6915,Preclinical
BX-795,IKK inhibitor,PDPK1,153,Preclinical
BX-912,pyruvate dehydrogenase kinase inhibitor,CDK2,154,Preclinical
BX-912,pyruvate dehydrogenase kinase inhibitor,CHEK1,155,Preclinical
BX-912,pyruvate dehydrogenase kinase inhibitor,GSK3B,4128,Preclinical
BX-912,pyruvate dehydrogenase kinase inhibitor,KDR,148,Preclinical
BX-912,pyruvate dehydrogenase kinase inhibitor,PDK1,147,Preclinical
BX-912,pyruvate dehydrogenase kinase inhibitor,PDPK1,146,Preclinical
BYK-204165,PARP inhibitor,PARP1,1813,Preclinical
C-021,CC chemokine receptor antagonist,CCR4,3269,Preclinical
C-1,protein kinase inhibitor,PRKCA,3358,Preclinical
cabazitaxel,microtubule inhibitor,TUBA1A,3362,Launched
cabazitaxel,microtubule inhibitor,TUBA1B,153,Launched
cabazitaxel,microtubule inhibitor,TUBA1C,154,Launched
cabazitaxel,microtubule inhibitor,TUBA3C,1576,Launched
cabazitaxel,microtubule inhibitor,TUBA3D,3783,Launched
cabazitaxel,microtubule inhibitor,TUBA3E,8856,Launched
cabazitaxel,microtubule inhibitor,TUBA4A,9970,Launched
cabazitaxel,microtubule inhibitor,TUBB,7226,Launched
cabazitaxel,microtubule inhibitor,TUBB1,54795,Launched
cabazitaxel,microtubule inhibitor,TUBB2A,79054,Launched
cabazitaxel,microtubule inhibitor,TUBB2B,338567,Launched
cabazitaxel,microtubule inhibitor,TUBB3,148,Launched
cabazitaxel,microtubule inhibitor,TUBB4A,147,Launched
cabazitaxel,microtubule inhibitor,TUBB4B,146,Launched
cabazitaxel,microtubule inhibitor,TUBB6,150,Launched
cabazitaxel,microtubule inhibitor,TUBB8,151,Launched
cabergoline,dopamine receptor agonist,ADRA1A,152,Launched
cabergoline,dopamine receptor agonist,ADRA1B,50632,Launched
cabergoline,dopamine receptor agonist,ADRA1D,1128,Launched
cabergoline,dopamine receptor agonist,ADRA2A,1129,Launched
cabergoline,dopamine receptor agonist,ADRA2B,1131,Launched
cabergoline,dopamine receptor agonist,ADRA2C,1132,Launched
cabergoline,dopamine receptor agonist,ADRB1,1133,Launched
cabergoline,dopamine receptor agonist,ADRB2,1812,Launched
cabergoline,dopamine receptor agonist,DRD1,1813,Launched
cabergoline,dopamine receptor agonist,DRD2,1814,Launched
cabergoline,dopamine receptor agonist,DRD3,1815,Launched
cabergoline,dopamine receptor agonist,DRD4,1816,Launched
cabergoline,dopamine receptor agonist,DRD5,3269,Launched
cabergoline,dopamine receptor agonist,HTR1A,59340,Launched
cabergoline,dopamine receptor agonist,HTR1B,3350,Launched
cabergoline,dopamine receptor agonist,HTR1D,3351,Launched
cabergoline,dopamine receptor agonist,HTR2A,3352,Launched
cabergoline,dopamine receptor agonist,HTR2B,3354,Launched
cabergoline,dopamine receptor agonist,HTR2C,3355,Launched
cabergoline,dopamine receptor agonist,HTR7,3356,Launched
cabozantinib,RET tyrosine kinase inhibitor|VEGFR inhibitor,KDR,3357,Launched
cabozantinib,RET tyrosine kinase inhibitor|VEGFR inhibitor,MET,3358,Launched
cabozantinib,RET tyrosine kinase inhibitor|VEGFR inhibitor,RET,3359,Launched
CaCCinh-A01,calcium-activated chloride channel inhibitor,CLCA1,3361,Preclinical
caffeic-acid,HIV integrase inhibitor|lipoxygenase inhibitor|nitric oxide production inhibitor|tumor necrosis factor production inhibitor,ALOX5,3362,Preclinical
caffeic-acid,HIV integrase inhibitor|lipoxygenase inhibitor|nitric oxide production inhibitor|tumor necrosis factor production inhibitor,MIF,3363,Preclinical
caffeic-acid-phenethyl-ester,HIV integrase inhibitor,RELA,155,Preclinical
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,ADORA1,7350,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,ADORA2A,7351,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,ADORA2B,7352,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,ADORA3,2798,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,ATM,1432,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,ITPR1,2890,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,ITPR2,2891,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,ITPR3,2892,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,PDE10A,2893,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,PDE11A,1956,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,PDE1A,695,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,PDE1B,2904,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,PDE1C,6329,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,PDE2A,6335,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,PDE3A,1576,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,PDE3B,2563,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,PDE4A,2564,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,PDE4B,2565,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,PDE4C,2566,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,PDE4D,2567,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,PDE5A,2568,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,PDE6A,55879,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,PDE6B,2891,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,PDE6C,2898,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,PDE7A,1636,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,PDE7B,6713,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,PDE8A,2730,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,PDE8B,760,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,PDE9A,3776,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,PIK3CA,3292,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,PIK3CB,5770,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,PIK3CD,5781,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,PRKDC,5771,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,RYR1,240,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,RYR2,240,Launched
caffeine,adenosine receptor antagonist|phosphodiesterase inhibitor,RYR3,4985,Launched
calcifediol,vitamin D receptor agonist,VDR,4988,Launched
calcipotriol,vitamin D receptor agonist,VDR,4985,Launched
calcitriol,vitamin D receptor agonist,VDR,4128,Launched
Calhex-231,calcium sensing receptor negative allosteric modulator,CASR,3356,Preclinical
camicinal,motilin receptor agonist,MLNR,3357,Phase 2
CaMKII-IN-1,calcium/calmodulin dependent protein kinase inhibitor,AKT1,3358,Preclinical
CaMKII-IN-1,calcium/calmodulin dependent protein kinase inhibitor,CAMK2A,1017,Preclinical
CaMKII-IN-1,calcium/calmodulin dependent protein kinase inhibitor,CAMK4,1111,Preclinical
CaMKII-IN-1,calcium/calmodulin dependent protein kinase inhibitor,MYLK,2932,Preclinical
camostat-mesilate,protease inhibitor,PRSS1,3791,Launched
camphor-(1R),TRPV activator,TRPV1,5163,Phase 1
camptothecin,topoisomerase inhibitor,TOP1,5170,Phase 3
canagliflozin,sodium/glucose cotransporter inhibitor,SLC5A1,1017,Launched
canagliflozin,sodium/glucose cotransporter inhibitor,SLC5A2,1111,Launched
candesartan,angiotensin receptor antagonist,AGTR1,2932,Launched
canertinib,EGFR inhibitor,AKT1,3791,Phase 3
canertinib,EGFR inhibitor,EGFR,5163,Phase 3
canertinib,EGFR inhibitor,ERBB2,5170,Phase 3
canertinib,EGFR inhibitor,ERBB4,142,Phase 3
canrenone,mineralocorticoid receptor antagonist,NR3C2,1233,Withdrawn
capadenoson,adenosine receptor agonist,ADORA1,5578,Phase 2
capecitabine,DNA synthesis inhibitor|thymidylate synthase inhibitor,TYMS,7846,Launched
capsaicin,TRPV agonist,CFTR,10376,Launched
capsaicin,TRPV agonist,TRPV1,84790,Launched
capsazepine,TRPV agonist,TRPV1,7278,Preclinical
capsazepine,TRPV agonist,TRPV4,113457,Preclinical
captopril,angiotensin converting enzyme inhibitor,ACE,112714,Launched
captopril,angiotensin converting enzyme inhibitor,LTA4H,7277,Launched
captopril,angiotensin converting enzyme inhibitor,MMP2,203068,Launched
captopril,angiotensin converting enzyme inhibitor,MMP9,81027,Launched
caracemide,ribonucleotide reductase inhibitor,RRM1,7280,Phase 2
caramiphen,cholinergic receptor antagonist,CHRM1,347733,Launched
caramiphen,cholinergic receptor antagonist,CHRM2,10381,Launched
carazolol,adrenergic receptor antagonist,ADRB1,10382,Launched
carazolol,adrenergic receptor antagonist,ADRB2,10383,Launched
carazolol,adrenergic receptor antagonist,ADRB3,84617,Launched
carbachol,cholinergic receptor agonist,CHRM1,347688,Launched
carbachol,cholinergic receptor agonist,CHRM2,148,Launched
carbachol,cholinergic receptor agonist,CHRM3,147,Launched
carbachol,cholinergic receptor agonist,CHRM4,146,Launched
carbachol,cholinergic receptor agonist,CHRM5,150,Launched
carbachol,cholinergic receptor agonist,CHRNA2,151,Launched
carbamazepine,carboxamide antiepileptic,SCN10A,152,Launched
carbamazepine,carboxamide antiepileptic,SCN11A,153,Launched
carbamazepine,carboxamide antiepileptic,SCN1A,154,Launched
carbamazepine,carboxamide antiepileptic,SCN2A,1812,Launched
carbamazepine,carboxamide antiepileptic,SCN3A,1813,Launched
carbamazepine,carboxamide antiepileptic,SCN4A,1814,Launched
carbamazepine,carboxamide antiepileptic,SCN5A,1815,Launched
carbamazepine,carboxamide antiepileptic,SCN7A,1816,Launched
carbamazepine,carboxamide antiepileptic,SCN8A,3350,Launched
carbamazepine,carboxamide antiepileptic,SCN9A,3351,Launched
carbendazim,microtubule inhibitor|tubulin polymerization inhibitor,TP53,3352,Launched
carbendazim,microtubule inhibitor|tubulin polymerization inhibitor,TUBB,3356,Launched
carbenoxolone,11-beta hydroxysteroid dehydrogenase inhibitor,GJA1,3357,Launched
carbenoxolone,11-beta hydroxysteroid dehydrogenase inhibitor,GJA10,3358,Launched
carbenoxolone,11-beta hydroxysteroid dehydrogenase inhibitor,GJA3,3363,Launched
carbenoxolone,11-beta hydroxysteroid dehydrogenase inhibitor,GJA4,3791,Launched
carbenoxolone,11-beta hydroxysteroid dehydrogenase inhibitor,GJA5,4233,Launched
carbenoxolone,11-beta hydroxysteroid dehydrogenase inhibitor,GJA8,5979,Launched
carbenoxolone,11-beta hydroxysteroid dehydrogenase inhibitor,GJA9,1179,Launched
carbenoxolone,11-beta hydroxysteroid dehydrogenase inhibitor,GJB1,240,Launched
carbenoxolone,11-beta hydroxysteroid dehydrogenase inhibitor,GJB2,4282,Launched
carbenoxolone,11-beta hydroxysteroid dehydrogenase inhibitor,GJB3,5970,Launched
carbenoxolone,11-beta hydroxysteroid dehydrogenase inhibitor,GJB4,134,Launched
carbenoxolone,11-beta hydroxysteroid dehydrogenase inhibitor,GJB5,135,Launched
carbenoxolone,11-beta hydroxysteroid dehydrogenase inhibitor,GJB6,136,Launched
carbenoxolone,11-beta hydroxysteroid dehydrogenase inhibitor,GJB7,140,Launched
carbenoxolone,11-beta hydroxysteroid dehydrogenase inhibitor,GJC1,472,Launched
carbenoxolone,11-beta hydroxysteroid dehydrogenase inhibitor,GJC2,3708,Launched
carbenoxolone,11-beta hydroxysteroid dehydrogenase inhibitor,GJC3,3709,Launched
carbenoxolone,11-beta hydroxysteroid dehydrogenase inhibitor,GJD2,3710,Launched
carbenoxolone,11-beta hydroxysteroid dehydrogenase inhibitor,GJD3,10846,Launched
carbenoxolone,11-beta hydroxysteroid dehydrogenase inhibitor,GJD4,50940,Launched
carbenoxolone,11-beta hydroxysteroid dehydrogenase inhibitor,GJE1,5136,Launched
carbenoxolone,11-beta hydroxysteroid dehydrogenase inhibitor,HSD11B1,5153,Launched
carbenoxolone,11-beta hydroxysteroid dehydrogenase inhibitor,PANX1,5137,Launched
carbenoxolone,11-beta hydroxysteroid dehydrogenase inhibitor,PANX2,5138,Launched
carbenoxolone,11-beta hydroxysteroid dehydrogenase inhibitor,PANX3,5139,Launched
carbetapentane,acetylcholine receptor antagonist,CHRM2,5159,Launched
carbetocin,oxytocin receptor agonist,OXTR,6564,Launched
carbidopa,aromatic L-amino acid decarboxylase inhibitor,DDC,6565,Launched
carbimazole,antithyroid agent,TPO,9356,Launched
carbinoxamine,histamine receptor antagonist,HRH1,9376,Launched
carboxyamidotriazole,calcium channel blocker,CXCL8,5444,Phase 3
carboxylosartan,angiotensin antagonist,AGTR1,4353,Phase 1
cardionogen-1,WNT signaling inhibitor,CTNNB1,1576,Preclinical
carebastine,histamine receptor antagonist,HRH1,771,Phase 1
carfilzomib,proteasome inhibitor,PSMA1,5170,Launched
carfilzomib,proteasome inhibitor,PSMA2,5743,Launched
carfilzomib,proteasome inhibitor,PSMA3,150,Launched
carfilzomib,proteasome inhibitor,PSMA4,153,Launched
carfilzomib,proteasome inhibitor,PSMA5,154,Launched
carfilzomib,proteasome inhibitor,PSMA6,673,Launched
carfilzomib,proteasome inhibitor,PSMA7,5894,Launched
carfilzomib,proteasome inhibitor,PSMA8,3717,Launched
carfilzomib,proteasome inhibitor,PSMB1,238,Launched
carfilzomib,proteasome inhibitor,PSMB10,238,Launched
carfilzomib,proteasome inhibitor,PSMB11,2322,Launched
carfilzomib,proteasome inhibitor,PSMB2,3480,Launched
carfilzomib,proteasome inhibitor,PSMB3,3643,Launched
carfilzomib,proteasome inhibitor,PSMB4,83942,Launched
carfilzomib,proteasome inhibitor,PSMB5,2194,Launched
carfilzomib,proteasome inhibitor,PSMB6,886,Launched
carfilzomib,proteasome inhibitor,PSMB7,5465,Launched
carfilzomib,proteasome inhibitor,PSMB8,5406,Launched
carfilzomib,proteasome inhibitor,PSMB9,3269,Launched
carglumic-acid,carbamoyl phosphate synthase activator,CPS1,2798,Launched
caricotamide,NADPH quinone oxidoreductase inhibitor,NQO2,3973,Phase 2
cariporide,sodium/hydrogen exchanger inhibitor,SLC9A1,1131,Phase 3
cariprazine,dopamine receptor antagonist,DRD2,203068,Launched
cariprazine,dopamine receptor antagonist,DRD3,10411,Launched
carmofur,thymidylate synthase inhibitor,TYMS,1080,Launched
carmoterol,adrenergic receptor agonist,ADRB2,134,Phase 2
carmoxirole,dopamine receptor agonist,DRD2,135,Phase 2
carmustine,DNA alkylating agent|DNA inhibitor,GSR,136,Launched
caroxazone,monoamine oxidase inhibitor,MAOA,140,Withdrawn
caroxazone,monoamine oxidase inhibitor,MAOB,134,Withdrawn
carprofen,cyclooxygenase inhibitor,PTGS2,136,Launched
carteolol,adrenergic receptor antagonist,ADRB1,140,Launched
carteolol,adrenergic receptor antagonist,ADRB2,472,Launched
carteolol,adrenergic receptor antagonist,ADRB3,545,Launched
carvedilol,adrenergic receptor antagonist,ADRB1,4193,Launched
carvedilol,adrenergic receptor antagonist,ADRB2,153,Launched
carvedilol,adrenergic receptor antagonist,ADRB3,154,Launched
carzenide,,CA1,155,Preclinical
carzenide,,CA12,2550,Preclinical
carzenide,,CA14,153,Preclinical
carzenide,,CA2,155,Preclinical
carzenide,,CA6,6546,Preclinical
carzenide,,CA9,2903,Preclinical
casin,GTPase inhibitor,CDC42,2904,Preclinical
castanospermine,glucosidase inhibitor,GAA,2905,Phase 2
castanospermine,glucosidase inhibitor,GBA,2906,Phase 2
cathepsin-inhibitor-1,cathepsin inhibitor,CTSB,1956,Preclinical
cathepsin-inhibitor-1,cathepsin inhibitor,CTSL,1956,Preclinical
cathepsin-inhibitor-1,cathepsin inhibitor,CTSV,5579,Preclinical
CAY10505,PI3K inhibitor,PIK3CG,2550,Preclinical
CB-03-01,androgen receptor antagonist,AR,9568,Phase 3
CB-5083,valosin-containing protein inhibitor,VCP,115207,Phase 1
CB-839,glutaminase inhibitor,GLS,57528,Phase 2
CBiPES,glutamate receptor positive allosteric modulator,GRM2,386617,Preclinical
CBS-1114,lipoxygenase inhibitor,ALOX5,2550,Phase 1
CC-115,DNA protein kinase inhibitor|mTOR inhibitor,MTOR,9568,Phase 2
CC-223,mTOR inhibitor,MTOR,115207,Phase 2
CC-401,JNK inhibitor,MAPK8,57528,Phase 1
CCG-1423,apoptosis stimulant,RHOC,386617,Preclinical
CCG-1423,apoptosis stimulant,SRF,9212,Preclinical
CCG-50014,G protein signaling inhibitor,RGS4,3932,Preclinical
CCG-50014,G protein signaling inhibitor,RGS8,8569,Preclinical
CCG-63802,G protein signaling inhibitor,RGS4,2872,Preclinical
CCG-63808,G protein signaling inhibitor,RGS4,6446,Preclinical
CCMI,acetylcholine receptor allosteric modulator,CHRNA7,983,Preclinical
CCT-031374,WNT signaling inhibitor,CTNNB1,1017,Preclinical
CCT018159,HSP inhibitor,HSP90AA1,4889,Preclinical
CCT018159,HSP inhibitor,HSP90AB1,983,Preclinical
CCT129202,Aurora kinase inhibitor,AURKA,2550,Preclinical
CCT129202,Aurora kinase inhibitor,AURKB,134,Preclinical
CCT129202,Aurora kinase inhibitor,AURKC,135,Preclinical
CCT137690,Aurora kinase inhibitor,AURKA,136,Preclinical
CCT137690,Aurora kinase inhibitor,AURKB,140,Preclinical
CCT137690,Aurora kinase inhibitor,AURKC,2554,Preclinical
CC4,nicotinic receptor agonist,CHRNB2,2555,Preclinical
CD-1530,retinoid receptor agonist,RARG,2556,Preclinical
CD-437,retinoid receptor agonist,RARG,2557,Preclinical
CDK1-5-inhibitor,CDK inhibitor|glycogen synthase kinase inhibitor,CDK1,2558,Preclinical
CDK1-5-inhibitor,CDK inhibitor|glycogen synthase kinase inhibitor,CDK5,2559,Preclinical
CDK1-5-inhibitor,CDK inhibitor|glycogen synthase kinase inhibitor,GSK3B,134,Preclinical
CDK9-IN-6,CDK inhibitor,CDK9,135,Preclinical
CDPPB,glutamate receptor positive allosteric modulator,GRM5,136,Preclinical
cebranopadol,opioid receptor agonist,OPRL1,140,Phase 3
cebranopadol,opioid receptor agonist,OPRM1,2554,Phase 3
cediranib,KIT inhibitor|VEGFR inhibitor,CSF1R,2561,Phase 3
cediranib,KIT inhibitor|VEGFR inhibitor,FLT1,2566,Phase 3
cediranib,KIT inhibitor|VEGFR inhibitor,FLT3,2260,Phase 3
cediranib,KIT inhibitor|VEGFR inhibitor,FLT4,2263,Phase 3
cediranib,KIT inhibitor|VEGFR inhibitor,KDR,2261,Phase 3
cediranib,KIT inhibitor|VEGFR inhibitor,KIT,6566,Phase 3
cediranib,KIT inhibitor|VEGFR inhibitor,PDGFRA,3290,Phase 3
cediranib,KIT inhibitor|VEGFR inhibitor,PDGFRB,5140,Phase 3
cefadroxil,bacterial cell wall synthesis inhibitor,SLC15A1,5141,Launched
cefadroxil,bacterial cell wall synthesis inhibitor,SLC15A2,5142,Launched
cefadroxil,bacterial cell wall synthesis inhibitor,SLC22A6,5143,Launched
cefadroxil,bacterial cell wall synthesis inhibitor,SLC22A8,5144,Launched
cefazolin,bacterial cell wall synthesis inhibitor,PON1,8654,Launched
cefdinir,bacterial cell wall synthesis inhibitor,MPO,5145,Launched
cefradine,bacterial cell wall synthesis inhibitor,CYP3A4,5158,Launched
celecoxib,cyclooxygenase inhibitor,CA12,5146,Launched
celecoxib,cyclooxygenase inhibitor,PDPK1,5150,Launched
celecoxib,cyclooxygenase inhibitor,PTGS2,27115,Launched
celiprolol,adrenergic receptor antagonist,ADRA2A,5151,Launched
celiprolol,adrenergic receptor antagonist,ADRB1,8622,Launched
celiprolol,adrenergic receptor antagonist,ADRB2,5152,Launched
CEP-32496,RAF inhibitor,BRAF,5290,Phase 1/Phase 2
CEP-32496,RAF inhibitor,RAF1,5291,Phase 1/Phase 2
CEP-33779,JAK inhibitor,JAK2,5293,Preclinical
CEP-37440,ALK tyrosine kinase receptor inhibitor,ALK,5591,Phase 1
ceritinib,ALK tyrosine kinase receptor inhibitor,ALK,6261,Launched
ceritinib,ALK tyrosine kinase receptor inhibitor,FLT3,6262,Launched
ceritinib,ALK tyrosine kinase receptor inhibitor,IGF1R,6263,Launched
ceritinib,ALK tyrosine kinase receptor inhibitor,INSR,7421,Launched
ceritinib,ALK tyrosine kinase receptor inhibitor,TSSK1B,7421,Launched
cerulenin,fatty acid synthase inhibitor,FASN,7421,Launched
ceruletide,CCK receptor agonist,CCKAR,846,Preclinical
cetaben,ACAT inhibitor|cholesterol inhibitor,PPARA,2862,Phase 2
cetilistat,triacylglycerol lipase inhibitor,PNLIP,207,Phase 3
cetirizine,histamine receptor antagonist,HRH1,815,Launched
cetrorelix,gonadotropin releasing factor hormone receptor antagonist,GNRHR,814,Launched
cetrorelix,gonadotropin releasing factor hormone receptor antagonist,LHCGR,4638,Launched
cevimeline,acetylcholine receptor agonist,CHRM3,5644,Launched
cevipabulin,microtubule stimulant|tubulin polymerization inhibitor,TUBB,7442,Phase 1
CE3F4,rap guanine nucleotide exchange factor inhibitor,RAPGEF3,7150,Preclinical
CFTRinh-172,chloride channel blocker,CFTR,6523,Preclinical
CF102,adenosine receptor agonist,ADORA1,6524,Phase 2
CF102,adenosine receptor agonist,ADORA2A,185,Phase 2
CF102,adenosine receptor agonist,ADORA2B,207,Phase 2
CF102,adenosine receptor agonist,ADORA3,1956,Phase 2
CGH2466,adenosine receptor antagonist,ADORA1,2064,Preclinical
CGH2466,adenosine receptor antagonist,ADORA2B,2066,Preclinical
CGH2466,adenosine receptor antagonist,ADORA3,4306,Preclinical
CGK-733,ATM kinase inhibitor|ATR kinase inhibitor,ATM,134,Preclinical
CGK-733,ATM kinase inhibitor|ATR kinase inhibitor,ATR,7298,Preclinical
CGM097,MDM inhibitor,MDM2,1080,Phase 1
CGP-12177,adrenergic receptor agonist,ADRB1,7442,Phase 1
CGP-12177,adrenergic receptor agonist,ADRB2,7442,Phase 1
CGP-12177,adrenergic receptor agonist,ADRB3,59341,Phase 1
CGP-13501,GABA receptor modulator,GABBR1,1636,Preclinical
CGP-20712A,adrenergic receptor antagonist,ADRB1,4048,Preclinical
CGP-20712A,adrenergic receptor antagonist,ADRB3,4313,Preclinical
CGP-37157,mitochondrial Na+/Ca2+ exchanger antagonist|sodium/calcium exchange inhibitor,SLC8A1,4318,Preclinical
CGP-37849,glutamate receptor antagonist,GRIN2A,6240,Phase 1
CGP-37849,glutamate receptor antagonist,GRIN2B,1128,Phase 1
CGP-37849,glutamate receptor antagonist,GRIN2C,1129,Phase 1
CGP-37849,glutamate receptor antagonist,GRIN2D,153,Phase 1
CGP-52411,EGFR inhibitor,EGFR,154,Preclinical
CGP-53353,EGFR inhibitor|PKC inhibitor,EGFR,155,Preclinical
CGP-53353,EGFR inhibitor|PKC inhibitor,PRKCB,1128,Preclinical
CGP-54626,GABA receptor antagonist,GABBR1,1129,Preclinical
CGP-54626,GABA receptor antagonist,GABBR2,1131,Preclinical
CGP-54626,GABA receptor antagonist,KCTD12,1132,Preclinical
CGP-54626,GABA receptor antagonist,KCTD16,1133,Preclinical
CGP-54626,GABA receptor antagonist,KCTD8,1135,Preclinical
CGP-55845,GABA receptor antagonist,GABBR1,6336,Preclinical
CGP-55845,GABA receptor antagonist,GABBR2,11280,Preclinical
CGP-55845,GABA receptor antagonist,KCTD12,6323,Preclinical
CGP-55845,GABA receptor antagonist,KCTD16,6326,Preclinical
CGP-55845,GABA receptor antagonist,KCTD8,6328,Preclinical
CGP-57380,MAP kinase inhibitor,AURKB,6329,Preclinical
CGP-57380,MAP kinase inhibitor,LCK,6331,Preclinical
CGP-57380,MAP kinase inhibitor,MKNK1,6332,Preclinical
CGP-57380,MAP kinase inhibitor,MKNK2,6334,Preclinical
CGP-57380,MAP kinase inhibitor,SGK1,6335,Preclinical
CGP-60474,CDK inhibitor,CDK1,7157,Preclinical
CGP-60474,CDK inhibitor,CDK2,203068,Preclinical
CGP-71683,neuropeptide receptor antagonist,NPY5R,2697,Preclinical
CGP-74514,CDK inhibitor,CDK1,84694,Preclinical
CGP-7930,GABA receptor modulator,GABBR1,2700,Preclinical
CGS-15943,adenosine receptor antagonist,ADORA1,2701,Preclinical
CGS-15943,adenosine receptor antagonist,ADORA2A,2702,Preclinical
CGS-15943,adenosine receptor antagonist,ADORA2B,2703,Preclinical
CGS-15943,adenosine receptor antagonist,ADORA3,81025,Preclinical
CGS-20625,benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist,GABRA1,2705,Phase 1
CGS-20625,benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist,GABRA2,2706,Phase 1
CGS-20625,benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist,GABRA3,2707,Phase 1
CGS-20625,benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist,GABRA4,127534,Phase 1
CGS-20625,benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist,GABRA5,2709,Phase 1
CGS-20625,benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist,GABRA6,10804,Phase 1
CGS-21680,adenosine receptor agonist,ADORA1,375519,Preclinical
CGS-21680,adenosine receptor agonist,ADORA2A,10052,Preclinical
CGS-21680,adenosine receptor agonist,ADORA2B,57165,Preclinical
CGS-21680,adenosine receptor agonist,ADORA3,349149,Preclinical
CGS-9896,GABA receptor antagonist,GABRA1,57369,Preclinical
CGS-9896,GABA receptor antagonist,GABRB2,125111,Preclinical
CGS-9896,GABA receptor antagonist,GABRG2,219770,Preclinical
CH-5183284,fibroblast growth factor inhibitor,FGFR1,100126572,Phase 2
CH-5183284,fibroblast growth factor inhibitor,FGFR2,3290,Phase 2
CH-5183284,fibroblast growth factor inhibitor,FGFR3,24145,Phase 2
CHC,monocarboxylate transporter inhibitor,SLC16A1,56666,Preclinical
chenodeoxycholic-acid,11-beta hydroxysteroid dehydrogenase inhibitor|FXR agonist,HSD11B1,116337,Launched
chenodeoxycholic-acid,11-beta hydroxysteroid dehydrogenase inhibitor|FXR agonist,NR1H4,1129,Launched
CHF5074,gamma secretase modulator,PSEN1,5021,Phase 2
chicago-sky-blue-6b,glutamate inhibitor|macrophage migration inhibiting factor inhibitor,MIF,1644,Preclinical
chidamide,HDAC inhibitor,HDAC10,7173,Launched
chidamide,HDAC inhibitor,HDAC3,3269,Launched
CHIR-124,CHK inhibitor,CHEK1,3576,Preclinical
CHIR-98014,glycogen synthase kinase inhibitor,GSK3A,185,Preclinical
CHIR-98014,glycogen synthase kinase inhibitor,GSK3B,1499,Preclinical
CHIR-99021,glycogen synthase kinase inhibitor,CDK1,3269,Preclinical
CHIR-99021,glycogen synthase kinase inhibitor,GSK3A,5682,Preclinical
CHIR-99021,glycogen synthase kinase inhibitor,GSK3B,5683,Preclinical
CHIR-99021,glycogen synthase kinase inhibitor,MAPK1,5684,Preclinical
chloramphenicol,bacterial 50S ribosomal subunit inhibitor,CD55,5685,Launched
chlorisondamine-diiodide,acetylcholine receptor antagonist,CHRNA1,5686,Preclinical
chlormadinone-acetate,5 alpha reductase inhibitor,PGR,5687,Launched
chlormezanone,GABA receptor modulator,GABRA1,5688,Withdrawn
chlorogenic-acid,antioxidant,SLC37A4,143471,Launched
chloroprocaine,sodium channel blocker,ATP1A1,5689,Launched
chloroprocaine,sodium channel blocker,CHRNA10,5699,Launched
chloroprocaine,sodium channel blocker,GRIN3A,122706,Launched
chloroprocaine,sodium channel blocker,HTR3A,5690,Launched
chloroprocaine,sodium channel blocker,SCN10A,5691,Launched
chloroprocaine,sodium channel blocker,SLC6A3,5692,Launched
chloropyramine,histamine receptor antagonist,HRH1,5693,Launched
chloroquine,antimalarial agent,MRGPRX1,5694,Launched
chlorothiazide,diuretic,CA1,5695,Launched
chlorothiazide,diuretic,CA2,5696,Launched
chlorothiazide,diuretic,CA4,5698,Launched
chlorothiazide,diuretic,SLC12A3,1373,Launched
chlorotrianisene,estrogenic hormone,ESR1,4835,Launched
chlorotrianisene,estrogenic hormone,ESR2,6548,Launched
chloroxine,opioid receptor antagonist,OPRK1,1813,Launched
chlorproguanil,dihydrofolate reductase inhibitor,DHFR,1814,Launched
chlorpromazine,dopamine receptor antagonist,ADRA1A,7298,Launched
chlorpromazine,dopamine receptor antagonist,ADRA1B,154,Launched
chlorpromazine,dopamine receptor antagonist,ADRA1D,1813,Launched
chlorpromazine,dopamine receptor antagonist,ADRA2A,2936,Launched
chlorpromazine,dopamine receptor antagonist,ADRA2B,4128,Launched
chlorpromazine,dopamine receptor antagonist,ADRA2C,4129,Launched
chlorpromazine,dopamine receptor antagonist,CALM1,5743,Launched
chlorpromazine,dopamine receptor antagonist,CHRM1,153,Launched
chlorpromazine,dopamine receptor antagonist,CHRM3,154,Launched
chlorpromazine,dopamine receptor antagonist,DRD1,155,Launched
chlorpromazine,dopamine receptor antagonist,DRD2,153,Launched
chlorpromazine,dopamine receptor antagonist,DRD3,154,Launched
chlorpromazine,dopamine receptor antagonist,DRD4,155,Launched
chlorpromazine,dopamine receptor antagonist,DRD5,759,Launched
chlorpromazine,dopamine receptor antagonist,HRH1,771,Launched
chlorpromazine,dopamine receptor antagonist,HRH4,23632,Launched
chlorpromazine,dopamine receptor antagonist,HTR1A,760,Launched
chlorpromazine,dopamine receptor antagonist,HTR2A,765,Launched
chlorpromazine,dopamine receptor antagonist,HTR2B,768,Launched
chlorpromazine,dopamine receptor antagonist,HTR2C,998,Launched
chlorpromazine,dopamine receptor antagonist,HTR6,2548,Launched
chlorpromazine,dopamine receptor antagonist,HTR7,2629//2630,Launched
chlorpromazine,dopamine receptor antagonist,KCNH2,1508,Launched
chlorpromazine,dopamine receptor antagonist,ORM1,1514,Launched
chlorpromazine,dopamine receptor antagonist,ORM2,1515,Launched
chlorpromazine,dopamine receptor antagonist,SMPD1,5294,Launched
chlorpromazine,dopamine receptor antagonist,TRPC5,367,Launched
chlorpropamide,ATP channel blocker,ABCC8,7415,Launched
chlorpropamide,ATP channel blocker,KCNJ10,2744,Launched
chlorprothixene,dopamine receptor antagonist,CHRM1,2912,Launched
chlorprothixene,dopamine receptor antagonist,CHRM2,240,Launched
chlorprothixene,dopamine receptor antagonist,CHRM3,2475,Launched
chlorprothixene,dopamine receptor antagonist,CHRM4,2475,Launched
chlorprothixene,dopamine receptor antagonist,CHRM5,5599,Launched
chlorprothixene,dopamine receptor antagonist,DRD1,389,Launched
chlorprothixene,dopamine receptor antagonist,DRD2,6722,Launched
chlorprothixene,dopamine receptor antagonist,DRD3,5999,Launched
chlorprothixene,dopamine receptor antagonist,HRH1,85397,Launched
chlorprothixene,dopamine receptor antagonist,HTR2A,5999,Launched
chlorprothixene,dopamine receptor antagonist,HTR2B,5999,Launched
chlorprothixene,dopamine receptor antagonist,HTR2C,1139,Launched
chlorpyrifos,acetylcholinesterase inhibitor,ACHE,1499,Launched
chlorthalidone,carbonic anhydrase inhibitor,CA1,3320,Launched
chlorthalidone,carbonic anhydrase inhibitor,CA12,3326,Launched
chlorthalidone,carbonic anhydrase inhibitor,CA14,6790,Launched
chlorthalidone,carbonic anhydrase inhibitor,CA2,9212,Launched
chlorthalidone,carbonic anhydrase inhibitor,CA4,6795,Launched
chlorthalidone,carbonic anhydrase inhibitor,CA7,6790,Launched
chlorthalidone,carbonic anhydrase inhibitor,SLC12A1,9212,Launched
chlorzoxazone,bacterial 30S ribosomal subunit inhibitor,KCNMA1,6795,Launched
chlorzoxazone,bacterial 30S ribosomal subunit inhibitor,KCNN4,1141,Launched
cholecalciferol,,VDR,5916,Launched
cholesterol,,RORA,5916,Preclinical
cholic-acid,bile acid,ADH1C,983,Launched
cholic-acid,bile acid,CES1,1020,Launched
cholic-acid,bile acid,COX4I1,2932,Launched
cholic-acid,bile acid,COX5A,1025,Launched
cholic-acid,bile acid,COX5B,2915,Launched
cholic-acid,bile acid,COX6A2,4987,Launched
cholic-acid,bile acid,COX6B1,4988,Launched
cholic-acid,bile acid,COX6C,1436,Launched
cholic-acid,bile acid,COX7A1,2321,Launched
cholic-acid,bile acid,COX7B,2322,Launched
cholic-acid,bile acid,COX7C,2324,Launched
cholic-acid,bile acid,COX8A,3791,Launched
cholic-acid,bile acid,ESRRG,3815,Launched
cholic-acid,bile acid,FABP6,5156,Launched
cholic-acid,bile acid,FECH,9971,Launched
cholic-acid,bile acid,GPBAR1,5663,Launched
cholic-acid,bile acid,MT-CO1,4282,Launched
cholic-acid,bile acid,MT-CO2,83933,Launched
cholic-acid,bile acid,MT-CO3,8841,Launched
cholic-acid,bile acid,PLA2G1B,1111,Launched
choline,acetylcholine precursor,ACHE,2931,Phase 3
choline,acetylcholine precursor,BCHE,2932,Phase 3
choline,acetylcholine precursor,CHRNA2,983,Phase 3
choline,acetylcholine precursor,PCYT1A,2931,Phase 3
choline,acetylcholine precursor,PCYT1B,2932,Phase 3
choline,acetylcholine precursor,PHOSPHO1,5594,Phase 3
choline,acetylcholine precursor,PLD1,1604,Phase 3
choline,acetylcholine precursor,PLD2,1134,Phase 3
CHPG,glutamate receptor agonist,GRM5,5241,Preclinical
CHR-6494,serine/threonine kinase inhibitor,GSG2,2554,Preclinical
chrysin,breast cancer resistance protein inhibitor,AKR1B1,2542,Phase 1
chrysin,breast cancer resistance protein inhibitor,CDK6,476,Phase 1
chrysin,breast cancer resistance protein inhibitor,CYP19A1,57053,Phase 1
chrysin,breast cancer resistance protein inhibitor,CYP1B1,116443,Phase 1
chrysophanic-acid,EGFR inhibitor,EGFR,3359,Preclinical
chrysophanic-acid,EGFR inhibitor,MTOR,6336,Preclinical
CH223191,aryl hydrocarbon receptor antagonist,AHR,6531,Preclinical
CH5132799,PI3K inhibitor,MTOR,3269,Phase 1
CH5132799,PI3K inhibitor,PIK3CA,259249,Phase 1
CH5132799,PI3K inhibitor,PIK3CB,759,Phase 1
CH5132799,PI3K inhibitor,PIK3CD,760,Phase 1
CH5132799,PI3K inhibitor,PIK3CG,762,Phase 1
CH55,retinoid receptor binder,RARA,6559,Preclinical
CH55,retinoid receptor binder,RARB,2099,Preclinical
CI-966,GAT inhibitor,SLC6A1,2100,Phase 1
CI-976,ACAT inhibitor,ACAT1,4986,Phase 1
CI-976,ACAT inhibitor,CES1,1719,Phase 1
cianidanol,fatty acid synthase inhibitor,PTGS1,148,Withdrawn
ciclesonide,glucocorticoid receptor agonist,NR3C1,147,Launched
ciclesonide,glucocorticoid receptor agonist,SERPINA6,146,Launched
ciclopirox,membrane integrity inhibitor,ATP1A1,150,Launched
cicloprofen,cyclooxygenase inhibitor,PTGS1,151,Preclinical
cicloprofen,cyclooxygenase inhibitor,PTGS2,152,Preclinical
CID-16020046,G protein-coupled receptor antagonist,GPR55,801,Preclinical
CID-2011756,protein kinase inhibitor,PKD1,1128,Preclinical
CID-2745687,G protein-coupled receptor antagonist,GPR35,1131,Preclinical
CID-5458317,MAP kinase phosphatase inhibitor,MAPK3,1812,Preclinical
ciglitazone,PPAR receptor agonist,PPARG,1813,Phase 2
cilastatin,dehydropeptidase inhibitor,DPEP1,1814,Launched
cilazapril,angiotensin converting enzyme inhibitor,ACE,1815,Launched
cilengitide,integrin antagonist,ITGAV,1816,Phase 3
cilengitide,integrin antagonist,ITGB3,3269,Phase 3
cilnidipine,calcium channel blocker,CACNA1B,59340,Launched
cilomilast,phosphodiesterase inhibitor,PDE4A,3350,Phase 3
cilomilast,phosphodiesterase inhibitor,PDE4B,3356,Phase 3
cilomilast,phosphodiesterase inhibitor,PDE4D,3357,Phase 3
cilostamide,phosphodiesterase inhibitor,PDE3A,3358,Preclinical
cilostamide,phosphodiesterase inhibitor,PDE3B,3362,Preclinical
cilostazol,phosphodiesterase inhibitor,PDE3A,3363,Launched
cilostazol,phosphodiesterase inhibitor,PDE3B,3757,Launched
CIM-0216,transient receptor potential channel agonist,TRPM3,5004,Preclinical
cimaterol,adrenergic receptor agonist,ADRB1,5005,Preclinical
cimaterol,adrenergic receptor agonist,ADRB2,6609,Preclinical
cimaterol,adrenergic receptor agonist,ADRB3,7224,Preclinical
cimetidine,histamine receptor antagonist,HRH2,6833,Launched
cimetidine,histamine receptor antagonist,SLC29A4,3766,Launched
cimetidine,histamine receptor antagonist,SLC47A1,1128,Launched
cimetidine,histamine receptor antagonist,SLC47A2,1129,Launched
cimetropium,acetylcholine receptor antagonist,CHRM1,1131,Launched
cinacalcet,calcium channel activator,CASR,1132,Launched
cinaciguat,guanylate cyclase activator,GUCY1A3,1133,Phase 2
cinaciguat,guanylate cyclase activator,GUCY1B3,1812,Phase 2
cinalukast,leukotriene receptor antagonist,CYSLTR1,1813,Phase 2
cinanserin,serotonin receptor antagonist,HTR2A,1814,Preclinical
cinchocaine,sodium channel blocker,CALM1,3269,Launched
cinchocaine,sodium channel blocker,SCN10A,3356,Launched
cinchocaine,sodium channel blocker,SCN5A,3357,Launched
cinchonine,P glycoprotein inhibitor,CYP2D6,3358,Preclinical
cinnamaldehyde,aldose reductase inhibitor|TRPV agonist,TRPA1,43,Preclinical
CINPA-1,CAR antagonist,NR1H4,759,Preclinical
CINPA-1,CAR antagonist,NR1I3,771,Preclinical
CINPA-1,CAR antagonist,PPARG,23632,Preclinical
cipemastat,metalloproteinase inhibitor,ADAM17,760,Phase 3
cipemastat,metalloproteinase inhibitor,MMP1,762,Phase 3
cipemastat,metalloproteinase inhibitor,MMP13,766,Phase 3
cipemastat,metalloproteinase inhibitor,MMP2,6557,Phase 3
cipemastat,metalloproteinase inhibitor,MMP3,3778,Phase 3
cipemastat,metalloproteinase inhibitor,MMP8,3783,Phase 3
cipemastat,metalloproteinase inhibitor,MMP9,7421,Phase 3
ciprofibrate,PPAR receptor agonist,PPARA,6095,Launched
ciprofloxacin,bacterial DNA gyrase inhibitor,TOP2A,126,Launched
ciproxifan,histamine receptor antagonist,ADRA2A,1066,Preclinical
ciproxifan,histamine receptor antagonist,ADRA2C,1327,Preclinical
ciproxifan,histamine receptor antagonist,HRH3,9377,Preclinical
ciproxifan,histamine receptor antagonist,HRH4,1329,Preclinical
ciproxifan,histamine receptor antagonist,HTR3A,1339,Preclinical
CIQ,glutamate receptor potentiator,GRIN2C,1340,Preclinical
CIQ,glutamate receptor potentiator,GRIN2D,1345,Preclinical
cirazoline,adrenergic receptor agonist,ADRA1A,1346,Preclinical
cis-aconitic-acid,,ACO2,1349,Preclinical
cis-ACPD,glutamate receptor agonist,GRM2,1350,Preclinical
cis-ACPD,glutamate receptor agonist,GRM3,1351,Preclinical
cis-ACPD,glutamate receptor agonist,GRM6,2104,Preclinical
cis-ACPD,glutamate receptor agonist,GRM7,2172,Preclinical
cis-ACPD,glutamate receptor agonist,GRM8,4522,Preclinical
"cis-exo-camphanediol-2,3",nitric oxide stimulant,NOS3,10797,Phase 1
cis-urocanic-acid,serotonin receptor agonist,HTR2A,4694,Phase 2
cisapride,serotonin receptor agonist,HTR2A,4705,Withdrawn
cisapride,serotonin receptor agonist,HTR3A,126328,Withdrawn
cisapride,serotonin receptor agonist,HTR4,55967,Withdrawn
cisapride,serotonin receptor agonist,KCNH2,51079,Withdrawn
cisatracurium,acetylcholine receptor antagonist,CHRNA2,4695,Launched
cisplatin,DNA alkylating agent|DNA synthesis inhibitor,XIAP,4696,Launched
citalopram,selective serotonin reuptake inhibitor (SSRI),ADRA1A,4697,Launched
citalopram,selective serotonin reuptake inhibitor (SSRI),CHRM1,56901,Launched
citalopram,selective serotonin reuptake inhibitor (SSRI),HRH1,4698,Launched
citalopram,selective serotonin reuptake inhibitor (SSRI),SLC6A2,4700,Launched
citalopram,selective serotonin reuptake inhibitor (SSRI),SLC6A3,4701,Launched
citalopram,selective serotonin reuptake inhibitor (SSRI),SLC6A4,4702,Launched
CITCO,constitutive androstane receptor (CAR) agonist,NR1I3,4704,Preclinical
citicoline,glutathione transferase stimulant|membrane permeability enhancer,ACHE,4706,Launched
citicoline,glutathione transferase stimulant|membrane permeability enhancer,SLC1A2,4707,Launched
citric-acid,coagulation factor inhibitor,AKR1B1,4716,Preclinical
citric-acid,coagulation factor inhibitor,ANG,4708,Preclinical
citric-acid,coagulation factor inhibitor,APRT,4709,Preclinical
citric-acid,coagulation factor inhibitor,BHMT,4710,Preclinical
citric-acid,coagulation factor inhibitor,C8G,4711,Preclinical
citric-acid,coagulation factor inhibitor,CA4,4712,Preclinical
citric-acid,coagulation factor inhibitor,CPB1,4713,Preclinical
citric-acid,coagulation factor inhibitor,CS,4714,Preclinical
citric-acid,coagulation factor inhibitor,CTDSP1,4715,Preclinical
citric-acid,coagulation factor inhibitor,GNMT,4717,Preclinical
citric-acid,coagulation factor inhibitor,HGS,4718,Preclinical
citric-acid,coagulation factor inhibitor,HS3ST3A1,4719,Preclinical
citric-acid,coagulation factor inhibitor,IL4I1,4720,Preclinical
citric-acid,coagulation factor inhibitor,ITPA,4722,Preclinical
citric-acid,coagulation factor inhibitor,LSM6,4724,Preclinical
citric-acid,coagulation factor inhibitor,MDH2,4725,Preclinical
citric-acid,coagulation factor inhibitor,MIF,4726,Preclinical
citric-acid,coagulation factor inhibitor,PDE5A,374291,Preclinical
citric-acid,coagulation factor inhibitor,PKD2L1,4728,Preclinical
citric-acid,coagulation factor inhibitor,PLEKHA1,4723,Preclinical
citric-acid,coagulation factor inhibitor,RNASE1,4729,Preclinical
citric-acid,coagulation factor inhibitor,RNASE3,4731,Preclinical
citric-acid,coagulation factor inhibitor,SRC,23530,Preclinical
citric-acid,coagulation factor inhibitor,TNFSF13B,4835,Preclinical
citric-acid,coagulation factor inhibitor,UCK2,50814,Preclinical
CJ-033466,serotonin receptor agonist,HTR4,4967,Preclinical
CK-636,actin related protein inhibitor,ACTR2,5160,Preclinical
CK-636,actin related protein inhibitor,ACTR3,5161,Preclinical
CK-636,actin related protein inhibitor,ARPC1B,5162,Preclinical
CK-636,actin related protein inhibitor,ARPC2,26227,Preclinical
CK-636,actin related protein inhibitor,ARPC3,5831,Preclinical
CK-636,actin related protein inhibitor,ARPC4,29920,Preclinical
CK-636,actin related protein inhibitor,ARPC5,5860,Preclinical
CKD-712,NFkB pathway inhibitor,JAK2,5959,Phase 1
CKD-712,NFkB pathway inhibitor,STAT1,6652,Phase 1
CKI-7,casein kinase inhibitor,CSNK1G2,-,Preclinical
CL-218872,benzodiazepine receptor agonist,GABRA1,7299,Phase 1
CL-218872,benzodiazepine receptor agonist,GABRA2,7358,Phase 1
CL-218872,benzodiazepine receptor agonist,GABRA3,2741,Phase 1
CL-218872,benzodiazepine receptor agonist,GABRA5,2742,Phase 1
CL-218872,benzodiazepine receptor agonist,GABRB2,7846,Phase 1
CL-218872,benzodiazepine receptor agonist,GABRG2,10376,Phase 1
cladribine,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,ADA,84790,Launched
cladribine,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,PNP,7278,Launched
cladribine,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,POLA1,113457,Launched
cladribine,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,POLE,112714,Launched
cladribine,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,POLE2,7277,Launched
cladribine,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,POLE3,203068,Launched
cladribine,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,POLE4,81027,Launched
cladribine,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,RRM1,7280,Launched
cladribine,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,RRM2,347733,Launched
cladribine,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,RRM2B,10381,Launched
clarithromycin,bacterial 50S ribosomal subunit inhibitor,CYP3A4,10382,Launched
clebopride,dopamine receptor antagonist,ACHE,10383,Launched
clebopride,dopamine receptor antagonist,DRD2,84617,Launched
clemastine,histamine receptor antagonist,HRH1,347688,Launched
clenbuterol,adrenergic receptor agonist,ABCC8,108,Launched
clenbuterol,adrenergic receptor agonist,ADRB2,111,Launched
clenbuterol,adrenergic receptor agonist,KCNJ11,23621,Launched
cleviprex,calcium channel blocker,CACNA1C,2475,Launched
cleviprex,calcium channel blocker,CACNA1D,5591,Launched
cleviprex,calcium channel blocker,CACNA1F,552,Launched
cleviprex,calcium channel blocker,CACNA1S,554,Launched
clidinium,acetylcholine receptor antagonist,CHRM1,5290,Launched
clidinium,acetylcholine receptor antagonist,CHRM3,5291,Launched
clinofibrate,lipase clearing factor inhibitor,LPL,5293,Launched
clioquinol,chelating agent,OPRK1,5294,Withdrawn
clobenpropit,histamine receptor antagonist,HRH1,51296,Preclinical
clobenpropit,histamine receptor antagonist,HRH2,121260,Preclinical
clobenpropit,histamine receptor antagonist,HRH3,92745,Preclinical
clobenpropit,histamine receptor antagonist,HRH4,1269,Preclinical
clobetasol-propionate,glucocorticoid receptor agonist,NR3C1,3290,Launched
clobetasol-propionate,glucocorticoid receptor agonist,PLA2G1B,5770,Launched
clobetasone-butyrate,corticosteroid agonist,NR3C1,3290,Launched
clocortolone-pivalate,steroid,NR3C1,8648,Launched
clocortolone-pivalate,steroid,PLA2G1B,4306,Launched
clodronic-acid,bone resorption inhibitor,SLC25A4,2908,Launched
clodronic-acid,bone resorption inhibitor,SLC25A5,2908,Launched
clodronic-acid,bone resorption inhibitor,SLC25A6,367,Launched
clofarabine,ribonucleotide reductase inhibitor,POLA1,1326,Launched
clofarabine,ribonucleotide reductase inhibitor,POLD1,1326,Launched
clofarabine,ribonucleotide reductase inhibitor,POLE,759,Launched
clofarabine,ribonucleotide reductase inhibitor,RRM1,2235,Launched
clofarabine,ribonucleotide reductase inhibitor,RRM2,151306,Launched
clofarabine,ribonucleotide reductase inhibitor,RRM2B,4512,Launched
clofedanol,histamine receptor antagonist,HRH1,4513,Launched
clofibrate,PPAR receptor agonist,LPL,4514,Launched
clofibrate,PPAR receptor agonist,PPARA,5319,Launched
clofibric-acid,PPAR receptor agonist,PPARA,43,Launched
clofilium,potassium channel blocker,KCNA5,590,Phase 2
clofilium,potassium channel blocker,KCNH1,1135,Phase 2
clomethiazole,GABA receptor antagonist|GABA receptor modulator,GABRA1,5130,Launched
clomifene,estrogen receptor antagonist,ESR1,9468,Launched
clomipramine,serotonin transporter (SERT) inhibitor,GSTP1,162466,Launched
clomipramine,serotonin transporter (SERT) inhibitor,HTR2A,5337,Launched
clomipramine,serotonin transporter (SERT) inhibitor,HTR2B,5338,Launched
clomipramine,serotonin transporter (SERT) inhibitor,HTR2C,2915,Launched
clomipramine,serotonin transporter (SERT) inhibitor,SLC6A2,83903,Launched
clomipramine,serotonin transporter (SERT) inhibitor,SLC6A3,231,Launched
clomipramine,serotonin transporter (SERT) inhibitor,SLC6A4,1021,Launched
clonidine,adrenergic receptor agonist,ADRA1A,1588,Launched
clonidine,adrenergic receptor agonist,ADRA1B,1545,Launched
clonidine,adrenergic receptor agonist,ADRA1D,1956,Launched
clonidine,adrenergic receptor agonist,ADRA2A,2475,Launched
clonidine,adrenergic receptor agonist,ADRA2B,196,Launched
clonidine,adrenergic receptor agonist,ADRA2C,2475,Launched
clonixin,cyclooxygenase inhibitor,PTGS1,5290,Preclinical
clonixin,cyclooxygenase inhibitor,PTGS2,5291,Preclinical
clopidogrel,purinergic receptor antagonist,P2RY12,5293,Launched
cloprostenol-(+/-),prostaglandin receptor agonist,PTGDR,5294,Launched
cloprostenol-(+/-),prostaglandin receptor agonist,PTGER1,5914,Launched
cloprostenol-(+/-),prostaglandin receptor agonist,PTGER3,5915,Launched
cloprostenol-(+/-),prostaglandin receptor agonist,PTGFR,6529,Launched
cloprostenol-(+/-),prostaglandin receptor agonist,TBXA2R,38,Launched
cloranolol,adrenergic receptor antagonist,ADRB1,1066,Launched
cloranolol,adrenergic receptor antagonist,ADRB2,5742,Launched
cloranolol,adrenergic receptor antagonist,ADRB3,2908,Launched
clorgiline,monoamine oxidase inhibitor,MAOA,866,Phase 2
clorotepine,adrenergic receptor antagonist|dopamine receptor antagonist,ADRA1A,476,Launched
clorotepine,adrenergic receptor antagonist|dopamine receptor antagonist,ADRA1B,5742,Launched
clorotepine,adrenergic receptor antagonist|dopamine receptor antagonist,ADRA1D,5743,Launched
clorotepine,adrenergic receptor antagonist|dopamine receptor antagonist,DRD2,9290,Launched
clorotepine,adrenergic receptor antagonist|dopamine receptor antagonist,HRH1,5310,Launched
clorotepine,adrenergic receptor antagonist|dopamine receptor antagonist,HTR2C,2859,Launched
clorotepine,adrenergic receptor antagonist|dopamine receptor antagonist,HTR6,5595,Launched
clorprenaline,adrenergic receptor agonist,ADRB1,5468,Launched
clorprenaline,adrenergic receptor agonist,ADRB2,1800,Launched
clotrimazole,cytochrome P450 inhibitor|imidazoline receptor ligand,CYP3A4,1636,Launched
clotrimazole,cytochrome P450 inhibitor|imidazoline receptor ligand,KCNN4,3685,Launched
clotrimazole,cytochrome P450 inhibitor|imidazoline receptor ligand,NR1I2,3690,Launched
clotrimazole,cytochrome P450 inhibitor|imidazoline receptor ligand,NR1I3,774,Launched
clotrimazole,cytochrome P450 inhibitor|imidazoline receptor ligand,TRPM2,5141,Launched
clotrimazole,cytochrome P450 inhibitor|imidazoline receptor ligand,TRPM4,5142,Launched
clotrimazole,cytochrome P450 inhibitor|imidazoline receptor ligand,TRPM8,5144,Launched
cloxyquin,potassium channel activator,KCNK18,5139,Preclinical
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A,5140,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1B,5139,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1D,5140,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,ADRA2A,80036,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,ADRA2B,153,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,ADRA2C,154,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,CALY,155,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,CHRM1,3274,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,CHRM2,222962,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,CHRM3,55244,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,CHRM4,146802,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,CHRM5,1128,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,DRD1,846,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,DRD2,-,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,DRD3,-,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,DRD4,10800,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,DRD5,3356,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,HRH1,801,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,HRH4,6336,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1A,6331,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1B,1565,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1D,8989,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1E,9971,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1F,9970,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR2A,5468,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR2B,6868,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR2C,4312,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR3A,4322,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR5A,4313,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR6,4314,Launched
clozapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR7,4317,Launched
CL316243,adrenergic receptor agonist,ADRB3,4318,Phase 2
CL316243,adrenergic receptor agonist,UCP1,5465,Phase 2
CL316243,adrenergic receptor agonist,UCP2,7153,Phase 2
CL316243,adrenergic receptor agonist,UCP3,150,Phase 2
CMPD-1,p38 MAPK inhibitor,GNRHR,152,Preclinical
CMPD-1,p38 MAPK inhibitor,MAPK14,11255,Preclinical
CNQX,glutamate receptor antagonist,GRIA1,59340,Phase 1
CNQX,glutamate receptor antagonist,GRIA2,3359,Phase 1
CNQX,glutamate receptor antagonist,GRIA3,2905,Phase 1
CNQX,glutamate receptor antagonist,GRIA4,2906,Phase 1
CNX-2006,EGFR inhibitor,EGFR,148,Preclinical
CNX-774,Bruton's tyrosine kinase (BTK) inhibitor,BTK,50,Preclinical
CO-101244,glutamate receptor antagonist,GRIN2B,2912,Preclinical
CO-102862,sodium channel blocker,SCN4A,2913,Phase 1
CO-102862,sodium channel blocker,SCN9A,2916,Phase 1
cobicistat,cytochrome P450 inhibitor,CYP3A4,2917,Launched
cobicistat,cytochrome P450 inhibitor,CYP3A43,2918,Launched
cobicistat,cytochrome P450 inhibitor,CYP3A5,4846,Launched
cobicistat,cytochrome P450 inhibitor,CYP3A7,3356,Launched
cobimetinib,MEK inhibitor,MAP2K1,3356,Launched
coenzyme-A,,ACAT2,3359,Launched
coenzyme-A,,CRAT,3360,Launched
coenzyme-A,,CS,3757,Launched
coenzyme-A,,DBI,1135,Launched
coenzyme-A,,HMGCR,331,Launched
coenzyme-A,,KAT2A,148,Launched
coenzyme-A,,KAT2B,1128,Launched
coenzyme-A,,KAT5,3269,Launched
coenzyme-I,,AASS,6530,Phase 2
coenzyme-I,,ACADS,6531,Phase 2
coenzyme-I,,ADH1A,6532,Phase 2
coenzyme-I,,ADH1B,9970,Phase 2
coenzyme-I,,ADH1C,43,Phase 2
coenzyme-I,,ADH4,6506,Phase 2
coenzyme-I,,ADH5,231,Phase 2
coenzyme-I,,ADH7,283,Phase 2
coenzyme-I,,AKR1B1,353,Phase 2
coenzyme-I,,AKR1C1,635,Phase 2
coenzyme-I,,AKR1C2,733,Phase 2
coenzyme-I,,AKR1C3,762,Phase 2
coenzyme-I,,AKR1C4,1360,Phase 2
coenzyme-I,,ALDH1A1,1431,Phase 2
coenzyme-I,,ALDH1A2,58190,Phase 2
coenzyme-I,,ALDH1A3,27232,Phase 2
coenzyme-I,,ALDH1B1,9146,Phase 2
coenzyme-I,,ALDH2,9955,Phase 2
coenzyme-I,,ALDH3A1,259307,Phase 2
coenzyme-I,,ALDH3A2,3704,Phase 2
coenzyme-I,,ALDH3B1,11157,Phase 2
coenzyme-I,,ALDH3B2,4191,Phase 2
coenzyme-I,,ALDH4A1,4282,Phase 2
coenzyme-I,,ALDH5A1,8654,Phase 2
coenzyme-I,,ALDH6A1,9033,Phase 2
coenzyme-I,,ALDH7A1,59338,Phase 2
coenzyme-I,,ALDH9A1,6035,Phase 2
coenzyme-I,,AMT,6037,Phase 2
coenzyme-I,,BDH1,6714,Phase 2
coenzyme-I,,BLVRA,10673,Phase 2
coenzyme-I,,BLVRB,7371,Phase 2
coenzyme-I,,CDO1,3360,Phase 2
coenzyme-I,,CYB5R3,10097,Phase 2
coenzyme-I,,CYP17A1,10096,Phase 2
coenzyme-I,,CYP4A11,10095,Phase 2
coenzyme-I,,DHCR7,10109,Phase 2
coenzyme-I,,DHFR,10094,Phase 2
coenzyme-I,,DLAT,10093,Phase 2
coenzyme-I,,DLD,10092,Phase 2
coenzyme-I,,EHHADH,3717,Phase 2
coenzyme-I,,GAPDH,6772,Phase 2
coenzyme-I,,GAPDHS,1455,Phase 2
coenzyme-I,,GLUD1,2554,Phase 2
coenzyme-I,,GLUD2,2555,Phase 2
coenzyme-I,,GPD1,2556,Phase 2
coenzyme-I,,GSR,2558,Phase 2
coenzyme-I,,H6PD,2561,Phase 2
coenzyme-I,,HADH,2566,Phase 2
coenzyme-I,,HADHA,100,Phase 2
coenzyme-I,,HIBADH,4860,Phase 2
coenzyme-I,,HMGCR,5422,Phase 2
coenzyme-I,,HMOX1,5426,Phase 2
coenzyme-I,,HMOX2,5427,Phase 2
coenzyme-I,,HPGD,54107,Phase 2
coenzyme-I,,HSD11B1,56655,Phase 2
coenzyme-I,,HSD11B2,6240,Phase 2
coenzyme-I,,HSD17B1,6241,Phase 2
coenzyme-I,,HSD17B10,50484,Phase 2
coenzyme-I,,HSD17B2,1576,Phase 2
coenzyme-I,,HSD17B3,43,Phase 2
coenzyme-I,,HSD17B4,1813,Phase 2
coenzyme-I,,HSD17B7,3269,Phase 2
coenzyme-I,,HSD17B8,6833,Phase 2
coenzyme-I,,HSD3B1,154,Phase 2
coenzyme-I,,HSD3B2,3767,Phase 2
coenzyme-I,,IDH3A,775,Phase 2
coenzyme-I,,IDH3B,776,Phase 2
coenzyme-I,,IDH3G,778,Phase 2
coenzyme-I,,IMPDH1,779,Phase 2
coenzyme-I,,IMPDH2,1128,Phase 2
coenzyme-I,,LDHA,1131,Phase 2
coenzyme-I,,LDHAL6A,4023,Phase 2
coenzyme-I,,LDHAL6B,4986,Phase 2
coenzyme-I,,LDHB,3269,Phase 2
coenzyme-I,,LDHC,3274,Phase 2
coenzyme-I,,MDH1,11255,Phase 2
coenzyme-I,,MDH2,59340,Phase 2
coenzyme-I,,ME1,2908,Phase 2
coenzyme-I,,ME2,5319,Phase 2
coenzyme-I,,ME3,2908,Phase 2
coenzyme-I,,MSMO1,2908,Phase 2
coenzyme-I,,MT-ND1,5319,Phase 2
coenzyme-I,,MT-ND2,291,Phase 2
coenzyme-I,,MT-ND3,292,Phase 2
coenzyme-I,,MT-ND4,293,Phase 2
coenzyme-I,,MT-ND4L,5422,Phase 2
coenzyme-I,,MT-ND5,5424,Phase 2
coenzyme-I,,MT-ND6,5426,Phase 2
coenzyme-I,,MTHFD1,64816,Phase 2
coenzyme-I,,MTHFD2,1577,Phase 2
coenzyme-I,,NDUFA1,1551,Phase 2
coenzyme-I,,NDUFA10,5604,Phase 2
coenzyme-I,,NDUFA11,39,Phase 2
coenzyme-I,,NDUFA12,1384,Phase 2
coenzyme-I,,NDUFA13,1431,Phase 2
coenzyme-I,,NDUFA2,1622,Phase 2
coenzyme-I,,NDUFA3,3156,Phase 2
coenzyme-I,,NDUFA4,2648,Phase 2
coenzyme-I,,NDUFA4L2,8850,Phase 2
coenzyme-I,,NDUFA5,10524,Phase 2
coenzyme-I,,NDUFA6,10157,Phase 2
coenzyme-I,,NDUFA7,35,Phase 2
coenzyme-I,,NDUFA8,124,Phase 2
coenzyme-I,,NDUFA9,125,Phase 2
coenzyme-I,,NDUFAB1,126,Phase 2
coenzyme-I,,NDUFB1,127,Phase 2
coenzyme-I,,NDUFB10,128,Phase 2
coenzyme-I,,NDUFB2,131,Phase 2
coenzyme-I,,NDUFB3,231,Phase 2
coenzyme-I,,NDUFB4,1645,Phase 2
coenzyme-I,,NDUFB5,1646,Phase 2
coenzyme-I,,NDUFB6,8644,Phase 2
coenzyme-I,,NDUFB7,1109,Phase 2
coenzyme-I,,NDUFB8,216,Phase 2
coenzyme-I,,NDUFB9,8854,Phase 2
coenzyme-I,,NDUFC1,220,Phase 2
coenzyme-I,,NDUFC2,219,Phase 2
coenzyme-I,,NDUFS1,217,Phase 2
coenzyme-I,,NDUFS2,218,Phase 2
coenzyme-I,,NDUFS3,224,Phase 2
coenzyme-I,,NDUFS4,221,Phase 2
coenzyme-I,,NDUFS5,222,Phase 2
coenzyme-I,,NDUFS6,8659,Phase 2
coenzyme-I,,NDUFS7,7915,Phase 2
coenzyme-I,,NDUFS8,4329,Phase 2
coenzyme-I,,NDUFV1,501,Phase 2
coenzyme-I,,NDUFV2,223,Phase 2
coenzyme-I,,NDUFV3,275,Phase 2
coenzyme-I,,NNT,622,Phase 2
coenzyme-I,,NQO2,644,Phase 2
coenzyme-I,,NSDHL,645,Phase 2
coenzyme-I,,OGDH,1036,Phase 2
coenzyme-I,,PDHA1,1727,Phase 2
coenzyme-I,,PDHA2,1586,Phase 2
coenzyme-I,,PDHB,1579,Phase 2
coenzyme-I,,PHGDH,1717,Phase 2
coenzyme-I,,PYCR1,1719,Phase 2
coenzyme-I,,PYCR2,1737,Phase 2
coenzyme-I,,QDPR,1738,Phase 2
coenzyme-I,,RDH5,1962,Phase 2
coenzyme-I,,SORD,2597,Phase 2
coenzyme-I,,TSTA3,26330,Phase 2
coenzyme-I,,TYR,2746,Phase 2
coenzyme-I,,UGDH,2747,Phase 2
colchicine,microtubule inhibitor,GLRA1,2819,Launched
colchicine,microtubule inhibitor,GLRA2,2936,Launched
colchicine,microtubule inhibitor,TUBA1A,9563,Launched
colchicine,microtubule inhibitor,TUBA1B,3033,Launched
colchicine,microtubule inhibitor,TUBA1C,3030,Launched
colchicine,microtubule inhibitor,TUBA3C,11112,Launched
colchicine,microtubule inhibitor,TUBA3D,3156,Launched
colchicine,microtubule inhibitor,TUBA3E,3162,Launched
colchicine,microtubule inhibitor,TUBA4A,3163,Launched
colchicine,microtubule inhibitor,TUBB,3248,Launched
colchicine,microtubule inhibitor,TUBB1,3290,Launched
colchicine,microtubule inhibitor,TUBB2A,3291,Launched
colchicine,microtubule inhibitor,TUBB2B,3292,Launched
colchicine,microtubule inhibitor,TUBB3,3028,Launched
colchicine,microtubule inhibitor,TUBB4A,3294,Launched
colchicine,microtubule inhibitor,TUBB4B,3293,Launched
colchicine,microtubule inhibitor,TUBB6,3295,Launched
colchicine,microtubule inhibitor,TUBB8,51478,Launched
colforsin,adenylyl cyclase activator,ADCY2,7923,Phase 2
colforsin,adenylyl cyclase activator,ADCY5,3283,Phase 2
compound-w,beta-secretase inhibitor,BACE1,3284,Preclinical
compound-401,DNA dependent protein kinase inhibitor,MTOR,3419,Preclinical
compound-401,DNA dependent protein kinase inhibitor,PRKDC,3420,Preclinical
conivaptan,vasopressin receptor antagonist,AVPR1A,3421,Launched
conivaptan,vasopressin receptor antagonist,AVPR2,3614,Launched
copanlisib,PI3K inhibitor,PIK3CA,3615,Launched
copanlisib,PI3K inhibitor,PIK3CB,3939,Launched
copanlisib,PI3K inhibitor,PIK3CD,160287,Launched
copanlisib,PI3K inhibitor,PIK3CG,92483,Launched
copper-histidine,,SLC15A3,3945,Phase 3
copper-histidine,,SLC15A4,3948,Phase 3
copper-histidine,,SLC38A5,4190,Phase 3
COR-170,cannabinoid receptor inverse agonist,CNR2,4191,Preclinical
corosolic-acid,PKC inhibitor|protein tyrosine kinase inhibitor,HSD11B1,4199,Phase 2
corosolic-acid,PKC inhibitor|protein tyrosine kinase inhibitor,PTPN1,4200,Phase 2
corticosterone,mineralocorticoid receptor agonist,HSD11B1,10873,Preclinical
corticosterone,mineralocorticoid receptor agonist,NCOA1,6307,Preclinical
corticosterone,mineralocorticoid receptor agonist,NR3C2,4535,Preclinical
cortisone,glucocorticoid receptor agonist,NR3C1,4536,Launched
cortisone-acetate,glucocorticoid receptor agonist,NR3C1,4537,Launched
cortodoxone,androgen receptor antagonist,AR,4538,Phase 3
cot-inhibitor-1,MAPK-interacting kinase inhibitor,MAP3K8,4539,Preclinical
cot-inhibitor-2,MAPK-interacting kinase inhibitor,MAP3K8,4540,Preclinical
coumarin,vitamin K antagonist,CA1,4541,Launched
coumarin,vitamin K antagonist,CA12,771,Launched
coumarin,vitamin K antagonist,CA14,23632,Launched
coumarin,vitamin K antagonist,CA2,760,Launched
coumarin,vitamin K antagonist,CA4,762,Launched
coumarin,vitamin K antagonist,CA6,765,Launched
coumarin,vitamin K antagonist,CA9,768,Launched
coumarin,vitamin K antagonist,CYP2A6,1548,Launched
CP-316819,glycogen phosphorylase inhibitor,PYGL,5836,Preclinical
CP-339818,potassium channel blocker,KCNA3,3738,Preclinical
CP-376395,corticotropin releasing factor receptor antagonist,CRHR1,1394,Phase 1
CP-471474,matrix metalloprotease inhibitor,MMP1,4312,Preclinical
CP-471474,matrix metalloprotease inhibitor,MMP13,4322,Preclinical
CP-471474,matrix metalloprotease inhibitor,MMP2,4313,Preclinical
CP-471474,matrix metalloprotease inhibitor,MMP3,4314,Preclinical
CP-471474,matrix metalloprotease inhibitor,MMP9,4318,Preclinical
CP-532623,cholesteryl ester transfer protein inhibitor,CETP,1071,Phase 1
CP-640186,acetyl-CoA carboxylase inhibitor,ACACA,31,Preclinical
CP-640186,acetyl-CoA carboxylase inhibitor,ACACB,32,Preclinical
CP-673451,PDGFR tyrosine kinase receptor inhibitor,KIT,3815,Preclinical
CP-673451,PDGFR tyrosine kinase receptor inhibitor,PDGFRA,5156,Preclinical
CP-673451,PDGFR tyrosine kinase receptor inhibitor,PDGFRB,5159,Preclinical
CP-724714,EGFR inhibitor|protein tyrosine kinase inhibitor,ERBB2,2064,Phase 2
CP-775146,PPAR receptor agonist,PPARA,5465,Preclinical
CP-91149,glycogen phosphorylase inhibitor,PYGL,5836,Preclinical
CP-93129,serotonin receptor agonist,HTR1A,3350,Preclinical
CP-94253,serotonin receptor agonist,HTR1B,3351,Preclinical
"CP-945,598",cannabinoid receptor antagonist,CNR1,1268,Phase 3
CP-99994,tachykinin antagonist,TACR1,6869,Phase 2
CPA-inhibitor,carboxypeptidase inhibitor,CPA1,1357,Preclinical
CPA-inhibitor,carboxypeptidase inhibitor,CPA2,1358,Preclinical
CPCCOEt,glutamate receptor antagonist,GRM1,2911,Preclinical
CPI-0610,bromodomain inhibitor,BRD4,23476,Phase 2
CPI-1189,tumor necrosis factor release inhibitor,TNF,7124,Phase 2
CPI-169,histone lysine methyltransferase inhibitor,EZH2,2146,Preclinical
CPI-203,bromodomain inhibitor,BRD4,23476,Preclinical
CPI-360,histone lysine methyltransferase inhibitor,EZH2,2146,Preclinical
CPI-613,pyruvate dehydrogenase inhibitor,PDHA1,5160,Phase 3
CPP,glutamate receptor antagonist,GRIN1,2902,Phase 2
CPP,glutamate receptor antagonist,GRIN2A,2903,Phase 2
CPP,glutamate receptor antagonist,GRIN2B,2904,Phase 2
CPP,glutamate receptor antagonist,GRIN2C,2905,Phase 2
CPP,glutamate receptor antagonist,GRIN2D,2906,Phase 2
CPSI-1306-(+/-),macrophage migration inhibiting factor inhibitor,MIF,4282,Preclinical
creatine,,CKB,1152,Launched
creatine,,CKM,1158,Launched
creatine,,CKMT1A,548596,Launched
creatine,,CKMT2,1160,Launched
creatine,,GAMT,2593,Launched
creatine,,SLC6A8,6535,Launched
crenolanib,PDGFR tyrosine kinase receptor inhibitor,CSF1R,1436,Phase 3
crenolanib,PDGFR tyrosine kinase receptor inhibitor,FLT3,2322,Phase 3
crenolanib,PDGFR tyrosine kinase receptor inhibitor,KIT,3815,Phase 3
crenolanib,PDGFR tyrosine kinase receptor inhibitor,PDGFRA,5156,Phase 3
crenolanib,PDGFR tyrosine kinase receptor inhibitor,PDGFRB,5159,Phase 3
cridanimod,progesterone receptor agonist,PGR,5241,Launched
crisaborole,phosphodiesterase inhibitor,PDE4A,5141,Launched
crisaborole,phosphodiesterase inhibitor,PDE4B,5142,Launched
crisaborole,phosphodiesterase inhibitor,PDE4C,5143,Launched
crisaborole,phosphodiesterase inhibitor,PDE4D,5144,Launched
crizotinib,ALK tyrosine kinase receptor inhibitor,ALK,238,Launched
crizotinib,ALK tyrosine kinase receptor inhibitor,MET,4233,Launched
crizotinib-(S),MTH1 inhibitor,NUDT1,4521,Preclinical
cromakalim,,KCNJ8,3764,Phase 2
cromoglicic-acid,immunosuppressant,KCNMA1,3778,Launched
cromoglicic-acid,immunosuppressant,S100P,6286,Launched
cryptotanshinone,acetylcholinesterase inhibitor|STAT inhibitor,STAT3,6774,Preclinical
CR8-(R),CDK inhibitor,CCNA2,890,Preclinical
CS-110266,dopamine receptor agonist,SLC6A3,6531,Preclinical
CS-917,fructose biphosphate inhibitor,FBP1,2203,Phase 2
CT-7758,integrin antagonist,ITGA4,3676,Phase 2
CTEP,glutamate receptor antagonist,GRM5,2915,Preclinical
CTS-1027,metalloproteinase inhibitor,MMP1,4312,Phase 2
CTS-1027,metalloproteinase inhibitor,MMP13,4322,Phase 2
CTS-1027,metalloproteinase inhibitor,MMP2,4313,Phase 2
CTS-1027,metalloproteinase inhibitor,MMP3,4314,Phase 2
CTS-1027,metalloproteinase inhibitor,MMP9,4318,Phase 2
CTS21166,beta-secretase inhibitor,BACE1,23621,Phase 1
CU-CPT-4a,toll-like receptor inhibitor,TLR3,7098,Preclinical
CU-T12-9,toll-like receptor agonist,TLR1,7096,Preclinical
CU-T12-9,toll-like receptor agonist,TLR2,7097,Preclinical
CUDC-101,EGFR inhibitor,EGFR,1956,Phase 1
CUDC-101,EGFR inhibitor,ERBB2,2064,Phase 1
CUDC-427,apoptosis inhibitor,XIAP,331,Phase 1
CUDC-907,PI3K inhibitor,HDAC2,3066,Phase 2
CUDC-907,PI3K inhibitor,PIK3R1,5295,Phase 2
CUR-61414,smoothened receptor antagonist,DHH,50846,Phase 1
CUR-61414,smoothened receptor antagonist,IHH,3549,Phase 1
CUR-61414,smoothened receptor antagonist,SMO,6608,Phase 1
curcumin,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,APP,351,Launched
curcumin,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,CA1,759,Launched
curcumin,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,CA12,771,Launched
curcumin,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,CA14,23632,Launched
curcumin,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,CA2,760,Launched
curcumin,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,CA4,762,Launched
curcumin,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,CA6,765,Launched
curcumin,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,CA9,768,Launched
curcumin,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,CHRM3,1131,Launched
curcumin,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,CYP3A4,1576,Launched
curcumin,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,DNMT3B,1789,Launched
curcumin,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,EP300,2033,Launched
curcumin,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,MMP13,4322,Launched
curcumin,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,MMP9,4318,Launched
curcumin,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,NOS2,4843,Launched
curcumin,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,PTGS1,5742,Launched
curcumin,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,PTGS2,5743,Launched
curcumin,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,XDH,7498,Launched
curcumol,JAK inhibitor,JAK1,3716,Phase 1
curcumol,JAK inhibitor,JAK2,3717,Phase 1
curcumol,JAK inhibitor,JAK3,3718,Phase 1
cutamesine,sigma receptor agonist,SIGMAR1,10280,Phase 2
CV-1808,adenosine receptor agonist,ADORA2A,135,Preclinical
CVT-10216,aldehyde dehydrogenase inhibitor,ALDH2,217,Phase 1
CW-008,PKA activator,PRKACA,5566,Preclinical
CX-4945,casein kinase inhibitor,CSNK2A1,1457,Phase 1/Phase 2
CX-4945,casein kinase inhibitor,CSNK2A2,1459,Phase 1/Phase 2
CX-4945,casein kinase inhibitor,DAPK3,1613,Phase 1/Phase 2
CX-4945,casein kinase inhibitor,HIPK3,10114,Phase 1/Phase 2
cyamemazine,serotonin receptor antagonist,HTR1A,3350,Launched
cyamemazine,serotonin receptor antagonist,HTR2A,3356,Launched
cyamemazine,serotonin receptor antagonist,HTR2C,3358,Launched
cyamemazine,serotonin receptor antagonist,HTR7,3363,Launched
cyanocobalamin,methylmalonyl CoA mutase stimulant|vitamin B,MUT,4594,Launched
cyanopindolol,adrenergic receptor antagonist,ADRB1,153,Phase 2
cyanopindolol,adrenergic receptor antagonist,HTR1A,3350,Phase 2
cyanopindolol,adrenergic receptor antagonist,HTR1D,3352,Phase 2
cyclic-AMP,,CNGA3,1261,Preclinical
cyclic-AMP,,TRPM7,54822,Preclinical
cyclizine,histamine receptor modulator,HRH1,3269,Launched
cyclizine,histamine receptor modulator,SULT1E1,6783,Launched
cyclobenzaprine,adrenergic receptor agonist|serotonin receptor agonist,HTR2A,3356,Launched
cycloheximide,protein synthesis inhibitor,RPL3,6122,Preclinical
cyclophosphamide,DNA alkylating agent,CYP2A6,1548,Launched
cyclophosphamide,DNA alkylating agent,CYP2B6,1555,Launched
cyclophosphamide,DNA alkylating agent,CYP2C18,1562,Launched
cyclophosphamide,DNA alkylating agent,CYP2C19,1557,Launched
cyclophosphamide,DNA alkylating agent,CYP2C8,1558,Launched
cyclophosphamide,DNA alkylating agent,CYP2C9,1559,Launched
cyclophosphamide,DNA alkylating agent,CYP2D6,1565,Launched
cyclophosphamide,DNA alkylating agent,CYP3A4,1576,Launched
cyclophosphamide,DNA alkylating agent,CYP3A5,1577,Launched
cyclophosphamide,DNA alkylating agent,CYP3A7,1551,Launched
cyclopiazonic-acid,ATPase inhibitor,ATP2A1,487,Preclinical
cycloserine-(D),bacterial cell wall synthesis inhibitor,GRIN1,2902,Launched
cyclosporin-A,calcineurin inhibitor,ABCB11,8647,Launched
cyclosporin-A,calcineurin inhibitor,CAMLG,819,Launched
cyclosporin-A,calcineurin inhibitor,FPR1,2357,Launched
cyclosporin-A,calcineurin inhibitor,PPIA,5478,Launched
cyclosporin-A,calcineurin inhibitor,PPIF,10105,Launched
cyclosporin-A,calcineurin inhibitor,PPP3CA,5530,Launched
cyclosporin-A,calcineurin inhibitor,PPP3R2,5535,Launched
cyclosporin-A,calcineurin inhibitor,SLC10A1,6554,Launched
cyclosporin-A,calcineurin inhibitor,SLCO1B1,10599,Launched
cyclosporin-A,calcineurin inhibitor,SLCO1B3,28234,Launched
cyclothiazide,glutamate receptor modulator,CA2,760,Launched
cyclothiazide,glutamate receptor modulator,GRIA1,2890,Launched
cyclothiazide,glutamate receptor modulator,GRIA2,2891,Launched
cyclothiazide,glutamate receptor modulator,GRIA3,2892,Launched
cyclothiazide,glutamate receptor modulator,GRIA4,2893,Launched
cyclothiazide,glutamate receptor modulator,SLC12A3,6559,Launched
cyclovalone,breast cancer resistance protein inhibitor,ABCG2,9429,Launched
CYC116,Aurora kinase inhibitor,AURKA,6790,Phase 1
CYC116,Aurora kinase inhibitor,AURKB,9212,Phase 1
CYC116,Aurora kinase inhibitor,KDR,3791,Phase 1
CYM-50260,sphingosine 1-phosphate receptor agonist,S1PR4,8698,Preclinical
CYM-50358,sphingosine 1-phosphate receptor antagonist,S1PR4,8698,Preclinical
CYM-50769,neuropeptide receptor antagonist,NPBWR1,2831,Preclinical
CYM-5442,sphingosine 1-phosphate receptor agonist,S1PR1,1901,Preclinical
CYM-5520,sphingosine 1-phosphate receptor agonist,S1PR2,9294,Preclinical
CYM-5541,sphingosine 1-phosphate receptor agonist,S1PR3,1903,Preclinical
cyproheptadine,histamine receptor antagonist,ADRA1A,148,Launched
cyproheptadine,histamine receptor antagonist,ADRA1B,147,Launched
cyproheptadine,histamine receptor antagonist,ADRA1D,146,Launched
cyproheptadine,histamine receptor antagonist,CHRM1,1128,Launched
cyproheptadine,histamine receptor antagonist,CHRM2,1129,Launched
cyproheptadine,histamine receptor antagonist,CHRM3,1131,Launched
cyproheptadine,histamine receptor antagonist,HRH1,3269,Launched
cyproheptadine,histamine receptor antagonist,HTR2A,3356,Launched
cyproheptadine,histamine receptor antagonist,HTR2C,3358,Launched
cyproheptadine,histamine receptor antagonist,HTR6,3362,Launched
cyproheptadine,histamine receptor antagonist,HTR7,3363,Launched
cyproterone-acetate,androgen receptor antagonist,ADORA1,134,Launched
cyproterone-acetate,androgen receptor antagonist,AR,367,Launched
cysteamine,tissue transglutaminase inhibitor,NPY2R,4887,Launched
cysteamine,tissue transglutaminase inhibitor,SST,6750,Launched
CYT-997,tubulin polymerization inhibitor,TUBB,203068,Phase 2
cytarabine,ribonucleotide reductase inhibitor,POLA1,5422,Launched
cytarabine,ribonucleotide reductase inhibitor,POLB,5423,Launched
cytarabine,ribonucleotide reductase inhibitor,POLD1,5424,Launched
cytarabine,ribonucleotide reductase inhibitor,POLE,5426,Launched
cytisine,acetylcholine receptor agonist,CHRNA2,1135,Launched
cytisine,acetylcholine receptor agonist,CHRNA3,1136,Launched
cytisine,acetylcholine receptor agonist,CHRNA4,1137,Launched
cytisine,acetylcholine receptor agonist,CHRNA6,8973,Launched
cytisine,acetylcholine receptor agonist,CHRNA7,1139,Launched
cytisine,acetylcholine receptor agonist,CHRNB2,1141,Launched
cytisine,acetylcholine receptor agonist,CHRNB4,1143,Launched
cytochalasin-B,microtubule inhibitor,ACTB,60,Phase 2
cyt387,JAK inhibitor,JAK1,3716,Phase 3
cyt387,JAK inhibitor,JAK2,3717,Phase 3
cyt387,JAK inhibitor,JAK3,3718,Phase 3
CY208-243,dopamine receptor agonist,CALY,6240,Phase 2
CZC-54252,leucine rich repeat kinase inhibitor,LRRK2,2099,Preclinical
CZC24832,PI3K inhibitor,PIK3CG,5241,Preclinical
C11-Acetate,,ABAT,240,Phase 3
C11-Acetate,,ACE,5742,Phase 3
C11-Acetate,,AKR1C3,2099,Phase 3
C11-Acetate,,CA2,2100,Phase 3
C11-Acetate,,CELA1,2103,Phase 3
C11-Acetate,,ESR2,2104,Phase 3
C11-Acetate,,FFAR2,2908,Phase 3
C11-Acetate,,FFAR3,5742,Phase 3
C11-Acetate,,HPRT1,5743,Phase 3
C11-Acetate,,LTA4H,2908,Phase 3
C11-Acetate,,MMP12,476,Phase 3
C11-Acetate,,NOS1,476,Phase 3
C11-Acetate,,NOS3,477,Phase 3
C11-Acetate,,PLA2G1B,478,Phase 3
C11-Acetate,,PTPN1,480,Phase 3
C11-Acetate,,SOD1,481,Phase 3
C11-Acetate,,TXN,482,Phase 3
C34,toll-like receptor inhibitor,TLR4,483,Preclinical
C646,histone acetyltransferase inhibitor,EP300,486,Preclinical
D-(+)-maltose,,MGAM,476,Preclinical
D-phenylalanine,enkephalinase inhibitor,CCBL1,5742,Preclinical
D-phenylalanine,enkephalinase inhibitor,CRH,5743,Preclinical
D-phenylalanine,enkephalinase inhibitor,HCAR3,1812,Preclinical
D-serine,glutamate receptor agonist,GLRA1,1813,Launched
D-serine,glutamate receptor agonist,GRIN1,1814,Launched
D-serine,glutamate receptor agonist,GRIN2A,1815,Launched
D-serine,glutamate receptor agonist,GRIN2B,1816,Launched
D-serine,glutamate receptor agonist,GRIN2C,148,Launched
D-serine,glutamate receptor agonist,GRIN2D,153,Launched
D-serine,glutamate receptor agonist,SERPINB3,1812,Launched
D-4476,TGF beta receptor inhibitor,CSNK1A1,1813,Preclinical
D-4476,TGF beta receptor inhibitor,CSNK1D,1814,Preclinical
D-4476,TGF beta receptor inhibitor,TGFB1,1815,Preclinical
D-64131,microtubule inhibitor,TUBB,1816,Preclinical
DAA-1106,benzodiazepine receptor agonist,TSPO,3350,Preclinical
dabigatran,thrombin inhibitor,F2,3356,Launched
dabigatran-etexilate,thrombin inhibitor,F2,3359,Launched
dabrafenib,RAF inhibitor,BRAF,3360,Launched
dabrafenib,RAF inhibitor,LIMK1,3361,Launched
dabrafenib,RAF inhibitor,NEK11,3362,Launched
dabrafenib,RAF inhibitor,RAF1,3363,Launched
dabrafenib,RAF inhibitor,SIK1,150,Launched
dacarbazine,DNA alkylating agent,PGD,1813,Launched
dacarbazine,DNA alkylating agent,POLA2,3351,Launched
dacinostat,HDAC inhibitor,HDAC1,3352,Phase 1
dacinostat,HDAC inhibitor,HDAC2,3354,Phase 1
dacinostat,HDAC inhibitor,HDAC3,3355,Phase 1
dacinostat,HDAC inhibitor,HDAC4,3357,Phase 1
dacinostat,HDAC inhibitor,HDAC5,3363,Phase 1
dacinostat,HDAC inhibitor,HDAC6,7421,Phase 1
dacinostat,HDAC inhibitor,HDAC7,2911,Phase 1
dacinostat,HDAC inhibitor,HDAC8,2915,Phase 1
dacinostat,HDAC inhibitor,HDAC9,2030,Phase 1
dacomitinib,EGFR inhibitor,EGFR,775,Launched
dacomitinib,EGFR inhibitor,ERBB2,779,Launched
dacomitinib,EGFR inhibitor,ERBB4,781,Launched
dactinomycin,RNA polymerase inhibitor,POLR2A,786,Launched
daidzein,estrogen receptor agonist,ESRRA,3359,Phase 2
daidzein,estrogen receptor agonist,ESRRB,3741,Phase 2
daidzein,estrogen receptor agonist,ESRRG,3274,Phase 2
daidzein,estrogen receptor agonist,TRPC5,11255,Phase 2
daidzin,antioxidant,ALDH2,59340,Phase 1
dalargin,opioid receptor agonist,OPRM1,10280,Phase 2
dalbavancin,bacterial cell wall synthesis inhibitor,PNLIP,3269,Launched
dalcetrapib,cholesteryl ester transfer protein inhibitor,CETP,1786,Phase 3
dalfampridine,potassium channel blocker,KCNA1,3269,Launched
dalfampridine,potassium channel blocker,KCNA10,9817,Launched
dalfampridine,potassium channel blocker,KCNA2,3269,Launched
dalfampridine,potassium channel blocker,KCNA3,26,Launched
dalfampridine,potassium channel blocker,KCNA4,25824,Launched
dalfampridine,potassium channel blocker,KCNA5,5644,Launched
dalfampridine,potassium channel blocker,KCNA6,43,Launched
dalfampridine,potassium channel blocker,KCNA7,983,Launched
dalfampridine,potassium channel blocker,KCNB1,1017,Launched
dalfampridine,potassium channel blocker,KCNB2,1020,Launched
dalfampridine,potassium channel blocker,KCNC1,1025,Launched
dalfampridine,potassium channel blocker,KCNC2,5729,Launched
dalfampridine,potassium channel blocker,KCNC3,11251,Launched
dalfampridine,potassium channel blocker,KCNC4,5731,Launched
dalfampridine,potassium channel blocker,KCND1,5732,Launched
dalfampridine,potassium channel blocker,KCND2,5733,Launched
dalfampridine,potassium channel blocker,KCND3,5734,Launched
dalfampridine,potassium channel blocker,KCNF1,5737,Launched
dalfampridine,potassium channel blocker,KCNG1,6915,Launched
dalfampridine,potassium channel blocker,KCNG2,117144,Launched
dalfampridine,potassium channel blocker,KCNG3,117155,Launched
dalfampridine,potassium channel blocker,KCNG4,347732,Launched
dalfampridine,potassium channel blocker,KCNH1,378807,Launched
dalfampridine,potassium channel blocker,KCNH2,5729,Launched
dalfampridine,potassium channel blocker,KCNH3,11251,Launched
dalfampridine,potassium channel blocker,KCNH4,5731,Launched
dalfampridine,potassium channel blocker,KCNH5,5732,Launched
dalfampridine,potassium channel blocker,KCNH6,5733,Launched
dalfampridine,potassium channel blocker,KCNH7,5734,Launched
dalfampridine,potassium channel blocker,KCNH8,5737,Launched
dalfampridine,potassium channel blocker,KCNJ13,6915,Launched
dalfampridine,potassium channel blocker,KCNJ5,2833,Launched
dalfampridine,potassium channel blocker,KCNQ1,50632,Launched
dalfampridine,potassium channel blocker,KCNQ2,120892,Launched
dalfampridine,potassium channel blocker,KCNQ3,5294,Launched
dalfampridine,potassium channel blocker,KCNQ4,18,Launched
dalfampridine,potassium channel blocker,KCNQ5,1636,Launched
dalfampridine,potassium channel blocker,KCNS1,8644,Launched
dalfampridine,potassium channel blocker,KCNS2,760,Launched
dalfampridine,potassium channel blocker,KCNS3,1990,Launched
dalfampridine,potassium channel blocker,KCNV1,2100,Launched
dalfampridine,potassium channel blocker,KCNV2,2867,Launched
daltroban,thromboxane receptor antagonist,TBXA2R,2865,Phase 3
daminozide,KDM2A inhibitor,KDM2A,3251,Preclinical
daminozide,KDM2A inhibitor,KDM7A,4048,Preclinical
daminozide,KDM2A inhibitor,PHF8,4321,Preclinical
danazol,estrogen receptor antagonist|progesterone receptor agonist,AR,4842,Launched
danazol,estrogen receptor antagonist|progesterone receptor agonist,CCL2,4846,Launched
danazol,estrogen receptor antagonist|progesterone receptor agonist,ESR1,5319,Launched
danazol,estrogen receptor antagonist|progesterone receptor agonist,GNRHR,5770,Launched
danazol,estrogen receptor antagonist|progesterone receptor agonist,GNRHR2,6647,Launched
danazol,estrogen receptor antagonist|progesterone receptor agonist,PGR,7295,Launched
danirixin,CC chemokine receptor antagonist,CXCR2,7099,Phase 2
dantrolene,calcium channel blocker,RYR1,2033,Launched
dantrolene,calcium channel blocker,RYR3,8972,Launched
danusertib,Aurora kinase inhibitor|growth factor receptor inhibitor,AURKA,883,Phase 2
danusertib,Aurora kinase inhibitor|growth factor receptor inhibitor,AURKB,1392,Phase 2
danusertib,Aurora kinase inhibitor|growth factor receptor inhibitor,AURKC,8843,Phase 2
danusertib,Aurora kinase inhibitor|growth factor receptor inhibitor,FGFR1,2741,Phase 2
danusertib,Aurora kinase inhibitor|growth factor receptor inhibitor,NTRK1,2902,Phase 2
danusertib,Aurora kinase inhibitor|growth factor receptor inhibitor,RET,2903,Phase 2
danusertib,Aurora kinase inhibitor|growth factor receptor inhibitor,SLK,2904,Phase 2
dapagliflozin,sodium/glucose cotransporter inhibitor,SLC5A1,2905,Launched
dapagliflozin,sodium/glucose cotransporter inhibitor,SLC5A2,2906,Launched
dapiprazole,adrenergic receptor antagonist,ADRA1A,6317,Launched
dapiprazole,adrenergic receptor antagonist,ADRA1B,1452,Launched
dapiprazole,adrenergic receptor antagonist,ADRA1D,1453,Launched
dapivirine,non-nucleoside reverse transcriptase inhibitor,CYP3A4,7040,Phase 3
dapivirine,non-nucleoside reverse transcriptase inhibitor,CYP3A5,203068,Phase 3
dapoxetine,selective serotonin reuptake inhibitor (SSRI),HTR1A,706,Launched
dapoxetine,selective serotonin reuptake inhibitor (SSRI),HTR1B,2147,Launched
dapoxetine,selective serotonin reuptake inhibitor (SSRI),HTR2C,2147,Launched
dapoxetine,selective serotonin reuptake inhibitor (SSRI),SLC6A4,673,Launched
daprodustat,hypoxia inducible factor inhibitor,EGLN1,3984,Phase 3
dapsone,bacterial antifolate,DHFR,79858,Launched
darapladib,phospholipase inhibitor,PLA2G7,5894,Phase 3
darglitazone,PPAR receptor antagonist,PPARG,150094,Phase 2
darifenacin,acetylcholine receptor antagonist,CHRM1,5226,Launched
darifenacin,acetylcholine receptor antagonist,CHRM2,23649,Launched
darifenacin,acetylcholine receptor antagonist,CHRM3,3065,Launched
darifenacin,acetylcholine receptor antagonist,CHRM4,3066,Launched
darifenacin,acetylcholine receptor antagonist,CHRM5,8841,Launched
darolutamide,androgen receptor antagonist,AR,9759,Launched
darunavir,HIV protease inhibitor,CYP3A4,10014,Launched
darusentan,endothelin receptor antagonist,EDNRA,10013,Phase 3
dasatinib,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,ABL1,51564,Launched
dasatinib,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,ABL2,55869,Launched
dasatinib,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,BLK,9734,Launched
dasatinib,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,EPHA2,1956,Launched
dasatinib,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,FGR,2064,Launched
dasatinib,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,FRK,2066,Launched
dasatinib,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,FYN,5430,Launched
dasatinib,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,HCK,2101,Launched
dasatinib,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,KIT,2103,Launched
dasatinib,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,LCK,2104,Launched
dasatinib,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,LYN,7224,Launched
dasatinib,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,PDGFRB,217,Launched
dasatinib,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,SRC,4988,Launched
dasatinib,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,SRMS,5406,Launched
dasatinib,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,STAT5B,1071,Launched
dasatinib,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,YES1,3736,Launched
DAU-5884,acetylcholine receptor antagonist,CHRM3,3744,Preclinical
daunorubicin,RNA synthesis inhibitor|topoisomerase inhibitor,TOP2A,3737,Launched
daunorubicin,RNA synthesis inhibitor|topoisomerase inhibitor,TOP2B,3738,Launched
dazmegrel,thromboxane synthase inhibitor,TBXAS1,3739,Phase 2
dazoxiben,thromboxane synthase inhibitor,TBXAS1,3741,Phase 2
DBeQ,ATPase inhibitor,CASP3,3742,Preclinical
DBPR108,dipeptidyl peptidase inhibitor,DPP4,3743,Phase 1
DC-260126,free fatty acid receptor antagonist,FFAR1,3745,Preclinical
DCC-2618,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,KIT,9312,Phase 1
DCC-2618,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,PDGFRA,3746,Phase 1
DCEBIO,potassium channel activator,KCNN2,3747,Preclinical
DCEBIO,potassium channel activator,KCNN3,3748,Preclinical
DCEBIO,potassium channel activator,KCNN4,3749,Preclinical
DCPIB,chloride channel blocker|gap junction modulator|glutamate inhibitor,SLC1A2,3750,Preclinical
DDR1-IN-1,discoidin domain receptor inhibitor,DDR1,3751,Preclinical
DDR1-IN-1,discoidin domain receptor inhibitor,DDR2,3752,Preclinical
debrisoquin,adrenergic neuron blocker,SLC6A2,3754,Launched
decamethonium,acetylcholine receptor agonist,ACHE,3755,Launched
decamethonium,acetylcholine receptor agonist,CHRNA2,26251,Launched
decernotinib,JAK inhibitor,JAK3,170850,Phase 2/Phase 3
decitabine,DNA methyltransferase inhibitor,DNMT1,93107,Launched
decitabine,DNA methyltransferase inhibitor,DNMT3A,3756,Launched
defactinib,focal adhesion kinase inhibitor,PTK2,3757,Phase 2
deferasirox,chelating agent,CYP3A4,23416,Launched
deferiprone,chelating agent,UGT1A6,23415,Launched
deflazacort,glucocorticoid receptor agonist,NR3C1,27133,Launched
deforolimus,mTOR inhibitor,MTOR,81033,Phase 3
degarelix,gonadotropin releasing factor hormone receptor antagonist,GNRHR,90134,Launched
dehydrocorydaline,acetylcholinesterase inhibitor,ACHE,131096,Phase 3
dehydroepiandrosterone,protein synthesis stimulant,ESR1,3769,Launched
dehydroepiandrosterone,protein synthesis stimulant,ESR2,3762,Launched
dehydroepiandrosterone,protein synthesis stimulant,G6PD,3784,Launched
dehydroepiandrosterone,protein synthesis stimulant,GABRA1,3785,Launched
dehydroepiandrosterone,protein synthesis stimulant,GABRA2,3786,Launched
dehydroepiandrosterone,protein synthesis stimulant,GABRA3,9132,Launched
dehydroepiandrosterone,protein synthesis stimulant,GABRA4,56479,Launched
dehydroepiandrosterone,protein synthesis stimulant,GABRA5,3787,Launched
dehydroepiandrosterone,protein synthesis stimulant,GABRA6,3788,Launched
dehydroepiandrosterone,protein synthesis stimulant,GABRB1,3790,Launched
dehydroepiandrosterone,protein synthesis stimulant,GABRB2,27012,Launched
dehydroepiandrosterone,protein synthesis stimulant,GABRB3,169522,Launched
dehydroepiandrosterone,protein synthesis stimulant,GABRD,6915,Launched
dehydroepiandrosterone,protein synthesis stimulant,GABRE,22992,Launched
dehydroepiandrosterone,protein synthesis stimulant,GABRG1,80853,Launched
dehydroepiandrosterone,protein synthesis stimulant,GABRG2,23133,Launched
dehydroepiandrosterone,protein synthesis stimulant,GABRG3,367,Launched
dehydroepiandrosterone,protein synthesis stimulant,GABRP,6347,Launched
dehydroepiandrosterone,protein synthesis stimulant,GABRQ,2099,Launched
dehydroepiandrosterone,protein synthesis stimulant,GRIN1,2798,Launched
dehydroepiandrosterone,protein synthesis stimulant,GRIN2A,114814,Launched
dehydroepiandrosterone,protein synthesis stimulant,GRIN2B,5241,Launched
dehydroepiandrosterone,protein synthesis stimulant,GRIN2C,3579,Launched
dehydroepiandrosterone,protein synthesis stimulant,GRIN2D,6261,Launched
dehydroepiandrosterone,protein synthesis stimulant,GRIN3A,6263,Launched
dehydroepiandrosterone,protein synthesis stimulant,GRIN3B,6790,Launched
dehydroepiandrosterone,protein synthesis stimulant,HSD17B1,9212,Launched
dehydroepiandrosterone,protein synthesis stimulant,NR1I2,6795,Launched
dehydroepiandrosterone,protein synthesis stimulant,NR1I3,2260,Launched
dehydroepiandrosterone,protein synthesis stimulant,PPARA,4914,Launched
dehydroepiandrosterone,protein synthesis stimulant,SIGMAR1,5979,Launched
dehydroepiandrosterone,protein synthesis stimulant,SULT2A1,9748,Launched
dehydroepiandrosterone,protein synthesis stimulant,SULT2B1,6523,Launched
dehydroepiandrosterone-sulfate,androgen receptor agonist|estrogen receptor agonist,AR,6524,Launched
dehydroepiandrosterone-sulfate,androgen receptor agonist|estrogen receptor agonist,ESR1,148,Launched
dehydroepiandrosterone-sulfate,androgen receptor agonist|estrogen receptor agonist,ESR2,147,Launched
delanzomib,proteasome inhibitor,CMA1,146,Phase 1/Phase 2
delanzomib,proteasome inhibitor,CTSG,1576,Phase 1/Phase 2
delanzomib,proteasome inhibitor,CYP3A4,1577,Phase 1/Phase 2
delanzomib,proteasome inhibitor,ELANE,3350,Phase 1/Phase 2
delapril,angiotensin converting enzyme inhibitor,ACE,3351,Launched
delavirdine,non-nucleoside reverse transcriptase inhibitor,CYP3A4,3358,Launched
delivert,angiotensin receptor agonist,AGTR1,6532,Launched
delivert,angiotensin receptor agonist,AGTR2,54583,Launched
delphinidin,membrane permeability inhibitor,GLO1,1719,Phase 2
delta-tocotrienol,HMGCR inhibitor,HMGCR,7941,Phase 1
deltarasin,phosphodiesterase inhibitor,KRAS,5468,Preclinical
demecarium,acetylcholinesterase inhibitor,ACHE,1128,Launched
demecarium,acetylcholinesterase inhibitor,BCHE,1129,Launched
deoxycholic-acid,biliverdin reductase A activator|G protein-coupled receptor agonist,FPR1,1131,Launched
deoxycholic-acid,biliverdin reductase A activator|G protein-coupled receptor agonist,GPBAR1,1132,Launched
deoxycorticosterone-acetate,progestogen hormone,NR3C2,1133,Preclinical
deoxyepinephrine,adrenergic receptor agonist|dopamine receptor agonist,ADRA1A,367,Preclinical
deoxyepinephrine,adrenergic receptor agonist|dopamine receptor agonist,DRD1,1576,Preclinical
deoxyepinephrine,adrenergic receptor agonist|dopamine receptor agonist,DRD2,1909,Preclinical
deptropine,histamine receptor antagonist,HRH1,25,Preclinical
dequalinium,PKC inhibitor,KCNN1,27,Launched
dequalinium,PKC inhibitor,KCNN3,640,Launched
deracoxib,cyclooxygenase inhibitor,PTGS2,1969,Launched
deserpidine,angiotensin converting enzyme inhibitor,ACE,2268,Launched
deserpidine,angiotensin converting enzyme inhibitor,SLC18A2,2444,Launched
desipramine,tricyclic antidepressant,ADRA1A,2534,Launched
desipramine,tricyclic antidepressant,ADRA1B,3055,Launched
desipramine,tricyclic antidepressant,ADRA1D,3815,Launched
desipramine,tricyclic antidepressant,ADRA2A,3932,Launched
desipramine,tricyclic antidepressant,ADRA2B,4067,Launched
desipramine,tricyclic antidepressant,ADRA2C,5159,Launched
desipramine,tricyclic antidepressant,ADRB1,6714,Launched
desipramine,tricyclic antidepressant,ADRB2,6725,Launched
desipramine,tricyclic antidepressant,CHRM1,6777,Launched
desipramine,tricyclic antidepressant,CHRM2,7525,Launched
desipramine,tricyclic antidepressant,CHRM3,1131,Launched
desipramine,tricyclic antidepressant,CHRM4,7153,Launched
desipramine,tricyclic antidepressant,CHRM5,7155,Launched
desipramine,tricyclic antidepressant,DRD2,6916,Launched
desipramine,tricyclic antidepressant,HRH1,6916,Launched
desipramine,tricyclic antidepressant,HTR1A,836,Launched
desipramine,tricyclic antidepressant,HTR2A,1803,Launched
desipramine,tricyclic antidepressant,HTR2C,2864,Launched
desipramine,tricyclic antidepressant,SLC6A2,3815,Launched
desipramine,tricyclic antidepressant,SLC6A4,5156,Launched
desipramine,tricyclic antidepressant,SMPD1,3781,Launched
deslanoside,Na/K-ATPase inhibitor,ATP1A1,3782,Launched
deslanoside,Na/K-ATPase inhibitor,ATP1A2,3783,Launched
deslanoside,Na/K-ATPase inhibitor,ATP1A3,6506,Launched
deslanoside,Na/K-ATPase inhibitor,ATP1A4,780,Launched
deslanoside,Na/K-ATPase inhibitor,ATP1B1,4921,Launched
deslanoside,Na/K-ATPase inhibitor,ATP1B2,6530,Launched
deslanoside,Na/K-ATPase inhibitor,ATP1B3,43,Launched
deslanoside,Na/K-ATPase inhibitor,FXYD2,1135,Launched
desloratadine,histamine receptor antagonist,HRH1,3718,Launched
desmethylclozapine,acetylcholine receptor agonist,HTR2C,1786,Phase 2
desmopressin-acetate,vasopressin receptor agonist,AVPR1A,1788,Launched
desmopressin-acetate,vasopressin receptor agonist,AVPR1B,5747,Launched
desmopressin-acetate,vasopressin receptor agonist,AVPR2,1576,Launched
desmopressin-acetate,vasopressin receptor agonist,OXTR,54578,Launched
desogestrel,progesterone receptor agonist,ESR1,2908,Launched
desogestrel,progesterone receptor agonist,PGR,2475,Launched
desonide,glucocorticoid receptor agonist,NR3C1,2798,Launched
desonide,glucocorticoid receptor agonist,PLA2G1B,43,Launched
desoximetasone,glucocorticoid receptor agonist,NR3C1,2099,Launched
desoximetasone,glucocorticoid receptor agonist,PLA2G1B,2100,Launched
desoxycorticosterone-pivalate,corticosteroid agonist,NR3C2,2539,Launched
desoxycortone,mineralocorticoid receptor agonist,NR3C1,2554,Preclinical
desoxycortone,mineralocorticoid receptor agonist,NR3C2,2555,Preclinical
desoxypeganine,acetylcholinesterase inhibitor|monoamine oxidase inhibitor,ACHE,2556,Phase 1
desvenlafaxine,serotoninâ€“norepinephrine reuptake inhibitor (SNRI),SLC6A2,2557,Launched
desvenlafaxine,serotoninâ€“norepinephrine reuptake inhibitor (SNRI),SLC6A3,2558,Launched
desvenlafaxine,serotoninâ€“norepinephrine reuptake inhibitor (SNRI),SLC6A4,2559,Launched
detomidine,adrenergic receptor agonist,ADRA2A,2560,Launched
dexamethasone,glucocorticoid receptor agonist,ANXA1,2561,Launched
dexamethasone,glucocorticoid receptor agonist,NOS2,2562,Launched
dexamethasone,glucocorticoid receptor agonist,NR0B1,2563,Launched
dexamethasone,glucocorticoid receptor agonist,NR3C1,2564,Launched
dexamethasone,glucocorticoid receptor agonist,NR3C2,2565,Launched
dexfosfoserine,membrane integrity inhibitor,CFTR,2566,Preclinical
dexfosfoserine,membrane integrity inhibitor,GRM4,2567,Preclinical
dexfosfoserine,membrane integrity inhibitor,GRM6,2568,Preclinical
dexfosfoserine,membrane integrity inhibitor,GRM7,55879,Preclinical
dexfosfoserine,membrane integrity inhibitor,GRM8,2902,Preclinical
dexfosfoserine,membrane integrity inhibitor,KCNC4,2903,Preclinical
dexfosfoserine,membrane integrity inhibitor,PDPK1,2904,Preclinical
dexfosfoserine,membrane integrity inhibitor,PIM1,2905,Preclinical
dexfosfoserine,membrane integrity inhibitor,PRKACA,2906,Preclinical
dexfosfoserine,membrane integrity inhibitor,PRKCQ,116443,Preclinical
dexfosfoserine,membrane integrity inhibitor,PYGL,116444,Preclinical
dexfosfoserine,membrane integrity inhibitor,PYGM,3292,Preclinical
dexfosfoserine,membrane integrity inhibitor,REG1A,8856,Preclinical
dexfosfoserine,membrane integrity inhibitor,RHO,9970,Preclinical
dexfosfoserine,membrane integrity inhibitor,SERPINB3,5465,Preclinical
dexfosfoserine,membrane integrity inhibitor,SMAD2,10280,Preclinical
dexfosfoserine,membrane integrity inhibitor,TAOK2,6822,Preclinical
dexlansoprazole,ATPase inhibitor,ATP4A,6820,Launched
dexloxiglumide,CCK receptor antagonist,CCKAR,367,Phase 3
dexmedetomidine,adrenergic receptor agonist,ADRA2A,2099,Launched
dexmedetomidine,adrenergic receptor agonist,ADRA2B,2100,Launched
dexmedetomidine,adrenergic receptor agonist,ADRA2C,1215,Launched
dexniguldipine,calmodulin antagonist,ADORA3,1511,Phase 2
dexrazoxane,chelating agent|topoisomerase inhibitor,TOP2A,1576,Launched
dexrazoxane,chelating agent|topoisomerase inhibitor,TOP2B,1991,Launched
dextromethorphan,glutamate receptor antagonist|sigma receptor agonist,CHRNA2,1636,Launched
dextromethorphan,glutamate receptor antagonist|sigma receptor agonist,CHRNA3,1576,Launched
dextromethorphan,glutamate receptor antagonist|sigma receptor agonist,CHRNA4,185,Launched
dextromethorphan,glutamate receptor antagonist|sigma receptor agonist,CHRNA7,186,Launched
dextromethorphan,glutamate receptor antagonist|sigma receptor agonist,CHRNB2,2739,Launched
dextromethorphan,glutamate receptor antagonist|sigma receptor agonist,CHRNB4,3156,Launched
dextromethorphan,glutamate receptor antagonist|sigma receptor agonist,CYBA,3845,Launched
dextromethorphan,glutamate receptor antagonist|sigma receptor agonist,CYBB,43,Launched
dextromethorphan,glutamate receptor antagonist|sigma receptor agonist,GRIN3A,590,Launched
dextromethorphan,glutamate receptor antagonist|sigma receptor agonist,NCF1,2357,Launched
dextromethorphan,glutamate receptor antagonist|sigma receptor agonist,NCF2,151306,Launched
dextromethorphan,glutamate receptor antagonist|sigma receptor agonist,NCF4,4306,Launched
dextromethorphan,glutamate receptor antagonist|sigma receptor agonist,OPRD1,148,Launched
dextromethorphan,glutamate receptor antagonist|sigma receptor agonist,OPRK1,1812,Launched
dextromethorphan,glutamate receptor antagonist|sigma receptor agonist,OPRM1,1813,Launched
dextromethorphan,glutamate receptor antagonist|sigma receptor agonist,PGRMC1,3269,Launched
dextromethorphan,glutamate receptor antagonist|sigma receptor agonist,RAC1,3780,Launched
dextromethorphan,glutamate receptor antagonist|sigma receptor agonist,RAC2,3782,Launched
dextromethorphan,glutamate receptor antagonist|sigma receptor agonist,SIGMAR1,5743,Launched
dextromethorphan,glutamate receptor antagonist|sigma receptor agonist,SLC6A2,1636,Launched
dextromethorphan,glutamate receptor antagonist|sigma receptor agonist,SLC6A4,6571,Launched
DFB,glutamate receptor agonist,GRM5,148,Preclinical
DG-172,PPAR receptor inverse agonist,PPARD,147,Preclinical
DH-97,melatonin receptor antagonist,MTNR1B,146,Preclinical
diacerein,interleukin inhibitor,IL1B,150,Launched
diadenosine-tetraphosphate,adenosine kinase inhibitor,P2RY13,151,Phase 1
diadenosine-tetraphosphate,adenosine kinase inhibitor,P2RY2,152,Phase 1
diarylpropionitrile,estrogen receptor agonist,ESR2,153,Preclinical
diazoxide,potassium channel activator,ATP1A1,154,Launched
diazoxide,potassium channel activator,CA1,1128,Launched
diazoxide,potassium channel activator,CA2,1129,Launched
diazoxide,potassium channel activator,KCNJ11,1131,Launched
diazoxide,potassium channel activator,KCNJ8,1132,Launched
diazoxide,potassium channel activator,KCNMA1,1133,Launched
diazoxide,potassium channel activator,SLC12A3,1813,Launched
dibutyl-phthalate,,TRPA1,3269,Preclinical
diclofenac,cyclooxygenase inhibitor,AKR1C3,3350,Launched
diclofenac,cyclooxygenase inhibitor,ALOX5,3356,Launched
diclofenac,cyclooxygenase inhibitor,ASIC1,3358,Launched
diclofenac,cyclooxygenase inhibitor,ASIC3,6530,Launched
diclofenac,cyclooxygenase inhibitor,KCNQ2,6532,Launched
diclofenac,cyclooxygenase inhibitor,KCNQ3,6609,Launched
diclofenac,cyclooxygenase inhibitor,PLA2G2A,476,Launched
diclofenac,cyclooxygenase inhibitor,PPARG,477,Launched
diclofenac,cyclooxygenase inhibitor,PTGS1,478,Launched
diclofenac,cyclooxygenase inhibitor,PTGS2,480,Launched
diclofenac,cyclooxygenase inhibitor,SCN4A,481,Launched
diclofenamide,carbonic anhydrase inhibitor,CA1,482,Launched
diclofenamide,carbonic anhydrase inhibitor,CA12,483,Launched
diclofenamide,carbonic anhydrase inhibitor,CA2,486,Launched
diclofenamide,carbonic anhydrase inhibitor,CA4,3269,Launched
diclofenamide,carbonic anhydrase inhibitor,CA7,3358,Launched
diclofensine,dopamine reuptake inhibitor,DRD1,552,Phase 3
diclofensine,dopamine reuptake inhibitor,MAOA,553,Phase 3
diclofensine,dopamine reuptake inhibitor,MAOB,554,Phase 3
dicoumarol,NADPH inhibitor,CRYZ,5021,Launched
dicoumarol,NADPH inhibitor,NQO1,2099,Launched
dicoumarol,NADPH inhibitor,VKORC1,5241,Launched
dicycloverine,acetylcholine receptor antagonist,CHRM1,2908,Launched
dicycloverine,acetylcholine receptor antagonist,CHRM2,5319,Launched
dicycloverine,acetylcholine receptor antagonist,CHRM3,2908,Launched
didanosine,nucleoside reverse transcriptase inhibitor,PNP,5319,Launched
didox,ribonucleotide reductase inhibitor,RRM1,4306,Launched
dienestrol,estrogen receptor agonist,ESR1,2908,Launched
dienogest,progesterone receptor agonist,PGR,4306,Launched
diethylcarbamazine,lipoxygenase inhibitor,ALOX5,43,Launched
diethylcarbamazine,lipoxygenase inhibitor,PTGS1,6530,Launched
diethylstilbestrol,estrogen receptor agonist,ESR1,6531,Withdrawn
diethylstilbestrol,estrogen receptor agonist,ESR2,6532,Withdrawn
diethylstilbestrol,estrogen receptor agonist,ESRRB,150,Withdrawn
diethylstilbestrol,estrogen receptor agonist,ESRRG,301,Withdrawn
diflorasone-diacetate,glucocorticoid receptor agonist,NR3C1,4843,Launched
diflunisal,prostanoid receptor antagonist,PTGS1,190,Launched
diflunisal,prostanoid receptor antagonist,PTGS2,2908,Launched
difluprednate,glucocorticoid receptor agonist,NR3C1,4306,Launched
digitoxigenin,ATPase inhibitor,ATP1A1,1080,Preclinical
digitoxin,ATPase inhibitor,ATP1A1,2914,Launched
digitoxin,ATPase inhibitor,ATP1A2,2916,Launched
digitoxin,ATPase inhibitor,ATP1A3,2917,Launched
digitoxin,ATPase inhibitor,ATP1A4,2918,Launched
digitoxin,ATPase inhibitor,ATP1B1,3749,Launched
digitoxin,ATPase inhibitor,ATP1B2,5170,Launched
digitoxin,ATPase inhibitor,ATP1B3,5292,Launched
digitoxin,ATPase inhibitor,FXYD2,5566,Launched
digoxin,ATPase inhibitor,ATP1A1,5588,Launched
dihomo-gamma-linolenic-acid,prostanoid receptor agonist,PTGS1,5836,Phase 2
dihomo-gamma-linolenic-acid,prostanoid receptor agonist,PTGS2,5837,Phase 2
dihydrexidine,dopamine receptor agonist,DRD1,5967,Phase 2
dihydrexidine,dopamine receptor agonist,DRD2,6010,Phase 2
dihydrexidine,dopamine receptor agonist,DRD3,6317,Phase 2
dihydrexidine,dopamine receptor agonist,DRD4,4087,Phase 2
dihydrexidine,dopamine receptor agonist,DRD5,9344,Phase 2
dihydroergocristine,adrenergic receptor antagonist|prolactin inhibitor,ADRA1A,495,Launched
dihydroergocristine,adrenergic receptor antagonist|prolactin inhibitor,ADRB1,886,Launched
dihydroergocristine,adrenergic receptor antagonist|prolactin inhibitor,DRD1,150,Launched
dihydroergocristine,adrenergic receptor antagonist|prolactin inhibitor,DRD2,151,Launched
dihydroergocristine,adrenergic receptor antagonist|prolactin inhibitor,DRD3,152,Launched
dihydroergocristine,adrenergic receptor antagonist|prolactin inhibitor,DRD4,140,Launched
dihydroergocristine,adrenergic receptor antagonist|prolactin inhibitor,DRD5,7153,Launched
dihydroergocristine,adrenergic receptor antagonist|prolactin inhibitor,HTR1A,7155,Launched
dihydroergocristine,adrenergic receptor antagonist|prolactin inhibitor,HTR2A,1135,Launched
dihydroergocristine,adrenergic receptor antagonist|prolactin inhibitor,HTR3A,1136,Launched
dihydroergocristine,adrenergic receptor antagonist|prolactin inhibitor,HTR4,1137,Launched
dihydroergocristine,adrenergic receptor antagonist|prolactin inhibitor,HTR5A,1139,Launched
dihydroergocristine,adrenergic receptor antagonist|prolactin inhibitor,HTR6,1141,Launched
dihydroergocristine,adrenergic receptor antagonist|prolactin inhibitor,HTR7,1143,Launched
dihydroergotamine,serotonin receptor agonist,ADRA2A,1535,Launched
dihydroergotamine,serotonin receptor agonist,DRD2,1536,Launched
dihydroergotamine,serotonin receptor agonist,HTR1B,116443,Launched
dihydroergotamine,serotonin receptor agonist,HTR1D,653361,Launched
dihydroergotamine,serotonin receptor agonist,HTR1E,4688,Launched
dihydroergotamine,serotonin receptor agonist,HTR1F,4689,Launched
dihydroergotamine,serotonin receptor agonist,HTR2B,4985,Launched
dihydroergotamine,serotonin receptor agonist,HTR7,4986,Launched
dihydrotachysterol,vitamin analog,VDR,4988,Launched
dihydroxyphenylglycine,glutamate receptor agonist,GRM1,10857,Preclinical
dihydroxyphenylglycine,glutamate receptor agonist,GRM5,5879,Preclinical
dilazep,adenosine reuptake inhibitor,SLC29A1,5880,Launched
diltiazem,calcium channel blocker,CACNA1C,10280,Launched
diltiazem,calcium channel blocker,CACNA1S,6530,Launched
diltiazem,calcium channel blocker,CACNA2D1,6532,Launched
diltiazem,calcium channel blocker,CACNG1,2915,Launched
diltiazem,calcium channel blocker,HTR3A,5467,Launched
diltiazem,calcium channel blocker,KCNA5,4544,Launched
dimaprit,histamine receptor agonist,HRH2,3553,Preclinical
dimaprit,histamine receptor agonist,HRH3,53829,Preclinical
dimaprit,histamine receptor agonist,HRH4,5029,Preclinical
dimemorfan,sigma receptor agonist,SIGMAR1,2100,Launched
dimenhydrinate,histamine receptor antagonist,HRH1,476,Launched
dimercaptosuccinic-acid,chelating agent,DNMT1,759,Launched
dimethindene-(S)-(+),acetylcholine receptor antagonist,HRH1,760,Preclinical
dimethyl-fumarate,nuclear factor erythroid derived|like (NRF2) activator,KEAP1,3767,Launched
dimetindene,cholinergic receptor antagonist|histamine receptor antagonist,HRH1,3764,Launched
diminazene-aceturate,angiotensin converting enzyme activator,AOC1,3778,Phase 3
diminazene-aceturate,angiotensin converting enzyme activator,PRDX5,6559,Phase 3
diminazene-aceturate,angiotensin converting enzyme activator,PRSS1,8989,Phase 3
dimpylate,acetylcholinesterase inhibitor,ACHE,8644,Launched
dinaciclib,CDK inhibitor,CDK1,240,Phase 3
dinaciclib,CDK inhibitor,CDK2,41,Phase 3
dinaciclib,CDK inhibitor,CDK5,9311,Phase 3
dinaciclib,CDK inhibitor,CDK9,3785,Phase 3
dinoprost,prostacyclin analog,PTGDR,3786,Launched
dinoprost,prostacyclin analog,PTGDR2,5320,Launched
dinoprost,prostacyclin analog,PTGER1,5468,Launched
dinoprost,prostacyclin analog,PTGER2,5742,Launched
dinoprost,prostacyclin analog,PTGER3,5743,Launched
dinoprost,prostacyclin analog,PTGER4,6329,Launched
dinoprost,prostacyclin analog,PTGFR,759,Launched
dinoprost,prostacyclin analog,TBXA2R,771,Launched
dinoprostone,prostanoid receptor agonist,CATSPER1,760,Withdrawn
dinoprostone,prostanoid receptor agonist,CATSPER2,762,Withdrawn
dinoprostone,prostanoid receptor agonist,CATSPER3,766,Withdrawn
dinoprostone,prostanoid receptor agonist,CATSPER4,1812,Withdrawn
dinoprostone,prostanoid receptor agonist,PTGDR,4128,Withdrawn
dinoprostone,prostanoid receptor agonist,PTGDR2,4129,Withdrawn
dinoprostone,prostanoid receptor agonist,PTGER1,1429,Withdrawn
dinoprostone,prostanoid receptor agonist,PTGER2,1728,Withdrawn
dinoprostone,prostanoid receptor agonist,PTGER3,79001,Withdrawn
dinoprostone,prostanoid receptor agonist,PTGER4,1128,Withdrawn
dinoprostone,prostanoid receptor agonist,PTGFR,1129,Withdrawn
dinoprostone,prostanoid receptor agonist,TBXA2R,1131,Withdrawn
dioscin,apoptosis stimulant,CXCR3,4860,Preclinical
diosmetin,aryl hydrocarbon receptor agonist,CYP1B1,5743,Launched
diosmin,aryl hydrocarbon receptor agonist|capillary stabilizing agent,AHR,51284,Launched
diphemanil,acetylcholine receptor antagonist,CHRM3,4069,Launched
diphenhydramine,histamine receptor antagonist,HRH1,5243,Launched
diphenidol,acetylcholine receptor agonist,CHRM1,3756,Launched
diphenidol,acetylcholine receptor agonist,CHRM2,3757,Launched
diphenidol,acetylcholine receptor agonist,CHRM3,3768,Launched
diphenidol,acetylcholine receptor agonist,CHRM4,3776,Launched
diphenyleneiodonium,nitric oxide synthase inhibitor,NOS2,3359,Preclinical
diphenyleneiodonium,nitric oxide synthase inhibitor,NOS3,203068,Preclinical
diphenylpyraline,dopamine reuptake inhibitor,HRH1,1576,Launched
diphenylpyraline,dopamine reuptake inhibitor,SLC6A3,1577,Launched
dipraglurant,glutamate receptor negative allosteric modulator,GRM5,1551,Phase 2
DIPT,dopamine reuptake inhibitor|serotonin reuptake inhibitor,HTR1A,5452,Launched
DIPT,dopamine reuptake inhibitor|serotonin reuptake inhibitor,HTR2A,54658,Launched
DIPT,dopamine reuptake inhibitor|serotonin reuptake inhibitor,HTR2C,1813,Launched
dipyridamole,phosphodiesterase inhibitor,ADA,1814,Launched
dipyridamole,phosphodiesterase inhibitor,PDE10A,43,Launched
dipyridamole,phosphodiesterase inhibitor,PDE1A,3350,Launched
dipyridamole,phosphodiesterase inhibitor,PDE1B,3351,Launched
dipyridamole,phosphodiesterase inhibitor,PDE1C,3352,Launched
dipyridamole,phosphodiesterase inhibitor,PDE2A,3354,Launched
dipyridamole,phosphodiesterase inhibitor,PDE3A,3355,Launched
dipyridamole,phosphodiesterase inhibitor,PDE3B,3356,Launched
dipyridamole,phosphodiesterase inhibitor,PDE4A,3361,Launched
dipyridamole,phosphodiesterase inhibitor,PDE4B,3362,Launched
dipyridamole,phosphodiesterase inhibitor,PDE4C,1621,Launched
dipyridamole,phosphodiesterase inhibitor,PDE4D,1812,Launched
dipyridamole,phosphodiesterase inhibitor,PDE5A,1813,Launched
dipyridamole,phosphodiesterase inhibitor,PDE6A,1814,Launched
dipyridamole,phosphodiesterase inhibitor,PDE6B,1815,Launched
dipyridamole,phosphodiesterase inhibitor,PDE6C,1816,Launched
dipyridamole,phosphodiesterase inhibitor,PDE6D,3350,Launched
dipyridamole,phosphodiesterase inhibitor,PDE6G,3363,Launched
dipyridamole,phosphodiesterase inhibitor,PDE6H,6530,Launched
dipyridamole,phosphodiesterase inhibitor,PDE7A,6531,Launched
dipyridamole,phosphodiesterase inhibitor,PDE7B,6532,Launched
dipyridamole,phosphodiesterase inhibitor,PDE8A,5600,Launched
dipyridamole,phosphodiesterase inhibitor,PDE8B,6300,Launched
dipyridamole,phosphodiesterase inhibitor,PDE9A,5603,Launched
dipyridamole,phosphodiesterase inhibitor,SLC29A1,1432,Launched
disodium-sebacate,,HBB,1800,Phase 1
disopyramide,sodium channel blocker,CHRM1,90,Launched
disopyramide,sodium channel blocker,CHRM2,657,Launched
disopyramide,sodium channel blocker,CHRM3,658,Launched
disopyramide,sodium channel blocker,KCND2,1969,Launched
disopyramide,sodium channel blocker,KCND3,2280,Launched
disopyramide,sodium channel blocker,KCNH2,2321,Launched
disopyramide,sodium channel blocker,SCN5A,2322,Launched
disulfiram,aldehyde dehydrogenase inhibitor|DNA methyltransferase inhibitor|TRPV agonist,ALDH2,3791,Launched
disulfiram,aldehyde dehydrogenase inhibitor|DNA methyltransferase inhibitor|TRPV agonist,DBH,3932,Launched
ditiocarb-sodium-trihydrate,immunostimulant,CA1,8569,Phase 3
ditiocarb-sodium-trihydrate,immunostimulant,CA2,5562,Phase 3
ditiocarb-sodium-trihydrate,immunostimulant,CA4,6195,Phase 3
ditolylguanidine,sigma receptor agonist,GRIN1,6714,Preclinical
ditolylguanidine,sigma receptor agonist,GRIN2A,759,Preclinical
ditolylguanidine,sigma receptor agonist,GRIN2B,771,Preclinical
ditolylguanidine,sigma receptor agonist,SIGMAR1,23632,Preclinical
dizocilpine-(+),glutamate receptor antagonist,GRIN1,760,Preclinical
dizocilpine-(+),glutamate receptor antagonist,GRIN2A,762,Preclinical
dizocilpine-(+),glutamate receptor antagonist,GRIN2B,766,Preclinical
dizocilpine-(+),glutamate receptor antagonist,GRIN2C,1128,Preclinical
dizocilpine-(+),glutamate receptor antagonist,GRIN2D,1129,Preclinical
DMAB-anabaseine,adrenergic receptor agonist,CHRNA7,1131,Preclinical
DMeOB,glutamate receptor modulator,GRM5,1132,Preclinical
DMH1,ALK tyrosine kinase receptor inhibitor,ACVR1,1133,Preclinical
DMH4,VEGFR inhibitor,KDR,3269,Preclinical
DMP-777,elastase inhibitor,MPO,6530,Phase 2
DNQX,glutamate receptor antagonist,GRIA1,6532,Preclinical
DNQX,glutamate receptor antagonist,GRIA2,1436,Preclinical
DNQX,glutamate receptor antagonist,GRIK1,1956,Preclinical
DNQX,glutamate receptor antagonist,GRIN1,2260,Preclinical
DNQX,glutamate receptor antagonist,GRIN2A,2263,Preclinical
DNQX,glutamate receptor antagonist,GRIN2B,2261,Preclinical
dobutamine,adrenergic receptor agonist,ADRB1,2321,Launched
dobutamine,adrenergic receptor agonist,ADRB2,2322,Launched
docebenone,lipoxygenase inhibitor,ALOX5,2324,Phase 2
docetaxel,tubulin polymerization inhibitor,BCL2,3643,Launched
docetaxel,tubulin polymerization inhibitor,MAP2,3791,Launched
docetaxel,tubulin polymerization inhibitor,MAP4,3815,Launched
docetaxel,tubulin polymerization inhibitor,MAPT,5156,Launched
docetaxel,tubulin polymerization inhibitor,NR1I2,5159,Launched
docetaxel,tubulin polymerization inhibitor,TUBA1A,148,Launched
docetaxel,tubulin polymerization inhibitor,TUBA1B,147,Launched
docetaxel,tubulin polymerization inhibitor,TUBA1C,146,Launched
docetaxel,tubulin polymerization inhibitor,TUBA3C,3269,Launched
docetaxel,tubulin polymerization inhibitor,TUBA3D,6530,Launched
docetaxel,tubulin polymerization inhibitor,TUBA3E,6532,Launched
docetaxel,tubulin polymerization inhibitor,TUBA4A,7421,Launched
docetaxel,tubulin polymerization inhibitor,TUBB,7298,Launched
docetaxel,tubulin polymerization inhibitor,TUBB1,134,Launched
docetaxel,tubulin polymerization inhibitor,TUBB2A,5141,Launched
docetaxel,tubulin polymerization inhibitor,TUBB2B,5142,Launched
docetaxel,tubulin polymerization inhibitor,TUBB3,5143,Launched
docetaxel,tubulin polymerization inhibitor,TUBB4A,5144,Launched
docetaxel,tubulin polymerization inhibitor,TUBB4B,7153,Launched
docetaxel,tubulin polymerization inhibitor,TUBB6,4317,Launched
docetaxel,tubulin polymerization inhibitor,TUBB8,3269,Launched
doconexent,PPAR receptor agonist,FFAR1,134,Launched
doconexent,PPAR receptor agonist,PTGS1,135,Launched
doconexent,PPAR receptor agonist,PTGS2,1545,Launched
docosanol,lipase clearing factor inhibitor,TLR7,196,Launched
dodecyl-sulfate,,LYZ,1131,Preclinical
dofequidar,MRP inhibitor|P glycoprotein inhibitor,ABCB1,3269,Phase 3
dofetilide,potassium channel blocker,KCNH1,1128,Withdrawn
dofetilide,potassium channel blocker,KCNH2,1129,Withdrawn
dofetilide,potassium channel blocker,KCNJ12,1131,Withdrawn
dofetilide,potassium channel blocker,KCNK2,1132,Withdrawn
dolasetron,serotonin receptor antagonist,HTR3A,4843,Launched
dolastatin-10,tubulin polymerization inhibitor,TUBB,4846,Phase 2
dolutegravir,HIV integrase inhibitor,CYP3A4,3269,Launched
dolutegravir,HIV integrase inhibitor,CYP3A5,6531,Launched
dolutegravir,HIV integrase inhibitor,CYP3A7,2915,Launched
dolutegravir,HIV integrase inhibitor,POU2F2,3350,Launched
dolutegravir,HIV integrase inhibitor,UGT1A1,3356,Launched
domperidone,dopamine receptor antagonist,DRD2,3358,Launched
domperidone,dopamine receptor antagonist,DRD3,100,Launched
donepezil,acetylcholinesterase inhibitor,ACHE,10846,Launched
donitriptan,serotonin receptor agonist,HTR1A,5136,Phase 2
donitriptan,serotonin receptor agonist,HTR1B,5153,Phase 2
donitriptan,serotonin receptor agonist,HTR1D,5137,Phase 2
donitriptan,serotonin receptor agonist,HTR1E,5138,Phase 2
donitriptan,serotonin receptor agonist,HTR1F,5139,Phase 2
donitriptan,serotonin receptor agonist,HTR2A,5140,Phase 2
donitriptan,serotonin receptor agonist,HTR5A,5141,Phase 2
donitriptan,serotonin receptor agonist,HTR6,5142,Phase 2
dopamine,dopamine receptor agonist,DBH,5143,Launched
dopamine,dopamine receptor agonist,DRD1,5144,Launched
dopamine,dopamine receptor agonist,DRD2,8654,Launched
dopamine,dopamine receptor agonist,DRD3,5145,Launched
dopamine,dopamine receptor agonist,DRD4,5158,Launched
dopamine,dopamine receptor agonist,DRD5,5146,Launched
dopamine,dopamine receptor agonist,HTR1A,5147,Launched
dopamine,dopamine receptor agonist,HTR7,5148,Launched
dopamine,dopamine receptor agonist,SLC6A2,5149,Launched
dopamine,dopamine receptor agonist,SLC6A3,5150,Launched
dopamine,dopamine receptor agonist,SLC6A4,27115,Launched
doramapimod,p38 MAPK inhibitor,MAPK11,5151,Phase 2
doramapimod,p38 MAPK inhibitor,MAPK12,8622,Phase 2
doramapimod,p38 MAPK inhibitor,MAPK13,5152,Phase 2
doramapimod,p38 MAPK inhibitor,MAPK14,2030,Phase 2
doripenem,bacterial cell wall synthesis inhibitor,DPEP1,3043,Launched
dorsomorphin,AMPK inhibitor,ACVR1,1128,Preclinical
dorsomorphin,AMPK inhibitor,BMPR1A,1129,Preclinical
dorsomorphin,AMPK inhibitor,BMPR1B,1131,Preclinical
dorsomorphin,AMPK inhibitor,EPHA2,3751,Preclinical
dorsomorphin,AMPK inhibitor,FKBP1A,3752,Preclinical
dorsomorphin,AMPK inhibitor,FLT1,3757,Preclinical
dorsomorphin,AMPK inhibitor,FLT3,6331,Preclinical
dorsomorphin,AMPK inhibitor,KDR,217,Preclinical
dorsomorphin,AMPK inhibitor,LCK,1621,Preclinical
dorsomorphin,AMPK inhibitor,MKNK1,759,Preclinical
dorsomorphin,AMPK inhibitor,PRKAA1,760,Preclinical
dorsomorphin,AMPK inhibitor,RPS6KA1,762,Preclinical
dorsomorphin,AMPK inhibitor,SRC,2902,Preclinical
dorzolamide,carbonic anhydrase inhibitor,CA1,2903,Launched
dorzolamide,carbonic anhydrase inhibitor,CA12,2904,Launched
dorzolamide,carbonic anhydrase inhibitor,CA14,10280,Launched
dorzolamide,carbonic anhydrase inhibitor,CA2,2902,Launched
dorzolamide,carbonic anhydrase inhibitor,CA4,2903,Launched
dorzolamide,carbonic anhydrase inhibitor,CA7,2904,Launched
dosulepin,norepinephrine reuptake inhibitor|serotoninâ€“norepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant,CHRM1,2905,Launched
dosulepin,norepinephrine reuptake inhibitor|serotoninâ€“norepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant,CHRM2,2906,Launched
dosulepin,norepinephrine reuptake inhibitor|serotoninâ€“norepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant,CHRM3,1139,Launched
dosulepin,norepinephrine reuptake inhibitor|serotoninâ€“norepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant,CHRM4,2915,Launched
dosulepin,norepinephrine reuptake inhibitor|serotoninâ€“norepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant,CHRM5,90,Launched
dosulepin,norepinephrine reuptake inhibitor|serotoninâ€“norepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant,HRH1,3791,Launched
dosulepin,norepinephrine reuptake inhibitor|serotoninâ€“norepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant,SLC6A2,4353,Launched
dosulepin,norepinephrine reuptake inhibitor|serotoninâ€“norepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant,SLC6A4,2890,Launched
dovitinib,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,CSF1R,2891,Phase 3
dovitinib,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,EGFR,2897,Phase 3
dovitinib,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FGFR1,2902,Phase 3
dovitinib,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FGFR2,2903,Phase 3
dovitinib,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FGFR3,2904,Phase 3
dovitinib,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FLT1,153,Phase 3
dovitinib,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FLT3,154,Phase 3
dovitinib,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FLT4,240,Phase 3
dovitinib,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,INSR,596,Phase 3
dovitinib,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KDR,4133,Phase 3
dovitinib,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KIT,4134,Phase 3
dovitinib,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,PDGFRA,4137,Phase 3
dovitinib,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,PDGFRB,8856,Phase 3
doxazosin,adrenergic receptor antagonist,ADRA1A,7846,Launched
doxazosin,adrenergic receptor antagonist,ADRA1B,10376,Launched
doxazosin,adrenergic receptor antagonist,ADRA1D,84790,Launched
doxepin,histamine receptor antagonist,HRH1,7278,Launched
doxepin,histamine receptor antagonist,SLC6A2,113457,Launched
doxepin,histamine receptor antagonist,SLC6A4,112714,Launched
doxercalciferol,vitamin D receptor agonist,VDR,7277,Launched
doxifluridine,thymidylate synthase inhibitor,TYMS,203068,Launched
doxofylline,adenosine receptor antagonist,ADORA1,81027,Launched
doxofylline,adenosine receptor antagonist,PDE4A,7280,Launched
doxofylline,adenosine receptor antagonist,PDE4B,347733,Launched
doxofylline,adenosine receptor antagonist,PDE4C,10381,Launched
doxofylline,adenosine receptor antagonist,PDE4D,10382,Launched
doxorubicin,topoisomerase inhibitor,TOP2A,10383,Launched
doxycycline,bacterial 30S ribosomal subunit inhibitor|metalloproteinase inhibitor,MMP8,84617,Launched
doxylamine,histamine receptor antagonist,HRH1,347688,Launched
DPCPX,adenosine receptor antagonist,ADORA1,2864,Phase 1
DPCPX,adenosine receptor antagonist,ADORA2A,5742,Phase 1
DPCPX,adenosine receptor antagonist,ADORA2B,834,Phase 1
DPCPX,adenosine receptor antagonist,ADORA3,836,Phase 1
DPI-201106,sodium channel activator,ADRB2,840,Phase 2
DPO-1,potassium channel blocker,KCNA5,1636,Preclinical
DPPE,histamine receptor antagonist,ABCB1,1636,Phase 3
DPPE,histamine receptor antagonist,HRH1,3417,Phase 3
DQP-1105,glutamate receptor antagonist,GRIN2C,2554,Preclinical
DQP-1105,glutamate receptor antagonist,GRIN2D,673,Preclinical
DR-2313,PARP inhibitor,PARP1,8658,Preclinical
DR-2313,PARP inhibitor,PARP3,80351,Preclinical
DR-4485,serotonin receptor antagonist,HTR7,2099,Preclinical
DRF053-(R),CDK inhibitor,CSNK1A1,2554,Preclinical
droloxifene,selective estrogen receptor modulator (SERM),ESR1,2555,Phase 3
dromostanolone-propionate,androgen receptor modulator,AR,2556,Launched
dronedarone,adrenergic receptor antagonist,ADRA1A,2557,Launched
dronedarone,adrenergic receptor antagonist,ADRA1B,2558,Launched
dronedarone,adrenergic receptor antagonist,ADRA1D,2559,Launched
dronedarone,adrenergic receptor antagonist,ADRA2A,2560,Launched
dronedarone,adrenergic receptor antagonist,ADRA2B,2561,Launched
dronedarone,adrenergic receptor antagonist,ADRA2C,2562,Launched
dronedarone,adrenergic receptor antagonist,ADRB1,2563,Launched
dronedarone,adrenergic receptor antagonist,CACNA1C,2564,Launched
dronedarone,adrenergic receptor antagonist,CACNA1D,2565,Launched
dronedarone,adrenergic receptor antagonist,CACNA1F,2566,Launched
dronedarone,adrenergic receptor antagonist,CACNA1S,2567,Launched
dronedarone,adrenergic receptor antagonist,CACNB1,2568,Launched
dronedarone,adrenergic receptor antagonist,CACNB2,55879,Launched
dronedarone,adrenergic receptor antagonist,CACNB3,2741,Launched
dronedarone,adrenergic receptor antagonist,CACNB4,2743,Launched
dronedarone,adrenergic receptor antagonist,KCNA5,54207,Launched
dronedarone,adrenergic receptor antagonist,KCNH2,338567,Launched
dronedarone,adrenergic receptor antagonist,KCNK2,3776,Launched
dronedarone,adrenergic receptor antagonist,SCN1A,3777,Launched
droperidol,dopamine receptor antagonist,ADRA1A,51305,Launched
droperidol,dopamine receptor antagonist,DRD2,1588,Launched
droperidol,dopamine receptor antagonist,DRD3,1544,Launched
droperidol,dopamine receptor antagonist,DRD4,1555,Launched
droperidol,dopamine receptor antagonist,HTR2A,1559,Launched
drospirenone,mineralocorticoid receptor antagonist,AR,1573,Launched
drospirenone,mineralocorticoid receptor antagonist,NR3C2,1576,Launched
drospirenone,mineralocorticoid receptor antagonist,PGR,1577,Launched
droxicam,cyclooxygenase inhibitor,PTGS1,8856,Launched
droxidopa,norepinephrine precursor,ADRA1A,5465,Launched
droxidopa,norepinephrine precursor,ADRA1B,5732,Launched
droxidopa,norepinephrine precursor,ADRA1D,316,Launched
droxidopa,norepinephrine precursor,ADRA2A,1806,Launched
droxidopa,norepinephrine precursor,ADRA2B,7498,Launched
droxidopa,norepinephrine precursor,ADRA2C,6790,Launched
droxidopa,norepinephrine precursor,ADRB1,2322,Launched
droxidopa,norepinephrine precursor,ADRB2,3791,Launched
droxidopa,norepinephrine precursor,ADRB3,5156,Launched
droxidopa,norepinephrine precursor,PAH,5747,Launched
droxinostat,HDAC inhibitor,HDAC6,6714,Preclinical
droxinostat,HDAC inhibitor,HDAC8,51727,Preclinical
DSR-6434,toll-like receptor agonist,TLR7,6240,Preclinical
DU-728,structural glycoprotein antagonist,ITGA2B,7298,Phase 1
DU-728,structural glycoprotein antagonist,ITGB3,7153,Phase 1
duloxetine,norepinephrine reuptake inhibitor|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),HTR2A,5139,Launched
duloxetine,norepinephrine reuptake inhibitor|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),HTR2C,3290,Launched
duloxetine,norepinephrine reuptake inhibitor|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),HTR6,134,Launched
duloxetine,norepinephrine reuptake inhibitor|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),SLC6A2,135,Launched
duloxetine,norepinephrine reuptake inhibitor|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),SLC6A3,136,Launched
duloxetine,norepinephrine reuptake inhibitor|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),SLC6A4,140,Launched
DUP-697,cyclooxygenase inhibitor,PTGS2,5141,Phase 1
dutasteride,5 alpha reductase inhibitor,SRD5A1,5142,Launched
dutasteride,5 alpha reductase inhibitor,SRD5A2,1312,Launched
dutasteride,5 alpha reductase inhibitor,SRD5A3,3065,Launched
duvelisib,PI3K inhibitor,PIK3CA,3066,Launched
duvelisib,PI3K inhibitor,PIK3CB,8841,Launched
duvelisib,PI3K inhibitor,PIK3CD,9734,Launched
duvelisib,PI3K inhibitor,PIK3CG,238,Launched
dyclonine,sodium channel blocker,SCN10A,4914,Launched
dyclonine,sodium channel blocker,SCN5A,4915,Launched
dydrogesterone,progesterone receptor agonist,PGR,4916,Launched
dynasore,dynamin inhibitor,DNM1,6098,Preclinical
dynasore,dynamin inhibitor,DNM1L,367,Preclinical
dynasore,dynamin inhibitor,DNM2,207,Preclinical
dynole-34-2,dynamin inhibitor,DNM1,2932,Preclinical
dyphylline,adenosine receptor antagonist|phosphodiesterase inhibitor,PDE4A,5578,Launched
DY131,estrogen-related receptor agonist,ESRRB,5579,Preclinical
DY131,estrogen-related receptor agonist,ESRRG,5580,Preclinical
E-2012,gamma secretase modulator,APH1A,5582,Phase 1
E-2012,gamma secretase modulator,APH1B,30001,Phase 1
E-2012,gamma secretase modulator,PSENEN,5600,Phase 1
E-4031,potassium channel blocker,KCNH1,1432,Phase 1
E-4031,potassium channel blocker,KCNH2,3620,Phase 1
E-64,calpain inhibitor|cysteine protease inhibitor,CTSS,231,Preclinical
eact,calcium-activated chloride channel inhibitor,ANO1,1573,Preclinical
EB-47,PARP inhibitor,PARP1,43,Preclinical
ebastine,histamine receptor antagonist,CYP3A4,148,Launched
ebastine,histamine receptor antagonist,HRH1,154,Launched
EBPC,aldose reductase inhibitor,AKR1B1,6571,Preclinical
ebrotidine,histamine receptor antagonist,HRH2,6530,Withdrawn
ebselen,cyclooxygenase inhibitor|glutathione peroxidase agonist|H+/K+-ATPase inhibitor|nitric oxide synthase inhibitor,ALB,148,Phase 2/Phase 3
EC-144,HSP inhibitor,HSP90AA1,150,Preclinical
EC-144,HSP inhibitor,HSP90AB1,153,Preclinical
EC-23,retinoid receptor agonist,RARA,154,Preclinical
EC-23,retinoid receptor agonist,RARB,466,Preclinical
EC-23,retinoid receptor agonist,RARG,1386,Preclinical
ecabet,gastrin inhibitor|urease inhibitor,NOXO1,467,Launched
econazole,lanosterol demethylase inhibitor|sterol demethylase inhibitor,NPY1R,136,Launched
econazole,lanosterol demethylase inhibitor|sterol demethylase inhibitor,NPY2R,140,Launched
econazole,lanosterol demethylase inhibitor|sterol demethylase inhibitor,TRPM2,154,Launched
econazole,lanosterol demethylase inhibitor|sterol demethylase inhibitor,TRPV5,3741,Launched
edaglitazone,PPAR receptor agonist,PPARG,5243,Phase 2
edaravone,nootropic agent,BCL2,3269,Launched
edoxaban,coagulation factor inhibitor,F10,2905,Launched
edrophonium,acetylcholinesterase inhibitor,ACHE,2906,Launched
edrophonium,acetylcholinesterase inhibitor,BCHE,142,Launched
EED226,polycomb protein inhibitor,EED,10039,Preclinical
efaproxiral,hemoglobin oxygen release stimulant,HBA1,3363,Phase 3
efaproxiral,hemoglobin oxygen release stimulant,HBB,1452,Phase 3
efaroxan,adrenergic receptor antagonist,ADORA2A,2099,Phase 2
efatutazone,PPAR receptor agonist,PPARG,367,Phase 2
efavirenz,HIV protease inhibitor,CYP1A2,148,Launched
efavirenz,HIV protease inhibitor,CYP2B6,147,Launched
efavirenz,HIV protease inhibitor,CYP2C19,146,Launched
efavirenz,HIV protease inhibitor,CYP2C9,150,Launched
efavirenz,HIV protease inhibitor,CYP2D6,151,Launched
efavirenz,HIV protease inhibitor,CYP3A4,152,Launched
efinaconazole,lanosterol demethylase inhibitor,CYP51A1,153,Launched
eflornithine,ornithine decarboxylase inhibitor,ARG2,775,Launched
eflornithine,ornithine decarboxylase inhibitor,ODC1,776,Launched
EGF816,EGFR inhibitor,EGFR,778,Phase 2
eglumetad,glutamate receptor agonist,GRM2,779,Phase 2
eglumetad,glutamate receptor agonist,GRM3,782,Phase 2
eglumetad,glutamate receptor agonist,GRM6,783,Phase 2
eglumetad,glutamate receptor agonist,GRM8,784,Phase 2
EG00229,neuropilin receptor antagonist,NRP1,785,Preclinical
EHop-016,Ras GTPase inhibitor,RAC1,3741,Preclinical
EHop-016,Ras GTPase inhibitor,RAC3,3757,Preclinical
EIPA,sodium/hydrogen exchanger inhibitor|transient receptor potential polycystic inhibitor,ADRA2A,3776,Preclinical
EIPA,sodium/hydrogen exchanger inhibitor|transient receptor potential polycystic inhibitor,ASIC1,6323,Preclinical
EIPA,sodium/hydrogen exchanger inhibitor|transient receptor potential polycystic inhibitor,PKD2L1,148,Preclinical
EIT-hydrobromide,nitric oxide synthase inhibitor,NOS2,1813,Preclinical
EIT-hydrobromide,nitric oxide synthase inhibitor,NOS3,1814,Preclinical
EI1,histone lysine methyltransferase inhibitor,EZH2,1815,Preclinical
elacridar,P glycoprotein inhibitor,ABCB1,3356,Phase 1
elactocin,exportin antagonist,XPO1,367,Phase 1
elacytarabine,antineoplastic agent,DCK,4306,Phase 3
elafibranor,PPAR receptor agonist,PPARA,5241,Phase 3
elafibranor,PPAR receptor agonist,PPARD,5742,Phase 3
elafibranor,PPAR receptor agonist,PPARG,148,Phase 3
elagolix,gonadotropin releasing factor hormone receptor antagonist,GNRHR,147,Launched
eldecalcitol,bone formation stimulant,VDR,146,Phase 3
elesclomol,oxidative stress inducer,HSPA1A,150,Phase 3
eletriptan,serotonin receptor agonist,HTR1A,151,Launched
eletriptan,serotonin receptor agonist,HTR1B,152,Launched
eletriptan,serotonin receptor agonist,HTR1D,153,Launched
eletriptan,serotonin receptor agonist,HTR1E,154,Launched
eletriptan,serotonin receptor agonist,HTR1F,155,Launched
eletriptan,serotonin receptor agonist,HTR2B,5053,Launched
eletriptan,serotonin receptor agonist,HTR7,10013,Launched
eliglustat,glycosyl transferase inhibitor,UGCG,55869,Launched
elinogrel,purinergic receptor antagonist,P2RY12,51284,Phase 2
eliprodil,glutamate receptor antagonist,GRIN1,3674,Phase 3
eliprodil,glutamate receptor antagonist,GRIN2B,3690,Phase 3
ellagic-acid,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,CA1,3356,Phase 2
ellagic-acid,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,CA12,3358,Phase 2
ellagic-acid,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,CA14,3362,Phase 2
ellagic-acid,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,CA2,6530,Phase 2
ellagic-acid,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,CA3,6531,Phase 2
ellagic-acid,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,CA4,6532,Phase 2
ellagic-acid,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,CA5A,5743,Phase 2
ellagic-acid,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,CA5B,6715,Phase 2
ellagic-acid,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,CA6,6716,Phase 2
ellagic-acid,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,CA7,79644,Phase 2
ellagic-acid,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,CA9,5290,Phase 2
ellagic-acid,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,CSNK2A1,5291,Phase 2
ellagic-acid,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,GSK3B,5293,Phase 2
ellagic-acid,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,PRKACA,5294,Phase 2
ellagic-acid,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,PRKCA,6336,Phase 2
ellagic-acid,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,PRKCB,6331,Phase 2
ellagic-acid,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,SQLE,5241,Phase 2
ellagic-acid,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,SYK,1759,Phase 2
ELN-441958,bradykinin receptor antagonist,BDKRB1,10059,Preclinical
eltanolone,GABA receptor positive allosteric modulator,GABRA1,1785,Phase 3
eltanolone,GABA receptor positive allosteric modulator,GABRA2,1759,Phase 3
eltanolone,GABA receptor positive allosteric modulator,GABRA3,5141,Phase 3
eltanolone,GABA receptor positive allosteric modulator,GABRA4,2103,Phase 3
eltanolone,GABA receptor positive allosteric modulator,GABRA5,2104,Phase 3
eltanolone,GABA receptor positive allosteric modulator,GABRA6,51107,Phase 3
eltanolone,GABA receptor positive allosteric modulator,GABRB2,83464,Phase 3
eltanolone,GABA receptor positive allosteric modulator,GABRG2,55851,Phase 3
eltoprazine,serotonin receptor agonist,HTR1A,3756,Phase 2
eltoprazine,serotonin receptor agonist,HTR1B,3757,Phase 2
eltrombopag,thrombopoietin receptor agonist,MPL,1520,Launched
eluxadoline,opioid receptor agonist|opioid receptor antagonist,OPRD1,55107,Launched
eluxadoline,opioid receptor agonist|opioid receptor antagonist,OPRK1,142,Launched
eluxadoline,opioid receptor agonist|opioid receptor antagonist,OPRM1,1576,Launched
embelin,HCV inhibitor|XIAP inhibitor,XIAP,3269,Preclinical
EMD-1214063,hepatocyte growth factor receptor inhibitor,MET,231,Phase 2
EMD-386088,serotonin receptor agonist,HTR6,3274,Preclinical
EMD-53998,phosphodiesterase inhibitor,TNNC1,213,Phase 1
EMD-66684,angiotensin receptor antagonist,AGTR1,3320,Preclinical
emedastine,histamine receptor antagonist,HRH1,3326,Launched
emetine,protein synthesis inhibitor,RPS2,5914,Phase 2
emodin,11-beta hydroxysteroid dehydrogenase inhibitor,CSNK2A1,5915,Preclinical
empagliflozin,sodium/glucose cotransporter inhibitor,SLC5A1,5916,Launched
empagliflozin,sodium/glucose cotransporter inhibitor,SLC5A2,124056,Launched
emricasan,caspase inhibitor,CASP1,4886,Phase 2
emricasan,caspase inhibitor,CASP3,4887,Phase 2
emricasan,caspase inhibitor,CASP7,7226,Phase 2
enalapril,angiotensin converting enzyme inhibitor,ACE,56302,Launched
enalaprilat,angiotensin converting enzyme inhibitor,ACE,5468,Launched
enasidenib,isocitrate dehydrogenase inhibitor,IDH1,596,Launched
enciprazine,GABA receptor modulator,GABRA1,2159,Phase 3
encorafenib,RAF inhibitor,BRAF,43,Launched
endo-IWR-1,PARP inhibitor,TNKS,590,Preclinical
endo-IWR-1,PARP inhibitor,TNKS2,8726,Preclinical
endoxifen,estrogen receptor antagonist,ESR1,3039,Phase 2
enflurane,membrane permeability inhibitor,GABRA1,3043,Launched
enflurane,membrane permeability inhibitor,GABRA2,135,Launched
enflurane,membrane permeability inhibitor,GABRA3,5468,Launched
enflurane,membrane permeability inhibitor,GABRA4,1544,Launched
enflurane,membrane permeability inhibitor,GABRA5,1555,Launched
enflurane,membrane permeability inhibitor,GABRA6,1557,Launched
enflurane,membrane permeability inhibitor,GABRB1,1559,Launched
enflurane,membrane permeability inhibitor,GABRB2,1565,Launched
enflurane,membrane permeability inhibitor,GABRB3,1576,Launched
enflurane,membrane permeability inhibitor,GABRD,1595,Launched
enflurane,membrane permeability inhibitor,GABRE,384,Launched
enflurane,membrane permeability inhibitor,GABRG1,4953,Launched
enflurane,membrane permeability inhibitor,GABRG2,1956,Launched
enflurane,membrane permeability inhibitor,GABRG3,2912,Launched
enflurane,membrane permeability inhibitor,GABRP,2913,Launched
enflurane,membrane permeability inhibitor,GABRQ,2916,Launched
enflurane,membrane permeability inhibitor,GLRA1,2918,Launched
enflurane,membrane permeability inhibitor,GLRB,8829,Launched
enflurane,membrane permeability inhibitor,KCNK10,5879,Launched
enflurane,membrane permeability inhibitor,KCNK18,5881,Launched
enflurane,membrane permeability inhibitor,KCNK2,150,Launched
enflurane,membrane permeability inhibitor,KCNK3,41,Launched
enflurane,membrane permeability inhibitor,KCNK9,9033,Launched
enilconazole,sterol demethylase inhibitor,CYP19A1,4843,Launched
enilconazole,sterol demethylase inhibitor,CYP1A2,4846,Launched
enilconazole,sterol demethylase inhibitor,CYP2B6,2146,Launched
enilconazole,sterol demethylase inhibitor,CYP2C9,5243,Launched
enilconazole,sterol demethylase inhibitor,CYP2J2,7514,Launched
enilconazole,sterol demethylase inhibitor,CYP3A4,1633,Launched
enilconazole,sterol demethylase inhibitor,CYP3A5,5465,Launched
enilconazole,sterol demethylase inhibitor,NR1I2,5467,Launched
enilconazole,sterol demethylase inhibitor,PPARA,5468,Launched
enilconazole,sterol demethylase inhibitor,PTGER2,2798,Launched
eniluracil,dihydropyrimidine dehydrogenase inhibitor,AOX1,7421,Phase 3
eniluracil,dihydropyrimidine dehydrogenase inhibitor,DPYD,3303,Phase 3
eniluracil,dihydropyrimidine dehydrogenase inhibitor,XDH,3350,Phase 3
ENMD-2076,Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor,AURKA,3351,Phase 2
ENMD-2076,Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor,FLT3,3352,Phase 2
ENMD-2076,Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor,KDR,3354,Phase 2
ENMD-2076,Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor,PDGFRA,3355,Phase 2
ENMD-2076,Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor,PTK2,3357,Phase 2
ENMD-2076,Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor,SRC,3363,Phase 2
enocitabine,DNA synthesis inhibitor,CMPK1,7357,Launched
enocitabine,DNA synthesis inhibitor,RRM1,64805,Launched
enocitabine,DNA synthesis inhibitor,TYMS,2902,Launched
enoxacin,topoisomerase inhibitor,TOP2A,2904,Launched
enoximone,phosphodiesterase inhibitor,PDE3A,759,Launched
enoxolone,gap junction modulator,HSD11B1,771,Launched
enprofylline,phosphodiesterase inhibitor,ADORA1,23632,Phase 3
enprofylline,phosphodiesterase inhibitor,ADORA2A,760,Phase 3
enprofylline,phosphodiesterase inhibitor,ADORA2B,761,Phase 3
enprofylline,phosphodiesterase inhibitor,ADORA3,762,Phase 3
enprofylline,phosphodiesterase inhibitor,PDE4A,763,Phase 3
enprofylline,phosphodiesterase inhibitor,PDE4B,11238,Phase 3
entacapone,catechol O methyltransferase inhibitor,COMT,765,Launched
entinostat,HDAC inhibitor,HDAC1,766,Phase 3
entinostat,HDAC inhibitor,HDAC2,768,Phase 3
entinostat,HDAC inhibitor,HDAC3,1457,Phase 3
entinostat,HDAC inhibitor,HDAC9,2932,Phase 3
entrectinib,ALK tyrosine kinase receptor inhibitor|proto-oncogene tyrosine protein kinase inhibitor,ALK,5566,Launched
entrectinib,ALK tyrosine kinase receptor inhibitor|proto-oncogene tyrosine protein kinase inhibitor,NTRK1,5578,Launched
entrectinib,ALK tyrosine kinase receptor inhibitor|proto-oncogene tyrosine protein kinase inhibitor,NTRK2,5579,Launched
entrectinib,ALK tyrosine kinase receptor inhibitor|proto-oncogene tyrosine protein kinase inhibitor,NTRK3,6713,Launched
entrectinib,ALK tyrosine kinase receptor inhibitor|proto-oncogene tyrosine protein kinase inhibitor,ROS1,6850,Launched
enzalutamide,androgen receptor antagonist,AR,623,Launched
enzastaurin,PKC inhibitor,AKT1,2554,Phase 3
enzastaurin,PKC inhibitor,GSK3B,2555,Phase 3
enzastaurin,PKC inhibitor,PRKCA,2556,Phase 3
enzastaurin,PKC inhibitor,PRKCB,2557,Phase 3
enzastaurin,PKC inhibitor,PRKCD,2558,Phase 3
enzastaurin,PKC inhibitor,PRKCG,2559,Phase 3
EN460,endoplasmic reticulum oxidation inhibitor,ERO1A,2561,Preclinical
EO-1428,p38 MAPK inhibitor,MAPK11,2566,Preclinical
EO-1428,p38 MAPK inhibitor,MAPK14,3350,Preclinical
epacadostat,"indoleamine 2,3-dioxygenase inhibitor",IDO1,3351,Phase 3
epalrestat,aldose reductase inhibitor,AKR1B1,4352,Launched
eperisone,acetylcholine receptor antagonist,CYP2J2,4985,Launched
ephedrine,adrenergic receptor agonist,ACHE,4986,Launched
ephedrine,adrenergic receptor agonist,ADRA1A,4988,Launched
ephedrine,adrenergic receptor agonist,ADRB2,331,Launched
ephedrine,adrenergic receptor agonist,SLC18A2,4233,Launched
ephedrine,adrenergic receptor agonist,SLC6A2,3362,Launched
ephedrine-(racemic),adrenergic receptor agonist,ADRA1A,7134,Launched
ephedrine-(racemic),adrenergic receptor agonist,ADRA2A,185,Launched
ephedrine-(racemic),adrenergic receptor agonist,ADRB1,3269,Launched
ephedrine-(racemic),adrenergic receptor agonist,ADRB2,6187,Launched
ephedrine-(racemic),adrenergic receptor agonist,ATF1,1457,Launched
ephedrine-(racemic),adrenergic receptor agonist,ATF2,6523,Launched
ephedrine-(racemic),adrenergic receptor agonist,ATF3,6524,Launched
ephedrine-(racemic),adrenergic receptor agonist,ATF4,468,Launched
ephedrine-(racemic),adrenergic receptor agonist,ATF5,22809,Launched
ephedrine-(racemic),adrenergic receptor agonist,ATF6,22926,Launched
ephedrine-(racemic),adrenergic receptor agonist,ATF7,11016,Launched
ephedrine-(racemic),adrenergic receptor agonist,FOS,2353,Launched
ephedrine-(racemic),adrenergic receptor agonist,IL2,3558,Launched
ephedrine-(racemic),adrenergic receptor agonist,JDP2,122953,Launched
ephedrine-(racemic),adrenergic receptor agonist,JUN,3725,Launched
ephedrine-(racemic),adrenergic receptor agonist,NFATC1,4772,Launched
ephedrine-(racemic),adrenergic receptor agonist,SLC6A2,6530,Launched
ephedrine-(racemic),adrenergic receptor agonist,SLC6A3,6531,Launched
ephedrine-(racemic),adrenergic receptor agonist,SLC6A4,6532,Launched
ephedrine-(racemic),adrenergic receptor agonist,TNF,7124,Launched
epiandrosterone,steroid,G6PD,2539,Preclinical
epicatechin-gallate-(-),bacterial DNA gyrase inhibitor,BACE1,23621,Phase 2
epicatechin-gallate-(-),bacterial DNA gyrase inhibitor,FASN,2194,Phase 2
epigallocatechin-gallate-(-),bacterial DNA gyrase inhibitor,ELANE,1991,Phase 2/Phase 3
epigallocatechin-gallate-(-),bacterial DNA gyrase inhibitor,EP300,2033,Phase 2/Phase 3
epigallocatechin-gallate-(-),bacterial DNA gyrase inhibitor,FASN,2194,Phase 2/Phase 3
epigallocatechin-gallate-(-),bacterial DNA gyrase inhibitor,KAT2B,8850,Phase 2/Phase 3
epigallocatechin-gallate-(-),bacterial DNA gyrase inhibitor,MMP14,4323,Phase 2/Phase 3
epigallocatechin-gallate-(-),bacterial DNA gyrase inhibitor,MMP2,4313,Phase 2/Phase 3
epinastine,histamine receptor antagonist,HRH1,3269,Launched
epinephrine,adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter,ADRA1A,148,Launched
epinephrine,adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter,ADRA1B,147,Launched
epinephrine,adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter,ADRA1D,146,Launched
epinephrine,adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter,ADRA2A,150,Launched
epinephrine,adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter,ADRA2B,151,Launched
epinephrine,adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter,ADRA2C,152,Launched
epinephrine,adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter,ADRB1,153,Launched
epinephrine,adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter,ADRB2,154,Launched
epinephrine,adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter,ADRB3,155,Launched
epinephrine,adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter,PAH,5053,Launched
epinephrine,adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter,TNF,7124,Launched
epirizole,cyclooxygenase inhibitor,PTGS1,5742,Launched
epirizole,cyclooxygenase inhibitor,PTGS2,5743,Launched
epirubicin,topoisomerase inhibitor,CHD1,1105,Launched
epirubicin,topoisomerase inhibitor,TOP2A,7153,Launched
epitiostanol,androgen receptor agonist,AR,367,Launched
eplerenone,cytochrome P450 inhibitor,NR3C2,4306,Launched
epomediol,cholesterol inhibitor,CYP7A1,1581,Launched
epoprostenol,prostacyclin analog,P2RY12,64805,Launched
epoprostenol,prostacyclin analog,PTGER1,5731,Launched
epoprostenol,prostacyclin analog,PTGER4,5734,Launched
epoprostenol,prostacyclin analog,PTGIR,5739,Launched
epoprostenol,prostacyclin analog,PTGIS,5740,Launched
epothilone-B,microtubule stabilizing agent|tubulin polymerization inhibitor,TUBB,203068,Phase 3
epothilone-D,microtubule stabilizing agent|tubulin polymerization inhibitor,TUBB,203068,Phase 2
EPPTB,trace amine associated receptor antagonist,TAAR1,134864,Preclinical
eprobemide,monoamine oxidase inhibitor,MAOA,4128,Launched
eprodisate,amyloid protein inhibitor|antiamyloidogenic agent,SAA1,6288,Phase 3
eprosartan,angiotensin receptor antagonist,AGTR1,185,Launched
eptifibatide,platelet aggregation inhibitor,ITGA2B,3674,Launched
eptifibatide,platelet aggregation inhibitor,ITGB3,3690,Launched
EPZ-5676,histone lysine methyltransferase inhibitor,DOT1L,84444,Phase 1
EPZ004777,histone lysine methyltransferase inhibitor,DOT1L,84444,Preclinical
EPZ005687,histone lysine methyltransferase inhibitor,EZH2,2146,Preclinical
EPZ011989,histone lysine methyltransferase inhibitor,EZH2,2146,Preclinical
EPZ015666,protein arginine N-methyltransferase inhibitor,PRMT5,10419,Preclinical
EPZ020411,protein arginine N-methyltransferase inhibitor,PRMT6,55170,Preclinical
equilin,estrogen receptor agonist,HSD17B1,3292,Preclinical
equol,estrogen receptor agonist,ESR1,2099,Launched
equol,estrogen receptor agonist,ESR2,2100,Launched
ER-27319,mediator release inhibitor|SYK inhibitor,SYK,6850,Preclinical
ER-50891,retinoid receptor antagonist,RARA,5914,Preclinical
erastin,ion channel antagonist,VDAC2,7417,Preclinical
erbstatin-analog,EGFR inhibitor|tyrosine kinase inhibitor,EGFR,1956,Preclinical
ercalcitriol,vitamin D receptor agonist,VDR,7421,Phase 1
erdafitinib,FGFR inhibitor,FGFR1,2260,Launched
erdafitinib,FGFR inhibitor,FGFR2,2263,Launched
erdafitinib,FGFR inhibitor,FGFR3,2261,Launched
erdafitinib,FGFR inhibitor,FGFR4,2264,Launched
ergocalciferol,vitamin analog,VDR,7421,Launched
ergonovine,adrenergic receptor agonist|serotonin receptor agonist,ADRA1A,148,Launched
ergonovine,adrenergic receptor agonist|serotonin receptor agonist,HTR1E,3354,Launched
ergotamine,adrenergic receptor antagonist,ADRA1A,148,Launched
ergotamine,adrenergic receptor antagonist,ADRA1B,147,Launched
ergotamine,adrenergic receptor antagonist,ADRA1D,146,Launched
ergotamine,adrenergic receptor antagonist,ADRA2A,150,Launched
ergotamine,adrenergic receptor antagonist,ADRA2B,151,Launched
ergotamine,adrenergic receptor antagonist,DRD1,1812,Launched
ergotamine,adrenergic receptor antagonist,DRD2,1813,Launched
ergotamine,adrenergic receptor antagonist,DRD5,1816,Launched
ergotamine,adrenergic receptor antagonist,HTR1A,3350,Launched
ergotamine,adrenergic receptor antagonist,HTR1B,3351,Launched
ergotamine,adrenergic receptor antagonist,HTR1D,3352,Launched
ergotamine,adrenergic receptor antagonist,HTR1E,3354,Launched
ergotamine,adrenergic receptor antagonist,HTR1F,3355,Launched
ergotamine,adrenergic receptor antagonist,HTR2A,3356,Launched
ergotamine,adrenergic receptor antagonist,HTR2B,3357,Launched
ergotamine,adrenergic receptor antagonist,HTR2C,3358,Launched
ergotamine,adrenergic receptor antagonist,HTR5A,3361,Launched
ergotamine,adrenergic receptor antagonist,HTR6,3362,Launched
ergotamine,adrenergic receptor antagonist,SLC6A2,6530,Launched
ERK5-IN-1,MAP kinase inhibitor,MAPK7,5598,Preclinical
erlotinib,EGFR inhibitor,EGFR,1956,Launched
erlotinib,EGFR inhibitor,NR1I2,8856,Launched
erteberel,estrogen receptor agonist,ESR1,2099,Phase 2
erteberel,estrogen receptor agonist,ESR2,2100,Phase 2
ertugliflozin,sodium/glucose cotransporter inhibitor,SLC5A2,6524,Launched
erythromycin,NFkB pathway inhibitor,MLNR,2862,Launched
erythromycin-estolate,bacterial 50S ribosomal subunit inhibitor,ABCB1,5243,Launched
erythromycin-estolate,bacterial 50S ribosomal subunit inhibitor,ALB,213,Launched
erythromycin-estolate,bacterial 50S ribosomal subunit inhibitor,CYP3A4,1576,Launched
erythromycin-estolate,bacterial 50S ribosomal subunit inhibitor,CYP51A1,1595,Launched
erythromycin-estolate,bacterial 50S ribosomal subunit inhibitor,KCNH2,3757,Launched
erythromycin-estolate,bacterial 50S ribosomal subunit inhibitor,MLNR,2862,Launched
erythromycin-estolate,bacterial 50S ribosomal subunit inhibitor,SLC47A1,55244,Launched
erythromycin-ethylsuccinate,cytochrome P450 inhibitor|protein synthesis inhibitor,ABCB1,5243,Launched
erythromycin-ethylsuccinate,cytochrome P450 inhibitor|protein synthesis inhibitor,ALB,213,Launched
erythromycin-ethylsuccinate,cytochrome P450 inhibitor|protein synthesis inhibitor,CYP3A4,1576,Launched
erythromycin-ethylsuccinate,cytochrome P450 inhibitor|protein synthesis inhibitor,CYP51A1,1595,Launched
erythromycin-ethylsuccinate,cytochrome P450 inhibitor|protein synthesis inhibitor,KCNH2,3757,Launched
erythromycin-ethylsuccinate,cytochrome P450 inhibitor|protein synthesis inhibitor,MLNR,2862,Launched
erythromycin-ethylsuccinate,cytochrome P450 inhibitor|protein synthesis inhibitor,SLC47A1,55244,Launched
escitalopram,selective serotonin reuptake inhibitor (SSRI),SLC6A4,6532,Launched
eseroline-(-),acetylcholinesterase inhibitor,OPRD1,4985,Preclinical
eseroline-(-),acetylcholinesterase inhibitor,OPRM1,4988,Preclinical
ESI-09,EPAC inhibitor,RAPGEF3,10411,Preclinical
ESI-09,EPAC inhibitor,RAPGEF4,11069,Preclinical
eslicarbazepine-acetate,sodium channel blocker,SCN10A,6336,Launched
eslicarbazepine-acetate,sodium channel blocker,SCN11A,11280,Launched
eslicarbazepine-acetate,sodium channel blocker,SCN1A,6323,Launched
eslicarbazepine-acetate,sodium channel blocker,SCN2A,6326,Launched
eslicarbazepine-acetate,sodium channel blocker,SCN3A,6328,Launched
eslicarbazepine-acetate,sodium channel blocker,SCN4A,6329,Launched
eslicarbazepine-acetate,sodium channel blocker,SCN5A,6331,Launched
eslicarbazepine-acetate,sodium channel blocker,SCN7A,6332,Launched
eslicarbazepine-acetate,sodium channel blocker,SCN8A,6334,Launched
eslicarbazepine-acetate,sodium channel blocker,SCN9A,6335,Launched
esmolol,adrenergic receptor antagonist,ADRB1,153,Launched
esomeprazole,ATPase inhibitor,ATP4A,495,Launched
estetrol,selective estrogen receptor modulator (SERM),ESR1,2099,Phase 3
estradiol,estrogen receptor agonist,ESR1,2099,Launched
estradiol,estrogen receptor agonist,ESR2,2100,Launched
estradiol,estrogen receptor agonist,GPER1,2852,Launched
estradiol,estrogen receptor agonist,KCNMA1,3778,Launched
estradiol,estrogen receptor agonist,NR1I2,8856,Launched
estradiol-acetate,estrogen receptor agonist,ESR1,2099,Launched
estradiol-benzoate,contraceptive agent,ESR1,2099,Preclinical
estradiol-cypionate,estrogen receptor agonist,ESR1,2099,Launched
estradiol-valerate,estrogen receptor agonist,ESR1,2099,Launched
estramustine,DNA alkylating agent,ESR1,2099,Launched
estramustine,DNA alkylating agent,ESR2,2100,Launched
estramustine,DNA alkylating agent,MAP1A,4130,Launched
estramustine,DNA alkylating agent,MAP2,4133,Launched
estramustine-phosphate,DNA synthesis inhibitor|microtubule inhibitor,ESR1,2099,Launched
estramustine-phosphate,DNA synthesis inhibitor|microtubule inhibitor,ESR2,2100,Launched
estramustine-phosphate,DNA synthesis inhibitor|microtubule inhibitor,MAP1A,4130,Launched
estramustine-phosphate,DNA synthesis inhibitor|microtubule inhibitor,MAP2,4133,Launched
estriol,estrogen receptor agonist,ESR1,2099,Launched
estriol,estrogen receptor agonist,ESR2,2100,Launched
estrone,estrogen receptor agonist|estrogenic hormone,ESR1,2099,Launched
estrone,estrogen receptor agonist|estrogenic hormone,ESR2,2100,Launched
estropipate,estrogen receptor agonist,ESR1,2099,Launched
estropipate,estrogen receptor agonist,ESR2,2100,Launched
etacrynic-acid,sodium/potassium/chloride transporter inhibitor,ATP1A1,476,Launched
etacrynic-acid,sodium/potassium/chloride transporter inhibitor,SLC12A1,6557,Launched
etazolate,phosphodiesterase inhibitor,GABRB3,2562,Phase 2
etazolate,phosphodiesterase inhibitor,PDE4A,5141,Phase 2
ETC-159,beta catenin inhibitor|porcupine inhibitor,PORCN,64840,Phase 1
ethanolamine-oleate,immunostimulant,F12,2161,Launched
ethanolamine-oleate,immunostimulant,FABP4,2167,Launched
ethanolamine-oleate,immunostimulant,FFAR1,2864,Launched
ethanolamine-oleate,immunostimulant,FFAR4,338557,Launched
ethanolamine-oleate,immunostimulant,PLD2,5338,Launched
ethinyl-estradiol,estrogen receptor agonist|estrogenic hormone,ESR1,2099,Launched
ethinyl-estradiol,estrogen receptor agonist|estrogenic hormone,ESR2,2100,Launched
ethinyl-estradiol,estrogen receptor agonist|estrogenic hormone,NR1I2,8856,Launched
ethisterone,progestogen hormone,TYR,7299,Launched
ethosuximide,succinimide antiepileptic,CACNA1G,8913,Launched
ethosuximide,succinimide antiepileptic,CACNA1H,8912,Launched
ethosuximide,succinimide antiepileptic,CACNA1I,8911,Launched
ethotoin,hydantoin antiepileptic,SCN5A,6331,Launched
ethoxzolamide,carbonic anhydrase inhibitor,CA1,759,Launched
ethoxzolamide,carbonic anhydrase inhibitor,CA12,771,Launched
ethoxzolamide,carbonic anhydrase inhibitor,CA13,377677,Launched
ethoxzolamide,carbonic anhydrase inhibitor,CA14,23632,Launched
ethoxzolamide,carbonic anhydrase inhibitor,CA2,760,Launched
ethoxzolamide,carbonic anhydrase inhibitor,CA3,761,Launched
ethoxzolamide,carbonic anhydrase inhibitor,CA4,762,Launched
ethoxzolamide,carbonic anhydrase inhibitor,CA5A,763,Launched
ethoxzolamide,carbonic anhydrase inhibitor,CA5B,11238,Launched
ethoxzolamide,carbonic anhydrase inhibitor,CA6,765,Launched
ethoxzolamide,carbonic anhydrase inhibitor,CA7,766,Launched
ethoxzolamide,carbonic anhydrase inhibitor,CA9,768,Launched
ethynodiol-diacetate,,ESR1,2099,Launched
ethynodiol-diacetate,,PGR,5241,Launched
eticlopride,dopamine receptor antagonist,DRD2,1813,Preclinical
eticlopride,dopamine receptor antagonist,DRD3,1814,Preclinical
eticlopride,dopamine receptor antagonist,DRD4,1815,Preclinical
etidronic-acid,bone resorption inhibitor,ATP6V1A,523,Launched
etidronic-acid,bone resorption inhibitor,PTPRS,5802,Launched
etifoxine,GABA receptor modulator,GABRA1,2554,Launched
etifoxine,GABA receptor modulator,GABRA2,2555,Launched
etifoxine,GABA receptor modulator,GABRA3,2556,Launched
etifoxine,GABA receptor modulator,GABRA5,2558,Launched
etilefrine,adrenergic receptor agonist,ADRA1A,148,Launched
etilefrine,adrenergic receptor agonist,ADRB1,153,Launched
etilevodopa,dopamine receptor agonist,DRD3,1814,Phase 3
etizolam,benzodiazepine receptor agonist,GABRA1,2554,Launched
etodolac,cyclooxygenase inhibitor,PTGS2,5743,Launched
etofenamate,cyclooxygenase inhibitor,PTGS1,5742,Launched
etofenamate,cyclooxygenase inhibitor,PTGS2,5743,Launched
etofibrate,PPAR receptor agonist,PPARA,5465,Launched
etofylline,adenosine receptor antagonist,ADORA1,134,Launched
etofylline-clofibrate,platelet aggregation inhibitor,PPARA,5465,Launched
etomidate,GABA receptor modulator,ADRA2B,151,Launched
etomidate,GABA receptor modulator,GABRA1,2554,Launched
etomidate,GABA receptor modulator,GABRA2,2555,Launched
etomidate,GABA receptor modulator,GABRA3,2556,Launched
etomidate,GABA receptor modulator,GABRA4,2557,Launched
etomidate,GABA receptor modulator,GABRA5,2558,Launched
etomidate,GABA receptor modulator,GABRA6,2559,Launched
etomidate,GABA receptor modulator,GABRB1,2560,Launched
etomidate,GABA receptor modulator,GABRB2,2561,Launched
etomidate,GABA receptor modulator,GABRB3,2562,Launched
etomidate,GABA receptor modulator,GABRD,2563,Launched
etomidate,GABA receptor modulator,GABRE,2564,Launched
etomidate,GABA receptor modulator,GABRG1,2565,Launched
etomidate,GABA receptor modulator,GABRG2,2566,Launched
etomidate,GABA receptor modulator,GABRG3,2567,Launched
etomidate,GABA receptor modulator,GABRP,2568,Launched
etomidate,GABA receptor modulator,GABRQ,55879,Launched
etomoxir,carnitine palmitoyltransferase inhibitor,CPT1A,1374,Phase 2
etonogestrel,progesterone receptor agonist,ESR1,2099,Launched
etonogestrel,progesterone receptor agonist,PGR,5241,Launched
etoposide,topoisomerase inhibitor,TOP2A,7153,Launched
etoposide,topoisomerase inhibitor,TOP2B,7155,Launched
etoposide-phosphate,topoisomerase inhibitor,TOP2A,7153,Launched
etoricoxib,cyclooxygenase inhibitor,PTGS2,5743,Launched
ETP-45658,PI3K inhibitor,PIK3CA,5290,Preclinical
ETP-45658,PI3K inhibitor,PIK3CB,5291,Preclinical
ETP-45658,PI3K inhibitor,PIK3CD,5293,Preclinical
ETP-45658,PI3K inhibitor,PIK3CG,5294,Preclinical
etravirine,non-nucleoside reverse transcriptase inhibitor,CYP2C19,1557,Launched
etravirine,non-nucleoside reverse transcriptase inhibitor,CYP2C9,1559,Launched
etravirine,non-nucleoside reverse transcriptase inhibitor,CYP3A4,1576,Launched
etretinate,protein synthesis inhibitor,RARA,5914,Withdrawn
etretinate,protein synthesis inhibitor,RXRG,6258,Withdrawn
eucalyptol,acetylcholinesterase inhibitor,ACHE,43,Launched
eugenol,androgen receptor antagonist,AR,367,Launched
EUK-134,catalase stimulant,APP,351,Preclinical
EUK-134,catalase stimulant,SOD2,6648,Preclinical
evacetrapib,cholesteryl ester transfer protein inhibitor,CETP,1071,Phase 3
evans-blue,glutamate receptor negative allosteric modulator,GRIA1,2890,Launched
evans-blue,glutamate receptor negative allosteric modulator,PTPN1,5770,Launched
evatanepag,prostaglandin inhibitor,PTGER2,5732,Phase 2
evatanepag,prostaglandin inhibitor,PTGER4,5734,Phase 2
everolimus,mTOR inhibitor,MTOR,2475,Launched
evodiamine,ATPase inhibitor|TRPV agonist,TRPV1,7442,Preclinical
EVP-6124,acetylcholine receptor agonist,CHRNA7,1139,Phase 3
EW-7197,TGF beta receptor inhibitor,ACVR1B,91,Phase 2
EW-7197,TGF beta receptor inhibitor,TGFBR1,7046,Phase 2
EX-527,SIRT inhibitor,SIRT1,23411,Phase 2
examorelin,growth hormone releasing factor agonist,GHRHR,2692,Phase 2
examorelin,growth hormone releasing factor agonist,GHSR,2693,Phase 2
exatecan-mesylate,topoisomerase inhibitor,TOP1,7150,Phase 3
exemestane,aromatase inhibitor,CYP19A1,1588,Launched
exenatide,GLP receptor agonist,GLP1R,2740,Launched
exherin,cadherin antagonist,CDH2,1000,Phase 2
exifone,nootropic agent,TYR,7299,Withdrawn
exisulind,phosphodiesterase inhibitor,PDE5A,8654,Phase 3
exo-IWR-1,WNT signaling inhibitor negative control,TNKS,8658,Preclinical
ezatiostat,glutathione transferase inhibitor,GSTP1,2950,Phase 2
ezetimibe,cholesterol inhibitor|Niemann-Pick C1-like 1 protein antagonist,ANPEP,290,Launched
ezetimibe,cholesterol inhibitor|Niemann-Pick C1-like 1 protein antagonist,NPC1L1,29881,Launched
ezetimibe,cholesterol inhibitor|Niemann-Pick C1-like 1 protein antagonist,SOAT1,6646,Launched
ezutromid,utrophin enhancer,UTRN,7402,Phase 2
E7449,PARP inhibitor,PARP1,142,Phase 2
E7449,PARP inhibitor,PARP2,10038,Phase 2
E7449,PARP inhibitor,TNKS,8658,Phase 2
E7449,PARP inhibitor,TNKS2,80351,Phase 2
F-11440,serotonin receptor agonist,HTR1A,3350,Phase 2
fadrozole,aromatase inhibitor,CYP11B1,1584,Launched
fadrozole,aromatase inhibitor,CYP19A1,1588,Launched
fagomine,glucosidase inhibitor,GLB1,2720,Phase 2
falecalcitriol,vitamin D receptor agonist,VDR,7421,Launched
famotidine,histamine receptor antagonist,HRH2,3274,Launched
fananserin,dopamine receptor antagonist|serotonin receptor antagonist,HTR2A,3356,Phase 2
farnesyl-thiosalicylic-acid-amide,Ras GTPase inhibitor,HRAS,3265,Phase 1
fasudil,rho associated kinase inhibitor,PKIA,5569,Launched
fasudil,rho associated kinase inhibitor,PRKACA,5566,Launched
fasudil,rho associated kinase inhibitor,ROCK1,6093,Launched
fasudil,rho associated kinase inhibitor,ROCK2,9475,Launched
febuxostat,xanthine oxidase inhibitor,XDH,7498,Launched
fedratinib,FLT3 inhibitor|JAK inhibitor,BRD4,23476,Launched
fedratinib,FLT3 inhibitor|JAK inhibitor,JAK1,3716,Launched
fedratinib,FLT3 inhibitor|JAK inhibitor,JAK2,3717,Launched
fedratinib,FLT3 inhibitor|JAK inhibitor,JAK3,3718,Launched
fedratinib,FLT3 inhibitor|JAK inhibitor,TYK2,7297,Launched
felbamate,glutamate receptor antagonist,GRIN1,2902,Launched
felbamate,glutamate receptor antagonist,GRIN2A,2903,Launched
felbamate,glutamate receptor antagonist,GRIN2B,2904,Launched
felbamate,glutamate receptor antagonist,GRIN2C,2905,Launched
felbamate,glutamate receptor antagonist,GRIN2D,2906,Launched
felbamate,glutamate receptor antagonist,GRIN3A,116443,Launched
felbamate,glutamate receptor antagonist,GRIN3B,116444,Launched
felbinac,cyclooxygenase inhibitor,CTSL,1514,Launched
felbinac-ethyl,cyclooxygenase inhibitor,PTGS1,5742,Launched
felbinac-ethyl,cyclooxygenase inhibitor,PTGS2,5743,Launched
felodipine,calcium channel blocker,CFTR,1080,Launched
fenbendazole,tubulin polymerization inhibitor,TUBB,203068,Launched
fenbufen,cyclooxygenase inhibitor,PTGS1,5742,Launched
fenbufen,cyclooxygenase inhibitor,PTGS2,5743,Launched
fenclonine-(+/-),tryptophan hydroxylase inhibitor,PAH,5053,Preclinical
fenclonine-(+/-),tryptophan hydroxylase inhibitor,TPH1,7166,Preclinical
fenclonine-(+/-),tryptophan hydroxylase inhibitor,TPH2,121278,Preclinical
fendiline,calcium channel blocker,HTR2B,3357,Preclinical
fenigam,benzodiazepine receptor agonist,GABBR1,2550,Launched
fenigam,benzodiazepine receptor agonist,GABBR2,9568,Launched
fenobam,glutamate receptor antagonist,GRM5,2915,Phase 2
fenofibrate,PPAR receptor agonist,MMP25,64386,Launched
fenofibrate,PPAR receptor agonist,PPARA,5465,Launched
fenofibric-acid,cytochrome P450 inhibitor,CLCN1,1180,Launched
fenofibric-acid,cytochrome P450 inhibitor,PPARA,5465,Launched
fenoldopam,dopamine receptor agonist,DRD1,1812,Launched
fenoldopam,dopamine receptor agonist,DRD4,1815,Launched
fenoprofen,prostaglandin inhibitor,PTGS1,5742,Launched
fenoprofen,prostaglandin inhibitor,SLC5A8,160728,Launched
fenoterol,adrenergic receptor agonist,ADRB2,154,Withdrawn
fenoxaprop-p-ethyl,,NOS3,4846,Preclinical
fenretinide,apoptosis stimulant|retinoid receptor agonist,RARA,5914,Phase 3
fentiazac,cyclooxygenase inhibitor,PTGS1,5742,Launched
fentiazac,cyclooxygenase inhibitor,PTGS2,5743,Launched
FERb-033,EGFR inhibitor,ERBB2,2064,Preclinical
ferulic-acid,antioxidant,CA1,759,Phase 2
ferulic-acid,antioxidant,CA12,771,Phase 2
ferulic-acid,antioxidant,CA14,23632,Phase 2
ferulic-acid,antioxidant,CA2,760,Phase 2
ferulic-acid,antioxidant,CA4,762,Phase 2
ferulic-acid,antioxidant,CA6,765,Phase 2
ferulic-acid,antioxidant,CA9,768,Phase 2
fesoterodine,acetylcholine receptor antagonist,CHRM1,1128,Launched
fesoterodine,acetylcholine receptor antagonist,CHRM2,1129,Launched
fesoterodine,acetylcholine receptor antagonist,CHRM3,1131,Launched
fesoterodine,acetylcholine receptor antagonist,CHRM4,1132,Launched
fesoterodine,acetylcholine receptor antagonist,CHRM5,1133,Launched
fexaramine,FXR agonist,NR1H4,9971,Preclinical
fexofenadine,histamine receptor antagonist,HRH1,3269,Launched
FG-2216,hypoxia inducible factor prolyl hydroxylase inhibitor,EGLN1,54583,Phase 2
FG-2216,hypoxia inducible factor prolyl hydroxylase inhibitor,EGLN2,112398,Phase 2
FG-2216,hypoxia inducible factor prolyl hydroxylase inhibitor,HIF1A,3091,Phase 2
FG-4592,hypoxia inducible factor prolyl hydroxylase inhibitor,EGLN1,54583,Phase 3
FG-4592,hypoxia inducible factor prolyl hydroxylase inhibitor,EGLN2,112398,Phase 3
FG-4592,hypoxia inducible factor prolyl hydroxylase inhibitor,EGLN3,112399,Phase 3
FGIN-1-27,inositol monophosphatase inhibitor,TSPO,706,Preclinical
FGIN-1-43,benzodiazepine receptor agonist,TSPO,706,Preclinical
FH-535,PPAR receptor antagonist|WNT signaling inhibitor,PPARD,5467,Preclinical
FH-535,PPAR receptor antagonist|WNT signaling inhibitor,PPARG,5468,Preclinical
fidarestat,aldose reductase inhibitor,AKR1B1,231,Phase 3
filanesib,kinesin inhibitor|kinesin-like spindle protein inhibitor,KIF11,3832,Phase 3
filgotinib,JAK inhibitor,JAK1,3716,Phase 3
filgotinib,JAK inhibitor,JAK2,3717,Phase 3
filgotinib,JAK inhibitor,JAK3,3718,Phase 3
filgotinib,JAK inhibitor,TYK2,7297,Phase 3
fimasartan,angiotensin receptor antagonist,AGTR1,185,Launched
finasteride,5 alpha reductase inhibitor,AKR1D1,6718,Launched
finasteride,5 alpha reductase inhibitor,SRD5A1,6715,Launched
finasteride,5 alpha reductase inhibitor,SRD5A2,6716,Launched
fingolimod,immunosuppressant|sphingosine 1-phosphate receptor agonist,S1PR1,1901,Launched
fingolimod,immunosuppressant|sphingosine 1-phosphate receptor agonist,S1PR5,53637,Launched
FIPI,phospholipase inhibitor,PLD1,5337,Preclinical
FIPI,phospholipase inhibitor,PLD2,5338,Preclinical
firategrast,integrin antagonist,ITGA4,3676,Phase 2
firocoxib,cyclooxygenase inhibitor,PTGS2,5743,Launched
fisetin,Aurora kinase inhibitor,CDK6,1021,Preclinical
fisetin,Aurora kinase inhibitor,FASN,2194,Preclinical
FIT,opioid receptor agonist,OPRD1,4985,Preclinical
FK-33-824,opioid receptor agonist,OPRM1,4988,Phase 2
FK-3311,cyclooxygenase inhibitor,PTGS2,5743,Phase 2
FK-866,niacinamide phosphoribosyltransferase inhibitor,NAMPT,10135,Phase 2
FK-888,tachykinin antagonist,TACR1,6869,Phase 2
FK-888,tachykinin antagonist,TACR2,6865,Phase 2
flavin-adenine-dinucleotide,,ACAD8,27034,Preclinical
flavin-adenine-dinucleotide,,ACADM,34,Preclinical
flavin-adenine-dinucleotide,,ACADS,35,Preclinical
flavin-adenine-dinucleotide,,ACOX1,51,Preclinical
flavin-adenine-dinucleotide,,AIFM1,9131,Preclinical
flavin-adenine-dinucleotide,,CYB5R1,51706,Preclinical
flavin-adenine-dinucleotide,,CYB5R3,1727,Preclinical
flavin-adenine-dinucleotide,,DAO,1610,Preclinical
flavin-adenine-dinucleotide,,DLD,1738,Preclinical
flavin-adenine-dinucleotide,,DPYD,1806,Preclinical
flavin-adenine-dinucleotide,,ERO1LB,-,Preclinical
flavin-adenine-dinucleotide,,FDXR,2232,Preclinical
flavin-adenine-dinucleotide,,GCDH,2639,Preclinical
flavin-adenine-dinucleotide,,GFER,2671,Preclinical
flavin-adenine-dinucleotide,,GSR,2936,Preclinical
flavin-adenine-dinucleotide,,IL4I1,259307,Preclinical
flavin-adenine-dinucleotide,,IVD,3712,Preclinical
flavin-adenine-dinucleotide,,MAOA,4128,Preclinical
flavin-adenine-dinucleotide,,MAOB,4129,Preclinical
flavin-adenine-dinucleotide,,NOS1,4842,Preclinical
flavin-adenine-dinucleotide,,NQO1,1728,Preclinical
flavin-adenine-dinucleotide,,NQO2,4835,Preclinical
flavin-adenine-dinucleotide,,POR,5447,Preclinical
flavin-adenine-dinucleotide,,TXNRD1,7296,Preclinical
flavin-adenine-dinucleotide,,XDH,7498,Preclinical
flavoxate,acetylcholine receptor antagonist,CHRM1,1128,Launched
flavoxate,acetylcholine receptor antagonist,CHRM2,1129,Launched
flecainide,sodium channel blocker,KCNA5,3741,Launched
flecainide,sodium channel blocker,KCNA7,3743,Launched
flecainide,sodium channel blocker,SCN5A,6331,Launched
fleroxacin,topoisomerase inhibitor,TOP2A,7153,Launched
flibanserin,serotonin receptor agonist,DRD4,1815,Launched
flibanserin,serotonin receptor agonist,HTR1A,3350,Launched
flibanserin,serotonin receptor agonist,HTR2A,3356,Launched
flindokalner,potassium channel agonist,KCNMA1,3778,Phase 3
flindokalner,potassium channel agonist,KCNN4,3783,Phase 3
flindokalner,potassium channel agonist,KCNQ2,3785,Phase 3
flindokalner,potassium channel agonist,KCNQ4,9132,Phase 3
flindokalner,potassium channel agonist,KCNQ5,56479,Phase 3
floctafenine,cyclooxygenase inhibitor,PTGS1,5742,Launched
floctafenine,cyclooxygenase inhibitor,PTGS2,5743,Launched
flopropione,serotonin receptor antagonist,HTR1A,3350,Launched
floxuridine,DNA synthesis inhibitor,TYMS,7298,Launched
flubendazole,tubulin polymerization inhibitor,TUBB,203068,Launched
fluconazole,sterol demethylase inhibitor,CYP51A1,1595,Launched
flucytosine,other antifungal,DNMT1,1786,Launched
fludarabine,ribonucleotide reductase inhibitor,ADA,100,Launched
fludarabine,ribonucleotide reductase inhibitor,DCK,1633,Launched
fludarabine,ribonucleotide reductase inhibitor,POLA1,5422,Launched
fludarabine,ribonucleotide reductase inhibitor,RRM1,6240,Launched
fludarabine,ribonucleotide reductase inhibitor,RRM2,6241,Launched
fludarabine-phosphate,ribonucleotide reductase inhibitor,POLA1,5422,Launched
fludarabine-phosphate,ribonucleotide reductase inhibitor,POLD1,5424,Launched
fludarabine-phosphate,ribonucleotide reductase inhibitor,POLE,5426,Launched
fludarabine-phosphate,ribonucleotide reductase inhibitor,RRM1,6240,Launched
fludarabine-phosphate,ribonucleotide reductase inhibitor,RRM2,6241,Launched
fludarabine-phosphate,ribonucleotide reductase inhibitor,RRM2B,50484,Launched
fludrocortisone-acetate,,NR3C2,4306,Launched
fludroxycortide,glucocorticoid receptor agonist,NR3C1,2908,Launched
fludroxycortide,glucocorticoid receptor agonist,SERPINA6,866,Launched
flufenamic-acid,chloride channel blocker,AKR1C3,8644,Preclinical
flufenamic-acid,chloride channel blocker,ANO1,55107,Preclinical
flufenamic-acid,chloride channel blocker,AR,367,Preclinical
flufenamic-acid,chloride channel blocker,GJA1,2697,Preclinical
flufenamic-acid,chloride channel blocker,GJA10,84694,Preclinical
flufenamic-acid,chloride channel blocker,GJA3,2700,Preclinical
flufenamic-acid,chloride channel blocker,GJA4,2701,Preclinical
flufenamic-acid,chloride channel blocker,GJA5,2702,Preclinical
flufenamic-acid,chloride channel blocker,GJA8,2703,Preclinical
flufenamic-acid,chloride channel blocker,GJA9,81025,Preclinical
flufenamic-acid,chloride channel blocker,GJB1,2705,Preclinical
flufenamic-acid,chloride channel blocker,GJB2,2706,Preclinical
flufenamic-acid,chloride channel blocker,GJB3,2707,Preclinical
flufenamic-acid,chloride channel blocker,GJB4,127534,Preclinical
flufenamic-acid,chloride channel blocker,GJB5,2709,Preclinical
flufenamic-acid,chloride channel blocker,GJB6,10804,Preclinical
flufenamic-acid,chloride channel blocker,GJB7,375519,Preclinical
flufenamic-acid,chloride channel blocker,GJC1,10052,Preclinical
flufenamic-acid,chloride channel blocker,GJC2,57165,Preclinical
flufenamic-acid,chloride channel blocker,GJC3,349149,Preclinical
flufenamic-acid,chloride channel blocker,GJD2,57369,Preclinical
flufenamic-acid,chloride channel blocker,GJD3,125111,Preclinical
flufenamic-acid,chloride channel blocker,GJD4,219770,Preclinical
flufenamic-acid,chloride channel blocker,GJE1,100126572,Preclinical
flufenamic-acid,chloride channel blocker,PANX1,24145,Preclinical
flufenamic-acid,chloride channel blocker,PANX2,56666,Preclinical
flufenamic-acid,chloride channel blocker,PANX3,116337,Preclinical
flufenamic-acid,chloride channel blocker,PKD2L1,9033,Preclinical
flufenamic-acid,chloride channel blocker,PTGS1,5742,Preclinical
flufenamic-acid,chloride channel blocker,PTGS2,5743,Preclinical
flufenamic-acid,chloride channel blocker,TRPC5,7224,Preclinical
flufenamic-acid,chloride channel blocker,TRPM2,7226,Preclinical
flufenamic-acid,chloride channel blocker,TRPM5,29850,Preclinical
flumatinib,Bcr-Abl kinase inhibitor,ABL1,25,Phase 3
flumatinib,Bcr-Abl kinase inhibitor,PDGFRB,5159,Phase 3
flumazenil,benzodiazepine receptor antagonist,GABRA1,2554,Launched
flumazenil,benzodiazepine receptor antagonist,GABRA2,2555,Launched
flumazenil,benzodiazepine receptor antagonist,GABRA3,2556,Launched
flumazenil,benzodiazepine receptor antagonist,GABRA4,2557,Launched
flumazenil,benzodiazepine receptor antagonist,GABRA5,2558,Launched
flumazenil,benzodiazepine receptor antagonist,GABRA6,2559,Launched
flumazenil,benzodiazepine receptor antagonist,GABRB1,2560,Launched
flumazenil,benzodiazepine receptor antagonist,GABRB2,2561,Launched
flumazenil,benzodiazepine receptor antagonist,GABRB3,2562,Launched
flumazenil,benzodiazepine receptor antagonist,GABRD,2563,Launched
flumazenil,benzodiazepine receptor antagonist,GABRE,2564,Launched
flumazenil,benzodiazepine receptor antagonist,GABRG1,2565,Launched
flumazenil,benzodiazepine receptor antagonist,GABRG2,2566,Launched
flumazenil,benzodiazepine receptor antagonist,GABRG3,2567,Launched
flumazenil,benzodiazepine receptor antagonist,GABRP,2568,Launched
flumazenil,benzodiazepine receptor antagonist,GABRQ,55879,Launched
flumethasone,glucocorticoid receptor agonist,NR3C1,2908,Launched
flumethasone,glucocorticoid receptor agonist,PLA2G1B,5319,Launched
flumethasone-pivalate,glucocorticoid receptor agonist,NR3C1,2908,Launched
flumethasone-pivalate,glucocorticoid receptor agonist,SERPINA6,866,Launched
flunarizine,calcium channel blocker,CACNA1G,8913,Launched
flunarizine,calcium channel blocker,CACNA1H,8912,Launched
flunarizine,calcium channel blocker,CACNA1I,8911,Launched
flunarizine,calcium channel blocker,CALM1,801,Launched
flunarizine,calcium channel blocker,HRH1,3269,Launched
flunisolide,cytochrome P450 inhibitor,NR3C1,2908,Launched
fluocinolone-acetonide,glucocorticoid receptor agonist,NR3C1,2908,Launched
fluocinolone-acetonide,glucocorticoid receptor agonist,SERPINA6,866,Launched
fluocinonide,glucocorticoid receptor agonist,NR3C1,2908,Launched
fluocinonide,glucocorticoid receptor agonist,SERPINA6,866,Launched
fluocinonide,glucocorticoid receptor agonist,SMO,6608,Launched
fluorescein,,SLC22A6,9356,Launched
fluorometholone,glucocorticoid receptor agonist,NR3C1,2908,Launched
fluorometholone-acetate,,NR3C1,2908,Launched
fluoxetine,selective serotonin reuptake inhibitor (SSRI),ANO1,55107,Launched
fluoxetine,selective serotonin reuptake inhibitor (SSRI),HTR2B,3357,Launched
fluoxetine,selective serotonin reuptake inhibitor (SSRI),SLC6A4,6532,Launched
flupentixol,dopamine receptor antagonist,ADRA1A,148,Launched
flupentixol,dopamine receptor antagonist,CHRM1,1128,Launched
flupentixol,dopamine receptor antagonist,DRD1,1812,Launched
flupentixol,dopamine receptor antagonist,DRD2,1813,Launched
flupentixol,dopamine receptor antagonist,DRD3,1814,Launched
flupentixol,dopamine receptor antagonist,DRD5,1816,Launched
flupentixol,dopamine receptor antagonist,HTR2A,3356,Launched
fluphenazine,dopamine receptor antagonist,CALM1,801,Launched
fluphenazine,dopamine receptor antagonist,DRD1,1812,Launched
fluphenazine,dopamine receptor antagonist,DRD2,1813,Launched
fluphenazine,dopamine receptor antagonist,DRD5,1816,Launched
fluphenazine,dopamine receptor antagonist,HRH1,3269,Launched
fluphenazine,dopamine receptor antagonist,HTR2A,3356,Launched
fluphenazine,dopamine receptor antagonist,HTR6,3362,Launched
fluphenazine,dopamine receptor antagonist,HTR7,3363,Launched
fluphenazine-decanoate,dopamine receptor antagonist,DRD2,1813,Launched
fluphenazine-decanoate,dopamine receptor antagonist,HTR1B,3351,Launched
fluphenazine-decanoate,dopamine receptor antagonist,HTR4,3360,Launched
flupirtine,glutamate receptor antagonist,ADRA2A,150,Launched
flupirtine,glutamate receptor antagonist,KCNQ1,3784,Launched
flupirtine,glutamate receptor antagonist,KCNQ2,3785,Launched
fluprazine,serotonin receptor agonist,HTR1A,3350,Phase 1
fluprazine,serotonin receptor agonist,HTR1B,3351,Phase 1
flurbiprofen-(S)-(+),cyclooxygenase inhibitor,PTGS1,5742,Launched
flurbiprofen-(S)-(+),cyclooxygenase inhibitor,PTGS2,5743,Launched
flurizan,gamma secretase inhibitor,APH1B,83464,Phase 3
flurizan,gamma secretase inhibitor,BACE1,23621,Phase 3
flurizan,gamma secretase inhibitor,IKBKG,8517,Phase 3
flurizan,gamma secretase inhibitor,PSEN1,5663,Phase 3
flurizan,gamma secretase inhibitor,PSEN2,5664,Phase 3
flurizan,gamma secretase inhibitor,PTGS1,5742,Phase 3
flurizan,gamma secretase inhibitor,PTGS2,5743,Phase 3
fluspirilene,dopamine receptor antagonist,CACNG1,786,Launched
fluspirilene,dopamine receptor antagonist,DRD2,1813,Launched
fluspirilene,dopamine receptor antagonist,HRH1,3269,Launched
fluspirilene,dopamine receptor antagonist,HTR1A,3350,Launched
fluspirilene,dopamine receptor antagonist,HTR1D,3352,Launched
fluspirilene,dopamine receptor antagonist,HTR1E,3354,Launched
fluspirilene,dopamine receptor antagonist,HTR2A,3356,Launched
flutamide,androgen receptor antagonist,AHR,196,Launched
flutamide,androgen receptor antagonist,AR,367,Launched
fluticasone-propionate,glucocorticoid receptor agonist,NR3C1,2908,Launched
fluticasone-propionate,glucocorticoid receptor agonist,NR3C2,4306,Launched
fluticasone-propionate,glucocorticoid receptor agonist,PGR,5241,Launched
fluticasone-propionate,glucocorticoid receptor agonist,PLA2G4A,5321,Launched
fluvastatin,HMGCR inhibitor,HMGCR,3156,Launched
fluvoxamine,selective serotonin reuptake inhibitor (SSRI),SLC6A4,6532,Launched
folic-acid,folate receptor ligand,FOLR2,2350,Launched
folic-acid,folate receptor ligand,FOLR3,2352,Launched
folic-acid,folate receptor ligand,SLC19A1,6573,Launched
folic-acid,folate receptor ligand,SLC46A1,113235,Launched
fomepizole,alcohol dehydrogenase inhibitor,ADH1A,124,Launched
fomepizole,alcohol dehydrogenase inhibitor,ADH1B,125,Launched
fomepizole,alcohol dehydrogenase inhibitor,ADH1C,126,Launched
fomepizole,alcohol dehydrogenase inhibitor,AKR1A1,10327,Launched
fomepizole,alcohol dehydrogenase inhibitor,CAT,847,Launched
fondaparinux,coagulation factor inhibitor,F10,2159,Launched
fondaparinux,coagulation factor inhibitor,SERPINC1,462,Launched
foretinib,VEGFR inhibitor,FLT1,2321,Phase 2
foretinib,VEGFR inhibitor,FLT4,2324,Phase 2
foretinib,VEGFR inhibitor,KDR,3791,Phase 2
foretinib,VEGFR inhibitor,MET,4233,Phase 2
formestane,aromatase inhibitor,CYP19A1,1588,Launched
formononetin,alcohol dehydrogenase inhibitor,ADH1C,126,Preclinical
formononetin,alcohol dehydrogenase inhibitor,SLC5A2,6524,Preclinical
formoterol,adrenergic receptor agonist,ADRB2,154,Launched
forodesine,purinergic receptor antagonist,PNP,4860,Launched
foropafant,platelet activating factor receptor antagonist,PTAFR,5724,Phase 3
forskolin,adenylyl cyclase activator,ADCY2,108,Launched
forskolin,adenylyl cyclase activator,ADCY5,111,Launched
forskolin,adenylyl cyclase activator,GNAS,2778,Launched
fosaprepitant-dimeglumine,tachykinin antagonist,TACR1,6869,Launched
fosbretabulin,tubulin polymerization inhibitor|VE-cadherin antagonist,CDH5,1003,Phase 3
fosfestrol,synthetic estrogen,ESR1,2099,Launched
fosfestrol,synthetic estrogen,ESR2,2100,Launched
fosfosal,phosphodiesterase inhibitor,PTGS1,5742,Launched
fosfosal,phosphodiesterase inhibitor,PTGS2,5743,Launched
fosinopril,angiotensin converting enzyme inhibitor,ACE,1636,Launched
fosinoprilat,angiotensin converting enzyme inhibitor,ACE,1636,Launched
fosphenytoin,sodium channel blocker,SCN5A,6331,Launched
fostamatinib,SYK inhibitor,SYK,6850,Launched
foxy-5,WNT5a peptide mimetic,WNT5A,7474,Phase 2
FPL-64176,calcium channel activator,CACNA1C,775,Preclinical
FPL-64176,calcium channel activator,CACNA1S,779,Preclinical
FPS-ZM1,RAGE receptor antagonist,AGER,177,Preclinical
FR-139317,endothelin receptor antagonist,EDNRA,1909,Phase 1
FR-180204,MAP kinase inhibitor,MAPK1,5594,Preclinical
FR-180204,MAP kinase inhibitor,MAPK3,5595,Preclinical
FRAX486,serine/threonine kinase inhibitor,PAK1,5058,Preclinical
FRAX486,serine/threonine kinase inhibitor,PAK2,5062,Preclinical
FRAX486,serine/threonine kinase inhibitor,PAK3,5063,Preclinical
FRAX486,serine/threonine kinase inhibitor,PAK4,10298,Preclinical
freselestat,elastase inhibitor,CELA1,1990,Preclinical
freselestat,elastase inhibitor,ELANE,1991,Preclinical
frovatriptan,serotonin receptor agonist,HTR1A,3350,Launched
frovatriptan,serotonin receptor agonist,HTR1B,3351,Launched
frovatriptan,serotonin receptor agonist,HTR1D,3352,Launched
fruquintinib,VEGFR inhibitor,KDR,3791,Launched
ftorafur,thymidylate synthase inhibitor,TYMS,7298,Launched
fulvestrant,estrogen receptor antagonist,ESR1,2099,Launched
fulvestrant,estrogen receptor antagonist,ESR2,2100,Launched
fulvestrant,estrogen receptor antagonist,GPER1,2852,Launched
fumagillin,methionine aminopeptidase inhibitor,METAP2,10988,Launched
fumonisin-B1,,CERS1,10715,Preclinical
furamidine,protein arginine N-methyltransferase inhibitor,PRMT1,3276,Preclinical
furegrelate,thromboxane synthase inhibitor,TBXAS1,6916,Phase 1
furosemide,diuretic,CA2,760,Launched
furosemide,diuretic,GPR35,2859,Launched
furosemide,diuretic,SLC12A1,6557,Launched
furosemide,diuretic,SLC12A2,6558,Launched
F351,TGF beta receptor inhibitor,TGFB1,7040,Phase 2
g-caryophyllene,acetylcholinesterase inhibitor,ACHE,43,Preclinical
G-1,G protein-coupled receptor agonist,GPER1,2852,Preclinical
G-15,estrogen receptor antagonist,GPER1,2852,Preclinical
gabapentin,calcium channel blocker,ADORA1,134,Launched
gabapentin,calcium channel blocker,CACNA1A,773,Launched
gabapentin,calcium channel blocker,CACNA1B,774,Launched
gabapentin,calcium channel blocker,CACNA1C,775,Launched
gabapentin,calcium channel blocker,CACNA1D,776,Launched
gabapentin,calcium channel blocker,CACNA1E,777,Launched
gabapentin,calcium channel blocker,CACNA1F,778,Launched
gabapentin,calcium channel blocker,CACNA1G,8913,Launched
gabapentin,calcium channel blocker,CACNA1H,8912,Launched
gabapentin,calcium channel blocker,CACNA1I,8911,Launched
gabapentin,calcium channel blocker,CACNA1S,779,Launched
gabapentin,calcium channel blocker,CACNA2D1,781,Launched
gabapentin,calcium channel blocker,CACNA2D2,9254,Launched
gabapentin,calcium channel blocker,CACNA2D3,55799,Launched
gabapentin,calcium channel blocker,CACNA2D4,93589,Launched
gabapentin,calcium channel blocker,CACNB1,782,Launched
gabapentin,calcium channel blocker,CACNB2,783,Launched
gabapentin,calcium channel blocker,CACNB3,784,Launched
gabapentin,calcium channel blocker,CACNB4,785,Launched
gabapentin,calcium channel blocker,CACNG1,786,Launched
gabapentin,calcium channel blocker,CACNG2,10369,Launched
gabapentin,calcium channel blocker,CACNG3,10368,Launched
gabapentin,calcium channel blocker,CACNG4,27092,Launched
gabapentin,calcium channel blocker,CACNG5,27091,Launched
gabapentin,calcium channel blocker,CACNG6,59285,Launched
gabapentin,calcium channel blocker,CACNG7,59284,Launched
gabapentin,calcium channel blocker,CACNG8,59283,Launched
gabapentin,calcium channel blocker,GRIN1,2902,Launched
gabapentin,calcium channel blocker,GRIN2A,2903,Launched
gabapentin,calcium channel blocker,GRIN2B,2904,Launched
gabapentin,calcium channel blocker,GRIN2C,2905,Launched
gabapentin,calcium channel blocker,GRIN2D,2906,Launched
gabapentin,calcium channel blocker,GRIN3A,116443,Launched
gabapentin,calcium channel blocker,GRIN3B,116444,Launched
gabapentin-enacarbil,adrenergic receptor agonist,CACNA1G,8913,Launched
gabazine,GABA receptor antagonist,GABRA1,2554,Preclinical
gabazine,GABA receptor antagonist,GABRA2,2555,Preclinical
gabazine,GABA receptor antagonist,GABRA3,2556,Preclinical
gabazine,GABA receptor antagonist,GABRA4,2557,Preclinical
gabazine,GABA receptor antagonist,GABRA5,2558,Preclinical
gabazine,GABA receptor antagonist,GABRA6,2559,Preclinical
gabazine,GABA receptor antagonist,GABRG2,2566,Preclinical
gabexate,serine protease inhibitor,PRSS1,5644,Launched
gabexate,serine protease inhibitor,TPSAB1,7177,Launched
gaboxadol,benzodiazepine receptor agonist,GABRA1,2554,Phase 3
gaboxadol,benzodiazepine receptor agonist,GABRA2,2555,Phase 3
gaboxadol,benzodiazepine receptor agonist,GABRA3,2556,Phase 3
gaboxadol,benzodiazepine receptor agonist,GABRA4,2557,Phase 3
gaboxadol,benzodiazepine receptor agonist,GABRA5,2558,Phase 3
gaboxadol,benzodiazepine receptor agonist,GABRA6,2559,Phase 3
gaboxadol,benzodiazepine receptor agonist,GABRD,2563,Phase 3
gaboxadol,benzodiazepine receptor agonist,GABRR1,2569,Phase 3
gaboxadol,benzodiazepine receptor agonist,GABRR2,2570,Phase 3
gaboxadol,benzodiazepine receptor agonist,GABRR3,200959,Phase 3
gadopentetic-acid,contrast agent,PGD,5226,Launched
galantamine,acetylcholinesterase inhibitor,ACHE,43,Launched
galantamine,acetylcholinesterase inhibitor,BCHE,590,Launched
galantamine,acetylcholinesterase inhibitor,CHRNA1,1134,Launched
galantamine,acetylcholinesterase inhibitor,CHRNA10,57053,Launched
galantamine,acetylcholinesterase inhibitor,CHRNA2,1135,Launched
galantamine,acetylcholinesterase inhibitor,CHRNA3,1136,Launched
galantamine,acetylcholinesterase inhibitor,CHRNA4,1137,Launched
galantamine,acetylcholinesterase inhibitor,CHRNA5,1138,Launched
galantamine,acetylcholinesterase inhibitor,CHRNA6,8973,Launched
galantamine,acetylcholinesterase inhibitor,CHRNA7,1139,Launched
galantamine,acetylcholinesterase inhibitor,CHRNA9,55584,Launched
galantamine,acetylcholinesterase inhibitor,CHRNB1,1140,Launched
galantamine,acetylcholinesterase inhibitor,CHRNB2,1141,Launched
galantamine,acetylcholinesterase inhibitor,CHRNB3,1142,Launched
galantamine,acetylcholinesterase inhibitor,CHRNB4,1143,Launched
galantamine,acetylcholinesterase inhibitor,CHRND,1144,Launched
galantamine,acetylcholinesterase inhibitor,CHRNE,1145,Launched
galantamine,acetylcholinesterase inhibitor,CHRNG,1146,Launched
galeterone,androgen receptor modulator,AR,367,Phase 3
galeterone,androgen receptor modulator,CYP17A1,1586,Phase 3
gallamine-triethiodide,acetylcholine receptor antagonist,CHRM2,1129,Launched
gallamine-triethiodide,acetylcholine receptor antagonist,CHRNA1,1134,Launched
gallic-acid,beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist,CA1,759,Preclinical
gallic-acid,beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist,CA12,771,Preclinical
gallic-acid,beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist,CA14,23632,Preclinical
gallic-acid,beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist,CA2,4128,Preclinical
gallic-acid,beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist,CA4,4129,Preclinical
gallic-acid,beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist,CA6,8648,Preclinical
gallic-acid,beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist,CA9,5465,Preclinical
gallic-acid,beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist,SELP,5467,Preclinical
gallopamil,L-type calcium channel blocker,ATP2A2,5468,Launched
gambogic-acid,caspase activator,BCL2,1576,Phase 2
gamma-aminobutyric-acid,benzodiazepine receptor agonist,GABBR1,1577,Preclinical
gamma-aminobutyric-acid,benzodiazepine receptor agonist,GABBR2,1551,Preclinical
gamma-aminobutyric-acid,benzodiazepine receptor agonist,GABRA1,2554,Preclinical
gamma-aminobutyric-acid,benzodiazepine receptor agonist,GABRA2,983,Preclinical
gamma-aminobutyric-acid,benzodiazepine receptor agonist,GABRA3,1020,Preclinical
gamma-aminobutyric-acid,benzodiazepine receptor agonist,GABRA5,2931,Preclinical
gamma-aminobutyric-acid,benzodiazepine receptor agonist,GABRB2,983,Preclinical
gamma-aminobutyric-acid,benzodiazepine receptor agonist,GABRG2,1017,Preclinical
gamma-aminobutyric-acid,benzodiazepine receptor agonist,GATM,1020,Preclinical
gamma-aminobutyric-acid,benzodiazepine receptor agonist,KCTD12,8851,Preclinical
gamma-aminobutyric-acid,benzodiazepine receptor agonist,KCTD16,2932,Preclinical
gamma-aminobutyric-acid,benzodiazepine receptor agonist,KCTD8,759,Preclinical
gamma-aminobutyric-acid,benzodiazepine receptor agonist,SLC6A1,771,Preclinical
gamma-linolenic-acid,cyclooxygenase inhibitor|prostanoid receptor agonist,PTGS1,23632,Phase 2
gamma-linolenic-acid,cyclooxygenase inhibitor|prostanoid receptor agonist,PTGS2,760,Phase 2
ganaxolone,GABA receptor modulator,GABRA1,765,Phase 3
ganaxolone,GABA receptor modulator,GABRA2,766,Phase 3
ganaxolone,GABA receptor modulator,GABRA3,768,Phase 3
ganaxolone,GABA receptor modulator,GABRA4,5742,Phase 3
ganaxolone,GABA receptor modulator,GABRA5,5743,Phase 3
ganaxolone,GABA receptor modulator,GABRA6,10599,Phase 3
ganetespib,HSP inhibitor,HSP90AA1,196,Phase 3
GANT-58,GLI antagonist,GLI1,2739,Preclinical
GANT-61,GLI antagonist,GLI1,5320,Preclinical
GANT-61,GLI antagonist,GLI2,5465,Preclinical
garenoxacin,topoisomerase inhibitor,TOP2A,5468,Launched
gavestinel,glutamate receptor antagonist,GLRB,11251,Phase 3
gavestinel,glutamate receptor antagonist,GRIN1,145482,Phase 3
gavestinel,glutamate receptor antagonist,GRIN2A,5742,Phase 3
gavestinel,glutamate receptor antagonist,GRIN2B,5743,Phase 3
gavestinel,glutamate receptor antagonist,GRIN2C,113235,Phase 3
gavestinel,glutamate receptor antagonist,GRIN2D,3577,Phase 3
gavestinel,glutamate receptor antagonist,GRIN3A,3579,Phase 3
gavestinel,glutamate receptor antagonist,GRIN3B,5742,Phase 3
GBR-12935,dopamine reuptake inhibitor,AGTR1,5743,Preclinical
GBR-12935,dopamine reuptake inhibitor,SLC6A3,148,Preclinical
GBR-13069,dopamine reuptake inhibitor,SLC6A3,147,Preclinical
GDC-0068,AKT inhibitor,AKT1,146,Phase 3
GDC-0068,AKT inhibitor,AKT2,151,Phase 3
GDC-0068,AKT inhibitor,AKT3,152,Phase 3
GDC-0068,AKT inhibitor,PRKG1,3620,Phase 3
GDC-0152,XIAP inhibitor,BIRC2,5580,Phase 1
GDC-0152,XIAP inhibitor,BIRC3,5581,Phase 1
GDC-0152,XIAP inhibitor,BIRC7,5578,Phase 1
GDC-0152,XIAP inhibitor,XIAP,5579,Phase 1
GDC-0349,Pim kinase inhibitor,PIK3CA,5580,Phase 1
GDC-0810,selective estrogen receptor destabilizer,ESR1,5581,Phase 2
GDC-0834,Bruton's tyrosine kinase (BTK) inhibitor,BTK,5582,Phase 1
GDC-0879,RAF inhibitor,BRAF,10403,Preclinical
GDC-0941,PI3K inhibitor,PIK3CA,142,Phase 2
GDC-0941,PI3K inhibitor,PIK3CB,142,Phase 2
GDC-0941,PI3K inhibitor,PIK3CD,4860,Phase 2
GDC-0941,PI3K inhibitor,PIK3CG,10423,Phase 2
GDC-0980,mTOR inhibitor|PI3K inhibitor,FGR,151306,Phase 2
GDC-0980,mTOR inhibitor|PI3K inhibitor,MAP3K9,3685,Phase 2
GDC-0980,mTOR inhibitor|PI3K inhibitor,MTOR,3694,Phase 2
GDC-0980,mTOR inhibitor|PI3K inhibitor,PIK3CA,213,Phase 2
GDC-0980,mTOR inhibitor|PI3K inhibitor,PIK3CB,11255,Phase 2
GDC-0980,mTOR inhibitor|PI3K inhibitor,PIK3CD,59340,Phase 2
GDC-0980,mTOR inhibitor|PI3K inhibitor,PIK3CG,1080,Phase 2
GDC-0980,mTOR inhibitor|PI3K inhibitor,SYK,54583,Phase 2
GDC-0994,MAP kinase inhibitor,MAPK1,55818,Phase 1
GDC-0994,MAP kinase inhibitor,MAPK3,23081,Phase 1
gedunin,HSP inhibitor,HSP90AA1,23135,Preclinical
gefitinib,EGFR inhibitor,EGFR,54583,Launched
geldanamycin,HSP inhibitor,HSP90AA1,22992,Preclinical
gemcitabine,ribonucleotide reductase inhibitor,CMPK1,8242,Launched
gemcitabine,ribonucleotide reductase inhibitor,RRM1,5058,Launched
gemcitabine,ribonucleotide reductase inhibitor,RRM2,43,Launched
gemcitabine,ribonucleotide reductase inhibitor,TYMS,6524,Launched
gemcitabine-elaidate,apoptosis inhibitor|DNA synthesis inhibitor,CMPK1,1128,Phase 1
gemcitabine-elaidate,apoptosis inhibitor|DNA synthesis inhibitor,RRM1,1129,Phase 1
gemcitabine-elaidate,apoptosis inhibitor|DNA synthesis inhibitor,TYMS,1131,Phase 1
gemfibrozil,lipoprotein lipase activator,LPL,1132,Launched
gemfibrozil,lipoprotein lipase activator,PPARA,1133,Launched
gemfibrozil,lipoprotein lipase activator,SLCO1B1,4128,Launched
gemfibrozil,lipoprotein lipase activator,SLCO1B3,4129,Launched
gemfibrozil,lipoprotein lipase activator,SLCO2B1,3350,Launched
geniposide,GLP receptor agonist,GLP1R,185,Preclinical
genistein,tyrosine kinase inhibitor,CFTR,3725,Phase 2/Phase 3
genistein,tyrosine kinase inhibitor,ESR1,6554,Phase 2/Phase 3
genistein,tyrosine kinase inhibitor,ESR2,7150,Phase 2/Phase 3
genistein,tyrosine kinase inhibitor,ESRRA,116447,Phase 2/Phase 3
genistein,tyrosine kinase inhibitor,ESRRB,1910,Phase 2/Phase 3
genistein,tyrosine kinase inhibitor,ESRRG,760,Phase 2/Phase 3
genistein,tyrosine kinase inhibitor,NCOA1,412,Phase 2/Phase 3
genistein,tyrosine kinase inhibitor,NCOA2,5141,Phase 2/Phase 3
genistein,tyrosine kinase inhibitor,PPARG,3350,Phase 2/Phase 3
genistein,tyrosine kinase inhibitor,PTK2B,3351,Phase 2/Phase 3
genistein,tyrosine kinase inhibitor,TOP2A,1576,Phase 2/Phase 3
genistein,tyrosine kinase inhibitor,TRPC5,4282,Phase 2/Phase 3
gentamycin,bacterial 50S ribosomal subunit inhibitor,HSPA8,3046,Launched
gentiopicrin,glutamate receptor downregulator,GRIN2B,3047,Phase 3
genz-123346,glucosylceramidase inhibitor,UGCG,760,Preclinical
genz-644282,topoisomerase inhibitor,TOP1,762,Phase 1
gestrinone,progesterone receptor antagonist,AR,765,Launched
gestrinone,progesterone receptor antagonist,ESR1,768,Launched
gestrinone,progesterone receptor antagonist,PGR,6403,Launched
GF109203X,PKC inhibitor,PDPK1,488,Preclinical
GF109203X,PKC inhibitor,PIM1,596,Preclinical
GF109203X,PKC inhibitor,PRKCI,2550,Preclinical
GF109203X,PKC inhibitor,PRKCZ,9568,Preclinical
GGsTop,gamma glutamyltransferase Inhibitor,GGT1,2554,Preclinical
GGTI-298,GGTase inhibitor,CDKN1A,2555,Preclinical
gilteritinib,FLT3 inhibitor,FLT3,2556,Launched
gimeracil,dihydropyrimidine dehydrogenase inhibitor,DPYD,2558,Launched
ginkgolide-A,GABA receptor antagonist,GLRA1,2561,Preclinical
ginkgolide-A,GABA receptor antagonist,GLRB,2566,Preclinical
ginkgolide-B,platelet activating factor receptor antagonist,GLRA1,2628,Phase 3
ginkgolide-B,platelet activating factor receptor antagonist,GLRA2,115207,Phase 3
ginkgolide-B,platelet activating factor receptor antagonist,GLRA3,57528,Phase 3
ginkgolide-B,platelet activating factor receptor antagonist,GLRB,386617,Phase 3
ginkgolide-B,platelet activating factor receptor antagonist,HTR3A,6529,Phase 3
ginkgolide-B,platelet activating factor receptor antagonist,HTR3B,5742,Phase 3
ginsenoside-C-K,NFkB pathway inhibitor|nitric oxide synthase inhibitor,PTGS2,5743,Phase 1
ginsenoside-RE3,angiogenesis inhibitor|apoptosis stimulant,KCNH2,2554,Launched
givinostat,HDAC inhibitor,HDAC1,2555,Phase 3
givinostat,HDAC inhibitor,HDAC2,2556,Phase 3
givinostat,HDAC inhibitor,HDAC3,2557,Phase 3
givinostat,HDAC inhibitor,HDAC4,2558,Phase 3
givinostat,HDAC inhibitor,HDAC5,2559,Phase 3
givinostat,HDAC inhibitor,HDAC6,3320,Phase 3
givinostat,HDAC inhibitor,HDAC7,2735,Phase 3
givinostat,HDAC inhibitor,HDAC8,2735,Phase 3
givinostat,HDAC inhibitor,HDAC9,2736,Phase 3
GKA-50,glucokinase activator,GCK,7153,Preclinical
GKT137831,NADPH oxidase inhibitor,NOX1,2743,Phase 2
GKT137831,NADPH oxidase inhibitor,NOX4,2902,Phase 2
GK921,transglutaminase inhibitor,TGM2,2903,Preclinical
glafenine,DeltaF508-CFTR Correctors,CFTR,2904,Withdrawn
glasdegib,hedgehog pathway inhibitor,SMO,2905,Launched
glimepiride,insulin secretagogue,ABCC8,2906,Launched
glimepiride,insulin secretagogue,KCNJ1,116443,Launched
glimepiride,insulin secretagogue,KCNJ11,116444,Launched
glipizide,sulfonylurea,ABCC8,185,Launched
glipizide,sulfonylurea,KCNJ10,6531,Launched
glipizide,sulfonylurea,KCNJ11,6531,Launched
glipizide,sulfonylurea,PPARG,207,Launched
gliquidone,sulfonylurea,ABCC8,208,Launched
gliquidone,sulfonylurea,KCNJ10,10000,Launched
gliquidone,sulfonylurea,KCNJ8,5592,Launched
GLPG0492,androgen receptor modulator,AR,329,Phase 1
GLPG0492-R-enantiomer,androgen receptor modulator,AR,330,Phase 1
gluconolactone,,LCT,79444,Launched
glucosamine,glycosylated protein precursor,IL1B,331,Launched
glutathione,antioxidant,ESD,5290,Phase 3
glutathione,antioxidant,GGT1,2099,Phase 3
glutathione,antioxidant,GLO1,695,Phase 3
glutathione,antioxidant,GLRX,673,Phase 3
glutathione,antioxidant,GLRX2,5290,Phase 3
glutathione,antioxidant,GPX1,5291,Phase 3
glutathione,antioxidant,GPX2,5293,Phase 3
glutathione,antioxidant,GPX3,5294,Phase 3
glutathione,antioxidant,GPX4,2268,Phase 3
glutathione,antioxidant,GPX5,4293,Phase 3
glutathione,antioxidant,GPX6,2475,Phase 3
glutathione,antioxidant,GPX7,5290,Phase 3
glutathione,antioxidant,GPX8,5291,Phase 3
glutathione,antioxidant,GSR,5293,Phase 3
glutathione,antioxidant,GSS,5294,Phase 3
glutathione,antioxidant,GSTA1,6850,Phase 3
glutathione,antioxidant,GSTA2,5594,Phase 3
glutathione,antioxidant,GSTA3,5595,Phase 3
glutathione,antioxidant,GSTA4,3320,Phase 3
glutathione,antioxidant,GSTA5,1956,Phase 3
glutathione,antioxidant,GSTK1,3320,Phase 3
glutathione,antioxidant,GSTM1,51727,Phase 3
glutathione,antioxidant,GSTM2,6240,Phase 3
glutathione,antioxidant,GSTM3,6241,Phase 3
glutathione,antioxidant,GSTM4,7298,Phase 3
glutathione,antioxidant,GSTM5,51727,Phase 3
glutathione,antioxidant,GSTO1,6240,Phase 3
glutathione,antioxidant,GSTO2,7298,Phase 3
glutathione,antioxidant,GSTP1,4023,Phase 3
glutathione,antioxidant,GSTT1,5465,Phase 3
glutathione,antioxidant,GSTZ1,10599,Phase 3
glutathione,antioxidant,HAGH,28234,Phase 3
glutathione,antioxidant,HPGDS,11309,Phase 3
glutathione,antioxidant,LTC4S,2740,Phase 3
glutathione,antioxidant,MGST1,1080,Phase 3
glutathione,antioxidant,MGST2,2099,Phase 3
glutathione,antioxidant,MGST3,2100,Phase 3
glutathione,antioxidant,TXNDC12,2101,Phase 3
glyburide,ATP channel blocker|insulin secretagogue|sulfonylurea,ABCA1,2103,Launched
glyburide,ATP channel blocker|insulin secretagogue|sulfonylurea,ABCB11,2104,Launched
glyburide,ATP channel blocker|insulin secretagogue|sulfonylurea,ABCC8,8648,Launched
glyburide,ATP channel blocker|insulin secretagogue|sulfonylurea,ABCC9,10499,Launched
glyburide,ATP channel blocker|insulin secretagogue|sulfonylurea,CFTR,5468,Launched
glyburide,ATP channel blocker|insulin secretagogue|sulfonylurea,CPT1A,2185,Launched
glyburide,ATP channel blocker|insulin secretagogue|sulfonylurea,KCNJ1,7153,Launched
glyburide,ATP channel blocker|insulin secretagogue|sulfonylurea,KCNJ11,7224,Launched
glyburide,ATP channel blocker|insulin secretagogue|sulfonylurea,KCNJ5,3312,Launched
glyburide,ATP channel blocker|insulin secretagogue|sulfonylurea,KCNJ8,2904,Launched
glyburide,ATP channel blocker|insulin secretagogue|sulfonylurea,SLCO2B1,11309,Launched
glycitein,tumor necrosis factor release inhibitor,TNF,7124,Phase 3
glycopyrrolate,acetylcholine receptor antagonist,CHRM1,1128,Launched
glycopyrrolate,acetylcholine receptor antagonist,CHRM2,1129,Launched
glycopyrrolate,acetylcholine receptor antagonist,CHRM3,1131,Launched
glycopyrrolate,acetylcholine receptor antagonist,CHRM4,1132,Launched
glycopyrrolate,acetylcholine receptor antagonist,CHRM5,1133,Launched
GM-1485,immunophilin ligand,FKBP1A,2280,Preclinical
GMX1778,NAMPT inhibitor,NAMPT,10135,Phase 1/Phase 2
GNF-2,Bcr-Abl kinase inhibitor,ABL1,25,Preclinical
GNF-2,Bcr-Abl kinase inhibitor,BCR,613,Preclinical
GNF-5,Bcr-Abl kinase inhibitor,ABL1,25,Preclinical
GNF-5,Bcr-Abl kinase inhibitor,BCR,613,Preclinical
GNF-5837,growth factor receptor inhibitor,NTRK1,4914,Preclinical
GNF-5837,growth factor receptor inhibitor,NTRK2,4915,Preclinical
GNF-5837,growth factor receptor inhibitor,NTRK3,4916,Preclinical
GNF-7,glucokinase inhibitor|protein kinase inhibitor,GCK,2645,Preclinical
GNF-7,glucokinase inhibitor|protein kinase inhibitor,TNK2,10188,Preclinical
GNTI,opioid receptor antagonist,OPRK1,4986,Preclinical
GNTI,opioid receptor antagonist,OPRM1,4988,Preclinical
go-6983,protein kinase inhibitor,PRKCA,5578,Preclinical
go-6983,protein kinase inhibitor,PRKCB,5579,Preclinical
go-6983,protein kinase inhibitor,PRKCD,5580,Preclinical
go-6983,protein kinase inhibitor,PRKCG,5582,Preclinical
go-6983,protein kinase inhibitor,PRKCZ,5590,Preclinical
golgicide-A,ARF inhibitor,GBF1,8729,Preclinical
golvatinib,VEGFR inhibitor,KDR,3791,Phase 2
golvatinib,VEGFR inhibitor,MET,4233,Phase 2
gonadorelin,gonadotropin releasing factor hormone receptor agonist,GNRHR,2798,Launched
goserelin-acetate,gonadotropin releasing factor hormone receptor agonist,GNRHR,2798,Launched
goserelin-acetate,gonadotropin releasing factor hormone receptor agonist,LHCGR,3973,Launched
gossypol,BCL inhibitor|MCL1 inhibitor,BCL2,596,Phase 2
GPBAR-A,G protein-coupled receptor agonist,GPBAR1,151306,Preclinical
GPI-1046,FKBP inhibitor,FKBP1A,2280,Preclinical
GPP-78,NAMPT inhibitor,NAMPT,10135,Preclinical
GPR120-modulator-1,G protein-coupled receptor modulator,FFAR4,338557,Preclinical
GP1a,cannabinoid receptor agonist,CNR2,1269,Preclinical
GP2a,cannabinoid receptor agonist,CNR2,1269,Preclinical
GR-103691,dopamine receptor antagonist,DRD3,1814,Preclinical
GR-113808,serotonin receptor antagonist,HTR4,3360,Preclinical
GR-127935,serotonin receptor antagonist,HTR1A,3350,Preclinical
GR-127935,serotonin receptor antagonist,HTR1B,3351,Preclinical
GR-127935,serotonin receptor antagonist,HTR1D,3352,Preclinical
GR-127935,serotonin receptor antagonist,HTR1E,3354,Preclinical
GR-127935,serotonin receptor antagonist,HTR1F,3355,Preclinical
GR-127935,serotonin receptor antagonist,HTR2A,3356,Preclinical
GR-127935,serotonin receptor antagonist,HTR2B,3357,Preclinical
GR-127935,serotonin receptor antagonist,HTR2C,3358,Preclinical
GR-127935,serotonin receptor antagonist,HTR6,3362,Preclinical
GR-144053,integrin antagonist,ITGA2B,3674,Preclinical
GR-144053,integrin antagonist,ITGB3,3690,Preclinical
GR-159897,tachykinin antagonist,TAC1,6863,Preclinical
GR-159897,tachykinin antagonist,TACR2,6865,Preclinical
GR-235,estrogen receptor agonist|FXR antagonist|progesterone receptor agonist,NR1H4,9971,Launched
GR-79236,adenosine receptor agonist,ADORA1,134,Phase 1
GR-79236,adenosine receptor agonist,ADORA2A,135,Phase 1
granisetron,serotonin receptor antagonist,HTR3A,3359,Launched
grapiprant,prostaglandin inhibitor,PTGER4,5734,Launched
griseofulvin,tubulin polymerization inhibitor,KRT12,3859,Launched
GR125487,serotonin receptor antagonist,HTR4,3360,Preclinical
GR46611,serotonin receptor agonist,HTR1D,3352,Preclinical
GS-143,ubiquitin ligase inhibitor,BTRC,8945,Preclinical
GS-143,ubiquitin ligase inhibitor,NFKBIA,4792,Preclinical
GS-39783,GABA receptor modulator,GABBR1,2550,Preclinical
GS-6201,adenosine receptor antagonist,ADORA1,134,Phase 1
GS-6201,adenosine receptor antagonist,ADORA2A,135,Phase 1
GS-6201,adenosine receptor antagonist,ADORA2B,136,Phase 1
GS-6201,adenosine receptor antagonist,ADORA3,140,Phase 1
GS-9620,toll-like receptor agonist,TLR7,51284,Phase 2
GS-9973,SYK inhibitor,SYK,6850,Phase 2
GSK-J1,histone demethylase inhibitor,KDM6B,23135,Preclinical
GSK-J4,histone lysine demethylase inhibitor,KDM6A,7403,Preclinical
GSK-J4,histone lysine demethylase inhibitor,KDM6B,23135,Preclinical
GSK-LSD-1,histone lysine demethylase inhibitor,KDM1A,23028,Preclinical
GSK-3-inhibitor-IX,glycogen synthase kinase inhibitor|lipoxygenase inhibitor,GSK3A,2931,Preclinical
GSK-3-inhibitor-IX,glycogen synthase kinase inhibitor|lipoxygenase inhibitor,GSK3B,2932,Preclinical
GSK0660,PPAR receptor antagonist,PPARD,5467,Preclinical
GSK1059615,PI3K inhibitor,PIK3CG,5294,Phase 1
GSK1070916,Aurora kinase inhibitor,AURKA,6790,Phase 1
GSK1070916,Aurora kinase inhibitor,AURKB,9212,Phase 1
GSK1070916,Aurora kinase inhibitor,AURKC,6795,Phase 1
GSK1070916,Aurora kinase inhibitor,CYP2D6,1565,Phase 1
GSK1070916,Aurora kinase inhibitor,CYP3A4,1576,Phase 1
GSK1292263,glucose dependent insulinotropic receptor agonist,GRPR,2925,Phase 2
GSK1562590,urotensin receptor antagonist,UTS2R,2837,Preclinical
GSK163090,serotonin receptor antagonist,HTR1A,3350,Phase 2
GSK163090,serotonin receptor antagonist,HTR1B,3351,Phase 2
GSK163090,serotonin receptor antagonist,HTR1D,3352,Phase 2
GSK1838705A,insulin growth factor receptor inhibitor,ALK,238,Preclinical
GSK1838705A,insulin growth factor receptor inhibitor,IGF1R,3480,Preclinical
GSK1838705A,insulin growth factor receptor inhibitor,INSR,3643,Preclinical
GSK1838705A,insulin growth factor receptor inhibitor,RPS6KA1,6195,Preclinical
GSK1904529A,IGF-1 inhibitor|insulin growth factor receptor inhibitor|insulin receptor ligand,IGF1R,3480,Preclinical
GSK1904529A,IGF-1 inhibitor|insulin growth factor receptor inhibitor|insulin receptor ligand,INSR,3643,Preclinical
GSK2110183,AKT inhibitor,AKT1,207,Phase 2
GSK2110183,AKT inhibitor,AKT2,208,Phase 2
GSK2110183,AKT inhibitor,AKT3,10000,Phase 2
GSK2126458,mTOR inhibitor|PI3K inhibitor,MTOR,2475,Phase 1
GSK2126458,mTOR inhibitor|PI3K inhibitor,PIK3CA,5290,Phase 1
GSK2126458,mTOR inhibitor|PI3K inhibitor,PIK3CB,5291,Phase 1
GSK2126458,mTOR inhibitor|PI3K inhibitor,PIK3CD,7357,Phase 1
GSK2126458,mTOR inhibitor|PI3K inhibitor,PIK3CG,7150,Phase 1
GSK2190915,lipoxygenase inhibitor,ALOX5AP,367,Phase 2
GSK2193874,transient receptor potential channel antagonist,TRPV4,2099,Preclinical
GSK2194069,fatty acid synthase inhibitor,FASN,5241,Preclinical
GSK2256294A,epoxide hydolase inhibitor,EPHX2,5170,Phase 1
GSK2330672,bile acid transporter inhibitor,SLC10A2,5292,Phase 2
GSK2334470,phosphoinositide dependent kinase inhibitor,AURKA,5584,Preclinical
GSK2334470,phosphoinositide dependent kinase inhibitor,AURKB,5590,Preclinical
GSK2334470,phosphoinositide dependent kinase inhibitor,PDPK1,2678,Preclinical
GSK256066,phosphodiesterase inhibitor,PDE4A,1026,Phase 2
GSK2578215A,leucine rich repeat kinase inhibitor,LRRK2,2322,Preclinical
GSK2606414,protein kinase inhibitor,EIF2AK3,1806,Preclinical
GSK2606414,protein kinase inhibitor,MYLK2,2741,Preclinical
GSK2636771,PI3K inhibitor,PIK3CB,2743,Phase 2
GSK269962,rho associated kinase inhibitor,ROCK1,2741,Preclinical
GSK269962,rho associated kinase inhibitor,ROCK2,2742,Preclinical
GSK2801,bromodomain inhibitor,BAZ2A,8001,Preclinical
GSK2801,bromodomain inhibitor,BAZ2B,2743,Preclinical
GSK2816126,histone lysine methyltransferase inhibitor,EZH2,3359,Phase 1
GSK2830371,protein phosphatase inhibitor,PPM1D,9177,Preclinical
GSK2837808A,lactate dehydrogenase inhibitor,LDHA,5743,Preclinical
GSK2879552,histone lysine demethylase inhibitor,KDM1A,3757,Phase 1/Phase 2
GSK37647,free fatty acid receptor agonist,FFAR4,3065,Preclinical
GSK3787,PPAR receptor antagonist,PPARD,3066,Preclinical
GSK429286A,rho associated kinase inhibitor,ROCK1,8841,Preclinical
GSK461364,PLK inhibitor,PLK1,9759,Phase 1
GSK503,histone lysine methyltransferase inhibitor,EZH2,10014,Preclinical
GSK650394,serum/glucocorticoid regulated kinase inhibitor,SGK1,10013,Preclinical
GSK650394,serum/glucocorticoid regulated kinase inhibitor,SGK2,51564,Preclinical
GSK690693,AKT inhibitor,AKT1,55869,Phase 1
GSK690693,AKT inhibitor,AKT2,9734,Phase 1
GSK690693,AKT inhibitor,AKT3,2645,Phase 1
GSK690693,AKT inhibitor,PAK4,27035,Phase 1
GSK690693,AKT inhibitor,PAK6,50507,Phase 1
GSK690693,AKT inhibitor,PAK7,7052,Phase 1
GSK690693,AKT inhibitor,PRKCQ,1080,Phase 1
GSK690693,AKT inhibitor,PRKG1,6608,Phase 1
GSK690693,AKT inhibitor,PRKX,6833,Phase 1
GSK9027,glucocorticoid receptor agonist,NR3C1,3758,Preclinical
GSK923295,centromere associated protein inhibitor,CENPE,3767,Phase 1
GTP-14564,FLT3 inhibitor|tyrosine kinase inhibitor,CSF1R,6833,Preclinical
GTP-14564,FLT3 inhibitor|tyrosine kinase inhibitor,FLT3,3766,Preclinical
GTP-14564,FLT3 inhibitor|tyrosine kinase inhibitor,KIT,3767,Preclinical
GTP-14564,FLT3 inhibitor|tyrosine kinase inhibitor,PDGFRB,5468,Preclinical
GTS21,cholinergic receptor agonist,CHRNA7,6833,Phase 1/Phase 2
guaiacol,local anesthetic,CA2,3766,Launched
guanaben-acetate,adrenergic receptor agonist,ADRA2A,3764,Launched
guanaben-acetate,adrenergic receptor agonist,ADRA2B,367,Launched
guanaben-acetate,adrenergic receptor agonist,ADRA2C,367,Launched
guanethidine,adrenergic inhibitor,SLC6A2,3938,Launched
guanfacine,adrenergic receptor agonist,ADRA2A,3553,Launched
guanfacine,adrenergic receptor agonist,ADRA2B,2098,Launched
guanfacine,adrenergic receptor agonist,ADRA2C,2678,Launched
guanidine,HSP inhibitor,ALDH2,2739,Launched
guanidine,HSP inhibitor,DLG4,2745,Launched
guanidine,HSP inhibitor,GAMT,51022,Launched
guanidine,HSP inhibitor,RNASE1,2876,Launched
guanidinoethyldisulfide-bicarbonate,nitric oxide synthase inhibitor,NOS2,2877,Phase 2
guanidinopropionic-acid,creatine kinase inhibitor,CKM,2878,Phase 2
guanosine,,PNP,2879,Preclinical
Gue-1654,oxoeicosanoid receptor modulator,OXER1,2880,Preclinical
guvacine,GABA uptake inhibitor,SLC6A1,257202,Preclinical
guvacine,GABA uptake inhibitor,SLC6A11,2882,Preclinical
guvacine,GABA uptake inhibitor,SLC6A12,493869,Preclinical
guvacine,GABA uptake inhibitor,SLC6A13,2936,Preclinical
GW-0742,PPAR receptor agonist,PPARD,2937,Preclinical
GW-1100,G protein-coupled receptor agonist,FFAR1,2938,Preclinical
GW-1929,PPAR receptor agonist,PPARG,2939,Preclinical
GW-2580,cFMS kinase inhibitor,CSF1R,2940,Preclinical
GW-311616,elastase inhibitor|leukocyte elastase inhibitor,ELANE,2941,Phase 1
GW-3965,LXR agonist,NR1H2,221357,Preclinical
GW-3965,LXR agonist,NR1H3,373156,Preclinical
GW-405833,cannabinoid receptor agonist,CNR2,2944,Preclinical
GW-4064,FXR agonist,NR1H4,2946,Preclinical
GW-438014A,neuropeptide receptor antagonist,NPY5R,2947,Preclinical
GW-441756,growth factor receptor inhibitor,NTRK1,2948,Preclinical
GW-501516,PPAR receptor agonist,PPARA,2949,Phase 2
GW-501516,PPAR receptor agonist,PPARD,9446,Phase 2
GW-5074,leucine rich repeat kinase inhibitor|RAF inhibitor,NTRK1,119391,Phase 1/Phase 2
GW-5074,leucine rich repeat kinase inhibitor|RAF inhibitor,RAF1,2950,Phase 1/Phase 2
GW-542573X,calcium channel activator,KCNN1,2952,Preclinical
GW-583340,EGFR inhibitor,EGFR,2954,Preclinical
GW-583340,EGFR inhibitor,ERBB2,3029,Preclinical
GW-627368,prostanoid receptor antagonist,PTGER4,27306,Preclinical
GW-6471,PPAR receptor antagonist,PPARA,4056,Preclinical
GW-7647,PPAR receptor agonist,PPARA,4257,Preclinical
GW-788388,ALK tyrosine kinase receptor inhibitor,LCK,4258,Preclinical
GW-788388,ALK tyrosine kinase receptor inhibitor,MAPK14,4259,Preclinical
GW-788388,ALK tyrosine kinase receptor inhibitor,TGFBR1,51060,Preclinical
GW-803430,melanin inhibitor,KCNH2,19,Phase 1
GW-803430,melanin inhibitor,MCHR1,8647,Phase 1
GW-842166,cannabinoid receptor agonist,CNR2,6833,Phase 2
GW-843682X,PLK inhibitor,PLK1,10060,Preclinical
GW-843682X,PLK inhibitor,PLK3,1080,Preclinical
GW-9508,free fatty acid receptor agonist|G protein-coupled receptor agonist,FFAR1,1374,Preclinical
GW-9508,free fatty acid receptor agonist|G protein-coupled receptor agonist,FFAR4,3758,Preclinical
GW-9662,PPAR receptor antagonist,NCOA2,3767,Preclinical
GW-9662,PPAR receptor antagonist,PPARG,3762,Preclinical
GW-9662,PPAR receptor antagonist,RXRA,3764,Preclinical
GYKI-52466,glutamate receptor antagonist,GRIA1,2890,Preclinical
GYKI-52466,glutamate receptor antagonist,GRIA2,2891,Preclinical
GYKI-52466,glutamate receptor antagonist,GRIA3,2892,Preclinical
GYKI-52466,glutamate receptor antagonist,GRIA4,2893,Preclinical
GZD824,Bcr-Abl kinase inhibitor,ABL1,25,Preclinical
GZD824,Bcr-Abl kinase inhibitor,BCR,613,Preclinical
G007-LK,tankyrase inhibitor,TNKS,8658,Preclinical
G007-LK,tankyrase inhibitor,TNKS2,80351,Preclinical
H-89,PKA inhibitor,GSG2,83903,Preclinical
H-89,PKA inhibitor,PKIA,5569,Preclinical
H-89,PKA inhibitor,PRKACA,5566,Preclinical
HA-130,autotaxin inhibitor,ENPP2,5168,Preclinical
HA-966-(R)-(+),glutamate receptor agonist,GRIA1,2890,Preclinical
HA-966-(S)-(-),glutamate receptor antagonist,GRIA1,2890,Preclinical
halcinonide,glucocorticoid receptor agonist,NR3C1,2908,Launched
halobetasol-propionate,glucocorticoid receptor agonist,NR3C1,2908,Launched
halobetasol-propionate,glucocorticoid receptor agonist,PLA2G1B,5319,Launched
halofantrine,antimalarial agent,KCNN4,3783,Launched
halofuginone,collagenase inhibitor,COL1A1,1277,Launched
halofuginone,collagenase inhibitor,MMP2,4313,Launched
halopemide,phospholipase inhibitor,PLD1,5337,Phase 2
halopemide,phospholipase inhibitor,PLD2,5338,Phase 2
haloperidol,dopamine receptor antagonist,DRD1,1812,Launched
haloperidol,dopamine receptor antagonist,DRD2,1813,Launched
haloperidol,dopamine receptor antagonist,DRD3,1814,Launched
haloperidol,dopamine receptor antagonist,DRD4,1815,Launched
haloperidol,dopamine receptor antagonist,DRD5,1816,Launched
haloperidol,dopamine receptor antagonist,GRIN2B,2904,Launched
haloperidol,dopamine receptor antagonist,HRH1,3269,Launched
haloperidol,dopamine receptor antagonist,HTR1A,3350,Launched
haloperidol,dopamine receptor antagonist,HTR1D,3352,Launched
haloperidol,dopamine receptor antagonist,HTR2A,3356,Launched
haloperidol,dopamine receptor antagonist,HTR2B,3357,Launched
haloperidol,dopamine receptor antagonist,HTR7,3363,Launched
haloperidol,dopamine receptor antagonist,KCNH1,3756,Launched
haloperidol-decanoate,psychoactive drug,DRD2,1813,Launched
haloperidol-decanoate,psychoactive drug,DRD3,1814,Launched
haloperidol-decanoate,psychoactive drug,DRD4,1815,Launched
haloperidol-decanoate,psychoactive drug,HTR2A,3356,Launched
halothane,glutamate receptor antagonist,GABRA1,2554,Launched
halothane,glutamate receptor antagonist,GABRA2,2555,Launched
halothane,glutamate receptor antagonist,GABRA3,2556,Launched
halothane,glutamate receptor antagonist,GABRA4,2557,Launched
halothane,glutamate receptor antagonist,GABRA5,2558,Launched
halothane,glutamate receptor antagonist,GABRA6,2559,Launched
halothane,glutamate receptor antagonist,GABRB1,2560,Launched
halothane,glutamate receptor antagonist,GABRB2,2561,Launched
halothane,glutamate receptor antagonist,GABRB3,2562,Launched
halothane,glutamate receptor antagonist,GABRD,2563,Launched
halothane,glutamate receptor antagonist,GABRE,2564,Launched
halothane,glutamate receptor antagonist,GABRG1,2565,Launched
halothane,glutamate receptor antagonist,GABRG2,2566,Launched
halothane,glutamate receptor antagonist,GABRG3,2567,Launched
halothane,glutamate receptor antagonist,GABRP,2568,Launched
halothane,glutamate receptor antagonist,GABRQ,55879,Launched
halothane,glutamate receptor antagonist,GLRA1,2741,Launched
halothane,glutamate receptor antagonist,GLRB,2743,Launched
halothane,glutamate receptor antagonist,KCNK10,54207,Launched
halothane,glutamate receptor antagonist,KCNK12,56660,Launched
halothane,glutamate receptor antagonist,KCNK13,56659,Launched
halothane,glutamate receptor antagonist,KCNK15,60598,Launched
halothane,glutamate receptor antagonist,KCNK18,338567,Launched
halothane,glutamate receptor antagonist,KCNK2,3776,Launched
halothane,glutamate receptor antagonist,KCNK3,3777,Launched
halothane,glutamate receptor antagonist,KCNK9,51305,Launched
harmane,monoamine oxidase inhibitor,MAOA,4128,Preclinical
harmane,monoamine oxidase inhibitor,MAOB,4129,Preclinical
HA14-1,BCL inhibitor,BCL2,596,Preclinical
HC-030031,TRPA1 channel blocker,TRPA1,8989,Phase 1
HC-067047,transient receptor potential channel antagonist,TRPV4,59341,Preclinical
heclin,ubiquitin ligase inhibitor,NEDD4,4734,Preclinical
heclin,ubiquitin ligase inhibitor,SMURF2,64750,Preclinical
heclin,ubiquitin ligase inhibitor,WWP1,11059,Preclinical
HEMADO,adenosine receptor agonist,ADORA1,134,Preclinical
HEMADO,adenosine receptor agonist,ADORA2A,135,Preclinical
HEMADO,adenosine receptor agonist,ADORA2B,136,Preclinical
HEMADO,adenosine receptor agonist,ADORA3,140,Preclinical
hemomex-s,,PPARG,5468,Launched
hesperadin,Aurora kinase inhibitor,AURKB,9212,Preclinical
hesperetin,ACAT inhibitor,DGAT1,8694,Launched
hesperetin,ACAT inhibitor,MTTP,4547,Launched
hesperetin,ACAT inhibitor,SOAT1,6646,Launched
hesperetin,ACAT inhibitor,SOAT2,8435,Launched
hesperidin,flavanone glycoside,AURKB,9212,Launched
hesperidin,flavanone glycoside,CACNA1B,774,Launched
hexachlorophene,potassium channel activator,GLUD1,2746,Launched
hexachlorophene,potassium channel activator,SDHD,6392,Launched
hexamethonium,cholinergic receptor antagonist,CHRNA2,1135,Preclinical
hexamethonium,cholinergic receptor antagonist,CHRNA3,1136,Preclinical
hexamethonium,cholinergic receptor antagonist,CHRNA4,1137,Preclinical
hexamethonium,cholinergic receptor antagonist,CHRNA6,8973,Preclinical
hexamethylenebisacetamide,AKT inhibitor|differentiation inducer|NFKB pathway inhibitor,AKT1,207,Phase 2
hexestrol,synthetic estrogen,AKR1C1,1645,Launched
hexestrol,synthetic estrogen,ESR1,2099,Launched
hexestrol,synthetic estrogen,ESR2,2100,Launched
hexoprenaline,adrenergic receptor agonist,ADRB2,154,Launched
hexylcaine,sodium channel blocker,SCN5A,6331,Launched
hexylene-glycol,,AKR1C3,8644,Preclinical
hexylene-glycol,,CTPS1,1503,Preclinical
hexylene-glycol,,DLG4,1742,Preclinical
hexylene-glycol,,HSP90AA1,5293,Preclinical
hexylene-glycol,,NOS3,5294,Preclinical
hexylene-glycol,,PGF,241,Preclinical
hexylene-glycol,,PLA2G1B,59341,Preclinical
hexylene-glycol,,PTPN1,2194,Preclinical
hexylene-glycol,,SELP,2053,Preclinical
hexylresorcinol,local anesthetic,TYR,6555,Launched
higenamine,adrenergic receptor agonist,ADRB2,6790,Phase 1
histamine,histamine receptor agonist,HRH1,9212,Launched
histamine,histamine receptor agonist,HRH2,5170,Launched
histamine,histamine receptor agonist,HRH3,5141,Launched
histamine,histamine receptor agonist,HRH4,120892,Launched
HJC-0350,GTPase inhibitor,RAPGEF4,9451,Preclinical
HKI-357,EGFR inhibitor,EGFR,85366,Phase 1
HLCL-61,protein arginine N-methyltransferase inhibitor,PRMT5,5291,Preclinical
HMN-214,PLK inhibitor,PLK1,6093,Phase 1
homatropine,acetylcholine receptor antagonist,CHRM1,9475,Launched
homatropine-methylbromide,acetylcholine receptor antagonist,CHRM5,11176,Launched
homochlorcyclizine,antihistamine,HRH1,29994,Launched
homoharringtonine,protein synthesis inhibitor,RPL3,2146,Launched
homoquinolinic-acid,glutamate receptor agonist,GRIN1,8493,Preclinical
homoquinolinic-acid,glutamate receptor agonist,GRIN2A,3939,Preclinical
homoquinolinic-acid,glutamate receptor agonist,GRIN2B,23028,Preclinical
homoquinolinic-acid,glutamate receptor agonist,GRIN2C,338557,Preclinical
homoquinolinic-acid,glutamate receptor agonist,GRIN2D,5467,Preclinical
honokiol,AKT inhibitor,ALOX5,6093,Phase 3
honokiol,AKT inhibitor,PTGS1,5347,Phase 3
honokiol,AKT inhibitor,PTGS2,2146,Phase 3
HTH-01-015,protein kinase inhibitor,NUAK1,6446,Preclinical
HTMT,histamine receptor agonist,HRH4,10110,Preclinical
huperzine-A,acetylcholinesterase inhibitor,ACHE,207,Phase 2
hyaluronic-acid,,C1QBP,208,Launched
hyaluronic-acid,,CD44,10000,Launched
hyaluronic-acid,,HABP2,10298,Launched
hyaluronic-acid,,HAPLN1,56924,Launched
hyaluronic-acid,,HAPLN3,-,Launched
hyaluronic-acid,,HAPLN4,5588,Launched
hyaluronic-acid,,HMMR,5592,Launched
hyaluronic-acid,,ICAM1,5613,Launched
hyaluronic-acid,,NCAN,2908,Launched
hyaluronic-acid,,VCAN,1062,Launched
hydrochlorothiazide,thiazide diuretic,CA1,1436,Launched
hydrochlorothiazide,thiazide diuretic,CA12,2322,Launched
hydrochlorothiazide,thiazide diuretic,CA2,3815,Launched
hydrochlorothiazide,thiazide diuretic,CA4,5159,Launched
hydrochlorothiazide,thiazide diuretic,CA9,1139,Launched
hydrochlorothiazide,thiazide diuretic,KCNMA1,760,Launched
hydrochlorothiazide,thiazide diuretic,SLC12A3,150,Launched
hydrocortisone,glucocorticoid receptor agonist,ANXA1,151,Launched
hydrocortisone,glucocorticoid receptor agonist,NOS2,152,Launched
hydrocortisone,glucocorticoid receptor agonist,NR3C1,6530,Launched
hydrocortisone,glucocorticoid receptor agonist,NR3C2,150,Launched
hydrocortisone-acetate,glucocorticoid receptor agonist,NR3C1,151,Launched
hydrocortisone-butyrate,glucocorticoid receptor agonist,NR3C1,152,Launched
hydrocortisone-valerate,glucocorticoid receptor agonist,NR3C1,217,Launched
hydroflumethiazide,sodium/potassium/chloride transporter inhibitor,ATP1A1,1742,Launched
hydroflumethiazide,sodium/potassium/chloride transporter inhibitor,CA1,2593,Launched
hydroflumethiazide,sodium/potassium/chloride transporter inhibitor,CA12,6035,Launched
hydroflumethiazide,sodium/potassium/chloride transporter inhibitor,CA2,4843,Launched
hydroflumethiazide,sodium/potassium/chloride transporter inhibitor,CA4,1158,Launched
hydroflumethiazide,sodium/potassium/chloride transporter inhibitor,CA9,4860,Launched
hydroflumethiazide,sodium/potassium/chloride transporter inhibitor,KCNMA1,165140,Launched
hydroflumethiazide,sodium/potassium/chloride transporter inhibitor,SLC12A1,6529,Launched
hydroflumethiazide,sodium/potassium/chloride transporter inhibitor,SLC12A3,6538,Launched
hydroquinone,melanin inhibitor,TYR,6539,Launched
hydroxyamphetamine,trace amine associated receptor agonist,TAAR1,6540,Launched
hydroxychloroquine,antimalarial agent,TLR7,5467,Launched
hydroxychloroquine,antimalarial agent,TLR9,2864,Launched
hydroxyfasudil,rho associated kinase inhibitor,PKIA,5468,Preclinical
hydroxyfasudil,rho associated kinase inhibitor,PRKACA,1436,Preclinical
hydroxyfasudil,rho associated kinase inhibitor,ROCK1,1991,Preclinical
hydroxyprogesterone,progesterone receptor agonist,PGR,7376,Launched
hydroxyprogesterone-acetate,progesterone receptor agonist,PGR,10062,Launched
"hydroxytacrine-maleate-(R,S)",cholinesterase inhibitor,ACHE,1269,Preclinical
hydroxyurea,ribonucleotide reductase inhibitor,RRM1,9971,Launched
hydroxyurea,ribonucleotide reductase inhibitor,RRM2,4889,Launched
hydroxyurea,ribonucleotide reductase inhibitor,RRM2B,4914,Launched
hydroxyzine,antihistamine,HRH1,5465,Launched
hymecromone,monoamine oxidase inhibitor,MAOA,5467,Phase 2
hymecromone,monoamine oxidase inhibitor,MAOB,4914,Phase 2
hyoscyamine,acetylcholine receptor antagonist,CHRM1,5894,Launched
hyoscyamine,acetylcholine receptor antagonist,CHRM2,3780,Launched
hyoscyamine,acetylcholine receptor antagonist,CHRM3,1956,Launched
hyoscyamine,acetylcholine receptor antagonist,CHRM4,2064,Launched
hyperin,aldose reductase inhibitor,ACE,5734,Preclinical
hyperin,aldose reductase inhibitor,AKR1B1,5465,Preclinical
hypoestoxide,IKK inhibitor,IKBKB,5465,Phase 1
hypoestoxide,IKK inhibitor,IL1B,3932,Phase 1
hypoestoxide,IKK inhibitor,TNF,1432,Phase 1
hypoxanthine,PARP inhibitor,PNP,7046,Preclinical
H2L-5765834,lysophosphatidic acid receptor antagonist,LPAR1,3757,Preclinical
H2L-5765834,lysophosphatidic acid receptor antagonist,LPAR3,2847,Preclinical
I-BET-762,bromodomain inhibitor,BRD2,1269,Phase 2
I-BET-762,bromodomain inhibitor,BRD3,5347,Phase 2
I-BET-762,bromodomain inhibitor,BRD4,1263,Phase 2
I-BET151,bromodomain inhibitor,BRD2,2864,Preclinical
I-BET151,bromodomain inhibitor,BRD3,338557,Preclinical
I-BET151,bromodomain inhibitor,BRD4,10499,Preclinical
I-BRD9,bromodomain inhibitor,BRD9,5468,Preclinical
I-CBP-112,bromodomain inhibitor,CREBBP,6256,Preclinical
I-CBP-112,bromodomain inhibitor,EP300,2033,Preclinical
IB-MECA,adenosine receptor agonist,ADORA1,134,Phase 3
IB-MECA,adenosine receptor agonist,ADORA2A,135,Phase 3
IB-MECA,adenosine receptor agonist,ADORA2B,136,Phase 3
IB-MECA,adenosine receptor agonist,ADORA3,140,Phase 3
ibandronate,bone resorption inhibitor,FDPS,2224,Launched
IBC-293,hydroxycarboxylic acid receptor agonist,HCAR3,8843,Preclinical
IBMX,phosphodiesterase inhibitor,ADORA1,134,Preclinical
IBMX,phosphodiesterase inhibitor,PDE2A,5138,Preclinical
IBMX,phosphodiesterase inhibitor,PDE3B,5140,Preclinical
IBMX,phosphodiesterase inhibitor,PDE4D,5144,Preclinical
IBMX,phosphodiesterase inhibitor,PDE5A,8654,Preclinical
IBMX,phosphodiesterase inhibitor,PDE6G,5148,Preclinical
IBMX,phosphodiesterase inhibitor,PDE7A,5150,Preclinical
IBMX,phosphodiesterase inhibitor,PDE8A,5151,Preclinical
IBMX,phosphodiesterase inhibitor,PDE9A,5152,Preclinical
ibotenic-acid,glutamate receptor agonist,GRIN1,2902,Preclinical
ibrolipim,lipoprotein lipase activator,LPL,4023,Phase 2
ibrutinib,Bruton's tyrosine kinase (BTK) inhibitor,BLK,640,Launched
ibrutinib,Bruton's tyrosine kinase (BTK) inhibitor,BMX,660,Launched
ibrutinib,Bruton's tyrosine kinase (BTK) inhibitor,BTK,695,Launched
ibudilast,leukotriene receptor antagonist|phosphodiesterase inhibitor,IL1B,3553,Launched
ibudilast,leukotriene receptor antagonist|phosphodiesterase inhibitor,IL6,3569,Launched
ibudilast,leukotriene receptor antagonist|phosphodiesterase inhibitor,PDE3A,5139,Launched
ibudilast,leukotriene receptor antagonist|phosphodiesterase inhibitor,PDE4A,5141,Launched
ibudilast,leukotriene receptor antagonist|phosphodiesterase inhibitor,PDE4B,5142,Launched
ibudilast,leukotriene receptor antagonist|phosphodiesterase inhibitor,PDE4C,5143,Launched
ibudilast,leukotriene receptor antagonist|phosphodiesterase inhibitor,PDE4D,5144,Launched
ibudilast,leukotriene receptor antagonist|phosphodiesterase inhibitor,PDE5A,8654,Launched
ibuprofen-(S),cyclooxygenase inhibitor,ASIC1,41,Launched
ibuprofen-(S),cyclooxygenase inhibitor,PTGS1,5742,Launched
ibuprofen-(S),cyclooxygenase inhibitor,PTGS2,5743,Launched
ibuprofen-(S),cyclooxygenase inhibitor,SLC5A8,160728,Launched
ibuprofen-piconol,cyclooxygenase inhibitor,PTGS1,5742,Launched
ibuprofen-piconol,cyclooxygenase inhibitor,PTGS2,5743,Launched
ibuproxam,cyclooxygenase inhibitor|prostaglandin inhibitor,ALOX5,240,Launched
ibutamoren,growth hormone secretagogue receptor agonist,GHR,2690,Phase 2
ibutamoren,growth hormone secretagogue receptor agonist,GHSR,2693,Phase 2
ibutilide,potassium channel blocker,CACNA1C,775,Launched
ibutilide,potassium channel blocker,KCNH2,3757,Launched
ICA-069673,voltage-gated potassium channel activator,KCNQ2,3785,Preclinical
ICA-069673,voltage-gated potassium channel activator,KCNQ3,3786,Preclinical
ICA-110381,voltage-gated potassium channel activator,KCNQ2,3785,Preclinical
ICA-121431,sodium channel blocker,SCN1A,6323,Preclinical
ICA-121431,sodium channel blocker,SCN3A,6328,Preclinical
icariin,phosphodiesterase inhibitor,PDE5A,8654,Phase 3
icaritin,PPAR receptor antagonist,PDE5A,8654,Phase 3
icatibant-acetate,bradykinin receptor antagonist,BDKRB2,624,Launched
ICG-001,beta-catenin inhibitor,CTNNB1,1499,Preclinical
"ICI-118,551",adrenergic receptor antagonist,ADRB2,154,Phase 2
"ICI-118,551",adrenergic receptor antagonist,ADRB3,155,Phase 2
ICI-162846,histamine receptor antagonist,HRH2,3274,Phase 1
ICI-192605,thromboxane receptor antagonist,TBXA2R,6915,Phase 2
ICI-199441,opioid receptor agonist,CYP2D6,1565,Preclinical
ICI-199441,opioid receptor agonist,OPRD1,4985,Preclinical
ICI-199441,opioid receptor agonist,OPRK1,4986,Preclinical
ICI-199441,opioid receptor agonist,OPRM1,4988,Preclinical
ICI-199441,opioid receptor agonist,UTS2R,2837,Preclinical
"ICI-215,001",adrenergic receptor agonist,ADRB3,155,Preclinical
ICI-89406,adrenergic receptor antagonist,ADRB1,153,Phase 1
ICI-89406,adrenergic receptor antagonist,ADRB2,154,Phase 1
icilin,TRPV agonist,TRPA1,8989,Phase 1
icilin,TRPV agonist,TRPM8,79054,Phase 1
icomucret,mucin production enhancer,LTB4R2,56413,Phase 3
icosapent,platelet aggregation inhibitor,ACSL3,2181,Launched
icosapent,platelet aggregation inhibitor,ACSL4,2182,Launched
icosapent,platelet aggregation inhibitor,FADS1,3992,Launched
icosapent,platelet aggregation inhibitor,FFAR1,2864,Launched
icosapent,platelet aggregation inhibitor,PPARD,5467,Launched
icosapent,platelet aggregation inhibitor,PPARG,5468,Launched
icosapent,platelet aggregation inhibitor,PTGS1,5742,Launched
icosapent,platelet aggregation inhibitor,PTGS2,5743,Launched
icosapent,platelet aggregation inhibitor,SLC8A1,6546,Launched
icosapent,platelet aggregation inhibitor,TRPV1,7442,Launched
icotinib,EGFR inhibitor,EGFR,1956,Launched
iCRT-14,beta catenin inhibitor|WNT signaling inhibitor,CTNNB1,1499,Preclinical
iCRT-14,beta catenin inhibitor|WNT signaling inhibitor,TCF4,6925,Preclinical
IC261,casein kinase inhibitor,CSNK1A1,1452,Preclinical
IC261,casein kinase inhibitor,CSNK1D,1453,Preclinical
IC261,casein kinase inhibitor,CSNK1E,1454,Preclinical
IC261,casein kinase inhibitor,CSNK1G2,1455,Preclinical
ID-1101,insulin sensitizer,INS,3630,Phase 1
idalopirdine,serotonin receptor antagonist,HTR6,3362,Phase 3
idarubicin,topoisomerase inhibitor,TOP2A,7153,Launched
idasanutlin,MDM inhibitor,MDM2,4193,Phase 3
idasanutlin,MDM inhibitor,TP53,7157,Phase 3
idazoxan,adrenergic receptor antagonist,ADRA2A,150,Phase 3
idazoxan,adrenergic receptor antagonist,PTGS2,5743,Phase 3
idelalisib,PI3K inhibitor,PIK3CA,5290,Launched
idelalisib,PI3K inhibitor,PIK3CB,5291,Launched
idelalisib,PI3K inhibitor,PIK3CD,5293,Launched
idelalisib,PI3K inhibitor,PIK3CG,5294,Launched
IDO5L,"indoleamine 2,3-dioxygenase inhibitor",IDO1,3620,Preclinical
IDRA-21,glutamate receptor positive allosteric modulator,GRIA1,2890,Preclinical
IDRA-21,glutamate receptor positive allosteric modulator,GRIA2,2891,Preclinical
IDRA-21,glutamate receptor positive allosteric modulator,GRIA3,2892,Preclinical
IDRA-21,glutamate receptor positive allosteric modulator,GRIA4,2893,Preclinical
idronoxil,XIAP inhibitor,ENOX2,10495,Phase 3
idronoxil,XIAP inhibitor,SPHK1,8877,Phase 3
IEM1460,glutamate receptor antagonist,GRIA2,2891,Preclinical
IEM1754,glutamate receptor antagonist,GRIA1,2890,Preclinical
ifenprodil,adrenergic receptor antagonist|glutamate receptor antagonist,GRIN2B,2904,Launched
ifosfamide,DNA alkylating agent,CYP2A6,1548,Launched
ifosfamide,DNA alkylating agent,CYP2B6,1555,Launched
ifosfamide,DNA alkylating agent,CYP2C18,1562,Launched
ifosfamide,DNA alkylating agent,CYP2C19,1557,Launched
ifosfamide,DNA alkylating agent,CYP2C8,1558,Launched
ifosfamide,DNA alkylating agent,CYP2C9,1559,Launched
ifosfamide,DNA alkylating agent,CYP3A4,1576,Launched
ifosfamide,DNA alkylating agent,CYP3A5,1577,Launched
ifosfamide,DNA alkylating agent,CYP3A7,1551,Launched
ifosfamide,DNA alkylating agent,PTGS1,5742,Launched
igmesine,sigma receptor agonist,SIGMAR1,10280,Phase 2
iguratimod,cyclooxygenase inhibitor|NFkB pathway inhibitor,PTGS2,5743,Launched
IKK-16,IKK inhibitor,IKBKB,3551,Preclinical
IKK-2-inhibitor,IKK inhibitor|SYK inhibitor,IKBKB,3551,Preclinical
IKK-2-inhibitor-V,IKK inhibitor|NFkB pathway inhibitor,IKBKB,3551,Phase 1
ilomastat,matrix metalloprotease inhibitor,ACAN,176,Phase 3
ilomastat,matrix metalloprotease inhibitor,ADAM28,10863,Phase 3
ilomastat,matrix metalloprotease inhibitor,MMP1,4312,Phase 3
ilomastat,matrix metalloprotease inhibitor,MMP12,4321,Phase 3
ilomastat,matrix metalloprotease inhibitor,MMP13,4322,Phase 3
ilomastat,matrix metalloprotease inhibitor,MMP14,4323,Phase 3
ilomastat,matrix metalloprotease inhibitor,MMP2,4313,Phase 3
ilomastat,matrix metalloprotease inhibitor,MMP3,4314,Phase 3
ilomastat,matrix metalloprotease inhibitor,MMP8,4317,Phase 3
ilomastat,matrix metalloprotease inhibitor,MMP9,4318,Phase 3
iloperidone,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A,148,Launched
iloperidone,dopamine receptor antagonist|serotonin receptor antagonist,ADRA2C,152,Launched
iloperidone,dopamine receptor antagonist|serotonin receptor antagonist,DRD1,1812,Launched
iloperidone,dopamine receptor antagonist|serotonin receptor antagonist,DRD2,1813,Launched
iloperidone,dopamine receptor antagonist|serotonin receptor antagonist,DRD3,1814,Launched
iloperidone,dopamine receptor antagonist|serotonin receptor antagonist,DRD4,1815,Launched
iloperidone,dopamine receptor antagonist|serotonin receptor antagonist,HRH1,3269,Launched
iloperidone,dopamine receptor antagonist|serotonin receptor antagonist,HTR1A,3350,Launched
iloperidone,dopamine receptor antagonist|serotonin receptor antagonist,HTR2A,3356,Launched
iloperidone,dopamine receptor antagonist|serotonin receptor antagonist,HTR6,3362,Launched
iloperidone,dopamine receptor antagonist|serotonin receptor antagonist,HTR7,3363,Launched
iloprost,platelet aggregation inhibitor|prostanoid receptor agonist,PTGDR,5729,Launched
iloprost,platelet aggregation inhibitor|prostanoid receptor agonist,PTGER1,5731,Launched
iloprost,platelet aggregation inhibitor|prostanoid receptor agonist,PTGER2,5732,Launched
iloprost,platelet aggregation inhibitor|prostanoid receptor agonist,PTGER3,5733,Launched
iloprost,platelet aggregation inhibitor|prostanoid receptor agonist,PTGER4,5734,Launched
iloprost,platelet aggregation inhibitor|prostanoid receptor agonist,PTGFR,5737,Launched
iloprost,platelet aggregation inhibitor|prostanoid receptor agonist,PTGIR,5739,Launched
iloprost,platelet aggregation inhibitor|prostanoid receptor agonist,TBXA2R,6915,Launched
imatinib,Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,ABL1,25,Launched
imatinib,Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,CSF1R,1436,Launched
imatinib,Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,DDR1,780,Launched
imatinib,Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,KIT,3815,Launched
imatinib,Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,NTRK1,4914,Launched
imatinib,Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,PDGFRA,5156,Launched
imatinib,Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,PDGFRB,5159,Launched
imatinib,Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,RET,5979,Launched
imetit,histamine receptor agonist,HRH3,11255,Preclinical
imetit,histamine receptor agonist,HRH4,59340,Preclinical
imidafenacin,acetylcholine receptor antagonist,CHRM1,1128,Launched
imidafenacin,acetylcholine receptor antagonist,CHRM3,1131,Launched
imidapril,angiotensin converting enzyme inhibitor,ACE,1636,Launched
imiloxan,adrenergic receptor antagonist,ADRA2A,150,Phase 1
imiloxan,adrenergic receptor antagonist,ADRA2B,151,Phase 1
imipramine,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,ADRA1A,148,Launched
imipramine,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,ADRA1B,147,Launched
imipramine,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,ADRA1D,146,Launched
imipramine,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,CHRM1,1128,Launched
imipramine,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,CHRM2,1129,Launched
imipramine,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,CHRM3,1131,Launched
imipramine,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,CHRM4,1132,Launched
imipramine,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,CHRM5,1133,Launched
imipramine,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,DRD1,1812,Launched
imipramine,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,DRD2,1813,Launched
imipramine,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,DRD5,1816,Launched
imipramine,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,HRH1,3269,Launched
imipramine,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,HTR1A,3350,Launched
imipramine,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,HTR2A,3356,Launched
imipramine,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,HTR2C,3358,Launched
imipramine,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,HTR6,3362,Launched
imipramine,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,HTR7,3363,Launched
imipramine,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,KCND2,3751,Launched
imipramine,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,KCND3,3752,Launched
imipramine,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,KCNH1,3756,Launched
imipramine,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,KCNH2,3757,Launched
imipramine,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,SLC6A2,6530,Launched
imipramine,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,SLC6A3,6531,Launched
imipramine,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,SLC6A4,6532,Launched
imiquimod,interferon inducer|toll-like receptor agonist,TLR7,51284,Launched
imiquimod,interferon inducer|toll-like receptor agonist,TLR8,51311,Launched
immepip,histamine receptor agonist,HRH3,11255,Preclinical
immepip,histamine receptor agonist,HRH4,59340,Preclinical
immethridine,histamine receptor agonist,HRH3,11255,Phase 1
impentamine,histamine receptor antagonist,HRH3,11255,Preclinical
INC-280,c-Met inhibitor,MET,4233,Phase 3
INCA-6,calcineurin inhibitor,NFATC1,4772,Preclinical
INCB-3284,CC chemokine receptor antagonist,CCR2,729230,Phase 2
indacaterol,adrenergic receptor agonist,ADRB1,153,Launched
indacaterol,adrenergic receptor agonist,ADRB2,154,Launched
indalpine,selective serotonin reuptake inhibitor (SSRI),SLC6A4,6532,Withdrawn
indapamide,thiazide diuretic,CA2,760,Launched
indapamide,thiazide diuretic,HTR3A,3359,Launched
indapamide,thiazide diuretic,KCNQ1,3784,Launched
indatraline,norepinephrine transporter inhibitor,MAOA,3320,Preclinical
indatraline,norepinephrine transporter inhibitor,MAOB,4846,Preclinical
indeglitazar,PPAR receptor agonist,NCOA1,5228,Phase 2
indeglitazar,PPAR receptor agonist,PPARA,5319,Phase 2
indeglitazar,PPAR receptor agonist,PPARD,5770,Phase 2
indeglitazar,PPAR receptor agonist,PPARG,6403,Phase 2
indinavir,HIV protease inhibitor,CYP3A4,7299,Launched
indinavir,HIV protease inhibitor,CYP3A5,154,Launched
indinavir,HIV protease inhibitor,CYP3A7,3269,Launched
indiplon,benzodiazepine receptor agonist,GABRA1,3274,Phase 3
indirubin,CDK inhibitor|glycogen synthase kinase inhibitor,CDK1,11255,Phase 2/Phase 3
indirubin,CDK inhibitor|glycogen synthase kinase inhibitor,CDK5,59340,Phase 2/Phase 3
indirubin,CDK inhibitor|glycogen synthase kinase inhibitor,GSK3A,11069,Phase 2/Phase 3
indirubin-3-monoxime,CDK inhibitor|glycogen synthase kinase inhibitor,CDK1,1956,Preclinical
indirubin-3-monoxime,CDK inhibitor|glycogen synthase kinase inhibitor,CDK2,10419,Preclinical
indirubin-3-monoxime,CDK inhibitor|glycogen synthase kinase inhibitor,CDK5,5347,Preclinical
indirubin-3-monoxime,CDK inhibitor|glycogen synthase kinase inhibitor,CDK5R1,1128,Preclinical
indirubin-3-monoxime,CDK inhibitor|glycogen synthase kinase inhibitor,GSK3B,1133,Preclinical
indisulam,CDK inhibitor,CA1,3269,Phase 2
indisulam,CDK inhibitor,CA12,6122,Phase 2
indisulam,CDK inhibitor,CA14,2902,Phase 2
indisulam,CDK inhibitor,CA2,2903,Phase 2
indisulam,CDK inhibitor,CA6,2904,Phase 2
indisulam,CDK inhibitor,CA7,2905,Phase 2
indisulam,CDK inhibitor,CA9,2906,Phase 2
indobufen,cyclooxygenase inhibitor|platelet aggregation inhibitor,PTGS1,240,Launched
indobufen,cyclooxygenase inhibitor|platelet aggregation inhibitor,PTGS2,5742,Launched
indocyanine-green,contrast agent,SLCO1B1,5743,Launched
indole-3-carbinol,"aryl hydrocarbon receptor agonist|indoleamine 2,3-dioxygenase inhibitor",AHR,9891,Phase 2/Phase 3
indomethacin,cyclooxygenase inhibitor,GLO1,59340,Launched
indomethacin,cyclooxygenase inhibitor,PLA2G2A,43,Launched
indomethacin,cyclooxygenase inhibitor,PPARA,708,Launched
indomethacin,cyclooxygenase inhibitor,PPARG,960,Launched
indomethacin,cyclooxygenase inhibitor,PTGDR2,3026,Launched
indomethacin,cyclooxygenase inhibitor,PTGR2,1404,Launched
indomethacin,cyclooxygenase inhibitor,PTGS1,145864,Launched
indomethacin,cyclooxygenase inhibitor,PTGS2,404037,Launched
indomethacin,cyclooxygenase inhibitor,SLC46A1,3161,Launched
indoprofen,cyclooxygenase inhibitor|prostanoid receptor antagonist,CXCR1,3383,Withdrawn
indoprofen,cyclooxygenase inhibitor|prostanoid receptor antagonist,CXCR2,1463,Withdrawn
indoprofen,cyclooxygenase inhibitor|prostanoid receptor antagonist,PTGS1,1462,Withdrawn
indoprofen,cyclooxygenase inhibitor|prostanoid receptor antagonist,PTGS2,759,Withdrawn
indoramin,adrenergic receptor antagonist,ADRA1A,771,Launched
indoramin,adrenergic receptor antagonist,ADRA1B,760,Launched
indoramin,adrenergic receptor antagonist,ADRA1D,762,Launched
indoramin,adrenergic receptor antagonist,ADRA2B,768,Launched
indoramin,adrenergic receptor antagonist,ADRA2C,3778,Launched
indoximod,"indoleamine 2,3-dioxygenase inhibitor",IDO1,6559,Phase 2
ingenol,PKC activator,PRKCD,301,Launched
ingenol,PKC activator,PRKCE,4843,Launched
ingenol-mebutate,PKC activator,PRKCA,2908,Launched
ingenol-mebutate,PKC activator,PRKCB,4306,Launched
ingenol-mebutate,PKC activator,PRKCD,2908,Launched
ingenol-mebutate,PKC activator,PRKCE,2908,Launched
ingenol-mebutate,PKC activator,PRKCG,2908,Launched
INH1,Hec1 inhibitor,NDC80,476,Preclinical
iniparib,PARP inhibitor,PARP1,759,Phase 3
inosine,neurotrophic agent,PARP1,771,Launched
inosine,neurotrophic agent,PNP,760,Launched
inositol,insulin sensitizer,CDIPT,762,Launched
INT-767,FXR agonist,GPBAR1,768,Phase 1
integrin-antagonist-1,integrin antagonist,ITGAV,3778,Phase 1
integrin-antagonist-1,integrin antagonist,ITGB6,6557,Phase 1
iodipamide,radiopaque medium,ALB,6559,Launched
iodophenpropit,histamine receptor antagonist,HRH3,7299,Preclinical
iodophenpropit,histamine receptor antagonist,HRH4,134864,Preclinical
IOWH032,CFTR channel antagonist,CFTR,51284,Phase 2
IOX1,histone demethylase inhibitor,EGLN1,54106,Preclinical
IOX1,histone demethylase inhibitor,KDM3A,5569,Preclinical
IOX1,histone demethylase inhibitor,KDM4C,5566,Preclinical
IOX1,histone demethylase inhibitor,KDM6B,6093,Preclinical
IOX2,hypoxia inducible factor inhibitor,EGLN1,5241,Preclinical
IOX2,hypoxia inducible factor inhibitor,KDM2A,5241,Preclinical
IOX2,hypoxia inducible factor inhibitor,KDM5C,43,Preclinical
IPA-3,p21 activated kinase inhibitor,PAK1,6240,Preclinical
ipidacrine,acetylcholinesterase inhibitor,ACHE,6241,Phase 3
ipragliflozin-L-proline,sodium/glucose cotransporter inhibitor,SLC5A2,50484,Launched
ipratropium,acetylcholine receptor antagonist,CHRM1,3269,Launched
ipratropium,acetylcholine receptor antagonist,CHRM2,4128,Launched
ipratropium,acetylcholine receptor antagonist,CHRM3,4129,Launched
ipratropium,acetylcholine receptor antagonist,CHRM4,1128,Launched
ipratropium,acetylcholine receptor antagonist,CHRM5,1129,Launched
iproniazid,monoamine oxidase inhibitor,MAOA,1131,Withdrawn
iproniazid,monoamine oxidase inhibitor,MAOB,1132,Withdrawn
ipsapirone,serotonin receptor agonist,HTR1A,1636,Phase 3
irbesartan,angiotensin receptor antagonist,AGTR1,231,Launched
irbesartan,angiotensin receptor antagonist,JUN,3551,Launched
irbesartan,angiotensin receptor antagonist,SLC10A1,3553,Launched
irinotecan,topoisomerase inhibitor,TOP1,7124,Launched
irinotecan,topoisomerase inhibitor,TOP1MT,4860,Launched
IRL-2500,endothelin receptor antagonist,EDNRB,1902,Preclinical
irosustat,steroid sulfatase inhibitor,CA2,23566,Phase 2
irosustat,steroid sulfatase inhibitor,STS,6046,Phase 2
irsogladine,phosphodiesterase inhibitor,PDE4A,8019,Launched
isamoltane,adrenergic receptor antagonist,HTR1A,23476,Phase 1
isamoltane,adrenergic receptor antagonist,HTR1B,6046,Phase 1
isavuconazole,cytochrome P450 inhibitor,CYP3A4,8019,Phase 3
ISO-1,macrophage migration inhibiting factor inhibitor,MIF,23476,Preclinical
isobutyramide,gene expression stimulant,HBE1,65980,Phase 2
isobutyramide,gene expression stimulant,HBG1,1387,Phase 2
isocarboxazid,monoamine oxidase inhibitor,MAOA,-,Launched
isocarboxazid,monoamine oxidase inhibitor,MAOB,79731,Launched
isoconazole,fungal lanosterol demethylase inhibitor,CYP17A1,6510,Launched
isoflupredone-acetate,,NR3C1,10991,Preclinical
isoflurane,inhaled anaesthetic,GABRA1,95,Launched
isoflurane,inhaled anaesthetic,GABRA2,91703,Launched
isoflurane,inhaled anaesthetic,GABRA3,159,Launched
isoflurane,inhaled anaesthetic,GABRA4,-,Launched
isoflurane,inhaled anaesthetic,GABRA5,440,Launched
isoflurane,inhaled anaesthetic,GABRA6,443,Launched
isoflurane,inhaled anaesthetic,GABRB1,444,Launched
isoflurane,inhaled anaesthetic,GABRB2,80150,Launched
isoflurane,inhaled anaesthetic,GABRB3,445,Launched
isoflurane,inhaled anaesthetic,GABRD,790,Launched
isoflurane,inhaled anaesthetic,GABRE,1615,Launched
isoflurane,inhaled anaesthetic,GABRG1,55157,Launched
isoflurane,inhaled anaesthetic,GABRG2,2805,Launched
isoflurane,inhaled anaesthetic,GABRG3,2806,Launched
isoflurane,inhaled anaesthetic,GABRP,2902,Launched
isoflurane,inhaled anaesthetic,GABRQ,2903,Launched
isoflurane,inhaled anaesthetic,GLRA1,2904,Launched
isoflurane,inhaled anaesthetic,GLRB,2905,Launched
isoflurane,inhaled anaesthetic,KCNK10,2906,Launched
isoflurane,inhaled anaesthetic,KCNK18,4069,Launched
isoflurane,inhaled anaesthetic,KCNK2,10606,Launched
isoflurane,inhaled anaesthetic,KCNK3,6035,Launched
isoflurane,inhaled anaesthetic,KCNK9,6505,Launched
isoflurophate,cholinesterase inhibitor,ACHE,8604,Launched
isoflurophate,cholinesterase inhibitor,BCHE,10165,Launched
isoguvacine,benzodiazepine receptor agonist,GABRA1,445,Preclinical
isoguvacine,benzodiazepine receptor agonist,GABRA2,23576,Preclinical
isoguvacine,benzodiazepine receptor agonist,GABRA3,23564,Preclinical
isoguvacine,benzodiazepine receptor agonist,GABRA4,222545,Preclinical
isoguvacine,benzodiazepine receptor agonist,GABRA5,4842,Preclinical
isoguvacine,benzodiazepine receptor agonist,GABRA6,4843,Preclinical
isoguvacine,benzodiazepine receptor agonist,GABRR1,4846,Preclinical
isoguvacine,benzodiazepine receptor agonist,GABRR2,5009,Preclinical
isoguvacine,benzodiazepine receptor agonist,GABRR3,29943,Preclinical
isoliquiritigenin,guanylate cyclase activator,GABBR1,11240,Preclinical
isoniazid,FABI inhibitor,CYP1A2,51702,Launched
isoniazid,FABI inhibitor,CYP2C19,23569,Launched
isoniazid,FABI inhibitor,CYP2C8,353238,Launched
isoniazid,FABI inhibitor,CYP2E1,833,Launched
isoniazid,FABI inhibitor,CYP3A4,79587,Launched
isoprenaline,adrenergic receptor agonist,ADRB1,875,Launched
isoprenaline,adrenergic receptor agonist,ADRB2,-,Launched
isoprenaline,adrenergic receptor agonist,ADRB3,1036,Launched
isopropamide-iodide,acetylcholine receptor antagonist,CHRM3,51380,Launched
isopropamide-iodide,acetylcholine receptor antagonist,CHRM4,1491,Launched
isosorbide-dinitrate,nitric oxide stimulant,GUCY1A2,2729,Launched
isosorbide-dinitrate,nitric oxide stimulant,GUCY1A3,2730,Launched
isosorbide-dinitrate,nitric oxide stimulant,GUCY1B2,2805,Launched
isosorbide-dinitrate,nitric oxide stimulant,GUCY1B3,2937,Launched
isosorbide-dinitrate,nitric oxide stimulant,NPR1,4255,Launched
isosorbide-mononitrate,nitric oxide stimulant,GUCY1A2,9054,Launched
isosorbide-mononitrate,nitric oxide stimulant,GUCY1A3,80704,Launched
isosorbide-mononitrate,nitric oxide stimulant,GUCY1B2,2911,Launched
isosorbide-mononitrate,nitric oxide stimulant,GUCY1B3,2915,Launched
isotretinoin,retinoid receptor agonist,RARA,2936,Launched
isotretinoin,retinoid receptor agonist,RARB,3158,Launched
isotretinoin,retinoid receptor agonist,RARG,10914,Launched
isoxicam,cyclooxygenase inhibitor,PTGS1,7001,Withdrawn
isoxicam,cyclooxygenase inhibitor,PTGS2,1497,Withdrawn
isoxsuprine,adrenergic receptor agonist,ADRB2,6519,Launched
ispinesib,kinesin inhibitor,KIF11,23657,Phase 2
isradipine,calcium channel blocker,CACNA1D,11136,Launched
isradipine,calcium channel blocker,CACNA1F,51166,Launched
isradipine,calcium channel blocker,CACNA2D1,10157,Launched
ISRIB,eukaryotic translation initiation factor inhibitor|PERK inhibitor,EIF2A,18,Preclinical
ISRIB,eukaryotic translation initiation factor inhibitor|PERK inhibitor,EIF2AK3,5832,Preclinical
istaroxime,ATPase inhibitor,ATP1A1,440,Phase 2
istradefylline,adenosine receptor antagonist,ADORA1,586,Launched
istradefylline,adenosine receptor antagonist,ADORA2A,587,Launched
istradefylline,adenosine receptor antagonist,ADORA2B,56267,Launched
istradefylline,adenosine receptor antagonist,ADORA3,23549,Launched
ISX-9,neural stem cell inducer,NEUROD1,124454,Preclinical
itacitinib,JAK inhibitor,JAK1,2028,Phase 3
ITD-1,TGF beta receptor inhibitor,TGFBR2,2058,Preclinical
ITE,aryl hydrocarbon receptor agonist,AHR,2346,Preclinical
ITI214,phosphodiesterase inhibitor,PDE1A,2356,Phase 1/Phase 2
itopride,dopamine receptor antagonist,CHRM3,10841,Launched
itopride,dopamine receptor antagonist,DRD2,2571,Launched
ITX3,GEF inhibitor,TRIO,2572,Preclinical
IT1t,CC chemokine receptor antagonist,CXCR4,5188,Preclinical
IU1,ubiquitin C-terminal hydrolase inhibitor,USP14,2729,Preclinical
ivabradine,HCN channel blocker|potassium channel blocker|sodium channel blocker,HCN1,2730,Launched
ivabradine,HCN channel blocker|potassium channel blocker|sodium channel blocker,HCN3,2677,Launched
ivabradine,HCN channel blocker|potassium channel blocker|sodium channel blocker,HCN4,2744,Launched
ivacaftor,CFTR channel potentiator,CFTR,27165,Launched
ivermectin,benzodiazepine receptor agonist,CHRNA7,2746,Launched
ivermectin,benzodiazepine receptor agonist,P2RX7,2747,Launched
ivosidenib,isocitrate dehydrogenase inhibitor,IDH1,2752,Launched
IWP-L6,porcupine inhibitor,PORCN,8833,Preclinical
ixabepilone,microtubule stabilizing agent,TUBB,2805,Launched
JAK3-inhibitor-V,JAK inhibitor,JAK3,2806,Preclinical
JDTic,opioid receptor antagonist,OPRK1,2875,Phase 1
JHW-007,dopamine reuptake inhibitor,SLC6A3,84706,Preclinical
JIB04,histone lysine demethylase inhibitor,KDM4E,2890,Preclinical
JLK-6,gamma secretase inhibitor,PSEN1,2891,Preclinical
JNJ-10191584,histamine receptor antagonist,HRH4,2892,Preclinical
JNJ-10397049,orexin receptor antagonist,HCRTR1,79896,Preclinical
JNJ-10397049,orexin receptor antagonist,HCRTR2,4889,Preclinical
JNJ-16259685,glutamate receptor antagonist,GRM1,5734,Preclinical
JNJ-1661010,FAAH inhibitor,FAAH,5467,Preclinical
JNJ-17203212,TRPV antagonist,TRPV1,2642,Preclinical
JNJ-26481585,HDAC inhibitor,HDAC1,886,Phase 2
JNJ-26481585,HDAC inhibitor,HDAC10,887,Phase 2
JNJ-26481585,HDAC inhibitor,HDAC11,3784,Phase 2
JNJ-26481585,HDAC inhibitor,HDAC2,552,Phase 2
JNJ-26481585,HDAC inhibitor,HDAC3,554,Phase 2
JNJ-26481585,HDAC inhibitor,HDAC4,5021,Phase 2
JNJ-26481585,HDAC inhibitor,HDAC5,2554,Phase 2
JNJ-26481585,HDAC inhibitor,HDAC6,2555,Phase 2
JNJ-26481585,HDAC inhibitor,HDAC7,2556,Phase 2
JNJ-26481585,HDAC inhibitor,HDAC8,2558,Phase 2
JNJ-26481585,HDAC inhibitor,HDAC9,2566,Phase 2
JNJ-26481585,HDAC inhibitor,MDM2,9536,Phase 2
JNJ-27141491,CC chemokine receptor antagonist,CCR2,2902,Preclinical
JNJ-37822681,dopamine receptor antagonist,DRD2,2903,Phase 2
JNJ-38877605,tyrosine kinase inhibitor,MET,2904,Phase 1
JNJ-40411813,glutamate receptor positive allosteric modulator,GRM2,2905,Phase 2
JNJ-42041935,hypoxia inducible factor prolyl hydroxylase inhibitor,PDK2,2906,Preclinical
JNJ-42165279,FAAH inhibitor,FAAH,3612,Phase 2
JNJ-47965567,purinergic receptor antagonist,P2RX7,1813,Preclinical
JNJ-63533054,G protein-coupled receptor agonist,GPR139,10280,Preclinical
JNJ-7706621,CDK inhibitor,AURKA,3350,Preclinical
JNJ-7706621,CDK inhibitor,AURKB,3351,Preclinical
JNJ-7706621,CDK inhibitor,CDK1,3352,Preclinical
JNJ-7706621,CDK inhibitor,CDK2,2902,Preclinical
JNJ-7777120,histamine receptor antagonist,HRH4,2902,Preclinical
JQ1-(+),bromodomain inhibitor,BRD4,2903,Preclinical
JQ1-(+),bromodomain inhibitor,BRDT,2904,Preclinical
JTC-801,opioid receptor antagonist,OPRL1,2905,Phase 2
JTE-013,lysophospholipid receptor antagonist,P2RY10,2906,Preclinical
JTE-013,lysophospholipid receptor antagonist,S1PR2,6869,Preclinical
JTE-607,cytokine production inhibitor,IL10,6865,Phase 2
JTE-607,cytokine production inhibitor,IL1B,6869,Phase 2
JTE-607,cytokine production inhibitor,IL6,1814,Phase 2
JTE-607,cytokine production inhibitor,TNF,1815,Phase 2
JTE-907,cannabinoid receptor inverse agonist,CNR2,6323,Phase 1
JW-55,tankyrase inhibitor,TNKS,6328,Preclinical
JW-55,tankyrase inhibitor,TNKS2,1812,Preclinical
JW-642,monoacylglycerol lipase inhibitor,MGLL,1813,Preclinical
JW-67,WNT pathway inhibitor,APC,1814,Preclinical
JW-67,WNT pathway inhibitor,AXIN1,1815,Preclinical
JW-67,WNT pathway inhibitor,GSK3B,3350,Preclinical
JW-74,tankyrase inhibitor|WNT signaling inhibitor,TNKS,3356,Preclinical
JW-74,tankyrase inhibitor|WNT signaling inhibitor,TNKS2,3362,Preclinical
JX-401,p38 MAPK inhibitor,MAPK14,3363,Preclinical
JZL-184,monoacylglucerol lipase inhibitor,MGLL,153,Preclinical
JZL-195,FAAH inhibitor|monoacylglycerol lipase inhibitor,FAAH,154,Preclinical
JZL-195,FAAH inhibitor|monoacylglycerol lipase inhibitor,MGLL,155,Preclinical
K-Ras(G12C)-inhibitor-12,K-Ras inhibitor,KRAS,6869,Preclinical
K-strophanthidin,ATPase inhibitor,ATP1A1,2339,Phase 2
K-858,kinesin-like spindle protein inhibitor,KIF11,2342,Preclinical
kaempferol,bone resorption inhibitor|estrogen-related receptor inverse agonist,AKR1B1,5229,Preclinical
kaempferol,bone resorption inhibitor|estrogen-related receptor inverse agonist,ALOX15B,5733,Preclinical
kaempferol,bone resorption inhibitor|estrogen-related receptor inverse agonist,ALOX5,2554,Preclinical
kaempferol,bone resorption inhibitor|estrogen-related receptor inverse agonist,AR,2555,Preclinical
kaempferol,bone resorption inhibitor|estrogen-related receptor inverse agonist,CYP1B1,2556,Preclinical
kaempferol,bone resorption inhibitor|estrogen-related receptor inverse agonist,GLO1,2558,Preclinical
kaempferol,bone resorption inhibitor|estrogen-related receptor inverse agonist,HSD17B1,146,Preclinical
kaempferol,bone resorption inhibitor|estrogen-related receptor inverse agonist,UGT3A1,153,Preclinical
kainic-acid,kainate receptor agonist,GRIA1,154,Preclinical
kainic-acid,kainate receptor agonist,GRIK1,775,Preclinical
kainic-acid,kainate receptor agonist,GRIK2,3274,Preclinical
kainic-acid,kainate receptor agonist,GRIK3,6336,Preclinical
kainic-acid,kainate receptor agonist,GRIK4,11280,Preclinical
kainic-acid,kainate receptor agonist,GRIK5,6323,Preclinical
karenitecin,topoisomerase inhibitor,TOP1,6326,Phase 3
kartogenin,chondrocyte differentiation stimulator,FLNA,6328,Preclinical
KB-R7943,sodium/calcium exchange inhibitor,SLC8A1,6329,Preclinical
KB-R7943,sodium/calcium exchange inhibitor,TRPC3,6331,Preclinical
KB-R7943,sodium/calcium exchange inhibitor,TRPC5,6332,Preclinical
KB-R7943,sodium/calcium exchange inhibitor,TRPC6,6334,Preclinical
KB-SRC-4,SRC inhibitor,SRC,6335,Preclinical
KBG,neprilysin inhibitor,MME,153,Phase 2
KD-023,ACAT inhibitor,ACACA,495,Phase 2
KD-023,ACAT inhibitor,ACACB,496,Phase 2
KD025,rho associated kinase inhibitor,ROCK2,1956,Phase 2
kenpaullone,CDK inhibitor|glycogen synthase kinase inhibitor,CCNB1,2064,Preclinical
kenpaullone,CDK inhibitor|glycogen synthase kinase inhibitor,CDK1,2920,Preclinical
kenpaullone,CDK inhibitor|glycogen synthase kinase inhibitor,CDK5,5729,Preclinical
kenpaullone,CDK inhibitor|glycogen synthase kinase inhibitor,GSK3B,11251,Preclinical
ketanserin,serotonin receptor antagonist,ADRA1A,5731,Launched
ketanserin,serotonin receptor antagonist,ADRA1B,5732,Launched
ketanserin,serotonin receptor antagonist,ADRA1D,5733,Launched
ketanserin,serotonin receptor antagonist,DRD1,5737,Launched
ketanserin,serotonin receptor antagonist,DRD5,5739,Launched
ketanserin,serotonin receptor antagonist,HTR1A,6915,Launched
ketanserin,serotonin receptor antagonist,HTR1B,4914,Launched
ketanserin,serotonin receptor antagonist,HTR1D,4915,Launched
ketanserin,serotonin receptor antagonist,HTR2A,4916,Launched
ketanserin,serotonin receptor antagonist,HTR2B,2099,Launched
ketanserin,serotonin receptor antagonist,HTR2C,2100,Launched
ketanserin,serotonin receptor antagonist,HTR5A,5737,Launched
ketanserin,serotonin receptor antagonist,HTR7,3269,Launched
ketanserin,serotonin receptor antagonist,SLC18A1,3362,Launched
ketanserin,serotonin receptor antagonist,SLC18A2,58,Launched
ketoconazole,sterol demethylase inhibitor,KCNA10,57591,Launched
ketoprofen,cyclooxygenase inhibitor,PTGS1,2893,Launched
ketoprofen,cyclooxygenase inhibitor,PTGS2,2894,Launched
ketoprofen,cyclooxygenase inhibitor,SLC5A8,2895,Launched
ketorolac,cyclooxygenase inhibitor,PTGS1,2897,Launched
ketorolac,cyclooxygenase inhibitor,PTGS2,2898,Launched
ketotifen,histamine receptor agonist|leukotriene receptor antagonist|phosphodiesterase inhibitor,HRH1,2899,Launched
KF-38789,P selectin inhibitor,SELP,2900,Preclinical
KG-5,RAF inhibitor,BRAF,2901,Preclinical
KG-5,RAF inhibitor,FLT3,2902,Preclinical
KG-5,RAF inhibitor,KIT,2903,Preclinical
KG-5,RAF inhibitor,PDGFRB,2904,Preclinical
KH-CB19,CDC inhibitor,CLK1,2905,Preclinical
KH-CB19,CDC inhibitor,CLK3,2906,Preclinical
KH-CB19,CDC inhibitor,DYRK1A,116443,Preclinical
KHK-IN-1,hexokinase inhibitor,KHK,116444,Preclinical
KHS-101,neural stem cell inducer,TACC3,2911,Preclinical
KI-16425,lysophosphatidic acid receptor antagonist,LPAR1,2912,Preclinical
KI-16425,lysophosphatidic acid receptor antagonist,LPAR3,2913,Preclinical
KI-20227,c-Fms inhibitor,CSF1R,2914,Preclinical
KI-20227,c-Fms inhibitor,KDR,2916,Preclinical
KI-20227,c-Fms inhibitor,KIT,2917,Preclinical
KI-20227,c-Fms inhibitor,PDGFRB,2918,Preclinical
KI-8751,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KDR,51557,Preclinical
kifunensine,mannosidase inhibitor,MAN1B1,55191,Phase 1
kifunensine,mannosidase inhibitor,MAN2A1,162417,Phase 1
ki16198,lipoprotein antagonist,LPA,26873,Preclinical
KL-001,proteasome inhibitor,CRY1,5198,Preclinical
KL-001,proteasome inhibitor,CRY2,10404,Preclinical
KML29,monoacylglucerol lipase inhibitor,MGLL,29968,Preclinical
KN-62,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,AKT1,6505,Preclinical
KN-62,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,CAMK2A,6506,Preclinical
KN-62,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,CHEK1,6507,Preclinical
KN-62,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,LCK,6511,Preclinical
KN-62,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,MAPK1,6512,Preclinical
KN-62,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,MAPK11,83733,Preclinical
KN-62,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,MAPK12,79751,Preclinical
KN-62,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,MAPK14,23657,Preclinical
KN-62,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,MAPK8,6898,Preclinical
KN-62,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,P2RX7,1503,Preclinical
KN-62,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,PRKCA,2752,Preclinical
KN-62,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,ROCK1,222545,Preclinical
KN-62,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,RPS6KB1,5471,Preclinical
KN-62,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,SGK1,586,Preclinical
KN-93,calcium/calmodulin dependent protein kinase inhibitor,CAMK2A,587,Preclinical
Ko143,BCRP inhibitor,ABCB1,51520,Preclinical
Ko143,BCRP inhibitor,ABCC1,23395,Preclinical
KPT-185,exportin antagonist,XPO1,51451,Preclinical
KPT-276,exportin antagonist,XPO1,9836,Preclinical
KRCA-0008,ALK inihibitor,ALK,222545,Preclinical
KRN-633,VEGFR inhibitor,FLT1,-,Preclinical
KRN-633,VEGFR inhibitor,FLT4,6541,Preclinical
KRN-633,VEGFR inhibitor,KDR,6542,Preclinical
KS-176,BCRP inhibitor,ABCG2,84889,Preclinical
KU-0063794,mTOR inhibitor,MTOR,6545,Preclinical
KU-55933,ATM kinase inhibitor,ATM,635,Preclinical
KU-55933,ATM kinase inhibitor,PRKDC,23743,Preclinical
KU-60019,ATM kinase inhibitor,ATM,10988,Preclinical
kuromanin,ribosyl cyclase inhibitor,CD38,4548,Preclinical
KW-2449,Abl kinase inhibitor|Aurora kinase inhibitor|FLT3 inhibitor,ABL1,4552,Phase 1
KW-2449,Abl kinase inhibitor|Aurora kinase inhibitor|FLT3 inhibitor,AURKA,1621,Phase 1
KW-2449,Abl kinase inhibitor|Aurora kinase inhibitor|FLT3 inhibitor,AURKB,1984,Phase 1
KW-2449,Abl kinase inhibitor|Aurora kinase inhibitor|FLT3 inhibitor,FLT3,4842,Phase 1
KW-3902,adenosine receptor antagonist,ADORA1,4843,Phase 3
KW-3902,adenosine receptor antagonist,ADORA2A,4846,Phase 3
KW-3902,adenosine receptor antagonist,ADORA2B,4842,Phase 3
KW-3902,adenosine receptor antagonist,ADORA3,4843,Phase 3
KX2-391,SRC inhibitor|tubulin polymerization inhibitor,SRC,4846,Phase 3
kynurenic-acid,glutamate receptor antagonist,GPR35,2058,Phase 1
kynurenic-acid,glutamate receptor antagonist,GRIN1,112849,Phase 1
kynurenic-acid,glutamate receptor antagonist,GRIN2A,64175,Phase 1
kynurenic-acid,glutamate receptor antagonist,GRIN2B,55214,Phase 1
KY02111,WNT pathway inhibitor,DKK1,10536,Preclinical
K02288,bone morphogenic protein inhibitor,BMP1,5033,Preclinical
K145,sphingosine kinase inhibitor,SPHK2,8974,Preclinical
L-alanine,,AARS,25973,Launched
L-alanine,,AARS2,5478,Launched
L-alanine,,ABAT,5479,Launched
L-alanine,,AGXT,5480,Launched
L-alanine,,AGXT2,10105,Launched
L-alanine,,GPRC6A,9360,Launched
L-alanine,,GPT,10465,Launched
L-alanine,,GPT2,5625,Launched
L-alanine,,KYNU,11212,Launched
L-alanine,,NFS1,5831,Launched
L-alanine,,PHYKPL,29920,Launched
L-alanine,,SLC1A4,65263,Launched
L-alanine,,SLC36A1,11254,Launched
L-alanine,,SLC7A8,6534,Launched
L-arginine,nitric oxide precursor,ARG2,2346,Launched
L-arginine,nitric oxide precursor,ASL,2891,Launched
L-arginine,nitric oxide precursor,ASS1,2897,Launched
L-arginine,nitric oxide precursor,AZIN2,2898,Launched
L-arginine,nitric oxide precursor,GPRC6A,2911,Launched
L-arginine,nitric oxide precursor,NOS2,2912,Launched
L-arginine,nitric oxide precursor,NOS3,2913,Launched
L-arginine,nitric oxide precursor,SLC7A1,2915,Launched
L-arginine,nitric oxide precursor,SLC7A3,2917,Launched
L-arginine,nitric oxide precursor,SLC7A4,2918,Launched
L-asparagine,,ASNS,6897,Phase 3
L-asparagine,,ASRGL1,80222,Phase 3
L-asparagine,,NARS,4128,Phase 3
L-asparagine,,NARS2,4129,Phase 3
L-asparagine,,SLC1A5,1586,Phase 3
L-asparagine,,SLC38A3,2908,Phase 3
L-aspartic-acid,metallic radical formation stimulant,ACY1,2554,Launched
L-aspartic-acid,metallic radical formation stimulant,ACY3,2555,Launched
L-aspartic-acid,metallic radical formation stimulant,ADSS,2556,Launched
L-aspartic-acid,metallic radical formation stimulant,ADSSL1,2557,Launched
L-aspartic-acid,metallic radical formation stimulant,ASNS,2558,Launched
L-aspartic-acid,metallic radical formation stimulant,ASPA,2559,Launched
L-aspartic-acid,metallic radical formation stimulant,ASPH,2560,Launched
L-aspartic-acid,metallic radical formation stimulant,ASRGL1,2561,Launched
L-aspartic-acid,metallic radical formation stimulant,ASS1,2562,Launched
L-aspartic-acid,metallic radical formation stimulant,CAD,2563,Launched
L-aspartic-acid,metallic radical formation stimulant,DARS,2564,Launched
L-aspartic-acid,metallic radical formation stimulant,DARS2,2565,Launched
L-aspartic-acid,metallic radical formation stimulant,GOT1,2566,Launched
L-aspartic-acid,metallic radical formation stimulant,GOT2,2567,Launched
L-aspartic-acid,metallic radical formation stimulant,GRIN1,2568,Launched
L-aspartic-acid,metallic radical formation stimulant,GRIN2A,55879,Launched
L-aspartic-acid,metallic radical formation stimulant,GRIN2B,2741,Launched
L-aspartic-acid,metallic radical formation stimulant,GRIN2C,2743,Launched
L-aspartic-acid,metallic radical formation stimulant,GRIN2D,54207,Launched
L-aspartic-acid,metallic radical formation stimulant,LYZ,338567,Launched
L-aspartic-acid,metallic radical formation stimulant,PAICS,3776,Launched
L-aspartic-acid,metallic radical formation stimulant,RNASE1,3777,Launched
L-aspartic-acid,metallic radical formation stimulant,SLC1A1,51305,Launched
L-aspartic-acid,metallic radical formation stimulant,SLC25A12,43,Launched
L-aspartic-acid,metallic radical formation stimulant,SLC25A13,590,Launched
L-citrulline,nitric oxide stimulant,ASS1,2554,Launched
L-citrulline,nitric oxide stimulant,DDAH1,2555,Launched
L-citrulline,nitric oxide stimulant,DDAH2,2556,Launched
L-citrulline,nitric oxide stimulant,GPRC6A,2557,Launched
L-citrulline,nitric oxide stimulant,NOS1,2558,Launched
L-citrulline,nitric oxide stimulant,NOS2,2559,Launched
L-citrulline,nitric oxide stimulant,NOS3,2569,Launched
L-citrulline,nitric oxide stimulant,OTC,2570,Launched
L-citrulline,nitric oxide stimulant,PADI1,200959,Launched
L-citrulline,nitric oxide stimulant,PADI2,2550,Launched
L-citrulline,nitric oxide stimulant,PADI3,1544,Launched
L-citrulline,nitric oxide stimulant,PADI4,1557,Launched
L-citrulline,nitric oxide stimulant,PADI6,1558,Launched
L-cysteine,,CARS,1571,Launched
L-cysteine,,CARS2,1576,Launched
L-cysteine,,CBS,153,Launched
L-cysteine,,CDO-1,154,Launched
L-cysteine,,CDO1,155,Launched
L-cysteine,,CSAD,1131,Launched
L-cysteine,,CTH,1132,Launched
L-cysteine,,GCLC,2977,Launched
L-cysteine,,GCLM,-,Launched
L-cysteine,,GOT1,2974,Launched
L-cysteine,,GSS,-,Launched
L-cysteine,,MGMT,4881,Launched
L-cysteine,,NFS1,2977,Launched
L-cysteine,,SLC19A3,-,Launched
L-cysteinesulfinic-acid,glutamate receptor agonist,GRM1,2974,Preclinical
L-cysteinesulfinic-acid,glutamate receptor agonist,GRM5,-,Preclinical
L-cysteinesulfinic-acid,glutamate receptor agonist,GSR,5914,Preclinical
L-cysteinesulfinic-acid,glutamate receptor agonist,HMGCS2,5915,Preclinical
L-cysteinesulfinic-acid,glutamate receptor agonist,PAPOLA,5916,Preclinical
L-cysteinesulfinic-acid,glutamate receptor agonist,PRDX2,5742,Preclinical
L-cystine,,CTNS,5743,Launched
L-cystine,,SLC3A1,154,Launched
L-cystine,,SLC7A11,3832,Launched
L-cystine,,SLC7A9,776,Launched
L-glutamic-acid,glutamate receptor agonist,AADAT,778,Launched
L-glutamic-acid,glutamate receptor agonist,AASS,781,Launched
L-glutamic-acid,glutamate receptor agonist,ABAT,83939,Launched
L-glutamic-acid,glutamate receptor agonist,ALDH18A1,9451,Launched
L-glutamic-acid,glutamate receptor agonist,ASNS,476,Launched
L-glutamic-acid,glutamate receptor agonist,BCAT1,134,Launched
L-glutamic-acid,glutamate receptor agonist,BCAT2,135,Launched
L-glutamic-acid,glutamate receptor agonist,CCBL2,136,Launched
L-glutamic-acid,glutamate receptor agonist,DNPEP,140,Launched
L-glutamic-acid,glutamate receptor agonist,EARS2,4760,Launched
L-glutamic-acid,glutamate receptor agonist,ENPEP,3716,Launched
L-glutamic-acid,glutamate receptor agonist,EPRS,7048,Launched
L-glutamic-acid,glutamate receptor agonist,FOLH1,196,Launched
L-glutamic-acid,glutamate receptor agonist,FPGS,5136,Launched
L-glutamic-acid,glutamate receptor agonist,FTCD,1131,Launched
L-glutamic-acid,glutamate receptor agonist,GAD1,1813,Launched
L-glutamic-acid,glutamate receptor agonist,GAD2,7204,Launched
L-glutamic-acid,glutamate receptor agonist,GATB,7852,Launched
L-glutamic-acid,glutamate receptor agonist,GCLC,9097,Launched
L-glutamic-acid,glutamate receptor agonist,GCLM,348980,Launched
L-glutamic-acid,glutamate receptor agonist,GGCX,57657,Launched
L-glutamic-acid,glutamate receptor agonist,GLS,10021,Launched
L-glutamic-acid,glutamate receptor agonist,GLS2,1080,Launched
L-glutamic-acid,glutamate receptor agonist,GLUD1,1139,Launched
L-glutamic-acid,glutamate receptor agonist,GLUD2,5027,Launched
L-glutamic-acid,glutamate receptor agonist,GLUL,3417,Launched
L-glutamic-acid,glutamate receptor agonist,GMPS,64840,Launched
L-glutamic-acid,glutamate receptor agonist,GOT1,203068,Launched
L-glutamic-acid,glutamate receptor agonist,GOT2,3718,Launched
L-glutamic-acid,glutamate receptor agonist,GPT,4986,Launched
L-glutamic-acid,glutamate receptor agonist,GPT2,6531,Launched
L-glutamic-acid,glutamate receptor agonist,GRIA1,390245,Launched
L-glutamic-acid,glutamate receptor agonist,GRIA2,5663,Launched
L-glutamic-acid,glutamate receptor agonist,GRIA3,59340,Launched
L-glutamic-acid,glutamate receptor agonist,GRIA4,84501,Launched
L-glutamic-acid,glutamate receptor agonist,GRID1,53831,Launched
L-glutamic-acid,glutamate receptor agonist,GRID2,3172,Launched
L-glutamic-acid,glutamate receptor agonist,GRIK1,4057,Launched
L-glutamic-acid,glutamate receptor agonist,GRIK2,23643,Launched
L-glutamic-acid,glutamate receptor agonist,GRIK3,5320,Launched
L-glutamic-acid,glutamate receptor agonist,GRIK4,7099,Launched
L-glutamic-acid,glutamate receptor agonist,GRIK5,4129,Launched
L-glutamic-acid,glutamate receptor agonist,GRIN1,329,Launched
L-glutamic-acid,glutamate receptor agonist,GRIN2A,331,Launched
L-glutamic-acid,glutamate receptor agonist,GRIN2B,8694,Launched
L-glutamic-acid,glutamate receptor agonist,GRIN2C,558,Launched
L-glutamic-acid,glutamate receptor agonist,GRIN2D,10461,Launched
L-glutamic-acid,glutamate receptor agonist,GRIN3A,7301,Launched
L-glutamic-acid,glutamate receptor agonist,GRIN3B,83903,Launched
L-glutamic-acid,glutamate receptor agonist,GRM1,25,Launched
L-glutamic-acid,glutamate receptor agonist,GRM2,90,Launched
L-glutamic-acid,glutamate receptor agonist,GRM3,8767,Launched
L-glutamic-acid,glutamate receptor agonist,GRM4,7052,Launched
L-glutamic-acid,glutamate receptor agonist,GRM6,90,Launched
L-glutamic-acid,glutamate receptor agonist,GRM7,657,Launched
L-glutamic-acid,glutamate receptor agonist,GRM8,5915,Launched
L-glutamic-acid,glutamate receptor agonist,LGSN,196,Launched
L-glutamic-acid,glutamate receptor agonist,NADSYN1,1723,Launched
L-glutamic-acid,glutamate receptor agonist,NAGS,2185,Launched
L-glutamic-acid,glutamate receptor agonist,OPLAH,3061,Launched
L-glutamic-acid,glutamate receptor agonist,PFAS,3062,Launched
L-glutamic-acid,glutamate receptor agonist,PGCP,7124,Launched
L-glutamic-acid,glutamate receptor agonist,PSAT1,2324,Launched
L-glutamic-acid,glutamate receptor agonist,SLC1A1,3791,Launched
L-glutamic-acid,glutamate receptor agonist,SLC1A2,781,Launched
L-glutamic-acid,glutamate receptor agonist,SLC1A3,3359,Launched
L-glutamic-acid,glutamate receptor agonist,SLC1A6,116085,Launched
L-glutamic-acid,glutamate receptor agonist,SLC1A7,2322,Launched
L-glutamic-acid,glutamate receptor agonist,SLC25A18,4914,Launched
L-glutamic-acid,glutamate receptor agonist,SLC25A22,1588,Launched
L-glutamic-acid,glutamate receptor agonist,SLC7A11,4137,Launched
L-glutamic-acid,glutamate receptor agonist,TAT,2798,Launched
L-glutamine,,CTPS1,154,Launched
L-glutamine,,GLUL,1135,Launched
L-glutamine,,GPRC6A,4988,Launched
L-glutamine,,PPAT,249,Launched
L-leucine,,BCAT1,3762,Phase 3
L-leucine,,BCAT2,774,Phase 3
L-leucine,,LARS,6323,Phase 3
L-leucine,,LARS2,9900,Phase 3
L-leucine,,LCMT1,1128,Phase 3
L-leucine,,LCMT2,153,Phase 3
L-lysine,serotonin receptor agonist,GPRC6A,154,Phase 2
L-lysine,serotonin receptor agonist,KARS,153,Phase 2
L-lysine,serotonin receptor agonist,SLC7A1,154,Phase 2
L-lysine,serotonin receptor agonist,SLC7A2,155,Phase 2
L-lysine,serotonin receptor agonist,SLC7A3,3269,Phase 2
L-lysine,serotonin receptor agonist,SLC7A4,23620,Phase 2
L-methionine,voltage-gated calcium channel ligand,BHMT,1384,Launched
L-methionine,voltage-gated calcium channel ligand,BHMT2,54677,Launched
L-methionine,voltage-gated calcium channel ligand,METAP2,1384,Launched
L-methionine,voltage-gated calcium channel ligand,MTR,3269,Launched
L-methionine,voltage-gated calcium channel ligand,MTRR,1812,Launched
L-mimosine,dopamine beta hydroxylase inhibitor|eukaryotic translation initiation factor inhibitor,DBH,1813,Preclinical
L-mimosine,dopamine beta hydroxylase inhibitor|eukaryotic translation initiation factor inhibitor,EIF5A,1814,Preclinical
L-monomethylarginine,nitric oxide synthase inhibitor,NOS1,1815,Phase 3
L-monomethylarginine,nitric oxide synthase inhibitor,NOS2,1816,Phase 3
L-NAME,nitric oxide synthase inhibitor,NOS3,4935,Phase 2/Phase 3
L-NIL,nitric oxide synthase inhibitor,NOS1,7153,Preclinical
L-NIL,nitric oxide synthase inhibitor,NOS2,4986,Preclinical
L-NIL,nitric oxide synthase inhibitor,NOS3,8989,Preclinical
L-proline,glutamate receptor agonist,EPRS,79054,Launched
L-proline,glutamate receptor agonist,L3HYPDH,162514,Launched
L-proline,glutamate receptor agonist,P3H1,148,Launched
L-proline,glutamate receptor agonist,P3H2,147,Launched
L-proline,glutamate receptor agonist,P3H3,146,Launched
L-proline,glutamate receptor agonist,P4HA1,150,Launched
L-proline,glutamate receptor agonist,P4HA2,151,Launched
L-proline,glutamate receptor agonist,PARS2,152,Launched
L-proline,glutamate receptor agonist,PPIA,1128,Launched
L-proline,glutamate receptor agonist,PPIB,1129,Launched
L-proline,glutamate receptor agonist,PPIC,1131,Launched
L-proline,glutamate receptor agonist,PPIF,1132,Launched
L-proline,glutamate receptor agonist,PPIG,1133,Launched
L-proline,glutamate receptor agonist,PPIH,1812,Launched
L-proline,glutamate receptor agonist,PRODH,1813,Launched
L-proline,glutamate receptor agonist,PROSC,1814,Launched
L-proline,glutamate receptor agonist,PYCR1,1815,Launched
L-proline,glutamate receptor agonist,PYCR2,1816,Launched
L-proline,glutamate receptor agonist,PYCRL,3269,Launched
L-proline,glutamate receptor agonist,SLC6A14,3356,Launched
L-proline,glutamate receptor agonist,SLC6A7,3358,Launched
L-quisqualic-acid,glutamate receptor agonist,FOLH1,3269,Preclinical
L-quisqualic-acid,glutamate receptor agonist,GRIA2,148,Preclinical
L-quisqualic-acid,glutamate receptor agonist,GRIK1,147,Preclinical
L-quisqualic-acid,glutamate receptor agonist,GRIK2,146,Preclinical
L-quisqualic-acid,glutamate receptor agonist,GRM1,150,Preclinical
L-quisqualic-acid,glutamate receptor agonist,GRM2,151,Preclinical
L-quisqualic-acid,glutamate receptor agonist,GRM3,152,Preclinical
L-quisqualic-acid,glutamate receptor agonist,GRM5,6530,Preclinical
L-quisqualic-acid,glutamate receptor agonist,GRM7,5241,Preclinical
L-quisqualic-acid,glutamate receptor agonist,GRM8,3767,Preclinical
L-threonine,,TARS,3764,Phase 2
L-threonine,,TARS2,5139,Phase 2
L-threonine,,THNSL1,3061,Phase 2
L-152804,neuropeptide receptor antagonist,NPY5R,3062,Preclinical
L-161982,prostanoid receptor antagonist,PTGER4,2911,Preclinical
L-165041,PPAR receptor agonist,PPARD,2166,Preclinical
L-168049,glucagon receptor antagonist,GCGR,7442,Preclinical
L-365260,CCK receptor antagonist,CCKAR,3065,Phase 2
L-365260,CCK receptor antagonist,CCKBR,83933,Phase 2
L-365260,CCK receptor antagonist,KCNQ1,79885,Phase 2
L-368899,oxytocin receptor antagonist,AVPR1A,3066,Phase 1
L-368899,oxytocin receptor antagonist,AVPR2,8841,Phase 1
L-368899,oxytocin receptor antagonist,OXTR,9759,Phase 1
"L-655,708",GABA receptor inverse agonist,GABRA1,10014,Preclinical
"L-655,708",GABA receptor inverse agonist,GABRA2,10013,Preclinical
"L-655,708",GABA receptor inverse agonist,GABRA3,51564,Preclinical
"L-655,708",GABA receptor inverse agonist,GABRA5,55869,Preclinical
"L-655,708",GABA receptor inverse agonist,GABRG2,9734,Preclinical
L-655240,thromboxane receptor antagonist,PTGES,4193,Phase 1
L-689560,glutamate receptor antagonist,GRIN1,729230,Preclinical
L-689560,glutamate receptor antagonist,GRIN2A,1813,Preclinical
L-689560,glutamate receptor antagonist,GRIN2B,4233,Preclinical
L-689560,glutamate receptor antagonist,GRIN2C,2912,Preclinical
L-689560,glutamate receptor antagonist,GRIN2D,5164,Preclinical
L-690330,inositol monophosphatase inhibitor,IMPA1,2166,Preclinical
L-693403,sigma receptor agonist|sigma receptor antagonist,DRD2,5027,Preclinical
L-693403,sigma receptor agonist|sigma receptor antagonist,SIGMAR1,124274,Preclinical
L-694247,serotonin receptor agonist,HTR1A,6790,Preclinical
L-694247,serotonin receptor agonist,HTR1B,9212,Preclinical
L-694247,serotonin receptor agonist,HTR1D,983,Preclinical
L-701252,glutamate receptor antagonist,GRIN1,1017,Preclinical
L-701324,glutamate receptor antagonist,GRIN1,59340,Preclinical
L-701324,glutamate receptor antagonist,GRIN2A,23476,Preclinical
L-701324,glutamate receptor antagonist,GRIN2B,676,Preclinical
L-701324,glutamate receptor antagonist,GRIN2C,4987,Preclinical
L-701324,glutamate receptor antagonist,GRIN2D,27334,Preclinical
"L-732,138",tachykinin antagonist,TACR1,9294,Preclinical
"L-732,138",tachykinin antagonist,TACR2,3586,Preclinical
L-733060,tachykinin antagonist,TACR1,3553,Preclinical
L-741742,dopamine receptor antagonist,DRD3,3569,Preclinical
L-741742,dopamine receptor antagonist,DRD4,7124,Preclinical
L-741742,dopamine receptor antagonist,SCN1A,1269,Preclinical
L-741742,dopamine receptor antagonist,SCN3A,8658,Preclinical
L-745870,dopamine receptor antagonist,DRD1,80351,Preclinical
L-745870,dopamine receptor antagonist,DRD2,11343,Preclinical
L-745870,dopamine receptor antagonist,DRD3,324,Preclinical
L-745870,dopamine receptor antagonist,DRD4,8312,Preclinical
L-745870,dopamine receptor antagonist,HTR1A,2932,Preclinical
L-745870,dopamine receptor antagonist,HTR2A,8658,Preclinical
L-745870,dopamine receptor antagonist,HTR6,80351,Preclinical
L-745870,dopamine receptor antagonist,HTR7,1432,Preclinical
L-755507,adrenergic receptor agonist,ADRB1,11343,Preclinical
L-755507,adrenergic receptor agonist,ADRB2,2166,Preclinical
L-755507,adrenergic receptor agonist,ADRB3,11343,Preclinical
L-760735,tachykinin antagonist,TACR1,3845,Preclinical
L-778123,farnesyltransferase inhibitor,FNTA,476,Phase 1
L-778123,farnesyltransferase inhibitor,FNTB,3832,Phase 1
L-778123,farnesyltransferase inhibitor,PGGT1B,231,Phase 1
L-798106,prostanoid receptor antagonist,PTGER3,247,Preclinical
L-838417,GABA receptor partial agonist,GABRA1,240,Preclinical
L-838417,GABA receptor partial agonist,GABRA2,367,Preclinical
L-838417,GABA receptor partial agonist,GABRA3,1545,Preclinical
L-838417,GABA receptor partial agonist,GABRA5,2739,Preclinical
labetalol,adrenergic receptor antagonist,ADRA1D,3292,Launched
labetalol,adrenergic receptor antagonist,ADRB1,133688,Launched
labetalol,adrenergic receptor antagonist,ADRB2,2890,Launched
lacidipine,calcium channel blocker,CACNA1C,2897,Launched
lafutidine,histamine receptor antagonist,HRH2,2898,Launched
lamotrigine,serotonin receptor antagonist|sodium channel blocker,SCN10A,2899,Launched
lamotrigine,serotonin receptor antagonist|sodium channel blocker,SCN11A,2900,Launched
lamotrigine,serotonin receptor antagonist|sodium channel blocker,SCN1A,2901,Launched
lamotrigine,serotonin receptor antagonist|sodium channel blocker,SCN2A,7150,Launched
lamotrigine,serotonin receptor antagonist|sodium channel blocker,SCN3A,2316,Launched
lamotrigine,serotonin receptor antagonist|sodium channel blocker,SCN4A,6546,Launched
lamotrigine,serotonin receptor antagonist|sodium channel blocker,SCN5A,7222,Launched
lamotrigine,serotonin receptor antagonist|sodium channel blocker,SCN7A,7224,Launched
lamotrigine,serotonin receptor antagonist|sodium channel blocker,SCN8A,7225,Launched
lamotrigine,serotonin receptor antagonist|sodium channel blocker,SCN9A,6714,Launched
landiolol,adrenergic receptor antagonist,ADRB1,4311,Launched
lansoprazole,ATPase inhibitor,ATP4A,31,Launched
lansoprazole,ATPase inhibitor,ATP4B,32,Launched
lapatinib,EGFR inhibitor,EGFR,9475,Launched
lapatinib,EGFR inhibitor,ERBB2,891,Launched
laquinimod,immunosuppressant,CXCL2,983,Phase 3
laropiprant,prostanoid receptor antagonist,PTGDR,1020,Launched
laropiprant,prostanoid receptor antagonist,PTGDR2,2932,Launched
laropiprant,prostanoid receptor antagonist,PTGER1,148,Launched
laropiprant,prostanoid receptor antagonist,PTGER2,147,Launched
laropiprant,prostanoid receptor antagonist,PTGER3,146,Launched
laropiprant,prostanoid receptor antagonist,PTGFR,1812,Launched
laropiprant,prostanoid receptor antagonist,PTGIR,1816,Launched
laropiprant,prostanoid receptor antagonist,TBXA2R,3350,Launched
larotrectinib,tropomyosin receptor kinase inhibitor,NTRK1,3351,Launched
larotrectinib,tropomyosin receptor kinase inhibitor,NTRK2,3352,Launched
larotrectinib,tropomyosin receptor kinase inhibitor,NTRK3,3356,Launched
lasofoxifene,selective estrogen receptor modulator (SERM),ESR1,3357,Launched
lasofoxifene,selective estrogen receptor modulator (SERM),ESR2,3358,Launched
latanoprost,prostanoid receptor agonist,PTGFR,3361,Launched
latrepirdine,glutamate receptor antagonist,HRH1,3363,Phase 3
latrepirdine,glutamate receptor antagonist,HTR6,6570,Phase 3
latrunculin-B,actin polymerization inhibitor,ACTA1,6571,Phase 1
latrunculin-B,actin polymerization inhibitor,MKL1,3744,Phase 1
latrunculin-B,actin polymerization inhibitor,SPIRE2,5742,Phase 1
lauric-acid,bacterial permeability inducer,GPR84,5743,Phase 3
lauric-acid,bacterial permeability inducer,HNF4A,160728,Phase 3
lauric-acid,bacterial permeability inducer,LTF,5742,Phase 3
lauric-acid,bacterial permeability inducer,LY96,5743,Phase 3
lauric-acid,bacterial permeability inducer,PLA2G2A,3269,Phase 3
lauric-acid,bacterial permeability inducer,TLR4,6403,Phase 3
lazabemide,monoamine oxidase inhibitor,MAOB,673,Phase 3
LCL-161,XIAP inhibitor,BIRC2,2322,Phase 2
LCL-161,XIAP inhibitor,XIAP,3815,Phase 2
LCQ908,diacylglycerol O acyltransferase inhibitor,DGAT1,5159,Phase 3
LDC1267,protein tyrosine kinase inhibitor,AXL,1195,Preclinical
LDC1267,protein tyrosine kinase inhibitor,MERTK,1198,Preclinical
LDC1267,protein tyrosine kinase inhibitor,TYRO3,1859,Preclinical
LDN-209929,haspin kinase inhibitor,GSG2,3795,Preclinical
LDN-212854,bone morphogenic protein inhibitor,ABL1,10460,Preclinical
LDN-212854,bone morphogenic protein inhibitor,ACVR1,1902,Preclinical
LDN-212854,bone morphogenic protein inhibitor,RIPK2,23566,Preclinical
LDN-27219,tissue transglutaminase inhibitor,TGM2,1436,Preclinical
LDN193189,bone morphogenic protein inhibitor,ACVR1,3791,Preclinical
LDN193189,bone morphogenic protein inhibitor,BMPR1A,3815,Preclinical
LE-135,retinoid receptor agonist,RARB,5159,Preclinical
leflunomide,dihydroorotate dehydrogenase inhibitor|PDGFR tyrosine kinase receptor inhibitor,AHR,3791,Launched
leflunomide,dihydroorotate dehydrogenase inhibitor|PDGFR tyrosine kinase receptor inhibitor,DHODH,11253,Launched
leflunomide,dihydroorotate dehydrogenase inhibitor|PDGFR tyrosine kinase receptor inhibitor,PTK2B,4124,Launched
lemborexant,orexin receptor antagonist,HCRTR1,4018,Launched
lemborexant,orexin receptor antagonist,HCRTR2,1407,Launched
lenalidomide,anticancer agent,TNF,1408,Launched
lenvatinib,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FLT4,11343,Launched
lenvatinib,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KDR,207,Launched
lercanidipine,calcium channel blocker,CACNA2D1,815,Launched
lerisetron,serotonin receptor antagonist,HTR3A,1111,Phase 3
lesinurad,uric acid diuretic,SLC22A12,3932,Launched
lestaurtinib,FLT3 inhibitor|growth factor receptor inhibitor|JAK inhibitor,FLT3,5594,Phase 3
lestaurtinib,FLT3 inhibitor|growth factor receptor inhibitor|JAK inhibitor,NTRK1,5600,Phase 3
letrozole,aromatase inhibitor,CYP19A1,6300,Launched
leucomethylene-blue,nitric oxide production inhibitor|tau aggregation inhibitor,MAPT,1432,Phase 3
leuprolide,gonadotropin releasing factor hormone receptor agonist,GNRHR,5599,Launched
levalbuterol,adrenergic receptor agonist,ADRB2,5027,Launched
levallorphan,opioid receptor antagonist,CHRNA2,5578,Launched
levallorphan,opioid receptor antagonist,OPRM1,6093,Launched
levamisole,acetylcholine receptor agonist,ALPL,6198,Withdrawn
levcromakalim,potassium channel activator,KCNJ5,6446,Phase 3
levetiracetam,calcium channel blocker,CACNA1B,815,Launched
levetiracetam,calcium channel blocker,SCN1A,5243,Launched
levetiracetam,calcium channel blocker,SV2A,4363,Launched
levo-phencynonate,acetylcholine receptor antagonist,CHRM1,7514,Launched
levobetaxolol,adrenergic receptor antagonist,ADRB1,7514,Launched
levobetaxolol,adrenergic receptor antagonist,ADRB2,238,Launched
levobunolol,adrenergic receptor antagonist,ADRB1,2321,Launched
levobunolol,adrenergic receptor antagonist,ADRB2,2324,Launched
levobunolol,adrenergic receptor antagonist,ADRB3,3791,Launched
levocabastine,histamine receptor antagonist,HRH1,9429,Launched
levocabastine,histamine receptor antagonist,NTSR2,2475,Launched
levocarnitine,,CRAT,472,Launched
levocarnitine,,CROT,5591,Launched
levocarnitine-propionate,carnitine palmitoyltransferase inhibitor,CRAT,472,Launched
levocetirizine,histamine receptor antagonist,HRH1,952,Launched
levodopa,dopamine precursor,DRD1,25,Launched
levodopa,dopamine precursor,DRD2,6790,Launched
levodopa,dopamine precursor,DRD3,9212,Launched
levodopa,dopamine precursor,DRD4,2322,Launched
levodopa,dopamine precursor,DRD5,134,Launched
levodopa,dopamine precursor,GPR143,135,Launched
levofloxacin,bacterial DNA gyrase inhibitor,TOP2A,136,Launched
levomenthol,,OPRK1,140,Launched
levomenthol,,TRPA1,6714,Launched
levomenthol,,TRPM8,2859,Launched
levomenthol,,TRPV3,2902,Launched
levomepromazine,dopamine receptor antagonist,ADRA1A,2903,Launched
levomepromazine,dopamine receptor antagonist,ADRA1B,2904,Launched
levomepromazine,dopamine receptor antagonist,ADRA1D,22943,Launched
levomepromazine,dopamine receptor antagonist,ADRA2A,649,Launched
levomepromazine,dopamine receptor antagonist,ADRA2B,56848,Launched
levomepromazine,dopamine receptor antagonist,ADRA2C,-,Launched
levomepromazine,dopamine receptor antagonist,CHRM1,57505,Launched
levomepromazine,dopamine receptor antagonist,CHRM2,18,Launched
levomepromazine,dopamine receptor antagonist,CHRM3,189,Launched
levomepromazine,dopamine receptor antagonist,CHRM4,64902,Launched
levomepromazine,dopamine receptor antagonist,CHRM5,222545,Launched
levomepromazine,dopamine receptor antagonist,DRD1,2875,Launched
levomepromazine,dopamine receptor antagonist,DRD2,84706,Launched
levomepromazine,dopamine receptor antagonist,DRD3,8942,Launched
levomepromazine,dopamine receptor antagonist,DRD4,9054,Launched
levomepromazine,dopamine receptor antagonist,DRD5,85007,Launched
levomepromazine,dopamine receptor antagonist,HRH1,6509,Launched
levomepromazine,dopamine receptor antagonist,HTR2A,206358,Launched
levomepromazine,dopamine receptor antagonist,HTR2C,23428,Launched
levomequitazine,histamine receptor antagonist,HRH1,384,Phase 2
levonordefrin,vasodilator,ADRA1A,435,Launched
levonordefrin,vasodilator,ADRA1B,445,Launched
levonordefrin,vasodilator,ADRA1D,113451,Launched
levonordefrin,vasodilator,ADRA2A,222545,Launched
levonordefrin,vasodilator,ADRA2B,4843,Launched
levonordefrin,vasodilator,ADRA2C,4846,Launched
levonordefrin,vasodilator,SLC6A2,6541,Launched
levonorgestrel,estrogen receptor agonist|glucocorticoid receptor antagonist|progesterone receptor agonist|progesterone receptor antagonist,PGR,84889,Launched
levosimendan,calcium sensitizer,KCNJ11,6545,Launched
levosimendan,calcium sensitizer,KCNJ8,440,Launched
levosimendan,calcium sensitizer,PDE3A,80150,Launched
levosimendan,calcium sensitizer,TNNC1,759,Launched
levosulpiride,dopamine receptor antagonist,CA1,771,Launched
levosulpiride,dopamine receptor antagonist,CA12,23632,Launched
levosulpiride,dopamine receptor antagonist,CA7,760,Launched
levosulpiride,dopamine receptor antagonist,DRD2,762,Launched
levosulpiride,dopamine receptor antagonist,DRD3,766,Launched
levothyroxine,thyroid hormone stimulant,THRA,7173,Launched
levothyroxine,thyroid hormone stimulant,THRB,10988,Launched
LFM-A13,Bruton's tyrosine kinase (BTK) inhibitor,BTK,1636,Preclinical
LGK-974,porcupine inhibitor,PORCN,759,Phase 2
LH846,casein kinase inhibitor,CSNK1D,1719,Preclinical
liarozole,cytochrome P450 inhibitor,CYP19A1,148,Phase 2/Phase 3
liarozole,cytochrome P450 inhibitor,CYP26A1,147,Phase 2/Phase 3
licarbazepine,voltage-gated sodium channel blocker,SCN5A,146,Phase 3
licochalcone-A,topoisomerase inhibitor,PTPN1,1543,Phase 3
licofelone,cyclooxygenase inhibitor|lipoxygenase inhibitor,ALOX5,1544,Phase 3
licofelone,cyclooxygenase inhibitor|lipoxygenase inhibitor,PLA2G2E,1553,Phase 3
licofelone,cyclooxygenase inhibitor|lipoxygenase inhibitor,PTGS2,1548,Phase 3
lidocaine,histamine receptor agonist,EGFR,1576,Launched
lidocaine,histamine receptor agonist,SCN10A,328,Launched
lidocaine,histamine receptor agonist,SCN5A,27032,Launched
lidocaine,histamine receptor agonist,SCN9A,-,Launched
lidoflazine,calcium channel blocker,SCN1A,2554,Launched
lidoflazine,calcium channel blocker,SCN3A,2555,Launched
lidoflazine,calcium channel blocker,SLC29A1,2556,Launched
ligustilide,tumor necrosis factor production inhibitor,TNF,2557,Preclinical
limaprost-alfadex,prostanoid receptor agonist,PTGER1,2558,Launched
LIMKi-3,LIM kinase inhibitor,LIMK1,2559,Preclinical
linaclotide,guanylate cyclase activator,GUCY2C,2560,Launched
linagliptin,dipeptidyl peptidase inhibitor,DPP4,2561,Launched
lindane,,GABRB1,2562,Launched
lindane,,GLRA1,2563,Launched
lindane,,GLRA2,2564,Launched
lindane,,GLRA3,2565,Launched
lindane,,GLRB,2566,Launched
linezolid,bacterial 50S ribosomal subunit inhibitor,MAOA,2567,Launched
linezolid,bacterial 50S ribosomal subunit inhibitor,MAOB,2568,Launched
linifanib,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,CSF1,55879,Phase 3
linifanib,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,CSF1R,2741,Phase 3
linifanib,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FLT1,2743,Phase 3
linifanib,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FLT3,2890,Phase 3
linifanib,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FLT4,3736,Phase 3
linifanib,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KDR,4535,Phase 3
linifanib,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KIT,1128,Phase 3
linifanib,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,PDGFRB,1129,Phase 3
linifanib,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,RET,1131,Phase 3
linifanib,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,TEK,8913,Phase 3
linoleic-acid,oxidative stress inducer,FABP4,8912,Phase 3
linoleic-acid,oxidative stress inducer,FFAR1,8911,Phase 3
linoleic-acid,oxidative stress inducer,FFAR4,6557,Phase 3
linoleic-acid,oxidative stress inducer,HNF4A,6559,Phase 3
linoleic-acid,oxidative stress inducer,KCNB1,2209,Phase 3
linoleic-acid,oxidative stress inducer,PPARG,2235,Phase 3
linoleic-acid,oxidative stress inducer,TRPM8,1128,Phase 3
linopirdine,potassium channel blocker,KCNQ2,150,Phase 3
linopirdine,potassium channel blocker,KCNQ3,151,Phase 3
linopirdine,potassium channel blocker,KCNQ4,152,Phase 3
linopirdine,potassium channel blocker,KCNQ5,1644,Phase 3
linsitinib,IGF-1 inhibitor,IGF1R,43,Phase 3
linsitinib,IGF-1 inhibitor,INSR,1812,Phase 3
linsitinib,IGF-1 inhibitor,INSRR,3354,Phase 3
liothyronine,thyroid hormone stimulant,THRA,3355,Launched
liothyronine,thyroid hormone stimulant,THRB,3356,Launched
liraglutide,GLP receptor agonist,GLP1R,3357,Launched
lisinopril,angiotensin converting enzyme inhibitor,ACE,3358,Launched
lisinopril,angiotensin converting enzyme inhibitor,ACE2,1139,Launched
lisuride,dopamine receptor agonist,ADRA1A,4985,Launched
lisuride,dopamine receptor agonist,ADRA2A,4986,Launched
lisuride,dopamine receptor agonist,ADRA2B,4988,Launched
lisuride,dopamine receptor agonist,ADRA2C,2908,Launched
lisuride,dopamine receptor agonist,DRD1,2908,Launched
lisuride,dopamine receptor agonist,DRD2,3351,Launched
lisuride,dopamine receptor agonist,DRD3,3352,Launched
lisuride,dopamine receptor agonist,DRD4,3354,Launched
lisuride,dopamine receptor agonist,DRD5,3355,Launched
lisuride,dopamine receptor agonist,HTR1A,3356,Launched
lisuride,dopamine receptor agonist,HTR1B,3357,Launched
lisuride,dopamine receptor agonist,HTR1D,3358,Launched
lisuride,dopamine receptor agonist,HTR2A,3361,Launched
lisuride,dopamine receptor agonist,HTR2B,3362,Launched
lisuride,dopamine receptor agonist,HTR2C,3363,Launched
lisuride,dopamine receptor agonist,HTR6,7054,Launched
lithium-acetoacetate,,FAH,3350,Preclinical
lithocholic-acid,FXR antagonist|vitamin D receptor agonist,GPBAR1,3351,Preclinical
lithocholic-acid,FXR antagonist|vitamin D receptor agonist,NR1H4,3352,Preclinical
lithocholic-acid,FXR antagonist|vitamin D receptor agonist,NR1I2,3354,Preclinical
lithocholic-acid,FXR antagonist|vitamin D receptor agonist,VDR,3355,Preclinical
litronesib,kinesin-like spindle protein inhibitor,KIF11,3356,Phase 2
lixivaptan,vasopressin receptor antagonist,AVPR2,3357,Phase 3
LM-22A4,tropomyosin receptor kinase inhibitor,NTRK2,3358,Preclinical
LMI070,survival motor neuron protein modulator,SMN1,3361,Phase 1/Phase 2
LMK-235,HDAC inhibitor,HDAC4,3362,Preclinical
LMK-235,HDAC inhibitor,HDAC5,3363,Preclinical
LM11A-31,neurotrophic agent,NGFR,1133,Phase 1
lobeline,acetylcholine receptor antagonist,CHRNA10,1128,Launched
lobeline,acetylcholine receptor antagonist,CHRNA9,1813,Launched
lobeline,acetylcholine receptor antagonist,SLC18A2,3359,Launched
lofepramine,norepinephrine reuptake inhibitor|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),HTR1A,9177,Launched
lofepramine,norepinephrine reuptake inhibitor|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),SLC6A2,3360,Launched
lofepramine,norepinephrine reuptake inhibitor|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),SLC6A4,1129,Launched
lomeguatrib,O6-alkylguanine-DNA alkyltransferase inhibitor,MGMT,4255,Phase 2
lomerizine,calcium channel blocker,CACNA1B,774,Launched
lomerizine,calcium channel blocker,SCN5A,6331,Launched
lometrexol,glycinamide ribonucleotide formyltransferase inhibitor,GART,2618,Phase 2
lomitapide,microsomal trigylceride transfer protein inhibitor,MTTP,4547,Launched
lonafarnib,farnesyltransferase inhibitor,FNTA,2339,Phase 3
lonafarnib,farnesyltransferase inhibitor,HRAS,3265,Phase 3
lonafarnib,farnesyltransferase inhibitor,KRAS,3845,Phase 3
lonafarnib,farnesyltransferase inhibitor,NRAS,4893,Phase 3
lonidamine,glucokinase inhibitor,GCK,2645,Launched
loperamide,opioid receptor agonist,CACNA1A,773,Launched
loperamide,opioid receptor agonist,CALM1,801,Launched
loperamide,opioid receptor agonist,OPRD1,4985,Launched
loperamide,opioid receptor agonist,OPRK1,4986,Launched
loperamide,opioid receptor agonist,OPRM1,4988,Launched
loperamide,opioid receptor agonist,POMC,5443,Launched
loratadine,histamine receptor antagonist,HRH1,3269,Launched
loreclezole,benzodiazepine receptor agonist,GABRB2,2561,Phase 2
loreclezole,benzodiazepine receptor agonist,GABRB3,2562,Phase 2
lorediplon,GABA receptor modulator,GABRA1,2554,Phase 2
lorglumide,CCK receptor antagonist,CCKAR,886,Phase 1
lorglumide,CCK receptor antagonist,CCKBR,887,Phase 1
lorlatinib,ALK tyrosine kinase receptor inhibitor,ALK,238,Launched
lornoxicam,cyclooxygenase inhibitor,PTGS1,5742,Launched
lornoxicam,cyclooxygenase inhibitor,PTGS2,5743,Launched
losartan,angiotensin receptor antagonist,AGTR1,185,Launched
losmapimod,p38 MAPK inhibitor,MAPK14,1432,Phase 3
loteprednol,glucocorticoid receptor agonist|phospholipase inhibitor,NR3C1,2908,Launched
lovastatin,HMGCR inhibitor,HDAC2,3066,Launched
lovastatin,HMGCR inhibitor,HMGCR,3156,Launched
lovastatin,HMGCR inhibitor,ITGAL,3683,Launched
lovastatin,HMGCR inhibitor,NR1I2,8856,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A,148,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1B,147,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,ADRA2A,150,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,ADRA2B,151,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,ADRA2C,152,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,ADRB1,153,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,CHRM1,1128,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,CHRM2,1129,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,CHRM3,1131,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,CHRM4,1132,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,CHRM5,1133,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,DRD1,1812,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,DRD2,1813,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,DRD3,1814,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,DRD4,1815,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,DRD5,1816,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,HRH1,3269,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,HRH2,3274,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,HRH4,59340,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1A,3350,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1B,3351,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1D,3352,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1E,3354,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR2A,3356,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR2C,3358,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR3A,3359,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR5A,3361,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR6,3362,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR7,3363,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,SLC6A2,6530,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,SLC6A3,6531,Launched
loxapine,dopamine receptor antagonist|serotonin receptor antagonist,SLC6A4,6532,Launched
loxistatin-acid,cysteine peptidase inhibitor,CTSB,1508,Preclinical
loxoprofen,cyclooxygenase inhibitor|prostanoid receptor antagonist,PTGS2,5743,Launched
LPA2-antagonist-1,lysophosphatidic acid receptor antagonist,LPAR2,9170,Preclinical
LRRK2-IN-1,leucine rich repeat kinase inhibitor,LRRK2,120892,Preclinical
LSN-2463359,glutamate receptor positive allosteric modulator,GRM5,2915,Preclinical
LTB4,leukocyte activator,LTB4R,1241,Phase 2
LTB4,leukocyte activator,LTB4R2,56413,Phase 2
Lu-AA-47070,adenosine receptor antagonist,ADORA2A,135,Phase 2
lubiprostone,chloride channel activator,CLCN2,1181,Launched
lucanthone,endonuclease inhibitor,APEX1,328,Phase 2
lucanthone,endonuclease inhibitor,TOP1,7150,Phase 2
lucanthone,endonuclease inhibitor,TOP2A,7153,Phase 2
lucitanib,FGFR inhibitor|VEGFR inhibitor,FGFR1,2260,Phase 2
lucitanib,FGFR inhibitor|VEGFR inhibitor,FLT1,2321,Phase 2
lucitanib,FGFR inhibitor|VEGFR inhibitor,KDR,3791,Phase 2
lucitanib,FGFR inhibitor|VEGFR inhibitor,KIT,3815,Phase 2
lucitanib,FGFR inhibitor|VEGFR inhibitor,PDGFRA,5156,Phase 2
lucitanib,FGFR inhibitor|VEGFR inhibitor,PDGFRB,5159,Phase 2
lucitanib,FGFR inhibitor|VEGFR inhibitor,RET,5979,Phase 2
LUF-5834,adenosine receptor agonist,ADORA2A,135,Preclinical
LUF-5834,adenosine receptor agonist,ADORA2B,136,Preclinical
lumacaftor,CFTR channel agonist,CFTR,1080,Launched
lumateperone,dopamine receptor modulator|serotonin receptor antagonist,DRD2,1813,Launched
lumateperone,dopamine receptor modulator|serotonin receptor antagonist,HTR2A,3356,Launched
lumefantrine,antimalarial agent,ATP1A1,476,Launched
lumiracoxib,cyclooxygenase inhibitor,PTGS1,5742,Withdrawn
lumiracoxib,cyclooxygenase inhibitor,PTGS2,5743,Withdrawn
lupanine,sodium channel blocker,INS,3630,Phase 1
lurasidone,dopamine receptor antagonist|serotonin receptor antagonist,ADRA2A,150,Launched
lurasidone,dopamine receptor antagonist|serotonin receptor antagonist,ADRA2C,152,Launched
lurasidone,dopamine receptor antagonist|serotonin receptor antagonist,DRD2,1813,Launched
lurasidone,dopamine receptor antagonist|serotonin receptor antagonist,HTR1A,3350,Launched
lurasidone,dopamine receptor antagonist|serotonin receptor antagonist,HTR2A,3356,Launched
lurasidone,dopamine receptor antagonist|serotonin receptor antagonist,HTR7,3363,Launched
luteolin,glucosidase inhibitor,TOP1,7150,Phase 2
luzindole,melatonin receptor antagonist,MTNR1A,4543,Preclinical
luzindole,melatonin receptor antagonist,MTNR1B,7134,Preclinical
LXR-623,LXR agonist,AR,759,Phase 1
LXR-623,LXR agonist,NR1H2,771,Phase 1
LXR-623,LXR agonist,NR1H3,766,Phase 1
LXR-623,LXR agonist,NR1I2,1813,Phase 1
LXR-623,LXR agonist,NR3C1,1814,Phase 1
LX1031,tryptophan hydroxylase inhibitor,TPH1,7067,Phase 2
LX7101,LIM kinase inhibitor|rho associated kinase inhibitor,LIMK2,7068,Phase 1/Phase 2
LX7101,LIM kinase inhibitor|rho associated kinase inhibitor,ROCK1,695,Phase 1/Phase 2
LX7101,LIM kinase inhibitor|rho associated kinase inhibitor,ROCK2,64840,Phase 1/Phase 2
lylamine,cannabinoid receptor agonist,CNR1,1453,Preclinical
lypressin,vasopressin receptor agonist,AVPR1A,1588,Launched
lypressin,vasopressin receptor agonist,AVPR1B,1592,Launched
lypressin,vasopressin receptor agonist,AVPR2,6331,Launched
LY2090314,glycogen synthase kinase inhibitor,GSK3B,5770,Phase 2
LY2109761,TGF beta receptor inhibitor,TGFBR1,240,Preclinical
LY2109761,TGF beta receptor inhibitor,TGFBR2,30814,Preclinical
LY2140023,glutamate receptor agonist,GRM3,5743,Phase 3
LY215490,glutamate receptor antagonist,GRIA1,1956,Phase 1
LY215490,glutamate receptor antagonist,GRIA2,6336,Phase 1
LY215490,glutamate receptor antagonist,GRIA3,6331,Phase 1
LY215490,glutamate receptor antagonist,GRIA4,6335,Phase 1
LY215490,glutamate receptor antagonist,GRIK1,6323,Phase 1
LY2157299,TGF beta receptor inhibitor,TGFBR1,6328,Phase 2/Phase 3
LY2183240,FAAH inhibitor|FAAH reuptake inhibitor,FAAH,2030,Preclinical
LY2228820,p38 MAPK inhibitor,MAPK14,7124,Phase 2
LY223982,leukotriene receptor antagonist,LTB4R,5731,Phase 2
LY225910,CCK receptor antagonist,CCKBR,3984,Preclinical
LY2365109,glycine transporter inhibitor,SLC6A9,2984,Preclinical
LY2452473,androgen receptor modulator,AR,1803,Phase 2
LY255283,leukotriene receptor antagonist,LTB4R,2560,Preclinical
LY255283,leukotriene receptor antagonist,LTB4R2,2741,Preclinical
LY2584702,ribosomal protein inhibitor,RPS6KB1,2742,Phase 1
LY2603618,CHK inhibitor,CHEK1,8001,Phase 2
LY2606368,CHK inhibitor,CHEK1,2743,Phase 2
LY2608204,glucokinase activator,GCK,4128,Phase 2
LY266097,serotonin receptor antagonist,HTR2B,4129,Preclinical
LY2784544,JAK inhibitor,JAK2,1435,Phase 2
LY2784544,JAK inhibitor,JAK3,1436,Phase 2
LY2801653,MET inhibitor,MET,2321,Phase 2
LY2811376,beta-secretase inhibitor,BACE1,2322,Phase 1
LY2857785,CDK inhibitor,CDK9,2324,Preclinical
LY2874455,FGFR antagonist,FGFR1,3791,Phase 1
LY2874455,FGFR antagonist,FGFR2,3815,Phase 1
LY2874455,FGFR antagonist,FGFR3,5159,Phase 1
LY2874455,FGFR antagonist,FGFR4,5979,Phase 1
LY2874455,FGFR antagonist,KDR,7010,Phase 1
LY288513,CCK receptor antagonist,CCKBR,2167,Preclinical
LY2886721,beta-secretase inhibitor,BACE1,2864,Phase 1/Phase 2
LY294002,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,AKT1,338557,Preclinical
LY294002,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,CHEK1,3172,Preclinical
LY294002,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,GSK3B,3745,Preclinical
LY294002,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,LCK,5468,Preclinical
LY294002,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,MAPK1,79054,Preclinical
LY294002,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,MAPK11,3785,Preclinical
LY294002,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,MAPK12,3786,Preclinical
LY294002,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,MAPK14,9132,Preclinical
LY294002,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,MAPK8,56479,Preclinical
LY294002,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,MTOR,3480,Preclinical
LY294002,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,PIK3CA,3643,Preclinical
LY294002,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,PIK3CB,3645,Preclinical
LY294002,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,PIK3CD,7067,Preclinical
LY294002,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,PIK3CG,7068,Preclinical
LY294002,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,PIM1,2740,Preclinical
LY294002,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,PLK1,1636,Preclinical
LY294002,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,PRKCA,59272,Preclinical
LY294002,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,PRKDC,148,Preclinical
LY294002,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,ROCK1,150,Preclinical
LY294002,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,RPS6KB1,151,Preclinical
LY294002,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,SGK1,152,Preclinical
LY2979165,glutamate receptor agonist,GRM2,1812,Phase 1
LY3000328,cathepsin inhibitor,CTSS,1813,Phase 1
LY3009120,RAF inhibitor,BRAF,1814,Phase 1
LY3009120,RAF inhibitor,RAF1,1815,Phase 1
LY3023414,mTOR inhibitor|PI3K inhibitor,MTOR,1816,Phase 2
LY303511,casein kinase inhibitor|mTOR inhibitor|PI3K inhibitor,BRD2,3350,Preclinical
LY303511,casein kinase inhibitor|mTOR inhibitor|PI3K inhibitor,BRD3,3351,Preclinical
LY303511,casein kinase inhibitor|mTOR inhibitor|PI3K inhibitor,BRD4,3352,Preclinical
LY310762,serotonin receptor antagonist,HTR1D,3356,Preclinical
LY320135,cannabinoid receptor antagonist,CNR1,3357,Preclinical
LY344864,serotonin receptor agonist,HTR1A,3358,Preclinical
LY344864,serotonin receptor agonist,HTR1B,3362,Preclinical
LY344864,serotonin receptor agonist,HTR1D,2184,Preclinical
LY344864,serotonin receptor agonist,HTR1E,151306,Preclinical
LY344864,serotonin receptor agonist,HTR1F,9971,Preclinical
LY344864,serotonin receptor agonist,HTR2A,8856,Preclinical
LY344864,serotonin receptor agonist,HTR2B,7421,Preclinical
LY344864,serotonin receptor agonist,HTR2C,3832,Preclinical
LY344864,serotonin receptor agonist,HTR7,554,Preclinical
LY364947,p38 MAPK inhibitor|TGF beta receptor inhibitor,TGFBR1,4915,Preclinical
LY393558,serotonin receptor antagonist,HTR1B,6606,Preclinical
LY393558,serotonin receptor antagonist,HTR1D,9759,Preclinical
LY393558,serotonin receptor antagonist,HTR2A,10014,Preclinical
LY393558,serotonin receptor antagonist,HTR2B,4804,Preclinical
LY404187,glutamate receptor positive allosteric modulator,GRIA1,57053,Preclinical
LY404187,glutamate receptor positive allosteric modulator,GRIA2,55584,Preclinical
LY404187,glutamate receptor positive allosteric modulator,GRIA3,6571,Preclinical
LY404187,glutamate receptor positive allosteric modulator,GRIA4,3350,Preclinical
LY456236,glutamate receptor antagonist,GRM1,6530,Preclinical
m-chlorophenylbiguanide,serotonin receptor agonist,HTR3A,6532,Preclinical
m-chlorophenylbiguanide,serotonin receptor agonist,HTR3B,4544,Preclinical
M-14157,ATP-sensitive potassium channel antagonist,KCNQ1,367,Phase 2
M-25,smoothened receptor antagonist,DHH,7376,Preclinical
M-25,smoothened receptor antagonist,IHH,10062,Preclinical
M-25,smoothened receptor antagonist,SMO,8856,Preclinical
m-3M3FBS,phospholipase activator,PLCB2,2908,Preclinical
m-3M3FBS,phospholipase activator,PLCB3,7166,Preclinical
m-3M3FBS,phospholipase activator,PLCD1,3985,Preclinical
m-3M3FBS,phospholipase activator,PLCG1,6093,Preclinical
m-3M3FBS,phospholipase activator,PLCG2,9475,Preclinical
M-344,HDAC inhibitor,HDAC8,1268,Preclinical
mabuterol,adrenergic receptor agonist,ADRB2,552,Launched
macitentan,endothelin receptor antagonist,EDNRA,553,Launched
macitentan,endothelin receptor antagonist,EDNRB,554,Launched
mafenide,carbonic anhydrase inhibitor,CA12,2932,Launched
mafenide,carbonic anhydrase inhibitor,CA14,7046,Launched
mafenide,carbonic anhydrase inhibitor,CA2,7048,Launched
mafenide,carbonic anhydrase inhibitor,CA4,2913,Launched
mafenide,carbonic anhydrase inhibitor,CA6,2890,Launched
mafenide,carbonic anhydrase inhibitor,CA9,2891,Launched
magnolol,PPAR receptor agonist,GABRA1,2892,Preclinical
magnolol,PPAR receptor agonist,PPARG,2893,Preclinical
malathion,cholinesterase inhibitor,ACHE,2897,Launched
malic-acid,,PKD2L1,7046,Launched
manidipine,calcium channel blocker,CACNA1C,2166,Launched
manidipine,calcium channel blocker,CACNA1D,1432,Launched
maprotiline,norepinephrine reputake inhibitor|tricyclic antidepressant,SLC6A2,1241,Launched
maraviroc,CC chemokine receptor antagonist,CCR5,887,Launched
maribavir,cytomegalovirus inhibitor|protein kinase inhibitor,PYGM,6536,Phase 3
marimastat,matrix metalloprotease inhibitor,MMP1,367,Phase 3
marimastat,matrix metalloprotease inhibitor,MMP10,1241,Phase 3
marimastat,matrix metalloprotease inhibitor,MMP11,56413,Phase 3
marimastat,matrix metalloprotease inhibitor,MMP12,6198,Phase 3
marimastat,matrix metalloprotease inhibitor,MMP13,1111,Phase 3
marimastat,matrix metalloprotease inhibitor,MMP14,1111,Phase 3
marimastat,matrix metalloprotease inhibitor,MMP15,2645,Phase 3
marimastat,matrix metalloprotease inhibitor,MMP16,3357,Phase 3
marimastat,matrix metalloprotease inhibitor,MMP17,3717,Phase 3
marimastat,matrix metalloprotease inhibitor,MMP19,3718,Phase 3
marimastat,matrix metalloprotease inhibitor,MMP2,4233,Phase 3
marimastat,matrix metalloprotease inhibitor,MMP20,23621,Phase 3
marimastat,matrix metalloprotease inhibitor,MMP21,1025,Phase 3
marimastat,matrix metalloprotease inhibitor,MMP23A,2260,Phase 3
marimastat,matrix metalloprotease inhibitor,MMP24,2263,Phase 3
marimastat,matrix metalloprotease inhibitor,MMP25,2261,Phase 3
marimastat,matrix metalloprotease inhibitor,MMP26,2264,Phase 3
marimastat,matrix metalloprotease inhibitor,MMP27,3791,Phase 3
marimastat,matrix metalloprotease inhibitor,MMP28,887,Phase 3
marimastat,matrix metalloprotease inhibitor,MMP3,23621,Phase 3
marimastat,matrix metalloprotease inhibitor,MMP7,207,Phase 3
marimastat,matrix metalloprotease inhibitor,MMP8,1111,Phase 3
marimastat,matrix metalloprotease inhibitor,MMP9,2932,Phase 3
maropitant,neurokinin receptor antagonist,TACR1,3932,Launched
masitinib,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor,FGFR3,5594,Launched
masitinib,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor,KIT,5600,Launched
masitinib,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor,PDGFRA,6300,Launched
masitinib,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor,PDGFRB,1432,Launched
masoprocol,lipoxygenase inhibitor,ALOX5,5599,Launched
matrine,opioid receptor agonist,OPRK1,2475,Phase 2
mavoglurant,glutamate receptor antagonist,GRM5,5290,Phase 2
maxacalcitol,vitamin D receptor agonist,VDR,5291,Launched
MBX-2982,glucose dependent insulinotropic receptor agonist,GPR119,5293,Phase 2
MC-1,,AADAT,5294,Phase 3
MC-1,,ABAT,5292,Phase 3
MC-1,,AGXT,5347,Phase 3
MC-1,,AGXT2,5578,Phase 3
MC-1,,ALAS1,5591,Phase 3
MC-1,,AZIN2,6093,Phase 3
MC-1,,BCAT1,6198,Phase 3
MC-1,,BCAT2,6446,Phase 3
MC-1,,CBS,2912,Phase 3
MC-1,,CCBL1,1520,Phase 3
MC-1,,CCBL2,673,Phase 3
MC-1,,CSAD,5894,Phase 3
MC-1,,CTH,2475,Phase 3
MC-1,,DDC,6046,Phase 3
MC-1,,FTCD,8019,Phase 3
MC-1,,GAD1,23476,Phase 3
MC-1,,GAD2,3352,Phase 3
MC-1,,GADL1,1268,Phase 3
MC-1,,GCAT,3350,Phase 3
MC-1,,GLDC,3351,Phase 3
MC-1,,GOT1,3352,Phase 3
MC-1,,GOT2,3354,Phase 3
MC-1,,GPT,3355,Phase 3
MC-1,,GPT2,3356,Phase 3
MC-1,,HDC,3357,Phase 3
MC-1,,IGSF10,3358,Phase 3
MC-1,,KYNU,3363,Phase 3
MC-1,,MOCOS,7046,Phase 3
MC-1,,NFS1,3351,Phase 3
MC-1,,OAT,3352,Phase 3
MC-1,,ODC1,3356,Phase 3
MC-1,,PDXDC1,3357,Phase 3
MC-1,,PDXP,2890,Phase 3
MC-1,,PHYKPL,2891,Phase 3
MC-1,,PNPO,2892,Phase 3
MC-1,,PROSC,2893,Phase 3
MC-1,,PSAT1,2911,Phase 3
MC-1,,PYGB,3359,Phase 3
MC-1,,PYGL,347732,Phase 3
MC-1,,PYGM,378807,Phase 3
MC-1,,SCLY,4987,Phase 3
MC-1,,SDS,10280,Phase 3
MC-1,,SDSL,6529,Phase 3
MC-1,,SEPSECS,5743,Phase 3
MC-1,,SGPL1,5604,Phase 3
MC-1,,SHMT1,27306,Phase 3
MC-1,,SHMT2,7298,Phase 3
MC-1,,SPTLC1,5241,Phase 3
MC-1,,SPTLC2,1813,Phase 3
MC-1,,SPTLC3,6530,Phase 3
MC-1,,SRR,6531,Phase 3
MC-1,,TAT,7442,Phase 3
MC-1,,THNSL1,4985,Phase 3
MCC950,NOD like receptor inhibitor,NLRP3,4986,Preclinical
MCOPPB,nociceptin/orphanin FQ receptor agonist,OPRL1,4988,Preclinical
mCPP,serotonin receptor agonist,HTR1A,5241,Phase 2
mCPP,serotonin receptor agonist,HTR1D,148,Phase 2
mCPP,serotonin receptor agonist,HTR1E,147,Phase 2
mCPP,serotonin receptor agonist,HTR2A,146,Phase 2
mCPP,serotonin receptor agonist,HTR2B,150,Phase 2
mCPP,serotonin receptor agonist,HTR2C,151,Phase 2
mCPP,serotonin receptor agonist,HTR6,152,Phase 2
MC1568,HDAC inhibitor,HDAC2,153,Preclinical
MD-920,NFkB pathway inhibitor,AADACL2,154,Phase 1
mdivi-1,dynamin inhibitor,DNM1,155,Preclinical
MDL-11939,serotonin receptor antagonist,HTR2A,5053,Phase 2
MDL-11939,serotonin receptor antagonist,HTR2B,6570,Phase 2
MDL-11939,serotonin receptor antagonist,HTR2C,6571,Phase 2
MDL-29951,glutamate receptor antagonist,FBP1,5241,Preclinical
MDL-72832,serotonin receptor agonist,HTR1A,5241,Preclinical
MDL-73005EF,serotonin receptor antagonist,HTR1A,5241,Phase 1
ME-0328,PPAR receptor antagonist,PARP3,7153,Preclinical
mebendazole,tubulin polymerization inhibitor,TUBA1A,3357,Launched
mebendazole,tubulin polymerization inhibitor,TUBB,2099,Launched
mebendazole,tubulin polymerization inhibitor,TUBB4B,5241,Launched
mebeverine,acetylcholine receptor antagonist,CHRM1,367,Launched
mecamylamine,acetylcholine receptor antagonist,CHRNA1,2099,Launched
mecamylamine,acetylcholine receptor antagonist,CHRNA2,5241,Launched
mecamylamine,acetylcholine receptor antagonist,CHRNA3,6715,Launched
mecamylamine,acetylcholine receptor antagonist,CHRNA4,148,Launched
mecamylamine,acetylcholine receptor antagonist,CHRNA6,147,Launched
mecamylamine,acetylcholine receptor antagonist,CHRNA7,146,Launched
mecamylamine,acetylcholine receptor antagonist,CHRNB4,150,Launched
meclinertant,neurotensin receptor antagonist,NTSR1,151,Phase 2/Phase 3
meclinertant,neurotensin receptor antagonist,NTSR2,152,Phase 2/Phase 3
meclizine,constitutive androstane receptor (CAR) agonist,NR1I3,153,Launched
meclofenamic-acid,cyclooxygenase inhibitor|prostanoid receptor antagonist,ALOX5,154,Launched
meclofenamic-acid,cyclooxygenase inhibitor|prostanoid receptor antagonist,CNR1,155,Launched
meclofenamic-acid,cyclooxygenase inhibitor|prostanoid receptor antagonist,KCNQ2,1128,Launched
meclofenamic-acid,cyclooxygenase inhibitor|prostanoid receptor antagonist,KCNQ3,1129,Launched
meclofenamic-acid,cyclooxygenase inhibitor|prostanoid receptor antagonist,PTGS1,1131,Launched
meclofenamic-acid,cyclooxygenase inhibitor|prostanoid receptor antagonist,PTGS2,1132,Launched
medetomidine,adrenergic receptor agonist,ADRA1A,1133,Launched
medetomidine,adrenergic receptor agonist,ADRA1B,1813,Launched
medetomidine,adrenergic receptor agonist,ADRA1D,3269,Launched
medetomidine,adrenergic receptor agonist,ADRA2A,3350,Launched
medetomidine,adrenergic receptor agonist,ADRA2B,3356,Launched
medetomidine,adrenergic receptor agonist,ADRA2C,3358,Launched
medica-16,ATP citrase lyase inhibitor,FFAR1,3362,Phase 2
medroxyprogesterone,progesterone receptor agonist,PGR,3766,Launched
medroxyprogesterone-acetate,progesterone receptor agonist,ESR1,10857,Launched
medroxyprogesterone-acetate,progesterone receptor agonist,PGR,10280,Launched
medrysone,glucocorticoid receptor agonist,NR3C1,6530,Launched
mefenamic-acid,cyclooxygenase inhibitor,KCNQ1,6532,Launched
mefenamic-acid,cyclooxygenase inhibitor,PTGS1,10280,Launched
mefenamic-acid,cyclooxygenase inhibitor,PTGS2,2936,Launched
mefenamic-acid,cyclooxygenase inhibitor,TRPM3,5468,Launched
megestrol-acetate,progesterone receptor agonist,NR3C1,55107,Launched
megestrol-acetate,progesterone receptor agonist,PGR,1181,Launched
meglitinide,potassium channel blocker,CCR2,1186,Phase 2
meglutol,HMGCR inhibitor,HMGCR,8989,Launched
meisoindigo,STAT inhibitor,STAT3,846,Phase 3
MEK1-2-inhibitor,MEK inhibitor,MAP2K2,4889,Preclinical
melatonin,melatonin receptor agonist|nitric oxide synthase inhibitor,ASMT,836,Launched
melatonin,melatonin receptor agonist|nitric oxide synthase inhibitor,CALM1,3716,Launched
melatonin,melatonin receptor agonist|nitric oxide synthase inhibitor,CALR,3717,Launched
melatonin,melatonin receptor agonist|nitric oxide synthase inhibitor,EPX,3718,Launched
melatonin,melatonin receptor agonist|nitric oxide synthase inhibitor,ESR1,7297,Launched
melatonin,melatonin receptor agonist|nitric oxide synthase inhibitor,HTR2B,3778,Launched
melatonin,melatonin receptor agonist|nitric oxide synthase inhibitor,MPO,3757,Launched
melatonin,melatonin receptor agonist|nitric oxide synthase inhibitor,MTNR1A,81033,Launched
melatonin,melatonin receptor agonist|nitric oxide synthase inhibitor,MTNR1B,3778,Launched
melatonin,melatonin receptor agonist|nitric oxide synthase inhibitor,NQO2,3778,Launched
melatonin,melatonin receptor agonist|nitric oxide synthase inhibitor,RORB,3780,Launched
meldonium,gamma butyrobetaine hydroxylase inhibitor,BBOX1,3781,Launched
melevodopa,dopamine precursor|dopamine receptor agonist,DDC,3782,Launched
meloxicam,cyclooxygenase inhibitor,PTGS1,3783,Launched
meloxicam,cyclooxygenase inhibitor,PTGS2,3757,Launched
melperone,dopamine receptor antagonist|serotonin receptor antagonist,DRD2,1136,Launched
melperone,dopamine receptor antagonist|serotonin receptor antagonist,HTR2A,1143,Launched
melphalan-n-oxide,hypoxia inducible factor inhibitor,HIF1A,3752,Phase 1
menadione,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,AOX1,3778,Launched
menadione,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,BGLAP,3780,Launched
menadione,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,F10,3781,Launched
menadione,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,F2,3782,Launched
menadione,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,F7,1137,Launched
menadione,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,F9,3065,Launched
menadione,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,GGCX,4312,Launched
menadione,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,NQO1,9177,Launched
menadione,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,NQO2,3784,Launched
menadione,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,PROC,50846,Launched
menadione,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,PROS1,3549,Launched
menadione,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,PROZ,6608,Launched
menadione,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,VKORC1,5330,Launched
menadione,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,VKORC1L1,5331,Launched
menadione-bisulfite,vitamin K,GGCX,5333,Phase 2
menadione-bisulfite,vitamin K,VKORC1,5335,Phase 2
menadione-bisulfite,vitamin K,VKORC1L1,5336,Phase 2
mepacrine,cytokine production inhibitor|NFkB pathway inhibitor|TP53 activator,PLA2G1B,55869,Launched
mepazine,MALT1 inhibitor (JH),MALT1,154,Phase 2
mephentermine,adrenergic receptor agonist,ADRA1A,1909,Launched
mephentermine,adrenergic receptor agonist,ADRA1B,1910,Launched
mephentermine,adrenergic receptor agonist,ADRA1D,771,Launched
mephentermine,adrenergic receptor agonist,ADRA2A,23632,Launched
mephentermine,adrenergic receptor agonist,ADRA2B,760,Launched
mephentermine,adrenergic receptor agonist,ADRA2C,762,Launched
mephentermine,adrenergic receptor agonist,ADRB1,765,Launched
mephentermine,adrenergic receptor agonist,ADRB2,768,Launched
mephentermine,adrenergic receptor agonist,ADRB3,2554,Launched
mephenytoin,hydantoin antiepileptic,SCN5A,5468,Launched
meprednisone,,NR3C1,43,Launched
meptazinol,opioid receptor agonist,BCHE,9033,Launched
mepyramine,histamine receptor antagonist,HRH1,775,Launched
mequinol,,TYR,776,Launched
merbarone,topoisomerase inhibitor,TOP2A,6530,Phase 2
mercaptopurine,immunosuppressant|protein synthesis inhibitor|purine antagonist,HPRT1,1234,Launched
mercaptopurine,immunosuppressant|protein synthesis inhibitor|purine antagonist,IMPDH1,5837,Launched
mercaptopurine,immunosuppressant|protein synthesis inhibitor|purine antagonist,IMPDH2,4312,Launched
mercaptopurine,immunosuppressant|protein synthesis inhibitor|purine antagonist,PPAT,4319,Launched
Merck60,HDAC inhibitor,HDAC1,4320,Preclinical
Merck60,HDAC inhibitor,HDAC2,4321,Preclinical
merimepodib,inosine monophosphate dehydrogenase inhibitor,IMPDH1,4322,Phase 2
mesalazine,cyclooxygenase inhibitor|lipoxygenase inhibitor|prostanoid receptor antagonist,ALOX5,4323,Launched
mesalazine,cyclooxygenase inhibitor|lipoxygenase inhibitor|prostanoid receptor antagonist,CHUK,4324,Launched
mesalazine,cyclooxygenase inhibitor|lipoxygenase inhibitor|prostanoid receptor antagonist,IKBKB,4325,Launched
mesalazine,cyclooxygenase inhibitor|lipoxygenase inhibitor|prostanoid receptor antagonist,MPO,4326,Launched
mesalazine,cyclooxygenase inhibitor|lipoxygenase inhibitor|prostanoid receptor antagonist,PPARG,4327,Launched
mesalazine,cyclooxygenase inhibitor|lipoxygenase inhibitor|prostanoid receptor antagonist,PTGS1,4313,Launched
mesalazine,cyclooxygenase inhibitor|lipoxygenase inhibitor|prostanoid receptor antagonist,PTGS2,9313,Launched
mesoridazine,dopamine receptor antagonist,DRD2,118856,Launched
mesoridazine,dopamine receptor antagonist,HTR2A,8511,Launched
mestinon,cholinesterase inhibitor,ACHE,10893,Launched
mestinon,cholinesterase inhibitor,BCHE,64386,Launched
mestranol,estrogen receptor agonist,ESR1,56547,Launched
mesulergine,dopamine receptor agonist,HTR2A,64066,Phase 2
mesulergine,dopamine receptor agonist,HTR2B,79148,Phase 2
mesulergine,dopamine receptor agonist,HTR2C,4314,Phase 2
mesulergine,dopamine receptor agonist,HTR3A,4316,Phase 2
mesulergine,dopamine receptor agonist,HTR3B,4317,Phase 2
mesulergine,dopamine receptor agonist,HTR6,4318,Phase 2
mesulergine,dopamine receptor agonist,HTR7,6869,Phase 2
metacresol,,INS,2261,Launched
metamizole,cyclooxygenase inhibitor|opioid receptor agonist,PTGS1,3815,Withdrawn
metaproterenol,adrenergic receptor agonist,ADRB2,5156,Launched
metaraminol,adrenergic receptor agonist,ADRA1A,5159,Launched
metatinib,Bcr-Abl kinase inhibitor,ABL1,240,Phase 1
metatinib,Bcr-Abl kinase inhibitor,BCR,4986,Phase 1
metazosin,adrenergic receptor antagonist,ADRA1A,2915,Phase 2
metenkephalin,immunostimulant,OPRD1,7421,Phase 2
metergoline,dopamine receptor agonist|serotonin receptor antagonist,HTR1A,139760,Launched
metergoline,dopamine receptor agonist|serotonin receptor antagonist,HTR1B,51166,Launched
metergoline,dopamine receptor agonist|serotonin receptor antagonist,HTR1D,18,Launched
metergoline,dopamine receptor agonist|serotonin receptor antagonist,HTR1E,189,Launched
metergoline,dopamine receptor agonist|serotonin receptor antagonist,HTR1F,64902,Launched
metergoline,dopamine receptor agonist|serotonin receptor antagonist,HTR2A,211,Launched
metergoline,dopamine receptor agonist|serotonin receptor antagonist,HTR2B,113451,Launched
metergoline,dopamine receptor agonist|serotonin receptor antagonist,HTR2C,586,Launched
metergoline,dopamine receptor agonist|serotonin receptor antagonist,HTR5A,587,Launched
metergoline,dopamine receptor agonist|serotonin receptor antagonist,HTR6,875,Launched
metergoline,dopamine receptor agonist|serotonin receptor antagonist,HTR7,883,Launched
metformin,insulin sensitizer,ACACB,56267,Launched
metformin,insulin sensitizer,PRKAB1,51380,Launched
methacholine,acetylcholine receptor agonist,CHRM2,1491,Launched
methacholine,acetylcholine receptor agonist,CHRM4,1644,Launched
methanesulfonyl-fluoride,acetylcholinesterase inhibitor,ACHE,10841,Phase 2
methantheline,acetylcholine receptor antagonist,CHRM1,2571,Launched
methantheline,acetylcholine receptor antagonist,HRH2,2572,Launched
methapyrilene,histamine receptor antagonist,HRH1,339896,Withdrawn
metharbital,GABA receptor modulator,CHRNA4,23464,Launched
metharbital,GABA receptor modulator,CHRNA7,2731,Launched
metharbital,GABA receptor modulator,GABRA1,2805,Launched
metharbital,GABA receptor modulator,GABRA2,2806,Launched
metharbital,GABA receptor modulator,GABRA3,2875,Launched
metharbital,GABA receptor modulator,GABRA4,84706,Launched
metharbital,GABA receptor modulator,GABRA5,3067,Launched
metharbital,GABA receptor modulator,GABRA6,285313,Launched
metharbital,GABA receptor modulator,GABRB1,8942,Launched
metharbital,GABA receptor modulator,GABRB2,55034,Launched
metharbital,GABA receptor modulator,GABRB3,9054,Launched
metharbital,GABA receptor modulator,GABRD,4942,Launched
metharbital,GABA receptor modulator,GABRE,4953,Launched
metharbital,GABA receptor modulator,GABRG1,23042,Launched
metharbital,GABA receptor modulator,GABRG2,57026,Launched
metharbital,GABA receptor modulator,GABRG3,85007,Launched
metharbital,GABA receptor modulator,GABRP,55163,Launched
metharbital,GABA receptor modulator,GABRQ,11212,Launched
metharbital,GABA receptor modulator,GRIA2,29968,Launched
metharbital,GABA receptor modulator,GRIK2,5834,Launched
methazolamide,carbonic anhydrase inhibitor,CA1,5836,Launched
methazolamide,carbonic anhydrase inhibitor,CA12,5837,Launched
methazolamide,carbonic anhydrase inhibitor,CA14,51540,Launched
methazolamide,carbonic anhydrase inhibitor,CA2,10993,Launched
methazolamide,carbonic anhydrase inhibitor,CA4,113675,Launched
methazolamide,carbonic anhydrase inhibitor,CA7,51091,Launched
methimazole,antithyroid agent,TPO,8879,Launched
methionine,,METAP2,6470,Launched
methiopril,angiotensin converting enzyme inhibitor,ACE,6472,Phase 2
methocarbamol,muscle relaxant,CA1,10558,Launched
methotrexate,dihydrofolate reductase inhibitor,DHFR,9517,Launched
methoxamine,adrenergic receptor agonist,ADRA1A,55304,Launched
methoxamine,adrenergic receptor agonist,ADRA1B,63826,Launched
methoxamine,adrenergic receptor agonist,ADRA1D,6898,Launched
methoxsalen,DNA synthesis inhibitor,CYP1A1,79896,Launched
methoxsalen,DNA synthesis inhibitor,CYP1A2,114548,Launched
methoxsalen,DNA synthesis inhibitor,CYP2A13,4987,Launched
methoxsalen,DNA synthesis inhibitor,CYP2A6,3350,Launched
methoxsalen,DNA synthesis inhibitor,CYP3A4,3352,Launched
methoxyamine,DNA repair enzyme inhibitor,APEX1,3354,Phase 2
methoxyflurane,membrane permeability inhibitor,ATP2C1,3356,Launched
methoxyflurane,membrane permeability inhibitor,ATP5D,3357,Launched
methoxyflurane,membrane permeability inhibitor,GABRA1,3358,Launched
methoxyflurane,membrane permeability inhibitor,GABRA2,3362,Launched
methoxyflurane,membrane permeability inhibitor,GABRA3,3066,Launched
methoxyflurane,membrane permeability inhibitor,GABRA4,344752,Launched
methoxyflurane,membrane permeability inhibitor,GABRA5,1759,Launched
methoxyflurane,membrane permeability inhibitor,GABRA6,3356,Launched
methoxyflurane,membrane permeability inhibitor,GABRB1,3357,Launched
methoxyflurane,membrane permeability inhibitor,GABRB2,3358,Launched
methoxyflurane,membrane permeability inhibitor,GABRB3,2203,Launched
methoxyflurane,membrane permeability inhibitor,GABRD,3350,Launched
methoxyflurane,membrane permeability inhibitor,GABRE,3350,Launched
methoxyflurane,membrane permeability inhibitor,GABRG1,10039,Launched
methoxyflurane,membrane permeability inhibitor,GABRG2,7846,Launched
methoxyflurane,membrane permeability inhibitor,GABRG3,203068,Launched
methoxyflurane,membrane permeability inhibitor,GABRP,10383,Launched
methoxyflurane,membrane permeability inhibitor,GABRQ,1128,Launched
methoxyflurane,membrane permeability inhibitor,GLRA1,1134,Launched
methoxyflurane,membrane permeability inhibitor,GLRB,1135,Launched
methoxyflurane,membrane permeability inhibitor,GRIA1,1136,Launched
methoxyflurane,membrane permeability inhibitor,KCNA1,1137,Launched
methoxyflurane,membrane permeability inhibitor,MT-ND1,8973,Launched
methscopolamine,acetylcholine receptor antagonist,CHRM1,1139,Launched
methscopolamine,acetylcholine receptor antagonist,CHRM2,1143,Launched
methscopolamine,acetylcholine receptor antagonist,CHRM3,4923,Launched
methsuximide,T-type calcium channel blocker,CACNA1G,23620,Launched
methsuximide,T-type calcium channel blocker,CACNA1H,9970,Launched
methsuximide,T-type calcium channel blocker,CACNA1I,240,Launched
methyclothiazide,chloride reabsorption inhibitor,SLC12A1,1268,Launched
methyclothiazide,chloride reabsorption inhibitor,SLC12A3,3785,Launched
methyl-aminolevulinate,oxidizing agent,FCGR1A,3786,Launched
methyl-aminolevulinate,oxidizing agent,FECH,5742,Launched
methylatropine-nitrate,acetylcholine receptor antagonist,CHRM1,5743,Preclinical
methyldopa,adrenergic receptor agonist,ADRA2A,148,Launched
methyldopa,adrenergic receptor agonist,ADRA2B,147,Launched
methyldopa,adrenergic receptor agonist,ADRA2C,146,Launched
methyldopa,adrenergic receptor agonist,DDC,150,Launched
methylene-blue,guanylyl cyclase inhibitor|nitric oxide production inhibitor,ACHE,151,Launched
methylergometrine,dopamine receptor antagonist|serotonin receptor antagonist,DRD1,152,Launched
methylergometrine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1E,2864,Launched
methylergometrine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1F,5241,Launched
methylergometrine,dopamine receptor antagonist|serotonin receptor antagonist,HTR2A,2099,Launched
methylergometrine,dopamine receptor antagonist|serotonin receptor antagonist,HTR2B,5241,Launched
methylergometrine,dopamine receptor antagonist|serotonin receptor antagonist,HTR2C,2908,Launched
methyllycaconitine,acetylcholine receptor antagonist,CHRNA7,3784,Preclinical
methylnaltrexone,opioid receptor antagonist,OPRD1,5742,Launched
methylnaltrexone,opioid receptor antagonist,OPRK1,5743,Launched
methylnaltrexone,opioid receptor antagonist,OPRM1,80036,Launched
methylprednisolone,glucocorticoid receptor agonist,NR3C1,2908,Launched
methylprednisolone-aceponate,anti-inflammatory agent|glucocorticoid receptor agonist,NR3C1,5241,Launched
methysergide,serotonin receptor antagonist,HTR1B,729230,Launched
methysergide,serotonin receptor antagonist,HTR1D,3156,Launched
methysergide,serotonin receptor antagonist,HTR1E,6774,Launched
methysergide,serotonin receptor antagonist,HTR1F,5605,Launched
methysergide,serotonin receptor antagonist,HTR2A,438,Launched
methysergide,serotonin receptor antagonist,HTR2B,801,Launched
methysergide,serotonin receptor antagonist,HTR2C,811,Launched
methysergide,serotonin receptor antagonist,HTR5A,8288,Launched
methysergide,serotonin receptor antagonist,HTR6,2099,Launched
methysergide,serotonin receptor antagonist,HTR7,3357,Launched
metirosine,tyrosine hydroxylase inhibitor,TH,4353,Launched
metitepine,anti-HCVE2,HTR1A,4543,Preclinical
metitepine,anti-HCVE2,HTR1B,4544,Preclinical
metitepine,anti-HCVE2,HTR1D,4835,Preclinical
metitepine,anti-HCVE2,HTR1E,6096,Preclinical
metitepine,anti-HCVE2,HTR1F,8424,Preclinical
metitepine,anti-HCVE2,HTR2A,1644,Preclinical
metitepine,anti-HCVE2,HTR2B,5742,Preclinical
metitepine,anti-HCVE2,HTR2C,5743,Preclinical
metitepine,anti-HCVE2,HTR5A,1813,Preclinical
metitepine,anti-HCVE2,HTR6,3356,Preclinical
metitepine,anti-HCVE2,HTR7,3091,Preclinical
metixene,acetylcholine receptor antagonist,CHRM5,316,Launched
metoclopramide,dopamine receptor antagonist|serotonin receptor antagonist,CHRM1,632,Launched
metoclopramide,dopamine receptor antagonist|serotonin receptor antagonist,DRD2,2159,Launched
metoclopramide,dopamine receptor antagonist|serotonin receptor antagonist,HTR3A,2147,Launched
metoclopramide,dopamine receptor antagonist|serotonin receptor antagonist,HTR3B,2155,Launched
metoclopramide,dopamine receptor antagonist|serotonin receptor antagonist,HTR4,2158,Launched
metocurine,acetylcholine receptor antagonist,CHRM2,2677,Launched
metocurine,acetylcholine receptor antagonist,CHRNA2,1728,Launched
metolazone,carbonic anhydrase inhibitor,SLC12A3,4835,Launched
metoprolol,adrenergic receptor antagonist,ADRB1,5624,Launched
metoprolol,adrenergic receptor antagonist,ADRB2,5627,Launched
metoxibutropate,cyclooxygenase inhibitor,PTGS1,8858,Launched
metoxibutropate,cyclooxygenase inhibitor,PTGS2,79001,Launched
metrifonate,acetylcholinesterase inhibitor,ACHE,154807,Phase 3
metronidazole,DNA inhibitor,CYP2C9,2677,Launched
metronidazole,DNA inhibitor,CYP3A4,79001,Launched
metyrapone,cytochrome P450 inhibitor,CYP11B1,154807,Launched
mevastatin,HMGCR inhibitor,HMGCR,5319,Preclinical
mexiletine,sodium channel blocker,PLAU,10892,Launched
mexiletine,sodium channel blocker,SCN4A,148,Launched
mexiletine,sodium channel blocker,SCN5A,147,Launched
ME0328,PARP inhibitor,PARP3,146,Preclinical
MF-101,estrogen receptor agonist,CYP19A1,150,Phase 3
MF-101,estrogen receptor agonist,XDH,151,Phase 3
MG-132,proteasome inhibitor,PSMB1,152,Preclinical
MG-624,acetylcholine receptor antagonist,CHRNA7,153,Preclinical
MGCD-265,VEGFR inhibitor,AXL,154,Preclinical
MGCD-265,VEGFR inhibitor,MET,155,Preclinical
MI-14,PI4K inhibitor,PI4KB,6331,Preclinical
mianserin,serotonin receptor antagonist,ADRA1A,2908,Launched
mianserin,serotonin receptor antagonist,ADRA1B,590,Launched
mianserin,serotonin receptor antagonist,ADRA1D,3269,Launched
mianserin,serotonin receptor antagonist,HRH1,7299,Launched
mianserin,serotonin receptor antagonist,HRH2,7153,Launched
mianserin,serotonin receptor antagonist,HTR2A,3251,Launched
mianserin,serotonin receptor antagonist,HTR2B,3614,Launched
mianserin,serotonin receptor antagonist,HTR2C,3615,Launched
mianserin,serotonin receptor antagonist,HTR6,5471,Launched
mianserin,serotonin receptor antagonist,HTR7,3065,Launched
mibampator,glutamate receptor modulator,GRIA1,3066,Phase 2
mibefradil,T-type calcium channel blocker,ANO1,3614,Withdrawn
mibefradil,T-type calcium channel blocker,CACNA1C,240,Withdrawn
mibefradil,T-type calcium channel blocker,CACNA1D,1147,Withdrawn
mibefradil,T-type calcium channel blocker,CACNA1F,3551,Withdrawn
mibefradil,T-type calcium channel blocker,CACNA1G,4353,Withdrawn
mibefradil,T-type calcium channel blocker,CACNA1H,5468,Withdrawn
mibefradil,T-type calcium channel blocker,CACNA1I,5742,Withdrawn
mibefradil,T-type calcium channel blocker,CACNA1S,5743,Withdrawn
mibefradil,T-type calcium channel blocker,CACNB1,1813,Withdrawn
mibefradil,T-type calcium channel blocker,CACNB2,3356,Withdrawn
mibefradil,T-type calcium channel blocker,CACNB3,43,Withdrawn
mibefradil,T-type calcium channel blocker,CACNB4,590,Withdrawn
mibefradil,T-type calcium channel blocker,CATSPER1,2099,Withdrawn
mibefradil,T-type calcium channel blocker,CATSPER2,3356,Withdrawn
mibefradil,T-type calcium channel blocker,CATSPER3,3357,Withdrawn
mibefradil,T-type calcium channel blocker,CATSPER4,3358,Withdrawn
miconazole,bacterial cell wall synthesis inhibitor,TRPM2,3359,Launched
miconazole,bacterial cell wall synthesis inhibitor,TRPV5,9177,Launched
midafotel,glutamate receptor antagonist,GRIN2A,3362,Phase 3
midafotel,glutamate receptor antagonist,GRIN2B,3363,Phase 3
midafotel,glutamate receptor antagonist,GRIN2C,3630,Phase 3
midafotel,glutamate receptor antagonist,GRIN2D,5742,Phase 3
midostaurin,FLT3 inhibitor|KIT inhibitor|PKC inhibitor,FLT3,154,Launched
midostaurin,FLT3 inhibitor|KIT inhibitor|PKC inhibitor,PRKCG,148,Launched
mifepristone,glucocorticoid receptor antagonist|progesterone receptor antagonist,AR,25,Launched
mifepristone,glucocorticoid receptor antagonist|progesterone receptor antagonist,NR1I2,613,Launched
mifepristone,glucocorticoid receptor antagonist|progesterone receptor antagonist,NR3C1,148,Launched
mifepristone,glucocorticoid receptor antagonist|progesterone receptor antagonist,PGR,4985,Launched
mifobate,PPAR receptor antagonist,PPARG,3350,Phase 2
miglitol,glucosidase inhibitor,GAA,3351,Launched
miglitol,glucosidase inhibitor,GANAB,3352,Launched
miglitol,glucosidase inhibitor,GANC,3354,Launched
miglitol,glucosidase inhibitor,MGAM,3355,Launched
miglustat,glycosyl transferase inhibitor,UGCG,3356,Launched
milacemide,monoamine oxidase inhibitor,MAOB,3357,Phase 3
milnacipran,serotoninâ€“norepinephrine reuptake inhibitor (SNRI),SLC6A2,3358,Launched
milnacipran,serotoninâ€“norepinephrine reuptake inhibitor (SNRI),SLC6A4,3361,Launched
milrinone,phosphodiesterase inhibitor,PDE2A,3362,Launched
milrinone,phosphodiesterase inhibitor,PDE3A,3363,Launched
milrinone,phosphodiesterase inhibitor,PDE3B,32,Launched
milrinone,phosphodiesterase inhibitor,PDE5A,5564,Launched
miltefosine,membrane integrity inhibitor,PLA2G1B,1129,Launched
mimosine,DNA replication inhibitor,CCL2,1132,Preclinical
mimosine,DNA replication inhibitor,SHMT1,43,Preclinical
mimosine,DNA replication inhibitor,SHMT2,1128,Preclinical
mimosine,DNA replication inhibitor,TYR,3274,Preclinical
minaprine,serotonin reuptake inhibitor,ACHE,3269,Withdrawn
minaprine,serotonin reuptake inhibitor,CHRM1,1137,Withdrawn
minaprine,serotonin reuptake inhibitor,DRD1,1139,Withdrawn
minaprine,serotonin reuptake inhibitor,DRD2,2554,Withdrawn
minaprine,serotonin reuptake inhibitor,HTR2A,2555,Withdrawn
minaprine,serotonin reuptake inhibitor,HTR2B,2556,Withdrawn
minaprine,serotonin reuptake inhibitor,HTR2C,2557,Withdrawn
minaprine,serotonin reuptake inhibitor,MAOA,2558,Withdrawn
minaprine,serotonin reuptake inhibitor,SLC6A4,2559,Withdrawn
minodronic-acid,bone resorption inhibitor,FDPS,2560,Launched
minodronic-acid,bone resorption inhibitor,GGPS1,2561,Launched
minoxidil,KATP activator|Kir6 channel (KATP) activator|vasodilator,ABCC9,2562,Launched
minoxidil,KATP activator|Kir6 channel (KATP) activator|vasodilator,KCNJ1,2563,Launched
minoxidil,KATP activator|Kir6 channel (KATP) activator|vasodilator,KCNJ10,2564,Launched
minoxidil,KATP activator|Kir6 channel (KATP) activator|vasodilator,KCNJ11,2565,Launched
minoxidil,KATP activator|Kir6 channel (KATP) activator|vasodilator,KCNJ8,2566,Launched
minoxidil,KATP activator|Kir6 channel (KATP) activator|vasodilator,PTGS1,2567,Launched
mirabegron,adrenergic receptor agonist,ADRB1,2568,Launched
mirabegron,adrenergic receptor agonist,ADRB2,55879,Launched
mirabegron,adrenergic receptor agonist,ADRB3,2891,Launched
mirin,MRE11A exonuclease inhibitor,MRE11A,2898,Preclinical
mirodenafil,phosphodiesterase inhibitor,PDE5A,8654,Launched
mirtazapine,adrenergic receptor antagonist|serotonin receptor antagonist,ADRA2A,150,Launched
mirtazapine,adrenergic receptor antagonist|serotonin receptor antagonist,ADRA2B,151,Launched
mirtazapine,adrenergic receptor antagonist|serotonin receptor antagonist,ADRA2C,152,Launched
mirtazapine,adrenergic receptor antagonist|serotonin receptor antagonist,HTR2A,3356,Launched
mirtazapine,adrenergic receptor antagonist|serotonin receptor antagonist,HTR2C,3358,Launched
misoprostol,prostanoid receptor agonist,PTGER2,5732,Launched
misoprostol,prostanoid receptor agonist,PTGER3,5733,Launched
misoprostol,prostanoid receptor agonist,PTGER4,5734,Launched
misoprostol,prostanoid receptor agonist,PTGIR,5739,Launched
mitiglinide,insulin secretagogue,ABCC8,6833,Launched
mitiglinide,insulin secretagogue,KCNJ10,3766,Launched
mitiglinide,insulin secretagogue,PPARG,5468,Launched
mitoflaxone,antitumor agent,VWF,7450,Phase 2
mitotane,antineoplastic agent,CYP11A1,1583,Launched
mitotane,antineoplastic agent,CYP11B1,1584,Launched
mitotane,antineoplastic agent,ESR1,2099,Launched
mitoxantrone,topoisomerase inhibitor,TOP2A,7153,Launched
mivacurium,acetylcholine receptor antagonist,CHRNA2,1135,Launched
mizolastine,histamine receptor antagonist,HRH1,3269,Launched
mizoribine,immunosuppressant|inosine monophosphate dehydrogenase inhibitor,IMPDH1,3614,Launched
MJ-15,cannabinoid receptor antagonist,CNR1,1268,Preclinical
MK-0354,niacin receptor agonist,HCAR2,338442,Phase 2
MK-0354,niacin receptor agonist,HCAR3,8843,Phase 2
MK-0773,androgen receptor modulator,AR,367,Phase 2
MK-0812,CC chemokine receptor antagonist,CCR2,729230,Phase 2
MK-0893,glucagon receptor antagonist,GCGR,2642,Phase 2
MK-1775,WEE1 kinase inhibitor,WEE1,7465,Phase 2
MK-2206,AKT inhibitor,AKT1,207,Phase 2
MK-2206,AKT inhibitor,AKT2,208,Phase 2
MK-2206,AKT inhibitor,AKT3,10000,Phase 2
MK-2295,TRPV antagonist,TRPV1,7442,Phase 2
MK-2461,FGFR inhibitor|VEGFR inhibitor,FGFR1,2260,Phase 1/Phase 2
MK-2461,FGFR inhibitor|VEGFR inhibitor,FGFR2,2263,Phase 1/Phase 2
MK-2461,FGFR inhibitor|VEGFR inhibitor,FGFR3,2261,Phase 1/Phase 2
MK-2461,FGFR inhibitor|VEGFR inhibitor,FLT1,2321,Phase 1/Phase 2
MK-2461,FGFR inhibitor|VEGFR inhibitor,FLT3,2322,Phase 1/Phase 2
MK-2461,FGFR inhibitor|VEGFR inhibitor,FLT4,2324,Phase 1/Phase 2
MK-2461,FGFR inhibitor|VEGFR inhibitor,KDR,3791,Phase 1/Phase 2
MK-2461,FGFR inhibitor|VEGFR inhibitor,MERTK,10461,Phase 1/Phase 2
MK-2461,FGFR inhibitor|VEGFR inhibitor,MET,4233,Phase 1/Phase 2
MK-2461,FGFR inhibitor|VEGFR inhibitor,MST1R,4486,Phase 1/Phase 2
MK-2461,FGFR inhibitor|VEGFR inhibitor,NTRK1,4914,Phase 1/Phase 2
MK-2461,FGFR inhibitor|VEGFR inhibitor,NTRK2,4915,Phase 1/Phase 2
MK-2461,FGFR inhibitor|VEGFR inhibitor,PDGFRB,5159,Phase 1/Phase 2
MK-2894,prostaglandin inhibitor,PTGER4,5734,Preclinical
MK-3207,calcitonin antagonist,CALCA,796,Phase 2
MK-3697,orexin receptor antagonist,HCRTR2,3062,Phase 2
MK-5046,bombesin receptor agonist,BRS3,680,Preclinical
MK-5046,bombesin receptor agonist,GRPR,2925,Preclinical
MK-5046,bombesin receptor agonist,NMBR,4829,Preclinical
MK-5108,Aurora kinase inhibitor,AURKA,6790,Phase 1
MK-5108,Aurora kinase inhibitor,AURKB,9212,Phase 1
MK-5108,Aurora kinase inhibitor,AURKC,6795,Phase 1
MK-571,leukotriene receptor antagonist,ABCC2,1244,Phase 2
MK-571,leukotriene receptor antagonist,CYSLTR1,10800,Phase 2
MK-6096,orexin receptor antagonist,HCRTR1,3061,Phase 2
MK-6096,orexin receptor antagonist,HCRTR2,3062,Phase 2
MK-8033,c-Met inhibitor,MET,4233,Phase 1
MK-8245,stearoyl-CoA desaturase inhibitor,SCD,6319,Phase 2
MK-8745,Aurora kinase inhibitor,AURKA,6790,Preclinical
MK2-IN-1,MAP kinase inhibitor,MAPKAPK2,9261,Preclinical
MLN0128,mTOR inhibitor,MTOR,2475,Phase 2
MLN0128,mTOR inhibitor,PIK3CA,5290,Phase 2
MLN0128,mTOR inhibitor,PIK3CD,5293,Phase 2
MLN0128,mTOR inhibitor,PIK3CG,5294,Phase 2
MLN1117,PI3K inhibitor,PIK3CA,5290,Phase 2
MLN8054,Aurora kinase inhibitor,AURKA,6790,Phase 1
ML10302,serotonin receptor partial agonist,HTR3A,3359,Preclinical
ML10302,serotonin receptor partial agonist,HTR3B,9177,Preclinical
ML10302,serotonin receptor partial agonist,HTR4,3360,Preclinical
ML141,GTPase inhibitor,CDC42,998,Preclinical
ML167,CLK inhibitor|DYRK inhibitor,CLK4,57396,Preclinical
ML167,CLK inhibitor|DYRK inhibitor,DYRK1B,9149,Preclinical
ML179,liver receptor homolog inverse agonist,NR5A2,2494,Preclinical
ML193,G protein-coupled receptor antagonist,GPR55,9290,Preclinical
ML204,transient receptor potential channel antagonist,TRPC4,7223,Preclinical
ML204,transient receptor potential channel antagonist,TRPC5,7224,Preclinical
ML213,potassium channel activator,KCNQ4,9132,Preclinical
ML218,T-type calcium channel blocker,CACNA1G,8913,Preclinical
ML218,T-type calcium channel blocker,CACNA1H,8912,Preclinical
ML218,T-type calcium channel blocker,CACNA1I,8911,Preclinical
ML228,hypoxia inducible factor activator,HIF1A,3091,Preclinical
ML277,potassium channel activator,KCNQ1,3784,Preclinical
ML281,serine/threonine kinase inhibitor,STK33,65975,Preclinical
ML297,inward rectifier potassium channel activator,KCNJ3,3760,Preclinical
ML298,phospholipase inhibitor,PLD2,5338,Preclinical
ML314,neurotensin agonist,NTSR1,4923,Preclinical
ML323,ubiquitin specific protease inhibitor,USP1,7398,Preclinical
ML324,histone lysine demethylase inhibitor,KDM4A,9682,Preclinical
ML3403,MAP kinase inhibitor,CYP3A4,1576,Preclinical
ML3403,MAP kinase inhibitor,MAPK11,5600,Preclinical
ML3403,MAP kinase inhibitor,MAPK12,6300,Preclinical
ML3403,MAP kinase inhibitor,MAPK14,1432,Preclinical
ML347,ALK tyrosine kinase receptor inhibitor,ACVR1,90,Preclinical
ML347,ALK tyrosine kinase receptor inhibitor,ACVRL1,94,Preclinical
ML347,ALK tyrosine kinase receptor inhibitor,BMPR1A,657,Preclinical
ML348,lysophospholipase inhibitor,LYPLA1,10434,Preclinical
ML365,potassium channel blocker,KCNK3,3777,Preclinical
ML365,potassium channel blocker,KCNK9,51305,Preclinical
ML786,RAF inhibitor,BRAF,1135,Preclinical
ML786,RAF inhibitor,RAF1,6559,Preclinical
ML9,myosin light chain kinase inhibitor,TRPC6,153,Preclinical
MM-11253,retinoid receptor antagonist,RARG,154,Preclinical
MM77,serotonin receptor antagonist,HTR1A,5742,Preclinical
MN-64,tankyrase inhibitor,TNKS,5743,Preclinical
mocetinostat,HDAC inhibitor,HDAC1,43,Phase 2
mocetinostat,HDAC inhibitor,HDAC11,1559,Phase 2
mocetinostat,HDAC inhibitor,HDAC2,1576,Phase 2
mocetinostat,HDAC inhibitor,HDAC3,1584,Phase 2
moclobemide,monoamine oxidase inhibitor,MAOA,3156,Launched
moclobemide,monoamine oxidase inhibitor,MAOB,5328,Launched
moexipril,angiotensin converting enzyme inhibitor,ACE,6329,Launched
moexipril,angiotensin converting enzyme inhibitor,ACE2,6331,Launched
mofegiline,monoamine oxidase inhibitor,MAOA,10039,Phase 1
mofegiline,monoamine oxidase inhibitor,MAOB,1588,Phase 1
mofezolac,cyclooxygenase inhibitor,PTGS1,7498,Launched
molidustat,hypoxia inducible factor inhibitor,EGLN2,5689,Phase 3
molindone,dopamine receptor antagonist,DRD2,1139,Launched
molindone,dopamine receptor antagonist,HRH1,558,Launched
molindone,dopamine receptor antagonist,HTR2A,4233,Launched
molsidomine,guanylate cyclase stimulant,GUCY1A3,5298,Launched
mometasone,glucocorticoid receptor agonist,NR3C1,148,Launched
mometasone-furoate,glucocorticoid receptor agonist,NR3C1,147,Launched
monastrol,kinesin inhibitor,KIF11,146,Preclinical
monobenzone,melanin inhibitor,TYR,3269,Launched
montelukast,leukotriene receptor antagonist,ALOX5,3274,Launched
montelukast,leukotriene receptor antagonist,CYSLTR1,3356,Launched
moracizine,sodium channel blocker,SCN5A,3357,Withdrawn
morin,cytochrome P450 inhibitor,ADORA2A,3358,Preclinical
morin,cytochrome P450 inhibitor,ESR2,3362,Preclinical
morin,cytochrome P450 inhibitor,FASN,3363,Preclinical
morin,cytochrome P450 inhibitor,MCL1,2890,Preclinical
morin,cytochrome P450 inhibitor,SLC22A12,55107,Preclinical
morinidazole,other antibiotic,CYP51A1,775,Launched
mosapride,serotonin receptor agonist,HTR4,776,Launched
motesanib,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FLT1,778,Phase 3
motesanib,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FLT4,8913,Phase 3
motesanib,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KDR,8912,Phase 3
motesanib,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KIT,8911,Phase 3
motolimod,toll-like receptor agonist,TLR8,779,Phase 2
moxifloxacin,bacterial DNA gyrase inhibitor,TOP2A,782,Launched
moxonidine,imidazoline receptor agonist,ADRA2A,783,Launched
moxonidine,imidazoline receptor agonist,ADRA2B,784,Launched
moxonidine,imidazoline receptor agonist,ADRA2C,785,Launched
mozavaptan,vasopressin receptor antagonist,AVPR1A,117144,Launched
mozavaptan,vasopressin receptor antagonist,AVPR1B,117155,Launched
mozavaptan,vasopressin receptor antagonist,AVPR2,347732,Launched
MPEP,glutamate receptor antagonist,GRM1,378807,Preclinical
MPEP,glutamate receptor antagonist,GRM4,7226,Preclinical
MPEP,glutamate receptor antagonist,GRM5,56302,Preclinical
MPI-0479605,mitotic kinase inhibitor,TTK,2903,Preclinical
Mps-BAY-2a,monopolar spindle 1 kinase inhibitor,TTK,2904,Preclinical
Mps1-IN-1,monopolar spindle 1 kinase inhibitor,TTK,2905,Preclinical
MR-948,thromboxane synthase inhibitor,TBXAS1,2906,Phase 1
MRK-016,GABA receptor inverse agonist,GABRA1,2322,Phase 1
MRK-016,GABA receptor inverse agonist,GABRA2,5582,Phase 1
MRK-016,GABA receptor inverse agonist,GABRA3,367,Phase 1
MRK-016,GABA receptor inverse agonist,GABRA5,8856,Phase 1
MRK-560,gamma secretase inhibitor,APP,2908,Preclinical
MRS-1220,adenosine receptor antagonist,ADORA2B,5241,Preclinical
MRS-1220,adenosine receptor antagonist,ADORA3,5468,Preclinical
MRS-1334,adenosine receptor antagonist,ADORA3,2548,Preclinical
MRS-2578,purinergic receptor antagonist,P2RY6,23193,Preclinical
MRS-3777,adenosine receptor antagonist,ADORA1,2595,Preclinical
MRS-3777,adenosine receptor antagonist,ADORA2A,8972,Preclinical
MRS-3777,adenosine receptor antagonist,ADORA2B,7357,Preclinical
MRS-3777,adenosine receptor antagonist,ADORA3,4129,Preclinical
MSX-122,CC chemokine receptor antagonist,CXCR4,6530,Phase 2
MTPG,glutamate receptor antagonist,GRM2,6532,Preclinical
MTPG,glutamate receptor antagonist,GRM3,5138,Preclinical
mubritinib,protein tyrosine kinase inhibitor,EGFR,5139,Phase 1
mubritinib,protein tyrosine kinase inhibitor,ERBB2,5140,Phase 1
muscimol,benzodiazepine receptor agonist,GABRA1,8654,Phase 1
muscimol,benzodiazepine receptor agonist,GABRA2,5319,Phase 1
muscimol,benzodiazepine receptor agonist,GABRA3,6347,Phase 1
muscimol,benzodiazepine receptor agonist,GABRA4,6470,Phase 1
muscimol,benzodiazepine receptor agonist,GABRA5,6472,Phase 1
muscimol,benzodiazepine receptor agonist,GABRA6,7299,Phase 1
muscimol,benzodiazepine receptor agonist,GABRR1,43,Phase 1
muscimol,benzodiazepine receptor agonist,GABRR2,1128,Phase 1
muscimol,benzodiazepine receptor agonist,GABRR3,1812,Phase 1
MY-5445,phosphodiesterase inhibitor|platelet aggregation inhibitor,PDE5A,1813,Preclinical
mycophenolate-mofetil,dehydrogenase inhibitor|inositol monophosphatase inhibitor,IMPDH1,3356,Launched
mycophenolate-mofetil,dehydrogenase inhibitor|inositol monophosphatase inhibitor,IMPDH2,3357,Launched
mycophenolic-acid,dehydrogenase inhibitor|inositol monophosphatase inhibitor,IMPDH1,3358,Launched
mycophenolic-acid,dehydrogenase inhibitor|inositol monophosphatase inhibitor,IMPDH2,4128,Launched
myricetin,androgen receptor agonist|cytochrome P450 inhibitor,PIK3CG,6532,Preclinical
myricitrin,PKC inhibitor,NOS1,2224,Preclinical
myricitrin,PKC inhibitor,PRKCA,9453,Preclinical
M8-B,transient receptor potential channel antagonist,TRPM8,10060,Preclinical
N-acetyl-D-glucosamine,,B4GALT1,3758,Phase 2/Phase 3
N-acetyl-D-glucosamine,,B4GALT2,3766,Phase 2/Phase 3
N-acetyl-D-glucosamine,,B4GALT3,3767,Phase 2/Phase 3
N-acetyl-D-glucosamine,,B4GALT4,3764,Phase 2/Phase 3
N-acetyl-D-glucosamine,,NAGK,5742,Phase 2/Phase 3
N-acetyl-D-glucosamine,,NAGLU,153,Phase 2/Phase 3
N-acetyl-D-glucosamine,,NAGPA,154,Phase 2/Phase 3
N-acetyl-D-glucosamine,,RENBP,155,Phase 2/Phase 3
N-alpha-methylhistamine-dihydrochloride,histamine receptor agonist,HRH4,4361,Phase 3
NAB-2,ubiquitin ligase transport promoter,NEDD4,673,Preclinical
nabumetone,cyclooxygenase inhibitor,PTGS1,5894,Launched
nabumetone,cyclooxygenase inhibitor,PTGS2,7225,Launched
nadide,free radical scavenger,AHCY,5916,Launched
nadide,free radical scavenger,AKR1A1,3350,Launched
nadide,free radical scavenger,ALDH2,8658,Launched
nadide,free radical scavenger,BLVRA,3065,Launched
nadide,free radical scavenger,DHPS,79885,Launched
nadide,free radical scavenger,DLD,3066,Launched
nadide,free radical scavenger,GALE,8841,Launched
nadide,free radical scavenger,HMGCR,4128,Launched
nadide,free radical scavenger,HSD17B1,4129,Launched
nadide,free radical scavenger,HSD17B4,1636,Launched
nadide,free radical scavenger,IMPDH2,59272,Launched
nadide,free radical scavenger,MGAM,4128,Launched
nadide,free radical scavenger,P2RY11,4129,Launched
nadide,free radical scavenger,SORD,5742,Launched
nadide,free radical scavenger,TRPM2,112398,Launched
nadolol,adrenergic receptor antagonist,ADRB1,1813,Launched
nadolol,adrenergic receptor antagonist,ADRB2,3269,Launched
nadolol,adrenergic receptor antagonist,ADRB3,3356,Launched
NADPH,,DRD2,-,Preclinical
NADPH,,DRD3,2908,Preclinical
NADPH,,DRD4,2908,Preclinical
NADPH,,GHSR,3832,Preclinical
NADPH,,HTR2A,7299,Preclinical
NADPH,,HTR2C,240,Preclinical
nafadotride,dopamine receptor antagonist,DRD2,10800,Preclinical
nafadotride,dopamine receptor antagonist,DRD3,6331,Preclinical
nafadotride,dopamine receptor antagonist,HTR1A,135,Preclinical
nafamostat,serine protease inhibitor,ASIC1,2100,Launched
nafamostat,serine protease inhibitor,ASIC2,2194,Launched
nafamostat,serine protease inhibitor,ASIC3,4170,Launched
nafamostat,serine protease inhibitor,C1R,116085,Launched
nafamostat,serine protease inhibitor,PRSS1,1595,Launched
nafamostat,serine protease inhibitor,TPSAB1,3360,Launched
nafamostat,serine protease inhibitor,TRPM7,2321,Launched
nafcillin,bacterial cell wall synthesis inhibitor,CYP1A2,2324,Launched
nafcillin,bacterial cell wall synthesis inhibitor,CYP3A4,3791,Launched
nafcillin,bacterial cell wall synthesis inhibitor,SLC22A6,3815,Launched
naftopidil,adrenergic receptor antagonist,ADRA1A,51311,Launched
nalbuphine,opioid receptor agonist|opioid receptor antagonist,OPRD1,7153,Launched
nalbuphine,opioid receptor agonist|opioid receptor antagonist,OPRK1,150,Launched
nalbuphine,opioid receptor agonist|opioid receptor antagonist,OPRM1,151,Launched
nalfurafine,opioid receptor agonist,OPRK1,152,Launched
nalfurafine,opioid receptor agonist,OPRM1,552,Launched
nalmefene,opioid receptor antagonist,OPRD1,553,Launched
nalmefene,opioid receptor antagonist,OPRK1,554,Launched
nalmefene,opioid receptor antagonist,OPRM1,2911,Launched
naloxegol,opioid receptor antagonist,OPRM1,2914,Launched
naloxone,opioid receptor antagonist,CREB1,2915,Launched
naloxone,opioid receptor antagonist,ESR1,7272,Launched
naloxone,opioid receptor antagonist,OPRD1,7272,Launched
naloxone,opioid receptor antagonist,OPRK1,7272,Launched
naloxone,opioid receptor antagonist,OPRM1,6916,Launched
naloxone,opioid receptor antagonist,TLR4,2554,Launched
naloxone-benzoylhydrazone,opioid receptor antagonist,OPRK1,2555,Preclinical
naloxone-benzoylhydrazone,opioid receptor antagonist,OPRM1,2556,Preclinical
naltrexone,opioid receptor antagonist,OPRD1,2558,Launched
naltrexone,opioid receptor antagonist,OPRK1,351,Launched
naltrexone,opioid receptor antagonist,OPRM1,136,Launched
naltrexone,opioid receptor antagonist,SIGMAR1,140,Launched
naltriben,opioid receptor antagonist,OPRD1,140,Preclinical
naltriben,opioid receptor antagonist,OPRK1,5031,Preclinical
naltriben,opioid receptor antagonist,OPRM1,134,Preclinical
naltrindole,opioid receptor antagonist,OPRD1,135,Preclinical
naltrindole,opioid receptor antagonist,OPRK1,136,Preclinical
naltrindole,opioid receptor antagonist,OPRM1,140,Preclinical
NAN-190,serotonin receptor agonist,ADRA1A,7852,Preclinical
NAN-190,serotonin receptor agonist,ADRA1B,2912,Preclinical
NAN-190,serotonin receptor agonist,ADRA1D,2913,Preclinical
NAN-190,serotonin receptor agonist,HTR1A,1956,Preclinical
NAN-190,serotonin receptor agonist,HTR1F,2064,Preclinical
napabucasin,STAT inhibitor,STAT3,2554,Phase 3
naphazoline,adrenergic receptor agonist,ADRA1A,2555,Launched
naphazoline,adrenergic receptor agonist,ADRA2A,2556,Launched
naproxen,cyclooxygenase inhibitor,PTGS1,2557,Launched
naproxen,cyclooxygenase inhibitor,PTGS2,2558,Launched
naratriptan,serotonin receptor agonist,HTR1A,2559,Launched
naratriptan,serotonin receptor agonist,HTR1B,2569,Launched
naratriptan,serotonin receptor agonist,HTR1D,2570,Launched
naratriptan,serotonin receptor agonist,HTR1E,200959,Launched
naratriptan,serotonin receptor agonist,HTR1F,8654,Launched
naringenin,aromatase inhibitor|TRPV antagonist,CYP19A1,3614,Phase 1
naringenin,aromatase inhibitor|TRPV antagonist,CYP1B1,3615,Phase 1
naringenin,aromatase inhibitor|TRPV antagonist,ESR2,3614,Phase 1
naringenin,aromatase inhibitor|TRPV antagonist,GLO1,3615,Phase 1
naringenin,aromatase inhibitor|TRPV antagonist,HSD17B1,5294,Phase 1
naringeninic-acid,,HCAR2,4842,Phase 1
naringeninic-acid,,PTGR1,5578,Phase 1
naringin,cytochrome P450 inhibitor,SLCO1A2,79054,Preclinical
NAS-181,serotonin receptor antagonist,HTR1B,2683,Preclinical
nastorazepide,CCK receptor antagonist,CCKBR,8704,Phase 2
nateglinide,insulin secretagogue,ABCC8,8703,Launched
nateglinide,insulin secretagogue,KCNJ10,8702,Launched
nateglinide,insulin secretagogue,KCNJ11,55577,Launched
nateglinide,insulin secretagogue,PPARG,4669,Launched
NAV-26,voltage-gated sodium channel blocker,SCN9A,51172,Preclinical
navarixin,CC chemokine receptor antagonist,CXCR1,5973,Phase 2
navarixin,CC chemokine receptor antagonist,CXCR2,59340,Phase 2
navitoclax,BCL inhibitor,BCL2,4734,Phase 2
navitoclax,BCL inhibitor,BCL2L1,5742,Phase 2
navitoclax,BCL inhibitor,BCL2L2,5743,Phase 2
NBI-27914,corticotropin releasing factor receptor antagonist,CRHR1,191,Preclinical
NBI-74330-(+/-),CC chemokine receptor antagonist,CXCR3,10327,Preclinical
NBQX,glutamate receptor antagonist,GRIA1,217,Preclinical
NBQX,glutamate receptor antagonist,GRIA2,644,Preclinical
NBQX,glutamate receptor antagonist,GRIA3,1725,Preclinical
NBQX,glutamate receptor antagonist,GRIA4,1738,Preclinical
NBQX,glutamate receptor antagonist,GRIK1,2582,Preclinical
NBQX,glutamate receptor antagonist,GRIN1,3156,Preclinical
NBQX,glutamate receptor antagonist,GRIN2A,3292,Preclinical
NBQX,glutamate receptor antagonist,GRIN2B,3295,Preclinical
NCS-382,GABA receptor antagonist,GABBR1,3615,Preclinical
NCS-382,GABA receptor antagonist,GABBR2,8972,Preclinical
NCS-382,GABA receptor antagonist,SLC52A2,5032,Preclinical
NDT-9513727,complement antagonist,C5AR1,6652,Preclinical
NE-100,sigma receptor antagonist,SIGMAR1,7226,Phase 2
nebivolol,adrenergic receptor antagonist,ADRB1,153,Launched
nebracetam,acetylcholine receptor agonist,CHRM1,154,Phase 3
NECA,adenosine receptor agonist,ADORA1,155,Launched
NECA,adenosine receptor agonist,ADORA2A,1813,Launched
NECA,adenosine receptor agonist,ADORA2B,1814,Launched
NECA,adenosine receptor agonist,ADORA3,1815,Launched
necrostatin-1,RIPK inhibitor,RIPK1,2693,Preclinical
necrostatin-2,necroptosis inhibitor|RIPK inhibitor,RIPK2,3356,Preclinical
nedocromil,histamine receptor antagonist,CYSLTR1,3358,Launched
nedocromil,histamine receptor antagonist,CYSLTR2,1813,Launched
nedocromil,histamine receptor antagonist,FPR1,1814,Launched
nedocromil,histamine receptor antagonist,HSP90AA1,3350,Launched
nedocromil,histamine receptor antagonist,PTGDR,41,Launched
nefazodone,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,ADRA1A,40,Withdrawn
nefazodone,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,ADRA1B,9311,Withdrawn
nefazodone,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,ADRA2A,715,Withdrawn
nefazodone,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,CYP3A4,5644,Withdrawn
nefazodone,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,HTR1A,7177,Withdrawn
nefazodone,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,HTR2A,54822,Withdrawn
nefazodone,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,HTR2C,1544,Withdrawn
nefazodone,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,SLC6A2,1576,Withdrawn
nefazodone,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,SLC6A3,9356,Withdrawn
nefazodone,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,SLC6A4,148,Withdrawn
nefiracetam,acetylcholine receptor agonist|benzodiazepine receptor agonist,CHRM1,4985,Phase 3
nelarabine,DNA synthesis inhibitor|T cell inhibitor,POLA1,4986,Launched
nelfinavir,HIV protease inhibitor,CYP1A2,4988,Launched
nelfinavir,HIV protease inhibitor,CYP2B6,4986,Launched
nelfinavir,HIV protease inhibitor,CYP2C19,4988,Launched
nelfinavir,HIV protease inhibitor,CYP2C9,4985,Launched
nelfinavir,HIV protease inhibitor,CYP2D6,4986,Launched
nelfinavir,HIV protease inhibitor,CYP3A4,4988,Launched
nelfinavir,HIV protease inhibitor,CYP3A7,4988,Launched
nemonapride,dopamine receptor antagonist,DRD2,1385,Launched
nemonapride,dopamine receptor antagonist,DRD3,2099,Launched
nemonapride,dopamine receptor antagonist,DRD4,4985,Launched
nemorubicin,topoisomerase inhibitor,TOP1,4986,Phase 2
nemorubicin,topoisomerase inhibitor,TOP2A,4988,Phase 2
neomycin,bacterial 30S ribosomal subunit inhibitor,CXCR4,7099,Launched
neostigmine,acetylcholinesterase inhibitor,ACHE,4986,Launched
nepafenac,cyclooxygenase inhibitor,PTGS1,4988,Launched
nepafenac,cyclooxygenase inhibitor,PTGS2,4985,Launched
nepicastat,dopamine beta hydroxylase inhibitor,DBH,4986,Phase 2
neratinib,EGFR inhibitor,EGFR,4988,Launched
neratinib,EGFR inhibitor,ERBB2,10280,Launched
neratinib,EGFR inhibitor,KDR,4985,Launched
neridronic-acid,bone resorption inhibitor,FDPS,4986,Launched
netupitant,tachykinin antagonist,TACR1,4988,Launched
neuropathiazol,neural stem cell inducer,BMP2,4985,Preclinical
neuropathiazol,neural stem cell inducer,LIF,4986,Preclinical
nevirapine,non-nucleoside reverse transcriptase inhibitor,CYP1A2,4988,Launched
nevirapine,non-nucleoside reverse transcriptase inhibitor,CYP2A6,148,Launched
nevirapine,non-nucleoside reverse transcriptase inhibitor,CYP2B6,147,Launched
nevirapine,non-nucleoside reverse transcriptase inhibitor,CYP2C9,146,Launched
nevirapine,non-nucleoside reverse transcriptase inhibitor,CYP2D6,3350,Launched
nevirapine,non-nucleoside reverse transcriptase inhibitor,CYP3A4,3355,Launched
nevirapine,non-nucleoside reverse transcriptase inhibitor,CYP3A5,6774,Launched
nexturastat-A,HDAC inhibitor,HDAC1,148,Preclinical
nexturastat-A,HDAC inhibitor,HDAC6,150,Preclinical
NFKB-activation-inhibitor-II,NFkB pathway inhibitor,RELA,5742,Preclinical
NG-nitro-arginine,nitric oxide synthase inhibitor,NOS1,5743,Phase 1
NG-nitro-arginine,nitric oxide synthase inhibitor,NOS2,3350,Phase 1
NG-nitro-arginine,nitric oxide synthase inhibitor,NOS3,3351,Phase 1
NGB-2904,dopamine receptor antagonist,DRD3,3352,Preclinical
NGD-94-1,dopamine receptor antagonist,DRD4,3354,Phase 1
NGD-98-2,corticotropin releasing factor receptor antagonist,CRHR1,3355,Preclinical
NHI-2,lactate dehydrogenase inhibitor,LDHA,1588,Preclinical
NI-57,bromodomain inhibitor,BRD1,1545,Preclinical
NI-57,bromodomain inhibitor,BRPF1,2100,Preclinical
NI-57,bromodomain inhibitor,BRPF3,2739,Preclinical
niacin,NAD precursor|vitamin B,DGAT2,3292,Launched
niacin,NAD precursor|vitamin B,HCAR1,338442,Launched
niacin,NAD precursor|vitamin B,HCAR2,22949,Launched
niacin,NAD precursor|vitamin B,HCAR3,6579,Launched
niacin,NAD precursor|vitamin B,NNMT,3351,Launched
niacin,NAD precursor|vitamin B,QPRT,887,Launched
nialamide,monoamine oxidase inhibitor,COMT,6833,Withdrawn
nialamide,monoamine oxidase inhibitor,MAOA,3766,Withdrawn
nialamide,monoamine oxidase inhibitor,MAOB,3767,Withdrawn
nicardipine,calcium channel blocker,ADORA3,5468,Launched
nicergoline,adrenergic receptor antagonist,ADRA1A,6335,Launched
niclosamide,DNA replication inhibitor|STAT inhibitor,STAT3,3577,Launched
nicorandil,nitric oxide donor|potassium channel activator,KCNJ11,3579,Launched
nicotinamide,protein synthesis stimulant,BST1,596,Launched
nicotinamide,protein synthesis stimulant,LDHA,598,Launched
nicotinamide,protein synthesis stimulant,PARP1,599,Launched
nicotinamide,protein synthesis stimulant,SIRT5,1394,Launched
nicotine,acetylcholine receptor agonist,CHAT,2833,Launched
nicotine,acetylcholine receptor agonist,CHRNA10,2890,Launched
nicotine,acetylcholine receptor agonist,CHRNA2,2891,Launched
nicotine,acetylcholine receptor agonist,CHRNA3,2892,Launched
nicotine,acetylcholine receptor agonist,CHRNA4,2893,Launched
nicotine,acetylcholine receptor agonist,CHRNA5,2897,Launched
nicotine,acetylcholine receptor agonist,CHRNA6,2902,Launched
nicotine,acetylcholine receptor agonist,CHRNA7,2903,Launched
nicotine,acetylcholine receptor agonist,CHRNA9,2904,Launched
nicotine,acetylcholine receptor agonist,CHRNB2,2550,Launched
nicotine,acetylcholine receptor agonist,CHRNB3,9568,Launched
nicotine,acetylcholine receptor agonist,CHRNB4,79581,Launched
nicotine,acetylcholine receptor agonist,CYP19A1,728,Launched
nicotine,acetylcholine receptor agonist,TBXAS1,10280,Launched
nicotine,acetylcholine receptor agonist,TRPA1,153,Launched
NIDA-41020,cannabinoid receptor antagonist,CNR1,1128,Preclinical
nifedipine,calcium channel blocker,CACNA1C,134,Launched
nifedipine,calcium channel blocker,CACNA1D,135,Launched
nifedipine,calcium channel blocker,CACNA1F,136,Launched
nifedipine,calcium channel blocker,CACNA1H,140,Launched
nifedipine,calcium channel blocker,CACNA1S,8737,Launched
nifedipine,calcium channel blocker,CACNA2D1,8767,Launched
nifedipine,calcium channel blocker,CACNB2,10800,Launched
nifedipine,calcium channel blocker,CALM1,57105,Launched
nifedipine,calcium channel blocker,GLRA1,2357,Launched
nifedipine,calcium channel blocker,GLRA3,3320,Launched
nifedipine,calcium channel blocker,GLRB,5729,Launched
nifedipine,calcium channel blocker,KCNA1,148,Launched
nifedipine,calcium channel blocker,KCNA5,147,Launched
nifedipine,calcium channel blocker,NR1I2,150,Launched
nifedipine,calcium channel blocker,TRPM3,1576,Launched
nifenalol,adrenergic receptor antagonist,ADRB1,3350,Launched
nifenalol,adrenergic receptor antagonist,ADRB2,3356,Launched
niflumic-acid,cyclooxygenase inhibitor,ANO1,3358,Launched
niflumic-acid,cyclooxygenase inhibitor,CLCN1,6530,Launched
niflumic-acid,cyclooxygenase inhibitor,CLCNKA,6531,Launched
niflumic-acid,cyclooxygenase inhibitor,CLCNKB,6532,Launched
niflumic-acid,cyclooxygenase inhibitor,KCNQ1,1128,Launched
niflumic-acid,cyclooxygenase inhibitor,PLA2G1B,5422,Launched
niflumic-acid,cyclooxygenase inhibitor,PLA2G4A,1544,Launched
niflumic-acid,cyclooxygenase inhibitor,PTGS1,1555,Launched
niflumic-acid,cyclooxygenase inhibitor,PTGS2,1557,Launched
niflumic-acid,cyclooxygenase inhibitor,UGT1A9,1559,Launched
niguldipine-(S)-(+),adrenergic receptor antagonist,ADRA1A,1565,Preclinical
nilotinib,Abl kinase inhibitor|Bcr-Abl kinase inhibitor,ABL1,1576,Launched
nilotinib,Abl kinase inhibitor|Bcr-Abl kinase inhibitor,KIT,1551,Launched
nilutamide,androgen receptor antagonist,AR,1813,Launched
nilvadipine,calcium channel blocker,CACNA1C,1814,Launched
nilvadipine,calcium channel blocker,CACNA1D,1815,Launched
nimesulide,cyclooxygenase inhibitor,LTF,7150,Launched
nimesulide,cyclooxygenase inhibitor,PLA2G2E,7153,Launched
nimesulide,cyclooxygenase inhibitor,PTGS1,7852,Launched
nimesulide,cyclooxygenase inhibitor,PTGS2,43,Launched
nimodipine,calcium channel blocker,CFTR,5742,Launched
nimodipine,calcium channel blocker,NR3C2,5743,Launched
nintedanib,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FGFR1,1621,Launched
nintedanib,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FGFR2,1956,Launched
nintedanib,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FGFR3,2064,Launched
nintedanib,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FGFR4,3791,Launched
nintedanib,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FLT1,2224,Launched
nintedanib,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FLT4,6869,Launched
nintedanib,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KDR,650,Launched
nintedanib,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,PDGFRA,3976,Launched
nintedanib,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,PDGFRB,1544,Launched
niraparib,PARP inhibitor,PARP1,1548,Launched
nisoldipine,calcium channel blocker,CACNA1C,1555,Launched
nisoldipine,calcium channel blocker,CACNA1D,1559,Launched
nisoldipine,calcium channel blocker,CACNA1F,1565,Launched
nisoldipine,calcium channel blocker,CACNA1S,1576,Launched
nisoxetine,norepinephrine reuptake inhibitor,SLC6A2,1577,Phase 1
nisoxetine,norepinephrine reuptake inhibitor,SLC6A3,3065,Phase 1
nisoxetine,norepinephrine reuptake inhibitor,SLC6A4,10013,Phase 1
nitecapone,catechol O methyltransferase inhibitor,COMT,5970,Phase 2
nitrendipine,calcium channel blocker,CACNA1D,4842,Launched
nitrendipine,calcium channel blocker,CACNA2D1,4843,Launched
nitrendipine,calcium channel blocker,KCNN4,4846,Launched
nitrocaramiphen,cholinergic receptor antagonist,CHRM1,1814,Preclinical
nitroxoline,cathepsin inhibitor,METAP2,1815,Launched
nizatidine,histamine receptor antagonist,HRH2,1394,Launched
NK-252,nuclear factor erythroid derived|like (NRF2) activator,NFE2L2,3939,Preclinical
NKY-80,adenylyl cyclase inhibitor,ADCY5,23774,Preclinical
NLG919,"indoleamine 2,3-dioxygenase inhibitor",IDO1,7862,Phase 1
NMDA,glutamate receptor agonist,GRIN1,27154,Preclinical
NMDA,glutamate receptor agonist,GRIN2A,84649,Preclinical
NMDA,glutamate receptor agonist,GRIN2B,27198,Preclinical
NMDA,glutamate receptor agonist,GRIN2C,338442,Preclinical
NMDA,glutamate receptor agonist,GRIN2D,8843,Preclinical
NMS-1286937,PLK inhibitor,FLT3,4837,Phase 2
NMS-1286937,PLK inhibitor,PLK1,23475,Phase 2
NMS-1286937,PLK inhibitor,PLK2,1312,Phase 2
NMS-1286937,PLK inhibitor,PLK3,4128,Phase 2
NMS-873,ATPase inhibitor,VCP,4129,Preclinical
NN-DNJ,glucosidase inhibitor,GBA,140,Preclinical
NNC-05-2090,GABA uptake inhibitor|GAT inhibitor,SLC6A12,148,Preclinical
NNC-55-0396,T-type calcium channel blocker,CATSPER1,6774,Preclinical
NNC-55-0396,T-type calcium channel blocker,CATSPER2,3767,Preclinical
NNC-55-0396,T-type calcium channel blocker,CATSPER3,683,Preclinical
NNC-55-0396,T-type calcium channel blocker,CATSPER4,3939,Preclinical
NNC-63-0532,opioid receptor agonist,OPRL1,142,Preclinical
NNC-711,GABA uptake inhibitor,SIGMAR1,23408,Preclinical
NNC-711,GABA uptake inhibitor,SLC6A1,1103,Preclinical
NO-ASA,cyclooxygenase inhibitor,PTGS2,57053,Phase 2
nobiletin,MEK inhibitor,MAP2K1,1135,Preclinical
nocodazole,tubulin polymerization inhibitor,HPGDS,1136,Preclinical
nolatrexed,thymidylate synthase inhibitor,TYMS,1137,Phase 3
nomegestrol-acetate,progesterone receptor agonist,PGR,1138,Launched
nomifensine,dopamine reuptake inhibitor|noradrenaline uptake inhibitor,DRD2,8973,Withdrawn
nomifensine,dopamine reuptake inhibitor|noradrenaline uptake inhibitor,SLC6A2,1139,Withdrawn
nomifensine,dopamine reuptake inhibitor|noradrenaline uptake inhibitor,SLC6A3,55584,Withdrawn
nonivamide,TRPV agonist,TRPV1,1141,Launched
nor-binaltorphimine,opioid receptor antagonist,OPRD1,1142,Preclinical
nor-binaltorphimine,opioid receptor antagonist,OPRK1,1143,Preclinical
nor-binaltorphimine,opioid receptor antagonist,OPRM1,1588,Preclinical
norelgestromin,,PGR,6916,Launched
norepinephrine,adrenergic receptor agonist,ADRA1A,8989,Launched
norepinephrine,adrenergic receptor agonist,ADRA1B,1268,Launched
norepinephrine,adrenergic receptor agonist,ADRA1D,775,Launched
norepinephrine,adrenergic receptor agonist,ADRA2A,776,Launched
norepinephrine,adrenergic receptor agonist,ADRA2B,778,Launched
norepinephrine,adrenergic receptor agonist,ADRA2C,8912,Launched
norepinephrine,adrenergic receptor agonist,ADRB1,779,Launched
norepinephrine,adrenergic receptor agonist,ADRB2,781,Launched
norepinephrine,adrenergic receptor agonist,ADRB3,783,Launched
norepinephrine,adrenergic receptor agonist,PAH,801,Launched
norepinephrine,adrenergic receptor agonist,SLC18A1,2741,Launched
norepinephrine,adrenergic receptor agonist,SLC18A2,8001,Launched
norethindrone,progesterone receptor agonist,PGR,2743,Launched
norethindrone-acetate,progesterone receptor agonist,PGR,3736,Launched
noretynodrel,progestogen hormone,PGR,3741,Launched
norfloxacin,bacterial DNA gyrase inhibitor,TOP2A,8856,Launched
norfluoxetine,selective serotonin reuptake inhibitor (SSRI),HTR2B,80036,Phase 1
norgestimate,progesterone receptor agonist,ESR1,153,Launched
norgestimate,progesterone receptor agonist,PGR,154,Launched
norgestrel,progesterone receptor agonist,AR,55107,Launched
norgestrel,progesterone receptor agonist,ESR1,1180,Launched
norgestrel,progesterone receptor agonist,PGR,1187,Launched
norgestrel,progesterone receptor agonist,SRD5A1,1188,Launched
nortriptyline,tricyclic antidepressant,ADRA1A,3784,Launched
nortriptyline,tricyclic antidepressant,ADRA1B,5319,Launched
nortriptyline,tricyclic antidepressant,ADRA1D,5321,Launched
nortriptyline,tricyclic antidepressant,ADRA2A,5742,Launched
nortriptyline,tricyclic antidepressant,ADRA2B,5743,Launched
nortriptyline,tricyclic antidepressant,ADRA2C,54600,Launched
nortriptyline,tricyclic antidepressant,ADRB1,148,Launched
nortriptyline,tricyclic antidepressant,ADRB2,25,Launched
nortriptyline,tricyclic antidepressant,ADRB3,3815,Launched
nortriptyline,tricyclic antidepressant,CHRM1,367,Launched
nortriptyline,tricyclic antidepressant,CHRM2,775,Launched
nortriptyline,tricyclic antidepressant,CHRM3,776,Launched
nortriptyline,tricyclic antidepressant,CHRM4,4057,Launched
nortriptyline,tricyclic antidepressant,CHRM5,30814,Launched
nortriptyline,tricyclic antidepressant,DRD2,5742,Launched
nortriptyline,tricyclic antidepressant,HRH1,5743,Launched
nortriptyline,tricyclic antidepressant,HTR1A,1080,Launched
nortriptyline,tricyclic antidepressant,HTR2A,4306,Launched
nortriptyline,tricyclic antidepressant,HTR2C,2260,Launched
nortriptyline,tricyclic antidepressant,HTR6,2263,Launched
nortriptyline,tricyclic antidepressant,KCNJ10,2261,Launched
nortriptyline,tricyclic antidepressant,PGRMC1,2264,Launched
nortriptyline,tricyclic antidepressant,SIGMAR1,2321,Launched
nortriptyline,tricyclic antidepressant,SLC6A2,2324,Launched
nortriptyline,tricyclic antidepressant,SLC6A4,3791,Launched
noscapine,bradykinin receptor antagonist|tubulin polymerization inhibitor,SIGMAR1,5156,Launched
NOV-002,,GSR,5159,Phase 3
NPC-15199,ICAM1 antagonist,PPARG,142,Phase 2
NPPB,chloride channel blocker,ANO1,775,Preclinical
NPPB,chloride channel blocker,CLCN2,776,Preclinical
NPPB,chloride channel blocker,CLCN7,778,Preclinical
NPPB,chloride channel blocker,TRPA1,779,Preclinical
NPS-2143,calcium receptor antagonist,CASR,6530,Preclinical
NPY-5RA972,neuropeptide receptor antagonist,NPY5R,6531,Preclinical
NQDI-1,caspase inhibitor,CASP3,6532,Preclinical
NS-018,JAK inhibitor,JAK1,1312,Phase 1/Phase 2
NS-018,JAK inhibitor,JAK2,776,Phase 1/Phase 2
NS-018,JAK inhibitor,JAK3,781,Phase 1/Phase 2
NS-018,JAK inhibitor,TYK2,3783,Phase 1/Phase 2
NS-11021,calcium-activated potassium channel activator,KCNMA1,1128,Preclinical
NS-1643,voltage-gated potassium channel activator,KCNH2,10988,Preclinical
NS-1643,voltage-gated potassium channel activator,KCNH6,3274,Preclinical
NS-1643,voltage-gated potassium channel activator,KCNMA1,4780,Preclinical
NS-19504,calcium-activated potassium channel activator,KCNMA1,111,Preclinical
NS-309,calcium-activated potassium channel activator,KCNN1,3620,Preclinical
NS-309,calcium-activated potassium channel activator,KCNN2,2902,Preclinical
NS-309,calcium-activated potassium channel activator,KCNN3,2903,Preclinical
NS-309,calcium-activated potassium channel activator,KCNN4,2904,Preclinical
NS-3623,voltage-gated potassium channel activator,KCNH2,2905,Preclinical
NS-3861,acetylcholine receptor agonist,CHRNA3,2906,Preclinical
NS-3861,acetylcholine receptor agonist,CHRNB4,2322,Preclinical
NS-5806,voltage-gated potassium channel activator,KCND3,5347,Preclinical
NS-8,potassium channel agonist,KCNMA1,10769,Phase 2
NS-8593,calcium-activated potassium channel modulator,KCNN1,1263,Preclinical
NS-8593,calcium-activated potassium channel modulator,KCNN2,7415,Preclinical
NS-8593,calcium-activated potassium channel modulator,KCNN3,2629//2630,Preclinical
NS-9283,acetylcholine receptor allosteric modulator,CHRNA4,6539,Preclinical
NSC-3852,HDAC inhibitor,HDAC1,117144,Preclinical
NSC-405020,matrix metalloprotease inhibitor,MMP1,117155,Preclinical
NSC-4644,ACAT inhibitor|sterol regulatory element binding protein (SREBP) inhibitor,PYGM,5837,Phase 2
NSC-5844,CC chemokine receptor agonist,CCR1,1230,Preclinical
NSC-625987,CDK inhibitor,CDK2,1017,Preclinical
NSC-625987,CDK inhibitor,CDK4,1019,Preclinical
NSC-632839,ubiquitin specific protease inhibitor,SENP2,59343,Preclinical
NSC-632839,ubiquitin specific protease inhibitor,USP1,7398,Preclinical
NSC-632839,ubiquitin specific protease inhibitor,USP2,9099,Preclinical
NSC-632839,ubiquitin specific protease inhibitor,USP7,7874,Preclinical
NSC-636819,histone demethylase inhibitor,KDM4A,9682,Preclinical
NSC-636819,histone demethylase inhibitor,KDM4B,23030,Preclinical
NSC-663284,CDC inhibitor,CDC25A,993,Preclinical
NSC-663284,CDC inhibitor,CDC25B,994,Preclinical
NSC-663284,CDC inhibitor,CDC25C,995,Preclinical
NSC-697923,ubiquitin-conjugating enzyme inhibitor,UBE2N,7334,Preclinical
NSC-95397,CDC inhibitor,CDC25A,993,Preclinical
NSC-95397,CDC inhibitor,CDC25B,994,Preclinical
NSC-9965,acetylcholine receptor antagonist,CHRNA4,1137,Preclinical
NSC-9965,acetylcholine receptor antagonist,CHRNB2,1141,Preclinical
NTNCB,neuropeptide receptor antagonist,NPY5R,4889,Preclinical
NTRC-824,neurotensin receptor antagonist,NTSR2,23620,Preclinical
nTZDpa,PPAR receptor agonist,PPARG,5468,Preclinical
NT157,IGF-1 inhibitor,IGF1R,3480,Preclinical
NU-1025,PARP inhibitor,PARP1,142,Preclinical
NU-2058,cyclin D inhibitor,CCNA2,890,Preclinical
NU-2058,cyclin D inhibitor,CDK2,1017,Preclinical
NU-6027,CDK inhibitor,CCNA2,890,Preclinical
NU-6027,CDK inhibitor,CDK2,1017,Preclinical
NU-7026,DNA dependent protein kinase inhibitor|mTOR inhibitor|PI3K inhibitor,PRKDC,5591,Preclinical
NU-7441,DNA dependent protein kinase inhibitor,PRKDC,5591,Preclinical
nutlin-3,MDM inhibitor,MDM2,4193,Preclinical
nutlin-3,MDM inhibitor,TP53,7157,Preclinical
NVP-ADW742,insulin growth factor receptor inhibitor,IGF1R,3480,Preclinical
NVP-AEW541,IGF-1 inhibitor,IGF1R,3480,Preclinical
NVP-AEW541,IGF-1 inhibitor,INSR,3643,Preclinical
NVP-AUY922,HSP inhibitor,HSP90AA1,3320,Phase 2
NVP-AUY922,HSP inhibitor,HSP90AB1,3326,Phase 2
NVP-BEZ235,mTOR inhibitor|PI3K inhibitor,ATR,545,Phase 3
NVP-BEZ235,mTOR inhibitor|PI3K inhibitor,MTOR,2475,Phase 3
NVP-BEZ235,mTOR inhibitor|PI3K inhibitor,PIK3CA,5290,Phase 3
NVP-BEZ235,mTOR inhibitor|PI3K inhibitor,PIK3CD,5293,Phase 3
NVP-BEZ235,mTOR inhibitor|PI3K inhibitor,PIK3CG,5294,Phase 3
NVP-BGJ398,FGFR inhibitor,FGFR1,2260,Phase 3
NVP-BGJ398,FGFR inhibitor,FGFR2,2263,Phase 3
NVP-BGJ398,FGFR inhibitor,FGFR3,2261,Phase 3
NVP-BGJ398,FGFR inhibitor,FGFR4,2264,Phase 3
NVP-BGJ398,FGFR inhibitor,KDR,3791,Phase 3
NVP-BHG712,ephrin inhibitor,EPHB4,2050,Preclinical
NVP-BSK805,JAK inhibitor,JAK2,3717,Preclinical
NVP-BVU972,MET inhibitor,MET,4233,Preclinical
NVP-DPP728,dipeptidyl peptidase inhibitor,DPP4,1803,Phase 2
NVP-HSP990,HSP inhibitor,HSP90AA1,3320,Phase 1
NVP-HSP990,HSP inhibitor,HSP90AB1,3326,Phase 1
NVP-TAE226,protein tyrosine kinase inhibitor,PTK2,5747,Preclinical
NVP-TAE684,ALK tyrosine kinase receptor inhibitor,ALK,238,Preclinical
NVP-TAE684,ALK tyrosine kinase receptor inhibitor,INSR,3643,Preclinical
NVP-TNKS656,tankyrase inhibitor,TNKS2,80351,Preclinical
NVP-231,ceramidase inhibitor,CERK,64781,Preclinical
NVS-PAK1-1,p21 activated kinase inhibitor,PAK1,5058,Preclinical
N6-cyclopentyladenosine,adenosine receptor agonist,ADORA1,134,Preclinical
N6-cyclopentyladenosine,adenosine receptor agonist,ADORA2A,135,Preclinical
N6-cyclopentyladenosine,adenosine receptor agonist,ADORA2B,136,Preclinical
N6-cyclopentyladenosine,adenosine receptor agonist,ADORA3,140,Preclinical
N6-cyclopentyladenosine,adenosine receptor agonist,SLC29A1,2030,Preclinical
N6022,alcohol dehydrogenase inhibitor,ADH5,128,Phase 1/Phase 2
O-acetyl-L-serine,,PTGS1,5742,Preclinical
OAC2,Oct activator,POU5F1,5460,Preclinical
obatoclax,BCL inhibitor,BCL2,596,Phase 3
obeticholic-acid,FXR agonist,NR1H4,9971,Launched
obidoxime,cholinesterase reactivator,ACHE,43,Launched
ochromycinone,STAT inhibitor,STAT3,6774,Phase 1
ocinaplon,GABA receptor modulator,GABRA1,2554,Phase 3
ocinaplon,GABA receptor modulator,GABRA2,2555,Phase 3
ocinaplon,GABA receptor modulator,GABRA3,2556,Phase 3
ocinaplon,GABA receptor modulator,GABRA5,2558,Phase 3
octopamine,trace amine associated receptor agonist,F10,2159,Preclinical
octopamine,trace amine associated receptor agonist,TAAR1,134864,Preclinical
octreotide,somatostatin receptor agonist,SSTR2,6752,Launched
octreotide,somatostatin receptor agonist,SSTR3,6753,Launched
octreotide,somatostatin receptor agonist,SSTR5,6755,Launched
OC000459,CRTH receptor antagonist,PTGDR2,11251,Phase 2
odanacatib,cathepsin inhibitor,CTSK,1513,Phase 3
ODQ,guanylyl cyclase inhibitor,GUCY1A2,2977,Preclinical
ODQ,guanylyl cyclase inhibitor,GUCY1A3,-,Preclinical
ODQ,guanylyl cyclase inhibitor,GUCY1B3,-,Preclinical
OF-1,bromodomain inhibitor,BRD1,23774,Preclinical
OG-L002,histone lysine demethylase inhibitor,KDM1A,23028,Preclinical
OICR-9429,WDR5/MLL interaction inhibitor,WDR5,11091,Preclinical
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A,148,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1B,147,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,ADRA2A,150,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,ADRA2B,151,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,ADRA2C,152,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,ADRB1,153,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,ADRB2,154,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,ADRB3,155,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,CHRM1,1128,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,CHRM2,1129,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,CHRM3,1131,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,CHRM4,1132,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,CHRM5,1133,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,DRD1,5293,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,DRD2,5294,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,DRD3,5591,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,DRD4,5298,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,DRD5,5289,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,GABRA1,5294,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,GABRA2,1128,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,GABRA3,1129,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,GABRA4,1131,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,GABRA5,1132,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,GABRA6,1133,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,GABRB1,6331,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,GABRB2,5292,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,GABRB3,1813,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,GABRD,3356,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,GABRE,5139,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,GABRG1,8911,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,GABRG2,801,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,GABRG3,1812,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,GABRP,1813,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,GABRQ,1814,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,HRH1,1815,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,HRH2,1816,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,HRH4,3269,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1A,3350,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1B,3356,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1D,3744,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1E,3757,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1F,6833,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR2A,10060,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR2B,775,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR2C,153,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR3A,154,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR5A,3350,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR6,3356,Launched
olanzapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR7,3357,Launched
olaparib,PARP inhibitor,PARP1,3350,Launched
olaparib,PARP inhibitor,PARP2,1545,Launched
OLDA,TRPV agonist,GPR119,5468,Preclinical
oleamide,cannabinoid receptor agonist,HTR7,80036,Preclinical
oleamide,cannabinoid receptor agonist,PLA2G2A,1813,Preclinical
oleanolic-acid,G protein-coupled receptor agonist,GPBAR1,3269,Preclinical
oleoylethanolamide,cannabinoid receptor agonist|glucose dependent insulinotropic receptor agonist|potassium channel blocker|PPAR receptor agonist,CNR1,3350,Preclinical
oleoylethanolamide,cannabinoid receptor agonist|glucose dependent insulinotropic receptor agonist|potassium channel blocker|PPAR receptor agonist,GPR119,3351,Preclinical
oleoylethanolamide,cannabinoid receptor agonist|glucose dependent insulinotropic receptor agonist|potassium channel blocker|PPAR receptor agonist,GPR55,3352,Preclinical
oleoylethanolamide,cannabinoid receptor agonist|glucose dependent insulinotropic receptor agonist|potassium channel blocker|PPAR receptor agonist,PPARA,3356,Preclinical
oleuropein,estrogen receptor agonist,GPER1,1129,Phase 2
oligomycin-A,ATP synthase inhibitor|ATPase inhibitor,ATP5A1,1131,Preclinical
olmesartan,angiotensin receptor antagonist,AGTR1,1135,Launched
olmesartan-medoxomil,angiotensin receptor antagonist,AGTR1,1128,Launched
olmutinib,Bruton's tyrosine kinase (BTK) inhibitor|EGFR inhibitor,BTK,2562,Launched
olmutinib,Bruton's tyrosine kinase (BTK) inhibitor|EGFR inhibitor,EGFR,1128,Launched
olomoucine,CDK inhibitor,CDK1,4128,Preclinical
olomoucine,CDK inhibitor,CDK2,4129,Preclinical
olomoucine,CDK inhibitor,CDK5,7442,Preclinical
olomoucine,CDK inhibitor,MAPK1,1812,Preclinical
olopatadine,histamine receptor antagonist,HRH1,1813,Launched
olopatadine,histamine receptor antagonist,S100A1,3350,Launched
olopatadine,histamine receptor antagonist,S100A12,3356,Launched
olopatadine,histamine receptor antagonist,S100A13,1812,Launched
olopatadine,histamine receptor antagonist,S100A2,1813,Launched
olopatadine,histamine receptor antagonist,S100B,3350,Launched
olprinone,phosphodiesterase inhibitor,PDE3A,3356,Launched
olsalazine,cyclooxygenase inhibitor,IFNG,2890,Launched
olsalazine,cyclooxygenase inhibitor,TPMT,2891,Launched
oltipraz,nuclear factor erythroid derived|like (NRF2) activator,ANG,2892,Phase 3
olvanil,TRPV agonist,CNR1,2893,Preclinical
olvanil,TRPV agonist,GPR119,7153,Preclinical
olvanil,TRPV agonist,TRPV1,3356,Preclinical
omapatrilat,metalloproteinase inhibitor,ACE,3363,Preclinical
omapatrilat,metalloproteinase inhibitor,MME,1128,Preclinical
omarigliptin,dipeptidyl peptidase inhibitor,DPP4,1129,Launched
OMDM-2,FAAH inhibitor,GPR119,1131,Preclinical
omecamtiv-mecarbil,cardiac myosin activator,MYBPC3,1132,Phase 3
omeprazole,ATPase inhibitor,ATP4A,1133,Launched
omeprazole,ATPase inhibitor,CLCN2,6557,Launched
omeprazole-magnesium,proton pump inhibitor,ATP4A,6558,Launched
omeprazole-magnesium,proton pump inhibitor,ATP4B,5045,Launched
ONC201,AKT inhibitor|MAP kinase inhibitor,TNFSF10,7124,Phase 2
ondansetron,serotonin receptor antagonist,HTR3A,148,Launched
ondansetron,serotonin receptor antagonist,HTR3B,150,Launched
ONO-AE3-208,prostanoid receptor antagonist,PTGER4,152,Preclinical
ONO-4059,Bruton's tyrosine kinase (BTK) inhibitor,BTK,1813,Phase 1
ONO-4817,matrix metalloprotease inhibitor,MMP8,1814,Phase 1
ONO-8130,prostanoid receptor antagonist,PTGER1,1815,Preclinical
ON123300,CDK inhibitor,CDK4,3350,Preclinical
ON123300,CDK inhibitor,NUAK1,3357,Preclinical
ON123300,CDK inhibitor,PDGFRB,3356,Preclinical
OPC-21268,vasopressin receptor antagonist,AVPR1A,5465,Phase 1
OPC-21268,vasopressin receptor antagonist,AVPR2,4128,Phase 1
OPC-21268,vasopressin receptor antagonist,OXTR,5742,Phase 1
opicapone,catechol O methyltransferase inhibitor,COMT,5743,Phase 3
OR-486,catechol O methyltransferase inhibitor,COMT,5139,Preclinical
orantinib,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,AURKA,5028,Phase 3
orantinib,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,AURKB,3156,Phase 3
orantinib,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,EGFR,11255,Phase 3
orantinib,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FGFR1,1394,Phase 3
orantinib,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FGFR2,1395,Phase 3
orantinib,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KDR,3065,Phase 3
orantinib,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,PDGFRA,3066,Phase 3
orantinib,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,PDGFRB,1812,Phase 3
ORE1001,angiotensin converting enzyme inhibitor,ACE2,1813,Phase 1/Phase 2
ORG-12962,serotonin receptor agonist,HTR2A,1814,Phase 2
ORG-12962,serotonin receptor agonist,HTR2B,1815,Phase 2
ORG-12962,serotonin receptor agonist,HTR2C,1816,Phase 2
ORG-25543,glycine transporter inhibitor,GLRB,2554,Preclinical
ORG-25543,glycine transporter inhibitor,SLC6A5,2555,Preclinical
ORG-27569,cannabinoid receptor modulator,CNR1,2556,Preclinical
ORG-9768,adrenergic receptor antagonist,ADRA2A,2557,Phase 1
oridonin,BCL inhibitor,BCL2,2558,Preclinical
orlistat,lipase inhibitor,CNR1,2559,Launched
orlistat,lipase inhibitor,DAGLA,2560,Launched
orlistat,lipase inhibitor,DAGLB,2561,Launched
orlistat,lipase inhibitor,FASN,2562,Launched
orlistat,lipase inhibitor,LIPF,2563,Launched
orlistat,lipase inhibitor,PNLIP,2564,Launched
ornithine,NFkB pathway modulator,GPRC6A,2565,Launched
orotic-acid,,DHODH,2566,Phase 2
orphanin-fq,opioid receptor agonist,OPRL1,2567,Phase 1
orphanin-fq,opioid receptor agonist,OPRM1,2568,Phase 1
orteronel,androgen biosynthesis inhibitor|androgen receptor antagonist|cytochrome P450 inhibitor,CYP17A1,55879,Phase 3
ORY-1001,histone lysine demethylase inhibitor,KDM1A,3269,Phase 1/Phase 2
oseltamivir-phosphate,neuraminidase inhibitor,CES1,3274,Launched
oseltamivir-phosphate,neuraminidase inhibitor,NEU1,59340,Launched
oseltamivir-phosphate,neuraminidase inhibitor,NEU2,3350,Launched
osemozotan,serotonin receptor agonist,HTR1A,3351,Phase 2/Phase 3
OSI-027,mTOR inhibitor,MTOR,3352,Phase 1
OSI-420,EGFR inhibitor,EGFR,3354,Preclinical
OSI-930,KIT inhibitor|VEGFR inhibitor,FLT1,3355,Phase 1
OSI-930,KIT inhibitor|VEGFR inhibitor,KDR,3356,Phase 1
OSI-930,KIT inhibitor|VEGFR inhibitor,KIT,3357,Phase 1
osimertinib,EGFR inhibitor,EGFR,3358,Launched
ospemifene,selective estrogen receptor modulator (SERM),ESR1,3359,Launched
ospemifene,selective estrogen receptor modulator (SERM),ESR2,3361,Launched
ostarine,androgen receptor modulator,AR,3362,Phase 3
OT-R-antagonist-1,oxytocin receptor antagonist,AVPR1A,3363,Preclinical
OT-R-antagonist-1,oxytocin receptor antagonist,OXTR,142,Preclinical
otamixaban,coagulation factor inhibitor,F10,10038,Phase 3
otenzepad,acetylcholine receptor antagonist,CHRM1,139760,Phase 3
otenzepad,acetylcholine receptor antagonist,CHRM2,3363,Phase 3
otenzepad,acetylcholine receptor antagonist,CHRM3,5320,Phase 3
otenzepad,acetylcholine receptor antagonist,CHRM4,151306,Phase 3
otenzepad,acetylcholine receptor antagonist,CHRM5,1268,Phase 3
otilonium,acetylcholine receptor antagonist,CACNA1C,139760,Launched
OTS167,maternal embryonic leucine zipper kinase inhibitor,MELK,9290,Phase 1/Phase 2
OTX015,bromodomain inhibitor,BRD2,5465,Phase 1/Phase 2
OTX015,bromodomain inhibitor,BRD3,2852,Phase 1/Phase 2
OTX015,bromodomain inhibitor,BRD4,-,Phase 1/Phase 2
ouabain,ATPase inhibitor,ATP1A1,185,Launched
OXA-06,rho associated kinase inhibitor,ROCK1,185,Preclinical
OXA-06,rho associated kinase inhibitor,ROCK2,695,Preclinical
oxaprozin,cyclooxygenase inhibitor,PTGS1,1956,Launched
oxaprozin,cyclooxygenase inhibitor,PTGS2,983,Launched
oxatomide,histamine receptor antagonist,HRH1,1017,Launched
oxcarbazepine,sodium channel blocker,SCN10A,1020,Launched
oxcarbazepine,sodium channel blocker,SCN11A,5594,Launched
oxcarbazepine,sodium channel blocker,SCN1A,3269,Launched
oxcarbazepine,sodium channel blocker,SCN2A,6271,Launched
oxcarbazepine,sodium channel blocker,SCN3A,6283,Launched
oxcarbazepine,sodium channel blocker,SCN4A,6284,Launched
oxcarbazepine,sodium channel blocker,SCN5A,6273,Launched
oxcarbazepine,sodium channel blocker,SCN7A,6285,Launched
oxcarbazepine,sodium channel blocker,SCN8A,5139,Launched
oxcarbazepine,sodium channel blocker,SCN9A,3458,Launched
OXF-BD-02,bromodomain inhibitor,BRD4,7172,Preclinical
oxfenicine,carnitine palmitoyltransferase inhibitor,CPT1A,283,Phase 1
oxfenicine,carnitine palmitoyltransferase inhibitor,CPT1B,1268,Phase 1
oxibendazole,tubulin polymerization inhibitor,TUBB,139760,Launched
oxibendazole,tubulin polymerization inhibitor,TUBB4B,7442,Launched
oxotremorine-M,acetylcholine receptor agonist,CHRM1,1636,Preclinical
oxotremorine-M,acetylcholine receptor agonist,CHRM2,4311,Preclinical
oxotremorine-M,acetylcholine receptor agonist,CHRM3,1803,Preclinical
oxotremorine-M,acetylcholine receptor agonist,CHRM4,139760,Preclinical
oxotremorine-sesquifumarate,cholinergic receptor agonist,CHRM1,4607,Preclinical
oxotremorine-sesquifumarate,cholinergic receptor agonist,CHRM2,495,Preclinical
oxotremorine-sesquifumarate,cholinergic receptor agonist,CHRM3,1181,Preclinical
oxotremorine-sesquifumarate,cholinergic receptor agonist,CHRM4,495,Preclinical
oxprenolol,adrenergic receptor antagonist,ADRB1,496,Launched
oxybenzone,lipase inhibitor,LIPE,8743,Launched
oxybuprocaine,local anesthetic,SCN10A,3359,Launched
oxybutynin,acetylcholine receptor antagonist,CHRM1,9177,Launched
oxybutynin,acetylcholine receptor antagonist,CHRM2,5734,Launched
oxybutynin,acetylcholine receptor antagonist,CHRM3,695,Launched
oxymetazoline,adrenergic receptor agonist,ADRA1A,4317,Launched
oxymetazoline,adrenergic receptor agonist,ADRA1B,5731,Launched
oxymetazoline,adrenergic receptor agonist,ADRA1D,1019,Launched
oxymetazoline,adrenergic receptor agonist,ADRA2A,9891,Launched
oxymetazoline,adrenergic receptor agonist,ADRA2B,5159,Launched
oxymetazoline,adrenergic receptor agonist,ADRA2C,552,Launched
oxymetazoline,adrenergic receptor agonist,HTR1B,554,Launched
oxymetazoline,adrenergic receptor agonist,HTR1D,5021,Launched
oxymetazoline,adrenergic receptor agonist,HTR2C,1312,Launched
oxyphenonium,cholinergic receptor antagonist,CHRM1,1312,Launched
oxyphenonium,cholinergic receptor antagonist,CHRM3,6790,Launched
oxypurinol,xanthine oxidase inhibitor,XDH,9212,Phase 2/Phase 3
oxyquinoline,chelating agent,METAP2,1956,Launched
oxytocin,oxytocin receptor agonist,AVPR1A,2260,Launched
oxytocin,oxytocin receptor agonist,AVPR1B,2263,Launched
oxytocin,oxytocin receptor agonist,AVPR2,3791,Launched
oxytocin,oxytocin receptor agonist,OXTR,5156,Launched
ozagrel,thromboxane synthase inhibitor,TBXAS1,150,Launched
ozanimod,sphingosine 1-phosphate receptor agonist,S1PR1,151,Phase 3
O4I1,Oct inducer,POU5F1,152,Preclinical
O6-benzylguanine,O6-alkylguanine-DNA alkyltransferase inhibitor,MGMT,79001,Phase 3
PA-452,retinoid receptor antagonist,RXRA,43,Preclinical
PAC-1,caspase activator,CASP3,590,Phase 1
paclitaxel,tubulin polymerization inhibitor,BCL2,148,Launched
paclitaxel,tubulin polymerization inhibitor,MAP2,147,Launched
paclitaxel,tubulin polymerization inhibitor,MAP4,146,Launched
paclitaxel,tubulin polymerization inhibitor,MAPT,150,Launched
paclitaxel,tubulin polymerization inhibitor,NR1I2,151,Launched
paclitaxel,tubulin polymerization inhibitor,TLR4,152,Launched
paclitaxel,tubulin polymerization inhibitor,TUBA1A,5740,Launched
paclitaxel,tubulin polymerization inhibitor,TUBA1B,5742,Launched
paclitaxel,tubulin polymerization inhibitor,TUBA1C,5743,Launched
paclitaxel,tubulin polymerization inhibitor,TUBA3C,3065,Launched
paclitaxel,tubulin polymerization inhibitor,TUBA3D,148,Launched
paclitaxel,tubulin polymerization inhibitor,TUBA3E,147,Launched
paclitaxel,tubulin polymerization inhibitor,TUBA4A,146,Launched
paclitaxel,tubulin polymerization inhibitor,TUBB,6336,Launched
paclitaxel,tubulin polymerization inhibitor,TUBB1,11280,Launched
paclitaxel,tubulin polymerization inhibitor,TUBB2A,6323,Launched
paclitaxel,tubulin polymerization inhibitor,TUBB2B,6326,Launched
paclitaxel,tubulin polymerization inhibitor,TUBB3,6328,Launched
paclitaxel,tubulin polymerization inhibitor,TUBB4A,6329,Launched
paclitaxel,tubulin polymerization inhibitor,TUBB4B,6331,Launched
paclitaxel,tubulin polymerization inhibitor,TUBB6,6332,Launched
paclitaxel,tubulin polymerization inhibitor,TUBB8,6334,Launched
PACOCF3,phospholipase inhibitor,PLA2G4A,6335,Preclinical
pacritinib,FLT3 inhibitor|JAK inhibitor,FLT3,7157,Phase 3
pacritinib,FLT3 inhibitor|JAK inhibitor,JAK1,366,Phase 3
pacritinib,FLT3 inhibitor|JAK inhibitor,JAK2,1182,Phase 3
pacritinib,FLT3 inhibitor|JAK inhibitor,JAK3,9963,Phase 3
palbociclib,CDK inhibitor,CDK4,6523,Launched
palbociclib,CDK inhibitor,CDK6,115584,Launched
paliperidone,dopamine receptor antagonist|serotonin receptor antagonist,DRD2,6524,Launched
paliperidone,dopamine receptor antagonist|serotonin receptor antagonist,HTR2A,6526,Launched
palmatine-chloride,dopamine synthesis inhibitor,CYP3A4,196,Preclinical
palmitoylethanolamide,cannabinoid receptor agonist,CNR2,2554,Launched
palmitoylethanolamide,cannabinoid receptor agonist,GPR119,2561,Launched
palmitoylethanolamide,cannabinoid receptor agonist,GPR55,2566,Launched
palomid-529,AKT inhibitor|mTOR inhibitor,MTOR,208,Phase 1
palonosetron,serotonin receptor antagonist,HTR3A,5170,Launched
palosuran,urotensin receptor antagonist,UTS2R,2100,Phase 2
palovarotene,retinoid receptor agonist,RARG,43,Phase 3
pamidronate,bone resorption inhibitor,FDPS,590,Launched
pancuronium,acetylcholine receptor antagonist,CHRM2,632,Launched
pancuronium,acetylcholine receptor antagonist,CHRM3,2677,Launched
pancuronium,acetylcholine receptor antagonist,CHRNA1,2475,Launched
pancuronium,acetylcholine receptor antagonist,CHRNA2,5290,Launched
panobinostat,HDAC inhibitor,HDAC1,5291,Launched
panobinostat,HDAC inhibitor,HDAC2,5293,Launched
panobinostat,HDAC inhibitor,HDAC3,5294,Launched
panobinostat,HDAC inhibitor,HDAC4,5591,Launched
panobinostat,HDAC inhibitor,HDAC6,3357,Launched
panobinostat,HDAC inhibitor,HDAC7,3360,Launched
panobinostat,HDAC inhibitor,HDAC8,495,Launched
panobinostat,HDAC inhibitor,HDAC9,-,Launched
pantoprazole,ATPase inhibitor,ATP4A,506,Launched
PAOPA,dopamine receptor modulator,DRD2,-,Preclinical
papaverine,phosphodiesterase inhibitor,PDE10A,3661,Launched
papaverine,phosphodiesterase inhibitor,PDE4B,5141,Launched
papaverine,phosphodiesterase inhibitor,PDE5A,5142,Launched
para-toluenesulfonamide,,CA12,5143,Phase 3
para-toluenesulfonamide,,CA2,5144,Phase 3
para-toluenesulfonamide,,CA6,6915,Phase 3
para-toluenesulfonamide,,CA9,2741,Phase 3
paracetamol,cyclooxygenase inhibitor,FAAH,2742,Launched
paracetamol,cyclooxygenase inhibitor,PTGS1,8001,Launched
paracetamol,cyclooxygenase inhibitor,PTGS2,2743,Launched
paracetamol,cyclooxygenase inhibitor,TRPV1,2741,Launched
paramethadione,anticonvulsant,CACNA1G,2742,Launched
parbendazole,tubulin polymerization inhibitor,TUBB,8001,Preclinical
pardoprunox,dopamine receptor agonist|serotonin receptor agonist,DRD2,2743,Phase 3
pardoprunox,dopamine receptor agonist|serotonin receptor agonist,DRD3,3359,Phase 3
pardoprunox,dopamine receptor agonist|serotonin receptor agonist,DRD4,9177,Phase 3
pardoprunox,dopamine receptor agonist|serotonin receptor agonist,HTR1A,10863,Phase 3
pardoprunox,dopamine receptor agonist|serotonin receptor agonist,HTR7,276,Phase 3
parecoxib,cyclooxygenase inhibitor,LTF,279,Launched
pargyline,monoamine oxidase inhibitor,MAOA,280,Launched
pargyline,monoamine oxidase inhibitor,MAOB,283,Launched
paricalcitol,vitamin D receptor agonist,VDR,6355,Launched
paroxetine,selective serotonin reuptake inhibitor (SSRI),CHRM1,3060,Launched
paroxetine,selective serotonin reuptake inhibitor (SSRI),CHRM2,3537,Launched
paroxetine,selective serotonin reuptake inhibitor (SSRI),CHRM3,440021,Launched
paroxetine,selective serotonin reuptake inhibitor (SSRI),CHRM4,7032,Launched
paroxetine,selective serotonin reuptake inhibitor (SSRI),CHRM5,7422,Launched
paroxetine,selective serotonin reuptake inhibitor (SSRI),HTR2A,7157,Launched
paroxetine,selective serotonin reuptake inhibitor (SSRI),SLC6A2,7157,Launched
paroxetine,selective serotonin reuptake inhibitor (SSRI),SLC6A4,3303,Launched
parthenolide-(-),NFkB pathway inhibitor,HDAC1,7157,Preclinical
parthenolide-(alternate-stereo),NFkB pathway inhibitor,IKBKB,5290,Preclinical
parthenolide-(alternate-stereo),NFkB pathway inhibitor,RELA,5291,Preclinical
pasireotide,somatostatin receptor agonist,SSTR1,5293,Launched
pasireotide,somatostatin receptor agonist,SSTR2,5294,Launched
pasireotide,somatostatin receptor agonist,SSTR3,5291,Launched
pasireotide,somatostatin receptor agonist,SSTR5,5293,Launched
pazopanib,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,CSF1R,5294,Launched
pazopanib,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FGF1,5290,Launched
pazopanib,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FGFR1,5291,Launched
pazopanib,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FGFR3,1787,Launched
pazopanib,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FLT1,57053,Launched
pazopanib,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FLT4,1136,Launched
pazopanib,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,ITK,1137,Launched
pazopanib,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KDR,1143,Launched
pazopanib,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KIT,100,Launched
pazopanib,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,PDGFRA,134,Launched
pazopanib,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,PDGFRB,135,Launched
pazopanib,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,SH2B3,136,Launched
PCA-4248,platelet activating factor receptor antagonist,PTAFR,151,Phase 1
PCI-24781,HDAC inhibitor,HDAC1,4907,Phase 3
PCI-24781,HDAC inhibitor,HDAC2,10846,Phase 3
PCI-24781,HDAC inhibitor,HDAC3,5136,Phase 3
PCI-24781,HDAC inhibitor,HDAC6,5153,Phase 3
PCI-29732,Bruton's tyrosine kinase (BTK) inhibitor,BTK,5137,Preclinical
PCI-34051,HDAC inhibitor,HDAC1,5138,Preclinical
PCI-34051,HDAC inhibitor,HDAC10,5139,Preclinical
PCI-34051,HDAC inhibitor,HDAC6,5140,Preclinical
PCI-34051,HDAC inhibitor,HDAC8,5141,Preclinical
PCO-400,potassium channel activator,KCNJ8,5142,Phase 1
PD-0325901,MEK inhibitor,MAP2K1,5143,Phase 2
PD-102807,acetylcholine receptor antagonist,CHRM4,5144,Preclinical
PD-118057,potassium channel activator,KCNH2,8654,Preclinical
PD-123319,angiotensin antagonist,AGTR2,5145,Phase 1
PD-128907,dopamine receptor agonist,DRD2,5158,Preclinical
PD-128907,dopamine receptor agonist,DRD3,5146,Preclinical
PD-153035,EGFR inhibitor,EGFR,5147,Phase 1
PD-153035,EGFR inhibitor,KDR,5148,Phase 1
PD-156707,endothelin receptor antagonist,EDNRA,5149,Preclinical
PD-156707,endothelin receptor antagonist,EDNRB,5150,Preclinical
PD-158780,EGFR inhibitor,EGFR,27115,Preclinical
PD-160170,neuropeptide receptor antagonist,NPY1R,5151,Preclinical
PD-161570,FGFR inhibitor,FGFR1,8622,Preclinical
PD-166285,SRC inhibitor,EGFR,5152,Preclinical
PD-166285,SRC inhibitor,FGFR1,7124,Preclinical
PD-166285,SRC inhibitor,PDGFRB,1508,Preclinical
PD-166285,SRC inhibitor,PKMYT1,1509,Preclinical
PD-166285,SRC inhibitor,SRC,1514,Preclinical
PD-166285,SRC inhibitor,WEE1,5972,Preclinical
PD-166793,collagenase inhibitor|metalloproteinase inhibitor,MMP13,6256,Preclinical
PD-166793,collagenase inhibitor|metalloproteinase inhibitor,MMP2,148,Preclinical
PD-166793,collagenase inhibitor|metalloproteinase inhibitor,MMP3,147,Preclinical
PD-168077,dopamine receptor agonist,DRD2,146,Preclinical
PD-168393,EGFR inhibitor,EGFR,150,Preclinical
PD-168393,EGFR inhibitor,ERBB2,151,Preclinical
PD-168393,EGFR inhibitor,SRC,152,Preclinical
PD-168568,dopamine receptor antagonist,DRD2,1812,Preclinical
PD-168568,dopamine receptor antagonist,DRD4,1813,Preclinical
PD-173074,FGFR inhibitor|VEGFR inhibitor,FGFR1,1814,Preclinical
PD-173074,FGFR inhibitor|VEGFR inhibitor,FGFR2,1815,Preclinical
PD-173074,FGFR inhibitor|VEGFR inhibitor,FGFR3,1816,Preclinical
PD-173074,FGFR inhibitor|VEGFR inhibitor,FGFR4,3350,Preclinical
PD-173074,FGFR inhibitor|VEGFR inhibitor,FLT1,3351,Preclinical
PD-173074,FGFR inhibitor|VEGFR inhibitor,FLT4,3352,Preclinical
PD-173074,FGFR inhibitor|VEGFR inhibitor,KDR,3356,Preclinical
PD-173074,FGFR inhibitor|VEGFR inhibitor,PDGFRA,3357,Preclinical
PD-173074,FGFR inhibitor|VEGFR inhibitor,PDGFRB,3358,Preclinical
PD-173212,calcium channel blocker,CACNA1B,1374,Preclinical
PD-184352,MEK inhibitor,MAP2K1,207,Phase 2
PD-184352,MEK inhibitor,MAP3K1,2339,Phase 2
PD-184352,MEK inhibitor,MAP3K2,1636,Phase 2
PD-198306,MAP kinase inhibitor|MEK inhibitor,MAP2K1,1636,Preclinical
PD-198306,MAP kinase inhibitor|MEK inhibitor,MAP2K2,1813,Preclinical
PD-407824,PKC inhibitor,WEE1,1814,Preclinical
PD-81723,adenosine receptor agonist,ADORA1,1815,Preclinical
PD-98059,MEK inhibitor,AKT1,801,Preclinical
PD-98059,MEK inhibitor,CHEK1,1812,Preclinical
PD-98059,MEK inhibitor,GSK3B,1813,Preclinical
PD-98059,MEK inhibitor,LCK,3269,Preclinical
PD-98059,MEK inhibitor,MAP2K1,3356,Preclinical
PD-98059,MEK inhibitor,MAPK1,3358,Preclinical
PD-98059,MEK inhibitor,MAPK11,3362,Preclinical
PD-98059,MEK inhibitor,MAPK12,3363,Preclinical
PD-98059,MEK inhibitor,MAPK14,2902,Preclinical
PD-98059,MEK inhibitor,MAPK8,2903,Preclinical
PD-98059,MEK inhibitor,PRKCA,2904,Preclinical
PD-98059,MEK inhibitor,RAF1,836,Preclinical
PD-98059,MEK inhibitor,ROCK1,8883,Preclinical
PD-98059,MEK inhibitor,RPS6KB1,9039,Preclinical
PD-98059,MEK inhibitor,SGK1,1436,Preclinical
PDE10-IN-1,phosphodiesterase inhibitor,PDE10A,2322,Preclinical
PDP-EA,FAAH activator,FAAH,3815,Preclinical
PD1-PDL-inhibitor-1,programmed death ligand inhibitor,CD274,1432,Preclinical
peficitinib,JAK inhibitor,JAK1,7010,Launched
peficitinib,JAK inhibitor,JAK2,10846,Launched
peficitinib,JAK inhibitor,JAK3,8654,Launched
pefloxacin,bacterial DNA gyrase inhibitor,TOP2A,10298,Launched
pelanserin,serotonin receptor antagonist,HTR2A,6790,Phase 2
pelitinib,EGFR inhibitor,EGFR,9212,Phase 2
pemetrexed,dihydrofolate reductase inhibitor|thymidylate synthase inhibitor,ATIC,4233,Launched
pemetrexed,dihydrofolate reductase inhibitor|thymidylate synthase inhibitor,DHFR,5732,Launched
pemetrexed,dihydrofolate reductase inhibitor|thymidylate synthase inhibitor,GART,5152,Launched
pemetrexed,dihydrofolate reductase inhibitor|thymidylate synthase inhibitor,TYMS,2166,Launched
pemirolast,mediator release inhibitor,HRH1,8694,Launched
penbutolol,adrenergic receptor antagonist,ADRB1,2475,Launched
penbutolol,adrenergic receptor antagonist,ADRB2,5290,Launched
penbutolol,adrenergic receptor antagonist,HTR1A,6336,Launched
penbutolol,adrenergic receptor antagonist,HTR1B,2645,Launched
penfluridol,T-type calcium channel blocker,CACNA1G,2693,Launched
pentagastrin,CCK receptor agonist,CCKBR,2475,Launched
pentamidine,anti-pneumocystis agent,TRDMT1,983,Launched
pentolinium,cholinergic receptor antagonist,CHRNA10,1019,Launched
pentolinium,cholinergic receptor antagonist,CHRNA3,1025,Launched
pentolinium,cholinergic receptor antagonist,CHRNA4,7874,Launched
pentolinium,cholinergic receptor antagonist,CHRNB4,10135,Launched
pentostatin,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,ADA,5139,Launched
pentoxifylline,phosphodiesterase inhibitor,ADORA1,5140,Launched
pentoxifylline,phosphodiesterase inhibitor,ADORA2A,-,Launched
pentoxifylline,phosphodiesterase inhibitor,ADORA2B,506,Launched
pentoxifylline,phosphodiesterase inhibitor,ADRA2B,-,Launched
pentoxifylline,phosphodiesterase inhibitor,NT5E,3055,Launched
pentoxifylline,phosphodiesterase inhibitor,PDE10A,26275,Launched
pentoxifylline,phosphodiesterase inhibitor,PDE1A,5294,Launched
pentoxifylline,phosphodiesterase inhibitor,PDE1B,5292,Launched
pentoxifylline,phosphodiesterase inhibitor,PDE1C,9262,Launched
pentoxifylline,phosphodiesterase inhibitor,PDE2A,133688,Launched
pentoxifylline,phosphodiesterase inhibitor,PDE3A,148,Launched
pentoxifylline,phosphodiesterase inhibitor,PDE3B,147,Launched
pentoxifylline,phosphodiesterase inhibitor,PDE4A,146,Launched
pentoxifylline,phosphodiesterase inhibitor,PDE4B,150,Launched
pentoxifylline,phosphodiesterase inhibitor,PDE4C,151,Launched
pentoxifylline,phosphodiesterase inhibitor,PDE4D,152,Launched
pentoxifylline,phosphodiesterase inhibitor,PDE5A,1128,Launched
pentoxifylline,phosphodiesterase inhibitor,PDE6A,1129,Launched
pentoxifylline,phosphodiesterase inhibitor,PDE6B,1131,Launched
pentoxifylline,phosphodiesterase inhibitor,PDE6C,1132,Launched
pentoxifylline,phosphodiesterase inhibitor,PDE6D,1133,Launched
pentoxifylline,phosphodiesterase inhibitor,PDE6G,1812,Launched
pentoxifylline,phosphodiesterase inhibitor,PDE6H,1813,Launched
pentoxifylline,phosphodiesterase inhibitor,PDE7A,1814,Launched
pentoxifylline,phosphodiesterase inhibitor,PDE7B,1815,Launched
pentoxifylline,phosphodiesterase inhibitor,PDE8A,1816,Launched
pentoxifylline,phosphodiesterase inhibitor,PDE8B,3269,Launched
pentoxifylline,phosphodiesterase inhibitor,PDE9A,3350,Launched
pentoxifylline,phosphodiesterase inhibitor,TNF,3351,Launched
pepstatin,aspartic protease inhibitor,CTSB,3352,Preclinical
pepstatin,aspartic protease inhibitor,CTSD,3354,Preclinical
pepstatin,aspartic protease inhibitor,CTSL,3355,Preclinical
pepstatin,aspartic protease inhibitor,REN,3356,Preclinical
peretinoin,retinoid receptor agonist,RXRA,3358,Phase 3
pergolide,dopamine receptor agonist,ADRA1A,3359,Withdrawn
pergolide,dopamine receptor agonist,ADRA1B,3362,Withdrawn
pergolide,dopamine receptor agonist,ADRA1D,3363,Withdrawn
pergolide,dopamine receptor agonist,ADRA2A,6530,Withdrawn
pergolide,dopamine receptor agonist,ADRA2B,240,Withdrawn
pergolide,dopamine receptor agonist,ADRA2C,241,Withdrawn
pergolide,dopamine receptor agonist,DRD1,1813,Withdrawn
pergolide,dopamine receptor agonist,DRD2,1636,Withdrawn
pergolide,dopamine receptor agonist,DRD3,1636,Withdrawn
pergolide,dopamine receptor agonist,DRD4,1813,Withdrawn
pergolide,dopamine receptor agonist,DRD5,1814,Withdrawn
pergolide,dopamine receptor agonist,HTR1A,2099,Withdrawn
pergolide,dopamine receptor agonist,HTR1B,2100,Withdrawn
pergolide,dopamine receptor agonist,HTR1D,3741,Withdrawn
pergolide,dopamine receptor agonist,HTR2A,3743,Withdrawn
pergolide,dopamine receptor agonist,HTR2B,3756,Withdrawn
pergolide,dopamine receptor agonist,HTR2C,3757,Withdrawn
perhexiline,carnitine palmitoyltransferase inhibitor,CPT1A,27133,Launched
perifosine,AKT inhibitor,AKT1,3775,Phase 3
perillyl-alcohol,apoptosis stimulant|farnesyltransferase inhibitor,FNTA,9424,Phase 2
perindopril,angiotensin converting enzyme inhibitor,ACE,6331,Launched
perindoprilat,angiotensin converting enzyme inhibitor,ACE,222962,Phase 2
perospirone,dopamine receptor antagonist|serotonin receptor antagonist,DRD2,2815,Launched
perospirone,dopamine receptor antagonist|serotonin receptor antagonist,DRD3,9312,Launched
perospirone,dopamine receptor antagonist|serotonin receptor antagonist,DRD4,3783,Launched
perphenazine,dopamine receptor antagonist,CALM1,222962,Launched
perphenazine,dopamine receptor antagonist,DRD1,1812,Launched
perphenazine,dopamine receptor antagonist,DRD2,1813,Launched
perphenazine,dopamine receptor antagonist,HRH1,1814,Launched
perphenazine,dopamine receptor antagonist,HTR2A,1815,Launched
perphenazine,dopamine receptor antagonist,HTR2C,3350,Launched
perphenazine,dopamine receptor antagonist,HTR6,3356,Launched
perphenazine,dopamine receptor antagonist,HTR7,3357,Launched
perzinfotel,glutamate receptor antagonist,GRIN1,3358,Phase 2
perzinfotel,glutamate receptor antagonist,GRIN2A,3350,Phase 2
perzinfotel,glutamate receptor antagonist,GRIN2B,3352,Phase 2
PETCM,caspase activator,CASP3,3356,Preclinical
pevonedistat,nedd activating enzyme inhibitor,NAE1,3357,Phase 3
pevonedistat,nedd activating enzyme inhibitor,UBA3,3358,Phase 3
pexidartinib,tyrosine kinase inhibitor,CSF1R,3359,Launched
pexidartinib,tyrosine kinase inhibitor,FLT3,9177,Launched
pexidartinib,tyrosine kinase inhibitor,KIT,3362,Launched
pexmetinib,MAP kinase inhibitor|TIE tyrosine kinase inhibitor,MAPK14,6532,Phase 1
pexmetinib,MAP kinase inhibitor|TIE tyrosine kinase inhibitor,TEK,1436,Phase 1
PF-02545920,phosphodiesterase inhibitor,PDE10A,2322,Phase 2
PF-03049423,phosphodiesterase inhibitor,PDE5A,3815,Phase 2
PF-03758309,p21 activated kinase inhibitor,PAK4,5156,Phase 1
PF-03814735,Aurora kinase inhibitor,AURKA,5159,Phase 1
PF-03814735,Aurora kinase inhibitor,AURKB,5979,Phase 1
PF-04217903,c-Met inhibitor,MET,1432,Phase 1
PF-04418948,prostaglandin inhibitor,PTGER2,7046,Phase 1
PF-04447943,phosphodiesterase inhibitor,PDE9A,3362,Phase 2
PF-04457845,FAAH inhibitor,FAAH,7046,Phase 2
PF-04620110,diacylglycerol O acyltransferase inhibitor,DGAT1,558,Phase 1
PF-04691502,mTOR inhibitor|PI3K inhibitor,MTOR,1606,Phase 2
PF-04691502,mTOR inhibitor|PI3K inhibitor,PIK3CA,3356,Phase 2
PF-04885614,voltage-gated sodium channel blocker,SCN10A,495,Preclinical
PF-04937319,glucokinase activator,GCK,2550,Phase 2
PF-05190457,growth hormone secretagogue receptor inverse agonist,GHSR,4311,Phase 2
PF-05212384,mTOR inhibitor|PI3K inhibitor,MTOR,1813,Phase 2
PF-05212384,mTOR inhibitor|PI3K inhibitor,PIK3CA,5290,Phase 2
PF-06447475,serine/threonine kinase inhibitor,LRRK2,120892,Preclinical
PF-06463922,ALK tyrosine kinase receptor inhibitor,ALK,238,Launched
PF-06463922,ALK tyrosine kinase receptor inhibitor,FES,2242,Launched
PF-06463922,ALK tyrosine kinase receptor inhibitor,ROS1,6098,Launched
PF-3274167,oxytocin receptor antagonist,AVPR1A,552,Phase 2
PF-3274167,oxytocin receptor antagonist,OXTR,5021,Phase 2
PF-3845,FAAH inhibitor,FAAH,2166,Preclinical
PF-429242,SREBP inhibitor,MBTPS1,8720,Preclinical
PF-431396,focal adhesion kinase inhibitor,PTK2,5747,Preclinical
PF-431396,focal adhesion kinase inhibitor,PTK2B,2185,Preclinical
PF-4708671,ribosomal protein inhibitor,RPS6KB1,6198,Preclinical
PF-477736,CHK inhibitor,CHEK1,1111,Phase 1
PF-477736,CHK inhibitor,CHEK2,11200,Phase 1
PF-4800567,casein kinase inhibitor,CSNK1D,1453,Preclinical
PF-4800567,casein kinase inhibitor,CSNK1E,1454,Preclinical
PF-4981517,cytochrome P450 inhibitor,CYP3A4,1576,Preclinical
PF-5274857,smoothened receptor antagonist,SMO,6608,Preclinical
PF-562271,focal adhesion kinase inhibitor,PTK2,5747,Phase 1
PF-562271,focal adhesion kinase inhibitor,PTK2B,2185,Phase 1
PF-573228,focal adhesion kinase inhibitor,CDK1,983,Preclinical
PF-573228,focal adhesion kinase inhibitor,CDK2,1017,Preclinical
PF-573228,focal adhesion kinase inhibitor,CDK7,1022,Preclinical
PF-573228,focal adhesion kinase inhibitor,GSK3B,2932,Preclinical
PF-573228,focal adhesion kinase inhibitor,IKBKB,3551,Preclinical
PF-670462,casein kinase inhibitor,CSNK1D,1453,Preclinical
PF-670462,casein kinase inhibitor,CSNK1E,1454,Preclinical
PF-750,FAAH inhibitor,FAAH,2166,Preclinical
PF-8380,autotaxin inhibitor,ENPP2,5168,Preclinical
PF-915275,11-beta hydroxysteroid dehydrogenase inhibitor,HSD11B1,3290,Phase 1
PFI-1,bromodomain inhibitor,BRD4,23476,Preclinical
PFI-3,bromodomain inhibitor,PBRM1,55193,Preclinical
PFI-3,bromodomain inhibitor,SMARCA4,6597,Preclinical
PFI-4,bromodomain inhibitor,BRPF1,7862,Preclinical
PFK-015,phosphofructokinase inhibitor,PFKFB3,5209,Phase 1
PFK-158,phosphofructokinase inhibitor,PFKFB3,5209,Phase 1
PGL5001,JNK inhibitor,MAPK10,5602,Phase 2
PGL5001,JNK inhibitor,MAPK8,5599,Phase 2
PGL5001,JNK inhibitor,MAPK9,5601,Phase 2
PH-797804,p38 MAPK inhibitor,MAPK11,5600,Phase 2
PH-797804,p38 MAPK inhibitor,MAPK14,1432,Phase 2
PHA-568487,nicotinic receptor agonist,CHRNA7,1139,Preclinical
PHA-665752,c-Met inhibitor,MET,4233,Preclinical
PHA-680632,Aurora kinase inhibitor,AURKA,6790,Preclinical
PHA-680632,Aurora kinase inhibitor,AURKB,9212,Preclinical
PHA-680632,Aurora kinase inhibitor,AURKC,6795,Preclinical
PHA-767491,CDC inhibitor,CDK1,983,Preclinical
PHA-767491,CDC inhibitor,RPS6KB1,6198,Preclinical
PHA-793887,CDK inhibitor,CDK1,983,Phase 1
PHA-793887,CDK inhibitor,CDK2,1017,Phase 1
PHA-793887,CDK inhibitor,CDK4,1019,Phase 1
PHA-793887,CDK inhibitor,CDK5,1020,Phase 1
PHA-793887,CDK inhibitor,CDK7,1022,Phase 1
PHA-793887,CDK inhibitor,CDK9,1025,Phase 1
PHA-848125,CDK inhibitor|growth factor receptor inhibitor,CDK2,1017,Phase 2
PHA-848125,CDK inhibitor|growth factor receptor inhibitor,CDK4,1019,Phase 2
PHA-848125,CDK inhibitor|growth factor receptor inhibitor,CDK7,1022,Phase 2
PHA-848125,CDK inhibitor|growth factor receptor inhibitor,NTRK1,4914,Phase 2
PHCCC,glutamate receptor agonist,GRM1,2911,Preclinical
PHCCC,glutamate receptor agonist,GRM4,2914,Preclinical
phenacemide,sodium channel blocker,SCN10A,6336,Launched
phenacemide,sodium channel blocker,SCN11A,11280,Launched
phenacemide,sodium channel blocker,SCN1A,6323,Launched
phenacemide,sodium channel blocker,SCN2A,6326,Launched
phenacemide,sodium channel blocker,SCN3A,6328,Launched
phenacemide,sodium channel blocker,SCN4A,6329,Launched
phenacemide,sodium channel blocker,SCN5A,6331,Launched
phenacemide,sodium channel blocker,SCN7A,6332,Launched
phenacemide,sodium channel blocker,SCN8A,6334,Launched
phenacemide,sodium channel blocker,SCN9A,6335,Launched
phenacetin,cyclooxygenase inhibitor,PTGS1,5742,Withdrawn
phenazone,cyclooxygenase inhibitor,PTGS1,5742,Launched
phenazone,cyclooxygenase inhibitor,PTGS2,5743,Launched
phenazopyridine,local anesthetic,SCN1A,6323,Launched
phenelzine,monoamine oxidase inhibitor,ABAT,18,Launched
phenelzine,monoamine oxidase inhibitor,AOC3,8639,Launched
phenelzine,monoamine oxidase inhibitor,GAD2,2572,Launched
phenelzine,monoamine oxidase inhibitor,GPT,2875,Launched
phenelzine,monoamine oxidase inhibitor,GPT2,84706,Launched
phenelzine,monoamine oxidase inhibitor,MAOA,4128,Launched
phenelzine,monoamine oxidase inhibitor,MAOB,4129,Launched
phenelzine,monoamine oxidase inhibitor,SLC6A2,6530,Launched
phenelzine,monoamine oxidase inhibitor,SLC6A3,6531,Launched
phenelzine,monoamine oxidase inhibitor,SLC6A4,6532,Launched
phenethyl-isothiocyanate,anticancer agent,CYP2E1,1571,Phase 2
phenformin,AMPK activator,KCNJ8,3764,Withdrawn
phenformin,AMPK activator,PRKAA1,5562,Withdrawn
phenindamine,histamine receptor antagonist,HRH1,3269,Launched
phenindione,vitamin K antagonist,VKORC1,79001,Launched
pheniramine,histamine receptor antagonist,HRH1,3269,Launched
phenol,,CA1,759,Preclinical
phenol,,CA12,771,Preclinical
phenol,,CA14,23632,Preclinical
phenol,,CA2,760,Preclinical
phenol,,CA4,762,Preclinical
phenol,,CA9,768,Preclinical
phenolphthalein,indicator dye,UGT1A9,54600,Withdrawn
phenoxybenzamine,adrenergic receptor antagonist,ADRA1A,148,Launched
phenoxybenzamine,adrenergic receptor antagonist,ADRA1B,147,Launched
phenoxybenzamine,adrenergic receptor antagonist,ADRA1D,146,Launched
phenoxybenzamine,adrenergic receptor antagonist,ADRA2A,2261,Launched
phenoxybenzamine,adrenergic receptor antagonist,ADRA2B,2321,Launched
phenoxybenzamine,adrenergic receptor antagonist,ADRA2C,2324,Launched
phenprocoumon,vitamin K antagonist,VKORC1,3702,Launched
phenserine,acetylcholinesterase inhibitor|beta amyloid synthesis inhibitor,ACHE,3791,Phase 3
phenserine,acetylcholinesterase inhibitor|beta amyloid synthesis inhibitor,BCHE,3815,Phase 3
phentolamine,adrenergic receptor antagonist,ADRA1A,5156,Launched
phentolamine,adrenergic receptor antagonist,ADRA1B,5159,Launched
phentolamine,adrenergic receptor antagonist,ADRA1D,10019,Launched
phentolamine,adrenergic receptor antagonist,ADRA2A,5724,Launched
phentolamine,adrenergic receptor antagonist,ADRA2B,3065,Launched
phentolamine,adrenergic receptor antagonist,ADRA2C,3066,Launched
phenylbutazone,cyclooxygenase inhibitor|prostanoid receptor antagonist,PTGIS,8841,Withdrawn
phenylbutazone,cyclooxygenase inhibitor|prostanoid receptor antagonist,PTGS1,10013,Withdrawn
phenylbutazone,cyclooxygenase inhibitor|prostanoid receptor antagonist,PTGS2,695,Withdrawn
phenylbutyrate,HDAC inhibitor,HDAC1,3065,Launched
phenylephrine,adrenergic receptor agonist,ADRA1A,83933,Launched
phenylephrine,adrenergic receptor agonist,ADRA1B,10013,Launched
phenylephrine,adrenergic receptor agonist,ADRA1D,55869,Launched
phenytoin,hydantoin antiepileptic,SCN10A,3764,Launched
phenytoin,hydantoin antiepileptic,SCN11A,5604,Launched
phenytoin,hydantoin antiepileptic,SCN1A,1132,Launched
phenytoin,hydantoin antiepileptic,SCN2A,3757,Launched
phenytoin,hydantoin antiepileptic,SCN3A,186,Launched
phenytoin,hydantoin antiepileptic,SCN4A,1813,Launched
phenytoin,hydantoin antiepileptic,SCN5A,1814,Launched
phenytoin,hydantoin antiepileptic,SCN7A,1956,Launched
phenytoin,hydantoin antiepileptic,SCN8A,3791,Launched
phenytoin,hydantoin antiepileptic,SCN9A,1909,Launched
PhiKan-083,p53 stabilizing agent,TP53,1910,Preclinical
phloretin,sodium/glucose cotransporter inhibitor,AQP9,1956,Launched
phloretin,sodium/glucose cotransporter inhibitor,CLCN3,4886,Launched
phloretin,sodium/glucose cotransporter inhibitor,SLC23A1,2260,Launched
phlorizin,sodium/glucose cotransporter inhibitor,SLC5A1,1956,Preclinical
phlorizin,sodium/glucose cotransporter inhibitor,SLC5A11,2260,Preclinical
phlorizin,sodium/glucose cotransporter inhibitor,SLC5A2,5159,Preclinical
phlorizin,sodium/glucose cotransporter inhibitor,SLC5A3,9088,Preclinical
phortress,aryl hydrocarbon receptor ligand,AHR,6714,Phase 1
PHP-501,GABA receptor antagonist,GABRA1,7465,Preclinical
PHP-501,GABA receptor antagonist,GABRB2,4322,Preclinical
PHP-501,GABA receptor antagonist,GABRG2,4313,Preclinical
PHT-427,AKT inhibitor|pyruvate dehydrogenase inhibitor,AKT2,4314,Preclinical
PHT-427,AKT inhibitor|pyruvate dehydrogenase inhibitor,PDPK1,1813,Preclinical
PHTPP,estrogen receptor antagonist,ESR2,1956,Preclinical
physostigmine,acetylcholinesterase inhibitor|cholinesterase inhibitor,ACHE,2064,Launched
physostigmine,acetylcholinesterase inhibitor|cholinesterase inhibitor,BCHE,6714,Launched
phytonadione,,BGLAP,1813,Launched
phytonadione,,GGCX,1815,Launched
PI-103,mTOR inhibitor|PI3K inhibitor,MTOR,2260,Preclinical
PI-103,mTOR inhibitor|PI3K inhibitor,PIK3CA,2263,Preclinical
PI-103,mTOR inhibitor|PI3K inhibitor,PIK3CB,2261,Preclinical
PI-103,mTOR inhibitor|PI3K inhibitor,PIK3CD,2264,Preclinical
PI-103,mTOR inhibitor|PI3K inhibitor,PIK3CG,2321,Preclinical
PI-103,mTOR inhibitor|PI3K inhibitor,PRKDC,2324,Preclinical
piboserod,serotonin receptor antagonist,HTR2B,3791,Phase 2
piboserod,serotonin receptor antagonist,HTR4,5156,Phase 2
picartamide,H+/K+-ATPase inhibitor,ATP4A,5159,Phase 2
piceatannol,SYK inhibitor,ATP5A1,774,Preclinical
piceatannol,SYK inhibitor,ATP5B,5604,Preclinical
piceatannol,SYK inhibitor,ATP5C1,4214,Preclinical
piceatannol,SYK inhibitor,IRF3,10746,Preclinical
piclamilast,phosphodiesterase inhibitor,PDE4A,5604,Phase 2
piclamilast,phosphodiesterase inhibitor,PDE4B,5605,Phase 2
piclamilast,phosphodiesterase inhibitor,PDE4C,7465,Phase 2
piclamilast,phosphodiesterase inhibitor,PDE4D,134,Phase 2
picotamide,thromboxane receptor antagonist|thromboxane synthase inhibitor,TBXA2R,207,Launched
picrotin,GABA receptor antagonist,GLRA1,1111,Phase 2
picrotin,GABA receptor antagonist,GLRA2,2932,Phase 2
picrotin,GABA receptor antagonist,GLRA3,3932,Phase 2
picrotin,GABA receptor antagonist,GLRB,5604,Phase 2
picrotoxinin,GABA receptor antagonist,GLRA1,5594,Preclinical
picrotoxinin,GABA receptor antagonist,GLRA2,5600,Preclinical
picrotoxinin,GABA receptor antagonist,GLRA3,6300,Preclinical
picrotoxinin,GABA receptor antagonist,GLRB,1432,Preclinical
picrotoxinin,GABA receptor antagonist,HTR3A,5599,Preclinical
picrotoxinin,GABA receptor antagonist,HTR3B,5578,Preclinical
pidolic-acid,,ADAM28,5894,Launched
pidolic-acid,,AMY1A,6093,Launched
pidolic-acid,,AMY2A,6198,Launched
pidolic-acid,,AMY2B,6446,Launched
pidolic-acid,,ANG,10846,Launched
pidolic-acid,,CCL8,2166,Launched
pidolic-acid,,HCRT,29126,Launched
pidolic-acid,,IGLC1,3716,Launched
pidolic-acid,,KRTAP5-2,3717,Launched
pidolic-acid,,TFF2,3718,Launched
pidolic-acid,,VEGFA,7153,Launched
pifithrin-alpha,TP53 inhibitor,TP53,3356,Preclinical
pifithrin-cyclic,TP53 inhibitor,TP53,1956,Preclinical
pifithrin-mu,HSP inhibitor,HSPA1A,471,Preclinical
pifithrin-mu,HSP inhibitor,TP53,1719,Preclinical
PIK-293,PI3K inhibitor,PIK3CA,2618,Preclinical
PIK-293,PI3K inhibitor,PIK3CB,7298,Preclinical
PIK-293,PI3K inhibitor,PIK3CD,3269,Preclinical
PIK-293,PI3K inhibitor,PIK3CG,153,Preclinical
PIK-294,PI3K inhibitor,PIK3CB,154,Preclinical
PIK-294,PI3K inhibitor,PIK3CD,3350,Preclinical
PIK-294,PI3K inhibitor,PIK3CG,3351,Preclinical
PIK-75,DNA protein kinase inhibitor|PI3K inhibitor,PIK3CA,8913,Preclinical
PIK-75,DNA protein kinase inhibitor|PI3K inhibitor,PIK3CB,887,Preclinical
PIK-75,DNA protein kinase inhibitor|PI3K inhibitor,PIK3CD,6916,Preclinical
PIK-75,DNA protein kinase inhibitor|PI3K inhibitor,PIK3CG,1901,Preclinical
PIK-75,DNA protein kinase inhibitor|PI3K inhibitor,PRKDC,5460,Preclinical
PIK-93,PI3K inhibitor,PI4KB,4255,Preclinical
PIK-93,PI3K inhibitor,PIK3C3,6256,Preclinical
PIK-93,PI3K inhibitor,PIK3CG,836,Preclinical
pilocarpine,acetylcholine receptor agonist,CHRM1,596,Launched
pilocarpine,acetylcholine receptor agonist,CHRM2,4133,Launched
pilocarpine,acetylcholine receptor agonist,CHRM3,4134,Launched
pilocarpine,acetylcholine receptor agonist,CHRM4,4137,Launched
pilocarpine,acetylcholine receptor agonist,CHRM5,8856,Launched
pilsicainide,sodium channel blocker,SCN5A,7099,Launched
PIM-1-Inhibitor-2,Pim kinase inhibitor,PIM1,7846,Preclinical
pimavanserin,serotonin receptor inverse agonist,DRD2,10376,Launched
pimavanserin,serotonin receptor inverse agonist,HTR2A,84790,Launched
pimobendan,calcium sensitizer|phosphodiesterase inhibitor,PDE3A,7278,Launched
pimozide,dopamine receptor antagonist,CACNA1I,113457,Launched
pimozide,dopamine receptor antagonist,CALM1,112714,Launched
pimozide,dopamine receptor antagonist,DRD1,7277,Launched
pimozide,dopamine receptor antagonist,DRD2,203068,Launched
pimozide,dopamine receptor antagonist,DRD3,81027,Launched
pimozide,dopamine receptor antagonist,DRD4,7280,Launched
pimozide,dopamine receptor antagonist,DRD5,347733,Launched
pimozide,dopamine receptor antagonist,HRH1,10381,Launched
pimozide,dopamine receptor antagonist,HTR1A,10382,Launched
pimozide,dopamine receptor antagonist,HTR2A,10383,Launched
pimozide,dopamine receptor antagonist,KCNA10,84617,Launched
pimozide,dopamine receptor antagonist,KCNH2,347688,Launched
pinacidil,ATP channel activator|potassium channel activator,ABCC8,5321,Launched
pinacidil,ATP channel activator|potassium channel activator,ABCC9,2322,Launched
pinaverium,T-type calcium channel blocker,CACNA1C,3716,Launched
pindolol,adrenergic receptor antagonist,ADRB1,3717,Launched
pindolol,adrenergic receptor antagonist,ADRB2,3718,Launched
pindolol,adrenergic receptor antagonist,HTR1A,1019,Launched
pindolol,adrenergic receptor antagonist,HTR2A,1021,Launched
pindolol,adrenergic receptor antagonist,HTR2B,1813,Launched
pindolol-(-),adrenergic receptor antagonist|serotonin receptor antagonist,HTR1A,3356,Phase 2
pinocembrin,cytochrome P450 inhibitor,CYP1B1,1576,Phase 2
pioglitazone,insulin sensitizer|PPAR receptor agonist,PPARG,1269,Launched
pioglitazone,insulin sensitizer|PPAR receptor agonist,TRPM3,139760,Launched
pipamperone,dopamine receptor antagonist,DRD2,9290,Launched
pipamperone,dopamine receptor antagonist,HRH1,2475,Launched
pipamperone,dopamine receptor antagonist,HTR1A,3359,Launched
pipamperone,dopamine receptor antagonist,HTR1B,2837,Launched
pipamperone,dopamine receptor antagonist,HTR1D,5916,Launched
pipamperone,dopamine receptor antagonist,HTR2A,2224,Launched
pipecuronium,neuromuscular blocker,CHRM2,1129,Launched
pipecuronium,neuromuscular blocker,CHRM3,1131,Launched
pipecuronium,neuromuscular blocker,CHRNA2,1134,Launched
pipenzolate,cholinergic receptor antagonist,CHRM1,1135,Launched
piperazine,benzodiazepine receptor agonist,GABRB3,3065,Launched
piperidolate,acetylcholine receptor antagonist,CHRM1,3066,Launched
piperine,monoamine oxidase inhibitor,MAOA,8841,Phase 1
piperine,monoamine oxidase inhibitor,MAOB,9759,Phase 1
piperine,monoamine oxidase inhibitor,TRPV1,10013,Phase 1
pipotiazine,dopamine receptor antagonist,DRD1,51564,Launched
pipotiazine,dopamine receptor antagonist,DRD2,55869,Launched
pipotiazine,dopamine receptor antagonist,HTR1A,9734,Launched
pipotiazine,dopamine receptor antagonist,HTR2A,495,Launched
pipotiazine-palmitate,dopamine receptor antagonist|serotonin receptor antagonist,DRD1,1813,Launched
pipotiazine-palmitate,dopamine receptor antagonist|serotonin receptor antagonist,DRD2,10846,Launched
pipotiazine-palmitate,dopamine receptor antagonist|serotonin receptor antagonist,HTR1A,5142,Launched
pipotiazine-palmitate,dopamine receptor antagonist|serotonin receptor antagonist,HTR2A,8654,Launched
piracetam,acetylcholine receptor agonist,GRIA1,771,Launched
piracetam,acetylcholine receptor agonist,GRIA2,760,Launched
piracetam,acetylcholine receptor agonist,GRIA3,765,Launched
piracetam,acetylcholine receptor agonist,GRIA4,768,Launched
pirarubicin,topoisomerase inhibitor,TOP2A,2166,Launched
pirenperone,serotonin receptor antagonist,HTR2A,5742,Preclinical
pirenperone,serotonin receptor antagonist,HTR7,5743,Preclinical
pirenzepine,acetylcholine receptor antagonist,CHRM1,7442,Launched
pirenzepine,acetylcholine receptor antagonist,CHRM2,8913,Launched
pirenzepine,acetylcholine receptor antagonist,CHRM3,203068,Launched
pirenzepine,acetylcholine receptor antagonist,CHRM4,1813,Launched
pirenzepine,acetylcholine receptor antagonist,CHRM5,1814,Launched
piretanide,glucocorticoid receptor agonist,SLC12A1,1815,Launched
piretanide,glucocorticoid receptor agonist,SLC12A2,3350,Launched
pirfenidone,TGF beta receptor inhibitor,FURIN,3363,Launched
pirfenidone,TGF beta receptor inhibitor,TNF,4057,Launched
piribedil,dopamine receptor agonist,ADRA1A,4128,Launched
piribedil,dopamine receptor agonist,ADRA2A,4129,Launched
piribedil,dopamine receptor agonist,ADRA2C,7421,Launched
piribedil,dopamine receptor agonist,DRD2,1128,Launched
piribedil,dopamine receptor agonist,DRD3,1129,Launched
piribedil,dopamine receptor agonist,DRD4,1131,Launched
piribedil,dopamine receptor agonist,HTR1A,1132,Launched
piribedil,dopamine receptor agonist,HTR2B,1133,Launched
piricapiron,dopamine receptor antagonist|serotonin receptor antagonist,HTR2A,3356,Phase 2
pirinixic-acid,PPAR receptor agonist,PPARA,6530,Preclinical
pirlindole,monoamine oxidase inhibitor,MAOA,6532,Launched
piroxicam,cyclooxygenase inhibitor,PTGS1,3065,Launched
piroxicam,cyclooxygenase inhibitor,PTGS2,3551,Launched
piroximone,phosphodiesterase inhibitor,PDE3A,5970,Phase 2
PIT,purinergic receptor antagonist,P2RY1,6751,Preclinical
pitavastatin,HMGCR inhibitor,HMGCR,6752,Launched
pitolisant,histamine receptor antagonist,HRH3,6753,Launched
pivagabine,corticotropin releasing factor receptor antagonist,CRHR1,6755,Launched
pivagabine,corticotropin releasing factor receptor antagonist,CRHR2,1436,Launched
pivanex,HDAC inhibitor,HDAC1,2246,Phase 2
pivanex,HDAC inhibitor,HDAC2,2260,Phase 2
pivanex,HDAC inhibitor,HDAC3,43,Phase 2
pivanex,HDAC inhibitor,HDAC8,590,Phase 2
pixantrone,topoisomerase inhibitor,TOP2A,43,Launched
pizotifen,serotonin receptor antagonist,HTR1A,590,Launched
pizotifen,serotonin receptor antagonist,HTR2A,150,Launched
pizotifen,serotonin receptor antagonist,HTR2C,151,Launched
PI4KIII-beta-inhibitor-1,PI4K inhibitor,PI4K2B,152,Preclinical
PJ-34,PARP inhibitor,EEF2,1812,Preclinical
PJ-34,PARP inhibitor,PARP1,1813,Preclinical
PJ-34,PARP inhibitor,PARP15,1814,Preclinical
PJ-34,PARP inhibitor,PARP3,1815,Preclinical
PK-THPP,potassium channel blocker,KCNK9,1816,Preclinical
PK-11195,benzodiazepine receptor antagonist,TSPO,3350,Phase 1
PK-44,dipeptidyl peptidase inhibitor,DPP4,3351,Preclinical
PKI-166,EGFR inhibitor,EGFR,3352,Phase 1
PKI-179,mTOR inhibitor|PI3K inhibitor,MTOR,3356,Phase 1
plerixafor,CC chemokine receptor antagonist,ACKR3,3357,Launched
plerixafor,CC chemokine receptor antagonist,CCR4,3358,Launched
plerixafor,CC chemokine receptor antagonist,CXCR4,775,Launched
plovamer-acetate,,TAT,10800,Phase 2
plovamer-acetate,,TH,57105,Phase 2
plovamer-acetate,,YARS,3567,Phase 2
plovamer-acetate,,YARS2,4583,Phase 2
plurisin-1,stearoyl-CoA desaturase inhibitor,SCD,4790,Preclinical
PLX4720,RAF inhibitor,BRAF,6037,Preclinical
PLX4720,RAF inhibitor,KDR,7124,Preclinical
PLX647,receptor tyrosine protein kinase inhibitor,CSF1R,64805,Preclinical
PLX647,receptor tyrosine protein kinase inhibitor,KIT,1268,Preclinical
PLX8394,serine/threonine kinase inhibitor,BRAF,1269,Phase 1/Phase 2
PMPA,glutamate receptor antagonist,FOLH1,3156,Preclinical
PNU-120596,acetylcholine receptor agonist,CHRNA7,10599,Preclinical
PNU-142633,serotonin receptor agonist,HTR1D,148,Phase 2
PNU-177864,dopamine receptor antagonist,DRD3,147,Preclinical
PNU-22394,serotonin receptor agonist,HTR2A,146,Phase 2
PNU-22394,serotonin receptor agonist,HTR2B,150,Phase 2
PNU-22394,serotonin receptor agonist,HTR2C,151,Phase 2
PNU-22394,serotonin receptor agonist,MAOA,152,Phase 2
PNU-22394,serotonin receptor agonist,MAOB,3757,Phase 2
PNU-282987,cholinergic receptor agonist,CHRNA7,81033,Preclinical
PNU-74654,beta-catenin inhibitor,CTNNB1,90134,Preclinical
PNU-74654,beta-catenin inhibitor,TCF4,10280,Preclinical
PNU-89843,benzodiazepine receptor agonist,GABBR1,1813,Preclinical
podophyllotoxin,microtubule inhibitor|tubulin polymerization inhibitor,IGF1R,5319,Launched
podophyllotoxin,microtubule inhibitor|tubulin polymerization inhibitor,TOP2A,2908,Launched
podophyllotoxin,microtubule inhibitor|tubulin polymerization inhibitor,TUBA4A,4306,Launched
podophyllotoxin,microtubule inhibitor|tubulin polymerization inhibitor,TUBB,866,Launched
polydatin,ICAM1 expression inhibitor,ICAM1,2908,Phase 2
polyinosine,immunostimulant,HPRT1,2908,Preclinical
polyinosine,immunostimulant,IMPDH2,2908,Preclinical
polyinosine,immunostimulant,PYGM,3290,Preclinical
polythiazide,sodium/chloride cotransporter inhibitor,SLC12A3,2908,Launched
ponatinib,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,ABL1,6820,Launched
ponatinib,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,BCR,1586,Launched
ponatinib,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,FGFR1,134,Launched
ponatinib,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,FGFR2,135,Launched
ponatinib,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,FGFR3,136,Launched
ponatinib,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,FGFR4,140,Launched
ponatinib,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,FLT3,2194,Launched
ponatinib,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,KDR,6331,Launched
ponatinib,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,KIT,43,Launched
ponatinib,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,LCK,1137,Launched
ponatinib,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,LYN,1139,Launched
ponatinib,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,PDGFRA,2554,Launched
ponatinib,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,RET,2555,Launched
ponatinib,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,SRC,2556,Launched
ponatinib,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,TEK,2557,Launched
ponesimod,sphingosine 1-phosphate receptor agonist,S1PR1,2558,Phase 3
posaconazole,sterol demethylase inhibitor,CYP3A4,2559,Launched
potassium-canrenoate,mineralocorticoid receptor antagonist,NR3C2,2560,Launched
pozanicline,acetylcholine receptor antagonist,CHRNA4,2561,Phase 2
pozanicline,acetylcholine receptor antagonist,CHRNB2,2562,Phase 2
poziotinib,EGFR inhibitor,EGFR,2563,Phase 2
poziotinib,EGFR inhibitor,ERBB2,2564,Phase 2
poziotinib,EGFR inhibitor,ERBB4,2565,Phase 2
PP-1,SRC inhibitor,HCK,2566,Preclinical
PP-1,SRC inhibitor,RET,2567,Preclinical
PP-121,protein tyrosine kinase inhibitor,ABL1,2568,Preclinical
PP-121,protein tyrosine kinase inhibitor,EGFR,55879,Preclinical
PP-121,protein tyrosine kinase inhibitor,HCK,2891,Preclinical
PP-121,protein tyrosine kinase inhibitor,KDR,2898,Preclinical
PP-121,protein tyrosine kinase inhibitor,MTOR,6336,Preclinical
PP-121,protein tyrosine kinase inhibitor,PDGFRA,11280,Preclinical
PP-121,protein tyrosine kinase inhibitor,PIK3CA,6323,Preclinical
PP-121,protein tyrosine kinase inhibitor,PIK3CB,6326,Preclinical
PP-121,protein tyrosine kinase inhibitor,PIK3CD,6328,Preclinical
PP-121,protein tyrosine kinase inhibitor,PIK3CG,6329,Preclinical
PP-121,protein tyrosine kinase inhibitor,PRKDC,6331,Preclinical
PP-121,protein tyrosine kinase inhibitor,SRC,6332,Preclinical
PP-2,SRC inhibitor,ABL1,6334,Preclinical
PP-2,SRC inhibitor,LCK,6335,Preclinical
PP-2,SRC inhibitor,RIPK2,2100,Preclinical
PP-2,SRC inhibitor,SRC,8648,Preclinical
PPT,estrogen receptor agonist,ESR1,774,Preclinical
PPY-A,Abl kinase inhibitor,ABL1,4842,Preclinical
PPY-A,Abl kinase inhibitor,BCR,24145,Preclinical
PP242,mTOR inhibitor,MTOR,55867,Preclinical
PP242,mTOR inhibitor,PASK,9356,Preclinical
PQ-401,IGF-1 inhibitor,IGF1R,9376,Preclinical
practolol,adrenergic receptor antagonist,ADRB1,53919,Withdrawn
pralatrexate,dihydrofolate reductase inhibitor,DHFR,19,Launched
pralidoxime,acetylcholinesterase inhibitor,ACHE,8647,Launched
pralidoxime,acetylcholinesterase inhibitor,BCHE,1066,Launched
pralidoxime-chloride,acetylcholinesterase inhibitor,ACHE,1786,Launched
pralidoxime-chloride,acetylcholinesterase inhibitor,BCHE,6331,Launched
pramipexole,dopamine receptor agonist,ADRA2A,1135,Launched
pramipexole,dopamine receptor agonist,ADRA2B,116443,Launched
pramipexole,dopamine receptor agonist,ADRA2C,3359,Launched
pramipexole,dopamine receptor agonist,DRD1,3778,Launched
pramipexole,dopamine receptor agonist,DRD2,3779,Launched
pramipexole,dopamine receptor agonist,DRD3,10242,Launched
pramipexole,dopamine receptor agonist,DRD4,27094,Launched
pramipexole,dopamine receptor agonist,DRD5,27345,Launched
pramipexole,dopamine receptor agonist,HTR1A,3780,Launched
pramipexole,dopamine receptor agonist,HTR1B,3781,Launched
pramipexole,dopamine receptor agonist,HTR1D,3782,Launched
pramipexole,dopamine receptor agonist,HTR2A,3783,Launched
pramipexole,dopamine receptor agonist,HTR2B,4128,Launched
pramipexole,dopamine receptor agonist,HTR2C,4129,Launched
pranidipine,calcium channel blocker,CACNA1C,6261,Phase 2
pranlukast,leukotriene receptor antagonist,CYSLTR1,6262,Launched
pranlukast,leukotriene receptor antagonist,CYSLTR2,6336,Launched
pranlukast,leukotriene receptor antagonist,IL5,6531,Launched
pranlukast,leukotriene receptor antagonist,MUC2,154,Launched
pranlukast,leukotriene receptor antagonist,NFKB1,1812,Launched
pranlukast,leukotriene receptor antagonist,RNASE3,1813,Launched
pranlukast,leukotriene receptor antagonist,TNF,1814,Launched
prasugrel,purinergic receptor antagonist,P2RY12,1815,Launched
pravadoline,cyclooxygenase inhibitor,CNR1,1128,Preclinical
pravadoline,cyclooxygenase inhibitor,CNR2,2147,Preclinical
pravastatin,HMGCR inhibitor,HMGCR,117144,Launched
pravastatin,HMGCR inhibitor,SLCO1B1,117155,Launched
prazosin,adrenergic receptor antagonist,ADRA1A,347732,Launched
prazosin,adrenergic receptor antagonist,ADRA1B,378807,Launched
prazosin,adrenergic receptor antagonist,ADRA1D,1586,Launched
prazosin,adrenergic receptor antagonist,ADRA2A,2099,Launched
prazosin,adrenergic receptor antagonist,ADRA2B,4306,Launched
prazosin,adrenergic receptor antagonist,ADRA2C,4986,Launched
prazosin,adrenergic receptor antagonist,KCNH2,5241,Launched
prazosin,adrenergic receptor antagonist,KCNH6,7224,Launched
prazosin,adrenergic receptor antagonist,KCNH7,5742,Launched
PRE-084,sigma receptor agonist,SIGMAR1,5743,Preclinical
preclamol,dopamine receptor agonist,DRD2,886,Phase 2
prednicarbate,phospholipase activator,PLA2G1B,887,Launched
prednisolone,glucocorticoid receptor agonist,NR3C1,1719,Launched
prednisolone,glucocorticoid receptor agonist,NR3C2,148,Launched
prednisolone,glucocorticoid receptor agonist,SERPINA6,147,Launched
prednisolone-acetate,glucocorticoid receptor agonist,NR3C1,146,Launched
prednisolone-hemisuccinate,glucocorticoid receptor agonist,NR3C1,1128,Preclinical
prednisolone-sodium-phosphate,glucocorticoid receptor agonist,NR3C1,1129,Launched
prednisone,glucocorticoid receptor agonist,HSD11B1,1131,Launched
prednisone,glucocorticoid receptor agonist,NR3C1,1132,Launched
pregnenolone,glutamate receptor modulator,SULT2B1,1133,Launched
pregnenolone-succinate,GABA receptor negative allosteric modulator,CYP17A1,1812,Preclinical
preladenant,adenosine receptor antagonist,ADORA1,1813,Phase 3
preladenant,adenosine receptor antagonist,ADORA2A,1814,Phase 3
preladenant,adenosine receptor antagonist,ADORA2B,1815,Phase 3
preladenant,adenosine receptor antagonist,ADORA3,3269,Phase 3
pretomanid,nitric oxide donor,FASN,3356,Launched
prilocaine,local anesthetic,SCN5A,3358,Launched
PRIMA1,TP53 inhibitor,ACHE,2099,Preclinical
primidone,GABA receptor antagonist,CHRNA4,3269,Launched
primidone,GABA receptor antagonist,CHRNA7,5743,Launched
primidone,GABA receptor antagonist,GABRA1,153,Launched
primidone,GABA receptor antagonist,GABRA2,154,Launched
primidone,GABA receptor antagonist,GABRA3,3741,Launched
primidone,GABA receptor antagonist,GABRA4,3757,Launched
primidone,GABA receptor antagonist,GABRA5,729230,Launched
primidone,GABA receptor antagonist,GABRA6,1128,Launched
primidone,GABA receptor antagonist,GABRB1,1129,Launched
primidone,GABA receptor antagonist,GABRB2,1131,Launched
primidone,GABA receptor antagonist,GABRB3,1132,Launched
primidone,GABA receptor antagonist,GABRD,5136,Launched
primidone,GABA receptor antagonist,GABRE,43,Launched
primidone,GABA receptor antagonist,GABRG1,1128,Launched
primidone,GABA receptor antagonist,GABRG2,2166,Launched
primidone,GABA receptor antagonist,GABRG3,2554,Launched
primidone,GABA receptor antagonist,GABRP,2555,Launched
primidone,GABA receptor antagonist,GABRQ,2556,Launched
primidone,GABA receptor antagonist,GRIA2,2557,Launched
primidone,GABA receptor antagonist,GRIK2,2558,Launched
primidone,GABA receptor antagonist,SCN10A,2559,Launched
primidone,GABA receptor antagonist,SCN11A,2560,Launched
primidone,GABA receptor antagonist,SCN1A,2561,Launched
primidone,GABA receptor antagonist,SCN2A,2562,Launched
primidone,GABA receptor antagonist,SCN3A,2563,Launched
primidone,GABA receptor antagonist,SCN4A,2564,Launched
primidone,GABA receptor antagonist,SCN5A,2565,Launched
primidone,GABA receptor antagonist,SCN7A,2566,Launched
primidone,GABA receptor antagonist,SCN8A,2567,Launched
primidone,GABA receptor antagonist,SCN9A,2568,Launched
prinaberel,estrogen receptor agonist,ESR2,55879,Phase 2
prinaberel,estrogen receptor agonist,NCOA1,6326,Phase 2
priralfinamide,sodium channel blocker,CACNA1B,6329,Phase 3
proadifen,nitric oxide synthase inhibitor,NOS1,153,Preclinical
probenecid,uricosuric blocker,PANX1,154,Launched
probenecid,uricosuric blocker,SLC22A11,154,Launched
probenecid,uricosuric blocker,SLC22A6,155,Launched
probenecid,uricosuric blocker,SLC22A8,153,Launched
probenecid,uricosuric blocker,SLCO1C1,3350,Launched
probucol,atherogenesis inhibitor,ABCA1,3361,Launched
probucol,atherogenesis inhibitor,ABCB11,5159,Launched
probucol,atherogenesis inhibitor,CES1,59272,Launched
procainamide,sodium channel blocker,DNMT1,3356,Launched
procainamide,sodium channel blocker,SCN5A,3357,Launched
procaine,HMGCR inhibitor,CHRNA2,3358,Launched
procaine,HMGCR inhibitor,GRIN3A,2743,Launched
procaine,HMGCR inhibitor,HTR3A,9152,Launched
procaine,HMGCR inhibitor,KCNMA1,1268,Launched
procaine,HMGCR inhibitor,KCNMB1,150,Launched
procaine,HMGCR inhibitor,KCNMB2,596,Launched
procaine,HMGCR inhibitor,KCNMB3,1268,Launched
procaine,HMGCR inhibitor,KCNMB4,747,Launched
procaine,HMGCR inhibitor,KCNN1,221955,Launched
procaine,HMGCR inhibitor,KCNN2,2194,Launched
procaine,HMGCR inhibitor,KCNN3,8513,Launched
procaine,HMGCR inhibitor,KCNN4,5406,Launched
procaine,HMGCR inhibitor,MAOA,222545,Launched
procaine,HMGCR inhibitor,MAOB,1723,Launched
procaine,HMGCR inhibitor,RYR1,4987,Launched
procaine,HMGCR inhibitor,RYR2,4988,Launched
procaine,HMGCR inhibitor,SCN10A,1586,Launched
procaine,HMGCR inhibitor,SLC6A3,23028,Launched
procaterol,adrenergic receptor agonist,ADRB2,1066,Launched
prochlorperazine,dopamine receptor antagonist,DRD1,4758,Launched
prochlorperazine,dopamine receptor antagonist,DRD2,4759,Launched
prochlorperazine,dopamine receptor antagonist,DRD3,3350,Launched
prochlorperazine,dopamine receptor antagonist,DRD4,2475,Launched
profenamine,butyrylcholinesterase inhibitor|cholinergic receptor antagonist,CHRM1,1956,Launched
proflavine-hemisulfate,topical anesthetic,F2,2321,Phase 2
progesterone,progesterone receptor agonist,CATSPER1,3791,Launched
progesterone,progesterone receptor agonist,CATSPER2,3815,Launched
progesterone,progesterone receptor agonist,CATSPER3,1956,Launched
progesterone,progesterone receptor agonist,CATSPER4,2099,Launched
progesterone,progesterone receptor agonist,CYP17A1,2100,Launched
progesterone,progesterone receptor agonist,ESR1,367,Launched
progesterone,progesterone receptor agonist,NR3C2,552,Launched
progesterone,progesterone receptor agonist,OPRK1,5021,Launched
progesterone,progesterone receptor agonist,PGR,2159,Launched
progesterone,progesterone receptor agonist,TRPC5,1128,Launched
proglumetacin,cyclooxygenase inhibitor,PTGS1,1129,Launched
proglumetacin,cyclooxygenase inhibitor,PTGS2,1131,Launched
proglumide,CCK receptor antagonist,CCKAR,1132,Withdrawn
proglumide,CCK receptor antagonist,CCKBR,1133,Withdrawn
proguanil,dihydrofolate reductase inhibitor,DHFR,775,Launched
promazine,dopamine receptor antagonist,ADRA1A,9833,Launched
promazine,dopamine receptor antagonist,ADRA1B,6046,Launched
promazine,dopamine receptor antagonist,ADRA1D,8019,Launched
promazine,dopamine receptor antagonist,CHRM1,23476,Launched
promazine,dopamine receptor antagonist,CHRM2,476,Launched
promazine,dopamine receptor antagonist,CHRM3,6093,Launched
promazine,dopamine receptor antagonist,CHRM4,9475,Launched
promazine,dopamine receptor antagonist,CHRM5,5742,Launched
promazine,dopamine receptor antagonist,DRD1,5743,Launched
promazine,dopamine receptor antagonist,DRD2,3269,Launched
promazine,dopamine receptor antagonist,DRD3,6336,Launched
promazine,dopamine receptor antagonist,DRD4,11280,Launched
promazine,dopamine receptor antagonist,HRH1,6323,Launched
promazine,dopamine receptor antagonist,HTR2A,6326,Launched
promazine,dopamine receptor antagonist,HTR2C,6328,Launched
promestriene,estrogen receptor agonist,ESR1,6329,Launched
promethazine,histamine receptor antagonist,HRH1,6331,Launched
propacetamol,cyclooxygenase inhibitor,PTGS2,6332,Launched
propafenone,antiarrhythmic,ADRB1,6334,Launched
propafenone,antiarrhythmic,ADRB2,6335,Launched
propafenone,antiarrhythmic,KCNA5,23476,Launched
propafenone,antiarrhythmic,KCNH2,1374,Launched
propagermanium,CCR agonist|interferon receptor agonist,CCR2,1375,Launched
propantheline,acetylcholine receptor antagonist,CHRM1,203068,Launched
propantheline,acetylcholine receptor antagonist,CHRM2,10383,Launched
propantheline,acetylcholine receptor antagonist,CHRM3,1128,Launched
propantheline,acetylcholine receptor antagonist,CHRM4,1129,Launched
propentofylline,adenosine reuptake inhibitor|phosphodiesterase inhibitor,PDE1A,1131,Launched
propidium-iodide,,ACHE,1132,Preclinical
propiverine,acetylcholine receptor antagonist,CHRM1,1128,Launched
propofol,benzodiazepine receptor agonist,FAAH,1129,Launched
propofol,benzodiazepine receptor agonist,GABRA1,1131,Launched
propofol,benzodiazepine receptor agonist,GABRA2,1132,Launched
propofol,benzodiazepine receptor agonist,GABRA3,153,Launched
propofol,benzodiazepine receptor agonist,GABRA4,3991,Launched
propofol,benzodiazepine receptor agonist,GABRA5,6336,Launched
propofol,benzodiazepine receptor agonist,GABRA6,1128,Launched
propofol,benzodiazepine receptor agonist,GABRB1,1129,Launched
propofol,benzodiazepine receptor agonist,GABRB2,1131,Launched
propofol,benzodiazepine receptor agonist,GABRB3,148,Launched
propofol,benzodiazepine receptor agonist,GABRD,147,Launched
propofol,benzodiazepine receptor agonist,GABRE,146,Launched
propofol,benzodiazepine receptor agonist,GABRG1,150,Launched
propofol,benzodiazepine receptor agonist,GABRG2,151,Launched
propofol,benzodiazepine receptor agonist,GABRG3,152,Launched
propofol,benzodiazepine receptor agonist,GABRP,3351,Launched
propofol,benzodiazepine receptor agonist,GABRQ,3352,Launched
propofol,benzodiazepine receptor agonist,SCN2A,3358,Launched
propofol,benzodiazepine receptor agonist,SCN4A,1128,Launched
propranolol,adrenergic receptor antagonist,ADRB1,1131,Launched
propranolol,adrenergic receptor antagonist,ADRB2,7498,Launched
propranolol-(R),adrenergic receptor antagonist,ADRB2,10988,Preclinical
propranolol-(R),adrenergic receptor antagonist,ADRB3,552,Preclinical
propranolol-(S),adrenergic receptor antagonist,ADRB1,553,Preclinical
propranolol-(S),adrenergic receptor antagonist,HTR1A,554,Preclinical
propranolol-(S),adrenergic receptor antagonist,HTR5A,5021,Preclinical
propranolol-(S),adrenergic receptor antagonist,SLC10A1,8841,Preclinical
propylthiouracil,thyroid peroxidase inhibitor,DIO1,55869,Launched
propylthiouracil,thyroid peroxidase inhibitor,TPO,7153,Launched
proquazone,cyclooxygenase inhibitor,PTGS1,3350,Launched
proquazone,cyclooxygenase inhibitor,PTGS2,3356,Launched
protirelin,thyrotropin releasing hormone receptor agonist,TRHR,3358,Launched
protoporphyrin-IX,heme oxygenase inhibitor,HMOX1,55300,Preclinical
protriptyline,tricyclic antidepressant,SLC6A2,1938,Launched
protriptyline,tricyclic antidepressant,SLC6A4,142,Launched
proxyfan,histamine receptor modulator,HRH3,165631,Preclinical
proxymetacaine,sodium channel blocker,SCN10A,10039,Launched
proxymetacaine,sodium channel blocker,SCN5A,51305,Launched
PRT062070,JAK inhibitor|SYK inhibitor,SYK,706,Phase 2/Phase 3
PRT062607,SYK inhibitor,FGR,1803,Phase 2
PRT062607,SYK inhibitor,MAP3K9,1956,Phase 2
PRT062607,SYK inhibitor,SYK,2475,Phase 2
PRT4165,polycomb repressive complex inhibitor,PRC1,57007,Preclinical
prucalopride,serotonin receptor agonist,HTR4,1233,Launched
pruvanserin,serotonin receptor antagonist,HTR2A,7852,Phase 2
pruvanserin,serotonin receptor antagonist,HTR2C,6898,Phase 2
PRX-08066,serotonin receptor antagonist,HTR2B,7054,Phase 2
PSB-06126,NTPDase inhibitor,ENTPD3,8565,Preclinical
PSB-11,adenosine receptor antagonist,ADORA1,51067,Preclinical
PSB-11,adenosine receptor antagonist,ADORA2A,6319,Preclinical
PSB-11,adenosine receptor antagonist,ADORA3,673,Preclinical
PSB-1115,adenosine receptor antagonist,ADORA1,3791,Preclinical
PSB-1115,adenosine receptor antagonist,ADORA2B,1436,Preclinical
PSB-1115,adenosine receptor antagonist,ADORA3,3815,Preclinical
PSB-36,adenosine receptor antagonist,ADORA1,673,Preclinical
PSB-36,adenosine receptor antagonist,ADORA2A,2346,Preclinical
PSB-36,adenosine receptor antagonist,ADORA2B,1139,Preclinical
PSB-36,adenosine receptor antagonist,ADORA3,3352,Preclinical
PSB-603,adenosine receptor antagonist,ADORA1,1814,Preclinical
PSB-603,adenosine receptor antagonist,ADORA2A,3356,Preclinical
PSB-603,adenosine receptor antagonist,ADORA2B,3357,Preclinical
PSB-603,adenosine receptor antagonist,ADORA3,3358,Preclinical
PSN-375963,glucose dependent insulinotropic receptor agonist,GPR119,4128,Preclinical
PSNCBAM-1,cannabinoid receptor modulator,CNR1,4129,Preclinical
psoralen,,MAOA,1139,Launched
psoralen,,MAOB,1499,Launched
PS178990,androgen receptor modulator,AR,6925,Phase 1
PT-2385,hypoxia inducible factor inhibitor,EPAS1,2550,Phase 1
pterostilbene,cyclooxygenase inhibitor|PPAR receptor agonist,PTGS2,3480,Phase 2/Phase 3
PU-H71,HSP inhibitor,HSP90AA1,7153,Phase 1
pumosetrag,serotonin receptor agonist,HTR3A,7277,Phase 2
pumosetrag,serotonin receptor agonist,HTR4,203068,Phase 2
purmorphamine,smoothened receptor agonist,SMO,3383,Preclinical
puromycin,protein synthesis inhibitor,NHP2L1,3251,Preclinical
puromycin,protein synthesis inhibitor,RPL10L,3615,Preclinical
puromycin,protein synthesis inhibitor,RPL11,5837,Preclinical
puromycin,protein synthesis inhibitor,RPL13A,6559,Preclinical
puromycin,protein synthesis inhibitor,RPL15,25,Preclinical
puromycin,protein synthesis inhibitor,RPL19,613,Preclinical
puromycin,protein synthesis inhibitor,RPL23,2260,Preclinical
puromycin,protein synthesis inhibitor,RPL23A,2263,Preclinical
puromycin,protein synthesis inhibitor,RPL26L1,2261,Preclinical
puromycin,protein synthesis inhibitor,RPL3,2264,Preclinical
puromycin,protein synthesis inhibitor,RPL37,2322,Preclinical
puromycin,protein synthesis inhibitor,RPL8,3791,Preclinical
puromycin,protein synthesis inhibitor,RSL24D1,3815,Preclinical
purvalanol-A,CDK inhibitor,CDK1,3932,Preclinical
purvalanol-A,CDK inhibitor,CDK2,4067,Preclinical
purvalanol-A,CDK inhibitor,CDK4,5156,Preclinical
purvalanol-A,CDK inhibitor,CDK5,5979,Preclinical
purvalanol-A,CDK inhibitor,CSNK1G3,6714,Preclinical
purvalanol-A,CDK inhibitor,RPS6KA1,7010,Preclinical
purvalanol-A,CDK inhibitor,SRC,1901,Preclinical
purvalanol-B,tyrosine kinase inhibitor,CDK2,1576,Preclinical
purvalanol-B,tyrosine kinase inhibitor,CDK4,4306,Preclinical
purvalanol-B,tyrosine kinase inhibitor,CDK5,1137,Preclinical
purvalanol-B,tyrosine kinase inhibitor,MAPK1,1141,Preclinical
purvalanol-B,tyrosine kinase inhibitor,MAPK3,1956,Preclinical
purvalanol-B,tyrosine kinase inhibitor,SRPK2,2064,Preclinical
putrescine,tissue transglutaminase inhibitor,AMD1,2066,Phase 2
putrescine,tissue transglutaminase inhibitor,KCNJ4,3055,Phase 2
putrescine,tissue transglutaminase inhibitor,ODC1,5979,Phase 2
PX-12,thioredoxin inhibitor,CNR1,25,Phase 2
PX-12,thioredoxin inhibitor,TXN,1956,Phase 2
pyrazinamide,fatty acid synthase inhibitor,FASN,3055,Launched
pyrazolanthrone,JNK inhibitor,MAPK10,3791,Preclinical
pyrazolanthrone,JNK inhibitor,MAPK8,2475,Preclinical
pyrazolanthrone,JNK inhibitor,MAPK8IP1,5156,Preclinical
pyrazolanthrone,JNK inhibitor,MAPK9,5290,Preclinical
pyrazolanthrone,JNK inhibitor,TTK,5291,Preclinical
pyrazoloacridine,topoisomerase inhibitor,TOP1,5293,Phase 2
pyrazoloacridine,topoisomerase inhibitor,TOP2A,5294,Phase 2
pyridoxal,,PDXK,5591,Launched
pyridoxine,vitamin B,DDC,6714,Launched
pyridoxine,vitamin B,PDXK,25,Launched
pyrimethamine,dihydrofolate reductase inhibitor,DHFR,3932,Launched
pyrimethamine,dihydrofolate reductase inhibitor,SLC47A1,8767,Launched
pyrithione-zinc,ATP synthase inhibitor,KCNQ1,6714,Launched
pyrithione-zinc,ATP synthase inhibitor,KCNQ2,2099,Launched
pyrithione-zinc,ATP synthase inhibitor,KCNQ4,25,Launched
pyrithione-zinc,ATP synthase inhibitor,KCNQ5,613,Launched
pyroxamide,HDAC inhibitor,HDAC1,2475,Phase 1
pyrrolidine-dithiocarbamate,NFkB pathway inhibitor,HSD11B1,23178,Preclinical
pyrrolidine-dithiocarbamate,NFkB pathway inhibitor,RELA,3480,Preclinical
pyrvinium-pamoate,androgen receptor antagonist,AR,153,Launched
P22077,ubiquitin specific protease inhibitor,USP7,1719,Preclinical
P276-00,CDK inhibitor,CDK1,6323,Phase 2
P276-00,CDK inhibitor,CDK4,6326,Phase 2
P276-00,CDK inhibitor,CDK9,6328,Phase 2
P5091,ubiquitin specific protease inhibitor,USP7,6329,Preclinical
P7C3,NAMPT inhibitor,NAMPT,6331,Preclinical
quazinone,phosphodiesterase inhibitor,PDE3A,6332,Phase 2
quazinone,phosphodiesterase inhibitor,PDE3B,6334,Phase 2
quercetin,polar auxin transport inhibitor,ATP5A1,6335,Launched
quercetin,polar auxin transport inhibitor,ATP5B,23657,Launched
quercetin,polar auxin transport inhibitor,ATP5C1,10280,Launched
quercetin,polar auxin transport inhibitor,HCK,796,Launched
quercetin,polar auxin transport inhibitor,HIBCH,2908,Launched
quercetin,polar auxin transport inhibitor,PIK3CG,866,Launched
quercetin,polar auxin transport inhibitor,PIM1,1268,Launched
quercetin,polar auxin transport inhibitor,STK17B,9290,Launched
quercetin,polar auxin transport inhibitor,UGT3A1,2977,Launched
quetiapine,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A,-,Launched
quetiapine,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1B,2974,Launched
quetiapine,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1D,-,Launched
quetiapine,dopamine receptor antagonist|serotonin receptor antagonist,ADRA2A,6093,Launched
quetiapine,dopamine receptor antagonist|serotonin receptor antagonist,ADRA2B,9475,Launched
quetiapine,dopamine receptor antagonist|serotonin receptor antagonist,ADRA2C,2554,Launched
quetiapine,dopamine receptor antagonist|serotonin receptor antagonist,CHRM1,2224,Launched
quetiapine,dopamine receptor antagonist|serotonin receptor antagonist,CHRM2,148,Launched
quetiapine,dopamine receptor antagonist|serotonin receptor antagonist,CHRM3,147,Launched
quetiapine,dopamine receptor antagonist|serotonin receptor antagonist,CHRM4,146,Launched
quetiapine,dopamine receptor antagonist|serotonin receptor antagonist,CHRM5,150,Launched
quetiapine,dopamine receptor antagonist|serotonin receptor antagonist,DRD1,151,Launched
quetiapine,dopamine receptor antagonist|serotonin receptor antagonist,DRD2,152,Launched
quetiapine,dopamine receptor antagonist|serotonin receptor antagonist,DRD3,1812,Launched
quetiapine,dopamine receptor antagonist|serotonin receptor antagonist,DRD4,1813,Launched
quetiapine,dopamine receptor antagonist|serotonin receptor antagonist,DRD5,1814,Launched
quetiapine,dopamine receptor antagonist|serotonin receptor antagonist,HRH1,1815,Launched
quetiapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1A,3269,Launched
quetiapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1B,3350,Launched
quetiapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1D,3351,Launched
quetiapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1E,3352,Launched
quetiapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1F,3354,Launched
quetiapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR2A,3355,Launched
quetiapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR2C,3356,Launched
quetiapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR3A,3358,Launched
quetiapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR6,3362,Launched
quetiapine,dopamine receptor antagonist|serotonin receptor antagonist,HTR7,3363,Launched
quetiapine,dopamine receptor antagonist|serotonin receptor antagonist,SLC6A2,4193,Launched
quiflapon,leukotriene synthesis inhibitor,ALOX5,148,Phase 2
quiflapon,leukotriene synthesis inhibitor,ALOX5AP,147,Phase 2
quinagolide,dopamine receptor agonist,DRD2,146,Launched
quinapril,angiotensin converting enzyme inhibitor,ACE,3350,Launched
quinaprilat,angiotensin converting enzyme inhibitor,ACE,3351,Launched
quinelorane,dopamine receptor agonist,DRD2,3352,Phase 3
quinelorane,dopamine receptor agonist,DRD3,3356,Phase 3
quinestrol,estrogen receptor agonist,ESR1,3357,Launched
quinestrol,estrogen receptor agonist,ESR2,3358,Launched
quinidine,sodium channel blocker,KCNA5,3361,Launched
quinidine,sodium channel blocker,KCNA7,3362,Launched
quinidine,sodium channel blocker,KCNH1,3363,Launched
quinidine,sodium channel blocker,KCNH2,1544,Launched
quinidine,sodium channel blocker,KCNH5,1555,Launched
quinidine,sodium channel blocker,KCNK1,1557,Launched
quinidine,sodium channel blocker,KCNK6,1558,Launched
quinidine,sodium channel blocker,SCN5A,1559,Launched
quinidine,sodium channel blocker,SLC29A4,1565,Launched
quinine,hemozoin biocrystallization inhibitor,GP9,1571,Launched
quinine,hemozoin biocrystallization inhibitor,KCNB2,1576,Launched
quinine,hemozoin biocrystallization inhibitor,KCNN4,1577,Launched
quinine,hemozoin biocrystallization inhibitor,SLC29A4,1551,Launched
quinpirol-(-),dopamine receptor agonist,DRD1,1137,Phase 2
quinpirol-(-),dopamine receptor agonist,DRD2,1141,Phase 2
quinpirol-(-),dopamine receptor agonist,DRD3,3576,Phase 2
quinpirol-(-),dopamine receptor agonist,DRD4,2159,Phase 2
quinpirol-(-),dopamine receptor agonist,HTR1A,43,Phase 2
quinpirol-(-),dopamine receptor agonist,HTR2A,590,Phase 2
quinpirol-(-),dopamine receptor agonist,HTR2B,3350,Phase 2
quinpirol-(-),dopamine receptor agonist,HTR2C,3351,Phase 2
quipazine,serotonin receptor agonist,HTR1A,3352,Preclinical
quipazine,serotonin receptor agonist,HTR1D,3354,Preclinical
quipazine,serotonin receptor agonist,HTR2A,3355,Preclinical
quipazine,serotonin receptor agonist,HTR2B,8476,Preclinical
quipazine,serotonin receptor agonist,HTR2C,1760,Preclinical
quipazine,serotonin receptor agonist,HTR3A,3984,Preclinical
quipazine,serotonin receptor agonist,HTR3B,4638,Preclinical
quipazine,serotonin receptor agonist,HTR6,5058,Preclinical
quipazine,serotonin receptor agonist,SLC6A4,5585,Preclinical
quizartinib,FLT3 inhibitor,CSF1R,6093,Phase 3
quizartinib,FLT3 inhibitor,FLT3,9475,Phase 3
quizartinib,FLT3 inhibitor,KIT,23028,Phase 3
quizartinib,FLT3 inhibitor,PDGFRA,59341,Phase 3
quizartinib,FLT3 inhibitor,PDGFRB,59341,Phase 3
quizartinib,FLT3 inhibitor,RET,2904,Phase 3
QX-314,sodium channel blocker,MAPK14,4803,Preclinical
QX-314,sodium channel blocker,TGFBR1,4804,Preclinical
R-1485,serotonin receptor antagonist,HTR6,1815,Phase 1
R-268712,serine/threonine kinase inhibitor,TGFBR1,5739,Preclinical
R-428,AXL kinase inhibitor,AXL,2554,Phase 2
R-59022,diacylglycerol kinase inhibitor|protein kinase inhibitor,DGKA,2555,Preclinical
R-96544,serotonin receptor antagonist,HTR2A,2556,Preclinical
rabeprazole,ATPase inhibitor|gastrin inhibitor,ATP4A,2557,Launched
rac-BHFF,GABA receptor positive allosteric modulator,GABBR1,2558,Preclinical
racecadotril,enkephalinase inhibitor,MME,2559,Launched
raclopride,dopamine receptor antagonist,DRD2,2561,Launched
raclopride,dopamine receptor antagonist,DRD3,3320,Launched
raclopride,dopamine receptor antagonist,HTR1A,216,Launched
radafaxine,dopamine-norepinephrine reuptake inhibitor,SLC6A3,8854,Phase 2
RAF265,RAF inhibitor|VEGFR inhibitor,BRAF,220,Phase 2
raloxifene,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),ESR1,9249,Launched
raloxifene,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),ESR2,10901,Launched
raltitrexed,thymidylate synthase inhibitor,FPGS,9227,Launched
raltitrexed,thymidylate synthase inhibitor,TYMS,7182,Launched
ramatroban,prostanoid receptor antagonist,PTGDR2,5947,Launched
ramatroban,prostanoid receptor antagonist,TBXA2R,5949,Launched
ramelteon,melatonin receptor agonist,MTNR1A,51109,Launched
ramelteon,melatonin receptor agonist,MTNR1B,145226,Launched
ramipril,angiotensin converting enzyme inhibitor,ACE,112724,Launched
ramosetron,serotonin receptor antagonist,HTR3A,57665,Launched
ranirestat,aldose reductase inhibitor,AKR1B1,5959,Phase 3
ranitidine,histamine receptor antagonist,HRH2,50700,Launched
ranolazine,sodium channel blocker,SCN10A,54884,Launched
ranolazine,sodium channel blocker,SCN9A,6010,Launched
rasagiline,monoamine oxidase inhibitor,BCL2,6017,Launched
rasagiline,monoamine oxidase inhibitor,MAOB,6256,Launched
rauwolscine,adrenergic receptor antagonist,ADRA2A,6257,Preclinical
rauwolscine,adrenergic receptor antagonist,ADRA2B,6258,Preclinical
rauwolscine,adrenergic receptor antagonist,ADRA2C,240,Preclinical
rauwolscine,adrenergic receptor antagonist,HTR1B,495,Preclinical
rauwolscine,adrenergic receptor antagonist,HTR1D,4363,Preclinical
rauwolscine,adrenergic receptor antagonist,HTR1E,9212,Preclinical
rauwolscine,adrenergic receptor antagonist,HTR2B,3619,Preclinical
ravoxertinib,ERK1 and ERK2 phosphorylation inhibitor,MAPK1,5604,Phase 1
ravoxertinib,ERK1 and ERK2 phosphorylation inhibitor,MAPK3,983,Phase 1
RBC8,Ral GTPase inhibitor,RALA,1017,Preclinical
RBC8,Ral GTPase inhibitor,RALB,1018,Preclinical
rebamipide,free radical scavenger,FPR1,1019,Launched
rebastinib,Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor,ABL1,1020,Phase 1/Phase 2
rebastinib,Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor,BCR,1021,Phase 1/Phase 2
rebastinib,Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor,FGR,1022,Phase 1/Phase 2
rebastinib,Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor,FLT3,1025,Phase 1/Phase 2
rebastinib,Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor,HCK,2322,Phase 1/Phase 2
rebastinib,Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor,LYN,2932,Phase 1/Phase 2
rebastinib,Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor,SRC,3717,Phase 1/Phase 2
reboxetine,adrenergic receptor antagonist,SLC6A2,6885,Launched
Rec-15/2615,adrenergic receptor antagonist,ADRA1A,5601,Phase 2
refametinib,MEK inhibitor,MAP2K1,8841,Phase 2
refametinib,MEK inhibitor,MAP2K2,1786,Phase 2
regadenoson,adenosine receptor agonist,ADORA1,1789,Launched
regadenoson,adenosine receptor agonist,ADORA2A,2260,Launched
regadenoson,adenosine receptor agonist,ADORA2B,2263,Launched
regadenoson,adenosine receptor agonist,ADORA3,3065,Launched
regorafenib,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,ABL1,8841,Launched
regorafenib,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,BRAF,5663,Launched
regorafenib,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,DDR2,4193,Launched
regorafenib,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,EPHA2,747,Launched
regorafenib,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,FGFR1,221955,Launched
regorafenib,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,FGFR2,3320,Launched
regorafenib,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,FLT1,5770,Launched
regorafenib,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,FLT4,5888,Launched
regorafenib,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,FRK,132,Launched
regorafenib,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,KDR,5167,Launched
regorafenib,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,KIT,3614,Launched
regorafenib,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,MAPK11,3615,Launched
regorafenib,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,NTRK1,22978,Launched
regorafenib,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,PDGFRA,1019,Launched
regorafenib,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,PDGFRB,1021,Launched
regorafenib,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,RAF1,645,Launched
regorafenib,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,RET,55312,Launched
regorafenib,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,TEK,645,Launched
relcovaptan,vasopressin receptor antagonist,AVPR1A,1723,Phase 2
relcovaptan,vasopressin receptor antagonist,AVPR1B,1806,Phase 2
relcovaptan,vasopressin receptor antagonist,AVPR2,54363,Phase 2
relcovaptan,vasopressin receptor antagonist,OXTR,51179,Phase 2
remacemide,glutamate receptor antagonist,GRIN1,4535,Phase 3
remimazolam,benzodiazepine receptor agonist,GABBR1,4842,Phase 3
remodelin,transferase inhibitor,NAT10,55163,Preclinical
remoxipride,dopamine receptor antagonist,DRD2,5447,Withdrawn
remoxipride,dopamine receptor antagonist,DRD3,60490,Withdrawn
remoxipride,dopamine receptor antagonist,DRD4,55312,Withdrawn
remoxipride,dopamine receptor antagonist,HTR2A,8986,Withdrawn
remoxipride,dopamine receptor antagonist,SIGMAR1,6446,Withdrawn
repaglinide,insulin secretagogue,ABCC8,5034,Launched
repaglinide,insulin secretagogue,KCNJ11,5733,Launched
repaglinide,insulin secretagogue,PPARG,8856,Launched
reparixin,CC chemokine receptor antagonist,CXCR1,6579,Phase 3
reparixin,CC chemokine receptor antagonist,CXCR2,10599,Phase 3
repsox,TGF beta receptor inhibitor,TGFBR1,28234,Preclinical
resatorvid,toll-like receptor inhibitor,TLR4,6579,Phase 3
reserpine,vesicular monoamine transporter inhibitor,SLC18A1,10599,Launched
reserpine,vesicular monoamine transporter inhibitor,SLC18A2,28234,Launched
resiquimod,toll-like receptor agonist,TLR7,11309,Phase 3
resiquimod,toll-like receptor agonist,TLR8,1558,Phase 3
resminostat,HDAC inhibitor,HDAC1,1559,Phase 2
resminostat,HDAC inhibitor,HDAC3,1576,Phase 2
resminostat,HDAC inhibitor,HDAC6,5347,Phase 2
resminostat,HDAC inhibitor,HDAC8,150,Phase 2
resorcinol,phosphodiesterase inhibitor,CA12,8856,Launched
resorcinol,phosphodiesterase inhibitor,CA14,6336,Launched
resorcinol,phosphodiesterase inhibitor,CA2,54207,Launched
resorcinol,phosphodiesterase inhibitor,PTGS1,3776,Launched
resveratrol,cytochrome P450 inhibitor|SIRT activator,CSNK2A1,50801,Launched
resveratrol,cytochrome P450 inhibitor|SIRT activator,NQO2,3783,Launched
resveratrol,cytochrome P450 inhibitor|SIRT activator,PTGS1,6336,Launched
resveratrol,cytochrome P450 inhibitor|SIRT activator,PTGS2,11280,Launched
retaspimycin,HSP inhibitor,HSP90AA1,2566,Phase 3
retinol,retinoid receptor ligand,ALDH1A1,2554,Launched
retinol,retinoid receptor ligand,ALDH1A2,2555,Launched
retinol,retinoid receptor ligand,ALDH1A3,2556,Launched
retinol,retinoid receptor ligand,DHRS3,2558,Launched
retinol,retinoid receptor ligand,DHRS4,5139,Launched
retinol,retinoid receptor ligand,LRAT,5141,Launched
retinol,retinoid receptor ligand,NR2C2,5142,Launched
retinol,retinoid receptor ligand,RBP1,5143,Launched
retinol,retinoid receptor ligand,RBP3,5144,Launched
retinol,retinoid receptor ligand,RDH11,2904,Launched
retinol,retinoid receptor ligand,RDH12,2645,Launched
retinol,retinoid receptor ligand,RDH13,5024,Launched
retinol,retinoid receptor ligand,RDH14,983,Launched
retinol,retinoid receptor ligand,RDH5,4047,Launched
retinol,retinoid receptor ligand,RDH8,5604,Launched
retinol,retinoid receptor ligand,RETSAT,673,Launched
retinol,retinoid receptor ligand,RHO,5604,Launched
retinol,retinoid receptor ligand,RLBP1,5605,Launched
retinol,retinoid receptor ligand,RXRA,5894,Launched
retinol,retinoid receptor ligand,RXRB,3356,Launched
retinol,retinoid receptor ligand,RXRG,3357,Launched
REV-5901,leukotriene receptor antagonist|lipoxygenase inhibitor,ALOX5,3358,Phase 2
revaprazan,potassium-competitive acid antagonist,ATP4A,8564,Launched
reversan,MRP inhibitor,ABCC1,2911,Preclinical
reversine,Aurora kinase inhibitor,AURKB,351,Preclinical
reversine,Aurora kinase inhibitor,INCENP,3350,Preclinical
reversine,Aurora kinase inhibitor,MAP2K1,1956,Preclinical
RGB-286638,CDK inhibitor,CDK1,1129,Phase 1
RGB-286638,CDK inhibitor,CDK2,1135,Phase 1
RGB-286638,CDK inhibitor,CDK3,3359,Phase 1
RGB-286638,CDK inhibitor,CDK4,2006,Phase 1
RGB-286638,CDK inhibitor,CDK5,5743,Phase 1
RGB-286638,CDK inhibitor,CDK6,5141,Phase 1
RGB-286638,CDK inhibitor,CDK7,5142,Phase 1
RGB-286638,CDK inhibitor,CDK9,5143,Phase 1
RGB-286638,CDK inhibitor,FLT3,5144,Phase 1
RGB-286638,CDK inhibitor,GSK3B,3065,Phase 1
RGB-286638,CDK inhibitor,JAK2,3066,Phase 1
RGB-286638,CDK inhibitor,MAP3K7,8841,Phase 1
RGB-286638,CDK inhibitor,MAPK9,9759,Phase 1
RGFP966,HDAC inhibitor,HDAC3,10014,Preclinical
RG108,DNA methyltransferase inhibitor,DNMT1,10013,Preclinical
RG108,DNA methyltransferase inhibitor,DNMT3B,51564,Preclinical
RG1530,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FGFR1,55869,Phase 1
RG1530,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FGFR2,9734,Phase 1
RG2833,HDAC inhibitor,HDAC1,150,Phase 1
RG2833,HDAC inhibitor,HDAC3,151,Phase 1
RG4733,gamma secretase inhibitor,PSEN1,152,Phase 2
RG7112,MDM inhibitor,MDM2,1812,Phase 1
RHC-80267,triacylglycerol lipase inhibitor,DAGLA,1813,Preclinical
RHC-80267,triacylglycerol lipase inhibitor,DAGLB,1814,Preclinical
rhein,,HSP90AA1,1815,Phase 1
rheochrysidin,protein tyrosine kinase inhibitor,PTPN1,1816,Preclinical
RI-1,,RAD51,3350,Preclinical
ribavirin,antiviral,ADK,3351,Launched
ribavirin,antiviral,ENPP1,3352,Launched
ribavirin,antiviral,IMPDH1,3356,Launched
ribavirin,antiviral,IMPDH2,3357,Launched
ribavirin,antiviral,NT5C2,3358,Launched
ribociclib,CDK inhibitor,CDK4,6336,Launched
ribociclib,CDK inhibitor,CDK6,1017,Launched
riboflavin,vitamin B,BLVRB,1025,Launched
riboflavin,vitamin B,RFK,2864,Launched
riboflavin-5-phosphate-sodium,,BLVRB,5468,Launched
riboflavin-5-phosphate-sodium,,DHODH,7224,Launched
riboflavin-5-phosphate-sodium,,DPYD,80036,Launched
riboflavin-5-phosphate-sodium,,HAO1,4170,Launched
riboflavin-5-phosphate-sodium,,HAO2,7299,Launched
riboflavin-5-phosphate-sodium,,MT-ND1,476,Launched
riboflavin-5-phosphate-sodium,,NOS1,3156,Launched
riboflavin-5-phosphate-sodium,,PNPO,151,Launched
riboflavin-5-phosphate-sodium,,POR,1812,Launched
riboflavin-5-phosphate-sodium,,PPCDC,1813,Launched
riboflavin-5-phosphate-sodium,,RFK,1814,Launched
riboflavin-5-phosphate-sodium,,RPS6KA4,1815,Launched
riboflavin-5-phosphate-sodium,,SGK1,1816,Launched
ribostamycin,bacterial 30S ribosomal subunit inhibitor,P4HB,3350,Launched
ricinoleic-acid,prostanoid receptor agonist,PTGER3,1812,Launched
rifampin,RNA polymerase inhibitor,NR1I2,1813,Launched
rifampin,RNA polymerase inhibitor,SLCO1A2,1814,Launched
rifampin,RNA polymerase inhibitor,SLCO1B1,3350,Launched
rifampin,RNA polymerase inhibitor,SLCO1B3,3274,Launched
rifamycin,DNA directed RNA polymerase inhibitor,SLCO1A2,2862,Launched
rifamycin,DNA directed RNA polymerase inhibitor,SLCO1B1,1901,Launched
rifamycin,DNA directed RNA polymerase inhibitor,SLCO1B3,79054,Launched
rifamycin,DNA directed RNA polymerase inhibitor,SLCO2B1,2539,Launched
rifapentine,RNA polymerase inhibitor,CYP2C8,148,Launched
rifapentine,RNA polymerase inhibitor,CYP2C9,146,Launched
rifapentine,RNA polymerase inhibitor,CYP3A4,3356,Launched
rigosertib,cell cycle inhibitor|PLK inhibitor,PLK1,3357,Phase 3
rilmenidine,adrenergic receptor agonist|imidazoline receptor agonist,ADRA2A,3358,Launched
rilpivirine,non-nucleoside reverse transcriptase inhibitor,NR1I2,729230,Launched
rilpivirine,non-nucleoside reverse transcriptase inhibitor,SCN10A,3356,Launched
riluzole,glutamate inhibitor,KCNK10,3357,Launched
riluzole,glutamate inhibitor,KCNK2,3358,Launched
riluzole,glutamate inhibitor,KCNK4,148,Launched
riluzole,glutamate inhibitor,KCNN4,146,Launched
riluzole,glutamate inhibitor,SCN10A,3360,Launched
riluzole,glutamate inhibitor,SCN11A,3360,Launched
riluzole,glutamate inhibitor,SCN1A,6554,Launched
riluzole,glutamate inhibitor,SCN2A,1733,Launched
riluzole,glutamate inhibitor,SCN3A,7173,Launched
riluzole,glutamate inhibitor,SCN4A,5742,Launched
riluzole,glutamate inhibitor,SCN5A,5743,Launched
riluzole,glutamate inhibitor,SCN7A,7201,Launched
riluzole,glutamate inhibitor,SCN8A,3162,Launched
riluzole,glutamate inhibitor,SCN9A,6530,Launched
riluzole,glutamate inhibitor,SLC7A11,6532,Launched
rimcazole,sigma receptor antagonist,SIGMAR1,11255,Phase 1
rimegepant,calcitonin antagonist,CALCA,6336,Launched
rimexolone,glucocorticoid receptor agonist,NR3C1,6331,Launched
rimexolone,glucocorticoid receptor agonist,SERPINA6,6850,Launched
rimonabant,cannabinoid receptor antagonist,CNR1,2268,Withdrawn
rimonabant,cannabinoid receptor antagonist,GPR55,4293,Withdrawn
riociguat,guanylate cyclase stimulant,GUCY1A2,6850,Launched
riociguat,guanylate cyclase stimulant,GUCY1A3,9055,Launched
riociguat,guanylate cyclase stimulant,GUCY1B2,3360,Launched
riociguat,guanylate cyclase stimulant,GUCY1B3,3356,Launched
ripasudil,rho associated kinase inhibitor,ROCK1,3358,Launched
ripasudil,rho associated kinase inhibitor,ROCK2,3357,Launched
ripazepam,benzodiazepine receptor agonist,GABRA1,956,Phase 2
risedronate,osteoclast inhibitor,FDPS,134,Launched
risperidone,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A,135,Launched
risperidone,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1B,140,Launched
risperidone,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1D,134,Launched
risperidone,dopamine receptor antagonist|serotonin receptor antagonist,ADRA2A,136,Launched
risperidone,dopamine receptor antagonist|serotonin receptor antagonist,ADRA2B,140,Launched
risperidone,dopamine receptor antagonist|serotonin receptor antagonist,ADRA2C,134,Launched
risperidone,dopamine receptor antagonist|serotonin receptor antagonist,DRD1,135,Launched
risperidone,dopamine receptor antagonist|serotonin receptor antagonist,DRD2,136,Launched
risperidone,dopamine receptor antagonist|serotonin receptor antagonist,DRD3,140,Launched
risperidone,dopamine receptor antagonist|serotonin receptor antagonist,DRD4,134,Launched
risperidone,dopamine receptor antagonist|serotonin receptor antagonist,HRH1,135,Launched
risperidone,dopamine receptor antagonist|serotonin receptor antagonist,HTR1A,136,Launched
risperidone,dopamine receptor antagonist|serotonin receptor antagonist,HTR1B,140,Launched
risperidone,dopamine receptor antagonist|serotonin receptor antagonist,HTR1D,139760,Launched
risperidone,dopamine receptor antagonist|serotonin receptor antagonist,HTR1E,1268,Launched
risperidone,dopamine receptor antagonist|serotonin receptor antagonist,HTR1F,4128,Launched
risperidone,dopamine receptor antagonist|serotonin receptor antagonist,HTR2A,4129,Launched
risperidone,dopamine receptor antagonist|serotonin receptor antagonist,HTR2C,367,Launched
risperidone,dopamine receptor antagonist|serotonin receptor antagonist,HTR6,2034,Launched
risperidone,dopamine receptor antagonist|serotonin receptor antagonist,HTR7,5743,Launched
RITA,MDM inhibitor,MDM2,3320,Preclinical
ritanserin,serotonin receptor antagonist,ADRA1A,3359,Phase 3
ritanserin,serotonin receptor antagonist,ADRA1B,3360,Phase 3
ritanserin,serotonin receptor antagonist,ADRA1D,6608,Phase 3
ritanserin,serotonin receptor antagonist,HTR1A,4809,Phase 3
ritanserin,serotonin receptor antagonist,HTR1B,140801,Phase 3
ritanserin,serotonin receptor antagonist,HTR1D,6135,Phase 3
ritanserin,serotonin receptor antagonist,HTR2A,23521,Phase 3
ritanserin,serotonin receptor antagonist,HTR2B,6138,Phase 3
ritanserin,serotonin receptor antagonist,HTR2C,6143,Phase 3
ritanserin,serotonin receptor antagonist,HTR5A,9349,Phase 3
ritanserin,serotonin receptor antagonist,HTR6,6147,Phase 3
ritanserin,serotonin receptor antagonist,HTR7,51121,Phase 3
ritonavir,HIV protease inhibitor,CYP1A2,6122,Launched
ritonavir,HIV protease inhibitor,CYP2B6,6167,Launched
ritonavir,HIV protease inhibitor,CYP2C19,6132,Launched
ritonavir,HIV protease inhibitor,CYP2C8,51187,Launched
ritonavir,HIV protease inhibitor,CYP2C9,983,Launched
ritonavir,HIV protease inhibitor,CYP2D6,1017,Launched
ritonavir,HIV protease inhibitor,CYP2E1,1019,Launched
ritonavir,HIV protease inhibitor,CYP3A4,1020,Launched
ritonavir,HIV protease inhibitor,CYP3A5,1456,Launched
ritonavir,HIV protease inhibitor,CYP3A7,6195,Launched
rivanicline,acetylcholine receptor agonist,CHRNA4,6714,Phase 2
rivanicline,acetylcholine receptor agonist,CHRNB2,1017,Phase 2
rivanicline,acetylcholine receptor agonist,CXCL8,1019,Phase 2
rivaroxaban,coagulation factor inhibitor,F10,1020,Launched
rivastigmine,acetylcholinesterase inhibitor,ACHE,5594,Launched
rivastigmine,acetylcholinesterase inhibitor,BCHE,5595,Launched
rizatriptan,serotonin receptor agonist,HTR1A,6733,Launched
rizatriptan,serotonin receptor agonist,HTR1B,262,Launched
rizatriptan,serotonin receptor agonist,HTR1D,3761,Launched
rizatriptan,serotonin receptor agonist,HTR1E,4953,Launched
rizatriptan,serotonin receptor agonist,HTR1F,1268,Launched
RKI-1447,rho associated kinase inhibitor,CDC42BPA,7295,Preclinical
RKI-1447,rho associated kinase inhibitor,DMPK,2194,Preclinical
RKI-1447,rho associated kinase inhibitor,LIMK1,5602,Preclinical
RKI-1447,rho associated kinase inhibitor,MYLK,5599,Preclinical
RKI-1447,rho associated kinase inhibitor,PAK1,9479,Preclinical
RKI-1447,rho associated kinase inhibitor,PKN1,5601,Preclinical
RKI-1447,rho associated kinase inhibitor,ROCK1,7272,Preclinical
RKI-1447,rho associated kinase inhibitor,ROCK2,7150,Preclinical
RN-1,histone demethylase inhibitor,KDM1A,7153,Preclinical
RN-1734,TRPV antagonist,TRPV4,8566,Preclinical
RN-1747,TRPV agonist,TRPV4,1644,Preclinical
Ro-04-5595,glutamate receptor antagonist,GRIN2B,8566,Preclinical
Ro-08-2750,NGF binding inhibitor,NGF,1719,Preclinical
Ro-08-2750,NGF binding inhibitor,NGFR,55244,Preclinical
Ro-10-5824,dopamine receptor agonist,DRD4,3784,Preclinical
Ro-1138452,prostanoid receptor antagonist,PTGIR,3785,Preclinical
Ro-15-4513,GABA benzodiazepine site receptor inverse agonist,GABRA1,9132,Preclinical
Ro-15-4513,GABA benzodiazepine site receptor inverse agonist,GABRA2,56479,Preclinical
Ro-15-4513,GABA benzodiazepine site receptor inverse agonist,GABRA3,3065,Preclinical
Ro-15-4513,GABA benzodiazepine site receptor inverse agonist,GABRA4,3290,Preclinical
Ro-15-4513,GABA benzodiazepine site receptor inverse agonist,GABRA5,5970,Preclinical
Ro-15-4513,GABA benzodiazepine site receptor inverse agonist,GABRA6,367,Preclinical
Ro-15-4513,GABA benzodiazepine site receptor inverse agonist,GABRB2,7874,Preclinical
Ro-15-4513,GABA benzodiazepine site receptor inverse agonist,GABRG2,1814,Preclinical
Ro-19-4605,GABA benzodiazepine site receptor inverse agonist,GABRA1,3350,Preclinical
Ro-19-4605,GABA benzodiazepine site receptor inverse agonist,GABRA2,6531,Preclinical
Ro-19-4605,GABA benzodiazepine site receptor inverse agonist,GABRA3,673,Preclinical
Ro-19-4605,GABA benzodiazepine site receptor inverse agonist,GABRA5,2099,Preclinical
Ro-20-1724,phosphodiesterase inhibitor,PDE3A,2100,Preclinical
Ro-20-1724,phosphodiesterase inhibitor,PDE4A,2356,Preclinical
Ro-20-1724,phosphodiesterase inhibitor,PDE4B,7298,Preclinical
Ro-20-1724,phosphodiesterase inhibitor,PDE4C,11251,Preclinical
Ro-20-1724,phosphodiesterase inhibitor,PDE4D,6915,Preclinical
Ro-25-6981,glutamate receptor antagonist|monamine transporter modulator,GRIN2B,4543,Preclinical
Ro-28-1675,glucokinase activator,GCK,4544,Preclinical
Ro-3,purinergic receptor antagonist,P2RX3,1636,Preclinical
Ro-3306,CDK inhibitor,CDK1,3359,Preclinical
Ro-48-8071,oxidosqualene cyclase inhibitor,LSS,231,Preclinical
Ro-4987655,MEK inhibitor,MAP2K1,3274,Phase 1
Ro-5126766,MEK inhibitor|RAF inhibitor,BRAF,6336,Phase 1
Ro-5126766,MEK inhibitor|RAF inhibitor,MAP2K1,6335,Phase 1
Ro-5126766,MEK inhibitor|RAF inhibitor,MAP2K2,596,Phase 1
Ro-5126766,MEK inhibitor|RAF inhibitor,RAF1,4129,Phase 1
Ro-60-0175,serotonin receptor agonist,HTR2A,150,Preclinical
Ro-60-0175,serotonin receptor agonist,HTR2B,151,Preclinical
Ro-60-0175,serotonin receptor agonist,HTR2C,152,Preclinical
Ro-61-8048,kynurenine 3-monooxygenase inhibitor,KMO,3351,Preclinical
Ro-67-7476,glutamate receptor positive allosteric modulator,GRM1,3352,Preclinical
Ro-90-7501,beta amyloid protein neurotoxicity inhibitor,APP,3354,Preclinical
robalzotan,serotonin receptor antagonist,HTR1A,3357,Phase 2
rociletinib,EGFR inhibitor,EGFR,5594,Phase 3
rocuronium,acetylcholine receptor antagonist,CHRM2,5595,Launched
rocuronium,acetylcholine receptor antagonist,CHRNA2,5898,Launched
rocuronium,acetylcholine receptor antagonist,HTR3A,5899,Launched
rofecoxib,cyclooxygenase inhibitor,ELN,2357,Withdrawn
rofecoxib,cyclooxygenase inhibitor,PTGS2,25,Withdrawn
roflumilast,phosphodiesterase inhibitor,PDE4A,613,Launched
roflumilast,phosphodiesterase inhibitor,PDE4B,2268,Launched
roflumilast,phosphodiesterase inhibitor,PDE4C,2322,Launched
roflumilast,phosphodiesterase inhibitor,PDE4D,3055,Launched
romidepsin,HDAC inhibitor,HDAC1,4067,Launched
romidepsin,HDAC inhibitor,HDAC2,6714,Launched
romidepsin,HDAC inhibitor,HDAC3,6530,Launched
romidepsin,HDAC inhibitor,HDAC4,148,Launched
romidepsin,HDAC inhibitor,HDAC5,5604,Launched
romidepsin,HDAC inhibitor,HDAC6,5605,Launched
romidepsin,HDAC inhibitor,HDAC7,134,Launched
romidepsin,HDAC inhibitor,HDAC8,135,Launched
romidepsin,HDAC inhibitor,HDAC9,136,Launched
ropinirole,dopamine receptor agonist,ADRA2A,140,Launched
ropinirole,dopamine receptor agonist,ADRA2B,25,Launched
ropinirole,dopamine receptor agonist,ADRA2C,673,Launched
ropinirole,dopamine receptor agonist,DRD1,4921,Launched
ropinirole,dopamine receptor agonist,DRD2,1969,Launched
ropinirole,dopamine receptor agonist,DRD3,2260,Launched
ropinirole,dopamine receptor agonist,DRD4,2263,Launched
ropinirole,dopamine receptor agonist,DRD5,2321,Launched
ropinirole,dopamine receptor agonist,HTR1A,2324,Launched
ropinirole,dopamine receptor agonist,HTR1B,2444,Launched
ropinirole,dopamine receptor agonist,HTR1D,3791,Launched
ropinirole,dopamine receptor agonist,HTR2A,3815,Launched
ropinirole,dopamine receptor agonist,HTR2B,5600,Launched
ropinirole,dopamine receptor agonist,HTR2C,4914,Launched
ropivacaine,sodium channel blocker,SCN10A,5156,Launched
roscovitine,CDK inhibitor,CDK2,5159,Phase 2
roscovitine,CDK inhibitor,CDK9,5894,Phase 2
rosiglitazone,insulin sensitizer|PPAR receptor agonist,FFAR1,5979,Withdrawn
rosiglitazone,insulin sensitizer|PPAR receptor agonist,PPARG,7010,Withdrawn
rosiglitazone,insulin sensitizer|PPAR receptor agonist,TRPC5,552,Withdrawn
rosiglitazone,insulin sensitizer|PPAR receptor agonist,TRPM3,553,Withdrawn
rosmarinic-acid,GABA transaminase inhibitor,MCL1,554,Launched
rosmarinic-acid,GABA transaminase inhibitor,TYR,5021,Launched
rostafuroxine,ATPase inhibitor,ATP1A1,2902,Phase 2
rosuvastatin,HMGCR inhibitor,HMGCR,2550,Launched
rotigotine,dopamine receptor agonist,ADRA2B,55226,Launched
rotigotine,dopamine receptor agonist,DRD1,1813,Launched
rotigotine,dopamine receptor agonist,DRD2,1814,Launched
rotigotine,dopamine receptor agonist,DRD3,1815,Launched
rotigotine,dopamine receptor agonist,DRD4,3356,Launched
rotigotine,dopamine receptor agonist,DRD5,10280,Launched
rotigotine,dopamine receptor agonist,HTR1A,6833,Launched
rotundine,serotonin receptor agonist,DRD1,3767,Launched
rotundine,serotonin receptor agonist,DRD2,5468,Launched
rotundine,serotonin receptor agonist,DRD3,3577,Launched
rotundine,serotonin receptor agonist,HTR1A,3579,Launched
roxatidine-acetate,histamine receptor antagonist,HRH2,7046,Launched
roxithromycin,bacterial 50S ribosomal subunit inhibitor,MLNR,7099,Launched
RP-001,sphingosine 1-phosphate receptor agonist,S1PR1,6570,Preclinical
RQ-00203078,transient receptor potential channel antagonist,TRPM8,6571,Preclinical
RRx-001,glucose 6-phosphate dehydrogenase inhibitor,G6PD,51284,Phase 3
RS-100329,adrenergic receptor antagonist,ADRA1A,51311,Preclinical
RS-100329,adrenergic receptor antagonist,ADRA1D,3065,Preclinical
RS-102221,serotonin receptor antagonist,HTR2A,8841,Preclinical
RS-102221,serotonin receptor antagonist,HTR2B,10013,Preclinical
RS-102221,serotonin receptor antagonist,HTR2C,55869,Preclinical
RS-102895,CCR antagonist,CCR2,771,Preclinical
RS-127445,serotonin receptor antagonist,HTR2A,23632,Phase 1
RS-127445,serotonin receptor antagonist,HTR2B,760,Phase 1
RS-127445,serotonin receptor antagonist,HTR2C,5742,Phase 1
RS-17053,adrenergic receptor antagonist,ADRA1A,1457,Preclinical
RS-17053,adrenergic receptor antagonist,ADRA1D,4835,Preclinical
RS-23597-190,serotonin receptor antagonist,HTR4,5742,Preclinical
RS-39604,serotonin receptor antagonist,HTR4,5743,Preclinical
RS-504393,CC chemokine receptor antagonist,CCL2,5293,Preclinical
RS-504393,CC chemokine receptor antagonist,CCR2,5294,Preclinical
RS-56812,serotonin receptor partial agonist,HTR3A,5600,Preclinical
RS-67333,serotonin receptor partial agonist,HTR4,1432,Preclinical
RS-67506,serotonin receptor partial agonist,HTR4,5743,Preclinical
RS-79948,adrenergic receptor antagonist,ADRA2A,3315,Preclinical
RTA-408,nitric oxide production inhibitor,NFE2L2,1432,Phase 2
RU-SKI-43,hedgehog pathway inhibitor,HHAT,3356,Preclinical
RU-24969,serotonin receptor agonist,HTR1A,3357,Phase 1
RU-24969,serotonin receptor agonist,HTR1B,3358,Phase 1
RU-24969,serotonin receptor agonist,HTR1D,3362,Phase 1
RU-24969,serotonin receptor agonist,HTR2A,3362,Phase 1
RU-24969,serotonin receptor agonist,HTR2B,796,Phase 1
RU-24969,serotonin receptor agonist,HTR2C,3363,Phase 1
RU-24969,serotonin receptor agonist,HTR5A,3362,Phase 1
RU-24969,serotonin receptor agonist,HTR6,1232,Phase 1
RU-28318,cytochrome P450 inhibitor,NR3C2,3061,Phase 2
RU-42173,adrenergic receptor agonist,ADRB2,3062,Phase 2
RU-58841,androgen receptor antagonist,AR,7442,Phase 2
rubitecan,topoisomerase inhibitor,TOP1,3362,Phase 3
rucaparib,PARP inhibitor,PARP1,3061,Phase 3
rucaparib,PARP inhibitor,PARP2,3062,Phase 3
rucinol,tyrosinase inhibitor,TYR,2931,Phase 1
rufinamide,voltage-gated sodium channel blocker,GRM5,2932,Launched
rufinamide,voltage-gated sodium channel blocker,SCN10A,6198,Launched
rufinamide,voltage-gated sodium channel blocker,SCN11A,130399,Launched
rufinamide,voltage-gated sodium channel blocker,SCN1A,7046,Launched
rufinamide,voltage-gated sodium channel blocker,SCN2A,7442,Launched
rufinamide,voltage-gated sodium channel blocker,SCN3A,7046,Launched
rufinamide,voltage-gated sodium channel blocker,SCN4A,7046,Launched
rufinamide,voltage-gated sodium channel blocker,SCN5A,673,Launched
rufinamide,voltage-gated sodium channel blocker,SCN7A,4987,Launched
rufinamide,voltage-gated sodium channel blocker,SCN8A,2837,Launched
rufinamide,voltage-gated sodium channel blocker,SCN9A,3676,Launched
rupatadine,histamine receptor antagonist|platelet activating factor receptor antagonist,HRH1,3685,Launched
rupatadine,histamine receptor antagonist|platelet activating factor receptor antagonist,PTAFR,3688,Launched
rutaecarpine,cyclooxygenase inhibitor,PTGS2,3695,Preclinical
rutin,antioxidant|capillary stabilizing agent|nitric oxide scavenger,AKR1C3,7442,Launched
ruxolitinib,JAK inhibitor,JAK1,2837,Launched
ruxolitinib,JAK inhibitor,JAK2,3362,Launched
ruxolitinib,JAK inhibitor,JAK3,3832,Launched
ruxolitinib,JAK inhibitor,TYK2,207,Launched
ruxolitinib-(S),JAK inhibitor,JAK1,10000,Preclinical
ruxolitinib-(S),JAK inhibitor,JAK2,6093,Preclinical
RWJ-21757,toll-like receptor agonist,TLR7,9252,Phase 2
RWJ-50271,integrin inhibitor,ICAM1,6198,Preclinical
RWJ-67657,MAP kinase inhibitor,MAPK14,151306,Phase 1
RWJ-67657,MAP kinase inhibitor,PTGS2,6093,Phase 1
RX-3117,CDK inhibitor|DNA synthesis inhibitor,CDK2,9475,Phase 1/Phase 2
RX-3117,CDK inhibitor|DNA synthesis inhibitor,DNMT1,3065,Phase 1/Phase 2
RX-821002,adrenergic receptor antagonist,ADRA1A,83933,Preclinical
RX-821002,adrenergic receptor antagonist,ADRA1B,3066,Preclinical
RX-821002,adrenergic receptor antagonist,ADRA1D,8841,Preclinical
RX-821002,adrenergic receptor antagonist,ADRA2A,9759,Preclinical
RX-821002,adrenergic receptor antagonist,ADRA2B,10014,Preclinical
RX-821002,adrenergic receptor antagonist,ADRA2C,10013,Preclinical
ryuvidine,histone lysine methyltransferase inhibitor,CDK2,9734,Preclinical
ryuvidine,histone lysine methyltransferase inhibitor,CDK4,5347,Preclinical
R112,SYK inhibitor,SYK,3065,Phase 1
R406,SYK inhibitor,RET,8841,Phase 1
R406,SYK inhibitor,SYK,5578,Phase 1
R547,CDK inhibitor,CDK1,3605,Phase 1
R547,CDK inhibitor,CDK2,5731,Phase 1
R547,CDK inhibitor,CDK4,5743,Phase 1
R547,CDK inhibitor,CDK7,5731,Phase 1
S-isopropylisothiourea,nitric oxide synthase inhibitor,NOS3,5742,Preclinical
S-methylcysteine,,CTSD,5578,Phase 1
S-methylcysteine,,MGMT,1128,Phase 1
S-nitrosoglutathione,nitric oxide stimulant,PTPN1,1129,Phase 1
S-07662,CAR antagonist,NR1I3,1812,Preclinical
S-111,PARP inhibitor,PARP1,1813,Phase 2
S-14506,serotonin receptor agonist,HTR1A,4987,Preclinical
SA-47,FAAH inhibitor,FAAH,1812,Preclinical
saccharin,DNA polymerase inhibitor,CA1,1816,Launched
saccharin,DNA polymerase inhibitor,CA12,3358,Launched
saccharin,DNA polymerase inhibitor,CA2,3761,Launched
saccharin,DNA polymerase inhibitor,CA9,3763,Launched
saclofen,GABA receptor antagonist,GABBR1,495,Preclinical
saclofen,GABA receptor antagonist,GABBR2,4521,Preclinical
saclofen,GABA receptor antagonist,KCTD12,134,Preclinical
saclofen,GABA receptor antagonist,KCTD16,135,Preclinical
saclofen,GABA receptor antagonist,KCTD8,136,Preclinical
sacubitril,neprilysin inhibitor,MME,140,Launched
safinamide,dopamine reuptake inhibitor|glutamate inhibitor|monoamine oxidase inhibitor,MAOB,1017,Launched
safingol,PKC inhibitor,TRPM3,1111,Phase 1
safranal,benzodiazepine receptor agonist,GABBR1,545,Phase 2
SAG,smoothened receptor agonist,SMO,2950,Preclinical
SAG,smoothened receptor agonist,TRPC6,1128,Preclinical
salicylic-acid,cyclooxygenase inhibitor|prostanoid receptor antagonist,AKR1C1,1129,Launched
salicylic-acid,cyclooxygenase inhibitor|prostanoid receptor antagonist,ASIC3,1131,Launched
salicylic-acid,cyclooxygenase inhibitor|prostanoid receptor antagonist,PTGS1,1132,Launched
salicylic-acid,cyclooxygenase inhibitor|prostanoid receptor antagonist,PTGS2,1133,Launched
salidroside,beta amyloid protein neurotoxicity inhibitor,APP,6476,Preclinical
salirasib,mTOR inhibitor,TRPA1,1128,Phase 2
salmeterol,adrenergic receptor agonist,ADRB2,1129,Launched
salubrinal,eukaryotic translation initiation factor inhibitor,EIF2S1,1131,Preclinical
salvianolic-acid-B,EGFR inhibitor|metalloproteinase inhibitor,MMP9,1132,Phase 2
salvinorin-A,opioid receptor agonist,OPRD1,3065,Phase 1
salvinorin-A,opioid receptor agonist,OPRK1,3066,Phase 1
salvinorin-A,opioid receptor agonist,OPRM1,8841,Phase 1
sal003,eukaryotic translation initiation factor inhibitor,EIF2A,83939,Preclinical
sanguinarium-chloride,apoptosis stimulant,CASP3,836,Phase 1
SANT-1,smoothened receptor antagonist,SHH,6469,Preclinical
SANT-1,smoothened receptor antagonist,SMO,6608,Preclinical
SANT-2,smoothened receptor antagonist,SHH,6469,Preclinical
SANT-2,smoothened receptor antagonist,SMO,6608,Preclinical
sapropterin,phenylalanine 4-hydroxylase stimulant,NOS3,4846,Launched
sapropterin,phenylalanine 4-hydroxylase stimulant,PAH,5053,Launched
sapropterin,phenylalanine 4-hydroxylase stimulant,TH,7054,Launched
sapropterin,phenylalanine 4-hydroxylase stimulant,TPH1,7166,Launched
saquinavir,HIV protease inhibitor,CYP3A4,1576,Launched
SAR-245409,PI3K inhibitor,MTOR,2475,Phase 1/Phase 2
SAR-245409,PI3K inhibitor,PIK3CG,5294,Phase 1/Phase 2
saracatinib,SRC inhibitor,ABL1,25,Phase 2/Phase 3
saracatinib,SRC inhibitor,LCK,3932,Phase 2/Phase 3
saracatinib,SRC inhibitor,SRC,6714,Phase 2/Phase 3
saracatinib,SRC inhibitor,YES1,7525,Phase 2/Phase 3
sarcosine,glycine transporter inhibitor,SLC6A9,6536,Phase 2
saroglitazar,PPAR receptor agonist,PPARA,5465,Launched
saroglitazar,PPAR receptor agonist,PPARG,5468,Launched
sarpogrelate,serotonin receptor antagonist,HTR2A,3356,Launched
sarpogrelate,serotonin receptor antagonist,HTR2B,3357,Launched
sarpogrelate,serotonin receptor antagonist,HTR2C,3358,Launched
SAR131675,VEGFR inhibitor,FLT4,2324,Preclinical
SAR405,PI3K inhibitor,PIK3C3,5289,Preclinical
SAR405838,MDM inhibitor,MDM2,4193,Phase 1
SAR407899,rho associated kinase inhibitor,ROCK1,6093,Phase 2
sasapyrine,NFkB pathway inhibitor,PTGS1,5742,Launched
sasapyrine,NFkB pathway inhibitor,PTGS2,5743,Launched
savolitinib,c-Met inhibitor,MET,4233,Phase 3
saxagliptin,dipeptidyl peptidase inhibitor,DPP4,1803,Launched
SB-200646,serotonin receptor antagonist,HTR2B,3357,Preclinical
SB-200646,serotonin receptor antagonist,HTR2C,3358,Preclinical
SB-202190,p38 MAPK inhibitor,AKT1,207,Preclinical
SB-202190,p38 MAPK inhibitor,ALOX5,240,Preclinical
SB-202190,p38 MAPK inhibitor,CHEK1,1111,Preclinical
SB-202190,p38 MAPK inhibitor,GSK3B,2932,Preclinical
SB-202190,p38 MAPK inhibitor,LCK,3932,Preclinical
SB-202190,p38 MAPK inhibitor,MAPK1,5594,Preclinical
SB-202190,p38 MAPK inhibitor,MAPK11,5600,Preclinical
SB-202190,p38 MAPK inhibitor,MAPK12,6300,Preclinical
SB-202190,p38 MAPK inhibitor,MAPK14,1432,Preclinical
SB-202190,p38 MAPK inhibitor,MAPK8,5599,Preclinical
SB-202190,p38 MAPK inhibitor,PRKCA,5578,Preclinical
SB-202190,p38 MAPK inhibitor,ROCK1,6093,Preclinical
SB-202190,p38 MAPK inhibitor,RPS6KB1,6198,Preclinical
SB-202190,p38 MAPK inhibitor,SGK1,6446,Preclinical
SB-203186,serotonin receptor antagonist,HTR4,3360,Preclinical
SB-203580,p38 MAPK inhibitor,AKT1,207,Preclinical
SB-203580,p38 MAPK inhibitor,ALOX5,240,Preclinical
SB-203580,p38 MAPK inhibitor,CHEK1,1111,Preclinical
SB-203580,p38 MAPK inhibitor,CYP2D6,1565,Preclinical
SB-203580,p38 MAPK inhibitor,CYP3A4,1576,Preclinical
SB-203580,p38 MAPK inhibitor,GAK,2580,Preclinical
SB-203580,p38 MAPK inhibitor,GSK3B,2932,Preclinical
SB-203580,p38 MAPK inhibitor,LCK,3932,Preclinical
SB-203580,p38 MAPK inhibitor,MAPK1,5594,Preclinical
SB-203580,p38 MAPK inhibitor,MAPK10,5602,Preclinical
SB-203580,p38 MAPK inhibitor,MAPK11,5600,Preclinical
SB-203580,p38 MAPK inhibitor,MAPK12,6300,Preclinical
SB-203580,p38 MAPK inhibitor,MAPK14,1432,Preclinical
SB-203580,p38 MAPK inhibitor,MAPK8,5599,Preclinical
SB-203580,p38 MAPK inhibitor,MAPK9,5601,Preclinical
SB-203580,p38 MAPK inhibitor,PRKCA,5578,Preclinical
SB-203580,p38 MAPK inhibitor,RAF1,5894,Preclinical
SB-203580,p38 MAPK inhibitor,RIPK2,8767,Preclinical
SB-203580,p38 MAPK inhibitor,ROCK1,6093,Preclinical
SB-203580,p38 MAPK inhibitor,RPS6KB1,6198,Preclinical
SB-203580,p38 MAPK inhibitor,SGK1,6446,Preclinical
SB-203580,p38 MAPK inhibitor,SRC,6714,Preclinical
SB-203580,p38 MAPK inhibitor,TNF,7124,Preclinical
SB-205384,GABA receptor modulator,GABRA3,2556,Preclinical
SB-205384,GABA receptor modulator,GABRA5,2558,Preclinical
SB-205384,GABA receptor modulator,GABRA6,2559,Preclinical
SB-206553,serotonin receptor antagonist,HTR2A,3356,Preclinical
SB-206553,serotonin receptor antagonist,HTR2B,3357,Preclinical
SB-206553,serotonin receptor antagonist,HTR2C,3358,Preclinical
SB-216641,serotonin receptor antagonist,HTR1A,3350,Preclinical
SB-216641,serotonin receptor antagonist,HTR1B,3351,Preclinical
SB-216641,serotonin receptor antagonist,HTR1D,3352,Preclinical
SB-216641,serotonin receptor antagonist,HTR2A,3356,Preclinical
SB-216641,serotonin receptor antagonist,HTR2B,3357,Preclinical
SB-216641,serotonin receptor antagonist,HTR2C,3358,Preclinical
SB-216763,glycogen synthase kinase inhibitor,CCNA2,890,Preclinical
SB-216763,glycogen synthase kinase inhibitor,CDK2,1017,Preclinical
SB-216763,glycogen synthase kinase inhibitor,GSK3A,2931,Preclinical
SB-216763,glycogen synthase kinase inhibitor,GSK3B,2932,Preclinical
SB-218078,CHK inhibitor,CHEK1,1111,Preclinical
SB-218795,tachykinin antagonist,TACR3,6870,Preclinical
SB-221284,serotonin receptor antagonist,HTR2A,3356,Preclinical
SB-221284,serotonin receptor antagonist,HTR2B,3357,Preclinical
SB-221284,serotonin receptor antagonist,HTR2C,3358,Preclinical
SB-222200,tachykinin antagonist,TACR3,6870,Preclinical
SB-225002,CC chemokine receptor antagonist,CXCR2,3579,Preclinical
SB-228357,serotonin receptor antagonist,HTR2A,3356,Preclinical
SB-228357,serotonin receptor antagonist,HTR2B,3357,Preclinical
SB-228357,serotonin receptor antagonist,HTR2C,3358,Preclinical
SB-2343,mTOR inhibitor|PI3K inhibitor,MTOR,2475,Phase 1
SB-2343,mTOR inhibitor|PI3K inhibitor,PIK3CA,5290,Phase 1
SB-2343,mTOR inhibitor|PI3K inhibitor,PIK3CB,5291,Phase 1
SB-2343,mTOR inhibitor|PI3K inhibitor,PIK3CD,6347,Phase 1
SB-2343,mTOR inhibitor|PI3K inhibitor,PIK3CG,729230,Phase 1
SB-239063,p38 MAPK inhibitor,MAPK11,3359,Preclinical
SB-239063,p38 MAPK inhibitor,MAPK14,3360,Preclinical
SB-239063,p38 MAPK inhibitor,PTGS2,3360,Preclinical
SB-242235,p38 MAPK inhibitor,HSPB1,150,Phase 1
SB-242235,p38 MAPK inhibitor,MAPK14,4780,Phase 1
SB-243213,serotonin receptor inverse agonist,HTR2A,55733,Phase 1
SB-243213,serotonin receptor inverse agonist,HTR2B,3350,Phase 1
SB-243213,serotonin receptor inverse agonist,HTR2C,3351,Phase 1
SB-243213,serotonin receptor inverse agonist,HTR6,3352,Phase 1
SB-258585,serotonin receptor antagonist,HTR6,3356,Preclinical
SB-268262,calcitonin antagonist,CALCA,3357,Preclinical
SB-269970,serotonin receptor antagonist,HTR7,3358,Preclinical
SB-271046,serotonin receptor antagonist,HTR6,3361,Phase 1
SB-297006,CC chemokine receptor antagonist,CCR3,3362,Preclinical
SB-334867,orexin receptor antagonist,HCRTR1,4306,Preclinical
SB-334867,orexin receptor antagonist,HCRTR2,154,Preclinical
SB-366791,TRPV antagonist,TRPV1,367,Preclinical
SB-399885,serotonin receptor antagonist,HTR6,7150,Preclinical
SB-408124,orexin receptor antagonist,HCRTR1,142,Preclinical
SB-408124,orexin receptor antagonist,HCRTR2,10038,Preclinical
SB-415286,glycogen synthase kinase inhibitor,GSK3A,7299,Preclinical
SB-415286,glycogen synthase kinase inhibitor,GSK3B,2915,Preclinical
SB-415286,glycogen synthase kinase inhibitor,RPS6KB1,6336,Preclinical
SB-431542,TGF beta receptor inhibitor,ACVR1C,11280,Preclinical
SB-431542,TGF beta receptor inhibitor,TGFBR1,6323,Preclinical
SB-452533,TRPV antagonist,TRPV1,6326,Preclinical
SB-505124,ALK tyrosine kinase receptor inhibitor,TGFBR1,6328,Preclinical
SB-525334,TGF beta receptor inhibitor,TGFBR1,6329,Preclinical
SB-590885,RAF inhibitor,BRAF,6331,Preclinical
SB-612111,nociceptin/orphanin FQ receptor antagonist,OPRL1,6332,Preclinical
SB-657510,urotensin receptor antagonist,UTS2R,6334,Preclinical
SB-683698,integrin antagonist,ITGA4,6335,Phase 1
SB-683698,integrin antagonist,ITGAV,3269,Phase 1
SB-683698,integrin antagonist,ITGB1,5724,Phase 1
SB-683698,integrin antagonist,ITGB7,5743,Phase 1
SB-705498,TRPV antagonist,TRPV1,8644,Phase 2
SB-706375,urotensin receptor antagonist,UTS2R,3716,Preclinical
SB-742457,serotonin receptor antagonist,HTR6,3717,Phase 3
SB-743921,kinesin-like spindle protein inhibitor,KIF11,3718,Phase 1/Phase 2
SB-747651A,kinase inhibitor,AKT1,7297,Preclinical
SB-747651A,kinase inhibitor,AKT3,3716,Preclinical
SB-747651A,kinase inhibitor,ROCK1,3717,Preclinical
SB-747651A,kinase inhibitor,RPS6KA5,51284,Preclinical
SB-747651A,kinase inhibitor,RPS6KB1,3383,Preclinical
SB-756050,G protein-coupled receptor agonist,GPBAR1,1432,Phase 1
SB-772077B,rho associated kinase inhibitor,ROCK1,5743,Preclinical
SB-772077B,rho associated kinase inhibitor,ROCK2,1017,Preclinical
SB-939,HDAC inhibitor,HDAC1,1786,Phase 3
SB-939,HDAC inhibitor,HDAC10,148,Phase 3
SB-939,HDAC inhibitor,HDAC2,147,Phase 3
SB-939,HDAC inhibitor,HDAC3,146,Phase 3
SB-939,HDAC inhibitor,HDAC4,150,Phase 3
SB-939,HDAC inhibitor,HDAC5,151,Phase 3
SB-939,HDAC inhibitor,HDAC6,152,Phase 3
SB-939,HDAC inhibitor,HDAC9,1017,Phase 3
SBE-13,PLK inhibitor,PLK1,1019,Preclinical
SBHA,HDAC inhibitor,HDAC1,6850,Preclinical
SBHA,HDAC inhibitor,HDAC3,5979,Preclinical
SC-10,protein kinase activator,PRKCA,6850,Preclinical
SC-12267,dihydroorotate dehydrogenase inhibitor,IL17A,983,Phase 2
SC-19220,prostanoid receptor antagonist,PTGER1,1017,Preclinical
SC-236,cyclooxygenase inhibitor,PTGS2,1019,Preclinical
SC-51089,prostanoid receptor antagonist,PTGER1,1022,Preclinical
SC-560,cyclooxygenase inhibitor,PTGS1,4846,Preclinical
SC-9,protein tyrosine kinase activator,PRKCA,1509,Preclinical
SCH-202676,G protein-coupled receptor modulator,CHRM1,4255,Preclinical
SCH-202676,G protein-coupled receptor modulator,CHRM2,5770,Preclinical
SCH-202676,G protein-coupled receptor modulator,DRD1,9970,Preclinical
SCH-202676,G protein-coupled receptor modulator,DRD2,142,Preclinical
SCH-221510,nociceptin/orphanin FQ receptor agonist,OPRL1,3350,Preclinical
SCH-23390,dopamine receptor antagonist,DRD1,2166,Preclinical
SCH-23390,dopamine receptor antagonist,DRD5,759,Preclinical
SCH-23390,dopamine receptor antagonist,HTR2C,771,Preclinical
SCH-23390,dopamine receptor antagonist,KCNJ4,760,Preclinical
SCH-23390,dopamine receptor antagonist,KCNJ6,768,Preclinical
SCH-28080,ATPase inhibitor,ATP4A,2550,Phase 1
SCH-51344,MTH1 inhibitor,NUDT1,9568,Preclinical
SCH-58261,adenosine receptor antagonist,ADORA1,115207,Preclinical
SCH-58261,adenosine receptor antagonist,ADORA2A,57528,Preclinical
SCH-58261,adenosine receptor antagonist,ADORA2B,386617,Preclinical
SCH-58261,adenosine receptor antagonist,ADORA3,4311,Preclinical
SCH-900776,CHK inhibitor,CDK2,4129,Phase 2
SCH-900776,CHK inhibitor,CHEK1,80036,Phase 2
schisandrin-B,antioxidant,ATR,2550,Preclinical
SCMC-Lys,mucolytic agent,GSTP1,6608,Launched
scopolamine,acetylcholine receptor antagonist,CHRM1,7225,Launched
scopolamine,acetylcholine receptor antagonist,CHRM2,1645,Launched
scopolamine,acetylcholine receptor antagonist,CHRM3,9311,Launched
scopolamine,acetylcholine receptor antagonist,CHRM4,5742,Launched
scopolamine,acetylcholine receptor antagonist,CHRM5,5743,Launched
scopolamine,acetylcholine receptor antagonist,SI,351,Launched
scopolamine-N-oxide,acetylcholine receptor antagonist,CHRM1,8989,Preclinical
scopolamine-N-oxide,acetylcholine receptor antagonist,CHRM2,154,Preclinical
scopolamine-N-oxide,acetylcholine receptor antagonist,CHRM3,1965,Preclinical
scopolamine-N-oxide,acetylcholine receptor antagonist,CHRM4,4318,Preclinical
scriptaid,HDAC inhibitor,HDAC1,4985,Preclinical
scriptaid,HDAC inhibitor,HDAC2,4986,Preclinical
scriptaid,HDAC inhibitor,HDAC3,4988,Preclinical
scriptaid,HDAC inhibitor,HDAC4,6531,Preclinical
scriptaid,HDAC inhibitor,HDAC5,2902,Preclinical
scriptaid,HDAC inhibitor,HDAC6,2903,Preclinical
scriptaid,HDAC inhibitor,HDAC7,2904,Preclinical
scriptaid,HDAC inhibitor,HDAC8,2905,Preclinical
scriptaid,HDAC inhibitor,HDAC9,2906,Preclinical
SD-169,p38 MAPK inhibitor,MAPK14,4128,Preclinical
SD-208,TGF beta receptor inhibitor,TGFBR1,27306,Preclinical
SD-2590,matrix metalloprotease inhibitor,MMP1,1195,Preclinical
SD-2590,matrix metalloprotease inhibitor,MMP13,57396,Preclinical
SD-2590,matrix metalloprotease inhibitor,MMP2,1859,Preclinical
SDM25N,opioid receptor antagonist,OPRD1,9149,Preclinical
SDZ-NKT-343,tachykinin antagonist,TACR1,983,Phase 1
SDZ-SER-082,serotonin receptor antagonist,HTR2A,1017,Preclinical
SDZ-SER-082,serotonin receptor antagonist,HTR2B,1022,Preclinical
SDZ-SER-082,serotonin receptor antagonist,HTR2C,1025,Preclinical
SDZ-WAG-994,adenosine receptor agonist,ADORA1,2322,Phase 2
SDZ-205-557,serotonin receptor antagonist,HTR3A,3717,Preclinical
SDZ-205-557,serotonin receptor antagonist,HTR3B,3791,Preclinical
SDZ-21009,adrenergic receptor antagonist|serotonin receptor antagonist,HTR1A,6714,Preclinical
SDZ-21009,adrenergic receptor antagonist|serotonin receptor antagonist,HTR1B,1445,Preclinical
SDZ-220-040,glutamate receptor antagonist,GRIN1,2260,Preclinical
SDZ-220-581,glutamate receptor antagonist,GRIN1,2321,Preclinical
secalciferol,vitamin D receptor agonist,VDR,2324,Launched
securinine,GABA receptor antagonist|TP53 activator,GABRA1,3791,Preclinical
segesterone-acetate,progesterone receptor agonist,PGR,6714,Launched
selegiline,monoamine oxidase inhibitor,MAOA,3717,Launched
selegiline,monoamine oxidase inhibitor,MAOB,3718,Launched
selexipag,IP1 prostacyclin receptor agonist|platelet aggregation inhibitor,PTGIR,5291,Launched
selfotel,glutamate receptor antagonist,GRIN2A,5293,Phase 3
selfotel,glutamate receptor antagonist,GRIN2B,5290,Phase 3
selfotel,glutamate receptor antagonist,GRIN2C,5291,Phase 3
selfotel,glutamate receptor antagonist,GRIN2D,5293,Phase 3
selinexor,exportin antagonist,XPO1,5294,Launched
selumetinib,MEK inhibitor,MAP2K1,4521,Phase 3
semagacestat,gamma secretase inhibitor,PSEN1,7124,Phase 3
semapimod,cytokine production inhibitor|p38 MAPK inhibitor,MAPK14,134,Phase 2
semaxanib,VEGFR inhibitor,FGFR1,135,Phase 3
semaxanib,VEGFR inhibitor,FLT1,5142,Phase 3
semaxanib,VEGFR inhibitor,KDR,-,Phase 3
semaxanib,VEGFR inhibitor,KIT,10560,Phase 3
semaxanib,VEGFR inhibitor,PDGFRA,80704,Phase 3
semaxanib,VEGFR inhibitor,PDGFRB,27010,Phase 3
semaxanib,VEGFR inhibitor,RET,2554,Phase 3
SEN-1269,beta amyloid inhibitor,APP,1812,Preclinical
senicapoc,intermediate conductance potassium channel blocker,KCNN4,1813,Phase 3
seocalcitol,vitamin D receptor agonist,VDR,1815,Phase 3
SEP-227900,D-amino acid oxidase Inhibitor,DAO,2554,Phase 1
seratrodast,prostanoid receptor antagonist,TBXA2R,2561,Launched
serdemetan,MDM inhibitor,MDM2,2566,Phase 1
serotonin,growth factor receptor activator,DRD1,2741,Launched
serotonin,growth factor receptor activator,DRD5,2743,Launched
serotonin,growth factor receptor activator,HTR1A,43,Launched
serotonin,growth factor receptor activator,HTR1B,5743,Launched
serotonin,growth factor receptor activator,HTR1D,3614,Launched
serotonin,growth factor receptor activator,HTR1E,3615,Launched
serotonin,growth factor receptor activator,HTR1F,5019,Launched
serotonin,growth factor receptor activator,HTR2A,2166,Launched
serotonin,growth factor receptor activator,HTR2B,11255,Launched
serotonin,growth factor receptor activator,HTR2C,59340,Launched
serotonin,growth factor receptor activator,HTR3A,148,Launched
serotonin,growth factor receptor activator,HTR3B,147,Launched
serotonin,growth factor receptor activator,HTR4,1812,Launched
serotonin,growth factor receptor activator,HTR5A,1813,Launched
serotonin,growth factor receptor activator,HTR6,3350,Launched
serotonin,growth factor receptor activator,HTR7,3356,Launched
serotonin,growth factor receptor activator,SLC36A1,1812,Launched
sertindole,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A,1813,Withdrawn
sertindole,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1B,1814,Withdrawn
sertindole,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1D,1815,Withdrawn
sertindole,dopamine receptor antagonist|serotonin receptor antagonist,DRD2,1816,Withdrawn
sertindole,dopamine receptor antagonist|serotonin receptor antagonist,DRD3,3269,Withdrawn
sertindole,dopamine receptor antagonist|serotonin receptor antagonist,DRD4,3350,Withdrawn
sertindole,dopamine receptor antagonist|serotonin receptor antagonist,HRH1,3356,Withdrawn
sertindole,dopamine receptor antagonist|serotonin receptor antagonist,HTR1A,3358,Withdrawn
sertindole,dopamine receptor antagonist|serotonin receptor antagonist,HTR1B,3362,Withdrawn
sertindole,dopamine receptor antagonist|serotonin receptor antagonist,HTR1D,3363,Withdrawn
sertindole,dopamine receptor antagonist|serotonin receptor antagonist,HTR1E,4311,Withdrawn
sertindole,dopamine receptor antagonist|serotonin receptor antagonist,HTR1F,2305,Withdrawn
sertindole,dopamine receptor antagonist|serotonin receptor antagonist,HTR2A,1555,Withdrawn
sertindole,dopamine receptor antagonist|serotonin receptor antagonist,HTR2C,1576,Withdrawn
sertindole,dopamine receptor antagonist|serotonin receptor antagonist,HTR6,1812,Withdrawn
sertindole,dopamine receptor antagonist|serotonin receptor antagonist,KCNH2,1813,Withdrawn
sertraline,selective serotonin reuptake inhibitor (SSRI),SLC6A3,3269,Launched
sertraline,selective serotonin reuptake inhibitor (SSRI),SLC6A4,3356,Launched
setipiprant,prostaglandin inhibitor,PTGDR2,3717,Phase 3
setiptiline,adrenergic receptor antagonist,HRH1,8989,Launched
setiptiline,adrenergic receptor antagonist,HTR2A,1022,Launched
setiptiline,adrenergic receptor antagonist,HTR2C,1022,Launched
sevoflurane,membrane integrity inhibitor,ATP2C1,1022,Launched
sevoflurane,membrane integrity inhibitor,ATP5D,6529,Launched
sevoflurane,membrane integrity inhibitor,GABRA1,4985,Launched
sevoflurane,membrane integrity inhibitor,GABRA2,4986,Launched
sevoflurane,membrane integrity inhibitor,GABRA3,4988,Launched
sevoflurane,membrane integrity inhibitor,GABRA4,1813,Launched
sevoflurane,membrane integrity inhibitor,GABRA5,1814,Launched
sevoflurane,membrane integrity inhibitor,GABRA6,5743,Launched
sevoflurane,membrane integrity inhibitor,GABRB1,2099,Launched
sevoflurane,membrane integrity inhibitor,GABRB2,64805,Launched
sevoflurane,membrane integrity inhibitor,GABRB3,64805,Launched
sevoflurane,membrane integrity inhibitor,GABRD,9759,Launched
sevoflurane,membrane integrity inhibitor,GABRE,10014,Launched
sevoflurane,membrane integrity inhibitor,GABRG1,10013,Launched
sevoflurane,membrane integrity inhibitor,GABRG2,51564,Launched
sevoflurane,membrane integrity inhibitor,GABRG3,55869,Launched
sevoflurane,membrane integrity inhibitor,GABRP,9734,Launched
sevoflurane,membrane integrity inhibitor,GABRQ,1432,Launched
sevoflurane,membrane integrity inhibitor,GLRA1,7046,Launched
sevoflurane,membrane integrity inhibitor,GLRB,4312,Launched
sevoflurane,membrane integrity inhibitor,GRIA1,4322,Launched
sevoflurane,membrane integrity inhibitor,KCNA1,4313,Launched
sevoflurane,membrane integrity inhibitor,KCNK10,4985,Launched
sevoflurane,membrane integrity inhibitor,KCNK18,6869,Launched
sevoflurane,membrane integrity inhibitor,KCNK2,3356,Launched
sevoflurane,membrane integrity inhibitor,KCNK3,3357,Launched
sevoflurane,membrane integrity inhibitor,KCNK9,3358,Launched
sevoflurane,membrane integrity inhibitor,MT-ND1,134,Launched
SEW-2871,lysophospholipid receptor agonist,S1PR1,3359,Preclinical
SF-11,neuropeptide receptor antagonist,MCOLN3,9177,Preclinical
SF-11,neuropeptide receptor antagonist,NPY2R,3350,Preclinical
SGC-CBP30,bromodomain inhibitor,CREBBP,3351,Preclinical
SGC-CBP30,bromodomain inhibitor,EP300,2902,Preclinical
SGC-707,protein arginine N-methyltransferase inhibitor,PRMT3,2902,Preclinical
SGI-1027,DNA methyltransferase inhibitor,DNMT1,7421,Preclinical
SGI-1027,DNA methyltransferase inhibitor,DNMT3A,2554,Preclinical
SGI-1027,DNA methyltransferase inhibitor,DNMT3B,5241,Preclinical
SGI-1776,Pim kinase inhibitor,FLT3,4128,Phase 1
SGI-1776,Pim kinase inhibitor,PIM1,4129,Phase 1
SGI-1776,Pim kinase inhibitor,PIM2,5739,Phase 1
SGI-1776,Pim kinase inhibitor,PIM3,2903,Phase 1
SGS-742,GABA receptor antagonist,GABBR1,2904,Preclinical
SGS-742,GABA receptor antagonist,GABBR2,2905,Preclinical
SGX523,hepatocyte growth factor receptor inhibitor,MET,2906,Phase 1
SHA-68,neuropeptide receptor antagonist,NPSR1,7514,Preclinical
SHP099,protein tyrosine kinase inhibitor,PTPN11,5604,Preclinical
SIB-1553A,acetylcholine receptor agonist,CHRNB4,5663,Phase 2
SIB-1757,glutamate receptor antagonist,GRM5,1432,Preclinical
SIB-1893,glutamate receptor antagonist,GRM4,2260,Preclinical
SIB-1893,glutamate receptor antagonist,GRM5,2321,Preclinical
SID-7969543,steroidogenic factor antagonist,NR5A1,3791,Preclinical
siguazodan,phosphodiesterase inhibitor,PDE3A,3815,Phase 1
sildenafil,phosphodiesterase inhibitor,PDE5A,5156,Launched
sildenafil,phosphodiesterase inhibitor,PDE6G,5159,Launched
sildenafil,phosphodiesterase inhibitor,PDE6H,5979,Launched
sildenafil,phosphodiesterase inhibitor,SLCO1B1,351,Launched
sildenafil,phosphodiesterase inhibitor,SLCO1B3,3783,Launched
silibinin,cytochrome P450 inhibitor,ALOX5,7421,Launched
silodosin,adrenergic receptor antagonist,ADRA1A,1610,Launched
silodosin,adrenergic receptor antagonist,ADRA1B,6915,Launched
silodosin,adrenergic receptor antagonist,ADRA1D,4193,Launched
simeprevir,HCV inhibitor,CYP1A2,1812,Launched
simeprevir,HCV inhibitor,CYP3A4,1816,Launched
simvastatin,HMGCR inhibitor,HMGCR,3350,Launched
simvastatin,HMGCR inhibitor,ITGB2,3351,Launched
sinefungin,DNA methyltransferase inhibitor|RNA synthesis inhibitor,CARM1,3352,Preclinical
sipatrigine,voltage-gated sodium channel blocker,CACNA1D,3354,Phase 2
sipatrigine,voltage-gated sodium channel blocker,SCN10A,3355,Phase 2
sipatrigine,voltage-gated sodium channel blocker,SCN1A,3356,Phase 2
sipatrigine,voltage-gated sodium channel blocker,SCN3A,3357,Phase 2
sipatrigine,voltage-gated sodium channel blocker,SCN4A,3358,Phase 2
sipatrigine,voltage-gated sodium channel blocker,SCN5A,3359,Phase 2
sipatrigine,voltage-gated sodium channel blocker,SCN9A,9177,Phase 2
siponimod,sphingosine 1-phosphate receptor modulator,S1PR1,3360,Launched
siramesine,sigma receptor antagonist,ADRA1A,3361,Phase 2
siramesine,sigma receptor antagonist,ADRA1B,3362,Phase 2
siramesine,sigma receptor antagonist,ADRA1D,3363,Phase 2
sirolimus,mTOR inhibitor,FKBP1A,206358,Launched
sirolimus,mTOR inhibitor,MTOR,148,Launched
SirReal-2,SIRT inhibitor,SIRT2,147,Preclinical
sirtinol,SIRT inhibitor,SIRT1,146,Preclinical
sirtinol,SIRT inhibitor,SIRT2,1813,Preclinical
SIS3,serine/threonine kinase inhibitor,SMAD3,1814,Preclinical
SIS3,serine/threonine kinase inhibitor,TGFBR1,1815,Preclinical
sitagliptin,dipeptidyl peptidase inhibitor,DPP4,3269,Launched
sitaxentan,endothelin receptor antagonist,EDNRA,3350,Withdrawn
sitaxentan,endothelin receptor antagonist,EDNRB,3351,Withdrawn
sivelestat,elastase inhibitor,CELA1,3352,Launched
sivelestat,elastase inhibitor,ELANE,3354,Launched
SJ-172550,MDM inhibitor,MDM4,3355,Preclinical
SK&F-10047-(+),sigma receptor agonist,SIGMAR1,3356,Phase 1
SKA-31,potassium channel activator,KCNN4,3358,Preclinical
skepinone-L,p38 MAPK inhibitor,MAPK14,3362,Preclinical
SKF-38393,dopamine receptor agonist,CALY,3757,Preclinical
SKF-38393,dopamine receptor agonist,DRD1,6531,Preclinical
SKF-38393,dopamine receptor agonist,DRD5,6532,Preclinical
SKF-77434,dopamine receptor agonist,DRD1,11251,Preclinical
SKF-81297,dopamine receptor agonist,DRD1,3269,Preclinical
SKF-81297,dopamine receptor agonist,DRD5,3356,Preclinical
SKF-83566,dopamine receptor antagonist,DRD1,3358,Preclinical
SKF-83566,dopamine receptor antagonist,DRD5,27032,Preclinical
SKF-86002,p38 MAPK inhibitor,ALOX5,-,Preclinical
SKF-86002,p38 MAPK inhibitor,MAPK14,2554,Preclinical
SKF-89976A,GABA uptake inhibitor,SLC6A1,2555,Preclinical
SKF-91488,histamine N-methyltransferase inhibitor,HNMT,2556,Preclinical
SKF-96365,calcium channel blocker,CYP3A4,2557,Preclinical
SKF-96365,calcium channel blocker,PKD2,2558,Preclinical
SKF-96365,calcium channel blocker,TRPC1,2559,Preclinical
SKF-96365,calcium channel blocker,TRPC3,2560,Preclinical
SKF-96365,calcium channel blocker,TRPC4,2561,Preclinical
SKF-96365,calcium channel blocker,TRPC5,2562,Preclinical
SKF-96365,calcium channel blocker,TRPV2,2563,Preclinical
SKI-II,sphingosine kinase inhibitor,SPHK1,2564,Preclinical
SKLB1002,VEGFR inhibitor,KDR,2565,Preclinical
SLV-319-(+/-),cannabinoid receptor antagonist,CNR1,2566,Phase 2
SLV-319-(+/-),cannabinoid receptor antagonist,DRD2,2567,Phase 2
SLV-319-(+/-),cannabinoid receptor antagonist,HTR1A,2568,Phase 2
SLV-320,adenosine receptor antagonist,ADORA1,55879,Phase 2
SLV-320,adenosine receptor antagonist,ADORA2A,2741,Phase 2
SLV-320,adenosine receptor antagonist,ADORA2B,2743,Phase 2
SLV-320,adenosine receptor antagonist,ADORA3,2890,Phase 2
SM-164,XIAP inhibitor,BIRC2,3736,Preclinical
SM-164,XIAP inhibitor,BIRC3,54207,Preclinical
SM-164,XIAP inhibitor,XIAP,338567,Preclinical
SM-21,sigma receptor antagonist,PGRMC1,3776,Preclinical
SMER-28,autophagy inducer,SNCA,3777,Preclinical
SMI-4a,Pim kinase inhibitor,PIM1,51305,Preclinical
SN-2,transient receptor potential channel agonist,MCOLN3,4535,Preclinical
SN-38,topoisomerase inhibitor,TOP1,1901,Launched
SNAP,nitric oxide donor,PTPN1,55283,Phase 2
SNAP-5089,adrenergic receptor antagonist,ADRA1A,4887,Preclinical
SNAP-5089,adrenergic receptor antagonist,ADRA1B,1387,Preclinical
SNAP-5089,adrenergic receptor antagonist,ADRA1D,2033,Preclinical
SNAP-5089,adrenergic receptor antagonist,ADRA2A,10196,Preclinical
SNAP-5089,adrenergic receptor antagonist,ADRA2B,1786,Preclinical
SNAP-5089,adrenergic receptor antagonist,ADRA2C,1788,Preclinical
SNAP-5089,adrenergic receptor antagonist,CACNA1C,1789,Preclinical
SNAP-5089,adrenergic receptor antagonist,CACNA1D,2322,Preclinical
SNAP-94847,,ADRA1A,5292,Preclinical
SNAP-94847,,DRD2,11040,Preclinical
SNC-80,,OPRD1,415116,Preclinical
SNG-1153,selective estrogen receptor modulator (SERM),ESR1,2550,Preclinical
SNS-314,Aurora kinase inhibitor,AURKA,9568,Phase 1
SNS-314,Aurora kinase inhibitor,AURKB,4233,Phase 1
SNS-314,Aurora kinase inhibitor,AURKC,387129,Phase 1
SNX-5422,HSP inhibitor,HSP90AA1,5781,Phase 1/Phase 2
SNX-5422,HSP inhibitor,HSP90AB1,1143,Phase 1/Phase 2
sobetirome,thyroid hormone receptor agonist,THRA,2915,Phase 1/Phase 2
sobetirome,thyroid hormone receptor agonist,THRB,2914,Phase 1/Phase 2
sodium-butyrate,HDAC inhibitor,BCHE,2915,Phase 2
sodium-butyrate,HDAC inhibitor,FFAR2,2516,Phase 2
sodium-butyrate,HDAC inhibitor,FFAR3,5139,Phase 2
sodium-butyrate,HDAC inhibitor,HDAC1,8654,Phase 2
sodium-butyrate,HDAC inhibitor,HDAC2,5148,Phase 2
sodium-butyrate,HDAC inhibitor,HDAC3,5149,Phase 2
sodium-butyrate,HDAC inhibitor,HDAC8,10599,Phase 2
sodium-dodecyl-sulfate,,ALB,28234,Launched
sodium-monofluorophosphate,,PYGM,240,Launched
sodium-stibogluconate,tyrosine phosphatase inhibitor,PTPN6,148,Launched
sodium-tetradecyl-sulfate,,PROC,147,Launched
sofalcone,mucus protecting agent,CBR1,146,Launched
solcitinib,JAK inhibitor,JAK1,1544,Phase 1
solifenacin-succinate,acetylcholine receptor antagonist,CHRM1,1576,Launched
solifenacin-succinate,acetylcholine receptor antagonist,CHRM2,3156,Launched
solifenacin-succinate,acetylcholine receptor antagonist,CHRM3,3689,Launched
solifenacin-succinate,acetylcholine receptor antagonist,CHRM4,10498,Launched
solifenacin-succinate,acetylcholine receptor antagonist,CHRM5,776,Launched
somatostatin,somatostatin receptor agonist,OPRD1,6336,Launched
somatostatin,somatostatin receptor agonist,OPRM1,6323,Launched
somatostatin,somatostatin receptor agonist,SSTR1,6328,Launched
somatostatin,somatostatin receptor agonist,SSTR2,6329,Launched
somatostatin,somatostatin receptor agonist,SSTR3,6331,Launched
somatostatin,somatostatin receptor agonist,SSTR4,6335,Launched
somatostatin,somatostatin receptor agonist,SSTR5,1901,Launched
sonidegib,smoothened receptor antagonist,SMO,148,Launched
sorafenib,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,BRAF,147,Launched
sorafenib,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,DDR2,146,Launched
sorafenib,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,FGFR1,2280,Launched
sorafenib,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,FLT1,2475,Launched
sorafenib,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,FLT3,22933,Launched
sorafenib,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,FLT4,23411,Launched
sorafenib,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,KDR,22933,Launched
sorafenib,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,KIT,4088,Launched
sorafenib,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,PDGFRB,7046,Launched
sorafenib,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,RAF1,1803,Launched
sorafenib,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,RET,1909,Launched
sorbinil,aldose reductase inhibitor,AKR1B1,1910,Phase 3
sotagliflozin,sodium/glucose cotransporter inhibitor,SLC5A1,1990,Phase 3
sotagliflozin,sodium/glucose cotransporter inhibitor,SLC5A2,1991,Phase 3
sotalol,adrenergic receptor antagonist,ADRB1,4194,Launched
sotalol,adrenergic receptor antagonist,ADRB2,10280,Launched
sotalol,adrenergic receptor antagonist,KCNH2,3783,Launched
sotrastaurin,PKC inhibitor,PRKCA,1432,Phase 2
sotrastaurin,PKC inhibitor,PRKCB,50632,Phase 2
sotrastaurin,PKC inhibitor,PRKCD,1812,Phase 2
sotrastaurin,PKC inhibitor,PRKCE,1816,Phase 2
sotrastaurin,PKC inhibitor,PRKCH,1812,Phase 2
sotrastaurin,PKC inhibitor,PRKCQ,1812,Phase 2
SP-100030,NFkB pathway inhibitor,JUN,1816,Preclinical
SP-100030,NFkB pathway inhibitor,NFKB1,1812,Preclinical
SP-141,ubiquitin ligase inhibitor,MDM2,1816,Preclinical
spaglumic-acid,glutamate receptor antagonist,GRM3,240,Launched
sparfloxacin,bacterial DNA gyrase inhibitor,TOP2A,1432,Withdrawn
sparfosate,aspartate carbamoyltransferase inhibitor,CA2,6529,Phase 3
sparfosate,aspartate carbamoyltransferase inhibitor,CA4,3176,Phase 3
spautin-1,deubiquitinase inhibitor,USP10,1576,Preclinical
spautin-1,deubiquitinase inhibitor,USP13,5311,Preclinical
spermidine,glutamate receptor modulator,KCNJ4,7220,Preclinical
spermidine,glutamate receptor modulator,TXNRD1,7222,Preclinical
spermine,,CA14,7223,Preclinical
spermine,,CA4,7224,Preclinical
spermine,,CA6,1128,Preclinical
spermine,,CA9,1129,Preclinical
spermine,,CASR,1131,Preclinical
spermine,,GRIN1,1132,Preclinical
spermine,,GRIN2A,1133,Preclinical
spermine,,KCNJ4,57053,Preclinical
spermine,,ODC1,55584,Preclinical
spermine,,SMOX,2741,Preclinical
spermine,,SMS,2742,Preclinical
spermine,,TRPM4,8001,Preclinical
spermine,,TRPM5,2743,Preclinical
sphingosylphosphorylcholine,gene expression stimulant,GPR12,6869,Preclinical
spiperone,dopamine receptor antagonist,ADRA1A,6865,Launched
spiperone,dopamine receptor antagonist,ADRA1B,6870,Launched
spiperone,dopamine receptor antagonist,ADRA1D,7915,Launched
spiperone,dopamine receptor antagonist,DRD1,444,Launched
spiperone,dopamine receptor antagonist,DRD2,8424,Launched
spiperone,dopamine receptor antagonist,DRD3,8630,Launched
spiperone,dopamine receptor antagonist,DRD4,5019,Launched
spiperone,dopamine receptor antagonist,DRD5,64064,Launched
spiperone,dopamine receptor antagonist,HTR1A,64175,Launched
spiperone,dopamine receptor antagonist,HTR1D,55214,Launched
spiperone,dopamine receptor antagonist,HTR2A,10536,Launched
spiperone,dopamine receptor antagonist,HTR2B,5033,Launched
spiperone,dopamine receptor antagonist,HTR2C,8974,Launched
spiperone,dopamine receptor antagonist,HTR6,5351,Launched
spiperone,dopamine receptor antagonist,HTR7,8985,Launched
spiradoline,opioid receptor agonist,OPRK1,6389,Phase 2
spironolactone,mineralocorticoid receptor antagonist,AR,6390,Launched
spironolactone,mineralocorticoid receptor antagonist,CACNA1A,6391,Launched
spironolactone,mineralocorticoid receptor antagonist,CACNA1B,6392,Launched
spironolactone,mineralocorticoid receptor antagonist,CACNA1C,6561,Launched
spironolactone,mineralocorticoid receptor antagonist,CACNA1D,9058,Launched
spironolactone,mineralocorticoid receptor antagonist,CACNA1F,64849,Launched
spironolactone,mineralocorticoid receptor antagonist,CACNA1G,1468,Launched
spironolactone,mineralocorticoid receptor antagonist,CACNA1H,8803,Launched
spironolactone,mineralocorticoid receptor antagonist,CACNA1I,8802,Launched
spironolactone,mineralocorticoid receptor antagonist,CACNA1S,8801,Launched
spironolactone,mineralocorticoid receptor antagonist,CACNA2D1,56670,Launched
spironolactone,mineralocorticoid receptor antagonist,CACNA2D2,55217,Launched
spironolactone,mineralocorticoid receptor antagonist,CACNA2D3,7412,Launched
spironolactone,mineralocorticoid receptor antagonist,CACNB1,89832,Launched
spironolactone,mineralocorticoid receptor antagonist,CACNB2,1128,Launched
spironolactone,mineralocorticoid receptor antagonist,CACNB3,1129,Launched
spironolactone,mineralocorticoid receptor antagonist,CACNB4,1131,Launched
spironolactone,mineralocorticoid receptor antagonist,CACNG1,1134,Launched
spironolactone,mineralocorticoid receptor antagonist,CYP11B2,57053,Launched
spironolactone,mineralocorticoid receptor antagonist,NR3C1,1719,Launched
spironolactone,mineralocorticoid receptor antagonist,NR3C2,58,Launched
spironolactone,mineralocorticoid receptor antagonist,PGR,475,Launched
spironolactone,mineralocorticoid receptor antagonist,SHBG,-,Launched
spiroxatrine,serotonin receptor antagonist,ADRA1A,4069,Preclinical
spiroxatrine,serotonin receptor antagonist,ADRA1B,1719,Preclinical
spiroxatrine,serotonin receptor antagonist,ADRA1D,1557,Preclinical
spiroxatrine,serotonin receptor antagonist,ADRA2A,1559,Preclinical
spiroxatrine,serotonin receptor antagonist,ADRA2B,1565,Preclinical
spiroxatrine,serotonin receptor antagonist,ADRA2C,1571,Preclinical
spiroxatrine,serotonin receptor antagonist,HTR1A,1576,Preclinical
spiroxatrine,serotonin receptor antagonist,HTR2B,1725,Preclinical
splitomycin,SIRT inhibitor,SIRT1,38,Preclinical
SPP301,endothelin receptor antagonist,EDNRA,240,Phase 3
SPP86,receptor tyrosine protein kinase inhibitor,RET,1147,Preclinical
SQ-109,bacterial cell wall synthesis inhibitor,FDFT1,3551,Phase 3
SQ-22536,adenylyl cyclase inhibitor,ADCY1,5319,Preclinical
SR-1078,retinoid receptor agonist,RORA,5468,Preclinical
SR-1078,retinoid receptor agonist,RORC,5742,Preclinical
SR-140333,neurokinin receptor antagonist,TACR1,5743,Phase 2
SR-1664,PPAR receptor ligand,PPARG,113235,Preclinical
SR-2211,retinoid receptor inverse agonist,RORC,23657,Preclinical
SR-2640,leukotriene receptor antagonist,CYSLTR1,6916,Phase 2
SR-27897,CCK receptor antagonist,CCKAR,4363,Phase 2
SR-3306,JNK inhibitor,MAPK10,2357,Preclinical
SR-3306,JNK inhibitor,MAPK8,116085,Preclinical
SR-3306,JNK inhibitor,MAPK9,4780,Preclinical
SR-3576,JNK inhibitor,MAPK10,231,Preclinical
SR-3677,rho associated kinase inhibitor,ROCK2,2520,Preclinical
SR-57227A,serotonin receptor agonist,HTR3A,760,Phase 2
SR-59230A,adrenergic receptor antagonist,ADRB1,1813,Preclinical
SR-59230A,adrenergic receptor antagonist,ADRB2,3350,Preclinical
SR-59230A,adrenergic receptor antagonist,ADRB3,3351,Preclinical
SR-95639A,acetylcholine receptor agonist,CHRM1,3352,Preclinical
SRC-kinase-inhibitor-I,SRC inhibitor,CSK,3354,Preclinical
SRC-kinase-inhibitor-I,SRC inhibitor,LCK,3355,Preclinical
SRC-kinase-inhibitor-I,SRC inhibitor,RIPK2,3361,Preclinical
SRPIN340,serine arginine protein kinase inhibitor,SRPK1,3362,Preclinical
SRPIN340,serine arginine protein kinase inhibitor,SRPK2,3363,Preclinical
SRT1720,SIRT activator,SIRT1,799,Preclinical
SRT2104,SIRT activator,SIRT1,2260,Phase 2
SSR180711,acetylcholine receptor agonist,CHRNA7,1436,Phase 2
ST-2825,myeloid differentiation primary response inhibitor,MYD88,2260,Preclinical
STA-5326,interleukin synthesis inhibitor,IL12A,2321,Phase 2
STAT3-inhibitor-VI,STAT inhibitor,STAT3,2322,Preclinical
stemregenin-1,aryl hydrocarbon receptor antagonist,AHR,2324,Preclinical
STF-083010,serine/threonine kinase inhibitor,ERN1,3791,Preclinical
STF-118804,NAMPT inhibitor,NAMPT,3815,Preclinical
STF-31,NAMPT inhibitor,NAMPT,5156,Preclinical
STF-31,NAMPT inhibitor,SLC2A1,5159,Preclinical
stiripentol,GABA uptake inhibitor,GABRA3,5979,Launched
stobadine,adrenergic receptor antagonist,ADRA1A,5742,Phase 2
strontium-ranelate,bone formation stimulant|bone resorption inhibitor,CASR,5743,Launched
strychnine,acetylcholine receptor antagonist,CHRM1,765,Preclinical
strychnine,acetylcholine receptor antagonist,CHRM2,768,Preclinical
strychnine,acetylcholine receptor antagonist,CHRM3,846,Preclinical
strychnine,acetylcholine receptor antagonist,CHRM4,2902,Preclinical
strychnine,acetylcholine receptor antagonist,CHRM5,2903,Preclinical
strychnine,acetylcholine receptor antagonist,CHRNA10,3761,Preclinical
strychnine,acetylcholine receptor antagonist,CHRNA9,4953,Preclinical
strychnine,acetylcholine receptor antagonist,GLRA1,54498,Preclinical
strychnine,acetylcholine receptor antagonist,GLRA2,6611,Preclinical
strychnine,acetylcholine receptor antagonist,GLRA3,54795,Preclinical
strychnine,acetylcholine receptor antagonist,GLRB,29850,Preclinical
substance-P,neurokinin receptor antagonist,TACR1,2835,Phase 1
substance-P,neurokinin receptor antagonist,TACR2,148,Phase 1
substance-P,neurokinin receptor antagonist,TACR3,147,Phase 1
succinic-acid,,ALDH5A1,146,Launched
succinic-acid,,ASPH,1812,Launched
succinic-acid,,BBOX1,1813,Launched
succinic-acid,,HSD17B6,1814,Launched
succinic-acid,,OXCT1,1815,Launched
succinic-acid,,OXCT2,1816,Launched
succinic-acid,,P3H1,3350,Launched
succinic-acid,,P3H2,3352,Launched
succinic-acid,,P3H3,3356,Launched
succinic-acid,,P4HA1,3357,Launched
succinic-acid,,P4HA2,3358,Launched
succinic-acid,,PLOD1,3362,Launched
succinic-acid,,PLOD3,3363,Launched
succinic-acid,,SDHA,4986,Launched
succinic-acid,,SDHB,367,Launched
succinic-acid,,SDHC,773,Launched
succinic-acid,,SDHD,774,Launched
succinic-acid,,SLC13A1,775,Launched
succinic-acid,,SLC13A2,776,Launched
succinic-acid,,SLC13A3,778,Launched
succinic-acid,,SLC25A10,8913,Launched
succinic-acid,,SUCLA2,8912,Launched
succinic-acid,,SUCLG1,8911,Launched
succinic-acid,,SUCLG2,779,Launched
succinic-acid,,SUCNR1,781,Launched
succinic-acid,,TMLHE,9254,Launched
succinobucol,antioxidant,VCAM1,55799,Phase 2/Phase 3
succinylcholine-chloride,,CHRFAM7A,782,Launched
succinylcholine-chloride,,CHRM1,783,Launched
succinylcholine-chloride,,CHRM2,784,Launched
succinylcholine-chloride,,CHRM3,785,Launched
succinylcholine-chloride,,CHRNA1,786,Launched
succinylcholine-chloride,,CHRNA10,1585,Launched
succinylsulfathiazole,dihydrofolate reductase inhibitor,DHFR,2908,Phase 2
sucrose,,ACTA1,4306,Launched
sucrose,,ATOX1,5241,Launched
sucrose,,C22orf28,6462,Launched
sucrose,,LYZ,148,Launched
sulfameter,dihydrofolate reductase inhibitor,DHFR,147,Launched
sulfanilamide,carbonic anhydrase inhibitor,CYP2C19,146,Launched
sulfanilamide,carbonic anhydrase inhibitor,CYP2C9,150,Launched
sulfanilamide,carbonic anhydrase inhibitor,CYP2D6,151,Launched
sulfanilamide,carbonic anhydrase inhibitor,CYP2E1,152,Launched
sulfanilamide,carbonic anhydrase inhibitor,CYP3A4,3350,Launched
sulfaphenazole,dihydropteroate synthetase inhibitor,DHPS,3357,Launched
sulfasalazine,cyclooxygenase inhibitor,ACAT1,23411,Launched
sulfasalazine,cyclooxygenase inhibitor,ALOX5,1909,Launched
sulfasalazine,cyclooxygenase inhibitor,CHUK,5979,Launched
sulfasalazine,cyclooxygenase inhibitor,IKBKB,2222,Launched
sulfasalazine,cyclooxygenase inhibitor,PLA2G1B,107,Launched
sulfasalazine,cyclooxygenase inhibitor,PPARG,6095,Launched
sulfasalazine,cyclooxygenase inhibitor,PTGS1,6097,Launched
sulfasalazine,cyclooxygenase inhibitor,PTGS2,6869,Launched
sulfasalazine,cyclooxygenase inhibitor,SLC46A1,5468,Launched
sulfasalazine,cyclooxygenase inhibitor,SLC7A11,6097,Launched
sulfasalazine,cyclooxygenase inhibitor,TBXAS1,10800,Launched
sulfinpyrazone,uricosuric blocker,ABCC1,886,Launched
sulfinpyrazone,uricosuric blocker,FPR1,5602,Launched
sulfinpyrazone,uricosuric blocker,SLC22A12,5599,Launched
sulforaphane,anticancer agent|aryl hydrocarbon receptor antagonist,NFE2L2,5601,Phase 2
sulindac,cyclooxygenase inhibitor,AKR1B1,5602,Launched
sulmetozine,gastrin inhibitor,GAST,9475,Launched
sultiame,carbonic anhydrase inhibitor,CA2,3359,Phase 3
sumanirole,dopamine receptor agonist,DRD2,153,Phase 3
sumatriptan,serotonin receptor agonist,HTR1A,154,Launched
sumatriptan,serotonin receptor agonist,HTR1B,155,Launched
sumatriptan,serotonin receptor agonist,HTR1D,1128,Launched
sumatriptan,serotonin receptor agonist,HTR1E,1445,Launched
sumatriptan,serotonin receptor agonist,HTR1F,3932,Launched
sumatriptan,serotonin receptor agonist,HTR5A,8767,Launched
sumatriptan,serotonin receptor agonist,HTR6,6732,Launched
sumatriptan,serotonin receptor agonist,HTR7,6733,Launched
SUN-B-8155,calcitonin agonist,CALCR,23411,Preclinical
SUN-11602,fibroblast growth factor mimetic,FGFR1,23411,Preclinical
sunitinib,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,CSF1R,1139,Launched
sunitinib,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,FGFR1,4615,Launched
sunitinib,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,FLT1,3592,Launched
sunitinib,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,FLT3,6774,Launched
sunitinib,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,FLT4,196,Launched
sunitinib,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,KDR,2081,Launched
sunitinib,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,KIT,10135,Launched
sunitinib,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,PDGFRA,10135,Launched
sunitinib,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,PDGFRB,6513,Launched
sunitinib,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,RET,2556,Launched
suprofen,cyclooxygenase inhibitor,PTGS1,148,Withdrawn
suprofen,cyclooxygenase inhibitor,PTGS2,846,Withdrawn
suramin,DNA synthesis inhibitor,F2,51393,Launched
suramin,DNA synthesis inhibitor,FSHR,8877,Launched
suramin,DNA synthesis inhibitor,P2RY1,3791,Launched
suramin,DNA synthesis inhibitor,P2RY11,1268,Launched
suramin,DNA synthesis inhibitor,P2RY13,1813,Launched
suramin,DNA synthesis inhibitor,P2RY2,3350,Launched
suramin,DNA synthesis inhibitor,PLA2G2A,134,Launched
suramin,DNA synthesis inhibitor,RYR1,135,Launched
suramin,DNA synthesis inhibitor,RYR2,136,Launched
suramin,DNA synthesis inhibitor,SIRT5,140,Launched
suritozole,GABA receptor inverse agonist,GABBR1,329,Phase 2
SU014813,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KDR,330,Phase 2
SU11274,hepatocyte growth factor receptor inhibitor|tyrosine kinase inhibitor,MET,331,Preclinical
SU16f,PDGFR tyrosine kinase receptor inhibitor,PDGFRB,10857,Preclinical
SU3327,JNK inhibitor,MAPK8,6622,Preclinical
SU4312,PDGFR tyrosine kinase receptor inhibitor|tyrosine kinase inhibitor|VEGFR inhibitor,KDR,5292,Preclinical
SU4312,PDGFR tyrosine kinase receptor inhibitor|tyrosine kinase inhibitor|VEGFR inhibitor,PDGFRB,55283,Preclinical
SU9516,CDK inhibitor,CDK1,7150,Preclinical
SU9516,CDK inhibitor,CDK2,5770,Preclinical
SU9516,CDK inhibitor,CDK4,148,Preclinical
SU9516,CDK inhibitor,CDK5,147,Preclinical
swainsonine,alpha mannosidase inhibitor,MAN2A1,146,Phase 2
SX-011,MAP kinase inhibitor,MAPK14,150,Preclinical
SYM-2081,kainate receptor antagonist,GRIK1,151,Preclinical
SYM-2081,kainate receptor antagonist,GRIK2,152,Preclinical
SYM-2081,kainate receptor antagonist,GRIK3,775,Preclinical
SYM-2081,kainate receptor antagonist,GRIK4,776,Preclinical
SYM-2081,kainate receptor antagonist,GRIK5,148,Preclinical
SYM-2081,kainate receptor antagonist,SLC1A2,1813,Preclinical
SYM-2206,glutamate receptor antagonist,GRIA1,4985,Preclinical
SYM-2206,glutamate receptor antagonist,GRIA2,2099,Preclinical
SYM-2206,glutamate receptor antagonist,GRIA3,6790,Preclinical
SYM-2206,glutamate receptor antagonist,GRIA4,9212,Preclinical
synephrine,adrenergic receptor agonist,ADRA1A,6795,Launched
S1P1-agonist-III,sphingosine kinase inhibitor,S1PR1,3320,Preclinical
S18986,glutamate receptor modulator,GRIA1,3326,Phase 2
S18986,glutamate receptor modulator,GRIA2,7067,Phase 2
S18986,glutamate receptor modulator,GRIA3,7068,Phase 2
S18986,glutamate receptor modulator,GRIA4,590,Phase 2
S26948,PPAR receptor agonist,PPARG,2867,Preclinical
S4,carbonic anhydrase inhibitor,CA12,2865,Preclinical
S4,carbonic anhydrase inhibitor,CA9,3065,Preclinical
T-0070907,PPAR receptor antagonist,PPARG,3066,Preclinical
T-0156,phosphodiesterase inhibitor,PDE5A,8841,Preclinical
T-0901317,LXR agonist,NCOA1,55869,Preclinical
T-0901317,LXR agonist,NCOA2,213,Preclinical
T-0901317,LXR agonist,NR1H2,5837,Preclinical
T-0901317,LXR agonist,NR1H3,5777,Preclinical
T-0901317,LXR agonist,NR1I2,5624,Preclinical
T-0901317,LXR agonist,RXRB,873,Preclinical
T-5224,AP inhibitor,JUN,3716,Phase 2
T-5601640,LIM kinase inhibitor,LIMK2,1128,Preclinical
T-62,adenosine receptor modulator,ADORA2A,1129,Phase 2
TA-01,casein kinase inhibitor|MAP kinase inhibitor,CSNK1D,1131,Preclinical
TA-01,casein kinase inhibitor|MAP kinase inhibitor,CSNK1E,1132,Preclinical
TA-01,casein kinase inhibitor|MAP kinase inhibitor,MAPK14,1133,Preclinical
tabimorelin,growth hormone secretagogue receptor agonist,GHSR,4985,Phase 2
tacalcitol,vitamin D receptor agonist,VDR,4988,Launched
tacedinaline,HDAC inhibitor,HDAC1,6751,Phase 3
tacrine,acetylcholinesterase inhibitor,ACHE,6752,Launched
tacrine,acetylcholinesterase inhibitor,BCHE,6753,Launched
tacrolimus,calcineurin inhibitor,FKBP1A,6754,Launched
tadalafil,phosphodiesterase inhibitor,PDE11A,6755,Launched
tadalafil,phosphodiesterase inhibitor,PDE5A,6608,Launched
tafamidis-meglumine,transthyretin amyloid inhibitor,TTR,673,Launched
tafluprost,prostaglandin inhibitor,PTGFR,4921,Launched
tagatose,phosphorylase inhibitor,PYGL,2260,Launched
TAK-063,phosphodiesterase inhibitor,PDE10A,2321,Phase 2
TAK-220,CC chemokine receptor antagonist,CCR5,2322,Phase 1
TAK-285,EGFR inhibitor,ERBB2,2324,Phase 1
TAK-593,VEGFR inhibitor,PDGFRA,3791,Phase 1
TAK-632,RAF inhibitor,BRAF,3815,Preclinical
TAK-715,p38 MAPK inhibitor,MAPK14,5159,Phase 2
TAK-733,MEK inhibitor,MAP2K1,5894,Phase 1
TAK-875,insulin secretagogue,FFAR1,5979,Phase 3
TAK-901,Aurora kinase inhibitor,AURKB,231,Phase 1
TAK-960,PLK inhibitor,PLK1,6523,Phase 1
talabostat,dipeptidyl peptidase inhibitor|fibroblast activation protein inhibitor,DPP4,6524,Phase 3
taladegib,smoothened receptor antagonist,DHH,153,Phase 2
taladegib,smoothened receptor antagonist,IHH,154,Phase 2
taladegib,smoothened receptor antagonist,SMO,3757,Phase 2
talampanel,glutamate receptor antagonist,GRIA1,5578,Phase 2
talampanel,glutamate receptor antagonist,GRIA2,5579,Phase 2
talampanel,glutamate receptor antagonist,GRIA3,5580,Phase 2
talampanel,glutamate receptor antagonist,GRIA4,5581,Phase 2
talarozole,cytochrome P450 inhibitor,CYP26A1,5583,Phase 2
talazoparib,PARP inhibitor,PARP2,5588,Launched
talinolol,adrenergic receptor antagonist,ADRB1,3725,Launched
talipexole,adrenergic receptor agonist|dopamine receptor agonist,ADRA2A,4790,Launched
talipexole,adrenergic receptor agonist|dopamine receptor agonist,DRD2,4193,Launched
talipexole,adrenergic receptor agonist|dopamine receptor agonist,HTR3A,2913,Launched
talmapimod,p38 MAPK inhibitor,IL1B,7153,Phase 2
talmapimod,p38 MAPK inhibitor,MAPK11,760,Phase 2
talmapimod,p38 MAPK inhibitor,MAPK14,762,Phase 2
talmapimod,p38 MAPK inhibitor,MT-CO2,9100,Phase 2
talmapimod,p38 MAPK inhibitor,TNF,8975,Phase 2
talnetant,tachykinin antagonist,TACR2,3761,Phase 2
talnetant,tachykinin antagonist,TACR3,7296,Phase 2
talniflumate,cyclooxygenase inhibitor,CLCA1,23632,Launched
talopram,adrenergic inhibitor,SLC6A2,762,Phase 2
taltirelin,thyrotropin releasing hormone receptor agonist,TRHR,2147,Launched
tamibarotene,retinoid receptor agonist,RARA,2492,Launched
tamibarotene,retinoid receptor agonist,RARB,5028,Launched
tamoxifen,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),EBP,5032,Launched
tamoxifen,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),ESR1,53829,Launched
tamoxifen,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),ESR2,5029,Launched
tamoxifen,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),GPER1,5320,Launched
tamoxifen,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),PRKCA,6261,Launched
tamoxifen,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),PRKCB,6262,Launched
tamoxifen,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),PRKCD,23408,Launched
tamoxifen,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),PRKCE,2550,Launched
tamoxifen,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),PRKCG,3791,Launched
tamoxifen,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),PRKCI,4233,Launched
tamoxifen,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),PRKCQ,5159,Launched
tamoxifen,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),PRKCZ,5599,Launched
tamsulosin,adrenergic receptor antagonist,ADRA1A,3791,Launched
tamsulosin,adrenergic receptor antagonist,ADRA1B,5159,Launched
tamsulosin,adrenergic receptor antagonist,ADRA1D,983,Launched
tanaproget,progesterone receptor agonist,PGR,1017,Phase 2
tandospirone,serotonin receptor agonist,HTR1A,1019,Launched
tandutinib,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,CSF1R,1020,Phase 2
tandutinib,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,FLT3,4124,Phase 2
tandutinib,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,KIT,1432,Phase 2
tandutinib,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,PDGFD,2897,Phase 2
tandutinib,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,PDGFRB,2898,Phase 2
tanespimycin,HSP inhibitor,HSP90AA1,2899,Phase 3
tannic-acid,PARG inhibitor,ANO1,2900,Launched
tanshinone-I,AP inhibitor,IFNG,2901,Phase 2
tanshinone-IIA,anti-inflammatory agent|interleukin inhibitor,IL1B,6506,Phase 2/Phase 3
tanshinone-IIA,anti-inflammatory agent|interleukin inhibitor,NR1I2,2890,Phase 2/Phase 3
tanshinone-IIA,anti-inflammatory agent|interleukin inhibitor,TNF,2891,Phase 2/Phase 3
taprenepag,prostaglandin receptor agonist,PTGER2,2892,Phase 2
tarafenacin,acetylcholine receptor antagonist,CHRM3,2893,Phase 2
taranabant,cannabinoid receptor inverse agonist,CNR1,148,Phase 3
targinine,nitric oxide synthase inhibitor,NOS3,1901,Phase 3
tariquidar,P glycoprotein inhibitor,ABCB1,2890,Phase 3
TAS-103,topoisomerase inhibitor,TOP1,2891,Phase 1
taselisib,PI3K inhibitor,PIK3CA,2892,Phase 3
tasimelteon,melatonin receptor agonist,MTNR1A,2893,Launched
tasimelteon,melatonin receptor agonist,MTNR1B,5468,Launched
tasquinimod,angiogenesis inhibitor|S100A9 inhibitor,HDAC4,771,Phase 3
taurocholate,G protein-coupled receptor agonist,CEL,768,Phase 1
taurocholate,G protein-coupled receptor agonist,FABP6,5468,Phase 1
taurocholate,G protein-coupled receptor agonist,SLCO1C1,8654,Phase 1
taxifolin,opioid receptor antagonist,ADIPOR2,8648,Phase 2
tazarotene,retinoid receptor agonist,RARA,10499,Launched
tazarotene,retinoid receptor agonist,RARB,7376,Launched
tazarotene,retinoid receptor agonist,RARG,10062,Launched
tazarotene,retinoid receptor agonist,RXRB,8856,Launched
tazemetostat,histone lysine methyltransferase inhibitor,EZH2,6257,Launched
TBOA-(DL),excitatory amino acid transporter inhibitor,SLC1A1,3725,Preclinical
TBOA-(DL),excitatory amino acid transporter inhibitor,SLC1A2,3985,Preclinical
TBOA-(DL),excitatory amino acid transporter inhibitor,SLC1A3,135,Preclinical
TBOA-(DL),excitatory amino acid transporter inhibitor,SLC1A6,1453,Preclinical
TBOA-(DL),excitatory amino acid transporter inhibitor,SLC1A7,1454,Preclinical
TC-A-2317,Aurora kinase inhibitor,AURKA,1432,Preclinical
TC-ASK-10,MAP kinase inhibitor,MAP3K5,2693,Preclinical
TC-ASK-10,MAP kinase inhibitor,MAP3K6,7421,Preclinical
TC-E-5002,histone demethylase inhibitor,KDM2A,3065,Preclinical
TC-E-5002,histone demethylase inhibitor,KDM4A,43,Preclinical
TC-E-5002,histone demethylase inhibitor,KDM4C,590,Preclinical
TC-E-5002,histone demethylase inhibitor,KDM5A,2280,Preclinical
TC-E-5002,histone demethylase inhibitor,KDM6A,50940,Preclinical
TC-E-5002,histone demethylase inhibitor,KDM7A,8654,Preclinical
TC-E-5002,histone demethylase inhibitor,PHF8,7276,Preclinical
TC-E-5006,gamma secretase modulator,APP,5737,Preclinical
TC-F-2,FAAH inhibitor,FAAH,5836,Preclinical
TC-FPR-43,formyl peptide receptor agonist,FPR2,10846,Preclinical
TC-G-1000,adrenergic receptor agonist,ADRA2A,1234,Preclinical
TC-G-1000,adrenergic receptor agonist,ADRA2B,2064,Preclinical
TC-G-1000,adrenergic receptor agonist,ADRA2C,5156,Preclinical
TC-G-1004,adenosine receptor antagonist,ADORA2A,673,Preclinical
TC-G-1005,G protein-coupled receptor agonist,GPBAR1,1432,Preclinical
TC-G-1008,G protein-coupled receptor agonist,GPR39,5604,Preclinical
TC-H-106,HDAC inhibitor,HDAC1,2864,Preclinical
TC-H-106,HDAC inhibitor,HDAC2,9212,Preclinical
TC-H-106,HDAC inhibitor,HDAC3,5347,Preclinical
TC-H-106,HDAC inhibitor,HDAC8,1803,Preclinical
TC-I-15,integrin inhibitor,ITGA2,50846,Preclinical
TC-I-15,integrin inhibitor,ITGB1,3549,Preclinical
TC-I-2000,transient receptor potential channel antagonist,TRPM8,6608,Preclinical
TC-I-2014,transient receptor potential channel antagonist,TRPM8,2890,Preclinical
TC-LPA5-4,lysophosphatidic acid receptor antagonist,LPAR5,2891,Preclinical
TC-Mps1-12,monopolar spindle 1 kinase inhibitor,TTK,2892,Preclinical
TC-N-1752,sodium channel blocker,SCN9A,2893,Preclinical
TC-NTR1-17,neurotensin agonist,NTSR1,1592,Preclinical
TC-O-9311,G protein-coupled receptor agonist,GPR139,10038,Preclinical
TC-OT-39,oxytocin receptor agonist|vasopressin receptor agonist,AVPR1A,153,Preclinical
TC-OT-39,oxytocin receptor agonist|vasopressin receptor agonist,OXT,150,Preclinical
TC-S-7003,SRC inhibitor,LCK,1813,Preclinical
TC-S-7004,DYRK inhibitor,DYRK1A,3359,Preclinical
TC-S-7004,DYRK inhibitor,DYRK1B,3553,Preclinical
TC-S-7005,PLK inhibitor,PLK2,5600,Preclinical
TC-S-7006,MAP kinase inhibitor,MAP3K8,1432,Preclinical
TC-S-7009,hypoxia inducible factor inhibitor,EPAS1,4513,Preclinical
TC-SP-14,sphingosine 1-phosphate receptor agonist,S1PR1,7124,Preclinical
TCN201,glutamate receptor antagonist,GRIN2A,6865,Preclinical
TCN238,glutamate receptor positive allosteric modulator,GRM4,6870,Preclinical
TCS-HDAC6-20b,HDAC inhibitor,HDAC6,1179,Preclinical
TCS-OX2-29,orexin receptor antagonist,HCRTR2,6530,Preclinical
TCS-PIM-1-1,Pim kinase inhibitor,PIM1,7201,Preclinical
TCS-2002,glycogen synthase kinase inhibitor,GSK3B,5914,Preclinical
TCS-21311,JAK inhibitor,JAK3,5915,Preclinical
TCS-2314,integrin inhibitor,ITGA4,10682,Preclinical
TCS-2314,integrin inhibitor,ITGB1,2099,Preclinical
TCS-3035,G protein-coupled receptor agonist,GPR35,2100,Preclinical
TCS-359,FLT3 inhibitor,FLT3,2852,Preclinical
TCS-5861528,transient receptor potential channel antagonist,TRPA1,5578,Preclinical
TC1,beta-secretase inhibitor,BACE1,5579,Preclinical
TC2559,acetylcholine receptor agonist,CHRNA4,5580,Preclinical
tebipenem,bacterial cell wall synthesis inhibitor,CNR1,5581,Launched
tecadenoson,adenosine receptor agonist,ADORA1,5582,Phase 2
tecalcet,calcium-sensing receptor agonist,CASR,5584,Phase 2
tecastemizole,histamine receptor antagonist,KCNH2,5588,Phase 3
tegaserod,serotonin receptor partial agonist,HTR2A,5590,Withdrawn
tegaserod,serotonin receptor partial agonist,HTR2B,148,Withdrawn
tegaserod,serotonin receptor partial agonist,HTR2C,147,Withdrawn
tegaserod,serotonin receptor partial agonist,HTR4,146,Withdrawn
teijin-compound-1,CC chemokine receptor antagonist,CCR2,5241,Preclinical
telaprevir,HCV inhibitor,CTSA,3350,Launched
telaprevir,HCV inhibitor,PGR,1436,Launched
telatinib,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KDR,2322,Phase 2
telcagepant,calcitonin antagonist,CALCRL,3815,Phase 3
telcagepant,calcitonin antagonist,RAMP1,80310,Phase 3
telenzepine,acetylcholine receptor antagonist,CHRM1,5159,Phase 3
telithromycin,bacterial 30S ribosomal subunit inhibitor|bacterial 50S ribosomal subunit inhibitor,CYP1A2,3320,Launched
telithromycin,bacterial 30S ribosomal subunit inhibitor|bacterial 50S ribosomal subunit inhibitor,CYP2D6,55107,Launched
telithromycin,bacterial 30S ribosomal subunit inhibitor|bacterial 50S ribosomal subunit inhibitor,CYP3A4,3458,Launched
telithromycin,bacterial 30S ribosomal subunit inhibitor|bacterial 50S ribosomal subunit inhibitor,CYP3A5,3553,Launched
telithromycin,bacterial 30S ribosomal subunit inhibitor|bacterial 50S ribosomal subunit inhibitor,CYP3A7,8856,Launched
telmisartan,angiotensin receptor antagonist,AGTR1,7124,Launched
telmisartan,angiotensin receptor antagonist,PPARG,5732,Launched
telotristat,tryptophan hydroxylase inhibitor,TPH1,1131,Launched
telotristat-ethyl,tryptophan hydroxylase inhibitor,TPH1,1268,Launched
temocapril,angiotensin converting enzyme inhibitor,ACE,4846,Launched
temozolomide,DNA alkylating agent,MGMT,5243,Launched
temsirolimus,mTOR inhibitor,MTOR,7150,Launched
tenatoprazole,ATPase inhibitor,IDO1,5290,Phase 2
teneligliptin,dipeptidyl peptidase inhibitor,DPP4,4543,Launched
tenidap,cyclooxygenase inhibitor,KCNJ4,4544,Phase 3
tenidap,cyclooxygenase inhibitor,PTGS1,9759,Phase 3
teniposide,topoisomerase inhibitor,TOP2A,1056,Launched
teniposide,topoisomerase inhibitor,TOP2B,2172,Launched
tenofovir-disoproxil,nucleoside reverse transcriptase inhibitor,CYP1A2,53919,Launched
tenovin-1,SIRT inhibitor|TP53 activator,SIRT1,79602,Preclinical
tenovin-6,SIRT inhibitor,SIRT1,5914,Preclinical
tenovin-6,SIRT inhibitor,SIRT2,5915,Preclinical
tenovin-6,SIRT inhibitor,SIRT3,5916,Preclinical
tenoxicam,cyclooxygenase inhibitor,PTGS1,6257,Launched
tenoxicam,cyclooxygenase inhibitor,PTGS2,2146,Launched
tepoxalin,cyclooxygenase inhibitor|lipoxygenase inhibitor,ALOX5,6505,Launched
TEPP-46,pyruvate kinase isozyme activator,PKM,6506,Preclinical
terameprocol,lipoxygenase inhibitor,BIRC5,6507,Phase 1/Phase 2
terameprocol,lipoxygenase inhibitor,CDK1,6511,Phase 1/Phase 2
terazosin,adrenergic receptor antagonist,ADRA1A,6512,Launched
terazosin,adrenergic receptor antagonist,ADRA1B,6790,Launched
terazosin,adrenergic receptor antagonist,ADRA1D,4217,Launched
terbinafine,fungal squalene epoxidase inhibitor,SQLE,9064,Launched
terbutaline,adrenergic receptor agonist,ADRB2,22992,Launched
terfenadine,histamine receptor antagonist,HRH1,9682,Withdrawn
terfenadine,histamine receptor antagonist,KCNH1,23081,Withdrawn
terfenadine,histamine receptor antagonist,KCNH2,5927,Withdrawn
terguride,dopamine receptor agonist|serotonin receptor antagonist,ADRA1A,7403,Launched
terguride,dopamine receptor agonist|serotonin receptor antagonist,ADRA2A,80853,Launched
terguride,dopamine receptor agonist|serotonin receptor antagonist,ADRA2B,23133,Launched
terguride,dopamine receptor agonist|serotonin receptor antagonist,ADRA2C,351,Launched
terguride,dopamine receptor agonist|serotonin receptor antagonist,DRD2,2166,Launched
terguride,dopamine receptor agonist|serotonin receptor antagonist,DRD3,2358,Launched
terguride,dopamine receptor agonist|serotonin receptor antagonist,DRD4,150,Launched
terguride,dopamine receptor agonist|serotonin receptor antagonist,HTR1A,151,Launched
terguride,dopamine receptor agonist|serotonin receptor antagonist,HTR1B,152,Launched
terguride,dopamine receptor agonist|serotonin receptor antagonist,HTR1D,135,Launched
terguride,dopamine receptor agonist|serotonin receptor antagonist,HTR2A,151306,Launched
terguride,dopamine receptor agonist|serotonin receptor antagonist,HTR2B,2863,Launched
terguride,dopamine receptor agonist|serotonin receptor antagonist,HTR2C,3065,Launched
teriflunomide,dihydroorotate dehydrogenase inhibitor,DHODH,3066,Launched
terlipressin,vasopressin receptor agonist,AVPR1A,8841,Launched
terreic-acid-(-),Bruton's tyrosine kinase (BTK) inhibitor,BTK,55869,Preclinical
terutroban,prostanoid receptor antagonist,TBXA2R,3673,Phase 3
tesaglitazar,insulin sensitizer|PPAR receptor agonist,PPARA,3688,Phase 3
tesaglitazar,insulin sensitizer|PPAR receptor agonist,PPARG,79054,Phase 3
tetomilast,phosphodiesterase inhibitor,PDE4D,79054,Phase 2
tetrabenazine,vesicular monoamine transporter inhibitor,SLC18A1,57121,Launched
tetrabenazine,vesicular monoamine transporter inhibitor,SLC18A2,7272,Launched
tetracaine,membrane integrity inhibitor,SCN10A,6335,Launched
tetracaine,membrane integrity inhibitor,SCN11A,4923,Launched
tetracaine,membrane integrity inhibitor,SCN1A,124274,Launched
tetracaine,membrane integrity inhibitor,SCN2A,552,Launched
tetracaine,membrane integrity inhibitor,SCN3A,5020,Launched
tetracaine,membrane integrity inhibitor,SCN4A,3932,Launched
tetracaine,membrane integrity inhibitor,SCN5A,1859,Launched
tetracaine,membrane integrity inhibitor,SCN7A,9149,Launched
tetracaine,membrane integrity inhibitor,SCN8A,10769,Launched
tetracaine,membrane integrity inhibitor,SCN9A,1326,Launched
tetraethylenepentamine,superoxide dismutase inhibitor,SOD1,2034,Phase 2/Phase 3
tetraethylenepentamine,superoxide dismutase inhibitor,SOD2,1901,Phase 2/Phase 3
tetrahydrofolic-acid,,FOLR2,2903,Launched
tetrahydrouridine,cytidine deaminase inhibitor,CDA,2914,Phase 2
tetramisole,immunostimulant,ALPPL2,10013,Launched
tetramisole,immunostimulant,CHRNA3,3062,Launched
tetrandrine,calcium channel blocker,SLC6A3,207,Preclinical
tetrazol-5-yl-glycine-(RS),glutamate receptor agonist,GRIN1,5594,Preclinical
tetrazol-5-yl-glycine-(RS),glutamate receptor agonist,GRIN2A,2932,Preclinical
tetrazol-5-yl-glycine-(RS),glutamate receptor agonist,GRIN2B,1559,Preclinical
tetrazol-5-yl-glycine-(RS),glutamate receptor agonist,GRIN2C,6557,Preclinical
tetrazol-5-yl-glycine-(RS),glutamate receptor agonist,GRIN2D,3791,Preclinical
tetrindole,monoamine oxidase inhibitor,MAOA,1432,Phase 3
TFC-007,prostaglandin inhibitor,HPGDS,6833,Preclinical
TG-003,CLK inhibitor,CLK1,3767,Preclinical
TG-003,CLK inhibitor,CLK4,523,Preclinical
TG-003,CLK inhibitor,DYRK1A,4313,Preclinical
TG-003,CLK inhibitor,DYRK1B,5770,Preclinical
TG-02,CDK inhibitor|FLT3 inhibitor|JAK inhibitor,CDK1,4023,Phase 1/Phase 2
TG-02,CDK inhibitor|FLT3 inhibitor|JAK inhibitor,CDK2,153,Phase 1/Phase 2
TG-02,CDK inhibitor|FLT3 inhibitor|JAK inhibitor,CDK7,154,Phase 1/Phase 2
TG-02,CDK inhibitor|FLT3 inhibitor|JAK inhibitor,CDK9,3274,Phase 1/Phase 2
TG-02,CDK inhibitor|FLT3 inhibitor|JAK inhibitor,FLT3,1128,Phase 1/Phase 2
TG-02,CDK inhibitor|FLT3 inhibitor|JAK inhibitor,JAK2,1129,Phase 1/Phase 2
TG-100572,SRC inhibitor|VEGFR inhibitor,KDR,1131,Preclinical
TG-100572,SRC inhibitor|VEGFR inhibitor,SRC,760,Preclinical
TG-100801,SRC inhibitor|VEGFR inhibitor,CSK,2339,Phase 2
TG-100801,SRC inhibitor|VEGFR inhibitor,FGFR1,2342,Phase 2
TG-100801,SRC inhibitor|VEGFR inhibitor,FLT1,5054,Phase 2
TG-100801,SRC inhibitor|VEGFR inhibitor,FLT4,153,Phase 2
TG-100801,SRC inhibitor|VEGFR inhibitor,KDR,154,Phase 2
TG-100801,SRC inhibitor|VEGFR inhibitor,SRC,155,Phase 2
TG-101209,JAK inhibitor,JAK2,6331,Preclinical
TG-101209,JAK inhibitor,JAK3,7067,Preclinical
TGX-221,PI3K inhibitor,PIK3CB,7068,Preclinical
TGX-221,PI3K inhibitor,PIK3CD,3674,Preclinical
TG100-115,PI3K inhibitor,PIK3CA,3690,Phase 1/Phase 2
TG100-115,PI3K inhibitor,PIK3CB,4233,Phase 1/Phase 2
TG100-115,PI3K inhibitor,PIK3CD,2321,Phase 1/Phase 2
TG100-115,PI3K inhibitor,PIK3CG,2324,Phase 1/Phase 2
TH-588,MTH1 inhibitor,NUDT1,3791,Preclinical
thalidomide,tumor necrosis factor production inhibitor,TNF,3815,Launched
theobromine,phosphodiesterase inhibitor,ADORA1,5156,Launched
theobromine,phosphodiesterase inhibitor,ADORA2A,5159,Launched
theobromine,phosphodiesterase inhibitor,PDE4B,150,Launched
thiamet-g,GLCNAC phosphotransferase inhibitor,MGEA5,151,Preclinical
thiamine,vitamin B,SLC19A2,152,Launched
thiamine,vitamin B,SLC19A3,11188,Launched
thiamine,vitamin B,TPK1,5478,Launched
thiamylal,glutamate receptor antagonist,GABRA1,10988,Launched
thiethylperazine,dopamine receptor antagonist,DRD1,6331,Launched
thiethylperazine,dopamine receptor antagonist,DRD2,2321,Launched
thiethylperazine,dopamine receptor antagonist,DRD4,2322,Launched
thiocolchicoside,GABA receptor antagonist,GABRA1,3791,Launched
thiocolchicoside,GABA receptor antagonist,GABRB2,5156,Launched
thiocolchicoside,GABA receptor antagonist,GABRG2,5159,Launched
thiocolchicoside,GABA receptor antagonist,GLRA1,3716,Launched
thiocolchicoside,GABA receptor antagonist,GLRB,3717,Launched
thioctic-acid,reducing agent,ACHE,3718,Launched
thioctic-acid,reducing agent,PTGS2,1576,Launched
thioguanine,purine antagonist,IMPDH1,2645,Launched
thioguanine,purine antagonist,IMPDH2,153,Launched
thiomersal,other antibiotic,OXCT1,154,Launched
thiopental,GABA receptor antagonist,FAAH,155,Launched
thioperamide,histamine receptor antagonist,HRH3,6833,Preclinical
thioperamide,histamine receptor antagonist,HRH4,3758,Preclinical
thioproperazine,dopamine receptor antagonist,ADRA1A,3766,Launched
thioproperazine,dopamine receptor antagonist,ADRA1B,3767,Launched
thioproperazine,dopamine receptor antagonist,DRD1,148,Launched
thioproperazine,dopamine receptor antagonist,DRD2,150,Launched
thioproperazine,dopamine receptor antagonist,HTR1A,151,Launched
thioproperazine,dopamine receptor antagonist,HTR2A,152,Launched
thioridazine,dopamine receptor antagonist,DRD1,3269,Withdrawn
thioridazine,dopamine receptor antagonist,DRD2,3274,Withdrawn
thioridazine,dopamine receptor antagonist,DRD3,6833,Withdrawn
thioridazine,dopamine receptor antagonist,DRD4,3758,Withdrawn
thioridazine,dopamine receptor antagonist,DRD5,3767,Withdrawn
thioridazine,dopamine receptor antagonist,HRH1,3764,Withdrawn
thioridazine,dopamine receptor antagonist,HTR1A,1312,Withdrawn
thioridazine,dopamine receptor antagonist,HTR2A,4067,Withdrawn
thioridazine,dopamine receptor antagonist,HTR2C,6714,Withdrawn
thioridazine,dopamine receptor antagonist,HTR6,5742,Withdrawn
thioridazine,dopamine receptor antagonist,HTR7,5743,Withdrawn
thiorphan,membrane metalloendopeptidase inhibitor,MME,150,Phase 1
thiostrepton,FOXM1 inhibitor|protein synthesis inhibitor,FOXM1,4128,Launched
thiotepa,cytochrome P450 inhibitor,CYP2B6,4129,Launched
thiotepa,cytochrome P450 inhibitor,CYP3A4,1557,Launched
thiothixene,dopamine receptor antagonist,DRD1,1565,Launched
thiothixene,dopamine receptor antagonist,DRD2,10327,Launched
thiothixene,dopamine receptor antagonist,HRH1,231,Launched
thiothixene,dopamine receptor antagonist,HTR2A,57016,Launched
thiram,,JAK2,1128,Launched
thymol,GABA receptor positive allosteric modulator,TRPA1,1129,Launched
THZ1,CDK inhibitor,CDK7,1131,Preclinical
THZ1-R,CDK inhibitor,CDK7,1132,Preclinical
THZ2,CDK inhibitor,CDK7,1133,Preclinical
tiagabine,GABA uptake inhibitor,SLC6A1,552,Launched
tianeptine,selective serotonin reuptake enhancer (SSRE),OPRD1,554,Launched
tianeptine,selective serotonin reuptake enhancer (SSRE),OPRK1,10800,Launched
tianeptine,selective serotonin reuptake enhancer (SSRE),OPRM1,759,Launched
tiapride,dopamine receptor antagonist,DRD2,771,Launched
tiapride,dopamine receptor antagonist,DRD3,760,Launched
tiaprofenic-acid,cyclooxygenase inhibitor,PTGS2,762,Launched
tibolone,androgen receptor agonist|estrogen receptor agonist|progesterone receptor agonist,ESR1,766,Launched
ticagrelor,purinergic receptor antagonist,P2RY12,2554,Launched
ticlopidine,purinergic receptor antagonist,P2RY12,2555,Launched
TIC10,AKT inhibitor|TRAIL modulator,AKT1,5292,Phase 2
TIC10,AKT inhibitor|TRAIL modulator,MAPK1,2932,Phase 2
tideglusib,glycogen synthase kinase inhibitor,GSK3B,3718,Phase 2
tienilic-acid,cytochrome P450 inhibitor|sodium/potassium/chloride transporter inhibitor,CYP2C9,3676,Withdrawn
tienilic-acid,cytochrome P450 inhibitor|sodium/potassium/chloride transporter inhibitor,SLC12A1,3688,Withdrawn
tie2-kinase-inhibitor,TIE tyrosine kinase inhibitor,KDR,2859,Preclinical
tie2-kinase-inhibitor,TIE tyrosine kinase inhibitor,MAPK14,2322,Preclinical
tifenazoxide,ATP-sensitive potassium channel agonist,ABCC8,8989,Phase 1
tifenazoxide,ATP-sensitive potassium channel agonist,KCNJ11,23621,Phase 1
tiludronate,bone resorption inhibitor|osteoclast inhibitor,ATP6V1A,1137,Launched
tiludronate,bone resorption inhibitor|osteoclast inhibitor,MMP2,1268,Launched
tiludronate,bone resorption inhibitor|osteoclast inhibitor,PTPN1,134,Launched
timofibrate,cholesterol inhibitor|lipase clearing factor inhibitor,LPL,846,Phase 2
timolol,adrenergic receptor antagonist,ADRB1,3757,Launched
timolol,adrenergic receptor antagonist,ADRB2,3356,Launched
tiotidine,histamine receptor antagonist,HRH2,3357,Phase 2
tiotropium,acetylcholine receptor antagonist,CHRM1,3358,Launched
tiotropium,acetylcholine receptor antagonist,CHRM2,3360,Launched
tiotropium,acetylcholine receptor antagonist,CHRM3,729230,Launched
tioxolone,carbonic anhydrase inhibitor,CA2,5476,Preclinical
tipifarnib,farnesyltransferase inhibitor,FNTA,5241,Phase 3
tipifarnib,farnesyltransferase inhibitor,FNTB,3791,Phase 3
tiplaxtinin,plasminogen activator inhibitor,SERPINE1,10203,Phase 1
tiprenolol,adrenergic receptor antagonist,ADRB1,10267,Phase 2
tiprenolol,adrenergic receptor antagonist,ADRB2,1128,Phase 2
tiprenolol,adrenergic receptor antagonist,ADRB3,1544,Phase 2
tiracizine,sodium channel blocker,SCN5A,1565,Withdrawn
tiratricol,thyroid hormone stimulant,THRA,1576,Launched
tiratricol,thyroid hormone stimulant,THRB,1577,Launched
tirofiban,platelet aggregation inhibitor|structural glycoprotein antagonist,ITGA2B,1551,Launched
tirofiban,platelet aggregation inhibitor|structural glycoprotein antagonist,ITGB3,185,Launched
tivantinib,tyrosine kinase inhibitor,MET,5468,Phase 3
tivozanib,VEGFR inhibitor,FLT1,7166,Launched
tivozanib,VEGFR inhibitor,FLT4,7166,Launched
tivozanib,VEGFR inhibitor,KDR,1636,Launched
tivozanib,VEGFR inhibitor,KIT,4255,Launched
tivozanib,VEGFR inhibitor,PDGFRA,2475,Launched
tivozanib,VEGFR inhibitor,PDGFRB,3620,Launched
tizanidine,adrenergic receptor agonist,ADRA2A,1803,Launched
tizanidine,adrenergic receptor agonist,ADRA2B,3761,Launched
tizanidine,adrenergic receptor agonist,ADRA2C,5742,Launched
tizanidine,adrenergic receptor agonist,NISCH,7153,Launched
TMN-355,cyclophilin inhibitor,PPIA,7155,Preclinical
TNP-470,methionine aminopeptidase inhibitor,METAP2,1544,Phase 2
tocainide,sodium channel blocker,SCN5A,23411,Launched
toceranib,protein tyrosine kinase inhibitor,FLT1,23411,Launched
toceranib,protein tyrosine kinase inhibitor,FLT3,22933,Launched
toceranib,protein tyrosine kinase inhibitor,KDR,23410,Launched
toceranib,protein tyrosine kinase inhibitor,PDGFRA,5742,Launched
toceranib,protein tyrosine kinase inhibitor,PDGFRB,5743,Launched
tofacitinib,JAK inhibitor,JAK1,240,Launched
tofacitinib,JAK inhibitor,JAK2,5315,Launched
tofacitinib,JAK inhibitor,JAK3,332,Launched
tofisopam,cytochrome P450 inhibitor|phosphodiesterase inhibitor,CYP3A4,983,Launched
tofogliflozin,sodium/glucose cotransporter inhibitor,GCK,148,Launched
tolamolol,adrenergic receptor antagonist,ADRB1,147,Phase 3
tolamolol,adrenergic receptor antagonist,ADRB2,146,Phase 3
tolamolol,adrenergic receptor antagonist,ADRB3,6713,Phase 3
tolazamide,ATP channel blocker,ABCC8,154,Launched
tolazamide,ATP channel blocker,KCNJ1,3269,Launched
tolazamide,ATP channel blocker,KCNJ10,3756,Launched
tolazamide,ATP channel blocker,KCNJ11,3757,Launched
tolazoline,adrenergic receptor antagonist,ADRA1A,148,Launched
tolazoline,adrenergic receptor antagonist,ADRA2A,150,Launched
tolazoline,adrenergic receptor antagonist,ADRA2B,151,Launched
tolazoline,adrenergic receptor antagonist,ADRA2C,152,Launched
tolazoline,adrenergic receptor antagonist,HRH1,1813,Launched
tolazoline,adrenergic receptor antagonist,HRH2,1814,Launched
tolbutamide,ATP channel blocker,ABCC8,1815,Launched
tolbutamide,ATP channel blocker,KCNJ1,3350,Launched
tolbutamide,ATP channel blocker,KCNJ11,3351,Launched
tolbutamide,ATP channel blocker,KCNJ8,3352,Launched
tolcapone,catechol O methyltransferase inhibitor,COMT,3356,Withdrawn
tolimidone,SRC activator,LYN,3357,Phase 2
tolimidone,SRC activator,SRC,3358,Phase 2
tolmetin,cyclooxygenase inhibitor,PTGS1,1723,Launched
tolmetin,cyclooxygenase inhibitor,PTGS2,552,Launched
tolonidine,adrenergic receptor antagonist,ADRA2A,695,Launched
toloxatone,monoamine oxidase inhibitor,MAOA,6915,Launched
toloxatone,monoamine oxidase inhibitor,MAOB,5465,Launched
tolperisone,voltage-gated sodium channel blocker,CYP2C19,5468,Launched
tolperisone,voltage-gated sodium channel blocker,CYP2D6,5144,Launched
tolrestat,aldose reductase inhibitor,AKR1A1,6570,Withdrawn
tolrestat,aldose reductase inhibitor,AKR1B1,6571,Withdrawn
tolrestat,aldose reductase inhibitor,AKR1B10,6336,Withdrawn
tolterodine,acetylcholine receptor antagonist,CHRM1,11280,Launched
tolterodine,acetylcholine receptor antagonist,CHRM2,6323,Launched
tolterodine,acetylcholine receptor antagonist,CHRM3,6326,Launched
tolterodine,acetylcholine receptor antagonist,CHRM4,6328,Launched
tolterodine,acetylcholine receptor antagonist,CHRM5,6329,Launched
tolvaptan,vasopressin receptor antagonist,AVPR1A,6331,Launched
tolvaptan,vasopressin receptor antagonist,AVPR2,6332,Launched
tomelukast,leukotriene receptor antagonist,CYSLTR1,6334,Phase 3
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,CA1,6335,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,CA12,6647,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,CA2,6648,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,CA4,2350,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,CA7,978,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,GABRA1,-,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,GABRA2,1136,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,GABRA3,2556,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,GABRA4,2557,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,GABRA5,2558,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,GABRA6,2559,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,GABRB1,2560,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,GABRB2,2561,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,GABRB3,2562,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,GABRD,2563,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,GABRE,2564,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,GABRG1,2565,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,GABRG2,2566,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,GABRG3,2567,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,GABRP,2568,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,GABRQ,55879,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,GRIA1,2890,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,GRIA2,2891,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,GRIA3,2892,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,GRIA4,2893,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,GRIK1,2897,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,GRIK2,2898,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,GRIK3,2899,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,GRIK4,2900,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,GRIK5,2901,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,SCN10A,6336,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,SCN11A,11280,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,SCN1A,6323,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,SCN2A,6326,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,SCN3A,6328,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,SCN4A,6329,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,SCN5A,6331,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,SCN7A,6332,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,SCN8A,6334,Launched
topiramate,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,SCN9A,6335,Launched
topiroxostat,xanthine oxidase inhibitor,XDH,7498,Launched
topotecan,topoisomerase inhibitor,TOP1,7150,Launched
topotecan,topoisomerase inhibitor,TOP1MT,116447,Launched
torasemide,electrolyte reabsorption inhibitor|thromboxane receptor antagonist,SLC12A1,6557,Launched
torcetrapib,cholesteryl ester transfer protein inhibitor,CETP,1071,Phase 3
torcitabine,DNA polymerase inhibitor,DCK,1633,Phase 2
torcitabine,DNA polymerase inhibitor,TK2,7084,Phase 2
toremifene,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),ESR1,2099,Launched
torin-1,mTOR inhibitor,MTOR,2475,Preclinical
torin-2,mTOR inhibitor,MTOR,2475,Preclinical
tosedostat,peptidase inhibitor,ANPEP,290,Phase 2
tosedostat,peptidase inhibitor,LAP3,51056,Phase 2
tosedostat,peptidase inhibitor,NPEPPS,9520,Phase 2
toyocamycin,serine/threonine kinase inhibitor,ERN1,2081,Phase 1
tozadenant,adenosine receptor antagonist,ADORA2A,135,Phase 3
tozasertib,Aurora kinase inhibitor|Bcr-Abl kinase inhibitor|FLT3 inhibitor|JAK inhibitor,AURKA,6790,Phase 2
tozasertib,Aurora kinase inhibitor|Bcr-Abl kinase inhibitor|FLT3 inhibitor|JAK inhibitor,AURKB,9212,Phase 2
tozasertib,Aurora kinase inhibitor|Bcr-Abl kinase inhibitor|FLT3 inhibitor|JAK inhibitor,AURKC,6795,Phase 2
tozasertib,Aurora kinase inhibitor|Bcr-Abl kinase inhibitor|FLT3 inhibitor|JAK inhibitor,LCK,3932,Phase 2
TP-003,GABA receptor inverse agonist,GABRA1,2554,Preclinical
TP-003,GABA receptor inverse agonist,GABRA2,2555,Preclinical
TP-003,GABA receptor inverse agonist,GABRA3,2556,Preclinical
TP-003,GABA receptor inverse agonist,GABRA5,2558,Preclinical
TP-0903,AXL kinase inhibitor,AXL,558,Phase 1/Phase 2
TPCA-1,IKK inhibitor,IKBKB,3551,Preclinical
tracazolate,GABA receptor modulator,GABRA1,2554,Phase 2
TRAM-34,potassium channel antagonist,KCNN4,3783,Preclinical
TRAM-39,calcium-activated potassium channel activator,KCNN4,3783,Preclinical
trametinib,MEK inhibitor,MAP2K1,5604,Launched
trametinib,MEK inhibitor,MAP2K2,5605,Launched
tramiprosate,beta amyloid protein neurotoxicity inhibitor,APP,351,Phase 3
trandolapril,angiotensin converting enzyme inhibitor,ACE,1636,Launched
tranexamic-acid,antifibrinolytic|plasminogen activator inhibitor,PLG,5340,Launched
tranilast,angiogenesis inhibitor,HPGDS,27306,Launched
tranilast,angiogenesis inhibitor,HRH1,3269,Launched
tranylcypromine,monoamine oxidase inhibitor,KDM1A,23028,Launched
tranylcypromine,monoamine oxidase inhibitor,MAOA,4128,Launched
tranylcypromine,monoamine oxidase inhibitor,MAOB,4129,Launched
trap-101,nociceptin/orphanin FQ receptor antagonist|opioid receptor antagonist,OPRL1,4987,Preclinical
trapidil,PDGFR tyrosine kinase receptor inhibitor,PDGFRA,5156,Launched
travoprost,prostanoid receptor agonist,PTGFR,5737,Launched
traxoprodil,glutamate receptor antagonist,GRIN2B,2904,Phase 2
trazodone,adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor,ADRA1A,148,Launched
trazodone,adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor,ADRA2A,150,Launched
trazodone,adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor,HRH1,3269,Launched
trazodone,adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor,HTR1A,3350,Launched
trazodone,adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor,HTR2A,3356,Launched
trazodone,adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor,HTR2B,3357,Launched
trazodone,adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor,HTR2C,3358,Launched
trazodone,adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor,SLC6A4,6532,Launched
trelagliptin,dipeptidyl peptidase inhibitor,DPP4,1803,Launched
trepibutone,cholinergic receptor antagonist,CHRM1,1128,Launched
trepibutone,cholinergic receptor antagonist,CHRM2,1129,Launched
trepibutone,cholinergic receptor antagonist,CHRM3,1131,Launched
trepibutone,cholinergic receptor antagonist,CHRM4,1132,Launched
treprostinil,prostanoid receptor agonist,P2RY12,64805,Launched
treprostinil,prostanoid receptor agonist,PPARD,5467,Launched
treprostinil,prostanoid receptor agonist,PTGIR,5739,Launched
trequinsin,phosphodiesterase inhibitor,PDE5A,8654,Phase 1
tretazicar,DNA replication inhibitor,NQO2,4835,Phase 2
tretinoin,retinoid receptor agonist|retinoid receptor ligand,ALDH1A1,216,Launched
tretinoin,retinoid receptor agonist|retinoid receptor ligand,ALDH1A2,8854,Launched
tretinoin,retinoid receptor agonist|retinoid receptor ligand,GPRC5A,9052,Launched
tretinoin,retinoid receptor agonist|retinoid receptor ligand,NR0B1,190,Launched
tretinoin,retinoid receptor agonist|retinoid receptor ligand,NR2C2,7182,Launched
tretinoin,retinoid receptor agonist|retinoid receptor ligand,PPARD,5467,Launched
tretinoin,retinoid receptor agonist|retinoid receptor ligand,RARA,5914,Launched
tretinoin,retinoid receptor agonist|retinoid receptor ligand,RARB,5915,Launched
tretinoin,retinoid receptor agonist|retinoid receptor ligand,RARG,5916,Launched
tretinoin,retinoid receptor agonist|retinoid receptor ligand,RARRES1,5918,Launched
tretinoin,retinoid receptor agonist|retinoid receptor ligand,RORB,6096,Launched
tretinoin,retinoid receptor agonist|retinoid receptor ligand,RORC,6097,Launched
tretinoin,retinoid receptor agonist|retinoid receptor ligand,RXRB,6257,Launched
tretinoin,retinoid receptor agonist|retinoid receptor ligand,RXRG,6258,Launched
triamcinolone,glucocorticoid receptor agonist,NR3C1,2908,Launched
triamcinolone-acetonide,glucocorticoid receptor agonist|immunosuppressant,NR3C1,2908,Launched
triamcinolone-acetonide,glucocorticoid receptor agonist|immunosuppressant,SERPINA6,866,Launched
triamterene,sodium channel blocker,SCNN1A,6337,Launched
triamterene,sodium channel blocker,SCNN1B,6338,Launched
triamterene,sodium channel blocker,SCNN1D,6339,Launched
triamterene,sodium channel blocker,SCNN1G,6340,Launched
triapine,ribonucleotide reductase inhibitor,RRM1,6240,Phase 2
triapine,ribonucleotide reductase inhibitor,RRM2,6241,Phase 2
trichlormethiazide,chloride channel blocker,PTGS1,5742,Launched
trichlormethiazide,chloride channel blocker,PTGS2,5743,Launched
trichlormethiazide,chloride channel blocker,SLC12A1,6557,Launched
trichostatin-a,HDAC inhibitor,HDAC1,3065,Phase 1
trichostatin-a,HDAC inhibitor,HDAC10,83933,Phase 1
trichostatin-a,HDAC inhibitor,HDAC2,3066,Phase 1
trichostatin-a,HDAC inhibitor,HDAC3,8841,Phase 1
trichostatin-a,HDAC inhibitor,HDAC4,9759,Phase 1
trichostatin-a,HDAC inhibitor,HDAC5,10014,Phase 1
trichostatin-a,HDAC inhibitor,HDAC6,10013,Phase 1
trichostatin-a,HDAC inhibitor,HDAC7,51564,Phase 1
trichostatin-a,HDAC inhibitor,HDAC8,55869,Phase 1
trichostatin-a,HDAC inhibitor,HDAC9,9734,Phase 1
triciribine,AKT inhibitor,AKT1,207,Phase 1/Phase 2
triciribine,AKT inhibitor,AKT2,208,Phase 1/Phase 2
triciribine,AKT inhibitor,AKT3,10000,Phase 1/Phase 2
triclabendazole,microtubule inhibitor,DNMT1,1786,Launched
triclosan,antibacterial agent,DNMT1,1786,Launched
trientine,chelating agent,CA14,23632,Launched
trifluoperazine,dopamine receptor antagonist,ADRA1A,148,Launched
trifluoperazine,dopamine receptor antagonist,CALM1,801,Launched
trifluoperazine,dopamine receptor antagonist,CALY,50632,Launched
trifluoperazine,dopamine receptor antagonist,DRD2,1813,Launched
trifluoperazine,dopamine receptor antagonist,DRD4,1815,Launched
trifluoperazine,dopamine receptor antagonist,HRH1,3269,Launched
trifluoperazine,dopamine receptor antagonist,HTR2A,3356,Launched
trifluoperazine,dopamine receptor antagonist,HTR2C,3358,Launched
trifluoperazine,dopamine receptor antagonist,S100A4,6275,Launched
trifluoperazine,dopamine receptor antagonist,TNNC1,7134,Launched
triflupromazine,dopamine receptor antagonist,CHRM1,1128,Launched
triflupromazine,dopamine receptor antagonist,CHRM2,1129,Launched
triflupromazine,dopamine receptor antagonist,DRD1,1812,Launched
triflupromazine,dopamine receptor antagonist,DRD2,1813,Launched
triflupromazine,dopamine receptor antagonist,HTR2B,3357,Launched
trifluridine,DNA directed DNA polymerase inhibitor|thymidylate synthase inhibitor,TYMS,7298,Launched
triflusal,cyclooxygenase inhibitor|platelet aggregation inhibitor|thromboxane synthase inhibitor,NFKB1,4790,Launched
triflusal,cyclooxygenase inhibitor|platelet aggregation inhibitor|thromboxane synthase inhibitor,NOS2,4843,Launched
triflusal,cyclooxygenase inhibitor|platelet aggregation inhibitor|thromboxane synthase inhibitor,PDE10A,10846,Launched
triflusal,cyclooxygenase inhibitor|platelet aggregation inhibitor|thromboxane synthase inhibitor,PTGS1,5742,Launched
trihexyphenidyl,acetylcholine receptor antagonist,CHRM1,1128,Launched
trimebutine,opioid receptor agonist,OPRD1,4985,Launched
trimebutine,opioid receptor agonist,OPRK1,4986,Launched
trimebutine,opioid receptor agonist,OPRM1,4988,Launched
trimetazidine,3-ketoacyl CoA thiolase inhibitor,ACAA2,10449,Launched
trimethadione,oxazolidine antiepileptic,CACNA1G,8913,Launched
trimethadione,oxazolidine antiepileptic,CACNA1H,8912,Launched
trimethadione,oxazolidine antiepileptic,CACNA1I,8911,Launched
trimethobenzamide,histamine receptor antagonist,DRD2,1813,Launched
trimethoprim,dihydrofolate reductase inhibitor,DHFR,1719,Launched
trimethoprim,dihydrofolate reductase inhibitor,TYMS,7298,Launched
trimethoquinol,adrenergic receptor antagonist,ADRB2,154,Launched
trimethoquinol,adrenergic receptor antagonist,ADRB3,155,Launched
trimetrexate,dihydrofolate reductase inhibitor,DHFR,1719,Phase 3
trimipramine,norepinephrine reputake inhibitor|tricyclic antidepressant,SLC6A2,6530,Launched
trimipramine,norepinephrine reputake inhibitor|tricyclic antidepressant,SLC6A3,6531,Launched
trimipramine,norepinephrine reputake inhibitor|tricyclic antidepressant,SLC6A4,6532,Launched
tripelennamine,histamine receptor antagonist,HRH1,3269,Launched
triprolidine,histamine receptor antagonist,HRH1,3269,Launched
triptan,serotonin receptor agonist,HTR1B,3351,Phase 1
triptan,serotonin receptor agonist,HTR1D,3352,Phase 1
triptolide,RNA polymerase inhibitor,RELA,5970,Phase 3
triptorelin,gonadotropin releasing factor hormone receptor agonist,GNRHR,2798,Launched
trofinetide,cytokine production inhibitor,IFNG,3458,Phase 2
trofinetide,cytokine production inhibitor,IL6,3569,Phase 2
trofinetide,cytokine production inhibitor,TNF,7124,Phase 2
troglitazone,insulin sensitizer|PPAR receptor agonist,CYP2C8,1558,Withdrawn
troglitazone,insulin sensitizer|PPAR receptor agonist,PPARG,5468,Withdrawn
troglitazone,insulin sensitizer|PPAR receptor agonist,TRPM3,80036,Withdrawn
trometamol,,AMD1,262,Launched
trometamol,,CANT1,124583,Launched
trometamol,,DCN,1634,Launched
trometamol,,NEIL1,79661,Launched
trometamol,,VEGFA,7422,Launched
"tropanyl-3,5-dimethylbenzoate",serotonin receptor antagonist,HTR3A,3359,Preclinical
"tropanyl-3,5-dimethylbenzoate",serotonin receptor antagonist,HTR3B,9177,Preclinical
tropesin,cyclooxygenase inhibitor,PTGS1,5742,Launched
tropesin,cyclooxygenase inhibitor,PTGS2,5743,Launched
tropicamide,acetylcholine receptor antagonist,CHRM3,1131,Launched
tropicamide,acetylcholine receptor antagonist,CHRM4,1132,Launched
tropisetron,serotonin receptor antagonist,GLRA1,2741,Launched
tropisetron,serotonin receptor antagonist,GLRA2,2742,Launched
tropisetron,serotonin receptor antagonist,GLRB,2743,Launched
tropisetron,serotonin receptor antagonist,HTR3A,3359,Launched
tropisetron,serotonin receptor antagonist,HTR4,3360,Launched
trospium,acetylcholine receptor antagonist,CHRM1,1128,Launched
trovafloxacin,bacterial DNA gyrase inhibitor,TOP2A,7153,Withdrawn
TRV130,opioid receptor agonist,OPRM1,4988,Phase 3
tryptanthrin,cyclooxygenase inhibitor,IDO1,3620,Preclinical
tryptophan,serotonin receptor partial agonist,CASR,846,Launched
tryptophan,serotonin receptor partial agonist,IDO1,3620,Launched
tryptophan,serotonin receptor partial agonist,SLC36A1,206358,Launched
tryptophan,serotonin receptor partial agonist,WARS,7453,Launched
tryptophan,serotonin receptor partial agonist,WARS2,10352,Launched
TTNPB,retinoid receptor agonist,RARA,5914,Phase 1
TTNPB,retinoid receptor agonist,RARB,5915,Phase 1
TTNPB,retinoid receptor agonist,RARG,5916,Phase 1
TTP-22,casein kinase inhibitor,CSNK2A1,1457,Preclinical
tubastatin-A,HDAC inhibitor,HDAC6,10013,Preclinical
tubocurarine,acetylcholine receptor antagonist,ACHE,43,Launched
tubocurarine,acetylcholine receptor antagonist,CHRNA2,1135,Launched
tubocurarine,acetylcholine receptor antagonist,HTR3A,3359,Launched
tubocurarine,acetylcholine receptor antagonist,HTR3B,9177,Launched
tubocurarine,acetylcholine receptor antagonist,KCNN1,3780,Launched
tubocurarine,acetylcholine receptor antagonist,KCNN2,3781,Launched
tubocurarine,acetylcholine receptor antagonist,KCNN3,3782,Launched
tubocurarine,acetylcholine receptor antagonist,ZACN,353174,Launched
tucatinib,EGFR inhibitor,ERBB2,2064,Phase 3
TUG-770,free fatty acid receptor agonist,FFAR1,2864,Preclinical
TUG-891,free fatty acid receptor agonist,FFAR4,338557,Preclinical
tulobuterol,adrenergic receptor agonist,ADRB2,154,Launched
TW-37,BCL inhibitor,BCL2,596,Preclinical
TW-37,BCL inhibitor,BCL2L1,598,Preclinical
TW-37,BCL inhibitor,MCL1,4170,Preclinical
TWS-119,glycogen synthase kinase inhibitor,GSK3B,2932,Preclinical
TWS-119,glycogen synthase kinase inhibitor,JUN,3725,Preclinical
TWS-119,glycogen synthase kinase inhibitor,MYC,4609,Preclinical
TY-52156,sphingosine 1-phosphate receptor antagonist,S1PR3,1903,Preclinical
tyrphostin-AG-1296,FLT3 inhibitor,FLT3,2322,Preclinical
tyrphostin-AG-1478,EGFR inhibitor,EGFR,1956,Preclinical
tyrphostin-AG-1478,EGFR inhibitor,MAPK14,1432,Preclinical
tyrphostin-AG-18,EGFR inhibitor|tyrosine kinase inhibitor,EGFR,1956,Preclinical
tyrphostin-AG-494,EGFR inhibitor,EGFR,1956,Preclinical
tyrphostin-AG-825,protein tyrosine kinase inhibitor,ERBB2,2064,Preclinical
tyrphostin-AG-835,protein tyrosine kinase inhibitor,EGFR,1956,Preclinical
tyrphostin-AG-879,tyrosine kinase inhibitor,ERBB2,2064,Preclinical
tyrphostin-AG-879,tyrosine kinase inhibitor,KDR,3791,Preclinical
tyrphostin-AG-879,tyrosine kinase inhibitor,NTRK1,4914,Preclinical
tyrphostin-AG-99,tyrosine kinase inhibitor,EGFR,1956,Preclinical
U-0126,MEK inhibitor,AKT1,207,Preclinical
U-0126,MEK inhibitor,CHEK1,1111,Preclinical
U-0126,MEK inhibitor,GSK3B,2932,Preclinical
U-0126,MEK inhibitor,LCK,3932,Preclinical
U-0126,MEK inhibitor,MAP2K1,5604,Preclinical
U-0126,MEK inhibitor,MAP2K2,5605,Preclinical
U-0126,MEK inhibitor,MAP2K7,5609,Preclinical
U-0126,MEK inhibitor,MAPK1,5594,Preclinical
U-0126,MEK inhibitor,MAPK11,5600,Preclinical
U-0126,MEK inhibitor,MAPK12,6300,Preclinical
U-0126,MEK inhibitor,MAPK14,1432,Preclinical
U-0126,MEK inhibitor,MAPK8,5599,Preclinical
U-0126,MEK inhibitor,PRKCA,5578,Preclinical
U-0126,MEK inhibitor,RAF1,5894,Preclinical
U-0126,MEK inhibitor,ROCK1,6093,Preclinical
U-0126,MEK inhibitor,RPS6KB1,6198,Preclinical
U-0126,MEK inhibitor,SGK1,6446,Preclinical
U-0521,catechol O methyltransferase inhibitor,COMT,1312,Preclinical
U-104,carbonic anhydrase inhibitor,CA1,759,Phase 1/Phase 2
U-104,carbonic anhydrase inhibitor,CA12,771,Phase 1/Phase 2
U-104,carbonic anhydrase inhibitor,CA2,760,Phase 1/Phase 2
U-104,carbonic anhydrase inhibitor,CA9,768,Phase 1/Phase 2
U-50488-(-),opioid receptor agonist,OPRK1,4986,Preclinical
U-54494A,opioid receptor agonist,OPRK1,4986,Preclinical
U-75799E,growth hormone releasing factor agonist,GHSR,2693,Phase 1
U-99194,dopamine receptor antagonist,DRD3,1814,Preclinical
UAMC-00039,dipeptidyl peptidase inhibitor,DPP4,1803,Preclinical
UAMC-00039,dipeptidyl peptidase inhibitor,DPP7,29952,Preclinical
UB-165,acetylcholine receptor agonist,CHRNA3,1136,Preclinical
UB-165,acetylcholine receptor agonist,CHRNA4,1137,Preclinical
UB-165,acetylcholine receptor agonist,CHRNB2,1141,Preclinical
ubenimex,leukotriene synthesis inhibitor,LTA4H,4048,Launched
ubenimex,leukotriene synthesis inhibitor,RNPEP,6051,Launched
UBP-296,glutamate receptor antagonist,GRIK1,2897,Preclinical
UBP-302,glutamate receptor antagonist,GRIK1,2897,Preclinical
UBP-310,glutamate receptor antagonist,GRIK1,2897,Preclinical
UBP-310,glutamate receptor antagonist,GRIK5,2901,Preclinical
UC-112,XIAP inhibitor,XIAP,331,Preclinical
UF-010,HDAC inhibitor,HDAC1,3065,Preclinical
UF-010,HDAC inhibitor,HDAC2,3066,Preclinical
UF-010,HDAC inhibitor,HDAC3,8841,Preclinical
UF-010,HDAC inhibitor,HDAC8,55869,Preclinical
ufenamate,cyclooxygenase inhibitor,PTGS1,5742,Launched
ufenamate,cyclooxygenase inhibitor,PTGS2,5743,Launched
UH-232-(+),dopamine receptor antagonist,DRD2,1813,Preclinical
UH-232-(+),dopamine receptor antagonist,DRD3,1814,Preclinical
UH-232-(+),dopamine receptor antagonist,DRD4,1815,Preclinical
UH-232-(+),dopamine receptor antagonist,HTR1A,3350,Preclinical
UK-356618,metalloproteinase inhibitor,MMP13,4322,Preclinical
UK-356618,metalloproteinase inhibitor,MMP14,4323,Preclinical
UK-356618,metalloproteinase inhibitor,MMP2,4313,Preclinical
UK-356618,metalloproteinase inhibitor,MMP3,4314,Preclinical
UK-356618,metalloproteinase inhibitor,MMP9,4318,Preclinical
UK-383367,procollagen C-endopeptidase inhibitor,BMP1,649,Phase 1
UK-5099,monocarboxylate transporter inhibitor,SLC16A1,6566,Preclinical
ulipristal,progesterone receptor antagonist,PGR,5241,Launched
umeclidinium,acetylcholine receptor antagonist,CHRM1,1128,Launched
umeclidinium,acetylcholine receptor antagonist,CHRM2,1129,Launched
umeclidinium,acetylcholine receptor antagonist,CHRM3,1131,Launched
UNC0224,histone lysine methyltransferase inhibitor,EHMT1,79813,Preclinical
UNC0224,histone lysine methyltransferase inhibitor,EHMT2,10919,Preclinical
UNC0321,histone lysine methyltransferase inhibitor,EHMT2,10919,Preclinical
UNC0631,histone lysine methyltransferase inhibitor,EHMT2,10919,Preclinical
UNC0638,histone lysine methyltransferase inhibitor,EHMT1,79813,Preclinical
UNC0638,histone lysine methyltransferase inhibitor,EHMT2,10919,Preclinical
UNC0642,histone lysine methyltransferase inhibitor,EHMT1,79813,Preclinical
UNC0642,histone lysine methyltransferase inhibitor,EHMT2,10919,Preclinical
UNC0646,histone lysine methyltransferase inhibitor,EHMT2,10919,Preclinical
UNC0737,histone lysine methyltransferase inhibitor,EHMT1,79813,Preclinical
UNC0737,histone lysine methyltransferase inhibitor,EHMT2,10919,Preclinical
UNC1215,L3MBTL antagonist,L3MBTL3,84456,Preclinical
UNC1999,histone lysine methyltransferase inhibitor,EZH2,2146,Preclinical
UNC2025,FLT3 inhibitor|MER tyrosine kinase inhibitor,FLT3,2322,Preclinical
UNC2025,FLT3 inhibitor|MER tyrosine kinase inhibitor,MERTK,10461,Preclinical
UNC2250,MER tyrosine kinase inhibitor,MERTK,10461,Preclinical
UNC2327,protein arginine N-methyltransferase inhibitor,PRMT3,10196,Preclinical
UNC3230,phosphatidyl-inositol activator,PIP5K1C,23396,Preclinical
UNC669,L3MBTL antagonist,L3MBTL1,26013,Preclinical
UNC926,MBT inhibitor,L3MBTL1,26013,Preclinical
UPF-1069,PARP inhibitor,PARP2,10038,Preclinical
uprosertib,AKT inhibitor,AKT1,207,Phase 2
uprosertib,AKT inhibitor,AKT2,208,Phase 2
uprosertib,AKT inhibitor,AKT3,10000,Phase 2
uracil,,DPYD,1806,Launched
uracil,,UCKL1,54963,Launched
urapidil,adrenergic receptor antagonist,HTR1A,3350,Launched
URB597,FAAH inhibitor,FAAH,2166,Phase 1
URB597,FAAH inhibitor,FAAH2,158584,Phase 1
URB597,FAAH inhibitor,TRPA1,8989,Phase 1
urea,hydroxy radical formation stimulant,ARG1,383,Launched
urea,hydroxy radical formation stimulant,CA2,760,Launched
urea,hydroxy radical formation stimulant,CTNNB1,1499,Launched
uric-acid,,PYGL,5836,Phase 3
uridine,dopamine receptor agonist,LSM6,11157,Phase 2
uridine,dopamine receptor agonist,TYMP,1890,Phase 2
uridine-5'-triphosphate,purinergic receptor activator,P2RY11,5032,Launched
uridine-5'-triphosphate,purinergic receptor activator,P2RY2,5029,Launched
uridine-5'-triphosphate,purinergic receptor activator,P2RY4,5030,Launched
uridine-5'-triphosphate,purinergic receptor activator,P2RY6,5031,Launched
uridine-5'-triphosphate,purinergic receptor activator,UCK2,7371,Launched
URMC-099,mixed lineage kinase inhibitor,CDKL2,8999,Preclinical
URMC-099,mixed lineage kinase inhibitor,DAPK3,1613,Preclinical
URMC-099,mixed lineage kinase inhibitor,FLT3,2322,Preclinical
URMC-099,mixed lineage kinase inhibitor,LRRK2,120892,Preclinical
URMC-099,mixed lineage kinase inhibitor,MAP3K10,4294,Preclinical
URMC-099,mixed lineage kinase inhibitor,MAP3K11,4296,Preclinical
URMC-099,mixed lineage kinase inhibitor,MAP3K2,10746,Preclinical
URMC-099,mixed lineage kinase inhibitor,MAP3K9,4293,Preclinical
URMC-099,mixed lineage kinase inhibitor,SRPK2,6733,Preclinical
ursodiol,nuclear factor erythroid derived|like (NRF2) activator,AKR1C2,1646,Launched
ursodiol,nuclear factor erythroid derived|like (NRF2) activator,NR1H4,9971,Launched
ursolic-acid,ATPase inhibitor|NFkB pathway inhibitor|STAT inhibitor,HSD11B1,3290,Phase 2/Phase 3
ursolic-acid,ATPase inhibitor|NFkB pathway inhibitor|STAT inhibitor,PLA2G1B,5319,Phase 2/Phase 3
ursolic-acid,ATPase inhibitor|NFkB pathway inhibitor|STAT inhibitor,PTPN1,5770,Phase 2/Phase 3
ursolic-acid,ATPase inhibitor|NFkB pathway inhibitor|STAT inhibitor,PYGM,5837,Phase 2/Phase 3
usniacin-(+),MAP kinase activator,PTPN1,5770,Preclinical
valdecoxib,cyclooxygenase inhibitor,CA12,771,Withdrawn
valdecoxib,cyclooxygenase inhibitor,PTGS2,5743,Withdrawn
valethamate,acetylcholine receptor antagonist,CHRM1,1128,Launched
valethamate,acetylcholine receptor antagonist,CHRM4,1132,Launched
valethamate,acetylcholine receptor antagonist,CHRM5,1133,Launched
valproic-acid,benzodiazepine receptor agonist|HDAC inhibitor,ABAT,18,Launched
valproic-acid,benzodiazepine receptor agonist|HDAC inhibitor,ACADSB,36,Launched
valproic-acid,benzodiazepine receptor agonist|HDAC inhibitor,ALDH5A1,7915,Launched
valproic-acid,benzodiazepine receptor agonist|HDAC inhibitor,HDAC1,3065,Launched
valproic-acid,benzodiazepine receptor agonist|HDAC inhibitor,HDAC2,3066,Launched
valproic-acid,benzodiazepine receptor agonist|HDAC inhibitor,HDAC9,9734,Launched
valproic-acid,benzodiazepine receptor agonist|HDAC inhibitor,OGDH,4967,Launched
valproic-acid,benzodiazepine receptor agonist|HDAC inhibitor,SCN10A,6336,Launched
valproic-acid,benzodiazepine receptor agonist|HDAC inhibitor,SCN11A,11280,Launched
valproic-acid,benzodiazepine receptor agonist|HDAC inhibitor,SCN1A,6323,Launched
valproic-acid,benzodiazepine receptor agonist|HDAC inhibitor,SCN1B,6324,Launched
valproic-acid,benzodiazepine receptor agonist|HDAC inhibitor,SCN2A,6326,Launched
valproic-acid,benzodiazepine receptor agonist|HDAC inhibitor,SCN2B,6327,Launched
valproic-acid,benzodiazepine receptor agonist|HDAC inhibitor,SCN3A,6328,Launched
valproic-acid,benzodiazepine receptor agonist|HDAC inhibitor,SCN3B,55800,Launched
valproic-acid,benzodiazepine receptor agonist|HDAC inhibitor,SCN4A,6329,Launched
valproic-acid,benzodiazepine receptor agonist|HDAC inhibitor,SCN4B,6330,Launched
valproic-acid,benzodiazepine receptor agonist|HDAC inhibitor,SCN5A,6331,Launched
valproic-acid,benzodiazepine receptor agonist|HDAC inhibitor,SCN7A,6332,Launched
valproic-acid,benzodiazepine receptor agonist|HDAC inhibitor,SCN8A,6334,Launched
valproic-acid,benzodiazepine receptor agonist|HDAC inhibitor,SCN9A,6335,Launched
valrubicin,DNA inhibitor|topoisomerase inhibitor,TOP2A,7153,Launched
valsartan,angiotensin receptor antagonist,AGTR1,185,Launched
valspodar,P glycoprotein inhibitor,ABCB1,5243,Phase 3
vandetanib,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,EGFR,1956,Launched
vandetanib,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,EPHA1,2041,Launched
vandetanib,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,EPHA10,284656,Launched
vandetanib,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,EPHA2,1969,Launched
vandetanib,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,EPHA3,2042,Launched
vandetanib,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,EPHA4,2043,Launched
vandetanib,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,EPHA5,2044,Launched
vandetanib,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,EPHA6,285220,Launched
vandetanib,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,EPHA7,2045,Launched
vandetanib,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,EPHA8,2046,Launched
vandetanib,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,EPHB1,2047,Launched
vandetanib,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,EPHB2,5338,Launched
vandetanib,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,EPHB3,2914,Launched
vandetanib,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,EPHB4,2913,Launched
vandetanib,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,EPHB6,1132,Launched
vandetanib,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,ERBB2,1132,Launched
vandetanib,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,ERBB3,2915,Launched
vandetanib,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,ERBB4,2915,Launched
vandetanib,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,FLT1,3758,Launched
vandetanib,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,FLT4,5594,Launched
vandetanib,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,KDR,3553,Launched
vandetanib,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,PTK6,3569,Launched
vandetanib,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,RET,5600,Launched
vandetanib,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,SRC,6300,Launched
vandetanib,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,TEK,1432,Launched
vandetanib,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,VEGFA,7124,Launched
vanillin,,ABAT,5600,Preclinical
vanillin,,ALDH5A1,6300,Preclinical
vanoxerine,dopamine reuptake inhibitor,SLC6A3,1432,Phase 3
vardenafil,phosphodiesterase inhibitor,PDE5A,834,Launched
vardenafil,phosphodiesterase inhibitor,PDE6G,728,Launched
vardenafil,phosphodiesterase inhibitor,PDE6H,79001,Launched
varenicline,acetylcholine receptor agonist,CHRNA3,3350,Launched
varenicline,acetylcholine receptor agonist,CHRNA4,3358,Launched
varenicline,acetylcholine receptor agonist,CHRNA6,4322,Launched
varenicline,acetylcholine receptor agonist,CHRNA7,2064,Launched
varespladib,secretory phospholipase inhibitor,PLA2G2A,2065,Phase 3
vasopressin,vasopressin receptor agonist,AVPR1A,2066,Launched
vasopressin,vasopressin receptor agonist,AVPR1B,2100,Launched
vasopressin,vasopressin receptor agonist,AVPR2,2798,Launched
vasopressin,vasopressin receptor agonist,OXTR,3274,Launched
vatalanib,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,EGFR,6865,Phase 3
vatalanib,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FLT1,1813,Phase 3
vatalanib,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FLT4,3356,Phase 3
vatalanib,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KDR,3358,Phase 3
vatalanib,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,PDGFRB,3362,Phase 3
VBY-825,cathepsin inhibitor,CTSB,3363,Preclinical
VBY-825,cathepsin inhibitor,CTSL,6506,Preclinical
VBY-825,cathepsin inhibitor,CTSS,6422,Preclinical
VE-821,ATR kinase inhibitor,ATR,9971,Preclinical
VE-822,ATR kinase inhibitor,ATM,2475,Phase 2
VE-822,ATR kinase inhibitor,ATR,3358,Phase 2
VE-822,ATR kinase inhibitor,MTOR,148,Phase 2
VE-822,ATR kinase inhibitor,PIK3CG,147,Phase 2
vecuronium,acetylcholine receptor antagonist,CHRNA2,146,Launched
vedaprofen,anti-inflammatory agent,PTGS2,150,Launched
veliflapon,leukotriene synthesis inhibitor,ALOX5AP,151,Phase 3
veliparib,PARP inhibitor,PARP1,152,Phase 3
veliparib,PARP inhibitor,PARP2,3350,Phase 3
velneperit,neuropeptide receptor antagonist,NPY5R,11091,Phase 2
vemurafenib,RAF inhibitor,BRAF,3932,Launched
vemurafenib,RAF inhibitor,RAF1,6714,Launched
venetoclax,BCL inhibitor,BCL2,1956,Launched
venlafaxine,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),SLC6A2,3716,Launched
venlafaxine,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotoninâ€“norepinephrine reuptake inhibitor (SNRI),SLC6A4,3717,Launched
VER-155008,HSP inhibitor,HSPA1A,3718,Preclinical
VER-49009,HSP inhibitor,HSP90AA1,80351,Preclinical
verapamil,calcium channel blocker,CACNA1A,8854,Launched
verapamil,calcium channel blocker,CACNA1B,624,Launched
verapamil,calcium channel blocker,CACNA1C,8976,Launched
verapamil,calcium channel blocker,CACNA1D,64840,Launched
verapamil,calcium channel blocker,CACNA1F,5297,Launched
verapamil,calcium channel blocker,CACNA1G,5298,Launched
verapamil,calcium channel blocker,CACNA1I,5290,Launched
verapamil,calcium channel blocker,CACNA1S,5293,Launched
verapamil,calcium channel blocker,CACNB1,5294,Launched
verapamil,calcium channel blocker,CACNB2,5295,Launched
verapamil,calcium channel blocker,CACNB3,5347,Launched
verapamil,calcium channel blocker,CACNB4,5591,Launched
verapamil,calcium channel blocker,CYP3A4,6774,Launched
verapamil,calcium channel blocker,KCNA10,3717,Launched
verapamil,calcium channel blocker,KCNA7,51377,Launched
verapamil,calcium channel blocker,KCNH2,9097,Launched
verapamil,calcium channel blocker,KCNJ11,8239,Launched
verapamil,calcium channel blocker,NALCN,7298,Launched
verapamil,calcium channel blocker,SCN5A,23491,Launched
verapamil,calcium channel blocker,SLC29A4,57406,Launched
verapamil,calcium channel blocker,SLC6A4,2475,Launched
vercirnon,CC chemokine receptor antagonist,CCR9,2475,Phase 3
verinurad,urate transporter inhibitor,SLC22A12,2475,Phase 2
vernakalant,potassium channel blocker,KCNA5,1956,Launched
verubulin,tubulin polymerization inhibitor,TUBB,1956,Phase 2
vesamicol,acetylcholinesterase inhibitor,SLC18A3,2064,Preclinical
vesnarinone,phosphodiesterase inhibitor,KCNH2,9891,Launched
vesnarinone,phosphodiesterase inhibitor,PDE3A,81788,Launched
VGX-1027,tumor necrosis factor receptor antagonist,TLR4,1956,Phase 1
vicriviroc,CC chemokine receptor antagonist,CCR5,7852,Phase 3
vidarabine,antiviral,ADA,3350,Launched
vigabatrin,GABA aminotransferase inhibitor,ABAT,153,Launched
vigabatrin,GABA aminotransferase inhibitor,SLC32A1,1128,Launched
vilanterol,adrenergic receptor agonist,ADRB2,1129,Launched
vilazodone,serotonin reuptake inhibitor,DRD2,1131,Launched
vilazodone,serotonin reuptake inhibitor,DRD3,1132,Launched
vilazodone,serotonin reuptake inhibitor,HRH1,1133,Launched
vilazodone,serotonin reuptake inhibitor,HTR1A,3350,Launched
vilazodone,serotonin reuptake inhibitor,HTR4,3351,Launched
vilazodone,serotonin reuptake inhibitor,SLC6A4,3352,Launched
vildagliptin,dipeptidyl peptidase inhibitor,DPP4,3354,Launched
viloxazine,norepinephrine reuptake inhibitor,SLC6A2,3355,Launched
vinblastine,microtubule inhibitor|tubulin polymerization inhibitor,JUN,3356,Launched
vinblastine,microtubule inhibitor|tubulin polymerization inhibitor,TUBA1A,3357,Launched
vinblastine,microtubule inhibitor|tubulin polymerization inhibitor,TUBB,3354,Launched
vinblastine,microtubule inhibitor|tubulin polymerization inhibitor,TUBD1,3355,Launched
vinblastine,microtubule inhibitor|tubulin polymerization inhibitor,TUBE1,3356,Launched
vinblastine,microtubule inhibitor|tubulin polymerization inhibitor,TUBG1,3357,Launched
vinburnine,adrenergic receptor antagonist,CHRM1,3358,Launched
vinburnine,adrenergic receptor antagonist,CHRM2,3361,Launched
vinburnine,adrenergic receptor antagonist,CHRM3,3362,Launched
vinburnine,adrenergic receptor antagonist,CHRM4,3363,Launched
vincamine,adrenergic receptor antagonist,CHRM1,1806,Withdrawn
vincamine,adrenergic receptor antagonist,CHRM2,7298,Withdrawn
vincamine,adrenergic receptor antagonist,CHRM3,7298,Withdrawn
vincamine,adrenergic receptor antagonist,CHRM4,1131,Withdrawn
vincristine,tubulin polymerization inhibitor,TUBA4A,206358,Launched
vincristine,tubulin polymerization inhibitor,TUBB,153201,Launched
vindesine,tubulin polymerization inhibitor,TUBB,1128,Launched
vindesine,tubulin polymerization inhibitor,TUBB1,1129,Launched
vinorelbine,tubulin polymerization inhibitor,TUBA1A,1131,Launched
vinorelbine,tubulin polymerization inhibitor,TUBA1B,1132,Launched
vinorelbine,tubulin polymerization inhibitor,TUBA1C,4543,Launched
vinorelbine,tubulin polymerization inhibitor,TUBA3C,4544,Launched
vinorelbine,tubulin polymerization inhibitor,TUBA3D,7442,Launched
vinorelbine,tubulin polymerization inhibitor,TUBA3E,2902,Launched
vinorelbine,tubulin polymerization inhibitor,TUBA4A,2903,Launched
vinorelbine,tubulin polymerization inhibitor,TUBB,2904,Launched
vinorelbine,tubulin polymerization inhibitor,TUBB1,2905,Launched
vinorelbine,tubulin polymerization inhibitor,TUBB2A,1813,Launched
vinorelbine,tubulin polymerization inhibitor,TUBB2B,1814,Launched
vinorelbine,tubulin polymerization inhibitor,TUBB3,1814,Launched
vinorelbine,tubulin polymerization inhibitor,TUBB4A,983,Launched
vinorelbine,tubulin polymerization inhibitor,TUBB4B,1111,Launched
vinorelbine,tubulin polymerization inhibitor,TUBB6,11200,Launched
vinorelbine,tubulin polymerization inhibitor,TUBB8,2932,Launched
vinpocetine,phosphodiesterase inhibitor|sodium channel blocker,PDE1A,3932,Launched
vinpocetine,phosphodiesterase inhibitor|sodium channel blocker,PDE1C,1432,Launched
vipadenant,adenosine receptor antagonist,ADORA1,4139,Phase 1
vipadenant,adenosine receptor antagonist,ADORA2A,4140,Phase 1
vipadenant,adenosine receptor antagonist,ADORA2B,5170,Phase 1
vipadenant,adenosine receptor antagonist,ADORA3,5578,Phase 1
vismodegib,hedgehog pathway inhibitor|smoothened receptor antagonist,SMO,5579,Launched
vitamin-E,LDL oxidation inhibitor|PKC inhibitor,ALOX5,5580,Launched
vitamin-E,LDL oxidation inhibitor|PKC inhibitor,DGKA,5581,Launched
vitamin-E,LDL oxidation inhibitor|PKC inhibitor,NR1I2,5582,Launched
vitamin-E,LDL oxidation inhibitor|PKC inhibitor,PPP2CA,43,Launched
vitamin-E,LDL oxidation inhibitor|PKC inhibitor,PPP2CB,4842,Launched
vitamin-E,LDL oxidation inhibitor|PKC inhibitor,PRKCA,4843,Launched
vitamin-E,LDL oxidation inhibitor|PKC inhibitor,PRKCB,4846,Launched
vitamin-E,LDL oxidation inhibitor|PKC inhibitor,SEC14L2,5592,Launched
vitamin-E,LDL oxidation inhibitor|PKC inhibitor,SEC14L3,3361,Launched
vitamin-E,LDL oxidation inhibitor|PKC inhibitor,SEC14L4,3363,Launched
VLX600,antitumor agent|ubiquitin C-terminal hydrolase inhibitor,TP53,1813,Phase 1
VLX600,antitumor agent|ubiquitin C-terminal hydrolase inhibitor,USP14,1814,Phase 1
voglibose,glucosidase inhibitor,MGAM,4543,Launched
volasertib,PLK inhibitor,PLK1,4544,Phase 3
volinanserin,serotonin receptor antagonist,HTR2A,7150,Phase 3
volinanserin,serotonin receptor antagonist,HTR2B,55107,Phase 3
volinanserin,serotonin receptor antagonist,HTR2C,1180,Phase 3
volinanserin,serotonin receptor antagonist,KCNH2,2048,Phase 3
vonoprazan,potassium-competitive acid antagonist,ATP4A,2049,Launched
vorapaxar,thrombin inhibitor,F2R,2050,Launched
voreloxin,topoisomerase inhibitor,TOP2A,2051,Phase 3
voriconazole,cytochrome P450 inhibitor,CYP2C19,2064,Launched
voriconazole,cytochrome P450 inhibitor,CYP2C9,2065,Launched
voriconazole,cytochrome P450 inhibitor,CYP3A4,2066,Launched
voriconazole,cytochrome P450 inhibitor,CYP3A5,2321,Launched
voriconazole,cytochrome P450 inhibitor,PTGS1,2324,Launched
vorinostat,HDAC inhibitor,HDAC1,3791,Launched
vorinostat,HDAC inhibitor,HDAC10,5753,Launched
vorinostat,HDAC inhibitor,HDAC11,5979,Launched
vorinostat,HDAC inhibitor,HDAC2,6714,Launched
vorinostat,HDAC inhibitor,HDAC3,7010,Launched
vorinostat,HDAC inhibitor,HDAC5,7422,Launched
vorinostat,HDAC inhibitor,HDAC6,18,Launched
vorinostat,HDAC inhibitor,HDAC8,7915,Launched
vorinostat,HDAC inhibitor,HDAC9,6531,Launched
vortioxetine,serotonin receptor agonist|serotonin receptor antagonist,HTR1A,8654,Launched
vortioxetine,serotonin receptor agonist|serotonin receptor antagonist,HTR1B,5148,Launched
vortioxetine,serotonin receptor agonist|serotonin receptor antagonist,HTR2A,5149,Launched
vortioxetine,serotonin receptor agonist|serotonin receptor antagonist,HTR2C,1136,Launched
vortioxetine,serotonin receptor agonist|serotonin receptor antagonist,HTR3A,1137,Launched
vortioxetine,serotonin receptor agonist|serotonin receptor antagonist,HTR5A,8973,Launched
vortioxetine,serotonin receptor agonist|serotonin receptor antagonist,HTR6,1139,Launched
vortioxetine,serotonin receptor agonist|serotonin receptor antagonist,HTR7,5320,Launched
vortioxetine,serotonin receptor agonist|serotonin receptor antagonist,SLC6A4,552,Launched
voxtalisib,mTOR inhibitor|PI3K inhibitor,MTOR,553,Phase 2
voxtalisib,mTOR inhibitor|PI3K inhibitor,PIK3CA,554,Phase 2
VP-20629,beta amyloid antagonist,PLA2G2E,5021,Phase 1
VP-20629,beta amyloid antagonist,SLC36A1,1956,Phase 1
VT-464,cytochrome P450 inhibitor,CYP17A1,2321,Phase 2
VTP-27999,renin inhibitor,REN,2324,Phase 1
VUF10166,serotonin receptor antagonist,HTR3A,3791,Preclinical
VUF10166,serotonin receptor antagonist,HTR3B,5159,Preclinical
VUF10460,histamine receptor agonist,HRH4,1508,Preclinical
VUF11207,CC chemokine receptor agonist,ACKR3,1514,Preclinical
VU0155069,phospholipase inhibitor,PLD1,1520,Preclinical
VU0238429,acetylcholine receptor allosteric modulator,CHRM5,545,Preclinical
VU0240551,potassium/chloride cotransporter inhibitor,SLC12A5,472,Preclinical
VU0357121,glutamate receptor positive allosteric modulator,GRM5,545,Preclinical
VU0360172,glutamate receptor positive allosteric modulator,GRM5,2475,Preclinical
VU0361737,glutamate receptor positive allosteric modulator,GRM4,5294,Preclinical
VU0364439,glutamate receptor positive allosteric modulator,GRM4,1135,Preclinical
VU0364739,phospholipase inhibitor,PLD2,5743,Preclinical
VU0364770,glutamate receptor positive allosteric modulator,GRM4,241,Preclinical
VU0422288,glutamate receptor positive allosteric modulator,GRM3,142,Preclinical
VU10010,acetylcholine receptor allosteric modulator,CHRM4,10038,Preclinical
VU152100,acetylcholine receptor allosteric modulator,CHRM4,4889,Preclinical
VU1545,glutamate receptor positive allosteric modulator,GRM5,673,Preclinical
VU29,glutamate receptor potentiator,GRM5,5894,Preclinical
VU591,potassium channel blocker,KCNJ1,596,Preclinical
VX-11e,MAP kinase inhibitor,MAPK1,6530,Preclinical
VX-702,p38 MAPK inhibitor,IL1B,6532,Phase 2
VX-702,p38 MAPK inhibitor,IL6,3303,Phase 2
VX-702,p38 MAPK inhibitor,MAPK11,3320,Phase 2
VX-702,p38 MAPK inhibitor,MAPK12,773,Phase 2
VX-702,p38 MAPK inhibitor,MAPK14,774,Phase 2
VX-702,p38 MAPK inhibitor,TNF,775,Phase 2
VX-745,p38 MAPK inhibitor,MAPK11,776,Phase 2
VX-745,p38 MAPK inhibitor,MAPK12,778,Phase 2
VX-745,p38 MAPK inhibitor,MAPK14,8913,Phase 2
VX-765,caspase inhibitor,CASP1,8911,Phase 2
W-54011,anaphylatoxin chemotactic receptor antagonist,C5AR1,779,Preclinical
warfarin,vitamin K antagonist,VKORC1,782,Launched
WAY-100635,serotonin receptor antagonist,HTR1A,783,Phase 1
WAY-161503,serotonin receptor agonist,HTR2C,784,Preclinical
WAY-170523,metalloproteinase inhibitor,MMP13,785,Preclinical
WAY-200070,estrogen receptor agonist,ERBB2,1576,Preclinical
WAY-200070,estrogen receptor agonist,ERBB3,3744,Preclinical
WAY-200070,estrogen receptor agonist,ERBB4,3743,Preclinical
WAY-200070,estrogen receptor agonist,ESR2,3757,Preclinical
WAY-207024,gonadotropin releasing factor hormone receptor antagonist,GNRHR,3767,Preclinical
WAY-207024,gonadotropin releasing factor hormone receptor antagonist,HRH2,259232,Preclinical
WAY-207024,gonadotropin releasing factor hormone receptor antagonist,TACR2,6331,Preclinical
WAY-208466,serotonin receptor agonist,DRD2,222962,Preclinical
WAY-208466,serotonin receptor agonist,HTR2A,6532,Preclinical
WAY-208466,serotonin receptor agonist,HTR2C,10803,Preclinical
WAY-208466,serotonin receptor agonist,HTR6,116085,Preclinical
WAY-208466,serotonin receptor agonist,HTR7,3741,Preclinical
WAY-213613,glutamate inhibitor,SLC1A2,203068,Preclinical
WAY-316606,secreted frizzled related protein inhibitor,SFRP1,6572,Preclinical
WAY-362450,FXR agonist,NR1H4,3757,Phase 1
WAY-600,mTOR inhibitor,MTOR,5139,Preclinical
WAY-629,serotonin receptor agonist,HTR2C,7099,Preclinical
WB-4101,adrenergic receptor antagonist,ADRA1A,1234,Preclinical
WB-4101,adrenergic receptor antagonist,ADRA1B,100,Preclinical
WB-4101,adrenergic receptor antagonist,ADRA1D,18,Preclinical
WB-4101,adrenergic receptor antagonist,ADRA2A,140679,Preclinical
WB-4101,adrenergic receptor antagonist,ADRA2B,154,Preclinical
WB-4101,adrenergic receptor antagonist,ADRA2C,1813,Preclinical
WB-4101,adrenergic receptor antagonist,HTR1A,1814,Preclinical
WDR5-0103,histone lysine methyltransferase inhibitor,WDR5,3269,Preclinical
WH-4-023,SRC inhibitor,LCK,3350,Preclinical
WH-4-023,SRC inhibitor,SRC,3360,Preclinical
WHI-P154,JAK inhibitor,EGFR,6532,Preclinical
WHI-P154,JAK inhibitor,JAK1,1803,Preclinical
WHI-P154,JAK inhibitor,JAK2,6530,Preclinical
WHI-P154,JAK inhibitor,JAK3,3725,Preclinical
WIKI4,tankyrase inhibitor|WNT pathway inhibitor,TNKS2,7846,Preclinical
WIN-18446,aldehyde dehydrogenase inhibitor,ALDH1A2,203068,Preclinical
WIN-64338,bradykinin receptor antagonist,BDKRB2,51174,Preclinical
wiskostatin,actin related protein inhibitor|neural Wiskott-Aldrich syndrome protein inhibitor,WASL,51175,Preclinical
wnt-c59,porcupine inhibitor,PORCN,7283,Preclinical
wortmannin,PI3K inhibitor,PI4KA,1128,Preclinical
wortmannin,PI3K inhibitor,PI4KB,1129,Preclinical
wortmannin,PI3K inhibitor,PIK3CA,1131,Preclinical
wortmannin,PI3K inhibitor,PIK3CD,1132,Preclinical
wortmannin,PI3K inhibitor,PIK3CG,1128,Preclinical
wortmannin,PI3K inhibitor,PIK3R1,1129,Preclinical
wortmannin,PI3K inhibitor,PLK1,1131,Preclinical
wortmannin,PI3K inhibitor,PRKDC,1132,Preclinical
WP1066,STAT inhibitor,STAT3,7277,Phase 1
WP1130,deubiquitinase inhibitor,JAK2,203068,Preclinical
WP1130,deubiquitinase inhibitor,UCHL5,203068,Preclinical
WP1130,deubiquitinase inhibitor,USP14,81027,Preclinical
WP1130,deubiquitinase inhibitor,USP9X,7846,Preclinical
WR99210,dihydrofolate reductase inhibitor,TYMS,10376,Preclinical
WWL-113,carboxylesterase inhibitor,CES3,84790,Preclinical
WWL-123,monoacylglycerol lipase inhibitor,ABHD6,7278,Preclinical
WYE-125132,mTOR inhibitor,MTOR,113457,Preclinical
WYE-354,mTOR inhibitor,MTOR,112714,Preclinical
WYE-687,mTOR inhibitor,MTOR,7277,Preclinical
WZ-3146,EGFR inhibitor,EGFR,203068,Preclinical
WZ-4002,EGFR inhibitor,EGFR,81027,Preclinical
WZ-4002,EGFR inhibitor,ERBB2,7280,Preclinical
WZ4003,AMPK inhibitor,NUAK1,347733,Preclinical
WZ4003,AMPK inhibitor,NUAK2,10381,Preclinical
WZ8040,EGFR inhibitor,EGFR,10382,Preclinical
WZ811,CC chemokine receptor antagonist,CXCR4,10383,Preclinical
xaliproden,serotonin receptor agonist,HTR1A,84617,Phase 3
xamoterol,adrenergic receptor agonist,ADRB1,347688,Phase 3
xanomeline,acetylcholine receptor agonist,CHRM1,5136,Phase 3
xanomeline,acetylcholine receptor agonist,CHRM2,5137,Phase 3
xanomeline,acetylcholine receptor agonist,CHRM3,134,Phase 3
xanomeline,acetylcholine receptor agonist,CHRM4,135,Phase 3
xanomeline,acetylcholine receptor agonist,CHRM5,136,Phase 3
xanomeline,acetylcholine receptor agonist,HTR1A,140,Phase 3
xanomeline,acetylcholine receptor agonist,HTR1B,6608,Phase 3
xanomeline,acetylcholine receptor agonist,HTR1D,240,Phase 3
xanomeline,acetylcholine receptor agonist,HTR1E,1606,Phase 3
xanomeline,acetylcholine receptor agonist,HTR1F,8856,Phase 3
xanomeline,acetylcholine receptor agonist,HTR2A,5515,Phase 3
xanomeline,acetylcholine receptor agonist,HTR2B,5516,Phase 3
xanomeline,acetylcholine receptor agonist,HTR2C,5578,Phase 3
xanomeline,acetylcholine receptor agonist,HTR6,5579,Phase 3
xanomeline,acetylcholine receptor agonist,HTR7,23541,Phase 3
XAV-939,tankyrase inhibitor,TNKS,266629,Preclinical
XAV-939,tankyrase inhibitor,TNKS2,284904,Preclinical
XBD173,benzodiazepine receptor ligand,TSPO,7157,Phase 2
XD-14,bromodomain inhibitor,BRD2,9097,Preclinical
XD-14,bromodomain inhibitor,BRD3,8972,Preclinical
XD-14,bromodomain inhibitor,BRD4,5347,Preclinical
XD-14,bromodomain inhibitor,BRDT,3356,Preclinical
XE-991,potassium channel blocker,KCNQ1,3357,Preclinical
XE-991,potassium channel blocker,KCNQ2,3358,Preclinical
XE-991,potassium channel blocker,KCNQ3,3757,Preclinical
XE-991,potassium channel blocker,KCNQ4,495,Preclinical
XE-991,potassium channel blocker,KCNQ5,2149,Preclinical
xipamide,carbonic anhydrase inhibitor,SLC12A3,7153,Launched
XL019,JAK inhibitor,JAK1,1557,Phase 1
XL019,JAK inhibitor,JAK2,1559,Phase 1
XL019,JAK inhibitor,JAK3,1576,Phase 1
XL147,PI3K inhibitor,PIK3CA,1577,Phase 2
XL147,PI3K inhibitor,PIK3CD,5742,Phase 2
XL147,PI3K inhibitor,PIK3CG,3065,Phase 2
XL228,Abl kinase inhibitor|insulin growth factor receptor inhibitor|SRC inhibitor,IGF1R,83933,Phase 1
XL228,Abl kinase inhibitor|insulin growth factor receptor inhibitor|SRC inhibitor,SRC,79885,Phase 1
XL388,mTOR inhibitor,MTOR,3066,Preclinical
XL647,EGFR inhibitor|VEGFR inhibitor,EGFR,8841,Phase 3
XL647,EGFR inhibitor|VEGFR inhibitor,EPHB4,10014,Phase 3
XL647,EGFR inhibitor|VEGFR inhibitor,ERBB2,10013,Phase 3
XL647,EGFR inhibitor|VEGFR inhibitor,FLT4,55869,Phase 3
XL647,EGFR inhibitor|VEGFR inhibitor,KDR,9734,Phase 3
XMD17-109,MAP kinase inhibitor,MAPK7,3350,Preclinical
XMD8-92,MAP kinase inhibitor,DCLK2,3351,Preclinical
XMD8-92,MAP kinase inhibitor,MAPK7,3356,Preclinical
XMD8-92,MAP kinase inhibitor,PLK4,3358,Preclinical
XMD8-92,MAP kinase inhibitor,TNK1,3359,Preclinical
xylazine,adrenergic receptor agonist,ADRA2A,3361,Launched
xylazine,adrenergic receptor agonist,ADRA2B,3362,Launched
xylazine,adrenergic receptor agonist,ADRA2C,3363,Launched
xylometazoline,adrenergic receptor agonist,ADRA1A,6532,Launched
xylometazoline,adrenergic receptor agonist,ADRA1B,2475,Launched
xylometazoline,adrenergic receptor agonist,ADRA1D,5290,Launched
xylometazoline,adrenergic receptor agonist,ADRA2A,30814,Launched
xylometazoline,adrenergic receptor agonist,ADRA2B,206358,Launched
xylometazoline,adrenergic receptor agonist,ADRA2C,1586,Launched
Y-11,focal adhesion kinase inhibitor,PTK2,5972,Preclinical
Y-134,estrogen receptor antagonist,ESR1,3359,Preclinical
Y-134,estrogen receptor antagonist,ESR2,9177,Preclinical
Y-26763,potassium channel activator,KCNJ8,59340,Phase 1
Y-27152,potassium channel activator,KCNJ8,57007,Phase 1
Y-27632,rho associated kinase inhibitor,PKIA,5337,Preclinical
Y-27632,rho associated kinase inhibitor,PKN2,1133,Preclinical
Y-27632,rho associated kinase inhibitor,PRKACA,57468,Preclinical
Y-27632,rho associated kinase inhibitor,PRKCE,2915,Preclinical
Y-27632,rho associated kinase inhibitor,ROCK1,2915,Preclinical
Y-27632,rho associated kinase inhibitor,ROCK2,2914,Preclinical
Y-29794,prolyl endopeptidase inhibitor,PREP,2914,Preclinical
Y-320,interleukin inhibitor,IL17A,3764,Preclinical
Y-39983,rho associated kinase inhibitor,ROCK1,4282,Phase 2
Y-39983,rho associated kinase inhibitor,ROCK2,5209,Phase 2
YC-1,guanylyl cyclase activator,GUCY1A2,387,Preclinical
YC-1,guanylyl cyclase activator,GUCY1A3,3359,Preclinical
YC-1,guanylyl cyclase activator,GUCY1B3,9177,Preclinical
YC-1,guanylyl cyclase activator,HIF1A,3360,Preclinical
YIL-781,ghrelin receptor antagonist,GHSR,3361,Preclinical
YK-4-279,apoptosis inhibitor,EWSR1,10800,Preclinical
YK-4-279,apoptosis inhibitor,FLI1,57105,Preclinical
YM-022,CCK receptor antagonist,CCKBR,801,Phase 2
YM-155,survivin inhibitor,BIRC5,3274,Phase 2
YM-298198,glutamate receptor antagonist,GRM1,1131,Preclinical
YM-298198-desmethyl,glutamate receptor antagonist,GRM1,4759,Preclinical
YM-511,aromatase inhibitor,CYP19A1,2859,Phase 2
YM-58483,calcium channel blocker,TRPC3,5136,Preclinical
YM-58483,calcium channel blocker,TRPC5,5144,Preclinical
YM-58483,calcium channel blocker,TRPM4,8654,Preclinical
YM-750,ACAT inhibitor,SOAT1,5152,Phase 1
YM-90709,IL5 inhibitor,CSF2RB,5144,Preclinical
YM-90709,IL5 inhibitor,IL5RA,348980,Preclinical
YM-976,phosphodiesterase inhibitor,PDE4A,610,Phase 1
yoda-1,piezo channel activator,PIEZO1,57657,Preclinical
yohimbine,adrenergic receptor antagonist,ADRA2A,10021,Launched
yohimbine,adrenergic receptor antagonist,ADRA2B,998,Launched
yohimbine,adrenergic receptor antagonist,ADRA2C,155,Launched
yohimbine,adrenergic receptor antagonist,DRD2,155,Launched
yohimbine,adrenergic receptor antagonist,DRD3,185,Launched
yohimbine,adrenergic receptor antagonist,HTR1A,348980,Launched
yohimbine,adrenergic receptor antagonist,HTR1B,610,Launched
yohimbine,adrenergic receptor antagonist,HTR1D,57657,Launched
yohimbine,adrenergic receptor antagonist,HTR1E,10021,Launched
yohimbine,adrenergic receptor antagonist,HTR1F,978,Launched
yohimbine,adrenergic receptor antagonist,HTR2A,1786,Launched
yohimbine,adrenergic receptor antagonist,HTR2B,1909,Launched
yohimbine,adrenergic receptor antagonist,HTR2C,7015,Launched
yohimbine,adrenergic receptor antagonist,HTR5A,240,Launched
yohimbine,adrenergic receptor antagonist,HTR7,154,Launched
yohimbine,adrenergic receptor antagonist,KCNJ1,4128,Launched
yohimbine,adrenergic receptor antagonist,KCNJ10,4129,Launched
yohimbine,adrenergic receptor antagonist,KCNJ11,6532,Launched
yohimbine,adrenergic receptor antagonist,KCNJ12,148,Launched
yohimbine,adrenergic receptor antagonist,KCNJ14,147,Launched
yohimbine,adrenergic receptor antagonist,KCNJ15,150,Launched
yohimbine,adrenergic receptor antagonist,KCNJ8,151,Launched
YZ9,phosphofructokinase inhibitor,MIF,152,Preclinical
YZ9,phosphofructokinase inhibitor,PFKFB3,1128,Preclinical
Y16,rho associated kinase inhibitor,RHOA,1129,Preclinical
zacopride,serotonin receptor antagonist,HTR3A,1131,Phase 2
zacopride,serotonin receptor antagonist,HTR3B,1132,Phase 2
zacopride,serotonin receptor antagonist,HTR4,1133,Phase 2
zacopride,serotonin receptor antagonist,HTR5A,1812,Phase 2
zafirlukast,leukotriene receptor antagonist,CYSLTR1,1813,Launched
zafirlukast,leukotriene receptor antagonist,CYSLTR2,1814,Launched
zaldaride,calmodulin antagonist,CALM1,1815,Phase 3
zaltidine,histamine receptor antagonist,HRH2,1816,Phase 3
zamifenacin,acetylcholine receptor antagonist,CHRM3,3269,Phase 3
zanamivir,neuraminidase inhibitor,NEU2,3350,Launched
zaprinast,phosphodiesterase inhibitor,GPR35,3351,Phase 2
zaprinast,phosphodiesterase inhibitor,PDE1A,3352,Phase 2
zaprinast,phosphodiesterase inhibitor,PDE4D,3354,Phase 2
zaprinast,phosphodiesterase inhibitor,PDE5A,3356,Phase 2
zaprinast,phosphodiesterase inhibitor,PDE9A,3358,Phase 2
zardaverine,phosphodiesterase inhibitor,PDE4D,3359,Phase 2
zatebradine,HCN channel blocker,HCN1,3362,Phase 3
zatebradine,HCN channel blocker,HCN2,3363,Phase 3
zatebradine,HCN channel blocker,HCN3,6532,Phase 3
zatebradine,HCN channel blocker,HCN4,2099,Phase 3
ZCL-278,CDC inhibitor,CDC42,2100,Preclinical
ZD-2079,adrenergic receptor agonist,ADRB3,1230,Phase 2
ZD-7114,adrenergic receptor agonist,ADRB3,2554,Phase 1
ZD-7155,angiotensin receptor antagonist,AGTR1,2555,Preclinical
ZD-7288,HCN channel blocker,HCN1,2556,Phase 2
ZD-7288,HCN channel blocker,HCN2,2558,Phase 2
ZD-7288,HCN channel blocker,HCN3,2561,Phase 2
ZD-7288,HCN channel blocker,HCN4,2566,Phase 2
zebularine,DNA methyltransferase inhibitor,CDA,2554,Preclinical
zebularine,DNA methyltransferase inhibitor,DNMT1,2555,Preclinical
zibotentan,endothelin receptor antagonist,EDNRA,2556,Phase 3
zidovudine,nucleoside reverse transcriptase inhibitor,TERT,2558,Launched
zileuton,leukotriene synthesis inhibitor|lipoxygenase inhibitor,ALOX5,5562,Launched
zilpaterol,adrenergic receptor agonist,ADRB2,5564,Launched
zimelidine,selective serotonin reuptake inhibitor (SSRI),MAOA,5571,Withdrawn
zimelidine,selective serotonin reuptake inhibitor (SSRI),MAOB,134,Withdrawn
zimelidine,selective serotonin reuptake inhibitor (SSRI),SLC6A4,135,Withdrawn
ziprasidone,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A,136,Launched
ziprasidone,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1B,140,Launched
ziprasidone,dopamine receptor antagonist|serotonin receptor antagonist,ADRA2A,1956,Launched
ziprasidone,dopamine receptor antagonist|serotonin receptor antagonist,ADRA2B,2321,Launched
ziprasidone,dopamine receptor antagonist|serotonin receptor antagonist,ADRA2C,2324,Launched
ziprasidone,dopamine receptor antagonist|serotonin receptor antagonist,CHRM1,3791,Launched
ziprasidone,dopamine receptor antagonist|serotonin receptor antagonist,CHRM2,3791,Launched
ziprasidone,dopamine receptor antagonist|serotonin receptor antagonist,CHRM3,673,Launched
ziprasidone,dopamine receptor antagonist|serotonin receptor antagonist,CHRM4,3932,Launched
ziprasidone,dopamine receptor antagonist|serotonin receptor antagonist,CHRM5,1432,Launched
ziprasidone,dopamine receptor antagonist|serotonin receptor antagonist,DRD1,5894,Launched
ziprasidone,dopamine receptor antagonist|serotonin receptor antagonist,DRD2,3716,Launched
ziprasidone,dopamine receptor antagonist|serotonin receptor antagonist,DRD3,3718,Launched
ziprasidone,dopamine receptor antagonist|serotonin receptor antagonist,DRD4,6790,Launched
ziprasidone,dopamine receptor antagonist|serotonin receptor antagonist,DRD5,9212,Launched
ziprasidone,dopamine receptor antagonist|serotonin receptor antagonist,HRH1,2707,Launched
ziprasidone,dopamine receptor antagonist|serotonin receptor antagonist,HTR1A,127534,Launched
ziprasidone,dopamine receptor antagonist|serotonin receptor antagonist,HTR1B,2709,Launched
ziprasidone,dopamine receptor antagonist|serotonin receptor antagonist,HTR1D,10804,Launched
ziprasidone,dopamine receptor antagonist|serotonin receptor antagonist,HTR1E,375519,Launched
ziprasidone,dopamine receptor antagonist|serotonin receptor antagonist,HTR2A,10052,Launched
ziprasidone,dopamine receptor antagonist|serotonin receptor antagonist,HTR2C,57165,Launched
ziprasidone,dopamine receptor antagonist|serotonin receptor antagonist,HTR3A,349149,Launched
ziprasidone,dopamine receptor antagonist|serotonin receptor antagonist,HTR6,57369,Launched
ziprasidone,dopamine receptor antagonist|serotonin receptor antagonist,HTR7,125111,Launched
ziprasidone,dopamine receptor antagonist|serotonin receptor antagonist,SLC6A4,219770,Launched
ZK-164015,estrogen receptor antagonist,ESR1,100126572,Preclinical
ZK-164015,estrogen receptor antagonist,ESR2,3359,Preclinical
ZK-811752,CC chemokine receptor antagonist,CCR1,9177,Phase 2
ZK-93423,benzodiazepine receptor agonist,GABRA1,5292,Phase 3
ZK-93423,benzodiazepine receptor agonist,GABRA2,7150,Phase 3
ZK-93423,benzodiazepine receptor agonist,GABRA3,343450,Phase 3
ZK-93423,benzodiazepine receptor agonist,GABRA5,59341,Phase 3
ZK-93423,benzodiazepine receptor agonist,GABRB2,4842,Phase 3
ZK-93423,benzodiazepine receptor agonist,GABRG2,4843,Phase 3
ZK-93426,benzodiazepine receptor antagonist,GABRA1,4846,Phase 1
ZK-93426,benzodiazepine receptor antagonist,GABRA2,3248,Phase 1
ZK-93426,benzodiazepine receptor antagonist,GABRA3,367,Phase 1
ZK-93426,benzodiazepine receptor antagonist,GABRA5,2099,Phase 1
ZLN024,AMPK activator,PRKAA1,2100,Preclinical
ZLN024,AMPK activator,PRKAB1,9971,Preclinical
ZLN024,AMPK activator,PRKAG1,8856,Preclinical
ZM-241385,adenosine receptor antagonist,ADORA1,2908,Preclinical
ZM-241385,adenosine receptor antagonist,ADORA2A,5241,Preclinical
ZM-241385,adenosine receptor antagonist,ADORA2B,134,Preclinical
ZM-241385,adenosine receptor antagonist,ADORA3,598,Preclinical
ZM-306416,Abl kinase inhibitor|SRC inhibitor|VEGFR inhibitor,EGFR,7295,Preclinical
ZM-306416,Abl kinase inhibitor|SRC inhibitor|VEGFR inhibitor,FLT1,351,Preclinical
ZM-306416,Abl kinase inhibitor|SRC inhibitor|VEGFR inhibitor,FLT4,3043,Preclinical
ZM-306416,Abl kinase inhibitor|SRC inhibitor|VEGFR inhibitor,KDR,2346,Preclinical
ZM-323881,VEGFR inhibitor,KDR,3360,Preclinical
ZM-336372,RAF inhibitor,BRAF,771,Preclinical
ZM-336372,RAF inhibitor,LCK,23632,Preclinical
ZM-336372,RAF inhibitor,MAPK14,760,Preclinical
ZM-336372,RAF inhibitor,RAF1,765,Preclinical
ZM-39923,JAK inhibitor,JAK1,768,Preclinical
ZM-39923,JAK inhibitor,JAK3,7220,Preclinical
ZM-447439,Aurora kinase inhibitor,AURKA,7222,Preclinical
ZM-447439,Aurora kinase inhibitor,AURKB,7223,Preclinical
zofenopril-calcium,angiotensin converting enzyme inhibitor,ACE,7224,Launched
zoledronic-acid,bone resorption inhibitor,FDPS,7225,Launched
zoledronic-acid,bone resorption inhibitor,GGPS1,57113,Launched
zolmitriptan,serotonin receptor agonist,HTR1A,7226,Launched
zolmitriptan,serotonin receptor agonist,HTR1B,80036,Launched
zolmitriptan,serotonin receptor agonist,HTR1D,140803,Launched
zolmitriptan,serotonin receptor agonist,HTR1E,7442,Launched
zolmitriptan,serotonin receptor agonist,HTR1F,55503,Launched
zomepirac,prostaglandin synthesis inhibitor,PTGDR2,150,Withdrawn
zoniporide,sodium/hydrogen exchanger inhibitor,SLC9A1,151,Phase 3
zonisamide,sodium channel blocker|T-type calcium channel blocker,CA1,152,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,CA10,4128,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,CA11,4129,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,CA12,134,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,CA13,135,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,CA14,136,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,CA2,140,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,CA3,134,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,CA4,135,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,CA5A,136,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,CA5B,1813,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,CA6,1815,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,CA7,6513,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,CA8,6514,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,CA9,6515,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,CACNA1G,6517,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,CACNA1H,3938,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,CACNA1I,367,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,MAOA,2550,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,MAOB,9568,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,SCN10A,4842,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,SCN11A,4843,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,SCN1A,4543,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,SCN1B,4544,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,SCN2A,4835,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,SCN2B,1312,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,SCN3A,1588,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,SCN3B,1543,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,SCN4A,1545,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,SCN4B,3091,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,SCN5A,203068,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,SCN7A,3351,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,SCN8A,3352,Launched
zonisamide,sodium channel blocker|T-type calcium channel blocker,SCN9A,3354,Launched
zopolrestat,,AKR1B1,3355,Phase 2
zopolrestat,,AKR1B10,3359,Phase 2
zosuquidar,P glycoprotein inhibitor,ABCB1,9177,Phase 3
zosuquidar,P glycoprotein inhibitor,ABCB4,3362,Phase 3
zotarolimus,mTOR inhibitor,FKBP1A,139760,Launched
zotepine,dopamine receptor antagonist|serotonin receptor antagonist,ADRA2B,27199,Launched
zotepine,dopamine receptor antagonist|serotonin receptor antagonist,DRD2,18,Launched
zotepine,dopamine receptor antagonist|serotonin receptor antagonist,DRD3,4543,Launched
zotepine,dopamine receptor antagonist|serotonin receptor antagonist,DRD4,4544,Launched
zotepine,dopamine receptor antagonist|serotonin receptor antagonist,HRH1,148,Launched
zotepine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1A,3269,Launched
zotepine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1B,239,Launched
zotepine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1D,3358,Launched
zotepine,dopamine receptor antagonist|serotonin receptor antagonist,HTR1E,3362,Launched
zotepine,dopamine receptor antagonist|serotonin receptor antagonist,HTR2A,3363,Launched
zotepine,dopamine receptor antagonist|serotonin receptor antagonist,HTR2C,8658,Launched
zotepine,dopamine receptor antagonist|serotonin receptor antagonist,HTR6,80351,Launched
zotepine,dopamine receptor antagonist|serotonin receptor antagonist,HTR7,706,Launched
zotepine,dopamine receptor antagonist|serotonin receptor antagonist,SLC6A2,6046,Launched
zotepine,dopamine receptor antagonist|serotonin receptor antagonist,SLC6A4,8019,Launched
ZSTK-474,PI3K inhibitor,PIK3CB,23476,Phase 1/Phase 2
ZSTK-474,PI3K inhibitor,PIK3CD,676,Phase 1/Phase 2
ZSTK-474,PI3K inhibitor,PIK3CG,3784,Phase 1/Phase 2
zuclopenthixol,dopamine receptor antagonist,ADRA1A,3785,Launched
zuclopenthixol,dopamine receptor antagonist,ADRA2A,3786,Launched
zuclopenthixol,dopamine receptor antagonist,DRD1,9132,Launched
zuclopenthixol,dopamine receptor antagonist,DRD2,56479,Launched
zuclopenthixol,dopamine receptor antagonist,DRD5,6559,Launched
zuclopenthixol,dopamine receptor antagonist,HRH1,3716,Launched
zuclopenthixol,dopamine receptor antagonist,HTR2A,3717,Launched
Z160,N-type calcium channel blocker,CACNA2D1,3718,Phase 2
"1,2,3,4,5,6-hexabromocyclohexane",JAK inhibitor,JAK2,5290,Preclinical
"1,4-butanediol",benzodiazepine receptor agonist|gamma hydroxybutyric acid agonist,MAN1B1,5293,Phase 1
"1,4-butanediol",benzodiazepine receptor agonist|gamma hydroxybutyric acid agonist,PLA2G2A,5294,Phase 1
"1,4-butanediol",benzodiazepine receptor agonist|gamma hydroxybutyric acid agonist,PLA2G2E,3480,Phase 1
1-azakenpaullone,glycogen synthase kinase inhibitor,CCNB1,6714,Preclinical
1-azakenpaullone,glycogen synthase kinase inhibitor,CDK1,2475,Preclinical
1-azakenpaullone,glycogen synthase kinase inhibitor,CDK5,1956,Preclinical
1-azakenpaullone,glycogen synthase kinase inhibitor,GSK3B,2050,Preclinical
1-deoxymannojirimycin,alpha mannosidase inhibitor,MAN2A1,2064,Preclinical
1-EBIO,potassium channel activator,KCNN1,2324,Preclinical
1-EBIO,potassium channel activator,KCNN2,3791,Preclinical
1-EBIO,potassium channel activator,KCNN3,5598,Preclinical
1-EBIO,potassium channel activator,KCNN4,166614,Preclinical
1-hexadecanal,sphingosine 1-phosphate receptor substrate,DBI,5598,Preclinical
1-hexadecanal,sphingosine 1-phosphate receptor substrate,RHO,10733,Preclinical
1-naphthyl-PP1,SRC inhibitor,SRC,8711,Preclinical
1-octanol,,GJA1,150,Phase 2
1-octanol,,GJA10,151,Phase 2
1-octanol,,GJA3,152,Phase 2
1-octanol,,GJA4,148,Phase 2
1-octanol,,GJA5,147,Phase 2
1-octanol,,GJA8,146,Phase 2
1-octanol,,GJA9,150,Phase 2
1-octanol,,GJB1,151,Phase 2
1-octanol,,GJB2,152,Phase 2
1-octanol,,GJB3,5747,Phase 2
1-octanol,,GJB4,2099,Phase 2
1-octanol,,GJB5,2100,Phase 2
1-octanol,,GJB6,3764,Phase 2
1-octanol,,GJB7,3764,Phase 2
1-octanol,,GJC1,5569,Phase 2
1-octanol,,GJC2,5586,Phase 2
1-octanol,,GJC3,5566,Phase 2
1-octanol,,GJD2,5581,Phase 2
1-octanol,,GJD3,6093,Phase 2
1-octanol,,GJD4,9475,Phase 2
1-octanol,,GJE1,5550,Phase 2
1-phenylbiguanide,serotonin receptor agonist,HTR3A,3605,Preclinical
1-phenylbiguanide,serotonin receptor agonist,HTR3B,6093,Preclinical
10-DEBC,AKT inhibitor,PIM1,9475,Preclinical
10-hydroxycamptothecin,topoisomerase inhibitor,TOP1,2977,Preclinical
12-O-tetradecanoylphorbol-13-acetate,PKC activator,KCNT2,-,Phase 2
12-O-tetradecanoylphorbol-13-acetate,PKC activator,TRPV4,-,Phase 2
1400W,nitric oxide synthase inhibitor,NOS1,3091,Preclinical
1400W,nitric oxide synthase inhibitor,NOS2,2693,Preclinical
1400W,nitric oxide synthase inhibitor,NOS3,2130,Preclinical
"16,16-dimethylprostaglandin-e2",prostanoid receptor agonist,HPGD,2313,Phase 2
17-hydroxyprogesterone-caproate,progesterone receptor agonist,AR,887,Launched
17-hydroxyprogesterone-caproate,progesterone receptor agonist,ESR1,332,Launched
17-hydroxyprogesterone-caproate,progesterone receptor agonist,ESR2,2911,Launched
17-hydroxyprogesterone-caproate,progesterone receptor agonist,NR1H4,2911,Launched
17-hydroxyprogesterone-caproate,progesterone receptor agonist,NR1I2,1588,Launched
17-hydroxyprogesterone-caproate,progesterone receptor agonist,NR3C1,7222,Launched
17-hydroxyprogesterone-caproate,progesterone receptor agonist,PGR,7224,Launched
2'-MeCCPA,adenosine receptor agonist,ADORA1,54795,Preclinical
"2,3-DCPE",BCL-XL downregulator,BCL2L1,6646,Preclinical
"2,4-dinitrochlorobenzene",thioredoxin inhibitor,TXN,1439,Phase 2
"2,4-dinitrophenol",ATP synthase inhibitor,APP,3568,Preclinical
"2,5-furandimethanol",hemoglobin modulator,HBB,5141,Phase 2
2-(3-mercaptopropyl)pentanedioic-acid,glutamate carboxypeptidase inhibitor,FOLH1,9780,Phase 1
2-[1-(4-piperonyl)piperazinyl]benzothiazole,serotonin receptor agonist,HTR4,150,Preclinical
2-aminobenzenesulfonamide,carbonic anhydrase inhibitor,CA12,151,Preclinical
2-aminobenzenesulfonamide,carbonic anhydrase inhibitor,CA14,152,Preclinical
2-aminobenzenesulfonamide,carbonic anhydrase inhibitor,CA2,1813,Preclinical
2-aminobenzenesulfonamide,carbonic anhydrase inhibitor,CA6,1814,Preclinical
2-aminobenzenesulfonamide,carbonic anhydrase inhibitor,CA9,3350,Preclinical
2-APB,"1,4,5-trisphosphate inhibitor",TRPC1,3351,Preclinical
2-APB,"1,4,5-trisphosphate inhibitor",TRPC3,3352,Preclinical
2-APB,"1,4,5-trisphosphate inhibitor",TRPC4,3354,Preclinical
2-APB,"1,4,5-trisphosphate inhibitor",TRPC5,3355,Preclinical
2-APB,"1,4,5-trisphosphate inhibitor",TRPC6,3356,Preclinical
2-APB,"1,4,5-trisphosphate inhibitor",TRPC7,3357,Preclinical
2-APB,"1,4,5-trisphosphate inhibitor",TRPM2,3358,Preclinical
2-APB,"1,4,5-trisphosphate inhibitor",TRPM3,3361,Preclinical
2-APB,"1,4,5-trisphosphate inhibitor",TRPM6,3363,Preclinical
2-APB,"1,4,5-trisphosphate inhibitor",TRPV1,3758,Preclinical
2-APB,"1,4,5-trisphosphate inhibitor",TRPV6,3766,Preclinical
2-BFI,imidazoline receptor ligand,ADRA2A,3767,Preclinical
2-BFI,imidazoline receptor ligand,ADRA2B,3768,Preclinical
2-BFI,imidazoline receptor ligand,ADRA2C,3770,Preclinical
2-BFI,imidazoline receptor ligand,MAOA,3772,Preclinical
2-BFI,imidazoline receptor ligand,MAOB,1636,Preclinical
2-chloro-N6-cyclopentyladenosine,adenosine receptor agonist,ADORA1,2224,Preclinical
2-chloro-N6-cyclopentyladenosine,adenosine receptor agonist,ADORA2A,9453,Preclinical
2-chloro-N6-cyclopentyladenosine,adenosine receptor agonist,ADORA2B,3350,Preclinical
2-chloro-N6-cyclopentyladenosine,adenosine receptor agonist,ADORA3,3351,Preclinical
2-chloroadenosine,adenosine receptor agonist,ADORA1,3352,Preclinical
2-chloroadenosine,adenosine receptor agonist,ADORA2A,3354,Preclinical
2-chloroadenosine,adenosine receptor agonist,ADORA2B,3355,Preclinical
2-CMDO,dopamine receptor antagonist,DRD2,11251,Preclinical
2-CMDO,dopamine receptor antagonist,DRD4,6548,Preclinical
2-deoxyglucose,glycolysis inhibitor,SLC2A1,759,Phase 2
2-deoxyglucose,glycolysis inhibitor,SLC2A2,56934,Phase 2
2-deoxyglucose,glycolysis inhibitor,SLC2A3,770,Phase 2
2-deoxyglucose,glycolysis inhibitor,SLC2A4,771,Phase 2
2-fluoro-2-deoxy-D-galactose,,LCT,377677,Phase 1
2-hydroxyflutamide,androgen receptor antagonist,AR,23632,Phase 2
2-hydroxysaclofen,GABA receptor antagonist,GABBR1,760,Preclinical
2-hydroxysaclofen,GABA receptor antagonist,GABBR2,761,Preclinical
2-iminobiotin,nitric oxide synthase inhibitor,NOS1,762,Phase 2
2-iminobiotin,nitric oxide synthase inhibitor,NOS2,763,Phase 2
2-iodomelatonin,melatonin receptor agonist,MTNR1A,11238,Preclinical
2-iodomelatonin,melatonin receptor agonist,MTNR1B,765,Preclinical
2-iodomelatonin,melatonin receptor agonist,NQO2,766,Preclinical
2-methoxyestradiol,hypoxia inducible factor inhibitor,COMT,767,Phase 2
2-methoxyestradiol,hypoxia inducible factor inhibitor,CYP19A1,768,Phase 2
2-methoxyestradiol,hypoxia inducible factor inhibitor,CYP1A1,8913,Phase 2
2-methoxyestradiol,hypoxia inducible factor inhibitor,CYP1B1,8912,Phase 2
2-methoxyestradiol,hypoxia inducible factor inhibitor,HIF1A,8911,Phase 2
2-methoxyestradiol,hypoxia inducible factor inhibitor,TUBB,4128,Phase 2
2-methyl-5-hydroxytryptamine,serotonin receptor agonist,HTR1B,4129,Preclinical
2-methyl-5-hydroxytryptamine,serotonin receptor agonist,HTR1D,6336,Preclinical
2-methyl-5-hydroxytryptamine,serotonin receptor agonist,HTR1E,11280,Preclinical
2-methyl-5-hydroxytryptamine,serotonin receptor agonist,HTR1F,6323,Preclinical
2-methyl-5-hydroxytryptamine,serotonin receptor agonist,HTR3A,6324,Preclinical
2-methyl-5-hydroxytryptamine,serotonin receptor agonist,HTR3B,6326,Preclinical
2-methyl-5-hydroxytryptamine,serotonin receptor agonist,HTR6,6327,Preclinical
2-oleoylglycerol,glucose dependent insulinotropic receptor ligand,GPR119,6328,Phase 1
2-oxoglutaric-acid,,OXGR1,55800,Preclinical
2-oxopropanoate,pyruvate dehydrogenase kinase inhibitor,ABAT,6329,Preclinical
2-phenylmelatonin,melatonin receptor agonist,MTNR1A,6330,Preclinical
2-phenylmelatonin,melatonin receptor agonist,MTNR1B,6331,Preclinical
2-PMDQ,adrenergic receptor antagonist,ADRA1A,6332,Preclinical
2-pyridylethylamine,histamine receptor agonist,HRH1,6334,Preclinical
2-TEDC,lipoxygenase inhibitor,ALOX12,6335,Preclinical
3'-fluorobenzylspiperone,dopamine receptor ligand,DRD2,231,Preclinical
"3,3'-dichlorobenzaldazine",glutamate receptor modulator,GRM5,57016,Preclinical
"3,3'-diindolylmethane","CHK inhibitor|cytochrome P450 activator|indoleamine 2,3-dioxygenase inhibitor",AR,5243,Phase 3
"3,3'-diindolylmethane","CHK inhibitor|cytochrome P450 activator|indoleamine 2,3-dioxygenase inhibitor",HIF1A,5244,Phase 3
"3,3'-diindolylmethane","CHK inhibitor|cytochrome P450 activator|indoleamine 2,3-dioxygenase inhibitor",IFNG,2280,Phase 3
"3,3'-diindolylmethane","CHK inhibitor|cytochrome P450 activator|indoleamine 2,3-dioxygenase inhibitor",PI3,151,Phase 3
"3,4-DCPG-(+/-)",glutamate receptor agonist,GRM8,1813,Preclinical
"3,4-DCPG-(S)",glutamate receptor agonist,GRM8,1814,Preclinical
"3,4-methylenedioxy-beta-nitrostyrene",SRC inhibitor|SYK inhibitor,SRC,1815,Preclinical
"3,4-methylenedioxy-beta-nitrostyrene",SRC inhibitor|SYK inhibitor,SYK,3269,Preclinical
"3,5-DHPG-(S)",glutamate receptor agonist,GRM1,3350,Preclinical
3-alpha-bis-(4-fluorophenyl)-methoxytropane,dopamine uptake inhibitor,CHRM1,3351,Preclinical
3-alpha-bis-(4-fluorophenyl)-methoxytropane,dopamine uptake inhibitor,SLC6A2,3352,Preclinical
3-alpha-bis-(4-fluorophenyl)-methoxytropane,dopamine uptake inhibitor,SLC6A3,3354,Preclinical
3-alpha-bis-(4-fluorophenyl)-methoxytropane,dopamine uptake inhibitor,SLC6A4,3356,Preclinical
3-alpha-hydroxy-5-beta-androstan-17-one,,HSD17B11,3358,Preclinical
3-alpha-hydroxy-5-beta-androstan-17-one,,IGHG2,3362,Preclinical
3-alpha-hydroxy-5-beta-androstan-17-one,,SULT2A1,3363,Preclinical
3-amino-benzamide,PARP inhibitor,PARP1,6530,Phase 2
3-AQC,serotonin receptor agonist,HTR3A,6532,Preclinical
3-bromo-7-nitroindazole,nitric oxide synthase inhibitor,NOS1,5291,Preclinical
3-bromo-7-nitroindazole,nitric oxide synthase inhibitor,NOS2,5293,Preclinical
3-bromo-7-nitroindazole,nitric oxide synthase inhibitor,NOS3,5294,Preclinical
3-bromopyruvate,hexokinase inhibitor,HK2,148,Preclinical
3-carboxy-4-hydroxyphenylglycine-(R),glutamate receptor antagonist,GRIN1,150,Preclinical
3-carboxy-4-hydroxyphenylglycine-(R),glutamate receptor antagonist,GRIN2A,1812,Preclinical
3-carboxy-4-hydroxyphenylglycine-(R),glutamate receptor antagonist,GRIN2B,1813,Preclinical
3-carboxy-4-hydroxyphenylglycine-(R),glutamate receptor antagonist,GRIN2C,1816,Preclinical
3-carboxy-4-hydroxyphenylglycine-(S),glutamate receptor antagonist,GRM1,3269,Preclinical
3-carboxy-4-hydroxyphenylglycine-(S),glutamate receptor antagonist,GRM5,3356,Preclinical
3-deazaadenosine,adenosylhomocysteinase inhibitor,AHCY,781,Phase 2
3-deazaneplanocin-A,histone lysine methyltransferase inhibitor,EZH2,3717,Preclinical
3-indolebutyric-acid,,B2M,11253,Preclinical
3-indolebutyric-acid,,HLA-A,5320,Preclinical
3-indolebutyric-acid,,TRAC,30814,Preclinical
3-indolebutyric-acid,,TRBC1,891,Preclinical
3-MATIDA,glutamate receptor antagonist,GRM1,983,Preclinical
3-methyl-GABA,GABA aminotransferase activator,ABAT,1020,Preclinical
3-methyladenine,PI3K inhibitor,PI3,2932,Preclinical
3-MPPI,adrenergic receptor ligand,ADRA1A,4124,Preclinical
3PO,phosphofructokinase inhibitor,PFKFB3,3780,Preclinical
"4,5,6,7-tetrabromobenzotriazole",casein kinase inhibitor,AKT1,3781,Preclinical
"4,5,6,7-tetrabromobenzotriazole",casein kinase inhibitor,CHEK1,3782,Preclinical
"4,5,6,7-tetrabromobenzotriazole",casein kinase inhibitor,CSNK2A1,3783,Preclinical
"4,5,6,7-tetrabromobenzotriazole",casein kinase inhibitor,GSK3B,1622,Preclinical
"4,5,6,7-tetrabromobenzotriazole",casein kinase inhibitor,LCK,6010,Preclinical
"4,5,6,7-tetrabromobenzotriazole",casein kinase inhibitor,MAP2K1,6714,Preclinical
"4,5,6,7-tetrabromobenzotriazole",casein kinase inhibitor,MAPK1,2697,Preclinical
"4,5,6,7-tetrabromobenzotriazole",casein kinase inhibitor,MAPK11,84694,Preclinical
"4,5,6,7-tetrabromobenzotriazole",casein kinase inhibitor,MAPK12,2700,Preclinical
"4,5,6,7-tetrabromobenzotriazole",casein kinase inhibitor,MAPK14,2701,Preclinical
"4,5,6,7-tetrabromobenzotriazole",casein kinase inhibitor,MAPK8,2702,Preclinical
"4,5,6,7-tetrabromobenzotriazole",casein kinase inhibitor,PRKCA,2703,Preclinical
"4,5,6,7-tetrabromobenzotriazole",casein kinase inhibitor,ROCK1,81025,Preclinical
"4,5,6,7-tetrabromobenzotriazole",casein kinase inhibitor,RPS6KB1,2705,Preclinical
"4,5,6,7-tetrabromobenzotriazole",casein kinase inhibitor,SGK1,2706,Preclinical
4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine,serotonin receptor antagonist,HTR2A,1813,Preclinical
4-aminohippuric-acid,,SLC22A6,2915,Launched
4-carboxy-3-hydroxyphenylglycine-(RS),glutamate receptor agonist|glutamate receptor antagonist,GRM1,367,Preclinical
4-carboxy-3-hydroxyphenylglycine-(S),glutamate receptor agonist|glutamate receptor antagonist,GRM1,3091,Preclinical
4-carboxy-3-hydroxyphenylglycine-(S),glutamate receptor agonist|glutamate receptor antagonist,GRM2,3458,Preclinical
4-chlorophenylguanidine,urokinase inhibitor,PLAUR,5266,Preclinical
4-CMTB,free fatty acid receptor agonist,FFAR2,2918,Preclinical
4-DAMP,cholinergic receptor antagonist,CHRM1,2918,Preclinical
4-DAMP,cholinergic receptor antagonist,CHRM2,6714,Preclinical
4-DAMP,cholinergic receptor antagonist,CHRM3,6850,Preclinical
4-DAMP,cholinergic receptor antagonist,CHRM4,2911,Preclinical
4-DAMP,cholinergic receptor antagonist,CHRM5,1128,Preclinical
4-HQN,PARP inhibitor,PARP1,6530,Preclinical
4-IBP,sigma receptor agonist,SIGMAR1,6531,Preclinical
4-iodo-L-phenylalanine,,DPP4,6532,Preclinical
4-iodo-6-phenylpyrimidine,macrophage migration inhibiting factor inhibitor,MIF,51170,Preclinical
4-methylgenistein,protein tyrosine kinase inhibitor,CYP19A1,3501,Preclinical
4-methylgenistein,protein tyrosine kinase inhibitor,ESRRA,6822,Preclinical
4-methylgenistein,protein tyrosine kinase inhibitor,ESRRB,142,Preclinical
4-methylgenistein,protein tyrosine kinase inhibitor,ESRRG,3359,Preclinical
4-methylgenistein,protein tyrosine kinase inhibitor,FASN,4842,Preclinical
4-methylhistamine,histamine receptor agonist,HRH4,4843,Preclinical
4-mu-8C,IRE1 inhibitor,ERN1,4846,Preclinical
4-P-PDOT,melatonin receptor antagonist,MTNR1A,3099,Preclinical
4-P-PDOT,melatonin receptor antagonist,MTNR1B,2902,Preclinical
4-PPBP,sigma receptor ligand,SIGMAR1,2903,Preclinical
4BP-TQS,nicotinic receptor agonist,CHRNA7,2904,Preclinical
4EGI-1,protein synthesis inhibitor,EIF4E,2905,Preclinical
4E1RCat,protein synthesis inhibitor,EIF4E,2911,Preclinical
4E1RCat,protein synthesis inhibitor,EIF4G1,2915,Preclinical
4SC-202,HDAC inhibitor,HDAC1,191,Phase 1
5'-chloro-5'-deoxy-ENBA-(+/-),adenosine receptor agonist,ADORA1,2146,Preclinical
"5,7-dichlorokynurenic-acid",glutamate receptor antagonist,GLRA2,567,Preclinical
"5,7-dichlorokynurenic-acid",glutamate receptor antagonist,GRIN1,3105,Preclinical
"5,7-dichlorokynurenic-acid",glutamate receptor antagonist,GRIN2A,28755,Preclinical
"5,7-dichlorokynurenic-acid",glutamate receptor antagonist,GRIN2B,28639,Preclinical
"5,7-dichlorokynurenic-acid",glutamate receptor antagonist,GRIN2C,2911,Preclinical
"5,7-dichlorokynurenic-acid",glutamate receptor antagonist,GRIN2D,18,Preclinical
"5-amino-3-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione",,TLR7,5266,Preclinical
5-aminolevulinic-acid,oxidizing agent,ALAD,148,Launched
5-BDBD,purinergic receptor antagonist,P2RX4,5209,Preclinical
5-carboxamidotryptamine,serotonin receptor agonist,HTR1A,207,Preclinical
5-carboxamidotryptamine,serotonin receptor agonist,HTR1B,1111,Preclinical
5-carboxamidotryptamine,serotonin receptor agonist,HTR1D,1457,Preclinical
5-carboxamidotryptamine,serotonin receptor agonist,HTR1E,2932,Preclinical
5-carboxamidotryptamine,serotonin receptor agonist,HTR1F,3932,Preclinical
5-carboxamidotryptamine,serotonin receptor agonist,HTR2A,5604,Preclinical
5-carboxamidotryptamine,serotonin receptor agonist,HTR2B,5594,Preclinical
5-carboxamidotryptamine,serotonin receptor agonist,HTR2C,5600,Preclinical
5-carboxamidotryptamine,serotonin receptor agonist,HTR5A,6300,Preclinical
5-carboxamidotryptamine,serotonin receptor agonist,HTR6,1432,Preclinical
5-carboxamidotryptamine,serotonin receptor agonist,HTR7,5599,Preclinical
5-fluorouracil,thymidylate synthase inhibitor,DPYD,5578,Launched
5-fluorouracil,thymidylate synthase inhibitor,TYMS,6093,Launched
5-FP,thymidylate synthase inhibitor,TYMS,6198,Phase 1
5-hydroxymethyl-tolterodine,acetylcholine receptor antagonist,CHRM3,6446,Phase 1
5-hydroxytryptophan,neurotransmitter,SLC36A1,3356,Launched
5-hydroxytryptophan,neurotransmitter,SLC36A2,9356,Launched
5-methylfurmethiodide,acetylcholine receptor agonist,CHRM1,2911,Preclinical
5-methylfurmethiodide,acetylcholine receptor agonist,CHRM2,2911,Preclinical
5-methylfurmethiodide,acetylcholine receptor agonist,CHRM3,2912,Preclinical
5-methylfurmethiodide,acetylcholine receptor agonist,CHRM4,5329,Preclinical
6-chloromelatonin,melatonin receptor agonist,MTNR1A,2867,Preclinical
6-chloromelatonin,melatonin receptor agonist,MTNR1B,1128,Preclinical
6-iodo-nordihydrocapsaicin,TRPV antagonist,TRPV1,1129,Preclinical
7-chlorokynurenic-acid,glutamate receptor antagonist,GRIN1,1131,Preclinical
7-chlorokynurenic-acid,glutamate receptor antagonist,GRIN2A,1132,Preclinical
7-chlorokynurenic-acid,glutamate receptor antagonist,GRIN2B,1133,Preclinical
7-chlorokynurenic-acid,glutamate receptor antagonist,GRIN2C,142,Preclinical
7-hydroxy-DPAT,dopamine receptor agonist,DRD2,10280,Preclinical
7-hydroxy-DPAT,dopamine receptor agonist,DRD3,1803,Preclinical
7-hydroxy-PIPAT,dopamine receptor ligand,DRD3,4282,Preclinical
7-hydroxystaurosporine,CDK inhibitor|CHK inhibitor|PKC inhibitor,CDK1,1588,Phase 2
7-hydroxystaurosporine,CDK inhibitor|CHK inhibitor|PKC inhibitor,CHEK1,2101,Phase 2
7-hydroxystaurosporine,CDK inhibitor|CHK inhibitor|PKC inhibitor,CHEK2,2103,Phase 2
7-hydroxystaurosporine,CDK inhibitor|CHK inhibitor|PKC inhibitor,GSK3B,2104,Phase 2
7-hydroxystaurosporine,CDK inhibitor|CHK inhibitor|PKC inhibitor,LCK,2194,Phase 2
7-hydroxystaurosporine,CDK inhibitor|CHK inhibitor|PKC inhibitor,MAPK14,59340,Phase 2
7-hydroxystaurosporine,CDK inhibitor|CHK inhibitor|PKC inhibitor,MARK1,2081,Phase 2
7-hydroxystaurosporine,CDK inhibitor|CHK inhibitor|PKC inhibitor,MARK3,4543,Phase 2
7-hydroxystaurosporine,CDK inhibitor|CHK inhibitor|PKC inhibitor,PDPK1,4544,Phase 2
7-hydroxystaurosporine,CDK inhibitor|CHK inhibitor|PKC inhibitor,PRKCA,10280,Phase 2
7-hydroxystaurosporine,CDK inhibitor|CHK inhibitor|PKC inhibitor,PRKCB,1139,Phase 2
7-hydroxystaurosporine,CDK inhibitor|CHK inhibitor|PKC inhibitor,PRKCD,1977,Phase 2
7-hydroxystaurosporine,CDK inhibitor|CHK inhibitor|PKC inhibitor,PRKCE,1977,Phase 2
7-hydroxystaurosporine,CDK inhibitor|CHK inhibitor|PKC inhibitor,PRKCG,1981,Phase 2
7-methoxytacrine,acetylcholinesterase inhibitor,ACHE,3065,Phase 2
7-nitroindazole,nitric oxide synthase inhibitor,NOS1,134,Preclinical
7-nitroindazole,nitric oxide synthase inhibitor,NOS2,2742,Preclinical
7-nitroindazole,nitric oxide synthase inhibitor,NOS3,2902,Preclinical
8-bromo-cGMP,PKA activator,PRKG1,2903,Preclinical
8-hydroxy-DPAT,serotonin receptor agonist,HTR5A,2904,Preclinical
8-hydroxy-DPAT,serotonin receptor agonist,HTR7,2905,Preclinical
8-hydroxy-PIPAT,dopamine receptor ligand,DRD2,2906,Preclinical
8-hydroxy-PIPAT,dopamine receptor ligand,DRD3,51284,Preclinical
8-M-PDOT,melatonin receptor agonist,MTNR1A,210,Preclinical
8-M-PDOT,melatonin receptor agonist,MTNR1B,5025,Preclinical
9-aminocamptothecin,topoisomerase inhibitor,TOP1,3350,Phase 2
9-anthracenecarboxylic-acid,,ANO1,3351,Preclinical
9-anthracenecarboxylic-acid,,CLCN1,3352,Preclinical
